

PROGRAM

PROGRAM

AMERICAN PSYCHIATRIC ASSOCIATION

2004 ANNUAL MEETING

Dissolving the Mind-Brain Barrier

Psychotherapy and Psychopharmacology:



New York, NY ■ May 1-6, 2004

2004 SCIENTIFIC PROGRAM COMMITTEE



Seated (left to right): Drs. Muskin, Goldfinger, Taylor, Jayaram (*Chairperson*), Judge (*Vice Chairperson*), Pandya, Ordonica, McDowell. **2ndst Row Standing (left to right):** Drs. Blinder, Pandurangi, D'Alli, Goldstein, Stabinsky, Gabbard, Horton, MacKenzie, Rothschild, Crone, Cheong, LeMelle, Foulks, Worley, Casey. **Not Pictured:** Drs. Anderson, Baker, Baron, Chou.

May 1, 2004

Dear Colleagues and Guests:

Welcome to the 157th Annual Meeting of the American Psychiatric Association. The coming week will highlight the best in our profession in the largest psychiatric meeting in the world. Our meeting has become an outstanding international forum to discuss the latest scientific advances and traditional humane values in psychiatry and how we will continue to integrate these bodies of knowledge to provide excellent patient care.

This year's Annual Meeting theme is "Psychotherapy and Psychopharmacology: Dissolving the Mind-Brain Barrier." Many sessions throughout the week will highlight important aspects of the theme. In addition, please make a special effort to attend the Presidential Symposia, from 2:00-5:00 p.m., on Monday, Tuesday, and Wednesday. On Tuesday evening, a special Presidential Forum will be presenting with the showing of the extraordinary film, "I Am Sam." An entire track of sessions, presented in collaboration with the National Institute on Drug Abuse have been scheduled throughout the meeting.


I join our colleagues from North America in greeting the thousands of colleagues from other parts of the world who have joined us in New York. At the Opening Session, from 5:00 p.m.-6:30 p.m., on Sunday, we will officially welcome the leaders from psychiatric societies in the U.S. and around the world. I will present my Presidential Address, and I look forward to seeing you there.

Please also make sure to attend the Convocation of Distinguished Fellows on Monday night at 5:30 p.m., where we will honor all those being inducted as fellows and distinguished fellows and many receiving awards from APA. The William C. Menninger Memorial lecture will be presented by the distinguished writer, Tom Wolfe.

Organizing a meeting like ours represents the best in collaboration between our members and our staff. Special congratulations go to Dr. Geetha Jayaram and the members of the Scientific Program Committee and to the APA staff who work on the Annual Meeting.

Welcome to New York.

Sincerely,



Marcia Kraft Goin, M.D.
APA President



American Psychiatric Association

1000 Wilson Boulevard
Suite 1825
Arlington, VA 22209-3901
Telephone: 703.907.7822
Fax: 703.907.1090
E-mail: apa@psych.org

May 1, 2004

157th Annual Meeting New York, NY May 1-6, 2004

President

Marcia Kraft Goin, M.D.

Scientific Program Committee 2003-2004

Geetha Jayaram, M.D., *Chairperson*
Sheila Judge, M.D.
Vice-Chairperson
Tanya Anderson, M.D.
Robert W. Baker, M.D.
David A. Baron, D.O.
David A. Casey, M.D.
Joseph A. Cheong, M.D.
Catherine C. Crone, M.D.
Richard E. D'Alli, M.D.
Leslie A. Horton, M.D.
Stephanie LeMelle, M.D.
Philip R. Muskin, M.D.
Patricia I. Ordorica, M.D.
Anand Pandya, M.D.
Anthony J. Rothschild, M.D.
Harvey Stabinsky, M.D.
David H. Taylor, M.D.
Linda L.M. Worley, M.D.

Consultants

Barton J. Blinder, M.D.
James C. Chou, M.D.
Edward Foulks, M.D.
Glen O. Gabbard, M.D.
Marion Z. Goldstein, M.D.
K. Roy MacKenzie, M.D.
David M. McDowell, M.D.
Ananda K. Pandurangi, M.D.

Committee on Commercial Support

Stephen M. Goldfinger, M.D.
Chairperson

Annual Meetings Department

Cathy L. Nash, *Director*
(703) 907-7822
Hope Ball-Mann
Registrar
(703) 907-7810
Vernetta V. Copeland
Associate Director
(703) 907-7811
Kendra Grant
*Administrator, Commercially-
Supported Activities*
(703) 907-7812
Sharita M. Morse
Scientific Program Coordinator
(703) 907-7807
Elizabeth Rumsey
Administrator, CME Courses
(703) 907-7813
Byron D. Phillips
Scientific Program Coordinator
(703) 907-7379
Catha Stewart
Scientific Program Coordinator
(703) 907-7805
Geraldyn Trujillo
Scientific Program Coordinator
(703) 907-7808

Dear APA Members and Guests:

Welcome to New York, NY, and the 157th Annual Meeting of the American Psychiatric Association. This historic city, with its vibrancy, cultural diversity, and excitement, provides a perfect setting for the scientific presentations we have planned. As you read through the *Program Book*, you will notice a number of sessions related to the theme "Psychotherapy and Psychopharmacology: Dissolving the Mind-Brain Barrier," chosen by our President, Dr. Marcia Kraft Goin. Let me draw your attention to just a few of the many exciting sessions presented this week. One Presidential Symposium will be presented each day on Monday-Wednesday from 2:00 p.m.-5:00 p.m. A Presidential Forum will be held on Tuesday evening where the film, "I Am Sam," will be shown and discussed.

The Business Meeting will be held on Sunday, from 12:30 p.m. to 1:30 p.m.; all voting members are encouraged to attend. The Opening Session will be held on Sunday, from 5:00 p.m. to 6:00 p.m. Exhibits will be open 10:00 a.m. to 4:30 p.m. on Sunday, 10:00 a.m. to 5:30 p.m. on Monday, 10:00 a.m.-6:00 p.m. on Tuesday, and from 10:00 a.m. to 3:00 p.m. on Wednesday. Please note that the Convocation of Distinguished Fellows will begin at 5:30 p.m., on Monday, May 3. Award-winning author, Tom Wolfe, will present the William C. Menninger Memorial Lecture during the Convocation.

The Advances in Research session will be held on Monday at 10:30 a.m. This session highlights the latest research findings in psychiatry and summarizes their relevance to clinical practice. This session has become an excellent way to start off the Annual Meeting's research programs, in conjunction with the Young Investigators' Poster and Oral/Slide Sessions also on Monday. You will find an expanded number of small group sessions, including Discussion Groups; Research Consultations with selected experts in the field; and Master Educator Clinical Consultations, a series of clinically-based seminars with outstanding clinician educators, offered to APA members only. A special series of sessions will be presented in collaboration with the National Institute on Drug Abuse. Please consult the brochure in your registration packet for further information.

You will note in the *Program Book* that we are continuing with an expanded series of noon Forums. This format allows us to schedule sessions that may not fit in the usual formats or that focus on late-breaking topics of importance to the field.

It is extremely important that you fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year's Annual Meeting.

Once again, welcome to New York. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Geetha Jayaram, M.D., M.B.A.
Chairperson
Scientific Program Committee



APA 157th ANNUAL MEETING

New York, NY • May 1-6, 2004

KEY LOCATIONS - JAVITS CENTER

American Journal of Psychiatry	APPI Bookstore, Halls 1A-C, Level 1
Annual Meetings Office	Rooms 1A02/3, Level 1
APA Communications Center	Rooms 1C02/3/4, Level 1
APA Exhibit	Halls 1A-C, Level 1
A/V Preview Room	Room 1B05, Level 1
CME Course Enrollment	North Pavilion, Level 1
Computerized Evaluation	Concourse, Level 2
Daily Bulletin	Rooms 1C02/3/4, Level 1
Education Office	Room 1C05, Level 1
Exhibit Office	North Concourse, Level 2
Exhibits/Publishers' Bookfair	Halls 1A-C, Level 1
Information/Locator Center	North Concourse, Level 2
Internet Village	Concourse, Level 2
Lost & Found	Rooms 1A02/3, Level 1
Message Center	North Concourse, Level 2
On-Site Job Bank and Placement Center	• APA Exhibit, Halls 1A-C, Level 1
Psychiatric Services Registration	APPI Bookstore, Halls 1A-C, Level 1 North Pavilion, Level 1

FIRST AID

Located in Hall 1D Rear Corridor, Level 1, Javits Center. Hours of operation: Tuesday, April 27, through Thursday, May 6, opens one hour prior to show opening and closes one hour after the last event of the evening. Information on emergency services may be found on page VII.

COURTESY SHUTTLE BUS SERVICE

Service will begin on Saturday, May 1, at approximately 7:30 a.m., and will operate daily throughout the meeting commensurate with the scientific program schedule, and will conclude on Thursday, May 6, at 6:00 p.m. The Javits Center will serve as the "hub" for all shuttle bus routes. A detailed Shuttle Bus Schedule will be included in each registration packet and posted in the lobbies of participating hotels. Refer to the city map on page VI for the location of hotels in relation to Javits Center.

EXHIBITS

Commercial and educational exhibits are located in Halls 1A-C, Level 1, Javits Center, along with the Publishers' Bookfair. As a convenience to registrants, the Publishers' Bookfair opens on Saturday, 10:00 a.m.-5:00 p.m. Hours for commercial and educational exhibits: Sunday, 10:00 a.m.-4:30 p.m.; Monday, 10:00 a.m.-5:30 p.m.; Tuesday, 10:00 a.m.-6:00 p.m., and Wednesday, 10:00 a.m.-3:00 p.m. All exhibits will close on Wednesday at 3:00 p.m. Please refer to the *APA Exhibits Guide* for additional information on participating companies. APA periodicals will be located in the APPI Bookstore.

INFORMATION/LOCATOR CENTER

Located on the North Concourse, Javits Center and staffed during registration hours (with the exception of Thursday, May 6, when the Center will be open until 5:00 p.m.). Up-to-date general information about the program, component meetings, the local area, and the locations of various activities and events can be obtained there. Meeting participants can also find out where colleagues who are registered for the meeting are staying.

MESSAGE CENTER

Located on the North Concourse, Javits Center and staffed during registration hours. Messages can be left and picked up at the Message Center. Message monitors will be strategically located in the Exhibit Hall and elsewhere in Javits Center. Registrants whose names appear on these monitors should pick up their messages at the Message Center.

AMERICAN PSYCHIATRIC ASSOCIATION EXHIBIT

Located in Halls 1A-C, Level 1, Javits Center, along with the Publishers' Bookfair. Hours of operation will be: Saturday, 10:00 a.m.-5:00 p.m.; Sunday, 8:00 a.m.-4:30 p.m.; Monday, 10:00 a.m.-5:30 p.m.; Tuesday, 10:00 a.m.-6:00 p.m.; and Wednesday, 10:00 a.m.-3:00 p.m. A few of the many APA activities exhibited include: membership, APA's internet-based programs, continuing medical education, quality improvement, psychiatric services, clinical resources, advocacy tools, career development, and APA Periodicals.

APA JOB BANK

Located in the APA Resource Center and open during the Center's hours of operation. Visit the APA on-site Job Bank at APA 2004! The online APA Job Bank will power the popular on-site Job Bank providing improved tools for both employers and candidates at the APA's Annual Meeting. Candidates and employers are encouraged to activate their resume and job postings in advance of the meeting for best results. For more information on the Job Bank, visit www.psych.org/jobbank.

APA COMMUNICATIONS OFFICE/PRESS OFFICE

Located in Rooms 1C02/3/4, Level 1, Javits Center. Hours of operation: Saturday, 12 noon-5:00 p.m.; Sunday-Wednesday, 8:00 a.m.-6:00 p.m.; and Thursday, 8:00 a.m.-11:00 a.m.

The Press Office is for the use of registered press only.

DAILY BULLETIN

The *Daily Bulletin* accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off in Rooms 1C02/3/4, Level 1, by 12 noon prior to the date of publication.

RESIDENTS' RESOURCE CENTER

Located in the Versailles Terrace, Second Floor, Sheraton New York. The Residents' Resource Center will be open from 7:00 a.m. to 6:00 p.m., Sunday, May 2, through Wednesday, May 5. Daily activities are scheduled for residents (such as the Residents Only Discussion Groups and Resident Summits) and for medical students as well. Meet and network with leaders in psychiatry and your colleagues. Resources specifically for residents and medical students available are available here.

WOMEN'S RESOURCE CENTER

The Center will be open from 7:00 a.m. to 5:00 p.m., Sunday, May 2, and Monday, May 3. The Center is located in Javits Center. On Sunday, in Room 1D06, Level 1, and on Monday in Room Room 2D16, Level 2. This is an informal networking Center with some workshops on topics such as "passing the boards."

CENTER FOR INTERNATIONAL GUESTS

Due to a lack of funding, we regret we are unable to provide an International Visitor Center this year.

BUSINESS CENTERS

Javits Center: Location: Mail Boxes, Etc., Crystal Palace (202-244-3744)
Times of operation: Open during show hours

Marriott: Location: 8th Floor (to the far left of the hotel check-in counters)
Times of operation: Saturday: 8:15 a.m.-6:00 p.m.; Sunday: 9:15 a.m.-7:00 p.m.; Monday-Friday: 6:30 a.m.-10:30 p.m.

Hilton: Location: 2nd Floor (behind the elevators)
Times of operation: Saturday-Sunday: 7:00 a.m.-7:00 p.m.; Monday-Friday: 7:00 a.m.-9:00 p.m.;

REGISTRATION

ADMISSION TO ALL SESSIONS BY REGISTRATION BADGE

Located in the North Pavilion, Level 1, Javits Center. Hours of operation: Saturday, 10:00 a.m.-5:00 p.m.; Sunday, 7:30 a.m.-5:00 p.m.; Monday, 7:30 a.m.-5:30 p.m.; Tuesday, 7:30 a.m.-6:00 p.m.; Wednesday, 7:30 a.m.-5:00 p.m.; and Thursday, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:

APA MEMBERS

Full-Time Registration (<i>North American Members</i>)	\$275.00
Full-Time Registration (<i>International Members</i>)	\$425.00
Members-in-Training (<i>Member Class MT</i>)	\$ 75.00
Daily Registration (<i>North American Members</i>)	\$140.00
Daily Registration (<i>International Members</i>)	\$215.00
Medical Students	no charge

NONMEMBERS

Full-Time Registration	\$790.00
Nonmember Residents, Students, Advocacy Group Members, or Mental Health Chaplains	95.00
Daily Registration (<i>all "Nonmember" categories</i>)	400.00
Medical Students	no charge

GUEST REGISTRATION

One only per full-time registrant 100.00
Only one guest is allowed to register with each full-time meeting registrant. *The guest must reside in the same household and be able to receive mail at the same address. APA members cannot register as a "guest"; they must register as an APA member.*

One-Day **Exhibit Hall Only** Pass (18 and older) 10.00
(Only **paid** registrant can purchase an exhibit hall pass)

On-site fees can be paid by cash, check, money order, American Express, VISA or MasterCard. Registration fees are waived only for *CME Course Faculty, APA Honorary Fellows (does not include APA Distinguished Fellows/Fellows/Life Fellows/Distinguished Life Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day(s) they present).*

NONMEMBER PSYCHIATRIC RESIDENTS AND OTHER FULL-TIME STUDENTS must present documentation to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

Note: There are no exemptions or reduced fees available for CME courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the *Program Book, APA Exhibits Guide, and New Research Program and Abstracts Books*, and for most categories, a copy of the *Syllabus*.

NAME BADGES

Badges are required for all sessions including the Opening Session and exhibit area. Only an APA member badge will admit you to the Business Meeting.

Badge Color Codes: Blue-Members, Yellow-Nonmembers, Silver-Press, Red-Exhibitors, Green-APA Staff, and White-Temporary Javits Personnel.

Registered exhibitors will receive red badges, which allow access only to his/her own booth in the exhibit hall and to ride the shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

CME COURSE ENROLLMENT TICKET PURCHASE REQUIRED FOR CME COURSES

Located in the North Pavilion, Level 1, Javits Center. Hours of operation are the same as registration. Tickets for CME Courses not sold by April 3 will be on sale to all registrants beginning at 10:00 a.m. on Saturday, May 1. You must show your registration badge before you can enroll in courses.

APA ART ASSOCIATION

Located in the Registration Area and staffed during the Resource Center's hours. The exhibit includes paintings, photography, ceramics, and crafts done by APA members and/or their significant others. Please stop by the exhibit for information on joining the APA Art Association.

APA AUXILIARY BOOTH

Located on the North Concourse, Level 2, Javits Center. Hours of operation: Saturday, May 1, through Wednesday, May 5, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Auxiliary's program schedule and information on membership.

APA PERIODICALS

Complimentary copies of the latest issues of *The American Journal of Psychiatry, Psychiatric Services, Academic Psychiatry, The American Journal of Geriatric Psychiatry, The Journal of Neuropsychiatry and Clinical Neuroscience, Psychosomatics*, and APA's new CME journal, *Focus*, may be obtained at the APA/APPI Periodicals Exhibit in the APPI Bookstore. Complimentary copies of *Psychiatric News* will be available at stands located throughout Javits Center. Staff will sell discounted subscriptions to all APA/APPI journals, demonstrate online access for subscribers, answer questions regarding submissions, and show authors and reviewers how to use Manuscript Central, the new Web-based manuscript submission and review system. Persons who wish to contact editors or reporters of *Psychiatric News* are asked to leave a message on the message board in the Annual Meetings Office. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper's consideration may be left with staff at the Periodicals Exhibit.

AUDIOTAPES

Audiotapes of most sessions are available shortly after each session concludes and may be purchased at the Mobiltape Booth located on the North Concourse, in Javits Center.

CONTINUING MEDICAL EDUCATION

Educational Objectives: At the conclusion of this meeting, participants will be able to:

- Better understand new research findings in the fields of psychiatry and neuroscience;
- Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
- Identify and remove barriers to the transfer of new knowledge for their practice, including provision of culturally competent care for diverse populations;
- Assess a variety of treatment choices, including psychotherapeutic and pharmacological options; and
- Better understand mental health service delivery issues, including barriers to care.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 66 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for category 1 CME credit. Sessions in the following program

formats are designated as category 1: Advances in Psychopharmacology, Advances in Research, Clinical Case and Continuous Clinical Case Conferences, CME Courses, Focus Live, Forums, Industry-Supported Symposia, Lectures, Medical Updates, New Research Oral/Slide Sessions, Research Advances in Medicine, Presidential Symposia, Review of Psychiatry, Scientific and Clinical Reports, Symposia, and Workshops. Other program activities may be reported as category 2: Debate, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, and Research Consultations. Scientific sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

PLEASE NOTE: APA MEMBERS ARE REQUIRED TO MAINTAIN THEIR OWN RECORDS OF CME HOURS. REPORTING OF CME CREDIT IS ON AN HONOR BASIS.

To document CME credit earned at the Annual Meeting, participants should record the sessions they attended on the *Certificate of Attendance* log sheet found in the front of the *2004 Annual Meeting CME Syllabus & Proceedings Summary Book*. Credit is earned on an hour-for-hour basis. A parchment *Certificate of Attendance* is also available.

The *Certificate of Attendance* (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires members to participate in a total of 150 hours of CME activities within a three-year reporting period. At least 60 hours must be in category 1 activities.

CME report forms may be obtained from the Department of CME at the APA or online at www.psych.org. Staff will be available in the APA Resource Center to answer any of your questions about CME.

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year's Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. **BEFORE YOU LEAVE THE MEETING, PLEASE COMPLETE YOUR FORM AND DROP IT IN ONE OF THE EVALUATION BOXES LOCATED THROUGHOUT THE MEETING SITES.** You can receive a parchment *Certificate of Attendance* at the Annual Meeting by returning your completed form (to the Annual Meetings Office, Information/Locator Center, or APA Exhibit, all located in Javits Center) or by completing the computerized general evaluation on the Concourse, Level 1, in Javits Center.

SESSION CAPACITY

So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

- Please find seating as far forward as possible.
- Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
- Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
- If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use and by members of the media. Registrants are welcome to use their own small, portable audiotape recorders to record any session **except the Master Educator Clinical Consultations, Clinical Case Conferences, and the Continuous Clinical Case Conference, or unless prohibited by the presenters.** Larger professional tape recorders, however, are not permitted other than those utilized by members of the media and personnel representing the professional taping firm authorized by APA to audiotape sessions. The badges of personnel representing this firm and members of the media will clearly identify them. **Non-media registrants are not permitted to videotape any session** because the intrusive nature of the recording may disrupt the session. More detailed guidelines for media representatives may be obtained in the Press Office.

SMOKING POLICY

There will be **NO SMOKING** in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.



GUIDE TO THE PROGRAM BOOK

On page V, you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. **NOTE: To make it easier for you to plan your day, we have prepared a separate "Days-at-a-Glance," which is included in your registration packet.**

If you have any questions about this book or the scientific sessions, please feel free to stop by the Annual Meetings Office in Javits Center, and we will be glad to help you. Also, all central office APA staff members will be wearing green badges. Please feel free to direct your questions to them.

FUTURE APA MEETINGS

APA ANNUAL MEETINGS

2005 May 21-26	Atlanta, GA
2006 May 20-25	Toronto, Ont., Canada

INSTITUTES ON PSYCHIATRIC SERVICES

2004 October 6-10	Atlanta, GA
2005 October 5-9	San Diego, CA
2006 October 6-10	New York, NY

Tentative program schedules and hotel information for the 2004 Institute on Psychiatric Services are available at the Information/Locator Center, located on the North Concourse, Javits Center.

TABLE OF CONTENTS


Floor Plans for Javits Center, New York Hilton, and Marriott Marquis	VI-XV
City Map.....	XVI
Local Information.....	XVII
Special Acknowledgments	XVIII-XX
Audiotape Sales Information	XXI
Format Descriptions.....	XXII-XXIII
Disclosure Information.....	XXIV-XXXIX
Saturday Sessions.....	1-4
Sunday Sessions	5-12
Monday Sessions	13-40
Tuesday Sessions	41-67
Call for 2005 Annual Meeting Papers	68
Wednesday Sessions	69-92
Thursday Sessions	93-106
Topic Index	107-121
Participant Index	122-134
Call for 2005 Annual Meeting Papers	135
Audiotape Sales Information	136
2004 Institute on Psychiatric Service	137
American Psychiatric Publishing Inc.	138-139
Industry-Supported Symposia.....	140-166
APA Exhibit	Back Cover

Refer to the *APA Exhibits Guide* for information on: Exhibits, Publishers' Bookfair, and Dining Facilities in Javits Center.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.


© American Psychiatric Association.

Getting Around the Javits Center




Javits Convention Center

LEVEL 1




Javits Convention Center


A Meeting Rooms




B Meeting Rooms




C Meeting Rooms



D Meeting Rooms





E Meeting Rooms



Javits Convention Center

Level 3


Level 2




Hilton New York

1335 Avenue of the Americas, New York, NY 10019
212-586-7000

Concourse Level




2nd Floor




Hilton New York

3rd Floor




4th Floor




Marriott Marquis

1535 Broadway, New York, NY 10036
212-398-1900


Fourth Floor




Marriott Marquis Westside Ballroom, Fifth Floor




Marriott Marquis Broadway Ballroom, Sixth Floor



Marriott Marquis Seventh Floor



New York City Map



- | | | |
|---------------------------------------|--------------------------------------|------------------------|
| AQ Algonquin | IB Inter-Continental The Barclay | RR Rihga Royal |
| BV Belvedere | LP Le Parker Meridien | RO Roosevelt |
| BW Best Western Convention Center | ME Marriott East Side | RY Royalton |
| CE Courtyard by Marriott East Side | MQ Marriott Marquis | SH Sheraton Manhattan |
| CY Courtyard by Marriott Times Square | MF Mayflower on the Park | ST Sheraton NY Hotel |
| CP Crowne Plaza Times Square | MI Milford Plaza | SG Southgate Tower |
| DB Doubletree Guest Suites | MB Millennium Broadway | TI The Time |
| GH Grand Hyatt | MU The Muse | TR Travel Inn |
| HI Hilton New York | NH New York Helmsley Square | WN W New York |
| HB Holiday Inn Martinique on Bway | NP New York Palace | WT W Times Square |
| HM Holiday Inn Midtown 57th | NR New York Renaissance Times Square | WA Warwick Hotel |
| HP Hotel Pennsylvania | NY New Yorker Hotel | WE Wellington |
| HU Hudson | NO Novotel New York | WS Westin Times Square |
| | PC Park Central | |

LOCAL INFORMATION

New York City is the Capital of the World. It's a magnet for meetings, because there's something for everyone: for high-rollers and the budget-conscious, art aficionados and sports fans, lovers of show tunes and lovers of Wagner. It's a city of architectural treasures and gorgeous parks, and it's easy to get to. New York is a city of over nine million people covering 301 square miles. New York City is made up of five distinct boroughs: Manhattan (where the vast majority of sights are located), the Bronx, Queens, Brooklyn, and Staten Island. Many of New York's oldest and newest buildings rub shoulders in Lower Manhattan. It is from here, too, that you can take the Staten Island ferry for breathtaking views of the famous skyline and the Statue of Liberty. The Theater District and Midtown offer Fifth Avenue's glittering shops as well as museums, entertainment, and such landmark skyscrapers as the glorious Chrysler Building. Museum Mile on the Upper East Side is a cultural paradise, and since it runs alongside Central Park, you can rest en-route and watch New Yorkers at play.

ACCESSIBILITY

Buses and trains have individual travel passes there is no joint travel pass. Avoid buses, taxis, and the subway during rush hour; walk instead.

Taxi stands are scarce: Hotels, Penn Station, and Grand Central Terminal are the best places to find one, or hail one in the street. All licensed taxi cabs are yellow, available when roof numbers are lit up.

The subway is open 24 hours a day, full service between 6:00 a.m. and midnight.

AIRPORT TRANSPORTATION

From JFK, Queens, NY

Distance to midtown = 25 miles

Means of transportation:

Yellow medallion taxi = \$35
Private car service = \$25 - \$150
Public bus (MTA) = \$2.00
Subway (MTA) = \$2.00
Shuttle services = \$13 - \$19

From LaGuardia, Queens, NY

Distance to midtown = 8 miles

Means of transportation:

Yellow medallion taxi = \$16 - \$26
Private car service = \$25 - \$130
Public bus (MTA) = \$2.00
Subway (MTA) = \$2.00
Shuttle services = \$10 - \$15

TAXI COMPANIES

New York City Taxi & Limousine Commission regulates the city's famous yellow fleet of 12,187 licensed medallion taxis. Within the city, taxis cruise the streets looking for passengers. Taxi stands are at many hotels and transportation terminals. Yellow medallion taxis are the only vehicles authorized to pick up street hails. One fare covers all passengers: cabs need not be shared. Fare begins at \$2.00, and then increases 30¢ for each fifth of a mile (or 90 seconds of waiting time). Nightly 50¢ surcharge 8:00 p.m.-6:00 a.m.

TOURS/VISITOR INFORMATION

APA has contracted with a company to provide a limited number of local tours. Detailed information may be viewed and you may sign up for tours by going to the APA website (www.psych.org) and clicking on the direct link to the tour company.

FOREIGN CURRENCY EXCHANGE

American Express at Bloomingdales, 59th Street and Lexington Avenue (10:00 a.m.-6:00 p.m.).

Chequepoint USA, 1568 Broadway, 8:00 a.m.-11:30 p.m.

Harold Reuter & Co.; Grand Central Station, 7:00 a.m.-7:00 p.m., Monday-Friday, 8:00 a.m.-3:00 p.m., Saturday and Sunday.
Kara International, 12225 Broadway, Suite 813, 9:00 a.m.-6:00 p.m., Monday-Friday, 9:00 a.m.-3:30 p.m., Saturday.

Thomas Cook, 1590 Broadway, 9:00 a.m.-7:00 p.m., Monday-Saturday.

MEDICAL EMERGENCIES

NY Hotel Urgent Medical Services/Travelers Medical Center
952 Fifth Avenue (76th - 77 Streets), # 1D, NYC 10021. Telephone: (212) 737-1212. Contact Sheila Martinez. Medical/dental services 24 hours for house calls or at urgent/care center, provided by caring, board-certified doctors.

APA GOLF TOURNAMENT

The Golfers of the APA (GAPA) invite you to participate in their 2004 golf tournament to benefit the American Psychiatric Foundation. The tournament is scheduled for Monday, May 3, 2004, at Cherry Creek Golf Links. This is a scenic links-style course with rolling fairways and elevated tees and greens situated in Riverhead on the eastern end of Long Island. The course, designed by Charles Jurgens can stretch to 7,187 yards with a par of 73 and the fairways are generous and long with water coming into play on four of the holes. If you are interested in registering for this event, please contact W. Stanley Jennings, Jr., M.D., at 804-320-7881, by email at wsjennings@tuckerpsychiatric.com or mbears@comcast.net or by mail, W.S. Jennings, Jr., M.D., 7149 Jahnke Road, Richmond, VA 23225.

TOP TEN NY RESTUARANTS (212-)

Café des Artistes, 1 W 67th St., 877-3500
Florent, 69 Gansevoort St., 989-5779
The Four Seasons, 99 E. 52nd St., 754-9494
Golden Unicorn, 18 E. Broadway, 941-0911
Hatsuhana, 17 E. 48th St., 355-3345
Lespinasse, St. Regis Hotel, 2 E. 55th St., 339-6719
Oyster Bar, Grand Central Terminal, Grand Central Station, Lower Level, 490-6650
The Rainbow Room, 65th Floor, GE Building, 30 Rockefeller Plaza, 632-5000
Union Square Café, 21 E. 16th St., 243-4020
Zen Palate, 663 9th Ave., 582-1669

BROADWAY THEATERS (212-)

Ambassador, 215 W. 49th St., 239-6200
Barrymore, 243 W. 47th St., 239-6200
Belasco, 111 W. 44th St., 239-6200
Booth, 222 W. 45th St., 239-6200
Broadhurst, 235 W. 44th St., 239-6200
Broadway, 1681 Broadway, 239-6200
Brooks Atkinson, 256 W. 47th St., 307-4100
Cort, 138 W. 48th St., 239-6200
Eugene O'Neill, 230 W. 49th St., 239-6200
Gershwin, 222 W. 51st St., 307-4100
John Golden, 252 W. 45th St., 239-6200
Helen Hayes, 240 W. 44th St., 307-4100
Imperial, 249 W. 45th St., 239-6200
Longacre, 220 W. 48th St., 239-6200
Lunt-Fontanne, 205 W. 46th St., 307-4100
Lyceum, 149 W. 45th St., 239-6200
Majestic, 245 W. 44th St., 239-6200
Marquis, 211 W. 45th St., 307-4100
Martin Beck, 302 W. 45th St., 239-6200
Minskoff, 200 W. 45th St., 307-4100
Music Box, 239 W. 45th St., 239-6200
Nedelander, 208 W. 41st St., 307-4100
Neil Simon, 250 W. 52nd St., 307-4100
Palace, 1564 Broadway, 307-4100
Plymouth, 236 W. 45th St., 239-6200
Richard Rodgers, 226 W.46th St., 307-4100
Roundabout, 1530 Broadway, 869-8400
Royale, 242 W. 45th St., 239-6200
St. James, 246 W. 44th St., 239-6200
Shubert, 225 W. 44th St., 239-6200

SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

Abbott Laboratories: support of the Industry-Supported Symposia, "Combination Therapy: New Strategies in the Management of Severe Mental Disorders," Sunday, May 2, 1:30 p.m.; and "Challenges in Treating Bipolar Illness and Comorbid Disorders," Tuesday, May 4, 7:00 p.m.;

American Academy of Psychiatry and the Law: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 2, 2:30 p.m.

American Association of Psychiatric Administrators: co-support of the Administrative Psychiatry Award Lecture, Wednesday, May 5, 11:00 a.m.

American Psychiatric Foundation: support of the Disaster Psychiatry Fellowship; and the APIRE Practice Research Network (PRN).

Association of Mental Health Clergy: co-support of the Oskar Pfister Award Lecture, Tuesday, May 4, 11:00 a.m.

Association of Women Psychiatrists: support of the joint AWP/APA Women's Career reception and meeting.

AstraZeneca Pharmaceuticals: support of the Industry-Supported Symposia, "The Role of Dopamine in Health and Illness: Science to Practice," Saturday, May 1, 6:00 p.m.; "Broadening the Horizon of Atypical Antipsychotic Applications," Sunday, May 2, 8:00 a.m.; and "Choosing the Right Dose of Atypical Antipsychotics: Art or Science?," Sunday, May 2, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Transcending Efficacy: Effective Treatment of Psychosis Across Disorders" Monday, May 3, and Tuesday, May 4, 7:00 a.m.; the APA/AstraZeneca Minority Fellowship and reception, Monday, May 3, 8:00 p.m.; the American Psychiatric Foundation "Conversations" event, Tuesday, May 4, 5:30 p.m.; the APIRE/AstraZeneca Young Minds in Psychiatry Award; and the AstraZeneca Young Minds and Minority Fellows Poster Session, Monday, May 3, 7:00 p.m.

Aventis: support of the Travel Fellowship for Women Resident Leaders in Psychiatry and Leadership Luncheon, Sunday, May 2, 12 noon.

Bristol-Myers Squibb Company: support of the Industry-Supported Symposia, "Effective Long-Term Management of Schizophrenia: Real-World Considerations," Sunday, May 2, 7:00 p.m.; "BPD: Regulation of Affect and Impulse Control," Monday, May 3, 7:00 p.m.; and "Optimizing Antipsychotic Treatment in Patients With Schizophrenia and Bipolar Disorder," Wednesday, May 5, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "New Advances in the Treatment of Psychosis," Monday, May 3, and Tuesday, May 4, 7:00 a.m.; the APA's Solomon Carter Fuller Award Lecture, Monday, May 3, 2:00 p.m.; and the Reception for the Solomon Carter Fuller Award Recipient.

Bristol-Myers Squibb Sweden: support of the Luncheon for U.S. and International Residents, "Patients Who Want to Die: Are they Suicidal and Where Do They Fit Into DSM?" Sunday, May 2, 12 noon.

Center for Mental Health Services: support of the APIRE Practice Research Network (PRN); and the APA's HIV-related education programs and materials.

Center for Substance Abuse Treatment: support of the APIRE Practice Research Network (PRN).

Cephalon, Inc.: support of the Industry-Supported Symposia, "Towards DSM-V: Phenomenology, Neurobiology, and Treatment Response in Depression," Saturday, May 1, 12:30 p.m.; "Targeting Executive Dysfunctions for Treatment," Sunday, May 2, 8:00 a.m.; and "Back to the Future: The Role of Gamma-Aminobutyric Acid in Psychiatric Disorders and Treatment," Wednesday, May 5, 7:00 p.m.; and the Industry-Supported Breakfast Symposium, "PTSD: Searching for Answers in Traumatic Times," Wednesday, May 5, and Thursday, May 6, 7:00 a.m.

Cyberonics, Inc.: support of the American Psychiatric Foundation "A Toast to New York" benefit event, Monday, May 3, 7:00 p.m.

Eisai, Inc., Pfizer Inc.: support of the Industry-Supported Symposium, "Novel Intervention Strategies Across the Spectrum of Dementia: Real Patients and Real Outcomes," Sunday, May 2, 7:00 p.m.

Eli Lilly and Company: support of the Industry-Supported Symposia, "Adult ADHD: Clinical Utility and Validity," Saturday, May 1, 12:30 p.m.; "Bipolar Disorder: Improving Outcomes When Theory, Science, and Clinical Practice Converge," Saturday, May 1, 6:00 p.m.; and "Recovering From Schizophrenia: How Treatment Can Improve Outcomes and Prevent Chronicity," Sunday, May 2, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Recognizing the Many Faces of Bipolar Disorder," Monday, May 3, and Tuesday, May 4, 7:00 a.m.; partial support of the Simon Bolivar Award Lecture, Wednesday, May 5, 9:00 a.m.; and support of the APA/Lilly Resident Research Awards.

Eli Lilly and Company, Boehringer-Ingelheim Pharmaceuticals, Inc.: support of the Industry-Supported Symposium, "Plotting a Course to Remission: Navigating the Intersection of Mind, Brain, and Body," Monday, May 3, 7:00 p.m.

Estate of Agnes Purcell McGavin: support of the Agnes Purcell McGavin Award for Distinguished Career Achievement in Child and Adolescent psychiatry.

Forest Laboratories, Inc.: support of the Industry-Supported Symposia, "From Pathology to Practice: Evolving Therapeutic Strategies for Alzheimer's Disease," Sunday, May 2, 8:00 a.m.; "Moderators and Mediators of Antidepressant Response," Sunday, May 2, 7:00 p.m.; and "Panic Anxiety: Understanding Its Nature and Nurturing Recovery," Tuesday, May 4, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Current Alzheimer's Disease Treatments and Beyond: Advances Impacting Clinical Practice,"

SPECIAL ACKNOWLEDGMENTS

Monday, May 3, and Tuesday, May 4, 7:00 a.m.; the American Psychiatric Foundation "A Toast to New York" benefit event, Monday, May 3, 7:00 p.m.; and the registration portfolios.

GlaxoSmithKline: support of the Industry-Supported Symposia, "Preventive Psychiatry in Mood Disorders: A New Frontier," Saturday, May 1, 12:30 p.m.; "Sex, Sexuality, and 5HT," Saturday, May 1, 6:00 p.m.; "The Hidden Faces of Anxiety," Sunday, May 2, 8:00 a.m.; "Psychopharmacology and Reproductive Transitions: Impact of Psychotropic Medications and Sex Hormones on Brain Functioning, Weight, and Reproductive Safety," Sunday, May 2, 7:00 p.m.; and "Does the Pharmacology of Antidepressant Drugs Matter?" Tuesday, May 4, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Bipolar Disorder in Women: Reproductive Implications of Treatment," Wednesday, May 5, and Thursday, May 6, 7:00 a.m.; the APA/GlaxoSmithKline Fellowship Program and reception; the annual contribution to the APA Presidential Fund; the APA/GlaxoSmithKline Young Faculty Award for Research Development in Biological Psychiatry; the APIRE/GlaxoSmithKline Severe Mental Illness Fellowship; and the American Psychiatric Foundation "A Toast to New York" benefit event, Monday, May 3.

Gralnick Foundation: support of the Alexander Gralnick, M.D., Award for Research in Schizophrenia.

Harding Foundation: co-support of the Oskar Pfister Award Lecture, Tuesday, May 4, 11:00 a.m.

Ittleson Foundation: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Janssen Pharmaceutica and Research Foundation: support of the Industry-Supported Symposia, "Treatment Resistance: Concepts and Management in Mood and Anxiety Disorders," Saturday, May 1, 12:30 p.m.; and "Unmasking Bipolar Disorder: Overcoming the Barriers to Treatment Success," Sunday, May 2, 1:30 p.m.; the Committee of Asian-American Psychiatrists recruitment reception; and the American Psychiatric Institute for Research and Education/Janssen Research Scholars on Severe Mental Illness Program.

Johnson & Johnson: support of an unrestricted educational grant to support international activities.

Lilly Research Laboratories, a Division of Eli Lilly & Company: support of the APA/Lilly Psychiatric Research Fellowship.

Merck & Co., Inc.: support of the Industry-Supported Symposium, "Beyond 5HT: New Treatments for Depression," Sunday, May 2, 1:30 p.m.; and the William C. Menninger Memorial Convocation Lecture, Monday, May 3, 5:30 p.m.; and the APA/Merck & Co., Inc., Early Academic Career Research Award.

National Institute of Mental Health: co-support of the APA/NIMH Vestermark Psychiatry Educator Award Lecture, Wednesday, May 5, 2:00 p.m.; support of the American Psychiatric Institute for Research in Education (APIRE) Annual Meeting activities for research trainees; the Program for Minority Research Training in Psychiatry (PMRTP); and the Research Colloquium for Junior Investigators.

National Institute on Drug Abuse: support of the special Annual Meeting series, "Integrating the Science of Addiction into Psychiatric Practice"; the American Psychiatric Institute for Research and Education/Research Training activities; and the Drug Abuse Research Scholars in Psychiatry Program (DARSPP).

Neurocrine Biosciences Inc.: support of the Industry-Supported Symposium, "Exploring the True Morbidity of Insomnia," Tuesday, May 4, 7:00 p.m.

Novartis Pharmaceuticals Corporation: support of the Industry-Supported Symposium, "Reaching Beyond Alzheimer's Disease With Cholinergic Therapy," Monday, May 3, 7:00 p.m.

Organon Inc.: support of the Industry-Supported Symposium, "Antidepressant Treatments You May Not Know About, But Should..." Sunday, May 2, 8:00 a.m.

Ortho-McNeil Pharmaceuticals: support of the Industry-Supported Symposia, "Bipolar Disorder and Alcoholism: Diagnostic Challenges and Therapeutic Interventions," Saturday, May 1, 12:30 p.m.; "Impulsivity: Emerging Clinical Perspectives," Saturday, May 1, 6:00 p.m.; and "Binge-Eating Disorder: Genes, Treatments, and Consequences," Tuesday, May 4, 7:00 p.m.

Otsuka America Pharmaceutical, Inc.: support of the International Medical Graduates (IMG) Caucus Reception; the Minority Mental Health Awards; and the American Psychiatric Foundation "A Toast to New York" benefit event, Monday, May 3, 7:00 p.m.

Pfizer Inc.: support of the Industry-Supported Symposia, "GAD: Evidence-Based Considerations From Pathophysiology to Long-Term Management," Saturday, May 1, 6:00 p.m., "The Many Faces of Anxiety: Origins, Pathogenesis, and Management," Sunday, May 2, 8:00 a.m.; and "Are All Atypical Antipsychotics Equal for Treatment of Cognitive and Affective Symptoms in Schizophrenia?" Sunday, May 2, 1:30 p.m.; partial support of the Simon Bolivar Award Lecture, Wednesday, May 5, 9:00 a.m.; support of the Residents' Session, "Meet the Experts: Sunny-Side Up," Monday, May 3, 7:00 a.m.; the "Abstracts-On-Disk" Program; and the APA *Daily Bulletin* newspaper.

Professional Risk Management Services, Inc.: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 2, 2:30 p.m. and the American Psychiatric Foundation "A Toast to New York" benefit event, Monday, May 3, 7:00 p.m.

Reckitt Benckiser Pharmaceuticals: support of the Industry-Supported Symposium, "Pharmacotherapy of Addictions: From Clinics Into Office Practice," Monday, May 3, 7:00 p.m.

SPECIAL ACKNOWLEDGMENTS

Roche Laboratories: support of the Industry-Supported Symposium, "Interferon-Induced Depression: Consequences of Treating Chronic Hepatitis C," Monday, May 3, 7:00 p.m.; and the Benjamin Rush Award Lecture, Monday, May 3, 9:00 a.m.

Sanofi-Synthelabo, Inc.: support of the Residents, Medical Students, and Training Directors Luncheon, Sunday, May 2, 12 noon and the American Psychiatric Foundation "A Toast to New York" benefit event, Monday, May 3, 7:00 p.m.

Sepracor, Inc.: support of the Industry-Supported Symposium, "Beyond Sleep Onset: New Perspectives on the Treatment of Insomnia," Sunday, May 2, 7:00 p.m.; and shuttle bus system.

Shire US, Inc.: support of the Industry-Supported Symposia, "Conceptualizing and Treating ADHD Adults," Monday, May 3, 7:00 p.m.; and "Adult ADHD Diagnosis and Treatment," Tuesday, May 4, 7:00 p.m.; and the nine APA/Shire Child and Adolescent Psychiatry Fellowships.

Substance Abuse and Mental Health Services Administration (CMHS, CSAP, CSAT): sponsorship of the APA/SAMHSA Minority Fellowship Program.

The Psychiatrist's Program, The APA-Endorsed Professional Liability Insurance Program: support of the ECP luncheon, Tuesday, May 4, 12 noon.


UCB Pharma, Inc.: support of the Industry-Supported Symposium, "Broadening Horizons: Advances in Understanding the Etiology, Effects, and Treatment of Anxiety Disorders," Sunday, May 2, 8:00 a.m.

University of California-Davis, Department of Psychiatry: support of the Residents, Fellows, and Medical Student's Reception, Monday, May 3, 5:00 p.m.

Wyeth Pharmaceuticals: support of the Industry-Supported Symposia, "Interface Between Depression and Medical Illness," Saturday, May 1, 6:00 p.m.; "The Treacherous Triad for Depression," Sunday, May 2, 1:30 p.m.; "Hormones, Mood, and Cognition: Treatment Considerations in Older Women," Monday, May 3, 7:00 p.m.; "Emotion Regulation and Plasticity of Underlying Circuitry: Implications for Depression, Anxiety, and Long-Term Brain Function," Tuesday, May 4, 7:00 p.m.; and "Core Symptom Domains in the Anxiety Disorders," Wednesday, May 5, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Evidence-Based Medicine: The Next Generation," Monday, May 3, and Tuesday, May 4, 7:00 a.m.; the APA/Wyeth Pharmaceuticals M.D., Ph.D., Research Fellowship; support of the Jeanne Spurlock, M.D. Congressional Fellowship; and the daily in-house TV program, "APA News Network."

American Psychiatric Association

**Audiotapes
Recorded Live!**



***High Quality Continues for
the 2004 Annual Meeting ...***

**Live recordings will be available
for most of the following:**

- Lectures • Advances in Research
- Advances in Psychopharmacology
- Presidential Symposia • Medical Updates
- Scientific and Clinical Reports • Symposia
- Debate • Roundtable Discussion
- Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth at the Javits Convention Center.

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 ♦ (800) 369-5718
Fax: (661) 295-8474
Website: www.mobiltape.com

FORMAT DESCRIPTIONS

ADVANCES IN PSYCHOPHARMACOLOGY

This three-and-one-half hour session will summarize important new clinical and research findings in the treatment of selected psychiatric disorders, with an emphasis on psychopharmacologic interventions. The session will be based in part, on material contained in *The American Psychiatric Publishing Textbook of Psychopharmacology, Third Edition*, edited by Drs. Alan F. Schatzberg and Charles B. Nemeroff. Authors of selected chapters from the textbook will present material from their chapters. The topics were selected by the editor to represent disorders of particular current interest to psychiatrists and to focus on aspects of psychopharmacology that may be of greatest importance to APA members.

ADVANCES IN RESEARCH

During this two-hour session, a brief overview of major advances in research in psychiatry and a preview of selected research presentations scheduled at the Annual Meeting, leading clinical researchers present the latest developments in four different, clinically-relevant areas of research.

CLINICAL CASE CONFERENCES

During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

CONTINUOUS CLINICAL CASE CONFERENCES

The presenters will review the progress of psychotherapy in two successive three-hour sessions on consecutive days (Monday-Tuesday and Wednesday-Thursday, beginning at 9:00 a.m.). Audience participation is encouraged throughout. Participants are requested to attend both sessions in their entirety. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

COURSES

Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day), six-hour (full-day), and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Participants must purchase tickets to attend.

DEBATE

Experts in the field, including psychiatrists and nonpsychiatrists, will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

DISCUSSION GROUPS

This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the expert. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

FOCUS LIVE

These 90-minute sessions allow participants to test their knowledge using an interactive Audience Response System (ARS), offering a new and entertaining way to learn. ARS sessions can make a group of 300 feel like they are having a small group consultation with an expert clinician. Experts, who served as guest editors of *FOCUS*, will lead lively multiple choice question-

based discussions, and the audience will enter their answers with hand-held devices. Results are instantly tallied and projected on the screen.

FORUMS

These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

LECTURES

Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

MASTER EDUCATOR CLINICAL CONSULTATIONS

These 90-minute, clinically-based seminars are presented by outstanding educators. Formats and subject matter will vary, but all will utilize clinical material offered by participants. These sessions are limited to 25 participants on a first-come, first-served basis. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

MEDICAL UPDATES

These 90-minute sessions are designed to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.

NEW RESEARCH

This format allows for presentation of the very recent findings. The three types of presentations include: Posters, which are visual, self-explanatory presentations; Young Investigators' Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators' Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

RESEARCH ADVANCES IN MEDICINE

This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.

RESEARCH CONSULTATIONS WITH

This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it's one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.

REVIEW OF PSYCHIATRY

There will be four, three-and-one-half hour sessions presented, based on the annual American Psychiatric Publishing Review of Psychiatry Series. Each session includes an abridged presentation by the senior author from each of the chapters in each volume. The topics were selected by the overall editors of the series to represent current areas of new research, new developments in clinical care, and special issues of importance to APA members.

FORMAT DESCRIPTIONS

SCIENTIFIC AND CLINICAL REPORT SESSIONS

Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

SYMPOSIA

Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposia" in this *Program Book*.

WORKSHOPS

Workshops are 90-minute sessions (either Issue or Component), which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.

Media Workshops are three-hour sessions held Monday-Thursday, in which a feature-length film is shown and discussed.

AMERICAN PSYCHIATRIC ASSOCIATION
CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure by presenters at CME activities of any significant financial or other affiliation with commercial goods/organization(s) regulated by the Food and Drug Administration, which may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include, holding a position on an advisory committee or some other role or benefit to a supporting organization. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if AV equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The following presenters have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s). The presenter's name and the company's name are listed below, along with the page # the presenter appears on in this *Program Book*. The nature of the presenter's relationship with the disclosed company is indicated by the following code: consultant or advisory board¹, full-time employment², research/grant support³, speakers' bureau⁴, stock or other financial options⁵, other financial or business relationships⁶. If a number has not been assigned, the presenter has not disclosed the relationship to the company.

Presenter	Manufacturer(s)	Program Page #
Susan E. Abbey, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ^{1, 4} ; Lundbeck ^{1, 4} ; GlaxoSmithKline ^{1, 4} ; U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Organon Pharmaceuticals Inc. ⁴	87
Anissa Abi-Dargham, M.D.	Bristol-Myers Squibb ⁶	11
Lenard A. Adler, M.D.	Novartis Pharmaceuticals Corporation ⁶ ; U.S. Pharmaceuticals, Pfizer Inc. ⁶ ; Eli Lilly and Company ⁶ ; Shire Ridgewood Pharmaceuticals ⁶ ; McNeil Pharmaceuticals ⁶ ; Johnson and Johnson PRD ⁶	2, 67
Nassima Ait-Daoud, M.D.	Johnson and Johnson PRD ¹	64
Hagop S. Akiskal, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ^{1, 4} ; GlaxoSmithKline ⁴ ; Bristol-Myers Squibb ⁵ ; Janssen Pharmaceutica Inc. ⁴ ; Abbott Laboratories, Inc. ⁴	65
George S. Alexopoulos, M.D.	Forest Laboratories, Inc. ^{3, 4} ; Cephalon Inc. ^{3, 4} ; U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ ; GlaxoSmithKline ⁴ ; Janssen Pharmaceutica Inc. ⁴ ; Wyeth-Ayerst Laboratories ⁴ ; SmithKline Beecham Pharmaceuticals ⁴	7
Jonathan E. Alpert, M.D.	Pharmavite ^{1, 3} ; Organon Pharmaceuticals Inc. ^{3, 4} ; Forest Laboratories, Inc. ³	34, 78
Gustavo Alva, M.D.	Corcept Therapeutics, Inc. ³ ; Novartis Pharmaceuticals Corporation ^{3, 4} ; Wyeth-Ayerst Laboratories ^{3, 4} ; Parke-Davis, Division of Warner-Lambert Company ³ ; U.S. Pharmaceuticals, Pfizer Inc. ^{3, 4} ; Otsuka Pharmaceuticals ⁴ ; Forest Laboratories, Inc. ⁴ ; Janssen Pharmaceutica Inc. ⁴ ; Bristol-Myers Squibb ⁴	40
Andrew F. Angelino, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; GlaxoSmithKline ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ ; Boehringer Ingelheim ⁴ ; Roche Laboratories, a member of the Roche Group ⁴ ; Abbott Laboratories, Inc. ⁴ ; Schering Corporation ⁴ ; Wyeth-Ayerst Laboratories ⁴	47, 56, 70
Raymond F. Anton, Jr., M.D.	Johnson and Johnson PRD ^{1, 4} ; Ortho McNeil Pharmaceuticals ^{1, 4} ; Bristol-Myers Squibb ^{1, 4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1, 4}	64
Michael R. Arambula, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴	46
David B. Arciniegas, M.D.	Novartis Pharmaceuticals Corporation ^{1, 4} ; U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Janssen Pharmaceutica Inc. ⁴	87, 93
Scott C. Armstrong, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Novartis Pharmaceuticals Corporation ⁴	71
Bruce A. Arnow, Ph.D.	Eli Lilly and Company ⁶	39
Louis J. Aronne, M.D.	Sanofi-Synthelabo Pharmaceuticals, Inc. ³ ; Regeneron ¹ ; Amgen ¹ ; TAP Pharmaceuticals ¹ ; Bristol-Myers Squibb ¹ ; Abbott Laboratories, Inc. ^{3, 4} ; Ortho McNeil Pharmaceuticals ^{1, 3} ; Roche Laboratories, a member of the Roche Group ^{3, 4}	67
Gregory M. Asnis, M.D.	Roche Laboratories, a member of the Roche Group ⁶	38
Claudia F. Baldassano, M.D.	AstraZeneca Pharmaceuticals ⁶	12
Russell A. Barkley, Ph.D.	Eli Lilly and Company ⁴ ; Shire Ridgewood Pharmaceuticals ¹ ; Novartis Pharmaceuticals Corporation ¹	39
Ernest S. Barratt, M.D.	Ortho McNeil Pharmaceuticals ¹	3
Barbara D. Bartlik, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ³ ; GlaxoSmithKline ³ ; Sensaquest, Inc. ⁴	60
Andrius Baskys, M.D.	AstraZeneca Pharmaceuticals ^{1, 3, 4} ; Novartis Pharmaceuticals Corporation ^{1, 4} ; Janssen Pharmaceutica Inc. ³	13
Elizabeth A. Baxter, M.D.	Eli Lilly and Company ¹	80
Joseph H. Beitchman, M.D.	Eli Lilly and Company ⁴	100

Bernard D. Beitman, M.D.	GlaxoSmithKline ⁴	45, 58, 82
Ayseril Belger, Ph.D.	Eli Lilly and Company ⁶	10
Ruth M. Benca, M.D.	Neurocrine ^{1,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,4} ; Takeda Pharmaceuticals ^{1,3,4} ; Sepracor Inc. ^{1,4} ;	67
Joseph Biederman, M.D.	Wyeth-Ayerst Laboratories ^{1,3,4} ; Merck & Co., Inc. ³ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,4} ;	2, 45, 85, 98,
	Shire Ridgewood Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Cephalon Inc. ^{1,3,4} ; NICHD ³ ;	106
	Wyeth-Ayerst Laboratories ^{3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{3,4} ; GlaxoSmithKline ⁴ ;	
	Stanley Foundation ³ ; Alza/McNeil Pharmaceuticals ^{1,4} ; National Institute on Drug Abuse ³	
Jed E. Black, M.D.	Noven Pharmaceutical ^{1,3}	
Mary Blehar, Ph.D.	Sepracor Inc. ⁶	11
Martin Bohus, M.D.	GlaxoSmithKline ⁶	12
Abba E. Borowich, M.D.	Bristol-Myers Squibb ⁶	38, 85
Kathleen T. Brady, M.D.	AstraZeneca Pharmaceuticals ⁴	89
	Abbott Laboratories, Inc. ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ¹ ; Forest Laboratories, Inc. ¹ ;	48, 65, 76
	Lilly Research Laboratories, a division of Eli Lilly and Company ² ; Bristol-Myers Squibb ⁴ ;	90
	SmithKline Beecham Pharmaceuticals ¹	
William Breitbart, M.D.	Cephalon Inc. ^{1,4} ; Janssen Pharmaceutica Inc. ^{1,4} ; Purdue Pharma ^{1,4} ; Eli Lilly and Company ¹ ;	82
	Bristol-Myers Squibb ⁴	
Ronald Brenner, M.D.	Janssen Pharmaceutica Inc. ³ ; Wyeth-Ayerst Laboratories ³ ; GlaxoSmithKline ³ ;	100
	Lilly Research Laboratories, a division of Eli Lilly and Company	
E. Sherwood Brown, M.D.	AstraZeneca Pharmaceuticals ³ ; Eli Lilly and Company ³ ; Bristol-Myers Squibb ³	5
Richard Brown, M.D.	Janssen Pharmaceutica Inc. ⁴ ; PurduePharma ⁴	30
Richard A. Brown, Ph.D.	U.S. Pharmaceuticals, Pfizer Inc. ^{1,5}	62
Thomas E. Brown, Ph.D.	Cephalon Inc. ³ ; Eli Lilly and Company ^{1,4} ; GlaxoSmithKline Beecham Healthcare ³ ;	1, 5, 14
	McNeil Consumer Healthcare ^{1,4} ; Novartis Pharmaceuticals Corporation ¹ ;	
	U.S. Pharmaceuticals, Pfizer Inc. ¹ ; Shire Ridgewood Pharmaceuticals ¹	
Robert S. Brown, Jr., M.D.	Schering Corporation ^{3,4} ; Roche Laboratories, a member of the Roche Group ³ ;	50
	Ortno Biotech ^{3,4} ; Glead ³ ; Amgen ³	
Peter F. Buckley, M.D.	Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals ¹ ; Bristol-Myers Squibb ¹ ;	12, 76
	Janssen Pharmaceutica Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Eli Lilly and Company ¹	
Cathy L. Budman, M.D.	Eli Lilly and Company ^{3,4}	48
Alan J. Budney, Ph.D.	Sanofi-Synthelabo Pharmaceuticals, Inc. ³	89
John W. Burruss, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Eli Lilly and Company ^{3,4} ; Wyeth-Ayerst Laboratories ⁴ ;	81, 94
	AstraZeneca Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,4}	
Vivien K. Burt, M.D.	Eli Lilly and Company ^{1,3,4} ; Wyeth-Ayerst Laboratories ⁴ ;	8, 39
	Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4}	
Marian I. Butterfield, M.D.	Bristol-Myers Squibb ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴	34, 35, 55, 74, 86, 105
Daniel J. Buysse, M.D.	Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Cephalon Inc. ¹ ; Sepracor Inc. ¹ ; Neurocrine ¹	67
Alexander Bystritsky, M.D.	Wyeth-Ayerst Laboratories ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{3,4} ;	86
	Merck & Co., Inc. ³ ; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc. ⁴	
Joseph R. Calabrese, M.D.	National Institute of Mental Health ⁶ ; Abbott Laboratories, Inc. ^{1,6} ; GlaxoSmithKline ^{1,6} ;	26, 75
	Gba Geigy Corporation, Pharmaceutical Division ⁶ ; Merck & Co., Inc. ⁶ ; Teva Pharmaceuticals ¹ ;	
	Janssen Pharmaceutica Inc. ⁶ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁶ ;	
	MacArthur Foundation ⁶ ; National Alliance for Research in Schizophrenia and Affective Disorders ⁶ ;	
	Parke-Davis, Division of Warner-Lambert Company ^{4,6} ; Robert Wood Johnson Pharmaceutical	
	Research Institute ^{1,6} ; Sandoz Pharmaceuticals Corporation ⁶ ; SmithKline Beecham Pharmaceuticals ^{1,6} ;	
	Stanley Foundation ⁶ ; Tap Holdings, Inc. ^{1,6} ; UCB Pharma, Inc. ^{1,6} ; Wyeth-Ayerst Laboratories ⁶ ;	
	AstraZeneca Pharmaceuticals ¹ ; Bristol-Myers Squibb ¹ ; Eli Lilly and Company ¹ ; Janssen Cilag ¹ ;	
	Novartis Pharmaceuticals Corporation ¹ ; Shire Ridgewood Pharmaceuticals ¹	
Lucile Capuron, Ph.D.	Roche Laboratories, a member of the Roche Group ⁶	38
Gabrielle Carlson, M.D.	Janssen Pharmaceutica Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Abbott Laboratories, Inc. ^{3,4} ;	13
	Novartis Pharmaceuticals Corporation ^{1,3,4} ; Johnson and Johnson PRD ^{1,3} ; Bristol-Myers Squibb ¹	
Linda L. Carpenter, M.D.	Organon Pharmaceuticals, Inc. ^{1,4} ; Cephalon Inc. ^{1,3} ; Cyberonics Inc. ^{3,4} ; Merck & Co., Inc. ³ ;	6, 9
	Corcept Therapeutics, Inc. ³ ; Abbott Laboratories, Inc. ⁴ ; Somerset Pharmaceuticals ⁴ ;	
	Wyeth-Ayerst Laboratories ⁴ ; U.S. Pharmaceuticals, Pfizer Inc. ^{3,4} ; Medtronics ³	
David A. Casey, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Forest Laboratories, Inc. ⁴	24
Giovanni B. Cassano, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ³	65
F. Xavier Castellanos, M.D.	McNeil Pharmaceuticals ³ ; Johnson and Johnson PRD ^{3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4}	39, 47, 65
Ruby C. Castilla-Puentes, M.D.	GlaxoSmithKline R&D ²	58, 77, 105
Wilma I. Castilla-Puentes, M.D.	GlaxoSmithKline ²	105

DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Kiki D. Chang, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ ; GlaxoSmithKline ^{1,3,4} ; Abbott Laboratories, Inc. ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,4} ; Janssen Pharmaceutica Inc. ¹ ; Ortho McNeil Pharmaceuticals ³ ; AstraZeneca Pharmaceuticals ^{1,4}	66
Dennis S. Charney, M.D.	AstraZeneca Pharmaceuticals ¹ ; Aventis Pharmaceuticals ¹ ; Bristol-Myers Squibb ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ¹ ; Somerset Pharmaceuticals ¹ ; Vela Pharmaceuticals ¹ ; Wyeth-Ayerst Laboratories ¹ ; Organon Pharmaceuticals ¹ , Inc.; Otsuka Pharmaceuticals ¹	4, 6
K.N. Roy Chengappa, M.D.	Eli Lilly and Company ^{3,4} ; Janssen Pharmaceutica Inc. ^{3,4} ; Ortho McNeil Pharmaceuticals ^{3,4} ; AstraZeneca Pharmaceuticals ^{3,4} ; Novartis Pharmaceuticals Corporation ³ ; Abbott Laboratories, Inc. ³	12
Joseph A. Cheong, M.D.	Janssen Pharmaceutica Inc. ⁴ ; GlaxoSmithKline ⁴ ; Ortho McNeil Pharmaceuticals ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Forest Laboratories, Inc. ⁴ ; U.S. Pharmaceuticals, Pfizer Inc. ⁴	28, 73
John A. Chiles, M.D.	Janssen Pharmaceutica Inc. ^{1,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,4} ; Bristol-Myers Squibb ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,4}	99
James C.Y. Chou, M.D.	Abbott Laboratories, Inc. ^{1,3,4}	43
Daniel D. Christensen, M.D.	Bayer Corporation, Pharmaceutical Division ^{1,4} ; Bristol-Myers Squibb ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; Designer Genes Inc. ^{1,3} ; LP; Eli Lilly and Company ¹ ; Eisai America Inc. ⁴ ; NPS Pharmaceuticals ^{1,3} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ^{1,3,4} ; Wyeth-Ayerst Laboratories ^{1,3,4} ; Abbott Laboratories, Inc. ^{3,4} ; Novartis Pharmaceuticals Corporation ⁴ ; Upjohn, Inc. ⁴ ; Eccles Institute of Human Genetics ³ ; Myriad Genetics, Inc. ^{1,3} ; Organon USA ³	11
Leslie L. Citrome, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3} ; Bristol-Myers Squibb ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3}	22, 73
Stephan Claes, M.D.	GlaxoSmithKline ⁴	2
H. Westley Clark, M.D.	Reckitt Benckiser Pharmaceuticals ⁶	39
Anita L.H. Clayton, M.D.	Bayer Corporation, Pharmaceutical Division ^{1,3} ; Boehringer-Ingelheim Pharmaceuticals ^{1,3} ; Eli Lilly and Company ^{1,3} ; U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; GlaxoSmithKline ^{1,3} ; Merck & Co., Inc. ³ ; Organon Pharmaceuticals, Inc. ^{1,3,4} ; Pherin Pharmaceuticals ³	4, 66, 105
Emil F. Coccaro, M.D.	Eli Lilly and Company ^{1,3,4,6} ; Abbott Laboratories, Inc. ^{1,3,6} ; SmithKline Beecham Pharmaceuticals ⁶ ; Forest Laboratories, Inc. ⁶	33, 38, 87
Bruce M. Cohen, M.D.	Eli Lilly and Company ¹ ; Merck & Co. ⁴ , Inc.; Variagenics ¹	13, 41, 61
Lee S. Cohen, M.D.	Forest Laboratories, Inc. ^{3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; Wyeth-Ayerst Laboratories ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; AstraZeneca Pharmaceuticals ⁴ ; U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Eli Lilly and Company ^{1,3,4} ; Berlex Laboratories ³	39, 69, 93
Michael Cohen	EEG Spectrum International ²	1
Robert R. Conley, M.D.	AstraZeneca Pharmaceuticals ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{3,4} ; Eli Lilly and Company ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Aventis ^{1,4} ; Pharmaceuticals; Otsuka Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,4} ; Zenith-Goldline ^{1,3,4}	15, 73
Kathryn M. Connor, M.D.	Eli Lilly and Company ³ ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Pure World Botanicals, Inc. ³ ; Forest Laboratories, Inc. ^{3,4} ; Ortho McNeil Pharmaceuticals ^{1,4} ; Cephalon Inc. ^{4,6} ; Wyeth-Ayerst Pharmaceutical Company ^{1,4} ; Solvay Pharmaceuticals, Inc. ⁴ ; Ancile Pharmaceuticals ¹ ; Nutrition 21 ⁶	34
Jeremy D. Coplan, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; GlaxoSmithKline ^{3,4} ; Eli Lilly and Company ¹	6
Sara A. Corya, M.D.	Eli Lilly and Company ³	78
Daniel J. Cox, Ph.D.	McNeil Pharmaceuticals ³	106
Joseph T. Coyle, Jr., M.D.	Abbott Laboratories, Inc. ^{1,5} ; Merck & Co., Inc. ^{1,5} ; Proctor & Gamble ⁵ ; Applied Biosystems ⁵ ; Aventis ¹ ; Johnson and Johnson PRD ¹ ; Pharmaceuticals; Cephalon Inc. ¹ ; Avera Pharm ^{1,5} ; Prestwick Pharm ⁵	71
Kelly L. Cozza, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ¹	71
Catherine C. Crone, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴	15, 56, 98
Jeffrey L. Cummings, M.D.	Novartis Pharmaceuticals Corporation ^{1,3} ; Eisai America Inc. ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ¹ ; Janssen Pharmaceutica Inc. ¹ ; AstraZeneca Pharmaceuticals ¹ ; Organon Pharmaceuticals, Inc. ¹ ; Ono Pharmaceuticals ¹ ; SynXPharma ¹ ; Bristol-Myers Squibb ¹ ; Cephalon Inc. ¹ ; Abbott Laboratories, Inc. ^{1,3}	7, 13, 65
Jonathan R.T. Davidson, M.D.	Solvay Pharmaceuticals, Inc. ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Wyeth-Ayerst Laboratories ^{3,4} ; Forest Laboratories, Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ¹ ; Pure World Botanicals, Inc. ³ ; Ancile Pharmaceuticals ¹ ; Roche Laboratories, a member of the Roche Group ¹ ; UCB Pharma, Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals, Inc. ^{1,3} ; Nutrition 21 ³ ; Boehringer-Ingelheim Pharmaceuticals ¹ ; Johnson and Johnson PRD ¹ ; Allergan ³ ; Schwabe ³ ; Pharmacia & Upjohn Company, Inc. ¹ ; Boots Pharmaceuticals ¹ ; Guilford Publications ⁵ ; Bristol-Myers Squibb ¹ ; Multi-Health Systems Inc. ⁵ ; Penguin Putnam ⁵	21, 35, 67, 69, 93

Lori L. Davis, M.D.	Abbott Laboratories, Inc. ^{3,4} ; Bristol-Myers Squibb ^{3,4} ; GlaxoSmithKline ^{3,4} ; Forest Laboratories, Inc. ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ² ; Janssen Pharmaceutica Inc. ³ ; Ortho McNeil Pharmaceuticals ^{3,4}	66, 104
Mary H. Davis, M.D.	Cephalon Inc. ⁴ ; Wyeth-Ayerst Laboratories ⁴ ; Forest Laboratories, Inc. ⁴	18
Charles DeBattista, M.D.	Abbott Laboratories, Inc. ⁴ ; Bristol-Myers Squibb ^{1,3,4} ; Cephalon Inc. ^{3,4} ; GlaxoSmithKline ^{1,3,4} ; Forest Laboratories, Inc. ⁴ ; Organon Pharmaceuticals, Inc. ⁴ ; Corcept Therapeutics, Inc. ^{1,5} ; Eli Lilly and Company ^{1,3,4} ; Wyeth-Ayerst Laboratories ^{1,3,4} ; Nancy Pritzker Network ³ ; Pharmacia & Upjohn Company, Inc. ^{3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; NARSAD ³ ; National Institute of Mental Health ³	2, 7 70
Melissa P. DelBello, M.D.	Abbott Laboratories, Inc. ^{3,4} ; AstraZeneca Pharmaceuticals; ^{1,3,4} ; Eli Lilly and Company ^{3,4} ; Ortho McNeil Pharmaceuticals ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; GlaxoSmithKline ⁴	5, 92
Pedro L. Delgado, M.D.	Bristol-Myers Squibb ^{3,4} ; Eli Lilly and Company ^{3,4} ; Glaxo-Wellcome ^{1,3,4} ; Organon, Inc. ^{3,4} ; Pharmacia & Upjohn Company, Inc. ^{3,4} ; Solvay Pharmaceuticals, Inc. ^{3,4} ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Inc. ^{1,3} ; Boehringer Ingelheim ¹ ; AstraZeneca Pharmaceuticals ³ ; Parke-Davis, Division of Warner-Lambert Company ² ; Wyeth-Ayerst Laboratories ^{1,4} ; Novartis Pharmaceuticals Corporation ³ ; U.S. Pharmaceuticals, Pfizer Inc. ³ ; SmithKline Beecham Pharmaceuticals ³	39, 43
Abhilash K. Desai, M.D.	Forest Laboratories, Inc. ⁴ ; Novartis Pharmaceuticals Corporation ⁴ ; Janssen Pharmaceutica Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴	69
Michael J. Detke, M.D.	Eli Lilly and Company ^{2,5}	24
Daniel A. Deutschman, M.D.	UCB Pharma, Inc. ^{3,4}	18
Mantosh J. Dewan, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; GlaxoSmithKline ⁴ ; Janssen Pharmaceutica Inc. ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³	18, 42, 64
Karl Doghramji, M.D.	Cephalon Inc. ³ ; GlaxoSmithKline ³ ; Merck & Co., Inc. ³	55, 69, 97
P. Murali Doraiswamy, M.D.	Pfizer Inc. ^{1,3,4} ; Eisai America Inc. ^{1,3,4} ; Merck & Co., Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Forest Laboratories, Inc. ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4}	11, 41
Martin Dossenbach, M.D.	Eli Lilly and Company ²	79
Robert E. Drake, M.D.	Eli Lilly and Company ⁶	10, 43
Roxanne C. Dryden-Edwards, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ⁴	47, 100
Eduardo Dunayevich, M.D.	Eli Lilly and Company ²	43
Boadie W. Dunlop, M.D.	Cephalon Inc. ^{3,4} ; UCB Pharma, Inc. ³ ; Janssen Pharmaceutica Inc. ³ ; Wyeth-Ayerst Laboratories ³	2
James M. Ellison, M.D.	Forest Laboratories, Inc. ⁴ ; Wyeth-Ayerst Laboratories ⁴ ; GlaxoSmithKline ^{3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ⁴	27
Abdelouahed Elmouchtari, M.D.	AstraZeneca Pharmaceuticals ³	3
Milton K. Erman, M.D.	Cephalon Inc. ^{1,3,4,5} ; Mallinckrodt Pharmaceuticals ^{1,3,4} ; Neurocrine Biosciences Inc. ^{1,3,4,5} ; Elan ^{1,3,4} ; Sepracor Inc. ^{3,5} ; Sanofi Pharmaceuticals, Inc. ^{1,3,4} ; Forest Laboratories, Inc. ^{1,4,5} ; Takeda Pharmaceuticals ³ ; Aventis Pharmaceuticals ³ ; Janssen Pharmaceutica Inc. ^{1,3} ; King Pharmaceuticals ^{1,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{3,5}	97
Javier I. Escobar, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ^{1,4} ; Orphan ^{1,3,4} ; Bristol-Myers Squibb ^{1,4}	20, 43
Dwight L. Evans, M.D.	GlaxoSmithKline ^{1,3,4} ; Abbott Laboratories ^{1,4} , Inc. ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,4} ; Eli Lilly and Company ^{1,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Organon Pharmaceuticals, Inc. ^{1,4} ; Wyeth-Ayerst Laboratories ^{1,4} ; Somerset Pharmaceuticals ^{1,4} ; Janssen Pharmaceutica Inc. ^{1,4} ; Forest Laboratories, Inc. ^{1,4}	4
Warachal E. Faison, M.D.	GlaxoSmithKline ² ; Forest Laboratories ⁴ , Inc.; Bristol-Myers Squibb ^{1,4} ; Otsuka Pharmaceuticals ^{1,4}	6, 17, 62
Stephen V. Faraone, Ph.D.	Shire Pharmaceutical Development, Inc. ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Noven ¹ ; McNeil Pharmaceuticals ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4}	39, 85, 98
Martin K. Farlow, M.D.	Novartis Pharmaceuticals Corporation ^{1,3}	40
Maurizio Fava, M.D.	GlaxoSmithKline ^{3,4} ; Glaxo-Wellcome ^{3,4} ; SmithKline Beecham Pharmaceuticals ^{3,4} ; Pharmavite ^{3,4} ; Eli Lilly and Company ^{3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{3,4} ; Pharmacia & Upjohn Company, Inc. ^{3,4} ; Wyeth-Ayerst Laboratories ^{3,4} ; Bristol-Myers Squibb ^{3,4} ; Novartis Pharmaceuticals Corporation ^{3,4} ; Organon Pharmaceuticals, Inc. ^{3,4} ; Sanofi\Synthelabo Pharmaceuticals, Inc. ^{3,4} ; Solvay Pharmaceuticals, Inc. ^{3,4} ; Forest Laboratories, Inc. ^{3,4} ; Cephalon Inc. ³ ; Bayer AG Corporation, Pharmaceutical Division ⁴ ; Janssen Pharmaceutica Inc. ⁴ ; Lundbeck ⁴ ; Knoll Pharmaceuticals ⁴ ; Abbott Laboratories, Inc. ³ ; Parke-Davis, Division of Warner-Lambert Company ⁴ ; Somerset Pharmaceuticals ⁴ ; Aspect Medical Systems ³ ; Roche Laboratories, a member of the Roche Group ³ ; Lorex Pharmaceuticals ³ ; Lichtwer Pharma GmbH ³	2, 66

DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Robert L. Findling, M.D.	Bristol-Myers Squibb ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3}	13, 26
Helen E. Fisher, Ph.D.	GlaxoSmithKline ⁴	4, 82
Alastair J. Flint, M.B.	Janssen Pharmaceutica Inc. ⁴ ; Pfizer Canada ⁴ ; Lundbeck Canada ⁴ ; Forest Laboratories, Inc. ⁴	85
Edna B. Foa, Ph.D.	Cephalon Inc. ⁶	1, 64, 93
Ellen Frank, Ph.D.	U.S. Pharmaceuticals, Pfizer Inc. ¹ ; Pfizer Italia ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ³ ; Merck & Co., Inc. ³ ; Janssen Pharmaceutica Inc. ³	1, 59, 102
Jean A. Frazier, M.D.	AstraZeneca Pharmaceuticals ⁴ ; Bristol-Myers Squibb ⁴ ; Janssen Pharmaceutica Inc. ⁴ ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,4}	61
Nick Freemantle, Ph.D.	Wyeth-Ayerst Laboratories ⁶ ; U.S. Pharmaceuticals, Pfizer Inc. ³	13
Edward S. Friedman, M.D.	Wyeth-Ayerst Laboratories ^{1,3,4} ; Cyberonics Inc. ³ ; Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{3,4} ; Organon Pharmaceuticals, Inc. ³ ; Forest Laboratories, Inc. ^{3,4} ; Merck & Co., Inc. ³ ; Pharmacia & Upjohn Company, Inc. ^{3,4} ; Cephalon Inc. ^{1,3} ; GlaxoSmithKline ^{1,4} ; Abbott Laboratories, Inc. ^{4,6} ; Upjohn (Kalamazoo, MI) ³	26
Matthew J. Friedman, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ¹ ; GlaxoSmithKline ¹ ; Johnson and Johnson PRD ¹	18, 25, 60
Mark A. Frye, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,4} ; Cephalon Inc. ¹ ; Elan Pharmaceuticals ¹ ; Eli Lilly and Company ^{1,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen-Cilag Pharmaceutica Inc. ^{1,4} ; Johnson and Johnson PRD ¹ ; Novartis Pharmaceuticals Corporation ^{1,4} ; Ortho McNeil Pharmaceuticals ^{1,4} ; Otsuka Pharmaceuticals ^{1,4} ; UCB Pharma, Inc. ¹ ; King Pharmaceuticals ³ ; National Institute of Mental Health ³ ; Solvay Pharmaceuticals, Inc. ³ ; Stanley Medical Research Institute ³	2, 66, 70
Glen O. Gabbard, M.D.	Bristol-Myers Squibb ⁶	22, 29, 38, 45
Joel Gallant, M.D.	Abbott Laboratories Inc. ^{1,4} ; Boehringer Ingelheim ^{1,3} ; Bristol-Myers Squibb ^{1,3,4} ; GlaxoSmithKline ^{1,4} ; Roche Laboratories, a member of the Roche Group ^{3,4} ; Gilead Sciences ^{1,3,4} ; Vertex ¹ ; Tanox ¹ ; Tibotec-Virco ^{1,3} ; ViroLogic ¹ ; Ortho Biotech, Inc. ^{1,3,4}	45
David R. Gastfriend, M.D.	Alkermes ^{1,3,4} ; Eli Lilly and Company ⁴ ; Bristol-Myers Squibb ⁴ ; CMHC Systems ¹ ; TeleSage ¹ ; Drug Abuse Sciences ³ ; Purdue Pharma ⁴	100
F. Moises Gavia, M.D.	GlaxoSmithKline ³ ; Novartis Pharmaceuticals Corporation ³ ; Janssen Pharmaceutica Inc. ³	74
David Geldmacher, M.D.	Pfizer Inc. ^{1,3,4} ; Eisai America Inc. ^{1,3,4} ; Janssen Pharmaceutica Inc. ³ ; Takeda Pharmaceuticals ³ ; Forest Laboratories, Inc. ⁶	11, 67
Joel Gelernter, M.D.	Janssen Pharmaceutica Inc. ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; GlaxoSmithKline ^{3,4} ; Parke-Davis, Division of Warner-Lambert Company ^{3,4} ; Medtronic ³ ; Amersham ^{3,4} ; Cyberonics Inc. ^{1,3,4} ; Philips ^{3,4} ; Dunphar ³ ; Dupont Pharma ³ ; Solvay Pharmaceuticals, Inc. ³ ; Mediphysics ^{3,4}	7, 30
Mark S. George, M.D.	Janssen Pharmaceutica Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; GlaxoSmithKline ^{1,4} ; Abbott Laboratories, Inc. ^{3,4} ; Elan Pharmaceuticals ³ ; Forest Laboratories, Inc. ⁴ ; Eli Lilly and Company ⁴ ; Novartis Pharmaceuticals Corporation ³	1, 9, 46, 66
S. Nassir Ghaemi, M.D.	Reckitt-Benckiser Pharmaceuticals ⁶	39
Walter Ginter	Medco Health ¹	87, 100
Leslie H. Gise, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ ; Wyeth-Ayerst Laboratories ⁴ ; GlaxoSmithKline ⁴ ; Bristol-Myers Squibb ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Janssen Pharmaceutica Inc. ⁴ ; U.S. Pharmaceuticals, Pfizer Inc. ⁴	88
Michael J. Gitlin, M.D.	AstraZeneca Pharmaceuticals ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4}	24, 50, 63, 99
Ira D. Glick, M.D.	Bristol-Myers Squibb ⁴	7, 10, 14, 22, 29, 37, 55, 67, 83, 102
Marcia Kraft Goin, M.D.	AstraZeneca Pharmaceuticals ⁴ ; Bristol-Myers Squibb ¹	71
Robert M. Goisman, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; UCB Pharma, Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Ortho McNeil Pharmaceuticals ^{1,3} ; Pfizer Inc. ^{1,3}	2, 4, 63, 88
Joseph F. Goldberg, M.D.	Bristol-Myers Squibb ⁶	38
Pablo Goldberg, M.D.	Bristol-Myers Squibb ¹ ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ^{1,4} ; Janssen Pharmaceutica Inc. ¹ ; Organon Pharmaceuticals, Inc. ^{3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{3,4} ; Wyeth-Ayerst Laboratories ^{1,4}	4
Robert N. Golden, M.D.	Bristol-Myers Squibb ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,4} ; Mallinckrodt Pharmaceuticals ^{1,4} ; IVAX ^{1,3,4}	27, 54, 77, 99
Stephen M. Goldfinger, M.D.	Eli Lilly and Company ¹	86
Marion Z. Goldstein, M.D.	Reckitt-Benckiser Pharmaceuticals ⁶	39
Gerardo Gonzalez, M.D.		

Jack M. Gorman, M.D.	National Institute of Mental Health ¹ ; NARSAD ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ¹ ; Merck & Co., Inc. ¹ ; GlaxoSmithKline ¹ ; AstraZeneca Pharmaceuticals ¹ ; Janssen Pharmaceutica Inc. ¹ ; Forest Laboratories, Inc. ¹	9, 19, 50, 77, 92
Elizabeth Gould, Ph.D.	Wyeth-Ayerst Laboratories ⁶	66
Barbara L. Gracious, M.D.	GlaxoSmithKline ⁶	12
Tana A. Grady-Weliky, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} ; Eli Lilly and Company ⁴	18, 96
John F. Greden, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ¹ ; Mallinckrodt Pharmaceuticals ¹ ; Wyeth-Ayerst Laboratories; Cyberonics Inc.; Pfizer Inc.; Neuronetics Inc. ¹ ; Merck & Co., Inc. ¹	8, 20, 47, 61
Benjamin D. Greenberg, M.D.	Medtronic, Inc. ³	83
Laurence L. Greenhill, M.D.	McNeil Pharmaceuticals ¹ ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3} ; Shire Ridgewood Pharmaceuticals ³	106
John H. Greist, M.D.	Abbott Laboratories, Inc. ^{3,6} ; Forest Laboratories, Inc. ^{3,4,6} ; Organon Pharmaceuticals, Inc. ^{1,3,4} ; Janssen Pharmaceutica Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3,4} ; Wyeth-Ayerst Laboratories ^{1,3,4} ; Bristol-Myers Squibb ^{1,4} ; Hoffman-LaRoche Pharmaceuticals ⁴ ; Healthcare Technology Systems, Inc. ⁶ ; GlaxoSmithKline ^{1,3,4} ; Novartis Pharmaceuticals Corporation ⁴	4
George T. Grossberg, M.D.	Forest Laboratories, Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Janssen Pharmaceutica Inc. ^{1,3} ; AstraZeneca Pharmaceuticals ¹ ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3} ; Abbott Laboratories, Inc. ^{1,3} ; Bristol-Myers Squibb ³ ; Organon Pharmaceuticals, Inc. ³ ; U.S. Pharmaceuticals, Pfizer Inc. ³ ; SmithKline Beecham Pharmaceuticals ³ ; Eunoe ¹	69
Silvia Hafliger, M.D.	Roche Laboratories, a member of the Roche Group ⁶	37, 50
Robert E. Hales, M.D.	Bristol-Myers Squibb ^{1,4} ; GlaxoSmithKline ⁴ ; Forest Laboratories, Inc. ⁴	13, 41
Faiq Hameedi, M.D.	Eli Lilly and Company ^{1,4} ; Bristol-Myers Squibb ^{1,4} ; Janssen Pharmaceutica Inc. ^{1,4}	53
Mark B. Hamner, M.D.	AstraZeneca Pharmaceuticals ^{3,4} ; Bristol-Myers Squibb ^{3,4} ; Otsuka Pharmaceuticals ⁴ ; Forest Laboratories, Inc. ^{3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; U.S. Pharmaceuticals, Pfizer Inc. ⁵ ; Merck & Co., Inc. ⁵ ; Johnson and Johnson PRD ^{1,4,5}	5
William Harlan, M.D.	GlaxoSmithKline ⁶	12
Phyllis Harrison-Ross, M.D.	Eli Lilly and Company ⁶ ; Caraco Pharmaceutical, LTD ⁵	29
Philip D. Harvey, Ph.D.	Janssen Pharmaceutica Inc. ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4}	25
Stephan H. Heckers, M.D.	Eli Lilly and Company ⁶	13, 41, 61
David C. Henderson, M.D.	Janssen Pharmaceutica Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4}	88
Michael E. Henry	GlaxoSmithKline ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4}	61
J. Paul Hieble, Ph.D.	GlaxoSmithKline ²	42
Alan R. Hirsch, M.D.	GlaxoSmithKline ^{1,3} ; Eli Lilly and Company ^{1,3} ; Pharmacia & Upjohn Company, Inc. ^{1,3} ; Ciba Geigy Corporation, Pharmaceutical Division; Johnson and Johnson PRD; Johnson and Johnson PRD ^{1,3} ; Warner Lambert ^{1,3} ; Ayerst ^{1,3}	95
Robert M.A. Hirschfeld, M.D.	Abbott Laboratories, Inc. ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; GlaxoSmithKline ^{1,3} ; Organon Pharmaceuticals, Inc. ^{1,3} ; UCB Pharma, Inc. ¹ ; Eli Lilly and Company ^{1,4} ; Wyeth-Ayerst Laboratories ^{1,3} ; Forest Laboratories, Inc. ^{1,4} ; Janssen Pharmaceutica Inc. ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹	9
Eric Hollander, M.D.	Ortho McNeil Pharmaceuticals ¹ ; Solvay Pharmaceuticals, Inc. ^{1,3} ; UCB Pharma, Inc. ³ ; Abbott Laboratories, Inc. ^{1,3} ; U.S. Pharmaceuticals, Pfizer Inc. ³ ; Wyeth-Ayerst Laboratories ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ³	3, 63, 75, 92, 103
Rona Hu, M.D.	Cephalon Inc. ⁶	7
James I. Hudson, M.D.	Eli Lilly and Company ^{1,3} ; U.S. Pharmaceuticals, Pfizer Inc. ³ ; Ortho McNeil Pharmaceuticals ^{1,3}	67
John R. Hughes, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,3,4} ; Pharmacia & Upjohn Company, Inc. ^{1,3,4}	61
Michael Y. Hwang, M.D.	Janssen Pharmaceutica Inc. ^{1,4} ; Eli Lilly and Company ^{2,4} ; U.S. Pharmaceuticals, Pfizer Inc. ⁴	53
Dan V. Iosifescu, M.D.	GlaxoSmithKline ⁴ ; Organon Pharmaceuticals, Inc. ⁴ ; Eli Lilly and Company ⁴ ; NARSAD ³ ; Janssen Pharmaceutica Inc. ³ ; National Institute of Mental Health ³ ; Aspect Medical Systems, Inc. ³	50, 66
Waguih W. Ishak, M.D.	Eli Lilly and Company ¹ ; AstraZeneca Pharmaceuticals ¹ ; Bristol-Myers Squibb ¹ ; Bayer Corporation, Pharmaceutical Division ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ¹	1, 95

DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Jeanne Jackson-Siegel, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ^{1,4} ; Abbott Laboratories, Inc. ⁴ ; Eli Lilly and Company ^{1,4} ; Organon Pharmaceuticals, Inc. ⁴ ; AstraZeneca Pharmaceuticals ^{1,4} ; Forest Laboratories, Inc. ^{1,4}	41
Philip G. Janicak, M.D.	Abbott Laboratories, Inc. ^{3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,4} ; Pfizer Inc. ^{1,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ² ; AstraZeneca Pharmaceuticals ⁴	14
Geetha Jayaram, M.D.	GlaxoSmithKline ⁴	6, 10, 20, 45, 71, 80, 94, 99
Richard T. Jermyn, D.O.	Merck & Co., Inc. ⁴ ; Cephalon Inc. ⁴ ; Parke-Davis, Division of Warner-Lambert Company ⁴ ; Ortho McNeil Pharmaceuticals ⁴	95
Dilip V. Jeste, M.D.	AstraZeneca Pharmaceuticals ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Inc. ^{1,3} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3}	13, 74
Michael D. Jibson, M.D.	AstraZeneca Pharmaceuticals ⁴ ; U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Janssen Pharmaceutica Inc. ⁴	73
Hadine Joffe, M.D.	Eli Lilly and Company ⁴ ; GlaxoSmithKline ⁴ ; U.S. Pharmaceuticals, Pfizer Inc. ^{3,4} ; Wyeth-Ayerst Laboratories ⁴ ; Abbott Laboratories, Inc. ³	39, 40, 93
Bankole A. Johnson, M.D.	Johnson and Johnson PRD ¹ ; Ortho McNeil Pharmaceuticals ⁶	2, 64, 77
Lewis L. Judd, M.D.	Roche Biosciences ^{1,3}	21, 65
Rajinder A. Judge, M.D.	Novartis Pharmaceuticals Corporation ² ; Organon Pharmaceuticals, Inc. ⁶ ; Merck & Co., Inc. ⁵ ; U.S. Pharmaceuticals, Pfizer Inc. ⁵ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁶	5
Ned H. Kalin, M.D.	National Institutes of Health ³ ; Dana Foundation ³ ; Janssen Pharmaceutica Inc. ^{1,4} ; GlaxoSmithKline ¹ ; Forest Laboratories, Inc. ¹ ; Wyeth-Ayerst Laboratories ^{1,4} ; Novartis Pharmaceuticals Corporation ¹ ; Bristol-Myers Squibb ¹ ; Somerset Pharmaceuticals ¹ ; Corcept Therapeutics ¹ ; Neurocrine Biosciences Inc. ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Otsuka Pharmaceuticals ¹ ; Cypress ¹	66
Peter W. Kalivas, Ph.D.	Janssen Pharmaceutica Inc. ³	90
John M. Kane, M.D.	Abbott Laboratories, Inc. ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Aventis Pharmaceuticals ^{1,4} ; Organon Pharmaceuticals, Inc. ^{1,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,4} ; Janssen Pharmaceutica Inc. ^{1,4}	11
Sandra J. Kaplan, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ³	54
Shitij Kapur, M.D.	Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Wyeth-Ayerst Laboratories ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,4} ; Solvay Kingswood ¹ ; Neuromolecular, Inc. ^{1,3} ; GlaxoSmithKline ⁴	3, 12
Wayne J. Katon, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,4} ; U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; SmithKline Beecham Pharmaceuticals ^{1,4} ; Wyeth-Ayerst Laboratories ^{1,4} ; Venlafaxine ¹ ; Paxil; Duloxetine ¹ ; Forest Laboratories, Inc. ⁴ ; Pharmacia & Upjohn Company, Inc. ³	32
Walter H. Kaye, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ² ; AstraZeneca Pharmaceuticals ³	6, 60
Paul E. Keck, Jr., M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; Corcept Therapeutics ¹ ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Inc. ^{1,3} ; Eli Lilly and Company ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; UCB Pharma, Inc. ^{1,3} ; Ortho McNeil Pharmaceuticals ^{1,3} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3} ; Wyeth-Ayerst Laboratories ¹ ; Shire Ridgewood Pharmaceuticals ¹ ; Elan Pharmaceuticals ³ ; Merck & Co., Inc. ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; Organon Pharmaceuticals, Inc. ³ ; the Stanley Medical Research Institute ³	6, 31
Richard S.E. Keefe, Ph.D.	AstraZeneca Pharmaceuticals ^{1,3} ; Janssen Pharmaceutica Inc. ^{1,3} ; Aventis Pharmaceuticals ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ¹ ; Abbott Laboratories, Inc. ¹ ; GlaxoSmithKline ¹ ; Pharmacia & Upjohn Company, Inc. ¹ ; Organon Pharmaceuticals, Inc. ¹ ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3}	10
Martin B. Keller, M.D.	Bristol-Myers Squibb ^{1,4} ; Cyberonics Inc. ^{1,4} ; Eli Lilly and Company ^{1,4} ; Forest Laboratories, Inc. ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,4} ; Merck & Co., Inc. ^{1,3,4} ; Organon Pharmaceuticals, Inc. ^{1,3,4} ; Pharmastar ^{1,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Pharmacia & Upjohn Company, Inc. ^{1,4} ; Sepracor Inc. ^{1,4} ; Vela Pharmaceuticals ^{1,4} ; Mitsubishi Pharma Corporation ¹ ; Scirex ¹ ; Cypress Bioscience ^{1,4} ; Collegium ^{1,4} ; Wyeth-Ayerst Laboratories ^{1,3,4} ; Cephalon Inc. ¹ ; GlaxoSmithKline ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Somerset Pharmaceuticals ¹ ; Otsuka Pharmaceuticals ^{1,4}	6, 84
Sidney H. Kennedy, M.D.	AstraZeneca Pharmaceuticals ^{3,4} ; Boehringer Ingelheim ^{3,4} ; Eli Lilly and Company ^{2,4} ; GlaxoSmithKline ^{3,4} ; Janssen-Ortho Pharmaceutica Inc. ^{3,4} ; Lundbeck ^{3,4} ; Wyeth-Ayerst Laboratories ^{3,4} ; Servier ^{3,4}	88
Justine M. Kent, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ¹ ; Cephalon Inc. ¹	34, 92
Ronald C. Kessler, Ph.D.	GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc. ¹ ; Eli Lilly and Company ¹	2, 4

Terence A. Ketter, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Elan Pharmaceuticals ^{1,3} ; Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Cephalon Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,4} ; Shire Ridgewood Pharmaceuticals ^{1,3}	51
Paul A. Kettl, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Organon Pharmaceuticals, Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; Wyeth-Ayerst Laboratories ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} U.S. Pharmaceuticals, Pfizer Inc.; ^{1,3,4}	81
Ali Khadivi, Ph.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ¹	46
Arifulla Khan, M.D.	Wyeth-Ayerst Laboratories ⁶	13
Edward Kim, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ^{3,4} ; Janssen Pharmaceutica Inc. ⁴ ; AstraZeneca Pharmaceuticals ^{3,4} ; Forest Laboratories, Inc. ³ ; Novartis Pharmaceuticals Corporation ^{3,4}	53, 75
Bryan H. King, M.D.	Janssen Pharmaceutica Inc. ⁴	18, 100
David G. Kingdon, M.D.	Eli Lilly and Company ^{4,6} ; Janssen Pharmaceutica Inc. ^{4,6} ; Bristol-Myers Squibb ^{4,6} ; Pfizer Inc. ^{3,4,6}	8, 46
Herbert D. Kleber, M.D.	Reckitt Benckiser Pharmaceuticals ¹	48, 81, 84, 97
James H. Kocsis, M.D.	Wyeth-Ayerst Laboratories ^{3,4} ; Forest Laboratories, Inc. ^{3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{3,4}	60
Lili Kopala, M.D.	AstraZeneca Pharmaceuticals ^{1,3} ; Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3} ; Bristol-Myers Squibb ^{1,3}	9
Amos Korczyn, M.D.	Novartis Pharmaceuticals Corporation ⁶	40
Susan G. Kornstein, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ^{1,3} ; Wyeth-Ayerst Laboratories ^{1,3} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ³ ; Merck & Co., Inc. ³ ; Mitsubishi-Tokyo, Inc. ³ ; Biovail Laboratories, Inc. ³ ; Pharmacia & Upjohn Company, Inc. ³ ; Berlex Laboratories, Inc. ³ ; Novartis Pharmaceuticals Corporation ³	11
Thomas R. Kosten, M.D.	Reckitt Benckiser Pharmaceuticals ⁶	19, 39, 70
Renu Kotwal, M.D.	Ortho McNeil Pharmaceuticals ⁶	3
K. Ranga R. Krishnan, M.D.	Novartis Pharmaceuticals Corporation ³ ; U.S. Pharmaceuticals, Pfizer Inc. ¹ ; UCB Pharma, Inc. ¹ ; Somerset Pharmaceuticals ¹ ; Lilly Research Laboratories, a division of Eli Lilly and Company ¹ ; Synaptic ¹ ; GlaxoSmithKline ¹ ; Merck & Co., Inc.; Organon Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories ¹ ; Vela ¹	9, 13, 28, 41
Kurt Kroenke, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Wyeth-Ayerst Laboratories ^{1,3} ; Eli Lilly and Company ^{1,3}	8
Andrew D. Krystal, M.D.	Sepracor Inc. ^{1,3} ; Wyeth-Ayerst Laboratories ^{3,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,3}	11
David J. Kupfer, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ¹	11
Sandra L. Kweder, M.D.	GlaxoSmithKline ⁶	12
Justine K. Lalonde, M.D.	Eli Lilly and Company ³ ; U.S. Pharmaceuticals, Pfizer Inc. ³ ; Ortho McNeil Pharmaceuticals ³	67
Raymond W. Lam, M.D.	Cyberonics Inc. ^{1,4} ; Eli Lilly Canada ^{1,3,4} ; GlaxoSmithKline Canada ^{1,3,4} ; Lundbeck Canada ^{1,4} ; Pfizer Canada ^{1,4} ; Wyeth-Ayerst Canada ^{1,3,4} ; Merck & Co., Canada ^{1,3} ; Litebook Company, Inc. ^{1,4} ; Roche Canada, a member of the Roche Group ^{1,3} ; Organon Canada ^{1,4} ; Servier Canada ^{1,3}	88, 99
John Lauriello, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ¹ ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ^{1,3} ; Bristol-Myers Squibb ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4}	28
Philip Lavori, Ph.D.	Cyberonics Inc. ¹ ; Forest Laboratories, Inc. ⁶ ; Neuronetics Inc. ¹	11
Helen Lavretsky, M.D.	Eisai America Inc. ⁶	11
Barry Levin	Merck & Co., Inc. ^{3,5} ; Proctor & Gamble ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,5}	35
Frances R. Levin, M.D.	Eli Lilly and Company ¹ ; PharmaNet, Inc. ¹	47, 51, 84
Jeffrey M. Levine, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Wyeth-Ayerst Laboratories ⁴ ; GlaxoSmithKline ⁴	99
Lydia J. Lewis, B.A.	Wyeth-Ayerst Laboratories ⁶	4
Roberto Lewis-Fernandez, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴	5, 91
Jeffrey A. Lieberman, M.D.	Eli Lilly and Company ⁶	10, 28, 38
Michael R. Liebowitz, M.D.	Wyeth-Ayerst Laboratories ^{1,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,4} ; GlaxoSmithKline ^{1,4}	92
Russell F. Lim, M.D.	Bristol-Myers Squibb ¹ ; Eli Lilly and Company ¹	5
Jean-Pierre Lindenmayer, M.D.	Novartis Pharmaceuticals Corporation ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{4,6} ; Janssen Pharmaceutica Inc. ⁶ ; Bristol-Myers Squibb ⁶ ; Abbott Laboratories, Inc. ⁴	73
Marsha M. Linehan, Ph.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ³	19, 27, 58
Walter Ling, M.D.	Reckitt Benckiser Pharmaceuticals ⁴	30, 39, 70
Sarah H. Lisanby, M.D.	Neuronetics Inc. ¹	30, 83, 93
James F. List, M.D.	Ortho McNeil Pharmaceuticals ⁶	67
Donna L. Londino, M.D.	Janssen Pharmaceutica Inc. ^{1,3} ; Eli Lilly and Company ¹ ; Abbott Laboratories, Inc. ³	80
Susan Lucak, M.D.	Solvay Pharmaceuticals, Inc. ¹ ; GlaxoSmithKline ^{1,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Forest Laboratories, Inc. ¹	22

DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Constantine Lyketsos, M.D.	Forest Laboratories, Inc. ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica Inc. ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; NeuroLogic Inc. ^{1,3} ; DuPont ^{1,4} ; AstraZeneca Pharmaceuticals ¹ ; Organon Pharmaceuticals, Inc. ¹ ; Abbott Laboratories, Inc. ^{1,3,4} ; Parke-Davis, Division of Warner-Lambert Company ^{3,4} ; Bayer Corporation, Pharmaceutical Division ^{3,4} ; Eisai America Inc. ⁴ ; Novartis Pharmaceuticals Corporation ⁴ ; Lundbeck ⁴ ; Bristol-Myers Squibb ^{1,3,4}	20, 65
Thomas Lynch, M.D.	Wyeth-Ayerst Laboratories ⁶	41
Robert J. Malcolm, Jr., M.D.	Johnson and Johnson PRD ¹	64
Jose R. Maldonado, M.D.	Abbott Laboratories, Inc. ³ ; U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Forest Laboratories, Inc. ⁴	7, 15, 43, 98
Anil K. Malhotra, M.D.	Pfizer Inc. ^{1,3} ; Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Inc. ¹ ; Abbott Laboratories, Inc. ¹	63
Theo C. Manschreck, M.D.	Bristol-Myers Squibb ^{1,4} ; Eli Lilly and Company ^{1,4} ; Pfizer Inc. ^{1,4} ; Abbott Laboratories, Inc. ^{1,4}	62
Lauren B. Marangell, M.D.	Cyberonics Inc. ^{1,3,4} ; Stanley Foundation ³ ; National Institutes of Health ³ ; Eli Lilly and Company ^{1,3,4} ; Abbott Laboratories, Inc. ³ ; Bristol-Myers Squibb ^{1,4} ; Forest Laboratories, Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} ; Janssen Pharmaceutica Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Wyeth-Ayerst Laboratories ^{1,4}	30, 70, 93
Sheila Marcus, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³	61
Stephen R. Marder, M.D.	Janssen Pharmaceutica Inc. ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4}	11, 14
John C. Markowitz, M.D.	National Institute of Mental Health ³ ; Forest Laboratories, Inc. ³ ; NARSAD ³	5, 59, 101
Randall D. Marshall, M.D.	Pfizer Inc. ^{3,4} ; GlaxoSmithKline ^{3,4} ; Bristol-Myers Squibb ³ ; UCB Pharma, Inc. ³ ; Cephalon Inc. ⁶	37, 51, 69
Humberto Martinez, M.D.	Eli Lilly and Company ¹ ; Janssen Pharmaceutica Inc.; Bristol-Myers Squibb ¹	36
Prakash S. Masand, M.D.	AstraZeneca Pharmaceuticals ^{3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Forest Laboratories, Inc. ^{1,3,4} ; Wyeth-Ayerst Laboratories ^{1,3,4} ; Organon Pharmaceuticals, Inc. ¹ ; Pfizer Inc. ^{1,4} ; Novartis Pharmaceuticals Corporation ⁴ ; Eli Lilly and Company ⁴ ; Bristol-Myers Squibb ^{1,4,5}	6, 9
Helen S. Mayberg, M.D.	GlaxoSmithKline ⁶	2
W. Vaughn McCall, M.D.	Sepracor Inc. ^{1,3} ; Wyeth-Ayerst Laboratories ^{1,3} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,3}	14, 89
Robin G. McCreddie, D.Sc.	Eli Lilly and Company ³ ; U.S. Pharmaceuticals, Pfizer Inc. ³	103
Stephen P. McDermott, M.D.	Shire Ridgewood Pharmaceuticals ⁶	67
William M. McDonald, M.D.	Wyeth-Ayerst Laboratories ⁴	4
David M. McDowell, M.D.	Mallinkrot Pharmaceuticals ⁴ ; Wyeth-Ayerst Laboratories ⁴ ; Bristol-Myers Squibb ⁴	27, 44, 50, 81, 84, 94, 99
Susan L. McElroy, M.D.	Abbott Laboratories, Inc. ¹ ; Bristol-Myers Squibb ¹ ; Elan Pharmaceuticals ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Inc. ¹ ; Eli Lilly and Company ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Ortho McNeil Pharmaceuticals ^{1,3} ; Wyeth-Ayerst Laboratories ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ³ ; Forest Laboratories, Inc. ³ ; Merck & Co., Inc. ³ ; U.S. Pharmaceuticals, Pfizer Inc. ³ ; UCB Pharma, Inc. ^{1,3}	2, 9
Bruce S. McEwen, Ph.D.	Wyeth-Ayerst Laboratories ⁶	8
Roger S. McIntyre, M.D.	Wyeth-Ayerst Laboratories ^{1,4} ; Lundbeck ^{1,4} ; Janssen Pharmaceutica Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,4} ; Organon Pharmaceuticals, Inc. ^{1,4} ; Oryx ^{1,4}	9
Ian G. McKeith, M.D.	Novartis Pharmaceuticals Corporation ⁶	40
A. Thomas McLellan, Ph.D.	Perdue Pharmaceuticals ¹	57
Kris A. McLoughlin, M.S.N.	U.S. Pharmaceuticals, Pfizer Inc. ⁵	18
Laura F. McNicholas, M.D.	Reckitt Benckiser Pharmaceuticals ⁶	39, 70
Herbert Y. Meltzer, M.D.	Bristol-Myers Squibb ^{1,3} ; AstraZeneca Pharmaceuticals ^{1,3} ; Janssen Pharmaceutica Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3}	9
Alan J. Mendelowitz, M.D.	Bristol-Myers Squibb ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Wyeth-Ayerst Laboratories ⁴	92
Julien Mendlewicz, M.D.	Lundbeck ¹ ; Wyeth-Ayerst Laboratories ¹	21, 65
Matthew A. Menza, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Cephalon Inc. ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Bayer Corporation, Pharmaceutical Division ¹ ; GlaxoSmithKline ³ ; Merck & Co., Inc. ³ ; Forest Laboratories, Inc. ³	65, 86
Jonathan M. Meyer, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁶	9, 15
Barnett S. Meyers, M.D.	Forest Laboratories, Inc. ^{3,4} ; Pfizer Inc. ^{3,4} ; Eli Lilly and Company ^{1,3} ; Organon Pharmaceuticals, Inc. ^{1,4}	85
David Miklowitz, Ph.D.	Eli Lilly and Company ⁴	88
Roumen V. Milev, M.D.	Eli Lilly and Company Canada ^{1,3,4} ; GlaxoSmithKline Canada ^{1,4} ; Lundbeck Canada ^{1,3,4} ; Janssen Pharmaceutica Inc. Canada ^{1,4} ; AstraZeneca Pharmaceuticals Canada ³	88
Alexander L. Miller, M.D.	Abbott Laboratories, Inc. ⁴ ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Eli Lilly and Company; Janssen Pharmaceutica Inc. ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ³	12

Mark D. Miller, M.D.	GlaxoSmithKline ⁴ ; Forest Laboratories, Inc. ⁴	24
Rachel Miller, M.S.W.	Bristol-Myers Squibb ¹	99
Jacobo E. Mintzer, M.D.	Abbott Laboratories ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3} ; Fujisawa Institute of America ³ ; Janssen Research Foundation ^{3,4} ; Eli Lilly and Company ^{1,4} ; Johnson and Johnson PRD ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company ² ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,4} ; Forest Laboratories, Inc. ³ ; Eisai America Inc. ^{1,3,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ³ ; Somerset Pharmaceuticals ³ ; UCB Pharma, Inc. ¹ ; SmithKline Beecham Corporation ³ ; Wyeth-Ayerst Research, Inc. ³	6, 43
Shaila Misri, M.D.	GlaxoSmithKline ³ ; Lundbeck ³ ; Wyeth-Ayerst Laboratories ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; U.S. Pharmaceuticals, Pfizer Inc. ⁴	3
James E. Mitchell, M.D.	Eli Lilly and Company; Lilly Research Laboratories, a division of Eli Lilly and Company ³ Abbott Laboratories, Inc. ³	7, 60
Martha J. Morrell, M.D.	GlaxoSmithKline ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Ortho McNeil Pharmaceuticals ¹ ;	93
John C. Morris, M.D.	Eli Lilly and Company ² ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Inc. ^{1,3} ; Ono Pharma ¹ ; AstraZeneca Pharmaceuticals ¹ ; Bayer Corporation, Pharmaceutical Division ¹ ; Bristol-Myers Squibb ¹ ; Pfizer Inc. ¹ ; GlaxoSmithKline ¹ ; Merck & Co., Inc. ¹ ; NeuroDX, LLC ¹ ; Aventis Pharmaceuticals ¹ ; Eisai Inc. ¹ ; Neurochem ¹	6
Benoit H. Mulsant, M.D.	AstraZeneca Pharmaceuticals ^{1,3,4,5} ; Bristol-Myers Squibb ¹ ; Corcept Therapeutics ³ ; Alkermes ⁵ ; Elan Pharmaceuticals ⁵ ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Immune Response ⁵ ; Janssen Pharmaceutica Inc. ^{1,3,4} ; Lundbeck; National Institutes of Health ³ ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Eisai Inc. ^{1,3,4} ; Biogen ⁵ ; Celsion ⁵ ; Akzo-Nobel ⁵	85
Philip R. Muskin, M.D.	Bristol-Myers Squibb ^{1,3,4} ; Cephalon Inc. ^{1,4} ; Forest Laboratories, Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} ; Janssen Pharmaceutica Inc. ^{1,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,4}	4, 22, 73, 77, 82
Hugh Myrick, M.D.	Ortho McNeil Pharmaceuticals ⁴ ; Pfizer Inc. ^{3,4} ; UCB Pharma, Inc. ^{3,4} ; Abbott Laboratories, Inc. ^{3,4}	2
Ziad H. Nahas, M.D.	Neuronetics Inc. ³ ; Cyberonics Inc. ^{1,3} ; Medtronics ³	93
Joseph C. Napoli, M.D.	GlaxoSmithKline ^{3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{3,4} ; AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ³ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Inc. ³ ; Organon Pharmaceuticals, Inc. ³ ; Solvay Pharmaceuticals, Inc. ³ ; Wyeth-Ayerst Laboratories ³	42
Jeffrey A. Naser, M.D.	Wyeth-Ayerst Laboratories ⁴ ; Novartis Pharmaceuticals Corporation ⁴	23, 72
Henry A. Nasrallah, M.D.	AstraZeneca Pharmaceuticals ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,4} ; Abbott Laboratories, Inc. ^{1,4}	9, 24, 92
J. Craig Nelson, M.D.	Abbott Laboratories, Inc. ^{1,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ^{3,4} ; Glaxo-Wellcome ¹ ; Janssen Pharmaceutica Inc. ^{3,4} ; Organon Pharmaceuticals, Inc. ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Wyeth-Ayerst Laboratories ⁴ ; GlaxoSmithKline ^{3,4}	66
Charles B. Nemeroff, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; AFSP ³ ; AstraZeneca Pharmaceuticals ^{1,3,4} ; NAMI ³ ; NARSAD ³ Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; Merck & Co., Inc. ^{1,3} ; National Institute of Mental Health ³ ; U.S. Pharmaceuticals, Pfizer Inc. ^{3,4} ; Stanley Foundation ³ ; Wyeth-Ayerst Laboratories ^{1,3,4} ; Otsuka Pharmaceuticals ^{1,4} ; GlaxoSmithKline ^{1,3,4} ; Organon Pharmaceuticals, Inc. ^{1,4} ; Acadia Pharmaceuticals ¹ ; Corcept Therapeutics ^{1,5} ; Cypress Biosciences ¹ ; Cyberonics Inc. ¹ ; Neurocrine Biosciences Inc. ^{1,5} ; Novartis Pharmaceuticals Corporation ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Scirex ¹ ; Somerset Pharmaceuticals ¹ ; Bristol-Myers Squibb ^{1,3,4}	1, 2, 4, 29, 58, 84
John W. Newcomer, M.D.	Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4}	13, 41
Michelle G. Newman, Ph.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁶	4
Andrew A. Nierenberg, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Wyeth-Ayerst Laboratories ^{1,3,4} ; Innapharma ¹ ; Janssen Pharmaceutica Inc. ¹ ; Cyberonics Inc. ^{3,4} ; Pfizer Inc. ^{3,4} ; Bristol-Myers Squibb ³ ; Lichtwer Pharma ³ ; Organon Pharmaceuticals, Inc. ⁴ ; Cederoth ³	5, 86
Philip T. Ninan, M.D.	Eli Lilly and Company ^{1,3} ; Cephalon Inc. ^{1,3} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3} ; Cyberonics Inc. ³ ; Solvay Pharmaceuticals, Inc. ^{1,3} ; Wyeth-Ayerst Laboratories ^{1,3,4} ; Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ^{3,4} ; Janssen Pharmaceutica Inc. ^{3,4} ; Bristol-Myers Squibb ⁴	2, 92
Ruta M. Nonacs, M.D.	GlaxoSmithKline ⁴	39
Douglas Noordsy, M.D.	Eli Lilly and Company ^{3,4}	43
Carol S. North, M.D.	GlaxoSmithKline ^{1,4} ; U.S. Pharmaceuticals, Pfizer Inc. ⁴	8, 17, 82
Andrei Novac, M.D.	GlaxoSmithKline ⁴ ; Forest Laboratories, Inc. ⁴ ; U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴	104, 105

DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
H. George Nurnberg, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; SmithKline Beecham Pharmaceuticals ^{1,3,4} ; Abbott Laboratories, Inc. ^{3,4} ; Glaxo-Wellcome ^{1,4} ; Wyeth-Ayerst Laboratories ^{3,4} ; Parke-Davis, Division of Warner-Lambert Company ³ ; Robert Wood Johnson Pharmaceutical Research Institute ³ ; LIPHA Pharmaceuticals ³	86
David J. Nutt, M.D.	Cephalon Inc. ⁶	69
Charles P. O'Brien, M.D.	Alkermes ¹ ; Drug Abuse Sciences ¹ ; Schering-Plough, France ¹	48, 49
Maurice M. Ohayon, M.D.	Eli Lilly and Company ⁶	39
John M. Oldham, M.D.	Bristol-Myers Squibb ⁶	23, 38, 59, 91
Mary B. O'Malley, M.D.	Cephalon Inc. ⁴ ; Neurocrine Biosciences Inc. ⁴	67
Maria A. Oquendo, M.D.	Bristol-Myers Squibb ⁶	47, 63, 94
Patricia I. Ordorica, M.D.	Eli Lilly and Company ⁴ ; Bristol-Myers Squibb ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ¹	18, 26, 44, 46, 73, 81
Michael J. Ostacher, M.D.	AstraZeneca Pharmaceuticals ⁴	78
Michael W. Otto, Ph.D.	GlaxoSmithKline ³ ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3} ; Janssen Pharmaceutica Inc. ¹ ; UCB Pharma, Inc. ⁶ ; Lilly Research Laboratories, a division of Eli Lilly and Company ² ; Wyeth-Ayerst Laboratories ¹	6, 9
Michele T. Pato, M.D.	Organon Pharmaceuticals, Inc. ⁴ ; Solvay Pharmaceuticals, Inc. ⁴ ; Forest Laboratories, Inc. ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴	42, 73
Diana O. Perkins, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ^{3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{3,4} ; AstraZeneca Pharmaceuticals ³ ; Otsuka Pharmaceuticals ³ ; Bristol-Myers Squibb ^{1,3}	92
Roy H. Perlis, M.D.	Eli Lilly and Company ^{1,4} ; GlaxoSmithKline ⁴ ; Bristol-Myers Squibb ^{1,4} ; Elan Pharmaceuticals ³ ; AstraZeneca Pharmaceuticals ⁴	4
Ethel S. Person, M.D.	GlaxoSmithKline ⁶	4
Eric D. Peselow, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; GlaxoSmithKline ⁴	47, 50
Timothy J. Petersen, Ph.D.	Organon Pharmaceuticals, Inc. ⁶	5
Debra A. Pinals, M.D.	Pfizer Inc. ⁴ ; Eli Lilly and Company ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Janssen Pharmaceutica Inc. ⁴	81
Mark H. Pollack, M.D.	Bristol-Myers Squibb ¹ ; Cephalon Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Otsuka Pharmaceuticals ¹ ; Roche Laboratories, a member of the Roche Group ¹ ; Solvay Pharmaceuticals, Inc. ⁴ ; Forest Laboratories, Inc. ^{1,3,4} ; Wyeth-Ayerst Laboratories ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; UCB Pharma, Inc. ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} GlaxoSmithKline ^{1,3,4}	6, 92
Teodor T. Postolache, M.D.	AstraZeneca Pharmaceuticals ⁴ ; Cephalon Inc. ^{1,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ⁴ ; Abbott Laboratories, Inc. ¹	78
Marc N. Potenza, M.D.	GlaxoSmithKline ³ ; Forest Laboratories, Inc. ³	54
Steven G. Potkin, M.D.	Novartis Pharmaceuticals Corporation ^{1,3,4}	40
Konasale M.R. Prasad, M.D.	GlaxoSmithKline ⁶ ; Janssen Pharmaceutica Inc. ⁶	52
Jefferson B. Prince, M.D.	Forest Laboratories, Inc. ⁴	1, 5, 14, 39
Maria A. Pugliese, M.D.	GlaxoSmithKline ²	42
Andres J. Pumariega, M.D.	Forest Laboratories, Inc. ^{3,4}	71, 79
David C. Purselle, M.D.	Forest Laboratories, Inc. ⁶	67
Cameron D. Quanbeck, M.D.	Ortho McNeil Pharmaceuticals ⁶	2
Charles Raison, M.D.	Schering Corporation; Roche Laboratories, a member of the Roche Group ⁴ ; Wyeth-Ayerst Laboratories ⁴	39
Luis F. Ramirez, M.D.	Bristol-Myers Squibb ^{1,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Otsuka Pharmaceuticals ^{1,4} ; Abbott Laboratories, Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} ; Organon Pharmaceuticals, Inc. ^{1,4}	8, 27
Mark H. Rapaport, M.D.	Eli Lilly and Company ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{3,4} ; Eli Lilly and Company ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{3,4} ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{3,4} ; Pharmacia & Upjohn Company, Inc. ^{3,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{3,4} ; Wyeth-Ayerst Laboratories ⁴ ; Janssen Pharmaceutica Inc. ^{1,4} ; SmithKline Beecham Pharmaceuticals ⁴	1, 16, 21, 28
Natalie L. Rasgon, M.D.	Forest Laboratories, Inc. ^{1,3,4} ; Abbott Laboratories, Inc. ^{1,4} ; Eli Lilly and Company ^{1,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} ; Wyeth-Ayerst Laboratories ^{1,4}	66, 70
John F. Reinus, M.D.	Roche Laboratories, a member of the Roche Group ⁶	38
John A. Renner, Jr., M.D.	Eli Lilly and Company ⁴	80
Perry F. Renshaw, M.D.	GlaxoSmithKline ¹ ; Eli Lilly and Company ¹	61
Roy O. Resnikoff, M.D.	AstraZeneca Pharmaceuticals ⁶ ; Forest Laboratories, Inc. ⁶ ; GlaxoSmithKline ⁶ ; Bristol-Myers Squibb ⁶ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁶ ; Pfizer Inc. ⁶ ; Wyeth-Ayerst Laboratories ⁶	5
Kerry J. Ressler, M.D.	Cephalon Inc. ⁶	2
Charles F. Reynolds III, M.D.	Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ^{3,4}	91

Richard K. Ries, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ ; Bristol-Myers Squibb ⁴ ; Janssen Pharmaceutica Inc. ⁴ ; U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Forest Laboratories, Inc. ⁴	19, 65
Gerald Rogan, M.D.	Ortho Biotech, Inc. ¹	80
Steven P. Roose, M.D.	Forest Laboratories, Inc. ^{1,3} ; Organon Pharmaceuticals, Inc. ¹ ; Wyeth-Ayerst Laboratories ^{1,3} ; Eli Lilly and Company ^{1,3}	5, 11
Jerrold F. Rosenbaum, M.D.	Bristol-Myers Squibb ¹ ; Cyberonics Inc. ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ^{1,4} ; GlaxoSmithKline ¹ ; Wyeth-Ayerst Laboratories ^{1,4}	5, 30, 88
Richard N. Rosenthal, M.D.	Alkermes (Cambridge, MA) ¹	18, 101
Erik J. Roskes, M.D.	Eli Lilly and Company ⁴ ; U.S. Pharmaceuticals, Pfizer Inc. ⁵	55
Thomas Roth, Ph.D.	Takeda Pharmaceuticals ^{1,3,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,3,4} ; Cephalon Inc. ^{1,3,4} ; Sepracor Inc. ^{1,3,4} ; Merck & Co., Inc. ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Lundbeck ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Aventis Pharmaceuticals ^{1,3,4} ; Neurocrine Biosciences, Inc. ^{1,3,4}	11
Eugenio M. Rothe, M.D.	Shire Ridgewood Pharmaceuticals ¹ ; McNeil Pharmaceuticals ¹ ; AstraZeneca Pharmaceuticals ¹	72
Anthony J. Rothschild, M.D.	Bristol-Myers Squibb ^{3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{3,4} ; Merck & Co., Inc. ^{3,4} ; Wyeth-Ayerst Laboratories ³ ; Abbott Laboratories, Inc. ⁴ ; Forest Laboratories, Inc. ⁴ ; U.S. Pharmaceuticals, Pfizer Inc. ⁴	85, 97
Peter P. Roy-Byrne, M.D.	GlaxoSmithKline ^{1,3,4} ; Cephalon Inc. ¹ ; Forest Laboratories, Inc. ^{1,3,4} ; Janssen Pharmaceutica Inc. ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Pharmacia & Upjohn Company, Inc. ^{1,4} ; Wyeth-Ayerst Laboratories ^{1,4} ; Roche Laboratories, a member of the Roche Group; Novartis Pharmaceuticals Corporation ⁴ ; Alza ¹	32, 67
Michael N. Rubenstein, M.D.	Janssen Pharmaceutica Inc. ⁶	42
A. John Rush, M.D.	Robert Wood Johnson Pharmaceutical Research Institute ³ ; National Institute of Mental Health ³ ; Stanley Foundation ³ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ^{1,4} ; Cyberonics Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} ; Merck & Co., Inc. ^{1,4} ; Wyeth-Ayerst Laboratories ⁴ ; Bristol-Myers Squibb ⁴	5, 27, 30, 84
J. Michael Ryan, M.D.	National Institute of Mental Health ³ ; Janssen Research Foundation ^{3,4} ; Eisai Inc. ⁴ ; Novartis Pharmaceuticals Corporation ¹ ; Bristol-Myers Squibb ^{1,4} ; U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Abbott Laboratories, Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Mitsubishi Pharma Corporation ³	13, 41
Gary S. Sachs, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,4} ; Eli Lilly and Company ^{1,4} ; Bristol-Myers Squibb ^{1,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Sigma-Tau ¹ ; Elan Pharmaceuticals ¹ ; Solvay Pharmaceuticals, Inc. ⁴ ; U.S. Pharmaceuticals, Pfizer Inc. ⁴	9
Harold A. Sackeim, Ph.D.	Cyberonics Inc. ^{1,3} ; Neuronetics, Inc. ¹ ; Forest Laboratories, Inc. ⁶	11, 30, 83
Martha Sajatovic, M.D.	Eli Lilly and Company ^{1,3,4} ; Bristol-Myers Squibb ^{3,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Abbott Laboratories, Inc. ³ ; Janssen Pharmaceutica Inc. ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,4}	27
Kenneth M. Sakarye, M.D.	Bristol-Myers Squibb ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ¹	17
Stephen P. Salloway, M.D.	Pfizer Inc. ^{1,3,4} ; Eisai Inc. ^{1,3,4} ; Johnson and Johnson PRD ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4}	11
Carl Salzman, M.D.	Otsuka Pharmaceuticals ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3}	4
Mary Sano, Ph.D.	Novartis Pharmaceuticals Corporation ¹ ; Janssen Pharmaceutica Inc. ¹ ; Forest Laboratories, Inc. ¹	6
Seddon R. Savage, M.D.	Ortho McNeil Pharmaceuticals ^{1,4} ; Janssen Pharmaceutica Inc. ⁴ ; Purdue Pharma ¹	30
Mary Ann Schaepper, M.D.	AstraZeneca Pharmaceuticals ¹ ; Bristol-Myers Squibb ¹	72
Martin B. Scharf, Ph.D.	Sepracor Inc. ^{1,3,4} ; Neurocrine Biosciences Inc. ^{1,3,4}	99
Alan F. Schatzberg, M.D.	Abbott Laboratories, Inc. ^{1,4} ; Aventis Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,3,4} ; Organon Pharmaceuticals, Inc. ^{1,4} ; Concept Therapeutics ^{1,4,5} ; Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} ; Innapharma ^{1,4} ; Janssen Pharmaceutica Inc. ^{1,4} ; Merck & Co., Inc. ^{1,4,5} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Somerset Pharmaceuticals ^{1,4} ; Pharmacia & Upjohn Company, Inc. ^{1,4} ; Wyeth-Ayerst Laboratories ^{1,4,5} ; U.S. Pharmaceuticals, Pfizer Inc. ⁵ ; Solvay Pharmaceuticals, Inc. ^{1,4} ; Cypress Biosciences ⁵ ; Elan Pharmaceuticals ⁵	28, 39, 44, 56, 66
S. Charles Schulz, M.D.	Abbott Laboratories, Inc. ³ ; Janssen Pharmaceutica Inc. ³ ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4}	5, 6
Larry J. Seidman, Ph.D.	Shire Ridgewood Pharmaceuticals ⁶	39
Stuart N. Seidman, M.D.	Bayer Corporation, Pharmaceutical Division ¹ ; GlaxoSmithKline ¹ ; ICOS ¹ ; Lilly Research Laboratories, a division of Eli Lilly and Company ¹	12

DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
David V. Sheehan, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ⁴ ; Boots Pharmaceuticals ⁴ ; Boehringer Ingelheim Pharmaceuticals; Bristol-Myers Squibb ^{3,4} ; GlaxoSmithKline ^{1,4} ; ICI ⁴ ; Burroughs-Wellcome Pharmaceutical Company ^{3,4} ; Eli Lilly and Company ⁴ ; Cephalon Inc. ¹ ; Giba Geigy Corporation, Pharmaceutical Division ⁴ ; Dista Products Company ⁴ ; Quintiles ³ ; Excerpta Medica Asia ⁴ ; Glaxo Pharmaceuticals ⁴ ; Humana ⁴ ; McNeil Pharmaceuticals ⁴ ; Kali-Duphar Laboratories, Inc. ^{3,4} ; Glaxo-Wellcome ³ ; Merck Sharp & Dohme ⁴ ; Organon Inc. ⁴ ; Parke-Davis, Division of Warner-Lambert Company ^{3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{3,4} ; Pharmacia & Upjohn Company, Inc. ^{1,4} ; Rhone-Poulenc Rorer Pharmaceuticals ⁴ ; Roerig ⁴ ; Roche Laboratories, a member of the Roche Group ^{1,4} ; Sandoz Pharmaceuticals ^{3,4} ; Faxmed, Inc. ¹ ; Schering Corporation ⁴ ; SmithKline Beecham Pharmaceuticals ^{3,4} ; Solvay Pharmaceuticals, Inc. ⁴ ; Tap Holdings, Inc. ^{3,4} ; The Upjohn Company ⁴ ; Wyeth-Ayerst Laboratories ^{1,4} ; Eisai America, Inc. ³ ; National Institutes of Health ⁴ ; Forest Laboratories, Inc. ³ ; International Clinical Research ³ ; Janssen Pharmaceutica Inc. ³ ; Novartis Pharmaceuticals Corporation ³ ; Marion-Merrell Dow ⁴ ; Sanofi-Synthelabo Recherche (L.E.R.S.) ³ ; Sanofi-Synthelabo Research; Cortex Pharmaceutical ¹	6, 22
Yvette I. Sheline, M.D.	Wyeth-Ayerst Laboratories ¹	20
Hong Shen, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁵	72
Kenneth I. Shulman, M.D.	Eli Lilly and Company ⁶	13
Sally A. Shumaker, Ph.D.	Eli Lilly and Company ⁴ ; Wyeth-Ayerst Laboratories ¹ ; GlaxoSmithKline ⁶	12, 40
Larry J. Siever, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ⁶	85
Jonathan M. Silver, M.D.	Novartis Pharmaceuticals Corporation ^{1,3}	87, 88, 93
Naomi M. Simon, M.D.	Cephalon Inc. ³ ; Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ^{3,4} ; UCB Pharma, Inc. ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Janssen Pharmaceutica Inc. ³ ; Novartis Pharmaceuticals Corporation ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ^{3,4} ; Wyeth-Ayerst Laboratories ³ ; Pharmacia & Upjohn Company, Inc. ³	6, 92
Samuel G. Siris, M.D.	Bristol-Myers Squibb ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ¹ ; Abbott Laboratories, Inc. ¹	53
Elizabeth Sirota, M.D.	Janssen Pharmaceutica Inc. ³	80
Andrew E. Skodol II, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁵ ; Bristol-Myers Squibb ⁶	38, 101
Christine E. Skotzko, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴	42
Gary W. Small, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ^{1,4} ; Eisai Inc. ^{1,4} ; Janssen Pharmaceutica Inc. ^{1,4} ; Amersham ^{1,4} ; Organon Pharmaceuticals, Inc. ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Abbott Laboratories, Inc. ^{1,4} ; Forest Laboratories, Inc. ^{1,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,4}	11
Michael W. Smith, M.D.	Janssen Pharmaceutica Inc. ^{3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ ; Bristol-Myers Squibb ^{3,4} ; Stanley Foundation ³	5
Claudio N. Soares, M.D.	Wyeth-Ayerst Laboratories ^{1,4} ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,4}	12, 39, 88
Thomas J. Spencer, M.D.	Shire Pharmaceuticals Development, Inc. ^{1,3} ; Abbott Laboratories, Inc. ³ ; Bristol-Myers Squibb ³ ; Cephalon Inc. ³ ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; McNeil Pharmaceuticals ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; Celltech Pharmaceuticals, Ltd. ^{3,4} ; Wyeth-Ayerst Laboratories ^{3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3} ; Shire US Inc. ^{3,4}	2, 67
David Spiegel, M.D.	Wyeth-Ayerst Laboratories ⁶	4, 7, 15, 51, 56, 87
Margaret G. Spinelli, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline ⁴	10, 70, 100
Stephen M. Stahl, M.D.	AstraZeneca Pharmaceuticals ^{1,3,4} ; Bayer Corporation, Pharmaceutical Division ^{1,3} ; Asahi ^{1,3} ; Boehringer Ingelheim ^{1,3} ; Bristol-Myers Squibb ^{1,3,4} ; Cephalon Inc. ^{1,3,4} ; Cypress Bioscience ^{1,3} ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Lundbeck ^{1,3,4} ; Organon Pharmaceuticals, Inc. ^{1,3,4} ; Watson ^{1,3,4} ; Parke-Davis, Division of Warner-Lambert Company ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Pharmacia & Upjohn Company, Inc. ^{1,3,4} ; Yamanouchi ^{1,3} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,3,4} ; Wyeth-Ayerst Laboratories ^{1,3,4} ; Abbott Laboratories, Inc. ¹ ; Aventis Pharmaceuticals ¹ ; Lorex ¹ ; Neurocrine Biosciences, Inc. ¹ ; Novartis Pharmaceuticals Corporation; Roche Laboratories, a member of the Roche Group ¹ ; Searle ¹ ; Sumitomo ¹ ; Takeda Abbott Pharmaceuticals ¹	7, 9
Dan J. Stein, M.D.	AstraZeneca Pharmaceuticals ⁶ ; Eli Lilly and Company ⁶ ; GlaxoSmithKline ⁶ ; Lundbeck ⁶ ; Orion ⁶ ; U.S. Pharmaceuticals, Pfizer Inc. ⁶ ; Pharmacia & Upjohn Company, Inc. ⁶ ; Servier ⁶ ; Solvay Pharmaceuticals, Inc. ⁶ ; Roche Laboratories, a member of the Roche Group ⁶ ; Wyeth-Ayerst Laboratories ⁶ ; Sumitomo ⁶ ; Ortho McNeil Pharmaceuticals ⁶	3, 63

Murray B. Stein, M.D.	Eli Lilly and Company ^{1,3,4} ; Forest Laboratories, Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ³ ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3} ; GlaxoSmithKline ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ^{1,3,4} ; Wyeth-Ayerst Laboratories ^{1,3,4} ; Allergan ¹ ; ALZA Corporation ¹ ; Alexza Molecular Delivery ¹ ; Janssen Research Foundation ¹ ; Vela Pharmaceuticals ¹ ; Hoffman-LaRoche Pharmaceuticals ¹ ; Johnson and Johnson PRD ¹ ; UCB Pharma, Inc. ^{1,3} ; Cephalon Inc. ¹ ; Pfizer Canada ^{1,3,4}	6, 34, 66, 67
Meir Steiner, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Lundbeck ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Wyeth-Ayerst Laboratories ^{1,3,4} ; Proctor & Gamble ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Ortho McNeil Pharmaceuticals ^{1,3,4} ; Merck & Co., Inc. ^{1,3,4} ; Berlex Laboratories ^{1,3,4} ; Barr Laboratories ^{1,3,4}	39, 61
Donna E. Stewart, M.D.	Eli Lilly and Company ^{1,3,4} ; Roche Laboratories, a member of the Roche Group ⁴ ; Wyeth-Ayerst Laboratories ^{1,4}	86, 104
Frederick J. Stoddard, Jr., M.D.	U.S. Pharmaceuticals, Pfizer Inc. ^{3,4} ; GlaxoSmithKline ³	45
Nada L. Stotland, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; GlaxoSmithKline ⁴ ; Wyeth-Ayerst Laboratories ⁴	7, 53, 73, 86
Zachary N. Stowe, M.D.	Pfizer Inc. ^{3,4} ; GlaxoSmithKline ^c ; Eli Lilly and Company ⁴ ; Wyeth-Ayerst Laboratories ⁴	2
Eric C. Strain, M.D.	Reckitt Benckiser Pharmaceuticals ⁶	70
T. Scott Stroup, M.D.	Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Inc. ⁴ ; Bristol-Myers Squibb ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ¹	10
Trey Sunderland, M.D.	Eisai Inc. ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ¹ ; Lundbeck ¹ ; Bristol-Myers Squibb ¹ ; Janssen Pharmaceutica Inc. ¹ ; Forest Laboratories, Inc. ¹	13, 41
Alan C. Swann, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; Ortho McNeil Pharmaceuticals ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; UCB Pharma, Inc. ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ² ; Shire Ridgewood Pharmaceuticals ^{1,3}	3, 33
James M. Swanson, M.D.	Janssen Pharmaceutica Inc. ^{1,3} ; Shire Ridgewood Pharmaceuticals ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Cephalon Inc. ^{1,3} ; McNeil Pharmaceuticals ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3}	7
Conrad M. Swartz, M.D.	Abbott Laboratories, Inc. ¹	33, 89
Holly A. Swartz, M.D.	Eli Lilly and Company ⁴ ; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline ⁴	59, 102
Robert M. Swift, M.D.	Johnson and Johnson PRD ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ¹ ; Drug Abuse Sciences ³	64
Rajiv Tandon, M.D.	AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; Otsuka Pharmaceuticals ^{1,3,4} ; Abbott Laboratories, Inc. ^{1,4} ; Eli Lilly and Company ^{1,3,4}	3, 14, 92
Rudolph Tanzi, Ph.D.	Forest Laboratories, Inc. ⁶	13
Pierre N. Tariot, M.D.	AstraZeneca Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4}	13, 41
Warren D. Taylor, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Wyeth-Ayerst Laboratories ⁴ ; Janssen Pharmaceutica Inc. ⁴	6, 41
Mugdha E. Thakur, M.D.	Sepracor Inc. ⁶	11
Michael E. Thase, M.D.	Bristol-Myers Squibb ^{1,4} ; Cephalon Inc. ¹ ; Pharmacia & Upjohn Company, Inc. ^{1,3,4} ; Forest Laboratories, Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc. ^{1,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,4} ; Cyberonics Inc. ^{1,3} ; Solvay Pharmaceuticals, Inc. ⁴ ; Wyeth-Ayerst Laboratories ^{1,3,4} ; Eli Lilly and Company ⁴	3, 9, 58, 66, 73, 86
Mauricio F. Tohen, M.D.	Eli Lilly and Company ²	79
Anna Marie Toto, M.Ed.	Eli Lilly and Company ⁶	75
Glenn J. Treisman, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Boehringer Ingelheim ⁴ ; Abbott Laboratories, Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Wyeth-Ayerst Laboratories ⁴ ; Roche Laboratories, a member of the Roche Group; Schering Corporation ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴	19, 20, 47, 50, 70
Richard N. Trosch, M.D.	AstraZeneca Pharmaceuticals ⁶	13
Werner Tschan, M.D.	Eli Lilly and Company ³ ; GlaxoSmithKline ³ ; Lundbeck ³	54
John W. Tsuang, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Inc. ⁴ ; Abbott Laboratories, Inc. ⁴	19, 82
Phebe M. Tucker, M.D.	Pharmacia & Upjohn Company, Inc. ^{3,4} ; Solvay Pharmaceuticals, Inc. ^{3,4} ; Cephalon Inc.; Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ³ ; U.S. Pharmaceuticals, Pfizer Inc. ³ ; Wyeth-Ayerst Laboratories ³ ; Ortho McNeil Pharmaceuticals ^{3,4}	8
Larry E. Tune, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Abbott Laboratories, Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4}	15, 71
Douglas Turkington, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Bristol-Myers Squibb ⁴ ; Janssen Pharmaceutica Inc. ^{4,6} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{4,6}	8, 46
T. Bedirhan Ustun, M.D.	Eli Lilly and Company ⁶	2

DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Michael A. Van Ameringen, M.D.	AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ³ ; Cephalon Inc. ¹ ; GlaxoSmithKline ^{1,3,4} ; Eli Lilly and Company ³ ; Janssen-Ortho Pharmaceutica Inc. ³ ; Lundbeck ³ ; Novartis Pharmaceuticals Corporation ¹ ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Wyeth-Ayerst Laboratories ^{1,3} ; Solvay Pharmaceuticals, Inc. ¹	23
Eve Van Cauter, M.D.	Neurocrine Biosciences, Inc. ⁶	67
George I. Viamontes, M.D.	Johnson and Johnson PRD ⁵ ; Wyeth-Ayerst Laboratories ³ ; GlaxoSmithKline ³ ; Pfizer Inc. ³	45, 58
Adele C. Viguera, M.D.	Eli Lilly and Company ⁶ ; GlaxoSmithKline ⁶	4, 69, 93
Nora D. Volkow, M.D.	AstraZeneca Pharmaceuticals ⁶	3, 20, 35, 44
Serena Y. Volpp, M.D.	GlaxoSmithKline ⁶	4
Elizabeth Vreeland, M.S.N.	Eli Lilly and Company ^{1,3,4,6} ; Johnson and Johnson PRD ⁵	75
Karen D. Wagner, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,3} ; Wyeth-Ayerst Laboratories ^{1,3} ; Cyberonics Inc. ¹ ; Forest Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,4} ; UCB Pharma, Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,4} ; Otsuka Pharmaceuticals ¹ ; Eli Lilly and Company ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; Organon Inc. ³ ; National Institute of Mental Health ³	9
B. Timothy Walsh, M.D.	Eli Lilly and Company ³ ; Ortho McNeil Pharmaceuticals ³	62, 67
James K. Walsh, Ph.D.	Cephalon Inc. ^{1,3}	97
James G. Waxmonsky, M.D.	Cephalon Inc. ¹ ; McNeil Pharmaceuticals ⁴ ; AstraZeneca Pharmaceuticals; Eli Lilly and Company ² ; Janssen Pharmaceutica Inc. ⁴	67
Allison M. Wehr, M.D.	Bristol-Myers Squibb ⁶	45, 57
Peter J. Weiden, M.D.	AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Janssen Pharmaceutica Inc. ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4}	3, 11
Risa B. Weisberg, Ph.D.	U.S. Pharmaceuticals, Pfizer Inc. ³	6
Jeffrey Weiss, Ph.D.	Bristol-Myers Squibb ⁵	19
Margaret D. Weiss, M.D.	Eli Lilly and Company ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Purdue Pharma ¹ ; Janssen-Ortho Pharmaceutica Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} ; Circa Dia ^{1,4} ; Johnson and Johnson PRD ^{1,4} ; Shire Ridgewood Pharmaceuticals ^{1,4} ; Pharmacia & Upjohn Company, Inc. ^{1,4}	2
Gary L. Wenk, Ph.D.	Forest Laboratories, Inc. ⁶	6
Paul Whalen, Ph.D.	Wyeth-Ayerst Laboratories ⁶	66
Timothy E. Wilens, M.D.	Abbott Laboratories, Inc. ^{1,3,4} ; Celltech Medieva ^{1,3,4} ; McNeil Pharmaceuticals ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; National Institute of Mental Health ^{1,3,4} ; National Institute on Drug Abuse ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; SmithKline Beecham Pharmaceuticals ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4}	39, 65, 67, 106
John W. Winkelman, M.D.	U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; UCB Pharma, Inc. ^{1,4} ; Ortho McNeil Pharmaceuticals ^{1,4} ; Cephalon Inc. ^{1,4} ; Sepracor Inc. ^{1,4} ; Elan Pharmaceuticals ^{1,4} ; Eli Lilly and Company ^{1,4} ; Wyeth-Ayerst Laboratories ^{1,4}	55, 67, 92
Daniel K. Winstead, M.D.	Abbott Laboratories, Inc. ^{3,4} ; AstraZeneca Pharmaceuticals ⁴ ; Bristol-Myers Squibb ⁴ ; CoCensys ⁴ ; Dista Products, A Division of Eli Lilly Company ⁴ ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ¹ ; Janssen Pharmaceutica Inc. ^{3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ³ ; Roerig Division, Pfizer, Inc. ^{3,4} ; SmithKline Beecham Pharmaceuticals ^{3,4} ; Wyeth-Ayerst Laboratories ^{3,4} ; The Upjohn Company (with Solvay) ^{3,4} ; Pharmacia & Upjohn Company, Inc. ³	27
Katherine L. Wisner, M.D.	Pfizer Inc. ^{1,3,4} ; GlaxoSmithKline ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,4}	70, 100
Tom Wolfe	Wyeth-Ayerst Laboratories ⁶	38
Janet Wozniak, M.D.	Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Inc. ⁴ ; GlaxoSmithKline ⁶	69, 85
Joel Yager, M.D.	Ortho McNeil Pharmaceuticals ¹	7, 15, 47, 60, 93
Rachel Yehuda, Ph.D.	Johnson and Johnson PRD ^{1,3,4} ; U.S. Pharmaceuticals, Pfizer Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Wyeth-Ayerst Laboratories ⁶ ; Novartis Pharmaceuticals Corporation ¹	75, 92, 105
Kimberly A. Yonkers, M.D.	Berlex Laboratories ³ ; GlaxoSmithKline Beecham Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ⁴ ; U.S. Pharmaceuticals, Pfizer Inc. ⁴ ; Wyeth-Ayerst Laboratories ⁴	6, 61, 100
Stuart C. Yudofsky, M.D.	Bristol-Myers Squibb ⁶	13, 41, 45, 70, 93
Deborah A. Yurgelun-Todd, Ph.D.	Eli Lilly and Company ²	4, 41, 61
Mary C. Zanarini, Ed.D.	Eli Lilly and Company ^{1,3}	23, 38, 64, 102
Wei Zhang, M.D.	Cephalon Inc. ⁶ ; U.S. Pharmaceuticals, Pfizer Inc. ⁶	4, 93
Douglas M. Ziedonis, M.D.	Janssen Pharmaceutica Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4}	48, 62, 84, 100
Joseph Zohar, M.D.	Novartis Pharmaceuticals Corporation ¹ ; Wyeth-Ayerst Laboratories ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,4} ; Lundbeck ^{1,3} ; Pfizer Inc. ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ²	92
Jon-Kar Zubieta, M.D.	Wyeth-Ayerst Laboratories ⁶	8, 30

Voting members of the Board of Trustees, Assembly officers, and members of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participation in Industry-Supported Symposia. In accordance with this policy, the following members are participating in an Industry-Supported Symposium and will not receive any compensation:

Presenter	Program Page #
Glen O. Gabbard, M.D.	38
Geetha Jayaram, M.D.	6
Philip R. Muskin, M.D.	4

The following presenters on this year's scientific program had not, at the time of this book's printing, returned the APA Disclosure Form. In accordance with APA policy, these presenters are required to submit a Disclosure Form and also provide oral or visual disclosure to participants at the session.

Margo S. Adams.....	53	Roy M. Gulick, M.D.	63	Alessandro Nicolo	46
Cristiano Adiutori.....	46	Erik W. Gunderson, M.D.	81	Stefania Papirio	46
Jeffrey S. Akman, M.D.	15, 43	Charles J. Hynes, J.D.	27	Trevor R. P. Price, M.D.	99
Jack D. Barchas, M.D.	44	Samuel C. Klagsbrun, M.D.	27	Ricardo Secin, M.D.	58
Gregory Brown, Ph.D.	19	Norwood Knight-Richardson, M.D.	83	Anne J. Swern, J.D.	27
Bill Burmester, M.A.	82	Lynn Lavendar, Esq.	99	Rozaliya Vernikov, M.D.	74
B.J. Casey, Ph.D.	72	Kenneth Linn, Esq.	27	Gabriel Weimann, Ph.D.	31
Lisa Colosimo.....	46	David B. Mallott, M.D.	99	Francine Weiss, Esq.	73
David W. Garland, Esq.	73	Michael L. Melamed, M.D.	74	Robert A. Wise, M.D.	45
Harvey R. Greenberg, M.D.	90	Melodie Morgan-Minott, M.D.	72		

This page intentionally left blank

SATURDAY, MAY 1, 2004

157TH ANNUAL MEETING

8:00 a.m. Sessions



COURSES 1-3

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 1 8:00 a.m.-12 noon
Room 1E06, Level 1, Javits Center

ASSESSMENT AND TREATMENT OF DRUG-INDUCED MOVEMENT DISORDERS

Director: Herman M. Van Praag, M.D.
Faculty: Anton J.M. Loonen, M.D.

COURSE 2 8:00 a.m.-12 noon
Room 1E09, Level 1, Javits Center

ADD IN CHILDREN AND ADOLESCENTS

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 3 8:00 a.m.-12 noon
Room 2D02/3, Level 2, Javits Center

USING NEUROFEEDBACK IN YOUR PRACTICE: INTRODUCTION WITH HANDS-ON EXPERIENCE

Co-Directors: Thomas M. Broad, M.D., Michael Cohen
Faculty: Laurence Hirshberg, Ph.D., Henry B. Mann, M.D.

9:00 a.m. Sessions



COURSES 4-6

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 4 9:00 a.m.-4:00 p.m.
Room 1E17, Level 1, Javits Center

INTERPERSONAL PSYCHOTHERAPY

Director: Scott P. Stuart, M.D.
Faculty: Paula Ravitz, M.D.

COURSE 5 9:00 a.m.-4:00 p.m.
Rooms 2D10/11, Level 2, Javits Center

THE BIOPSYCHOSOCIAL FORMULATION: AN APPROACH TO ORAL BOARD PRESENTATIONS

Co-Directors: William H. Campbell, M.D., Robert M. Rohrbaugh, M.D.
Faculty: Catherine Chiles, M.D., Paul D. Kirwin, M.D.

COURSE 6 9:00 a.m.-4:00 p.m.
Rooms 2D14/15, Level 2, Javits Center

THE CONCEPTUAL BASIS OF PSYCHIATRY

Co-Directors: S. Nassir Ghaemi, M.D., David H. Brendel, M.D.

12:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 1-5

INDUSTRY-SUPPORTED SYMPOSIUM 1
12:30 p.m.-3:30 p.m.
Special Events Hall 1D, Level 1, Javits Center

TREATMENT RESISTANCE: CONCEPTS AND MANAGEMENT IN MOOD AND ANXIETY DISORDERS
Supported by Janssen Pharmaceutica and Research Foundation

Chp.: Mark H. Rapaport, M.D.

A Treatment Resistance in Mood and Anxiety Disorders: Evidence From Clinical Trials
Ellen Frank, Ph.D.

B Psychotherapeutic Approaches for Patients With Treatment-Resistant Mood and Anxiety Disorders
Edna B. Foa, Ph.D.

C Clinical Pathways for Mood and Anxiety Disorders
Waguih W. Ishak, M.D.

D Emerging Treatment Options in Treatment-Resistant Mood and Anxiety Disorders
Mark H. Rapaport, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 2
12:30 p.m.-3:30 p.m.
Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

PREVENTIVE PSYCHIATRY IN MOOD DISORDERS: A NEW FRONTIER
Supported by GlaxoSmithKline

Chp.: Charles B. Nemeroff, M.D.

(Continued on next page)

SATURDAY

A Identification of Risk Factors for Development of Depression: Focus on Early-Life Trauma
Charles B. Nemeroff, M.D.

B Achieving the Optimal Balance Between Treatment of Maternal Depression and Infant Medication Exposure
Zachary N. Stowe, M.D.

C Functional Brain Imaging: Subtyping Depression
Helen S. Mayberg, M.D.

D Genetic Research in Psychiatry: Diagnostic and Therapeutic Implications
Stephan Claes, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 3

12:30 p.m.-3:30 p.m.

Grand Ballroom East, Third Floor, Hilton New York

BIPOLAR DISORDER AND ALCOHOLISM: DIAGNOSTIC CHALLENGES AND THERAPEUTIC INTERVENTIONS

Supported by Ortho-McNeil Pharmaceuticals

Chp.: Mark A. Frye, M.D.

A Neurobiology of Alcohol Withdrawal
Hugh Myrick, M.D.

B Pharmacotherapy for Alcoholism
Bankole A. Johnson, M.D.

C The Impact of Alcoholism on the Presentation and Course of Bipolar Disorder
Susan L. McElroy, M.D.

D The Role of Mood Stabilizers in Bipolar Disorder With Comorbid Alcohol Dependence
Joseph F. Goldberg, M.D.

E Bipolar Illness, Substance Abuse Comorbidity, and the Legal System
Cameron D. Quanbeck, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 4

12:30 p.m.-3:30 p.m.

Broadway Ballroom, Sixth Floor, Marriott Marquis

ADULT ADHD: CLINICAL UTILITY AND VALIDITY

Supported by Eli Lilly and Company

Chp.: T. Bedirhan Üstün, M.D.

A Prevalence of Adult ADHD in the United States: Results From the National Comorbidity Survey Replication (NCS-R)
Ronald C. Kessler, Ph.D.

B Adult ADHD Diagnostic and Self-Report Symptom Scales: Development and Validation in the National Comorbidity Survey Replication (NCS-R) Cohort
Lenard A. Adler, M.D.

C Current Concepts in the Neurobiology of ADHD
Joseph Biederman, M.D.

D Treatment Options and Response Patterns in Adult ADHD
Margaret D. Weiss, M.D.

E Our New Understanding of the Prevalence, Impairments, Comorbidity, and Treatment of Adults With ADHD
Thomas J. Spencer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 5

12:30 p.m.-3:30 p.m.

Imperial Ballroom A, Second Floor, Sheraton New York

TOWARDS DSM-V: PHENOMENOLOGY, NEUROBIOLOGY, AND TREATMENT RESPONSE IN DEPRESSION

Supported by Cephalon, Inc.

Chp.: Philip T. Ninan, M.D.

A Pathophysiology of Major Depression: Monoamines, Peptides, and Neurotrophins
Kerry J. Ressler, M.D.

B Homology Between Pathophysiology and Symptoms in Major Depression
Boadie W. Dunlop, M.D.

C Enhancing Emergence of Antidepressant Benefit
Charles DeBattista, M.D.

D Pharmacological Approaches to Management of Residual Symptoms in Depression
Maurizio Fava, M.D.

E MIND: Lessons From the Brain
Philip T. Ninan, M.D.

1:00 p.m. Sessions



COURSES 7-12

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 7 1:00 p.m.-5:00 p.m.
Room 1E01/2, Level 1, Javits Center

MANAGEMENT OF PSYCHIATRIC DISORDERS IN PREGNANT AND POSTPARTUM MOTHERS: OVERVIEW

Co-Directors: Shaila Misri, M.D., Diana Carter, M.B.
Faculty: Maria R. Corral, M.D., Deirdre M. Ryan, M.B.

COURSE 8 1:00 p.m.-5:00 p.m.
Room 1E06, Level 1, Javits Center

BEHAVIORAL NEUROANATOMY: AN INTRODUCTION

Director: Nashaat N. Boutros, M.D.
Faculty: David L. Clark, Ph.D., Edward C. Lauterbach, M.D.

COURSE 9 1:00 p.m.-5:00 p.m.
Room 1E09, Level 1, Javits Center

PSYCHIATRIC GENOMICS: APPLICATIONS FOR CLINICAL PRACTICE

Director: David A. Mrazek, M.D.
Faculty: John L. Black, M.D., Brett A. Koplin, M.D.

COURSE 10 1:00 p.m.-5:00 p.m.
Rooms 2D02/3, Level 2, Javits Center

COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS

Director: Jesse H. Wright, M.D.
Faculty: Michael E. Thase, M.D., Monica A. Basco, Ph.D.

COURSE 11 1:00 p.m.-5:00 p.m.
Rooms 2D04/5, Level 2, Javits Center

ASSESSING THE RISK OF VIOLENCE IN BOTH FORENSIC AND SEX OFFENDER SETTINGS

Director: Bradley R. Johnson, M.D.
Faculty: Judith V. Becker, Ph.D.

COURSE 12 1:00 p.m.-5:00 p.m.
Rooms 2D06/7, Level 2, Javits Center

SYSTEMIC THERAPIES FOR SUBSTANCE ABUSE DISORDERS

Co-Directors: Peter J. Steinglass, M.D., Marc Galanter, M.D.

6:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 6-11

INDUSTRY-SUPPORTED SYMPOSIUM 6

6:00 p.m.-9:00 p.m.

Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

THE ROLE OF DOPAMINE IN HEALTH AND ILLNESS: SCIENCE TO PRACTICE

Supported by AstraZeneca Pharmaceuticals

Chp.: Peter J. Weiden, M.D.

A The Role of Dopamine as a Mediator of Normal Human Reward

Nora D. Volkow, M.D.

B From Dopamine to Salience to Psychosis: Why Antipsychotics Are Antipsychotic

Shitij Kapur, M.D.

C Dopamine and Neuroleptic Dysphoria in Practice

Peter J. Weiden, M.D.

D The Role of Dopaminergic/Cholinergic Interaction in Cognition and Psychosis

Rajiv Tandon, M.D.

E The Role of Dopamine in the Neurobiology of Sexual Dysfunction

Abdelouahed Elmouchtari, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 7

6:00 p.m.-9:00 p.m.

Grand Ballroom East, Third Floor, Hilton New York

IMPULSIVITY: EMERGING CLINICAL PERSPECTIVES

Supported by Ortho-McNeil Pharmaceuticals

Chp.: Eric Hollander, M.D.

A Neurobiology of Impulsive Behavior

Alan C. Swann, M.D.

B When Does Impulsive Behavior Become Pathologic?

Ernest S. Barratt, M.D.

C Clinical Issues of Impulsivity in Psychiatry

Dan J. Stein, M.D.

D Addressing Impulsive Behavior in Eating Disorders

Renu Kotwal, M.D.

E Identifying the Spectrum of Impulse-Control Disorders

Eric Hollander, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 8

6:00 p.m.-9:00 p.m.

Broadway Ballroom, Sixth Floor, Marriott Marquis

**BIPOLAR DISORDER: IMPROVING OUTCOMES
WHEN THEORY, SCIENCE, AND CLINICAL
PRACTICE CONVERGE**

Supported by Eli Lilly and Company

Chp.: Joseph F. Goldberg, M.D.

**A The Convergence of Pharmacotherapy and
Psychotherapy in Maintenance Treatment of Bipolar
Disorder**

Paul E. Keck, Jr., M.D.

**B Considerations in the Female Patient During
Childbearing Years**

Adele C. Viguera, M.D.

**C Choosing Treatments in Bipolar Depression: What,
When, and Why?**

Roy H. Perlis, M.D.

**D Cognitive Functioning Outcomes: From First Episode
to Functional Recovery**

Deborah A. Yurgelun-Todd, Ph.D.

**E Translating Research Into Clinical Practice: From the
Bench to the Trenches**

Joseph F. Goldberg, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 9

6:00 p.m.-9:00 p.m.

Grand Ballroom, Mezzanine Level, Roosevelt

**GAD: EVIDENCE-BASED CONSIDERATIONS FROM
PATHOPHYSIOLOGY TO LONG-TERM
MANAGEMENT**

Supported by Pfizer Inc.

Chp.: John H. Greist, M.D.

**A Prevalence of GAD in the U.S.: Results From the
National Comorbidity Survey Replication**

Ronald C. Kessler, Ph.D.

B Distinguishing GAD: Unique Characteristics

Wei Zhang, M.D.

C The Molecular and Cellular Pathophysiology of GAD

Carl Salzman, M.D.

D Cognitive-Behavior Therapy for the Treatment of GAD

Michelle G. Newman, Ph.D.

**E Pharmacotherapies for GAD: From Rough Empiricism
to Elegant Evidence**

John H. Greist, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 10

6:00 p.m.-9:00 p.m.

Imperial Ballroom A, Second Floor, Sheraton New York

SEX, SEXUALITY, AND 5HT

Supported by GlaxoSmithKline

Chp.: Philip R. Muskin, M.D.

**A Do Sexual Side Effects of Most Antidepressants
Jeopardize Romantic Love and Marriage?**

Helen E. Fisher, Ph.D.

B Love and Sex

Ethel S. Person, M.D.

**C Talking to Gay Patients About Sex: What Do You Need
to Know?**

Serena Y. Volpp, M.D.

**D Effects of Psychiatric Illness and Medication on Sexual
Function**

Anita L.H. Clayton, M.D.

**E Talking About Sexual Dysfunction to Enhance
Adherence With Medication**

Philip R. Muskin, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 11

6:00 p.m.-9:00 p.m.

Imperial Ballroom B, Second Floor, Sheraton New York

**INTERFACE BETWEEN DEPRESSION AND
MEDICAL ILLNESS**

Supported by Wyeth Pharmaceuticals

Chp.: Dwight L. Evans, M.D.

Co-Chp.: Dennis S. Charney, M.D.

**A Heartache and Heartbreak: Depression and
Cardiovascular Disease**

Charles B. Nemeroff, M.D.

**B The Relationship of Depression to Cancer and HIV
Infection**

David Spiegel, M.D.

C Comorbidity of Depression in Neurological Disorders

William M. McDonald, M.D.

**D Mood Disorders and Medical Illness: Diabetes,
Osteoporosis, Obesity, and Pain**

Robert N. Golden, M.D., Dominique L. Musselman, M.D.,
Philip W. Gold, M.D., Albert J. Stunkard, M.D., Frank Keefe

**E Mood Disorders in the Medically Ill: The Patient's
Perspective**

Lydia J. Lewis, B.A.

8:00 a.m. Sessions



COURSES 13-19

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 13 8:00 a.m.-12 noon
Rooms 1E01/2, Level 1, Javits Center

RISK ASSESSMENT FOR VIOLENCE

Director: Phillip J. Resnick, M.D.

COURSE 14 8:00 a.m.-12 noon
Rooms 1E03/4/5, Level 1, Javits Center

ADD IN ADULTS

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 15 8:00 a.m.-12 noon
Room 1E06, Level 1, Javits Center

ENGAGING RESISTANT AND HOSTILE PATIENTS INTO PARTICIPATORY TREATMENT

Director: David Mee-Lee, M.D.

COURSE 16 8:00 a.m.-12 noon
Rooms 2D06/7, Level 2, Javits Center

DSM-IV-TR CULTURAL FORMULATIONS: DIAGNOSIS AND THERAPY

Director: Russell F. Lim, M.D.
Faculty: Candace M. Fleming, Ph.D., Roberto Lewis-Fernandez, M.D., Francis G. Lu, M.D., J. Charles Ndlela, M.D., Michael W. Smith, M.D.

COURSE 17 8:00 a.m.-12 noon
Rooms 2D10/11, Level 2, Javits Center

INTERPERSONAL PSYCHOTHERAPY

Director: John C. Markowitz, M.D.

COURSE 18 8:00 a.m.-12 noon
Rooms 2D12/13, Level 2, Javits Center

TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!

Director: Steven E. Hyler, M.D.
Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D.

COURSE 19 8:00 a.m.-12 noon
Rooms 2D14/15, Level 2, Javits Center

PERSONALITY DISORDERS: COMBINING RELATIONAL THERAPY AND PSYCHOPHARMACOLOGY

Director: Roy O. Resnikoff, M.D.

INDUSTRY-SUPPORTED SYMPOSIA 12-18

INDUSTRY-SUPPORTED SYMPOSIUM 12
8:00 a.m.-11:00 a.m.
Special Events Hall 1D, Level 1, Javits Center

ANTIDEPRESSANT TREATMENTS YOU MAY NOT KNOW ABOUT, BUT SHOULD . . .

Supported by Organon Inc.

Chp.: Jerrold F. Rosenbaum, M.D.

A The Next Generation of Antidepressants: What Is in the Pipeline?

Rajinder A. Judge, M.D.

B Alternative Medications for Depression
Andrew A. Nierenberg, M.D.

C Evidence-Based Psychotherapy for Depression: Principles and Practice
Timothy J. Petersen, Ph.D.

D Device-Based Treatments for Depression
A. John Rush, M.D.

E The Future of Treatment-Matching in Depression
Steven P. Roose, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 13
8:00 a.m.-11:00 a.m.

Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

BROADENING THE HORIZON OF ATYPICAL ANTIPSYCHOTIC APPLICATIONS

Supported by AstraZeneca Pharmaceuticals

Chp.: S. Charles Schulz, M.D.

A Atypical Antipsychotics in Anxiety and PTSD
Mark B. Hamner, M.D.

B Atypical Antipsychotics Treatment of Substance Abuse
E. Sherwood Brown, M.D.

C Role of Atypicals in the Treatment of Pediatric Psychotic Disorders and Common Comorbidities
Melissa P. DelBello, M.D.

(Continued on next page)

SUNDAY

D Atypicals in the Treatment of Anorexia Nervosa
Walter H. Kaye, M.D.

E Atypicals in BPD
S. Charles Schulz, M.D., A. Adityanjee, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 14
8:00 a.m.-11:00 a.m.
Grand Ballroom East, Third Floor, Hilton New York

THE MANY FACES OF ANXIETY: ORIGINS, PATHOGENESIS, AND MANAGEMENT
Supported by Pfizer Inc

Chp.: Martin B. Keller, M.D.

A Generalized Anxiety, Social Anxiety, and Panic Disorder: New Views on Validity and Nosology
Risa B. Weisberg, Ph.D.

B Origins and Pathogenesis of Anxiety Symptoms and Syndromes
Dennis S. Charney, M.D.

C Pharmacologic Approaches for Panic Disorder
David V. Sheehan, M.D.

D GAD: Current Opinions and Future Options
Linda L. Carpenter, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 15
8:00 a.m.-11:00 a.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

FROM PATHOLOGY TO PRACTICE: EVOLVING THERAPEUTIC STRATEGIES FOR ALZHEIMER'S DISEASE
Supported by Forest Laboratories, Inc

Chp.: Jacobo E. Mintzer, M.D.

A Synaptic Dysfunction and Neurodegeneration in Alzheimer's Disease
Gary L. Wenk, Ph.D.

B Alzheimer's Disease Update: New Targets, New Options
Jacobo E. Mintzer, M.D.

C Alzheimer's Disease and Vascular Dementia: Where Is the Overlap?
John C. Morris, M.D.

D Multicultural Issues in Addressing Barriers to Diagnosis and Treatment
Warachal E. Faison, M.D.

E A Rational Approach to Combination Treatment
Mary Sano, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 16
8:00 a.m.-11:00 a.m.
Grand Ballroom, Mezzanine Level, Roosevelt

BROADENING HORIZONS: ADVANCES IN UNDERSTANDING THE ETIOLOGY, EFFECTS, AND TREATMENT OF ANXIETY DISORDERS
Supported by UCB Pharma, Inc

Chp.: Naomi M. Simon, M.D.
Co-Chp.: Mark H. Pollack, M.D.

A Anxiety on the Upswing? A Public Health Perspective
Murray B. Stein, M.D.

B The Neurobiology of Anxiety and Stress: The Role of Glutamate
Jeremy D. Coplan, M.D.

C Treating Anxiety: Current Therapies and Beyond
Mark H. Pollack, M.D.

D Gender and Anxiety Disorders: Impact and Treatment Implications
Naomi M. Simon, M.D.

E Treatment Works: Now What Do We Do? Strategies to Enhance Treatment Adherence
Michael W. Otto, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 17
8:00 a.m.-11:00 a.m.
Imperial Ballroom A, Second Floor, Sheraton New York

THE HIDDEN FACES OF ANXIETY
Supported by GlaxoSmithKline

Chp.: Prakash S. Masand, M.D.

A The Somatic Face of Anxiety
Prakash S. Masand, M.D.

B Anxiety in Men and Women: Two Faces of the Same Coin
Kimberly A. Yonkers, M.D.

C The Many Faces of Anxiety: Understanding Cultural and Ethnic Variation in Psychiatric Illness
Geetha Jayaram, M.D.

D Facets of Psychiatric Illness in the Elderly
Warren D. Taylor, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 18

8:00 a.m.-11:00 a.m.

Imperial Ballroom B, Second Floor, Sheraton New York

TARGETING EXECUTIVE DYSFUNCTIONS FOR TREATMENT

Supported by Cephalon, Inc.

Chp.: Charles DeBattista, M.D.

A Executive Function: Circuits and Symptoms

Stephen M. Stahl, M.D.

B Addressing the Neurobiological Dysfunctions of Deficit Syndrome

Rona Hu, M.D.

C Late-Life Depression of Executive Dysfunction: Novel Treatment Development

George S. Alexopoulos, M.D.

D Cognitive and Executive Dysfunction in Major Depression

Charles DeBattista, M.D.

E Addressing Executive Dysfunctions in ADHD

James M. Swanson, M.D.

9:00 a.m. Sessions



COURSES 20-23

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 20

9:00 a.m.-4:00 p.m.

Room 1E15, Level 1, Javits Center

ADVANCES IN NEUROPSYCHIATRY

American Neuropsychiatric Association

Director: C. Edward Coffey, M.D.

Faculty: Jeffrey L. Cummings, M.D., Mark S. George, M.D., Michael R. Trimble, M.D.

COURSE 21

9:00 a.m.-4:00 p.m.

Room 1E17, Level 1, Javits Center

EVIDENCE-BASED MEDICINE: AN INTRODUCTION FOR PSYCHIATRISTS

Director: Gregory E. Gray, M.D.

Faculty: Gabrielle F. Beaubrun, M.D., Letitia A. Pinson, M.D.

COURSE 22

9:00 a.m.-4:00 p.m.

Rooms 2D02/3, Level 2, Javits Center

THERAPEUTIC INTERVENTIONS IN EATING DISORDERS: BASIC PRINCIPLES

Director: David C. Jimerson, M.D.

Faculty: Katherine A. Halmi, M.D., James E. Mitchell, M.D., Barbara E. Wolfe, Ph.D., Joel Yager, M.D.

COURSE 23

9:00 a.m.-4:00 p.m.

Rooms 2D04/5, Level 2, Javits Center

BASIC HYPNOSIS: PRINCIPLES AND APPLICATIONS

Director: Jose R. Maldonado, M.D.

Faculty: David Spiegel, M.D., Matthew May, M.D., Herbert Spiegel, M.D., Marcia Greenleaf, Ph.D.

12:30 p.m. Session

BUSINESS MEETING

(Voting Members Only*)

12:30 p.m.-1:30 p.m.

Westside Ballroom, 5th Floor, Marriott Marquis

CALL TO ORDER

Marcia Kraft Goin, M.D., *President*

MEMORIAL TO DECEASED MEMBERS

ANNOUNCEMENT OF ELECTION RESULTS

Liza H. Gold, M.D., *Chairperson, Committee of Tellers*

REPORTS TO THE MEMBERSHIP

Secretary: Nada L. Stotland, M.D.*Treasurer:* Carol A. Bernstein, M.D.*Speaker, Assembly:* Prakash N. Desai, M.D.*Speaker-Elect, Assembly:* James E. Ninninger, M.D.*Chairperson, By-Laws Committee:* Derek Puddester, M.D.*Chairperson, Elections Committee:* Yvonne B. Ferguson, M.D.*Chairperson, Membership Committee:* Mary K. Marrocco, M.D.*Medical Director:* James H. Scully, Jr., M.D.

ANNUAL FORUM

ADJOURNMENT

*Members-in-Training, General Members, Distinguished Fellows, Fellows, Life Fellows, Distinguished Life Fellows, and Life Members. Badge or APA membership card necessary for admission. No cameras or tape recorders will be permitted.

1:00 p.m. Sessions



COURSES 24-31

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 24 1:00 p.m.-5:00 p.m.
Rooms 1E01/2, Level 1, Javits Center

MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP, AND OTHER BODY CLOCK DISORDERS

Director: Alfred J. Lewy, M.D.
Faculty: Michael Terman, Ph.D.

COURSE 25 1:00 p.m.-5:00 p.m.
Rooms 1E03/4/5, Level 1, Javits Center

COGNITIVE THERAPY FOR SCHIZOPHRENIA

Director: Jesse H. Wright, M.D.
Faculty: Douglas Turkington, M.B., David G. Kingdon, M.D.

COURSE 26 1:00 p.m.-5:00 p.m.
Room 1E06, Level 1, Javits Center

DETERMINING MEDICAL FITNESS TO DRIVE: RELEVANT ISSUES FOR PSYCHIATRISTS

Director: Ian A. Gillespie, M.D.

COURSE 27 - CANCELLED

COURSE 28 1:00 p.m.-5:00 p.m.
Room 1E12, Level 1, Javits Center

CURRENT CONCEPTS IN CHILD AND ADOLESCENT EATING DISORDERS

Director: Mae S. Sokol, M.D.
Faculty: Kristina Hoffman-Rieken, R.D.

COURSE 29 1:00 p.m.-5:00 p.m.
Rooms 2D06/7, Level 2, Javits Center

USING BOUNDARY CROSSINGS AS CREATIVE THERAPY INSTEAD OF SLIPPERY SLOPES

Director: Gail E. Robinson, M.D.
Faculty: Gary R. Schoener, Psy.D., Howard E. Book, M.D., Linda M. Jorgenson, J.D.

COURSE 30 1:00 p.m.-5:00 p.m.
Rooms 2D10/11, Level 2, Javits Center

PSYCHIATRIC INTERVENTIONS IN DISASTERS: LESSONS FROM EXPERIENCE

Co-Directors: Carol S. North, M.D., Betty Pfefferbaum, M.D.
Faculty: Anthony T. Ng, M.D., Phebe M. Tucker, M.D.

COURSE 31 1:00 p.m.-5:00 p.m.
Rooms 2D14/15, Level 2, Javits Center

IMPROVING YOUR PRESENTATION SKILLS: A COACHING APPROACH

Director: Luis F. Ramirez, M.D.

1:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 19-23

INDUSTRY-SUPPORTED SYMPOSIUM 19
1:30 p.m.-4:30 p.m.
Special Events Hall 1D, Level 1, Javits Center

THE TREACHEROUS TRIAD FOR DEPRESSION
Supported by Wyeth Pharmaceuticals

Chp.: John F. Greden, M.D.

- A Underdetection and Inadequate Treatment of Physical Symptoms of Depression: The Real Barriers to Remission**
Kurt Kroenke, M.D.
- B Neurochemical Systems Interfacing Physical and Emotional Stressors**
Jon-Kar Zubieta, M.D.
- C Stress Effects on the Hippocampus: Relevance to Depression**
Bruce S. McEwen, Ph.D.
- D Gender Considerations in the Treatment of Physical Symptoms of Depression**
Vivien K. Burt, M.D.
- E Best Practices for Achieving Remission in Depression With Physical Symptoms: Current and Future Trends**
John F. Greden, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 20

1:30 p.m.-4:30 p.m.

Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

BEYOND 5HT: NEW TREATMENTS FOR DEPRESSION*Supported by Merck & Co, Inc.*

Chp.: Jack M. Gorman, M.D.

A Combining Treatment to Enhance SSRI Response

Jack M. Gorman, M.D.

B What to Do for SSRI Nonresponders?

Michael E. Thase, M.D.

C The Relationship Between Substance P, 5HT, and Other Neurotransmitter Systems

Linda L. Carpenter, M.D.

D Substance P Antagonists: Mechanism of Action and Clinical Implications

K. Ranga R. Krishnan, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 21

1:30 p.m.-4:30 p.m.

Grand Ballroom East, Third Floor, Hilton New York

ARE ALL ATYPICAL ANTIPSYCHOTICS EQUAL FOR TREATMENT OF COGNITIVE AND AFFECTIVE SYMPTOMS IN SCHIZOPHRENIA?*Supported by Pfizer Inc.*

Chp.: Stephen M. Stahl, M.D.

A Schizophrenia: From Circuits to Symptoms

Stephen M. Stahl, M.D.

B Effect of Atypical Antipsychotic Drugs on Cognition and Negative Symptoms

Herbert Y. Meltzer, M.D.

C Optimal Health Outcomes in Schizophrenia

Jonathan M. Meyer, M.D.

D Maximizing Function in Patients With Schizophrenia

Lili Kopala, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 22

1:30 p.m.-4:30 p.m.

Broadway Ballroom, Sixth Floor, Marriott Marquis

COMBINATION THERAPY: NEW STRATEGIES IN THE MANAGEMENT OF SEVERE MENTAL DISORDERS*Supported by Abbott Laboratories*

Chp.: Susan L. McElroy, M.D.

A Rational Combination Therapy Versus Irrational Polypharmacy

Susan L. McElroy, M.D.

B Combination Treatment for Acute Mania

Gary S. Sachs, M.D.

C Management of Bipolar Depression: Combination Therapy Versus Monotherapy

Robert M.A. Hirschfeld, M.D.

D Managing Bipolar Disorder in Children and Adolescents

Karen D. Wagner, M.D.

E Evidence for the Mechanisms and Efficacy of Anticonvulsants in the Treatment of Schizophrenia

Henry A. Nasrallah, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 23

1:30 p.m.-4:30 p.m.

Imperial Ballroom A, Second Floor, Sheraton New York

UNMASKING BIPOLAR DISORDER: OVERCOMING THE BARRIERS TO TREATMENT SUCCESS*Supported by Janssen Pharmaceutica and Research Foundation*

Chp.: S. Nassir Ghaemi, M.D.

A Bipolar Disorder: A National Health Concern

Roger S. McIntyre, M.D.

B Redefining Mood Stabilizing Agents: Improved Treatment Options for Bipolar Disorder

S. Nassir Ghaemi, M.D.

C Safety Considerations in Treating the Bipolar Disorder Patient

Prakash S. Masand, M.D.

D The Essential Role of Psychotherapy in Managing Bipolar Disorder

Michael W. Otto, Ph.D.

2:30 p.m. Session

LECTURE 1

2:30 p.m.-4:00 p.m.
Rooms 1E07/8, Level 1, Javits Center

AAPL/APA'S MANFRED S. GUTTMACHER
AWARD LECTURE

Margaret G. Spinelli, M.D.

Infanticide: The Hope of Prevention
and the Promise of Saved Lives

Chp.: Michael A. Norko, M.D.

Margaret G. Spinelli, M.D., is Assistant Professor of Clinical Psychiatry, Columbia University College of Physicians and Surgeons; and Director of the Maternal Mental Health Program, New York State Psychiatric Institute. Dr. Spinelli came to the field of perinatal psychiatry after a 15-year career as a nurse in Obstetrics and Gynecology. She graduated from Cornell University Medical College in New York, and completed her residency training in psychiatry at the Payne Whitney Clinic/Cornell University/The New York Hospital. A clinical clerkship on the Mother-Infant Postpartum Unit of the Royal Maudsley and Bethlem Hospital in London inspired her clinical philosophy. A career in academic and research psychiatry followed a Postdoctoral Research Fellowship at Columbia University College of Physicians and Surgeons and The New York State Psychiatric Institute. Her area of NIMH Clinical Research includes Interpersonal Psychotherapy for Antepartum Depression. Her field of publications includes Pregnancy and Postpartum Psychiatric disorders, Postpartum Psychosis, Infanticide, Neonaticide, Neurohormones and Mood. Dr. Spinelli's clinical work focuses on the treatment of women with psychiatric disorders during pregnancy and postpartum periods. She has testified in criminal cases of mentally ill mothers who have killed their infants and works with Project Liberty 9/11 and the New York Police Department.

THIS SESSION WILL BE AUDIOTAPED.

5:00 p.m. Session

OFFICIAL OPENING SESSION

5:00 p.m.-6:30 p.m.
Hall 3E, Level 3, Javits Center

CALL TO ORDER

Marcia Kraft Goin, M.D., *President*

INTRODUCTION OF STAGE GUESTS

INTRODUCTION OF CHAIRPERSON OF
THE SCIENTIFIC PROGRAM COMMITTEE

Geetha Jayaram, M.D.
Chairperson, Annual Meeting Scientific Program Committee

INTRODUCTION OF VISITING
DIGNITARIES

PRESIDENTIAL ADDRESS

Marcia Kraft Goin, M.D.
To be introduced by George M. Simpson, M.D.

RESPONSE OF THE PRESIDENT-ELECT

Michelle B. Riba, M.D.
To be introduced by Allan Tasman, M.D.

ADJOURNMENT

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 24-30

INDUSTRY-SUPPORTED SYMPOSIUM 24

7:00 p.m.-10:00 p.m.
Special Events Hall 1D, Level 1, Javits Center

RECOVERING FROM SCHIZOPHRENIA: HOW
TREATMENT CAN IMPROVE OUTCOMES AND
PREVENT CHRONICITY

Supported by Eli Lilly and Company

Chp.: Jeffrey A. Lieberman, M.D.

A Laboratory and Imaging Aids to Diagnosis and
Assessment of Schizophrenia

Aysenil Belger, Ph.D.

B Treating First-Episode Schizophrenia: Differential
Effects of Atypical and Typical Antipsychotics on Brain
Pathomorphology

Jeffrey A. Lieberman, M.D.

C Approaches to Improved Maintenance Treatment and
Relapse Prevention

T. Scott Stroup, M.D.

D Psychiatric Rehabilitation

Robert E. Drake, M.D.

E Cognitive Improvement and Therapeutic Alliance

Richard S. Keefe, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 25

7:00 p.m.-10:00 p.m.

Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

NOVEL INTERVENTION STRATEGIES ACROSS THE SPECTRUM OF DEMENTIA: REAL PATIENTS AND REAL OUTCOMES

Supported by Eisai, Inc.

Chp.: Gary W. Small, M.D.

A Identifying Early Dementia: Mild Cognitive Impairment and Early-Stage Alzheimer's Disease

P. Murali Doraiswamy, M.D.

B Identifying and Treating Early Dementia: Case Studies

Daniel D. Christensen, M.D.

C Exploring Vascular Dementia: Diagnosis, Treatment, and Behavior

Helen Lavretsky, M.D.

D Exploring Differences Between Vascular Dementia and Alzheimer's Disease: Case Studies

Stephen P. Salloway, M.D.

E Defining and Achieving Positive Outcomes in Dementia Pharmacotherapy

David Geldmacher, M.D.

F Alzheimer's Disease Prevention: Strategies for Improving Brain and Memory Fitness

Gary W. Small, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 26

7:00 p.m.-10:00 p.m.

Grand Ballroom East, Third Floor, Hilton New York

EFFECTIVE LONG-TERM MANAGEMENT OF SCHIZOPHRENIA: REAL-WORLD CONSIDERATIONS

Supported by Bristol-Myers Squibb Company

Chp.: John M. Kane, M.D.

A The Evolution of Antipsychotic Agents: A Mechanism-Based Review

Anissa Abi-Dargham, M.D.

B Optimizing the Long-Term Effectiveness of Antipsychotic Therapy

Stephen R. Marder, M.D.

C Managing Patients With Treatment-Resistant Schizophrenia

John M. Kane, M.D.

D What Is Effectiveness With Medications?

Peter J. Weiden, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 27

7:00 p.m.-10:00 p.m.

Broadway Ballroom, Sixth Floor, Marriott Marquis

MODERATORS AND MEDIATORS OF ANTIDEPRESSANT RESPONSE

Supported by Forest Laboratories, Inc.

Chp.: Steven P. Roose, M.D.

A Moderators and Mediators of Treatment Effects in Antidepressant Trials

Philip Lavori, Ph.D.

B Gender as a Moderator of Antidepressant Response

Susan G. Kornstein, M.D.

C Moving the Goalposts: Is Response a Mediator of Remission?

David J. Kupfer, M.D.

D Antidepressant Treatment Duration: The Decision to Continue or Switch Treatment

Harold A. Sackeim, Ph.D.

E Placebo, Comparator, or Open Treatment? Design Counts

Steven P. Roose, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 28

7:00 p.m.-10:00 p.m.

Grand Ballroom, Mezzanine Level, Roosevelt

BEYOND SLEEP ONSET: NEW PERSPECTIVES ON THE TREATMENT OF INSOMNIA

Supported by Sepracor, Inc.

Chp.: Andrew D. Krystal, M.D.

A Prevalence and Impact of Insomnia: Treating the Entire Insomnia Syndrome

Mugdha E. Thakur, M.D.

B Differential Diagnosis of Insomnia and Comorbid Conditions: Importance of Sleep History

Jed E. Black, M.D.

C Measures of Treatment Efficacy

Thomas Roth, Ph.D.

D Overview of Insomnia Treatment

Andrew D. Krystal, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 29

7:00 p.m.- 10:00 p.m.

Imperial Ballroom A, Second Floor, Sheraton New York

PSYCHOPHARMACOLOGY AND REPRODUCTIVE TRANSITIONS: IMPACT OF PSYCHOTROPIC MEDICATIONS AND SEX HORMONES ON BRAIN FUNCTIONING, WEIGHT, AND REPRODUCTIVE SAFETY

Supported by GlaxoSmithKline

Chp.: Claudio N. Soares, M.D.

Co-Chp.: Mary Blehar, Ph.D.

A Labeling Products for Use in Pregnancy: Moving Forward
Sandra L. Kweder, M.D.

B Weight Gain, Psychotropic Medications, and Gender: Potential Pharmacologic Strategies
Barbara L. Gracious, M.D.

C Testosterone Decline in the Aging Male: Does Andropause Exist?
Stuart N. Seidman, M.D.

D Perimenopause-Related Mood Disturbance: An Update on Risk Factors and Novel Treatment Strategies Available
Claudio N. Soares, M.D.

E Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study Updates
Sally A. Shumaker, Ph.D., Claudine Legault, Ph.D., Stephen R. Rapp, Ph.D.

Discussant: William Harlan, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 30

7:00 p.m.-10:00 p.m.

Imperial Ballroom B, Second Floor, Sheraton New York

CHOOSING THE RIGHT DOSE OF ATYPICAL ANTIPSYCHOTICS: ART OR SCIENCE?

Supported by AstraZeneca Pharmaceuticals

Chp.: Peter F. Buckley, M.D.

A Dosing With Atypicals: Receptor Occupancy as a Guide to Titration and Maintenance
Shitij Kapur, M.D.

B Acute Stabilization of Psychosis: Options and Approaches
K.N. Roy Chengappa, M.D.

C Strategies for Maintenance Pharmacotherapy: High, Low, or Switch?
Peter F. Buckley, M.D.

D Administration of Atypicals in Bipolar Disorder
Claudia F. Baldassano, M.D.

E Is Polypharmacy the Result of Confused Dosing Strategies for Atypical Antipsychotics?
Alexander L. Miller, M.D.

7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 31-35

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 1

7:00 a.m.-8:30 a.m.

Grand Ballroom East, Third Floor, Hilton New York

NEW ADVANCES IN THE TREATMENT OF PSYCHOSIS

Supported by Bristol-Myers Squibb Company

Chp.: Robert E. Hales, M.D.

Co-Chp.: Stuart C. Yudofsky, M.D.

**A Psychosis Associated With Dementia: Efficacy of the
Newer Antipsychotics**
Dilip V. Jeste, M.D.

**B Antipsychotic Therapies in Pediatric Patients: The
Importance of Safety and Tolerability**
Robert L. Findling, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 1

7:00 a.m.-8:30 a.m.

Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

CURRENT ALZHEIMER'S DISEASE TREATMENTS AND BEYOND: ADVANCES IMPACTING CLINICAL PRACTICE

Supported by Forest Laboratories, Inc.

Chp.: Trey Sunderland, M.D.

A The Molecular Genetics of Alzheimer's Disease
Rudolph Tanzi, Ph.D.

**B Diversity of Neuropsychiatric Impairment: Cognitive
and Behavioral Implications**
Jeffrey L. Cummings, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 33, PART 1

7:00 a.m.-8:30 a.m.

Broadway Ballroom, Sixth Floor, Marriott Marquis

RECOGNIZING THE MANY FACES OF BIPOLAR DISORDER

Supported by Eli Lilly and Company

Chp.: Bruce M. Cohen, M.D.

**A Differential Diagnosis of Bipolar Disorder: Clinical
Findings**

Stephan H. Heckers, M.D.

**B Recognizing Bipolar Disorder in Children and
Adolescents**

Gabrielle Carlson, M.D.

**C Bipolarity in Old Age: Diagnostic and Management
Issues**

Kenneth I. Shulman, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 34, PART 1

7:00 a.m.-8:30 a.m.

Imperial Ballroom A, Second Floor, Sheraton New York

EVIDENCE-BASED MEDICINE: THE NEXT GENERATION

Supported by Wyeth Pharmaceuticals

Chp.: K. Ranga R. Krishnan, M.D.

A How to Make Judgments Under Uncertainty
K. Ranga R. Krishnan, M.D.

B Improving Outcomes in Anxiety Disorders
Nick Freemantle, Ph.D.

**C Study Designs and Outcome in Antidepressant Clinical
Trials**

Arifulla Khan, M.D., Shirin R.F. Khan, B.S.,
Russel Korts, Ph.D., Michael E. Thase, M.D.,
Walter A. Brown, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 35, PART 1

7:00 a.m.-8:30 a.m.

Imperial Ballroom B, Second Floor, Sheraton New York

TRANSCENDING EFFICACY: EFFECTIVE TREATMENT OF PSYCHOSIS ACROSS DISORDERS

Supported by AstraZeneca Pharmaceuticals

Chp.: Pierre N. Tariot, M.D.

Co-Chp.: John W. Newcomer, M.D.

A Managing Psychosis and Agitation in Dementia
J. Michael Ryan, M.D.

**B Movement Disorders in the Elderly: How Safe Are the
Atypical Neuroleptics?**

Richard N. Trosch, M.D.

**C Lewy Body Dementia: What the Psychiatrist Needs to
Know**

Andrius Baskys, M.D.

MONDAY

RESIDENT'S SESSION

7:00 a.m.-8:30 a.m.

Versailles Ballroom, Second Floor, Sheraton New York

MEET THE EXPERTS: SUNNY-SIDE UP

Chp.: Marcia Kraft Goin, M.D.

Co-Chp.: Michelle B. Riba, M.D.

At this breakfast, nationally recognized "experts" will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include: Addiction/Substance Abuse, AIDS/HIV, Child and Adolescent Psychiatry, Consultation-Liaison, Cultural Competence, Forensic, Law and Ethics in Psychiatry, Geriatric, Medical Student Issues, Public and Community Mental Health, Professional and Leadership Development, Psychodynamic Psychotherapy, and Research in Psychiatry.

8:00 a.m. Sessions



COURSES 32-40

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 32 8:00 a.m.-12 noon

Concourse B, Concourse Level, Hilton New York

IRRESISTIBLE SLEEP: NARCOLEPSY UPDATE

Director: Lois E. Krahn, M.D.

Faculty: Steven I. Altkhuler, M.D., Mark R. Hansen, M.D., Jarrett W. Richardson, M.D.

COURSE 33 8:00 a.m.-12 noon

Concourse E, Concourse Level, Hilton New York

RECOVERY FROM MENTAL ILLNESS AND STIGMA: INTEGRATING MEDICINE AND REHABILITATION

Co-Directors: Eugene A. Oulvey, Ph.D., Karen L. Lee, M.A.

Faculty: Vivek Jain, M.D., Shyam K. Bhat, M.D., Denise Sommers, M.A., Thomas O. Osinowo, M.D.

COURSE 34 8:00 a.m.-12 noon

Concourse G, Concourse Level, Hilton New York

DRUG TREATMENT OF SCHIZOPHRENIA

Director: Philip G. Janicak, M.D.

Faculty: Stephen R. Marder, M.D., Rajiv Tandon, M.D., Morris B. Goldman, M.D.

COURSE 35 8:00 a.m.-12 noon

Gramercy A, Second Floor, Hilton New York

THE PSYCHIATRIST AS EXPERT WITNESS

Director: Phillip J. Resnick, M.D.

COURSE 36 8:00 a.m.-12 noon

Gramercy B, Second Floor, Hilton New York

CURRENT CPT CODING AND DOCUMENTATION REQUIREMENTS

Co-Directors: Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D.

COURSE 37 8:00 a.m.-12 noon

Nassau Suite A, Second Floor, Hilton New York

FAMILIES COPING WITH MEDICAL ILLNESS: AN INTEGRATIVE TREATMENT APPROACH

Director: John S. Rolland, M.D.

COURSE 38 8:00 a.m.-12 noon

Rhineland Gallery North/Center, Second Floor, Hilton New York

ADVANCED ASSESSMENT AND TREATMENT OF ADD

Director: Thomas E. Brown, Ph.D.

Faculty: Jefferson B. Prince, M.D.

COURSE 39 8:00 a.m.-12 noon

Sutton North, Second Floor, Hilton New York

ECT PRACTICE UPDATE

Director: Charles H. Kellner, M.D.

Faculty: Richard L. Jaffe, M.D., W. Vaughn McCall, M.D., Richard D. Weiner, M.D.

COURSE 40 8:00 a.m.-12 noon

Sutton Center, Second Floor, Hilton New York

COGNITIVE-BEHAVIOR THERAPY FOR ADULT AND PEDIATRIC OCD: THE BASICS

Co-Directors: Jonathan Abramowitz, Ph.D., Stephen Whiteside, Ph.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 1

9:00 a.m.-10:30 a.m.

Rooms 3D06/7, Level 3, Javits Center

BOUNDARY ISSUES AND THE CHALLENGE OF THE SOMATIZING PATIENT**Moderator:** James L. Levenson, M.D.**Presenter:** Catherine C. Crone, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 1: PART 1

9:00 a.m.-12 noon

Rooms 3D01/12, Level 3, Javits Center

HELPING PATIENTS COUNTER DEMORALIZATION WHILE LIVING WITH A CHRONIC OR RECURRENT PSYCHIATRIC ILLNESS**Moderator:** James L. Griffith, M.D.**Presenters:** Lynne M. Gaby, M.D., Julia B. Frank, M.D., Robert W. Keisling, M.D., Jeffrey S. Akman, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

**COURSES 41-44**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 41 9:00 a.m.-4:00 p.m.

Clinton Suite, Second Floor, Hilton New York

MONEY MATTERS I: USING THEORY IN CLINICAL PRACTICE**Director:** Cecilia M. Mikalac, M.D.**COURSE 42** 9:00 a.m.-4:00 p.m.

Murray Hill A, Second Floor, Hilton New York

TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT**Director:** Robert P. Granacher, Jr., M.D.**COURSE 43**

9:00 a.m.-4:00 p.m.

Murray Hill B, Second Floor, Hilton New York

DAVANLOO'S INTENSIVE SHORT-TERM DYNAMIC PSYCHOTHERAPY IN CLINICAL PRACTICE**Director:** James Q. Schubmehl, M.D.**Faculty:** Alan R. Beeber, M.D., Tewfik Said, M.D.**COURSE 44**

9:00 a.m.-4:00 p.m.

Nassau Suite B, Second Floor, Hilton New York

ADVANCED HYPNOSIS: APPLICATIONS IN PSYCHIATRY**Director:** Jose R. Maldonado, M.D.**Faculty:** David Spiegel, M.D., Matthew May, M.D., Herbert Spiegel, M.D., Marcia Greenleaf, Ph.D.**DEBATE**

9:00 a.m.-10:30 a.m.

Room 1E10, Level 1, Javits Center

RESOLVED: THE RRC SHOULD CONTINUE TO REQUIRE THAT PSYCHIATRIC RESIDENCY PROGRAMS MUST DEMONSTRATE THAT THE RESIDENTS HAVE ACHIEVED COMPETENCY IN PSYCHODYNAMIC PSYCHOTHERAPY**Moderator:** Sheila Judge, M.D.**Affirmative:** Allan Tasman, M.D., Lisa A. Mellman, M.D.**Negative:** Joel Yager, M.D., Eugene H. Rubin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

DISCUSSION GROUPS 1-4

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- Jonathan M. Meyer, M.D., on the Medical Care for the Chronically Mentally Ill: The Role of the Psychiatrist
(*Meet the Authors*)
Rooms 2D02/3, Level 2, Javits Center
- Robert Michels, M.D., on Who Should Be Psychoanalyzed?
Rooms 2D04/5, Level 2, Javits Center
- Robert R. Conley, M.D., on What Is the Best Medication for People Suffering From Schizophrenia?
Rooms 2D06/7, Level 2, Javits Center
- Larry E. Tune, M.D., on Dementia and Delirium
Room 2D08, Level 2, Javits Center

FOCUS LIVE SESSION 1

9:00 a.m.- 10:30 a.m.
 Room 1E14, Level 1, Javits Center

Moderator: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenters: Laura W. Roberts, M.D., Paul S. Appelbaum, M.D.,
 on **Forensic and Ethical Issues in Psychiatry**

Expert clinicians, who served as the guest editors of the first two issues of *Focus*, will lead lively multiple-choice, question-based discussions. This session covers Forensic and Ethical Issues in Psychiatry, the second session at 11:00 a.m. covers PTSD and Anxiety Disorders, and the third session at 2:00 p.m. covers Schizophrenia and Other Psychotic Disorders. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 2-4

LECTURE 2

9:00 a.m.- 10:30 a.m.
 Rooms 1E07/8, Level 1, Javits Center

Paul Greengard, Ph.D.

Signal Integration in the Brain
*Collaborative Session With the National Institute
 on Drug Abuse*

Chp.: Satish C. Varma, M.D.
Co-Chp.: Marianne T. Guschwan, M.D.

Paul Greengard, Ph.D., is the Vincent Astor Professor and Head of the Laboratory of Molecular and Cellular Neuroscience at the Rockefeller University in New York City. In 2000, Dr. Greengard received the Nobel Prize in Physiology or Medicine for his discovery of how dopamine and other neurotransmitters exert their action in the nervous system. A member of the U.S. National Academy of Sciences and the Institute of Medicine, Dr. Greengard is the recipient of numerous other honors, including the Metropolitan Life Foundation Award for Medical Research, the Charles A. Dana Award for Pioneering Achievements in Health, the Lieber Prize for Outstanding Achievement in Schizophrenia Research, and the National Academy of Sciences Award in the Neurosciences. Dr. Greengard is the Founder and Series Editor of *Advances in Biochemical Psychopharmacology* and *Advances in Cyclic Nucleotide and Protein Phosphorylation Research*. He is a member of the Scientific Council of the National Alliance for Research on Schizophrenia and Depression and a member of the Board of Directors of

the Research Foundation for Mental Hygiene, Inc. Dr. Greengard received his doctorate in biophysics at Johns Hopkins University in Baltimore and received advanced training in brain biochemistry at the University of London and at the National Institute of Medical Research in London.
Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 3

9:00 a.m.- 10:30 a.m.
 Room 1E15, Level 1, Javits Center

APA'S BENJAMIN RUSH AWARD LECTURE

David Mechanic, Ph.D.

The Changing Face of Mental Health Services

Chp.: Avram H. Mack, M.D.

David Mechanic, Ph.D., examines changing patterns of mental health services, with a focus on the contribution of managed behavioral health care to the shaping of professional practice and delivery of services, particularly for persons with serious mental illness and those receiving behavioral health care through Medicaid. Dr. Mechanic is René Dubos University Professor of Behavioral Sciences and Founder and Director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University in New Brunswick, New Jersey. He is the author of more than 400 research articles and book chapters and the author or editor of 24 books, including *Inescapable Decisions: The Imperatives of Health Reform* and *Mental Health and Social Policy: The Emergence of Managed Care*. A member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of Medicine, Dr. Mechanic has received numerous awards, including the Distinguished Career Award, the Lifetime Contributions Award in Mental Health from the American Sociological Association, the Rema Lapouse Award, the first Carl Taube Award for Distinguished Contributions to Mental Health Services Research from the American Public Health Association, and the Baxter Health Services Research Prize. Dr. Mechanic received his doctorate in sociology from Stanford University in Stanford, California.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 4

9:00 a.m.-10:30 a.m.
Hall 3E, Level 3, Javits Center

Sri Sri Ravi Shankar

Psychiatry and Spirituality: A Holistic Perspective

Chp.: Richard P. Brown, M.D.
Co-Chp.: Geetha Jayaram, M.D.

Sri Sri Ravi Shankar, a humanitarian teacher, philosopher, and spiritual leader, was born in 1956 in Papanasum, a village in south India. He completed advanced degrees in modern science and Vedic studies by age 17 years. In 1982 he began to teach Sudarshan Kriya, a yogic breath technique that reduces stress, anxiety, and depression and promotes health. Sudarshan Kriya is now taught in more than 100 countries as part of the Art of Living Course. In the late 1990s, the Sudarshan Kriya technique gained increased recognition when additional medical studies confirming its benefits were published. Sri Sri Ravi Shankar created the Art of Living Foundation, which offers programs around the world to eliminate stress, restore human values, and encourage people from all backgrounds to join in service to humanity. He is also a founding member of the International Association for Human Values. Sri Sri Ravi Shankar has addressed large audiences at universities and institutions around the world, including the World Economic Forum, the International Conference of Human Values and Spiritual Regeneration, and the United Nations Millennium World Peace Summit of Religious and Spiritual Leaders. He is the author of several books, including *Wisdom for the New Millennium*.
International Psychiatrist Lecture Series

MASTER EDUCATOR CLINICAL CONSULTATIONS 1-2

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 1 John C. Racy, M.D., on Treating One's Students and Colleagues: The Eternal Challenge of Boundaries
Room 1D04, Level 1, Javits Center
- 2 Eugene V. Beresin, M.D., on Evaluation and Treatment of Eating Disorders
Room 1D05, Level 1, Javits Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

NEW RESEARCH YOUNG INVESTIGATORS' POSTER SESSION 1

9:00 a.m.-10:30 a.m.
Galleria, Level 4, Javits Center

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

WORKSHOPS

COMPONENTS 1-11

COMPONENT WORKSHOP 1 9:00 a.m.-10:30 a.m.
Room 1D06, Level 1, Javits Center

HOW TO TEACH AND LEARN CULTURAL
COMPETENCE IN GERIATRIC PSYCHIATRY
APA Committee on Ethnic Minority Elderly

Chp.: Iqbal Ahmed, M.D.
Participants: Warachal E. Faison, M.D., Walter P. Bland, M.D.,
Kenneth M. Sakauye, M.D., Angela L. Guerrero, M.D.

COMPONENT WORKSHOP 2 9:00 a.m.-10:30 a.m.
Rooms 1E01/2, Level 1, Javits Center

CAN'T WORK, SHOULDN'T WORK, MUSTN'T
WORK: ASSESSING FUNCTION AND MENTAL
IMPAIRMENT IN PSYCHIATRIC ILLNESS
APA Corresponding Committee on Psychiatry in the Workplace

Chp.: Marcia A. Scott, M.D.
Participants: Andrea G. Stolar, M.D., Steven E. Pflanz, M.D.

COMPONENT WORKSHOP 3 9:00 a.m.-10:30 a.m.
Rooms 1E03/4/5, Level 1, Javits Center

PUBLIC HEALTH AND MENTAL HEALTH
PARTNERSHIP IN TERRORISM AND DISASTERS
APA Committee on Psychiatric Dimensions of Disaster

Chp.: Robert J. Ursano, M.D.
Participants: Carol S. North, M.D., Dori B. Reissman, M.D.

COMPONENT WORKSHOP 4 9:00 a.m.-10:30 a.m.
Room 1E09, Level 1, Javits Center

CHILD SOLDIERS: CHILD VICTIMS OF WAR AND
TERRORISM: PSYCHOSOCIAL AND SPIRITUAL
NEEDS
APA Alliance

Co-Chps.: Mohammad Shafii, M.D., Rosalind Hayes, B.A.
Participants: Chet Lowe, M.A., Jon A. Shaw, M.D., Peter
Moszynski, M.A.

MONDAY

COMPONENT WORKSHOP 5 9:00 a.m.-10:30 a.m.
Rooms 2D10/11, Level 2, Javits Center

CAREER CHOICES IN PSYCHIATRY: EXPLORING FELLOWSHIP TRAINING
APA Assembly Committee of Area Member-in-Training Representatives

Chp.: Thor J. Cornelius, M.D.
Participants: David M. Gellerman, M.D., Richard A. Montgomery, M.D., Charles V. Panadero, M.D., Shauna P. Reinblatt, M.D.

COMPONENT WORKSHOP 6 9:00 a.m.-10:30 a.m.
Rooms 2D12/13, Level 2, Javits Center

FACILITATING RESEARCH ON MINORITY POPULATIONS BY MINORITY RESEARCHERS
APA Assembly Committee of Representatives of Minority/Underrepresented Groups

Chp.: Jagannathan Srinivasaraghavan, M.D.
Participants: Renato D. Alarcon, M.D., Mantosh J. Dewan, M.D., Roger D. Walker, M.D., Tana A. Grady-Weliky, M.D.

COMPONENT WORKSHOP 7 9:00 a.m.-10:30 a.m.
Odets Room, Fourth Floor, Marriott Marquis

STATE HOSPITAL PSYCHIATRY: BEEN DOWN SO LONG IT LOOKS LIKE UP TO ME
APA Caucus of State Hospital Psychiatrists and American Association of Psychiatric Administrators

Co-Chps.: Yad M. Jabbarpour, M.D., Beatrice M. Kovaszny, M.D.
Participants: Jeffrey L. Geller, M.D., Michael F. Hogan, Ph.D., Kris A. McLoughlin, M.S.N.

COMPONENT WORKSHOP 8 9:00 a.m.-10:30 a.m.
O'Neill Room, Fourth Floor, Marriott Marquis

LEADERSHIP SKILLS FOR PUBLIC ADVOCACY
APA Committee on Public Affairs

Chp.: Mary H. Davis, M.D.
Participants: Nicholas Myers, B.S.C., Ericka L. Goodwin, M.D.

COMPONENT WORKSHOP 9 9:00 a.m.-10:30 a.m.
Ziegfeld Room, Fourth Floor, Marriott Marquis

MISSION POSSIBLE: THE SCIENCE OF PSYCHIATRY AND THE ART OF ADVOCACY
APA Committee on Developmental Disabilities

Chp.: Donald J. Mordecai, M.D.
Participants: Jeremy Veenstra-VanderWeele, M.D., Bryan H. King, M.D., Lee Combrinck-Graham, M.D., Mark Combrinck-Hertz

COMPONENT WORKSHOP 10 9:00 a.m.-10:30 a.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

BRIDGING ACROSS CULTURE AND GENERATIONS: AN ASIAN-AMERICAN PERSPECTIVE
APA Committee of Asian-American Psychiatrists

Chp.: Eric C. Li, M.D.
Participants: Yujuan Choy, M.D., John S. Luo, M.D., Salman Akhtar, M.D., Surinder S. Nand, M.D.

COMPONENT WORKSHOP 11 9:00 a.m.-10:30 a.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

VA MENTAL HEALTH'S RESPONSE TO TERRORISM
APA Caucus of VA Psychiatrists

Co-Chps.: Albert C. Gaw, M.D., Patricia I. Ordorica, M.D.
Participants: Laurent S. Lehmann, M.D., Matthew J. Friedman, M.D., Harold S. Kudler, M.D., Mara Kushner, C.S.W.

ISSUES 1-18

ISSUE WORKSHOP 1 9:00 a.m.-10:30 a.m.
Room 1E11, Level 1, Javits Center

DISRUPTIVE EMPLOYEES: FEEDBACK-ASSISTED COUNSELING AND TREATMENT

Co-Chps.: Eva C. Ritvo, M.D., Gonzalo F. Quesada, M.D.
Participant: Larry Harmon, Ph.D.

ISSUE WORKSHOP 2 9:00 a.m.-10:30 a.m.
Room 1E12, Level 1, Javits Center

THE OFFICE OF THE FUTURE: TECHNOLOGY IN PSYCHIATRY
American Association for Technology in Psychiatry

Co-Chps.: Robert C. Hsiung, M.D., Ronnie S. Stangler, M.D.
Participants: Seth M. Powsner, M.D., Daniel A. Deutschman, M.D., Michael Bauer, M.D.

ISSUE WORKSHOP 3 9:00 a.m.-10:30 a.m.
Room 1E13, Level 1, Javits Center

E, K, AND GHB: THE NEW ABCS OF SUBSTANCE ABUSE
Collaborative Session With the National Institute on Drug Abuse

Chp.: Richard N. Rosenthal, M.D.
Participants: Ramon Solhkhah, M.D., Petros Levounis, M.D.

ISSUE WORKSHOP 4 9:00 a.m.-10:30 a.m.
 Room 1E16, Level 1, Javits Center

FUNCTIONAL IMAGING IN COURT: USES AND CONTROVERSIES

Chp.: Daniel G. Amen, M.D.
Participants: Joseph C. Wu, M.D., Steven E. Rudolph, D.O., Harold J. Bursztajn, M.D.

ISSUE WORKSHOP 5 9:00 a.m.-10:30 a.m.
 Rooms 2D14/15, Level 2, Javits Center

REINVENTING CAREERS: TRANSITIONS AND LATER-LIFE STRATEGIES FOR PSYCHIATRISTS

Chp.: Carolyn B. Robinowitz, M.D.
Participants: Carol C. Nadelson, M.D., Edward Hanin, M.D., Mary V. Seeman, M.D.

ISSUE WORKSHOP 6 9:00 a.m.-10:30 a.m.
 Room 3D02/11, Level 3, Javits Center

DRUG ABUSE AND SUICIDAL BEHAVIOR
Collaborative Session With the National Institute on Drug Abuse

Chp.: Eric D. Caine, M.D.
Participants: Richard K. Ries, M.D., David B. Goldston, Ph.D., Marsha M. Linehan, Ph.D., Gregory Brown, Ph.D.

ISSUE WORKSHOP 7 9:00 a.m.-10:30 a.m.
 Room 3D03/10, Level 3, Javits Center

THE BENZODIAZEPINE CONTROVERSY REVISITED

Chp.: Christopher K. Chung, M.D.
Participants: Dean M. De Crisce, M.D., John W. Tsuang, M.D., Richardo Medoza, M.D., Karl S. Burgoyne, M.D.

ISSUE WORKSHOP 8 9:00 a.m.-10:30 a.m.
 Rooms 3D04/9, Level 3, Javits Center

ARE THERE LIMITS TO BOUNDARY LIMITS?

Chp.: Malkah T. Notman, M.D.
Participants: Elissa P. Benedek, M.D., Linda M. Jorgenson, J.D., Carl P. Malmquist, M.D., Lawrence B. Inderbitzin, M.D.

ISSUE WORKSHOP 9 9:00 a.m.-10:30 a.m.
 Rooms 3D05/8, Level 3, Javits Center

BROOKLYN MENTAL HEALTH COURT: FELONY OFFENDERS WITH MENTAL ILLNESS

Co-Chps.: Nancy J. Needell, M.D., Carol Fisler, J.D.
Participants: Matthew D'Emic, J.D., Lucille Jackson, M.S.W., Kelly O'Keefe, M.P.H., David Kelly, J.D., Mary Beth Anderson, J.D., Lisa Schreibersdorf, J.D.

ISSUE WORKSHOP 10 9:00 a.m.-10:30 a.m.
 Wilder Room, Fourth Floor, Marriott Marquis

CAN EARLY INTERVENTION PREVENT PSYCHOSIS? MANAGEMENT OF THE PRODROMAL PHASE

Chp.: Clarice J. Kestenbaum, M.D.
Participants: Eric R. Marcus, M.D., Ian E. Alger, M.D., Lewis A. Opler, M.D.

ISSUE WORKSHOP 11 9:00 a.m.-10:30 a.m.
 Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

DETOXIFICATION OF THE OPIOID-DEPENDENT CHRONIC-PAIN PATIENT

Chp.: Jon M. Streltzer, M.D.
Participants: Carl R. Sullivan, M.D., Thomas R. Kosten, M.D., Brian Johnson, M.D.

ISSUE WORKSHOP 12 9:00 a.m.-10:30 a.m.
 Booth/Edison Rooms, Fifth Floor, Marriott Marquis

DEATH BY SUICIDE: THE WORDS OF THOSE LEFT BEHIND

Chp.: Michael F. Myers, M.D.
Participants: James E. Barrett, Carla Fine, M.S., Michelle M. Barwell, M.D.

ISSUE WORKSHOP 13 9:00 a.m.-10:30 a.m.
 Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

THE AFTER-DEATH TELEPHONE CALL TO FAMILY MEMBERS: CLINICAL PERSPECTIVES

Co-Chps.: Sheila M. Loboprabhu, M.D., James W. Lomax II, M.D.
Participant: Jennifer E. Pate, M.D.

ISSUE WORKSHOP 14 9:00 a.m.-10:30 a.m.
 Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis

EARLY TRAUMA, PTSD, AND HIV: ASSOCIATION WITH TRANSMISSION AND NONADHERENCE

Co-Chps.: Mary Ann Cohen, M.D., Jack M. Gorman, M.D.
Participants: Rosalind G. Hoffman, M.D., Heidi E. Hutton, Ph.D., Glenn J. Treisman, M.D., Jeffrey Weiss, Ph.D.

ISSUE WORKSHOP 15 9:00 a.m.-10:30 a.m.
 Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

RESPONDING TO THE IMPACT OF SUICIDE ON CLINICIANS

Chp.: Eric M. Plakun, M.D.
Participants: Jane G. Tillman, Ph.D., Edward R. Shapiro, M.D.

MONDAY

ISSUE WORKSHOP 16 9:00 a.m.-10:30 a.m.
Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

COCAINE AND TOBACCO USE DURING PREGNANCY: ADVERSE OUTCOMES IN OFFSPRING
Collaborative Session With the National Institute on Drug Abuse

Chp.: Vincent L. Smeriglio, Ph.D.
Participants: Linda C. Mayes, M.D., Barry M. Lester, Ph.D., Lauren S. Wakschlag, Ph.D., Daniel Pine, M.D.

ISSUE WORKSHOP 17 9:00 a.m.-10:30 a.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

CONTROVERSIES AT THE INTERFACE BETWEEN RELIGION AND PSYCHIATRIC PRACTICE

Co-Chps.: Allan M. Josephson, M.D., John R. Peteet, M.D.
Participants: Yousef Abou-Allaban, M.D., Irving S. Wiesner, M.D., Nalini V. Juthani, M.D.

ISSUE WORKSHOP 18 9:00 a.m.-10:30 a.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

PSYCHIATRIC RESEARCH PERSPECTIVES IN LATIN AMERICA

Co-Chps.: Rodrigo A. Munoz, M.D., Pedro Ruiz, M.D.
Participants: Javier I. Escobar, M.D., Nora D. Volkow, M.D., Rodolfo D. Fahrner, M.D., Gerardo Heinze, M.D., Jose M. Caldas de Almeida, M.D.

MEDIA 1-2

MEDIA WORKSHOP 1 9:00 a.m.-12 noon
1E06, Level 1, Javits Center

Drummer Boy

Chp.: David L. Dawson, M.D.

MEDIA WORKSHOP 2 9:00 a.m.-12 noon
Room 1E17, Level 1, Javits Center

The Movie *Traffic* Hollywood, Teen Substance Abuse, and U.S. Drug Policy

Co-Chps.: Steven E. Hyler, M.D., Isabel Burk, M.S.

10:30 a.m. Session

ADVANCES IN RESEARCH
10:30 a.m.-12:30 p.m.
Special Events Hall 1D, Level 1, Javits Center

FRONTIERS IN THE TREATMENT OF PSYCHIATRIC DISORDERS
APA Scientific Program Committee and APA Council on Research

Chp.: Herbert Pardes, M.D.
Co-Chps.: John F. Greden, M.D., Geetha Jayaram, M.D.

Participants: Gerald Nestadt, M.D., on **Epidemiology and Treatment Implications of Personality Disorders**
Anthony F. Lehman, M.D., on **Evidence-Based Treatment in Schizophrenia**
John S. March, M.D., on **Treatment of Child Adolescent Anxiety and Depression: What Have We Learned?**
Yvette I. Sheline, M.D., on **Hippocampal Volume in Major Depression: Effect of Antidepressant Treatment**
THIS SESSION WILL BE AUDIOTAPED.

11:00 a.m. Sessions

DISCUSSION GROUPS 5-9

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 5 **Gregory E. Gray, M.D.**, on Evidence-Based Psychiatry
(Meet the Authors)
Rooms 2D02/3, Level 2, Javits Center
- 6 **Paul R. McHugh, M.D.**, on the Future Structure of Psychiatric Classification and Its Role in Enhancing Therapy, Teaching, and Research
Rooms 2D04/5, Level 2, Javits Center
- 7 **Eric R. Marcus, M.D.**, on Untying the Gordian Knot: Comorbid Bipolar II Illness and Personality Disorders
Rooms 2D06/7, Level 2, Javits Center
- 8 **Constantine Lyketsos, M.D.**, on Depression in Alzheimer's and Other Neurologic Conditions: Evaluation and Treatment
Room 2D08, Level 2, Javits Center
- 9 **Glenn J. Treisman, M.D.**, on HIV *(For Residents Only)*
Versailles Terrace, Second Floor, Sheraton New York

FOCUS LIVE SESSION 2

11:00 a.m.-12:30 p.m.

Room 1E14, Level 1, Javits Center

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.**Presenter:** Jonathan R.T. Davidson, M.D., on PTSD and**Anxiety Disorders: Test Your Knowledge**

Expert clinicians, who served as the guest editors of the first two issues of *Focus*, will lead lively multiple-choice, question-based discussions. This session covers PTSD and Anxiety Disorders, the first session at 9:00 a.m. covers Forensic and Ethical Issues in Psychiatry, and the third session at 2:00 p.m. covers Schizophrenia and Other Psychotic Disorders. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 5-7

LECTURE 5

11:00 a.m.-12:30 p.m.

Rooms 1E07/8, Level 1, Javits Center

Robert Lipsyte

Surviving Jock Culture

Chp.: Ronald L. Kamm, M.D.**Co-Chp.:** David A. Baron, D.O.

Robert Lipsyte, a longtime city and sports columnist for *The New York Times*, is the author of 16 books, including *In the Country of Illness: Comfort and Advice for the Journey*, and such best-selling young adult novels as *The Contender*, *One Fat Summer*, and *Warrior Angel*. A former network correspondent at CBS and NBC, Mr. Lipsyte won an Emmy Award in 1990 for on-camera achievement as host of the WNET nightly public affairs broadcast, "The Eleventh Hour." He was also host of "The Health Show," a weekly, live half-hour program of medical and health-related reportage. He contributes to the *USA Today* op-ed page and ESPN.com. In 1966 and in 1996, he won Columbia University's Meyer Berger Award for distinguished reporting. In 2001, he won the American Library Association's Margaret A. Edwards Award for lifetime achievement in young adult literature.

LECTURE 6

11:00 a.m.-12:30 p.m.

Room 1E15, Level 1, Javits Center

Julien Mendlewicz, M.D.

The Search for Genes of Bipolar Disorder: From Classical Genetics to Novel Molecular Targets**Chp.:** Lewis L. Judd, M.D.**Co-Chp.:** K. Roy MacKenzie, M.D.

Julien Mendlewicz, M.D., is Professor of Psychiatry on the Faculties of Medicine, Psychology, and Law at the University of Brussels in Brussels, Belgium; Chairman of the Department of Psychiatry at Erasme Hospital in Brussels; and Director of the Laboratory of Psychiatric Research of the Faculty of Medicine at the Free University of Brussels. Professor Mendlewicz's research interests include molecular neurobiology and behavioral genetics, particularly of affective disorders; chronobiology and sleep; and neuropharmacology. The author of more than 600 scientific articles, Professor Mendlewicz is the Founding and Principal Editor of *Neuropsychobiology* and former Editor of the international series *Advances in Biological Psychiatry*. An active member of many international scientific societies, Professor Mendlewicz is President-Elect of the European College of Neuropsychopharmacology. The numerous honors he has received include the A.E. Bennett Research Award from the Society of Biological Psychiatry, the Anna Monika International Foundation Prize for Research in Depression, the Lieber Prize from the National Alliance for Research on Schizophrenia and Depression, the Emil Kraepelin Award from the Max-Planck-Institut für Psychiatrie, the APA Special Presidential Commendation 2003, and the International Forum Award on Mood and Anxiety Disorders 2003. Professor Mendlewicz received his medical and psychiatric degree from the Free University of Brussels and his doctorate in human genetics and development from Columbia University in New York City.

International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 7

11:00 a.m.- 12:30 p.m.
Hall 3E, Level 3, Javits Center

APA'S ADOLF MEYER AWARD LECTURE

Glen O. Gabbard, M.D.

Mind, Brain, and Personality Disorders

Chp.: Marcia Kraft Goin, M.D.

Glen O. Gabbard, M.D., is Brown Foundation Chair of Psychoanalysis and Professor in the Department of Psychiatry at Baylor College of Medicine in Houston. He is also Training and Supervising Analyst in the Houston-Galveston Psychoanalytic Institute, Joint Editor-in-Chief of the *International Journal of Psychoanalysis*, and Associate Editor of the *American Journal of Psychiatry*. He is the author of more than 240 scientific papers and book chapters and the author or editor of 17 books, including *Psychodynamic Psychiatry in Clinical Practice, Psychiatry and the Cinema*, and *Long-Term Psychodynamic Psychotherapy: A Basic Text*. A Distinguished Fellow of APA, Dr. Gabbard has received numerous awards and honors, including the APA Distinguished Service Award, the Edward A. Strecker, M.D. Award from the Institute of Pennsylvania Hospital, and the Mary S. Sigourney Award for Outstanding Contributions to Psychoanalysis. Dr. Gabbard graduated from Rush Medical College in Chicago, completed his residency in psychiatry at the Karl Menninger School of Psychiatry in Topeka, Kansas; and received his psychoanalytic training at the Topeka Institute for Psychoanalysis. THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATION 3-4

11:00 a.m.- 12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 3 Robert G. Robinson, M.D., on Neuropsychiatry of Stroke: Recent Advances
Room 1D04, Level 1, Javits Center
- 4 Elizabeth Auchincloss, M.D., on Finding the Hidden Self: Engaging Difficult Patients in Exploratory Psychotherapy
Room 1D05, Level 1, Javits Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATE 1

11:00 a.m.- 12:30 p.m.
Room 1E13, Level 1, Javits Center

IRRITABLE BOWEL SYNDROME

Chp.: Philip R. Muskin, M.D.
Presenter: Susan Lucak, M.D.
THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH

11:00 a.m.- 12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

- 1 David V. Sheehan, M.D., on Evaluating Evidence in Clinical Trials and Research Papers
Room 1D03, Level 1, Javits Center

SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-8

SCIENTIFIC AND CLINICAL REPORT SESSION 1

11:00 a.m.- 12:30 p.m.
Room 1E01/2, Level 1, Javits Center

ISSUES IN SCHIZOPHRENIA

Chp.: David L. Garver, M.D.
Co-Chp.: Jamie Mullen, M.D.

- 11:00 a.m.
- 2 Rivastigmine and Glantamine Treatment of Schizophrenic Cognitive Impairment
Mohammad Z. Hussain, M.D., Zubaida A. Chaudhry, M.D.

- 11:30 a.m.
- 3 Dosing of Second-Generation Antipsychotics in a Large State Hospital System
Leslie L. Citrome, M.D., Ari B. Jaffe, M.D., Jerome Levine, M. D.

- 12 noon
- 4 The Meaning of Response in Acute Schizophrenia
Mary Anne Pressman, M.D., Eric D. Peselow, M.D., Scott Solloway, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 2

11:00 a.m.-12:30 p.m.

Room 1E11, Level 1, Javits Center

ANXIETY DISORDERS

Chp.: Gregory B. Sullivan, M.D.

Co-Chp.: Jeffrey A. Naser, M.D.

11:00 a.m.

5 Carbon Dioxide Test in Respiratory Panic Disorder: A Clonazepam TrialAntonio E. Nardi, M.D., Alexandre M. Valenca, M.D.,
Fabiana L. Lopes, M.D., Walter A. Zin, M.D., Isabella
Nascimento, M.D., Marco A. Mazzasalma, M.D.

11:30 a.m.

6 Child Abuse and the Development of PTSD in a Canadian Epidemiological SampleMichael A. Van Ameringen, M.D., Catherine L.
Mancini, M.D., Beth Pipe, B.S.C., Jonathan Oakman, Ph.D.,
Michael Boyle, Ph.D.

12 noon

7 Tiagabine Treatment of Social Anxiety Disorder

Laszlo A. Papp, M.D., Philip T. Ninan, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SCIENTIFIC AND CLINICAL REPORT SESSION 3**

11:00 a.m.-12:30 p.m.

Room 1E12, Level 1, Javits Center

SPECTRUM OF PERSONALITY DISORDERS

Chp.: John M. Oldham, M.D.

Co-Chp.: Robert Kelly, M.D.

11:00 a.m.

8 Childhood Prevalence of BPDMary C. Zanarini, Ed.D., Dieter Wolke, Ph.D., Jeremy
Horwood, M.S.C., Andrea Waylen, Ph.D.

11:30 a.m.

9 Apparent Versus Reported Sadness: Correlation With Personality Traits

Anand Pandya, M.D., Eric D. Peselow, M.D.

12 noon

10 High-Lethality Suicide Attempts in BPDPaul H. Soloff, M.D., Anthony Fabio, Ph.D., Thomas M.
Kelly, Ph.D., Kevin M. Malone, M.D., John J. Mann, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 4**

11:00 a.m.-12:30 p.m.

Room 3D03/10, Level 3, Javits Center

RECOVERY ISSUES WITH SCHIZOPHRENIA

Chp.: Francine Cournos, M.D.

Co-Chp.: Vital N. Shah, M.D.

11:00 a.m.

11 Do Patients With Schizophrenia Show Periods of Complete Recovery? A 20-Year Follow-UpMartin Harrow, Ph.D., Linda S. Grossman, Ph.D., Thomas
H. Jobe, M.D., Joseph F. Goldberg, M.D., Robert Faull, B.S.

11:30 a.m.

12 Twenty-Year Outcome in Schizophrenia: What's Sex Got to Do With It?Linda S. Grossman, Ph.D., Martin Harrow, Ph.D., Cherise
Rosen, M.A., Ellen S. Herbener, Ph.D., Christopher G.
Fichtner, M.D.

12 noon

13 Recovery From Schizophrenic Psychoses Until Age 35Erika Lauronen, Johanna Koskinen, Juha M. Veijola, Ph.D.,
Jouko Miettunen, M.S.C., Peter B. Jones, M.D., Wayne S.
Fenton, M.D., Matti K. Isohanni, Ph.D.**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 5**

11:00 a.m.-12:30 p.m.

Room 3D04/9, Level 3, Javits Center

COMPLICATIONS WITH ATYPICAL ANTIPSYCHOTICS

Chp.: Evaristo O. Akerele, M.D.

Co-Chp.: Anton C. Trinidad, M.D.

11:00 a.m.

14 A Program for Treating Weight Gain Induced by Atypical AntipsychoticsYael Nehama, M.D., Faina Tsodikov, M.S.C., Yaacov
Ashkenazy, M.D., Henry Szor, M.D.

11:30 a.m.

15 Increased Lipid Levels and Antipsychotic MedicationHannu J. Koponen, M.D., Kaisa Saari, M.D., Sari
Lindeman, M.D., Markku J. Savolainen, M.D., Matti K.
Isohanni, Ph.D.

12 noon

16 QTc Prolongation Associated With ZiprasidoneJohn W. Goethe, M.D., Bonnie L. Szarek, R.N., Charles F.
Caley, Pharm.D., Deborah A. Piez, M.S.**THIS SESSION WILL BE AUDIOTAPED.**

MONDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 6

11:00 a.m.-12:30 p.m.
3D05/8, Level 3, Javits Center

PSYCHOTHERAPY AND PSYCHOPHARMACOLOGY: DISSOLVING THE MIND-BRAIN BARRIER

Chp.: David A. Casey, M.D.
Co-Chp.: Andrew O. Skinner, M.D.

11:00 a.m.
17 **Interpersonal Psychotherapy for Depressed Elders With Cognitive Dysfunction**
Mark D. Miller, M.D.

11:30 a.m.
18 **Integrating Psychotherapy With Medication to Improve Outcome**
Ira D. Glick, M.D.

12 noon
19 **Review of Psychotherapy Research Involving a Pill-Placebo Control**
Arthur Rifkin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 7

11:00 a.m.-12:30 p.m.
Room 3D06/7, Level 3, Javits Center

TREATMENT OF DEPRESSION

Chp.: Thomas L. Schwartz, M.D.
Co-Chp.: Marketa M. Wills, M.D.

11:00 a.m.
20 **Duloxetine Versus Placebo in the Prevention of Relapse of MDD**
Michael J. Detke, M.D., Inmaculada Gilaberte, M.D.,
David G. Perahia, M.D., Fujun Wang, Ph.D., Thomas C. Lee, M.S., Pierre V. Tran, M.D.

11:30 a.m.
21 **Response to Antidepressants Is Independent of Gender**
Tamar D. Wohlfarth, Ph.D., Jitschak G. Storoosum, M.D.,
Andre J. A. Elferink, M.D., Barbara J. van Zwieten, Ph.D.,
Annemarie Fouwels, M.D., Wim Van Den Brink, M.D.

12 noon
22 **Depression and BPD During the Immediate Postpartum Period**
Gisele Apter-Danon, M.D., Rozenn Graignic-Phillippe,
Marina Gianoli-Valente, Emmanuel Devouche, Ph.D.,
Annick Le Nestour, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 8

11:00 a.m.-12:30 p.m.
Wilder Room, Fourth Floor, Marriott Marquis

HEALTH SERVICES

Chp.: Mary Jane England, M.D.
Co-Chp.: Steven A. Epstein, M.D.

11:00 a.m.
23 **Treatment Effectiveness and Functional Recovery in Schizophrenia**
Henry A. Nasrallah, M.D.

11:30 a.m.
24 **Ethnic-Matched, Culturally-Competent, Model-Based ACT Team: Early Outcome Report**
Samuel F. Law, M.D., Jian Yang, M.D., Rosalie Steinberg, M.S.C., Wendy Chow, M.S.W., Joel Sadavoy, M.D.

12 noon
25 **Work Disability and Treatment Access in Psychiatry**
Farifteh F. Duffy, Ph.D., Joyce C. West, Ph.D., Ilze Ruditis, M.S.W., William E. Narrow, M.D., Darrel A. Regier, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 12-20

COMPONENT WORKSHOP 12 11:00 a.m.-12:30 p.m.
Rooms 1E03/4/5, Level 1, Javits Center

WHITHER OUR OWN HISTORY? DEBATING THE VALUE OF THE STUDY OF PSYCHIATRY'S PAST
APA Corresponding Committee on History and Library

Chp.: Avram H. Mack, M.D.

COMPONENT WORKSHOP 13 11:00 a.m.-12:30 p.m.
Room 1E09, Level 1, Javits Center

WHAT'S NEW IN PSYCHIATRY AND THE LAW AT APA?
APA Council on Psychiatry and Law and APA Committee on Judicial Action

Chp.: Renee L. Binder, M.D.
Participants: Jeffrey L. Metzner, M.D., Alan A. Stone, M.D.,
Richard G. Taranto, J.D., Howard V. Zonana, M.D.

COMPONENT WORKSHOP 14 11:00 a.m.-12:30 p.m.
Rooms 2D10/11, Level 2, Javits Center

NOVEL CAREERS IN PSYCHIATRY: WOMEN WHO HAVE MADE THEIR OWN WAY

APA Committee on Women

Co-Chps.: Melva I. Green, M.D., Madelaine M. Wohlreich, M.D.

COMPONENT WORKSHOP 15 11:00 a.m.-12:30 p.m.
Rooms 2D12/13, Level 2, Javits Center

UPDATE ON PRACTICE GUIDELINES: PTSD AND ACUTE STRESS DISORDER

APA Steering Committee on Practice Guidelines

Chp.: John S. McIntyre, M.D.

Participants: Robert J. Ursano, M.D., Matthew J. Friedman, M.D., Douglas F. Zatzick, M.D., David M. Benedek, M.D.

COMPONENT WORKSHOP 16 11:00 a.m.-12:30 p.m.
Rooms 2D14/15, Level 2, Javits Center

PUBLIC PSYCHIATRY: LEADING THE WAY IN TRANSFORMING SERVICE DELIVERY IN THE 21ST CENTURY

APA Council on Social Issues and Public Psychiatry

Co-Chps.: Altha J. Stewart, M.D., Jeffrey L. Geller, M.D.

Participants: Stephen M. Thielke, M.D., Kenneth S. Thompson, M.D., Joy D. McQuery, M.D.

COMPONENT WORKSHOP 17 11:00 a.m.-12:30 p.m.
Odets Room, Fourth Floor, Marriott Marquis

FITNESS TO PRACTICE MEDICINE: THE ROLES OF THE EVALUATING PSYCHIATRIST

APA Corresponding Committee on Physician Health, Illness, and Impairment

Chp.: John A. Fromson, M.D.

Participants: Richard F. Limoges, M.D., Stuart A. Anfang, M.D., Linda Logsdon, M.D., Michael H. Gendel, M.D., Suzanne E. Vogel-Scibilia, M.D.

COMPONENT WORKSHOP 18 11:00 a.m.-12:30 p.m.
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

TERROR AT HOME: ADDRESSING DOMESTIC VIOLENCE IN YOUR PRACTICE

APA Committee on Family Violence and Abuse

Chp.: Carole L. Warshaw, M.D.

Participants: Graeme Hanson, M.D., Sandra L. Bloom, M.D.

COMPONENT WORKSHOP 19 11:00 a.m.-12:30 p.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

APPROACHES TO ASSESSMENT AND DIAGNOSIS OF INFANTS AND SMALL CHILDREN

APA Council on Children, Adolescents, and Their Families

Chp.: William C. Wood, M.D.

Participants: Joan L. Luby, M.D., Jean M. Thomas, M.D., Brian K. Wise, M.D., Harry H. Wright, M.D.

COMPONENT WORKSHOP 20 11:00 a.m.-12:30 p.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

HELPING OLDER PERSONS WITH SCHIZOPHRENIA: TREATMENT, RESEARCH, AND POLICY

APA Council on Aging

Chp.: Carl I. Cohen, M.D.

Participants: Susan K. Schultz, M.D., Harriet P. Lefley, Ph.D., Philip D. Harvey, Ph.D., Stephen J. Bartels, M.D.

ISSUES 19-32

ISSUE WORKSHOP 19 11:00 a.m.-12:30 p.m.
Room 1D06, Level 1, Javits Center

PSYCHIATRY IN THE PRIMARY CARE SETTING: MAKING IT WORK FOR THE PSYCHIATRIST

Chp.: John C. Urbaitis, M.D.

Participants: Ian M. Pullen, Joseph M. Schwartz, M.D., Shauna P. Reinblatt, M.D.

ISSUE WORKSHOP 20 11:00 a.m.-12:30 p.m.
Room 3D02/11, Level 3, Javits Center

NO-SUICIDE DECISIONS, CONTRACTS, AND ASSESSMENT OF RISK: VALUES AND CAUTIONS

Chp.: Robert C. Dye, M.D.

Participants: Cynthia R. Pfeffer, M.D., Robert I. Simon, M.D.

ISSUE WORKSHOP 21 11:00 a.m.-12:30 p.m.
O'Neill Room, Fourth Floor, Marriott Marquis

CHRONIC FATIGUE SYNDROME: DISEASE OR ABNORMAL ILLNESS BEHAVIOR?

Chp.: Peter Manu, M.D.

MONDAY

ISSUE WORKSHOP 22 11:00 a.m.-12:30 p.m.
Ziegfeld Room, Fourth Floor, Marriott Marquis

CAREER DEVELOPMENT FOR MINORITY WOMEN PSYCHIATRISTS

Chp.: Surinder S. Nand, M.D.
Participants: Nalini V. Juthani, M.D., Tanya R. Anderson, M.D., Patricia I. Ordorica, M.D., Kathleen M. Kim, M.D., Nutan A. Vaidya, M.D.

ISSUE WORKSHOP 23 11:00 a.m.-12:30 p.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

WHAT PSYCHIATRY RESIDENTS CAN EXPECT FROM NIMH-SPONSORED RESEARCH TRAINING

Co-Chps.: Joseph R. Calabrese, M.D., Della M. Hann, Ph.D.
Participants: Robert L. Findling, M.D., Omar Elhaj, M.D.

ISSUE WORKSHOP 24 11:00 a.m.-12:30 p.m.
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

TREATING PHYSICIANS: ISSUES IN DIVERSITY

Chp.: Michael F. Myers, M.D.
Participants: Daniel P. Chapman, Ph.D., Donna M. Norris, M.D., David W. Hodo, M.D.

ISSUE WORKSHOP 25 11:00 a.m.-12:30 p.m.
Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

DRUG ABUSE AND MENTAL HEALTH TREATMENT IN LIEU OF IMPRISONMENT

Chp.: Rodrigo A. Munoz, M.D.
Participants: David Deitch, Ph.D., Gretchen Burns, Igor Koutsemok, M.D.

ISSUE WORKSHOP 26 11:00 a.m.-12:30 p.m.
Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

OBTAINING RESEARCH FUNDING FROM NIH: KEYS TO SUCCESSFUL GRANT WRITING

Collaborative Session With the National Institute on Drug Abuse

Chp.: Lucinda L. Miner, Ph.D.
Participant: Marina Volkov, Ph.D.

ISSUE WORKSHOP 27 11:00 a.m.-12:30 p.m.
Gotham Room, Seventh Floor, Marriott Marquis

TO SMOKE OR NOT TO SMOKE: THE DILEMMAS OF TOBACCO-FREE ADDICTION TREATMENTS

Collaborative Session With the National Institute on Drug Abuse

Co-Chps.: Petros Levounis, M.D., Edward V. Nunes, M.D.
Participants: Paul J. Rinaldi, Ph.D., Ronald B. Lonesome, M.D., Lisa Koen, M.A.

ISSUE WORKSHOP 28 11:00 a.m.-12:30 p.m.
Gramercy Room, Seventh Floor, Marriott Marquis

THE TRANSITIONAL OBJECT IN DEMENTIA

Co-Chps.: Sheila M. Loboprabhu, M.D., James W. Lomax II, M.D.
Participant: Pamela J. Petersen-Crair, M.D.

ISSUE WORKSHOP 29 11:00 a.m.-12:30 p.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

BOUNDARY VIOLATION: HISTORY, TYPOLOGY, AND PREVENTION

Chp.: Albert C. Gaw, M.D.
Participants: Axel Hoffer, M.D., Thomas G. Gutheil, M.D., Andrea Celenza, Ph.D.

ISSUE WORKSHOP 30 11:00 a.m.-12:30 p.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

COGNITIVE THERAPY AND PHARMACOTHERAPY: TEACHING RESIDENTS INTEGRATED TREATMENT METHODS

Chp.: Donna M. Sudak, M.D.
Participants: Judith S. Beck, Ph.D., Jesse H. Wright, M.D., Edward S. Friedman, M.D.

ISSUE WORKSHOP 31 11:00 a.m.-12:30 p.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

TREATING AFRICAN-AMERICAN PATIENTS WITH PSYCHOTHERAPY: A TRAINING DILEMMA

Co-Chps.: Anu A. Matorin, M.D., Henry L. McCurtis, M.D.
Participants: Billy E. Jones, M.D., Pedro Ruiz, M.D., Sudhandshu Nene, M.D.

ISSUE WORKSHOP 32 11:00 a.m.-12:30 p.m.
Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

RISK-MANAGEMENT ISSUES IN PSYCHIATRIC PRACTICE

Psychiatrists' Purchasing Group, Inc

Chp.: Alan I. Levenson, M.D.
Participants: Ellen R. Fischbein, M.D., Martin G. Tracy, J.D., Jacqueline M. Melonas, J.D., Charles D. Cash, J.D.

12 noon Sessions

FORUMS 1-5

FORUM 1 12 noon- 1:30 p.m.
 Room 1E 10, Level 1, Javits Center

EVIDENCE-BASED PSYCHOTHERAPY

Chp.: Darrel A. Regier, M.D.
Co-Chp.: John S. McIntyre, M.D.
Participants: A. John Rush, M.D., David Barlow, Ph.D.,
 Joshua E. Wilk, Ph.D., Lisa A. Mellman, M.D., Marsha M.
 Linehan, Ph.D., Anthony F. Lehman, M.D.
Discussants: Myrna M. Weissman, Ph.D., Robert
 Michels, M.D.

FORUM 2 12 noon- 1:30 p.m.
 Room 1E 16, Level 1, Javits Center

ETHICAL DILEMMAS IN PRACTICE AND RESEARCH

Chp.: David M. McDowell, M.D.
Participants: David J. Hellerstein, M.D., David A.
 Lowenthal, M.D., Samuel C. Klagsbrun, M.D.

FORUM 3 12 noon- 1:30 p.m.
 Petit Trianon, Third Floor, Hilton New York

ABPN UPDATE: REQUIREMENTS FOR ABPN EXAMINATION

Chp.: Stephen C. Scheiber, M.D.
Participants: Michael H. Ebert, M.D., Larry R. Faulkner, M.D.,
 David A. Mrazek, M.D., Burton V. Reifler, M.D., Victor I.
 Reus, M.D., James H. Scully, Jr., M.D., Elizabeth B.
 Weller, M.D., Daniel K. Winstead, M.D.

FORUM 4 12 noon- 1:30 p.m.
 Rendezvous Trianon, Third Floor, Hilton New York

JAILS OR TREATMENT? ALTERNATIVES TO INCARCERATION

Chp.: Stephen M. Goldfinger, M.D.
Participants: Charles J. Hynes, J.D., Anne J. Swern, J.D.,
 Matthew D'Emic, J.D., Lisa Schreibersdorf, J.D.,
 Kenneth Linn, Esq.

FORUM 5 12 noon- 1:30 p.m.
 Astor Ballroom, Seventh Floor, Marriott Marquis

MUSIC AND THE MIND: BEETHOVEN

Chp.: Richard Kogan, M.D.

1:00 p.m. Sessions



COURSES 45-52

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 45 1:00 p.m.-5:00 p.m.
 Concourse A, Concourse Level, Hilton New York

DEPRESSION IN LATER LIFE: AN INTERDISCIPLINARY APPROACH

Co-Directors: James M. Ellison, M.D., Yusuf Sivrioglu, M.D.
Faculty: Francesca Cannavo Antognini, Ph.D., Donald A.
 Davidoff, Ph.D.

COURSE 46 1:00 p.m.-5:00 p.m.
 Concourse B, Concourse Level, Hilton New York

DREAM TRANSLATION: ONE EMPIRICALLY-BASED APPROACH

Director: Milton Kramer, M.D.

COURSE 47 1:00 p.m.-5:00 p.m.
 Concourse E, Concourse Level, Hilton New York

DIMENSIONS OF PSYCHOTHERAPY SUPERVISION: A CASE-BASED APPROACH

Director: Paul Rodenhauer, M.D.
Faculty: Ramona Dvorak, M.D., Albert F. Painter, Psy.D.,
 John R. Rudisill, Ph.D.

COURSE 48 1:00 p.m.-5:00 p.m.
 Concourse G, Concourse Level, Hilton New York

GAY MEN AND THE PROBLEM OF ROMANTIC LOVE

Director: Richard A. Isay, M.D.

COURSE 49 1:00 p.m.-5:00 p.m.
 Gibson Suite, Second Floor, Hilton New York

THE ADVANCED PRACTICE OF PSYCHOTHERAPY

Director: T. Byram Karasu, M.D.

COURSE 50 1:00 p.m.-5:00 p.m.
 Gramercy B, Second Floor, Hilton New York

RATING SCALES: A BASIC OVERVIEW

Co-Directors: Luis F. Ramirez, M.D., Martha Sajatovic, M.D.

COURSE 51 1:00 p.m.-5:00 p.m.
 Madison Suite, Second Floor, Hilton New York

TEMPORAL LOBE AND LIMBIC SYSTEM ANATOMY AND THE RELATION TO PSYCHIATRIC ILLNESS

Co-Directors: Andrew L. Lantin, M.D., Jack Davis, M.S.
Faculty: Adam Wolkin, M.D., Ronald A. Jones, M.D., Hamada Hamid, M.D.

COURSE 52 1:00 p.m.-5:00 p.m.
 Nassau Suite A, Second Floor, Hilton New York

CHILD MURDER BY PARENTS

Director: Phillip J. Resnick, M.D.

NEW RESEARCH YOUNG INVESTIGATORS' ORAL/SLIDE SESSIONS 2-4

1:00 p.m.-2:30 p.m.

- 2 **Evidence-Based Medicine**
 Rooms 3D01/12, Level 3, Javits Center
- 3 **Genetics and Brain Imaging: Recent Findings**
 Rooms 3D03/10, Level 3, Javits Center
- 4 **Addictions, Alcoholism, and College Students**
 Rooms 3D06/7, Level 3, Javits Center

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

2:00 p.m. Sessions

ADVANCES IN PSYCHOPHARMACOLOGY

2:00 p.m.-5:30 p.m.
 Special Events Hall 1D, Level 1, Javits Center

AN UPDATE FOR CLINICIANS

Chp.: Alan F. Schatzberg, M.D.
Co-Chp.: Jeffrey A. Lieberman, M.D.

- 1 **Introduction to Neurotransmitters, Receptors, Signal Transduction, and Second Messengers**
 Husseini K. Manji, M.D.
- 2 **Immune System Pathology in Psychiatric Disease**
 Andrew H. Miller, M.D.
- 3 **Second Generation Antipsychotics**
 Jeffrey A. Lieberman, M.D.

- 4 **MAOIs**
 K. Ranga R. Krishnan, M.D.
- 5 **Principles of Pharmacokinetics**
 C. Lindsay DeVane, Pharm.D.

FOCUS LIVE SESSION 3

2:00 p.m.-3:30 p.m.
 Room 1E14, Level 1, Javits Center

Moderator: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenters: John Lauriello, M.D., on **Schizophrenia and Other Psychotic Disorders**

Expert clinicians, who served as the guest editors of the first two issues of *Focus*, will lead lively multiple-choice, question-based discussions. This session covers Schizophrenia and Other Psychotic Disorders, the first session at 9:00 a.m. covers Forensic and Ethical Issues in Psychiatry, and the second session at 11:00 a.m. covers PTSD and Anxiety Disorders. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 8-10

LECTURE 8

2:00 p.m.-3:30 p.m.
 Rooms 1E07/8, Level 1, Javits Center

Thomas R. Insel, M.D.

Social Neuroscience: A New Basic Science for Psychiatry

Chp.: Josepha A. Cheong, M.D.
Co-Chp.: Barton J. Blinder, M.D.

Thomas R. Insel, M.D., is Director of the National Institute of Mental Health in Bethesda, Maryland. He formerly was W.E. Timmie Professor of Psychiatry and Behavioral Sciences and Director of the Center for Behavioral Neuroscience at Emory University. In his research, Dr. Insel has used molecular, cellular, and pharmacological approaches to explore the neurobiology of complex social behaviors, including maternal behavior, pairbond formation, and aggression. Dr. Insel has served on over 10 editorial boards for both neuroscience and psychiatric journals. A Fellow of the American College of Neuropsychopharmacology, Dr. Insel has received the Distinguished Investigator Award from the National Alliance for Research on Schizophrenia and Depression, the A.E. Bennett Award from the Society of Biological Psychia-

try, and the Outstanding Service Award from the U.S. Public Health Service. He is the author of more than 200 scientific articles and book chapters and the author or editor of four books, including *The Psychobiology of Obsessive-Compulsive Disorder* and *The Neurobiology of Parental Behavior*. Dr. Insel received his medical degree from Boston University Medical School and completed his residency in psychiatry at Langley Porter Neuropsychiatric Institute—University of California, San Francisco.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 9

2:00 p.m.-3:30 p.m.

Room 1E15, Level 1, Javits Center

APA'S SOLOMON CARTER FULLER AWARD LECTURE

Phyllis Harrison-Ross, M.D.

I Am a Fact, Not a Fiction

Chp.: Michelle O. Clark, M.D.

Phyllis Harrison-Ross, M.D., is Emeritus Professor of Psychiatry and Behavioral Health Services at the NY Medical College and Emeritus Attending Psychiatrist and Chief of Psychiatry at Metropolitan Hospital Center in New York City. She is also in the private practice of child and adult psychiatry. Since 2000 she has served as the Founder and Managing Partner of the Black Psychiatrists of Greater NY and Associates. Dr. Harrison-Ross currently is a member of the Medical Review Board of the NY State Commission of Corrections, a Board member of the Medical Health and Research Association of NY City, the Board of Directors of Northside Center for Child Development, and the Editorial Board of the NY Amsterdam News. In the 1970s she was a member of the President's Advisory Council on Drug Abuse Prevention and helped form the New York City Federation of Mental Health, Mental Retardation, and Alcoholism Services. Her books include *The Black Child* and *Getting It Together*. She has written articles and book chapters on prison health issues. A Distinguished Life Fellow of the APA, Dr. Harrison-Ross is Past President of Black Psychiatrists of America. She received her medical degree from Wayne State University College of Medicine in Detroit, completed her residency in pediatrics at Cornell Medical College—NY Hospital in New York City, and completed her residency in adult psychiatry and a fellowship in child psychiatry at Albert Einstein College of Medicine and Bronx Municipal Hospital in the Bronx, NY. Recently, the use of Telepsychiatry to reach underserved populations has captured her interest.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 10

2:00 p.m.-3:30 p.m.

Trianon Ballroom, Third Floor, Hilton New York

Timothy J. Crow, M.B.

Language, Psychosis, and the Speciation Event

Chp.: Ananda K. Pandurangi, M.D.

Co-Chp.: Michael D. Garrett, M.D.

Timothy J. Crow, M.B., is Professor of Psychiatry at the University of Oxford in Oxford, England, a member of the United Kingdom Medical Research Council (MRC) External Staff, Fellow of the Academy of Medical Sciences, and Honorary Director of the Prince of Wales Centre for SANE Research on Schizophrenia and Depression in Oxford. Previously he was Deputy Director and Head of the Division of Psychiatry at the MRC Clinical Sciences Centre and a member of the Scientific Staff of the Division of Neurophysiology and Neuropharmacology at the National Institute for Medical Research in London. Dr. Crow has received numerous awards in recognition of his work on brain structure and function in patients with schizophrenia, including the Alexander Gralnick Award for Research in Schizophrenia from the American Psychiatric Association, the Research Prize of the World Federation of Societies of Biological Psychiatry, and the Lieber Prize for Schizophrenia Research from the National Alliance for Research on Schizophrenia and Depression. Dr. Crow is a Fellow of the Royal College of Psychiatrists. He received his medical degree from London Hospital Medical College and completed his doctoral work in physiology at the University of Aberdeen, Aberdeen, Scotland.

Distinguished Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIUM 1

2:00 p.m.-5:00 p.m.

Room 1E10, Level 1, Javits Center

THE BIOPSYCHOSOCIAL MODEL: MYTH OR REALITY?

Chp.: J. Pierre Loebel, M.D.

Co-Chp.: Marcia Kraft Goin, M.D.

A Biopsychosocial Model: History

John D. Wynn, M.D.

B Biopsychosocial Integration in Residency Training

Deborah S. Cowley, M.D.

C The Biopsychosocial Model: Contribution of Research

Charles B. Nemeroff, M.D.

D Biopsychosocial Psychiatry in Clinical Practice

Glen O. Gabbard, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIA 1-26

SYMPOSIUM 1 2:00 p.m.-5:00 p.m.
Rooms 1E01/2, Level 1, Javits Center

BRAIN STIMULATION: NEW TREATMENTS FOR MOOD DISORDERS

Chp.: A. John Rush, M.D.
Co-Chp.: Harold A. Sackeim, Ph.D.

- A ECT: Role in Brain Stimulation**
Harold A. Sackeim, Ph.D.
- B Magnetic Seizure Therapy: Development of a Novel Convulsive Treatment**
Sarah H. Lisanby, M.D.
- C Repeated Prefrontal Repetitive Transcranial Magnetic Stimulation as an Antidepressant: An Update**
Mark S. George, M.D., Ziad H. Nahas, M.D., Andrew F. Kozel, M.D., Alexander Mishory, M.D., Xingbao Li, M.D., Berry Anderson, R.N.
- D The Use of Vagus Nerve Stimulation (VNS) in the Long-Term Treatment of Mood Disorders**
Lauren B. Marangell, M.D.

Discussant: Jerrold F. Rosenbaum, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 2 2:00 p.m.-5:00 p.m.
Rooms 1E03/4/5, Level 1, Javits Center

TREATMENT OF MALADAPTIVE PERSONALITY TRAITS

Chp.: James H. Reich, M.D.

- A Drug Treatment of Maladaptive Personality Traits**
James H. Reich, M.D.
- B Neurobiology, Comorbidity, and Drug Treatment of Childhood Abused BPD Patients**
Thomas Rinne, M.D., Wim Van Den Brink, M.D., Jaap G. Goekoop, M.D., Roel H. Ryk, Ph.D., Ronald de Kloet, Ph.D.
- C Development and Treatment of Family Pathology Around Cluster-B Traits**
David M. Allen, M.D.
- D Cognitive Therapy for Maladaptive Personality Traits**
David P. Bernstein, Ph.D.
- E Affective Deficits in Recurrent Suicidal Behavior**
Paul S. Links, M.D., Yvonne Bergmans, M.S.W., A. Barr, Ph.D.

F Narcissistic Traits in Substance Abusers: Any Treatment Implications?
Per Vaglum, M.D.

Discussant: John Livesley, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 3 2:00 p.m.-5:00 p.m.
Room 1E09, Level 1, Javits Center

FUNCTIONAL BRAIN IMAGING OF ADDICTION
Collaborative Session With the National Institute on Drug Abuse

Chp.: Elliot A. Stein, Ph.D.

- A Neuropsychiatric Implications of Mapping Reward/Aversion Circuitry**
Hans C. Breiter, M.D., Gregory P. Gasic, Ph.D.
- B Endogenous Opioid Neurotransmissions: Interfacing Reward and Stress Regulation**
Jon-Kar Zubieta, M.D.
- C Chronic Effects of Drug Use and HIV**
Linda Chang, M.D.

D Neurobiological Substrates of Stimulant Action and Reward
Elliot A. Stein, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 4 2:00 p.m.-5:00 p.m.
Room 1E11, Level 1, Javits Center

TREATMENT OF CHRONIC PAIN IN RECOVERING ADDICTS

Collaborative Session With the National Institute on Drug Abuse

Chp.: Jag Khalsa, Ph.D.

- A Pain Assessment and Issues in Screening**
Russ Portenoy, M.D.
- B Assessing Aberrant Drug-Taking Behaviors in Medically Ill Patients With Pain**
Steve Passik, Ph.D.
- C The Development and Treatment of Opioid-Induced Hyperalgesia**
Walter Ling, M.D.
- D Prescribing Pain Medications for Recovering Addicts With Chronic Pain**
Richard Brown, M.D.
- E Principles of Pain Treatment in Addictive Disorders**
Seddon R. Savage, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 5 2:00 p.m.-5:00 p.m.
Room 1E12, Level 1, Javits Center

**CHILD SOLDIERS, CHILD AND ADOLESCENT
 VICTIMS OF WAR AND TERRORISM:
 BIOPSYCHOSOCIAL TREATMENT FOR
 REINTEGRATION INTO FAMILY AND
 SOCIETY**

APA Alliance

Chp.: Frank G. Njenga, M.D.
Co-Chp.: Rosalind Hayes, B.A.

**A Children's Response to Terrorism in Nairobi: The 1998
 U.S. Embassy Bombing in Kenya**
 Frank G. Njenga, M.D.

B The Voices of Girl-Child Soldiers
 Yvonne Keairns, Ph.D.

**C Terror and Terrorism: Community Responses and
 Needs**
 Robert J. Ursano, M.D., Carol Fullerton, Ph.D.

**D Child Soldiers Reintegration: A Holistic Community-
 Based Approach**
 Michael Wessells, Ph.D.

**E Survey of Youth, Violence, and Public Health in Bogota,
 Colombia**
 Luis Duque, M.D., L.F. Klevins, M.D., C. Ramirez

Discussants: Robert J. Ursano, M.D., Yvonne Keairns, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 6 2:00 p.m.-5:00 p.m.
Room 1E13, Level 1, Javits Center

**NEW DIRECTIONS IN TERRORISM AND
 POLITICAL VIOLENCE: CAUSES AND RESPONSES**
*International Society for Political Psychology and APA Council on Global
 Psychiatry*

Chp.: Jerrold M. Post, M.D.

A Path to Collective Madness
 Dipak Gupta, Ph.D.

B When Hatred Is Bred in the Bone
 Jerrold M. Post, M.D.

**C Terror on the Internet: The New Arena, The New
 Challenges**
 Gabriel Weimann, Ph.D.

D Cultural Approaches Linking Terrorism and Traumas
 Stevan M. Weine, M.D.

**E Resource Loss and Impact on Civilian Populations:
 Individuals and System Outcomes**
 Stevan Hobfoll, Ph.D.

Discussant: David Rothstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 7 2:00 p.m.-5:00 p.m.
Room 1E16, Level 1, Javits Center

I REST MY CASE
American Association of Practicing Psychiatrists

Chp.: Janis G. Chester, M.D.

A The HIPAA Suit
 Robert L. Pyles, M.D.

B Shrager Versus Magellan
 Daniel Shrager, M.D.

C The RICO Suit
 Janis G. Chester, M.D.

D Eist Versus Maryland BPQA
 Harold I. Eist, M.D.

Discussants: Deborah C. Peel, M.D., Roger Peele, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 8 2:00 p.m.-5:00 p.m.
Room 3D02/11, Level 3, Javits Center

**FROM RESPONSE TO RECOVERY: THE CONSUMER
 AND CLINICIAN COLLABORATION IN
 DEPRESSION AND PSYCHOSIS**

Chp.: Shervert H. Frazier, M.D.
Co-Chp.: Evelyn Barkin

**A Sarah's Struggle: Adolescence, Abandonment, and
 Bipolar Disorder**
 Sarah Duckworth

**B To Be or Not To Be? The Hidden Crisis of Adult and
 Adolescent Male Depression and Suicide**
 William S. Pollack, Ph.D.

C From Illness to Wellness: New Strategies for Recovery
 Anne Whitman, Ph.D.

D Bipolar and MDD in Mid-Life
 Paul E. Keck, Jr., M.D.

E Geriatric Depression, Alcohol Abuse, and Suicidality
 Everet Page

(Continued on next page)

MONDAY

- F Late-Life Depression: Is Getting Well Enough?**
Sumer Verma, M.D.

Discussant: Christopher M. Palmer, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 9 2:00 p.m.-5:00 p.m.
Rooms 3D04/9, Level 3, Javits Center

**RECENT ADVANCES IN THE TREATMENT OF
PSYCHIATRIC DISORDERS IN PRIMARY CARE: A
U.S./U.K. PERSPECTIVE**

Chp.: Wayne J. Katon, M.D.
Co-Chp.: Lawrence Mynors-Wallis, D.M.

- A The Pathways Study: A Randomized Trial of
Collaborative Care in Patients With Diabetes and
Depression**
Wayne J. Katon, M.D., Michael Von Korff, Sc.D., Elizabeth
Lin, M.D., Gregory Simon, M.D., Paul Ciechanowski, M.D.,
Evette Ludman, Ph.D., Edward A. Walker, M.D.

- B Cognitive-Behavior Therapy and Medication for
Primary Care Panic Disorder: Sustained Superiority to
Usual Care**
Peter P. Roy-Byrne, M.D., Michelle G. Craske, Ph.D.,
Murray B. Stein, M.D., J. Greer Sullivan, M.D., Alexander
Bystritsky, M.D., Wayne J. Katon, M.D., Cathy D.
Sherbourne, Ph.D.

- C Problem-Solving Treatment by Nurses for Psychological
Disorders in Primary Care**
Lawrence Mynors-Wallis, D.M., Anthony Kendrick, M.D.,
Christopher Thompson, M.D., Judith Lathlean, M.A., Lucy
Simons, B.A., Ruth Pickering, B.S.C.

- D Cost-Effectiveness of Antidepressants in Primary Care**
Robert C. Peveler, M.D., Anthony Kendrick, M.D.,
Christopher Thompson, M.D., Martin Buxton
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 10 2:00 p.m.-5:00 p.m.
Rooms 3D05/8, Level 3, Javits Center

**MENTAL HEALTH TEAMS: HEALTH PROMOTION
AND PRESERVATION IN WAR AND PEACE**

Chp.: James J. Staudenmeier, Jr., M.D.
Co-Chp.: William F. Haning III, M.D.

- A Mental Health Teams: Background and Recent History**
James J. Staudenmeier, Jr., M.D., Bryan Bacon, D.O.,
William F. Haning III, M.D., Thomas A. Hicklin, M.D.

- B Psychology of War**
Jason L. Engeriser, M.D.

- C Recent Mental Health Team Efforts in the Combat-
Support Hospital**
Robert D. Forsten, M.D.

- D Mental Health Intervention in Mortuary Affairs Workers
During Combat**
Panakkal David, M.D.

- E Health-Promotion and Preventive-Medicine Efforts in
the Most Recent Gulf Wars**
Robert T. Ruiz, M.D.

- F Jealous in Honor, Sudden in Quarrel: Psychiatric
Practice in Iraqi Freedom**
William F. Haning III, M.D.

- G Emotional Cycle of Deployment: Family and Military
Member Perspective**
Simon H. Pincus, M.D.

Discussants: Robert D. Forsten, M.D., Panakkal David, M.D.,
Robert T. Ruiz, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 11 2:00 p.m.-5:00 p.m.
Odets Room, Fourth Floor, Marriott Marquis

**PTSD IN PERSONS WITH SERIOUS MENTAL
ILLNESS**

Chp.: Kristina H. Muenzenmaier, M.D.
Co-Chp.: Lewis A. Opler, M.D.

- A Prevalence and Patterns of PTSD Among Persons With
Severe Mental Illness**
David B. Albert, Ph.D., Linda A. Teplin, Ph.D.,
Karen M. Abram, Ph.D., Gary M. McClelland, Ph.D.

- B An Exploration of PTSD and MDD Comorbidity**
Patricia Resnick, Ph.D.

- C Assessment and Treatment of Trauma in Persons With
Serious Mental Illness**
Kristina H. Muenzenmaier, M.D., Lewis A. Opler, M.D.,
Anne-Marie Shelley, Ph.D., Mary-Jane Alexander, Ph.D.,
Michelle Fox, B.A.

- D Cognitive-Behavioral Treatment of PTSD in Clients
With Severe Mental Illness**
Kim T. Mueser, Ph.D., Stanley Rosenberg, Ph.D., Kay
Jankowski, Ph.D., Jessica Hamblen, Ph.D., Patricia
Carty, M.S.

Discussant: Judith Herman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 12 2:00 p.m.-5:00 p.m.
 O'Neill Room, Fourth Floor, Marriott Marquis

BEHAVIORAL DIMENSIONS OF PSYCHIATRIC DISORDERS

Chp.: Stephen B. Shanfield, M.D.

A Impulsivity in Psychiatric Disorders

Alan C. Swann, M.D.

B Aggression in Personality Disorders

Emil F. Coccaro, M.D.

C Mood Reactivity Dimension in Diagnosis

Conrad M. Swartz, M.D.

D The Dimensional Construct in Psychiatric Disorders

Stephen B. Shanfield, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 13 2:00 p.m.-5:00 p.m.
 Wilder Room, Fourth Floor, Marriott Marquis

NEURODEVELOPMENT AND SCHIZOPHRENIA: CLINICAL AND BASIC SCIENCE PERSPECTIVES

Chp.: Alan S. Brown, M.D.

A In-Utero Exposure to Infection and Schizophrenia in Adult Offspring

Alan S. Brown, M.D., Melissa D. Begg, Sc.D., Catherine A. Schaefer, Ph.D., Stefan Gravenstein, M.D., Richard J. Wyatt, M.D., Michaeline Bresnahan, Ph.D., Ezra S. Susser, M.D.

B Prenatal Viral Infection, Brain Development, and Schizophrenia

S. Hossein Fatemi, M.D., M. Araghiniknam, Ph.D., Jessica Laurence, B.S., Robert Sidwell, Ph.D., Susanne Lee, Ph.D., Joel Stry, B.S.

C Advanced Paternal Age and Risk for Schizophrenia

Dolores Malaspina, M.D., Alan S. Brown, M.D., Ezra S. Susser, M.D., Susan Harlap, M.D., Raymond Goetz, Ph.D.

D Early Gestational Irradiation in the Primate as a Model of Schizophrenia

Lynn D. Selemon, Ph.D., John G. Csernansky, M.D., Lei Wang, Ph.D., Patricia S. Goldman-Rakic, Ph.D., Pasko Rakic, M.D.

Discussant: Ezra S. Susser, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 14 2:00 p.m.-5:00 p.m.
 Ziegfeld Room, Fourth Floor, Marriott Marquis

CURRENT CONCEPTS OF THE NEUROBIOLOGY OF THE SELF

Chp.: Todd E. Feinberg, M.D.

Co-Chp.: Julian P. Keenan, Ph.D.

A What Neuropathology Can Teach Us About the Neurobiology of the Self

Todd E. Feinberg, M.D.

B Neuroimaging the Self

Julian P. Keenan, Ph.D.

C Self, Memory, and the Brain

Joseph LeDoux, Ph.D.

D Affect Regulation, the Right Hemisphere, and the Self

Allan N. Schore, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 15 2:00 p.m.-5:00 p.m.
 Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

THE DEVELOPMENT OF ADAP: THE ADOLESCENT DEPRESSION AWARENESS PROGRAM

Chp.: Karen L. Swartz, M.D.

Co-Chp.: Todd S. Cox, M.D.

A Current Status of Depression Education in Schools

Boglarka Szabo, M.D., Todd S. Cox, M.D., Elizabeth A. Kastelic, M.D., Karen L. Swartz, M.D.

B Development of a Model Depression Education Curriculum

Karen L. Swartz, M.D., Todd S. Cox, M.D., Elizabeth A. Kastelic, M.D., Sallie Mink, B.S.N., Sally G. Hess, B.S.N., Lizza C. Gonzales, B.A., Boglarka Szabo, M.D.

C Creation of Supplemental Learning Tools for Depression Education

Sallie Mink, B.S.N., Elizabeth A. Kastelic, M.D., Todd S. Cox, M.D., Sally G. Hess, B.S.N., Lizza C. Gonzales, B.A., Sandra Durfee, M.L.A., Karen L. Swartz, M.D.

D Evaluation of the ADAP Teenage Depression Curriculum

Todd S. Cox, M.D., Elizabeth A. Kastelic, M.D., Karen L. Swartz, M.D.

E Change in Adolescent Attitudes About Depression Treatment

Elizabeth A. Kastelic, M.D., Sally G. Hess, B.S.N., Lizza C. Gonzales, B.A., Todd S. Cox, M.D., Karen L. Swartz, M.D.

(Continued on next page)

MONDAY

F Training of ADAP Educators: Bringing the Curriculum to Schools

Sally G. Hess, B.S.N., Todd S. Cox, M.D., Elizabeth A. Kastelic, M.D., Sallie Mink, B.S.N., Lizza C. Gonzales, B.A., Boglarka Szabo, M.D., Karen L. Swartz, M.D.

Discussants: J. Raymond DePaulo, Jr., M.D., Paramjit Joshi, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 16 2:00 p.m.-5:00 p.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

THE DEATH PENALTY: LAW AND MEDICAL ETHICS IN THE FACE OF NEW COURT OPINIONS

Chp.: Alfred M. Freedman, M.D.

A Capital Punishment and American Exceptionalism
Carol Steiker, J.D.

B Human Rights and Medical Ethics: The American Conflict
Alan A. Stone, M.D.

C Mental Disabilities and the Death Penalty: Evaluations and Legal Protections After Atkins Versus Virginia
James W. Ellis, J.D.

D Competency to Be Executed and Forced Medication: Singleton Versus Norris, Ethical Considerations
Howard V. Zonana, M.D.

E Diagnosis of Diminished Responsibility and the Death Penalty: Implications of Atkins Versus Virginia
Richard Bonnie, J.D.

Discussants: Paul S. Appelbaum, M.D., Ezra E.H. Griffith, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 17 2:00 p.m.-5:00 p.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

THE SCIENTIFIC BASIS OF EXPERT TESTIMONY: ITS APPLICATION TO MATRIMONIAL DISPUTES

Chp.: Alex Weintrob, M.D.

A Psychiatric Testimony: Science or Wizardry?
Alex Weintrob, M.D.

B The Uses and Misuses of Psychological Tests in Child-Custody Evaluations
Paul Hymowitz, Ph.D.

C The Expectation for Evidence-Based Testimony Under Daubert
Diane H. Schetky, M.D.

D An Attorney's Approach to Cross-Examination of an Expert in a Custody Dispute
Harold A. Mayers

E The Court's Role Regarding Expert Testimony in Child-Custody Proceedings
Anthony Marano, J.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 18 2:00 p.m.-5:00 p.m.
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

EVOLUTIONARY AND ETHOLOGICAL PERSPECTIVES ON SOCIAL ANXIETY DISORDER

Chp.: Franklin R. Schneier, M.D.

A What Social Phobia Reveals About Our Evolved Human Nature and Vice Versa
Randolph M. Nesse, M.D., James L. Abelson, M.D.

B Gene-Environment Interactions and the Development of Fearfulness in Monkeys
Stephen J. Suomi, Ph.D.

C Subordinate Status, Social Anxiety Disorder, and Dopamine Function
Franklin R. Schneier, M.D., Richard G. Heimberg, Ph.D., Marc Laruelle, M.D., Michael R. Liebowitz, M.D.

D Eye Contact as a Threat in Social Anxiety Disorder
Justine M. Kent, M.D.

Discussant: Murray B. Stein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 19 2:00 p.m.-5:00 p.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

BEYOND B12: AN UPDATE ON NUTRITION AND PSYCHIATRY

Chp.: Kathryn M. Connor, M.D.

Co-Chp.: Marian I. Butterfield, M.D.

A Nutrition and Psychiatry: A Historical Perspective
Kathryn M. Connor, M.D.

B Omega-3, Essential Fatty Acids, and Psychiatric Disorders
Jerry M. Cott, Ph.D.

C SAME, Folate, and B12: One-Carbon Metabolism and Depression
Jonathan E. Alpert, M.D., David Mischoulon, M.D., George I. Papakostas, M.D., Timothy J. Petersen, Ph.D., John J. Worthington III, M.D., Andrew A. Nierenberg, M.D., Maurizio Fava, M.D.

D Psychiatric Applications of Chromium
Jonathan R.T. Davidson, M.D.

E Glyconutritionals: Review and Relevance to Psychiatry
Marian I. Butterfield, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 20 2:00 p.m.-5:00 p.m.
Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis

TELLING STORIES: THE PSYCHIATRIST AS NOVELIST

Chp.: Dinah Miller, M.D.

A Two Views of Human Nature: Depth Perception or Diplopia?
Roderick J. Anscombe, M.D.

B Taming Demons: The Novel as a Way of Working Through Trauma
Alvin A. Rosenfeld, M.D.

C The Novel as Grist for the Mill: Whose Psychotherapy Is It Anyway?
Paul A. Buttenwieser, M.D.

D Empathy and the Mystery Novel: Getting to the Truth
Keith R. Ablow, M.D.

E Narrative Truths: Fiction and Nonfiction
Peter D. Kramer, M.D.

F From the Laptop to the Bookstore: On Getting Your Creative Writing Published
David J. Hellerstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 21 2:00 p.m.-5:00 p.m.
Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

DO CHILDREN BENEFIT WHEN THEIR PARENTS WITH DEPRESSION ARE TREATED SUCCESSFULLY?

Chp.: Myrna M. Weissman, Ph.D.
Co-Chp.: Daniel J. Pilowsky, M.D.

A Children at High Risk for Depression: Current Knowledge and Future Directions
Myrna M. Weissman, Ph.D.

B STAR-D Child Study: Background and Preliminary Data
Daniel J. Pilowsky, M.D., Jonathan E. Alpert, M.D., Gabrielle M. Cerda, M.D., Judy Garber, Ph.D., Carrol Hughes, Ph.D., Cheryl King, Ph.D., Erin M. Malloy, M.D., Bella Sood, M.D., Myrna M. Weissman, Ph.D.

C Good and Bad News for Low-Income Children Whose Mothers Are Treated for Depression
Anne Riley, Ph.D., Marina Broitmand, Ph.D., MaryJo Coiro, Ph.D., Judith Robertson, B.S.

D The Effect on Children of Treating Parents for Depression
Judy Garber, Ph.D., Elizabeth McCauley, Ph.D., Guy Diamond, Ph.D., Kelly Schloredt, Ph.D., Ginny Burks, Ph.D., Russ Hanford, Ph.D., Cynthia Flynn, M.S.

E Preventive Intervention for Families With Depression: Lessons From a Three-Year Follow-Up
William R. Beardslee, M.D.

Discussant: Patricia R. Cohen, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 22 2:00 p.m.-5:00 p.m.
Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

OBESITY: LESSONS LEARNED FROM ADDICTION
Collaborative Session With the National Institute on Drug Abuse

Chp.: Joseph Frascella, Ph.D.

A Genetic, Motivational, and Metabolic Factors Modulate the Neural Drive to Maintain Body Weight
Barry Levin, M.D.

B Cortico-Striatal-Hypothalamic Networks and Motivation for Food: Integration of Cognition, Reward, and Energy
Ann E. Kelley, Ph.D.

C Food and Drug Cravings: Metaphor or Common Mechanism?
Marcia L. Pelchat, Ph.D.

D Common and Diverging Neurobiological Features of Feeding and Drug Self-Administration in Humans
Dana Small, Ph.D.

E Obesity and Addiction: Neuroimaging Studies
Gene-Jack Wang, M.D., Nora D. Volkow, M.D., Joanna S. Fowler, Ph.D.

Discussant: Nora D. Volkow, M.D.
THIS SESSION WILL BE AUDIOTAPED.

MONDAY

SYMPOSIUM 23 2:00 p.m.-5:00 p.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

**ALCOHOL, DRUG, AND PSYCHIATRIC DISORDERS
IN THE U.S.: CURRENT STATUS AND TRENDS**
Collaborative Session With the National Institute on Drug Abuse

Chp.: Deborah S. Hasin, Ph.D.
Co-Chp.: Bridget F. Grant, Ph.D.

- A Prevalence, Disability, and Time Trends in Alcohol Abuse and Dependence in the U.S., 1992 to 2002**
Frederick S. Stinson, Ph.D., Bridget F. Grant, Ph.D.,
Deborah A. Dawson, Ph.D., S. Patricia Chou, Ph.D., Mary C.
Dufour, M.D., Roger P. Pickering, M.S.
- B A Second Look at Binge Drinking and Alcohol Use Disorders Among College and Noncollege Youth**
Deborah A. Dawson, Ph.D., Bridget F. Grant, Ph.D.,
Frederick S. Stinson, Ph.D., S. Patricia Chou, Ph.D.
- C Major Depression and Alcohol, and Drug Use Disorders in the U.S.: Variations in Co-Occurrence**
Deborah S. Hasin, Ph.D., Bridget F. Grant, Ph.D.
- D Trends in Prevalence of Marijuana Use Disorders in the U.S., 1992 to 2002**
Wilson Compton III, M.D., James Colliver, Ph.D., Bridget F.
Grant, Ph.D., Frederick S. Stinson, Ph.D.
- E U.S. Prevalence of Personality Disorders and Co-Occurrence With Alcohol and Drug Use Disorders**
Bridget F. Grant, Ph.D., Frederick S. Stinson, Ph.D.,
Deborah A. Dawson, Ph.D., S. Patricia Chou, Ph.D.,
Roger P. Pickering, M.S.

Discussant: Norman Sartorius, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 24 2:00 p.m.-5:00 p.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

**GENETIC AND ENVIRONMENTAL FACTORS
CONTRIBUTING TO VULNERABILITY TO
ADDICTION**
Collaborative Session With the National Institute on Drug Abuse

Chp.: Jonathan D. Pollock, Ph.D.

- A Using Twin Data to Identify Alternative Drug Abuse Phenotypes**
Ming T. Tsuang, M.D., Michael Lyons, Ph.D., Stephen V.
Faraone, Ph.D., William Kremen, Ph.D., Stephen
Glatt, Ph.D.

- B Common and Specific Genetic Factors in the Development of Substance Dependence**
Laura J. Bierut, M.D., Alison Goate, D.Phil., John
Rice, Ph.D., Anthony Hinrichs, Ph.D., Tatiana
Foroud, Ph.D., Howard Edenberg, Ph.D.,
Raymond R. Crowe, M.D.

- C Addiction Molecular Genetics: Remarkably Converging Results**
George Uhl, M.D.

- D Using the Systems Biology of Motivation for Genetic Studies in Psychiatry**
Gregory P. Gasic, Ph.D., Hans C. Breiter, M.D.

- E Genetic and Environmental Factors Modulate Cocaine Abuse in Monkey Models**
Michael Nader, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 25 2:00 p.m.-5:00 p.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

**PSYCHIATRIC REHABILITATION: INTEGRATING
MIND AND BODY GLOBALLY**
*World Psychiatric Association's Section on Rehabilitation and World
Association for Psychosocial Rehabilitation*

Chp.: Zebulon C. Taintor, M.D.
Co-Chp.: Ida Kosza, M.D.

- A Brain Responses to the Environment: Showing Rehabilitation Works**
Robert Cancro, M.D., Zebulon C. Taintor, M.D.
- B Schizophrenia and Drug-Abuse Outcomes: Poverty, Culture, and Community**
Gregory C. Bunt, M.D., Carole Siegel, Ph.D.
- C Human Rights for Individuals With Mental Illnesses**
Humberto Martinez, M.D.
- D The Worldwide Family Movement**
Geraldine Marshall
- E Penetrating Prisons With Rehabilitation**
Zebulon C. Taintor, M.D.

Discussant: Naotaka Shinfuku
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 26 2:00 p.m.-5:00 p.m.
Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

EFFECTIVE TREATMENT OF PTSD: WHAT WORKS BEST FOR WHOM?

Chp.: Bessel A. Van Der Kolk, M.D.
Co-Chp.: Marylene Cloitre, Ph.D.

A Exposure Versus Pharmacological Treatment of PTSD: Differential Response and Long-Term Outcome
Bessel A. Van Der Kolk, M.D., Joseph F. Spinazzola, Ph.D., James Hopper, Ph.D., Margaret Blaustein, Ph.D., William Simpson, Ph.D., Elise Hopper, Ph.D.

B What Works Best for Whom? Case Studies in Combination Treatment
Randall D. Marshall, M.D.

C Emotion Regulation and Interpersonal Skills Training for Chronic PTSD Related to Childhood Abuse and Multiple Traumatization
Marylene Cloitre, Ph.D.

D PTSD Treatment Outcome Research: The Study of Unrepresentative Samples
Joseph F. Spinazzola, Ph.D., Margaret Blaustein, Ph.D., Bessel A. Van Der Kolk, M.D.

THIS SESSION WILL BE AUDIOTAPED.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 5

3:00 p.m.-5:00 p.m.
Galleria, Level 4, Javits Center

ANXIETY, STRESS, ADDICTIONS, AND ALCOHOL DISORDERS

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

5:30 p.m. Session

CONVOCATION OF DISTINGUISHED FELLOWS

5:30 p.m.-6:30 p.m.
Hall 3E, Level 3, Javits Center

All Distinguished Life Fellows, Distinguished Fellows, members, and registered guests are invited.

Presiding: Marcia Kraft Goin, M.D., *President*

Grand Marshals: Ian E. Alger, M.D., Sheila B. Blume, M.D.

Marshals: Nalini V. Juthani, M.D., J. Richard Ciccone, M.D.

INTRODUCTION OF DISTINGUISHED LIFE FELLOWS

Michelle B. Riba, M.D., *President-Elect*

INDUCTION OF DISTINGUISHED FELLOWS

Michelle B. Riba, M.D.

INTRODUCTION OF FIFTY-YEAR DISTINGUISHED LIFE FELLOWS, FIFTY-YEAR LIFE MEMBERS, AND INTERNATIONAL FELLOWS

Marcia Kraft Goin, M.D.

INTRODUCTION OF FELLOWS

Marcia Kraft Goin, M.D.

PRESENTATION OF SPECIAL PRESIDENTIAL COMMENDATIONS

Marcia Kraft Goin, M.D.

PRESENTATION OF DISTINGUISHED SERVICE AWARDS

Marcia Kraft Goin, M.D.

INTRODUCTION OF THE MEMBERSHIP COMMITTEE CHAIRPERSON AND AWARD BOARD CHAIRPERSONS

Marcia Kraft Goin, M.D.

PRESENTATION OF AWARDS

Marcia Kraft Goin, M.D.

APA/Lilly Resident Research Awards
APIRE/Kempf Fund Awards for Research
Development in Psychobiological Psychiatry
Human Rights Awards
Blanche F. Ittleson Award for Research
in Child Psychiatry
Agnes Purcell McGavin Award for Distinguished Career
Achievement in Child and Adolescent Psychiatry
Jack Weinberg Memorial Award for
Geriatric Psychiatry

WILLIAM C. MENNINGER MEMORIAL CONVOCATION LECTURE

Tom Wolfe

LECTURE 11

5:30 p.m.-6:30 p.m.
Hall 3E, Level 3, Javits Center

WILLIAM C. MENNINGER
MEMORIAL LECTURE

Tom Wolfe

Body and Soul

Tom Wolfe is recognized around the world as the pre-eminent social commentator of our time. For over three decades he has chronicled and forecast American mass culture with a wit and insight that eludes most futurists. His runaway best seller *The Bonfire of the Vanities* stands as a brilliant evocation of both the peculiar class structure and politics of New York City, and the economic excesses of the 1980s. His most recent novel, *A Man in Full* has received both outstanding, critical, and popular success. Hailed by *Time* and *The Wall Street Journal* as even better than its phenomenally successful predecessor, it had an unprecedented first-run printing of 1.2 million copies and was nominated for the National Book Award four weeks prior to publication. As *Newsweek* states, "no writer - reporter or novelist - is getting our world on paper better than Tom Wolfe." Called the father of "New Journalism," Wolfe is the author of twelve books, including the national best sellers *The Right Stuff*, *The Electric Kool-Aid Acid Test*, *Radical Chic and Mau-Mauing the Flak Catchers*, and *The Bonfire of the Vanities*. In 1979, Wolfe won the American Book Award for general nonfiction for *The Right Stuff*. In 1980, he was named recipient of the Harold D. Vursell Memorial Award by The American Academy and Institute of Arts and Letters and received the Columbia Journalism Award for distinguished service in the field of journalism that same year. Raised in Richmond, Virginia, Wolfe received his bachelor's degree from Washington and Lee University and his doctorate in American Studies from Yale University. Afterward, he went to work as a reporter for *The Springfield Union* (in Massachusetts), *The Washington Post*, and *The New York Herald Tribune*, where he first began to push the envelope of conventional journalistic license. Since then, his writing has appeared in *New York Magazine*, *Rolling Stone*, *Esquire*, and *Harpers's*.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 36-42

INDUSTRY-SUPPORTED SYMPOSIUM 36

7:00 p.m.-10:00 p.m.

Grand Ballroom East, Third Floor, Hilton New York

BPD: REGULATION OF AFFECT AND IMPULSE CONTROL

Supported by Bristol-Myers Squibb Company

Chp.: John M. Oldham, M.D.

Co-Chp.: Andrew E. Skodol II, M.D.

A New Findings on the Biology of BPD

Martin Bohus, M.D., Christian G. Schmahl, M.D.

B BPD and Mood Disorder Spectrum

Pablo Goldberg, M.D., Maria A. Oquendo, M.D., Barbara H. Stanley, Ph.D.

C BPD and the Impulse-Control Spectrum

Emil F. Coccaro, M.D.

D Evidence-Based Psychotherapy for BPD

Glen O. Gabbard, M.D.

E Pharmacological Treatment of BPD: Current and Future Strategies

Jeffrey A. Lieberman, M.D.

Discussant: Mary C. Zanarini, Ed.D.

INDUSTRY-SUPPORTED SYMPOSIUM 37

7:00 p.m.-10:00 p.m.

Westside Ballroom 1-2, Fifth Floor, Marriott Marquis

INTERFERON-INDUCED DEPRESSION: CONSEQUENCES OF TREATING CHRONIC HEPATITIS C

Supported by Roche Laboratories

Chp.: Gregory M. Asnis, M.D.

A Interferon-Induced Depression: An Overview and Analysis

Gregory M. Asnis, M.D.

B Pathophysiological Mechanisms of Interferon Alpha-Induced Neuropsychiatric Symptoms

Lucile Capuron, Ph.D.

C Pegylated Interferon: Therapy of Hepatitis C With Fewer Depressive Effects

John F. Reinus, M.D.

- D Diagnosis and Treatment of Interferon Alpha-Psychiatric Side Effects in Patients With Hepatitis C Virus**
Charles Raison, M.D.

Discussant: Silvia Hafliger, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 38

7:00 p.m.-10:00 p.m.

Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

CONCEPTUALIZING AND TREATING ADHD ADULTS

Supported by Shire US, Inc

Chp.: Timothy E. Wilens, M.D.

A ADHD Adult Case

Jefferson B. Prince, M.D.

B Adult ADHD: A Conceptual Model

Russell A. Barkley, Ph.D.

C Neurobiology of Adult ADHD

Francisco Castellanos, M.D.

D Adult ADHD: A Family-Genetic Perspective

Stephen V. Faraone, Ph.D.

E Adult ADHD: What Does Neuropsychology Tell Us?

Larry J. Seidman, Ph.D.

F Pharmacologic Treatment of Adult ADHD

Timothy E. Wilens, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 39

7:00 p.m.-10:00 p.m.

Broadway Ballroom, Sixth Floor, Marriott Marquis

**PLOTTING A COURSE TO REMISSION:
NAVIGATING THE INTERSECTION OF MIND,
BRAIN, AND BODY**

Supported by Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc

Chp.: Alan F. Schatzberg, M.D.

Co-Chp.: Ruta M. Nonacs, M.D.

A Does Everybody Hurt? Epidemiology of Physical Symptoms and Depression

Maurice M. Ohayon, M.D.

B Comorbidity With Painful Physical Symptoms: Understanding the Intersection of Brain and Body

Bruce A. Arnow, Ph.D.

C 5HT and Norepinephrine: Navigating the Broad Range of Symptoms

Pedro L. Delgado, M.D.

D Plotting the Course to Remission: Balanced Strategies to Improve Outcomes

Vivien K. Burt, M.D.

E Looking Beyond the Symptoms of Depression: Considerations for Special Populations

Ruta M. Nonacs, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 40

7:00 p.m.-10:00 p.m.

Grand Ballroom, Mezzanine Level, Roosevelt

PHARMACOTHERAPY OF ADDICTIONS: FROM CLINICS INTO OFFICE PRACTICE

Supported by Reckitt Benckiser Pharmaceuticals

Chp.: Thomas R. Kosten, M.D.

A A Patient's Perspective on Office-Based Opiate Treatment

Walter Ginter

B Prescription Drug Abuse and Psychiatric Comorbidity

H. Westley Clark, M.D.

C Opiate Pharmacotherapy and the Neurobiology of Opiate Abuse and Dependence

Thomas R. Kosten, M.D.

D Pain and Depression: Gateway to Addiction and Opportunity for Treatment

Walter Ling, M.D.

E Buprenorphine for Opiate Addiction Treatment: Pharmacology and Clinical Use

Laura F. McNicholas, M.D.

F Cultural Sensitivity in Addictions Treatment

Gerardo Gonzalez, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 41

7:00 p.m.-10:00 p.m.

Imperial Ballroom A, Second Floor, Sheraton New York

**HORMONES, MOOD, AND COGNITION:
TREATMENT CONSIDERATIONS IN OLDER
WOMEN**

Supported by Wyeth Pharmaceuticals

Chp.: Lee S. Cohen, M.D.

Co-Chp.: Hadine Joffe, M.D.

A Gonadal Steroids and the Brain: Implications in Aging Women

Meir Steiner, M.D.

B Depression in Perimenopausal Women: Women at Risk and Response to Antidepressants

Lee S. Cohen, M.D.

(Continued on next page)

MONDAY

C Menopause and Mood Disturbances: From Theory to Novel Treatment Strategies
Claudio N. Soares, M.D.

D Assessment and Treatment of Hot Flashes in Menopausal Women
Hadine Joffe, M.D.

E The Women's Health Institute Memory Study: Updates on the Effect of Estrogen Plus Progestin on the Incidence of Dementia and Cognitive Impairment in Menopausal Women
Sally A. Shumaker, Ph.D., Claudine Legault, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 42

7:00 p.m.- 10:00 p.m.

Imperial Ballroom B, Second Floor, Sheraton New York

REACHING BEYOND ALZHEIMER'S DISEASE WITH CHOLINERGIC THERAPY

Supported by Novartis Pharmaceuticals Corporation

Chp.: Steven G. Potkin, M.D.

A Dementia With Lewy Bodies Within Our Grasp
Ian G. McKeith, M.D.

B Parkinson's Disease Beyond Dopaminergic Therapy
Amos Korczyn, M.D.

C Exploring and Managing Vascular Features of Dementia
Martin K. Farlow, M.D.

D Extending Treatment Options and Not Letting Go
Gustavo Alva, M.D.

TUESDAY, MAY 4, 2004

157TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 31-35

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 2

7:00 a.m.-8:30 a.m.

Grand Ballroom East, Third Floor, Hilton New York

NEW ADVANCES IN THE TREATMENT OF PSYCHOSIS, PART 2

Supported by Bristol-Myers Squibb Company

Chp.: Robert E. Hales, M.D.

Co-Chp.: Stuart C. Yudofsky, M.D.

A Antipsychotic Therapies in Geriatric Patients: The Importance of Safety and Tolerability

J. Michael Ryan, M.D.

B Unique Challenges in the Pharmacotherapy of First-Episode Schizophrenia

Diana O. Perkins, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 2

7:00 a.m.-8:30 a.m.

Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

CURRENT ALZHEIMER'S DISEASE TREATMENTS AND BEYOND: ADVANCES IMPACTING CLINICAL PRACTICE, PART 2

Supported by Forest Laboratories, Inc.

Chp.: Trey Sunderland, M.D.

A Neuroimaging in Alzheimer's Disease: Diagnosis, Treatment and Prevention

P. Murali Doraiswamy, M.D.

B New Treatment Strategies for Alzheimer's Disease: The Role of Early Diagnosis

Trey Sunderland, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 33, PART 2

7:00 a.m.-8:30 a.m.

Broadway Ballroom, Sixth Floor, Marriott Marquis

RECOGNIZING THE MANY FACES OF BIPOLAR DISORDER, PART 2

Supported by Eli Lilly and Company

Chp.: Bruce M. Cohen, M.D.

A Optimizing Functional Outcome in Bipolar Disorder

Deborah A. Yurgelun-Todd, Ph.D.

B Neuroimaging Findings in Bipolar Disorder

Stephan H. Heckers, M.D.

C New Directions in Medication Development for Bipolar Disorder

Bruce M. Cohen, M.D., William Carlezon, Ph.D., Perry F. Renshaw, M.D., Andrew L. Stoll, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 34, PART 2

7:00 a.m.-8:30 a.m.

Imperial Ballroom A, Second Floor, Sheraton New York

EVIDENCE-BASED MEDICINE: THE NEXT GENERATION, PART 2

Supported by Wyeth Pharmaceuticals

Chp.: K. Ranga R. Krishnan, M.D.

A Psychotherapy for Treatment of Depression: Recent Developments

Thomas Lynch, M.D.

B Pharmacological Treatment of Agitation in Dementia: Evidence-Based Recommendations

Warren D. Taylor, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 35, PART 2

7:00 a.m.-8:30 a.m.

Imperial Ballroom B, Second Floor, Sheraton New York

TRANSCENDING EFFICACY: EFFECTIVE TREATMENT OF PSYCHOSIS ACROSS DISORDERS, PART 2

Supported by AstraZeneca Pharmaceuticals

Chp.: Pierre N. Tariot, M.D.

Co-Chp.: John W. Newcomer, M.D.

A Avoiding Comorbidities in Treatment

John W. Newcomer, M.D.

B Transcending Efficacy in Psychosis: Where the Rubber Meets the Road

Jeanne Jackson-Siegel, M.D.

8:00 a.m. Sessions



COURSES 53-61

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 53 8:00 a.m.-12 noon
Concourse B, Concourse Level, Hilton New York

DOING RESEARCH ON A SHOESTRING BUDGET

Director: Mantosh J. Dewan, M.D.
Faculty: Michele T. Pato, M.D., Edward K. Silberman, M.D.

COURSE 54 8:00 a.m.-12 noon
Concourse E, Concourse Level, Hilton New York

EXPANDING HEALTH CARE DELIVERY? LET TELEPSYCHIATRY HELP!

Director: Steven E. Hyler, M.D.
Faculty: Clarice J. Kestenbaum, M.D., Namita Rajouria, M.D., Gerald Segal, M.S., William M. Tucker, M.D.

COURSE 55 8:00 a.m.-12 noon
Concourse G, Concourse Level, Hilton New York

THE WAY OF YOGA AND HERBS IN THE TREATMENT OF STRESS, DEPRESSION, AND AGGRESSION

Co-Directors: Richard P. Brown, M.D., Patricia L. Gerbarg, M.D.

COURSE 56 8:00 a.m.-12 noon
Beekman Parlor, Second Floor, Hilton New York

HOW TO USE YOUR PALM OS PDA IN PSYCHIATRIC PRACTICE: BASIC

Co-Directors: John S. Luo, M.D., Richard A. Montgomery, M.D.
Faculty: Robert J. Boland, M.D., Carlyle H. Chan, M.D., Robert C. Hsiung, M.D., Christopher R. Thomas, M.D.

COURSE 57 8:00 a.m.-12 noon
Bryant Suite, Second Floor, Hilton New York

THE MISSING PIECE OF THE PUZZLE: TIC DISORDERS IN ADULTS WITH OCD OR ADD

Director: Maria A. Pugliese, M.D.
Faculty: J. Paul Hieble, Ph.D., Michael N. Rubenstein, M.D., Orrin Palmer, M.D., Paul F. Kriger, B.S., Laura J. Umbrell, L.P.N.

COURSE 58 8:00 a.m.-12 noon
Gramercy A, Second Floor, Hilton New York

THE DETECTION OF MALINGERED MENTAL ILLNESS

Director: Phillip J. Resnick, M.D.

COURSE 59 8:00 a.m.-12 noon
Nassau Suite A, Second Floor, Hilton New York

TREATING MEDICAL STUDENTS AND PHYSICIANS

Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D.

COURSE 60 8:00 a.m.-12 noon
Nassau Suite B, Second Floor, Hilton New York

DISASTER PSYCHIATRY: TERRORISM, TRAUMA, AND THINGS TO DO

APA Committee on Psychiatric Dimensions of Disaster

Director: Joseph C. Napoli, M.D.
Faculty: Michael Blumenfield, M.D., V. Alex Kehayan, Ed.D.

COURSE 61 8:00 a.m.-12 noon
Sutton North, Second Floor, Hilton New York

PAIN MANAGEMENT FOR PSYCHIATRISTS: AN OVERVIEW OF TREATMENT APPROACHES

Director: Raphael J. Leo, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 2

9:00 a.m.-10:30 a.m.
Rooms 3D06/7, Level 3, Javits Center

ASSESSING AND TREATING PSYCHIATRIC SYMPTOMS IN INDIVIDUALS WITH CARDIOVASCULAR DISEASE

Moderator: Christine E. Skotzko, M.D.
Presenters: Lynnette Krueger, M.S.N., Maria A. Rueda-Lara, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

**CONTINUOUS CLINICAL CASE CONFERENCE 1:
PART 2**

9:00 a.m.-12 noon

Rooms 3D01/12, Level 3, Javits Center

**HELPING PATIENTS COUNTER DEMORALIZATION
WHILE LIVING WITH A CHRONIC OR RECURRENT
PSYCHIATRIC ILLNESS****Moderator:** James L. Griffith, M.D.**Presenters:** Lynne M. Gaby, M.D., Julia B. Frank, M.D.,
Robert W. Keisling, M.D., Jeffrey S. Akman, M.D.**THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP
CARD REQUIRED FOR ADMITTANCE.****COURSES 62-68**Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.**COURSE 62** 9:00 a.m.-4:00 p.m.

Concourse A, Concourse Level, Hilton New York

**TREATING THE SELF AND INTERPERSONAL
PROBLEMS OF PERSONALITY DISORDER****Director:** John Livesley, M.D.**COURSE 63** 9:00 a.m.-4:00 p.m.

Clinton Suite, Second Floor, Hilton New York

PSYCHIATRY UPDATE: IN SPANISH*American Society of Hispanic Psychiatry***Co-Directors:** Gabriel Kaplan, M.D., Javier I. Escobar, M.D.**Faculty:** Pedro L. Delgado, M.D., Eduardo Dunayevich, M.D.,
Jacobo E. Mintzer, M.D., Humberto Marin, M.D.,
Ana Kaplan, M.D.**COURSE 64** 9:00 a.m.-4:00 p.m.

Gramercy B, Second Floor, Hilton New York

**INTEGRATED DUAL DISORDER TREATMENT:
EVIDENCE-BASED PRACTICE****Co-Directors:** Mary F. Brunette, M.D., Robert E. Drake, M.D.**Faculty:** Lindy Fox, M.A., Kim T. Mueser, Ph.D., Douglas
Noordsy, M.D.**COURSE 65** 9:00 a.m.-4:00 p.m.

Madison Suite, Second Floor, Hilton New York

**A PSYCHODYNAMIC APPROACH TO TREATMENT-
REFRACTORY MOOD DISORDERS****Director:** Eric M. Plakun, M.D.**Faculty:** David L. Mintz, M.D., Edward R. Shapiro, M.D.**COURSE 66** 9:00 a.m.-4:00 p.m.

Murray Hill A, Second Floor, Hilton New York

**UPDATES IN NEUROPSYCHIATRY: DELIRIUM,
TRAUMATIC BRAIN INJURY, AND POST-STROKE
DEPRESSION****Director:** Jose R. Maldonado, M.D.**COURSE 67** 9:00 a.m.-4:00 p.m.

Murray Hill B, Second Floor, Hilton New York

PERSONALITY AND POLITICAL BEHAVIOR*International Society for Political Psychology and APA Council on Global
Psychiatry***Director:** Jerrold M. Post, M.D.**COURSE 68** 9:00 a.m.-4:00 p.m.Rhineland Gallery North/Center, Second Floor, Hilton
New York**HOW TO PASS THE BOARDS! THE PART II ORAL
EXAM****Co-Directors:** James C.Y. Chou, M.D., Gregory C. Bunt, M.D.**DISCUSSION GROUPS 10-13**

9:00 a.m.-10:30 a.m.

**These sessions are limited to 25 participants on a first-come,
first-served basis.****10 Robert I. Simon, M.D.**, on Assessing and Managing Suicide
Risk: Clinically-Based Guidelines for Risk Management (*Meet
the Authors*)

Rooms 2D02/3, Level 2, Javits Center

11 Peter V. Rabins, M.D., on What Can Brain Diseases Teach
Us About the Mind-Brain Interface?

Rooms 2D04/5, Level 2, Javits Center

12 Salman Akhtar, M.D., on Cross-Cultural Psychotherapy
Rooms 2D06/7, Level 2, Javits Center**13 Altha J. Stewart, M.D.**, on Public Psychiatry: Leading the
Way in Transforming Service Delivery in the 21st Century
Room 2D08, Level 2, Javits Center

LECTURES 12-13

LECTURE 12

9:00 a.m.-10:30 a.m.
Rooms 1E07/8, Level 1, Javits Center

APA'S RESEARCH IN PSYCHIATRY
AWARD LECTURE

Jack D. Barchas, M.D.

Adventures in Psychiatric Research: Neurobiology
to Public Policy

Chp.: Alan F. Schatzberg, M.D.
Co-Chp.: Darrel A. Regier, M.D.

Jack D. Barchas, M.D., is Barklie McKee Henry Professor and Chair of the Department of Psychiatry at Weill Medical College of Cornell University and Psychiatrist-in-Chief at New York Hospital in New York City. He is also Executive Director of the Pritzker Depression Network, Chair of the Board of Trustees of the New York Academy of Medicine and of the Board of Trustees of the Association for Research in Nervous and Mental Disease, and President and Chair of the Board of Directors of the Robert J. and Claire Pasarow Foundation. Dr. Barchas formerly was Editor of *Archives of General Psychiatry*. His scholarly activities have centered on the study of neuroregulators and have included research projects in the areas of molecular regulation, biochemical neuroanatomy, analytical neurochemistry, behavioral neurochemistry, and clinical biochemistry and pharmacology. A Distinguished Life Fellow of the American Psychiatric Association and a member of the Institute of Medicine of the National Academy of Sciences, Dr. Barchas is a recipient of the A.E. Bennett Award and the Lifetime Achievement Award from the Society of Biological Psychiatry. Dr. Barchas received his medical degree from Yale University School of Medicine in New Haven, Connecticut, and completed his residency in psychiatry at Stanford University in Stanford, California.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 13

9:00 a.m.-10:30 a.m.
Room 1E15, Level 1, Javits Center

Nora D. Volkow, M.D.

Why Does the Human Brain Become Addicted?
*Collaborative Session With the National Institute
on Drug Abuse*

Chp.: David M. McDowell, M.D.
Co-Chp.: Patricia I. Ordorica, M.D.

Nora D. Volkow, M.D., is Director of the National Institute on Drug Abuse (NIDA) in Bethesda, Maryland. Before assuming this position in May 2003, she was Associate Director of Life Sciences, Director of Nuclear Medicine, and Director of the NIDA-Department of Energy Regional Neuroimaging Center at Brookhaven National Laboratory in Upton, New York. She was also Professor of Psychiatry and Associate Dean of the School of Medicine at the State University of New York at Stony Brook. Her research has focused on the mechanisms underlying the reinforcing, addictive, and toxic properties of drugs of abuse in the human brain. She has also investigated the rewarding and therapeutic actions of stimulant drugs and the changes that occur in dopamine brain activity with aging. Dr. Volkow is the author or coauthor of more than 280 peer-reviewed publications and more than 50 book chapters and other manuscripts and is the editor of three books. She has received numerous awards for her research and has been elected to the Institute of Medicine of the National Academy of Sciences. Dr. Volkow received her medical degree from the National University of Mexico in Mexico City and completed her residency in psychiatry at New York University.

Distinguished Psychiatrist Series
THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL
CONSULTATION 5

9:00 a.m.-10:30 a.m.

This session is limited to 25 participants on a first-come, first-served basis.

Francisco Fernandez, M.D., on Neuropsychiatric
Complications of HIV-1 Infection
Room 1D05, Level 1, Javits Center

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP
CARD REQUIRED FOR ADMITTANCE.

RESEARCH ADVANCES IN MEDICINE

9:00 a.m.-11:00 a.m.

Room 1E09, Level 1, Javits Center

THE EPIDEMIOLOGY AND TREATMENT OF PSYCHIATRIC COMORBIDITIES*Collaborative Session With the National Institute on Drug Abuse*

Chp.: Joel J. Wallack, M.D.

Co-Chp.: Geetha Jayaram, M.D.

Participants: Kathleen Merikangas, Ph.D., on **Epidemiology of Comorbid Psychiatric and Addictive Disorders**Joseph Biederman, M.D., on **Comorbidity of Psychiatric and Addictive Disorders in Children**Paul Thuluvath, M.D., on **Depression in Hepatitis C Patients and Interferon Treatment**Joel Gallant, M.D., on **Research Advances in HIV Care****THIS SESSION WILL BE AUDIOTAPED.****REVIEW OF PSYCHIATRY: SECTION 1**

9:00 a.m.-12:30 p.m.

Special Events Hall 1D, Level 1, Javits Center

NEUROPSYCHIATRIC ASSESSMENT

Chp.: Stuart C. Yudofsky, M.D.

Co-Chp.: Florence Kim, M.D.

- 1 **Withdrawn**
- 2 **Neurological and Neuropsychological Exam of the Psychiatric Patient**
Mark Lovell, Ph.D., Glen Getz, M.A.
- 3 **Electrophysiological Testing**
Nashaat N. Boutros, M.D., Struve Frederick, Ph.D.
- 4 **Neuropsychiatric Lab Testing**
Florence Kim, M.D., Stuart C. Yudofsky, M.D.
- 5 **Selected Neuroimaging Topics in Psychiatric Disorders**
Thomas E. Nordahl, M.D., Ruth E. Salo, Ph.D.

ROUND TABLE DISCUSSION

9:00 a.m.-10:30 a.m.

Room 1E10, Level 1, Javits Center

COERCION AND TREATMENT: MEDICAL, LEGAL, AND ETHICAL ISSUES**Moderator:** Carol Fisler, J.D.**Participants:** A. Sasha Bardey, M.D., Mary Zdanowicz, J.D., Heather Barr, J.D., Thomasetta Harper**WORKSHOPS****COMPONENTS 21-26****COMPONENT WORKSHOP 21**

9:00 a.m.-10:30 a.m.

Room 1E11, Level 1, Javits Center

THE NEUROBIOLOGY OF SELF-AWARENESS: LEARNING FROM AUTISM AND BPD ABOUT HOW WE KNOW OURSELVES*APA Committee on Psychotherapy by Psychiatrists*

Chp.: Bernard D. Beitman, M.D.

Participants: George I. Viamontes, M.D., Jyotsna Nair, M.D., Glen O. Gabbard, M.D., Eva M. Szigethy, M.D.**COMPONENT WORKSHOP 22**

9:00 a.m.-10:30 a.m.

Rooms 2D10/11, Level 2, Javits Center

BLOOD ON THE FLOOR: RESPONDING TO CATASTROPHIC EVENTS AND HIGH RISKS*APA Committee on Standards and Survey Procedures*

Chp.: Steven I. Altchuler, M.D.

Participants: Marlin R.A. Mattson, M.D., Robert A. Wise, M.D.**COMPONENT WORKSHOP 23**

9:00 a.m.-10:30 a.m.

Rooms 2D12/13, Level 2, Javits Center

THE TIES THAT BIND: CONSIDERATIONS OF CULTURE AND FAMILY IN MENTAL HEALTH TREATMENT*APA/SAMHSA Minority Fellowship Selection and Program Corresponding Committee*

Chp.: Timothy G. Benson, M.D.

Participants: Marketa M. Wills, M.D., Shanta P. Henderson, M.D., Osvaldo Gaytan, Jr., M.D., Denise M. Richardson, M.D.**COMPONENT WORKSHOP 24**

9:00 a.m.-10:30 a.m.

O'Neill Room, Fourth Floor, Marriott Marquis

UNIVERSAL HEALTH CARE AND OTHER MODELS*APA Council on Healthcare Systems and Financing*

Chp.: Barry F. Chaitin, M.D.

Participants: Anita S. Everett, M.D., Bruce J. Schwartz, M.D., Paul H. Wick, M.D., Frederick J. Stoddard, Jr., M.D., Allison M. Wehr, M.D., Manoj R. Shah, M.D., Carrie L. Ernst, M.D., Rodrigo A. Munoz, M.D., Captane P. Thomson, M.D.

TUESDAY

COMPONENT WORKSHOP 25 9:00 a.m.-10:30 a.m.
Palace Room, Sixth Floor, Marriott Marquis

**REVISION OF THE APA ETHICS ANNOTATIONS:
FOSTERING DIALOGUE**

APA Task Force to Update the Ethics Annotations

Chp.: Laura W. Roberts, M.D.
Participants: Michael R. Arambula, M.D., Richard D. Milone, M.D., Philip Candilis, M.D., S. Nassir Ghaemi, M.D., Scott Y. Kim, M.D., Jennifer Radden, Ph.D.

COMPONENT WORKSHOP 26 9:00 a.m.-10:30 a.m.
Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

**THE JUVENILE JUSTICE SYSTEM: ASSESSMENT,
SERVICES, AND DATA USE**

APA Corresponding Committee on Juvenile Justice Issues

Co-Chps.: R. Gregg Dwyer, M.D., Carl C. Bell, M.D.
Participants: Johnny L. Williamson, M.D., Richard L. Frierson, M.D.

ISSUES 33-58

ISSUE WORKSHOP 33 9:00 a.m.-10:30 a.m.
Rooms 1E01/2, Level 1, Javits Center

**MENTAL HEALTH NEEDS OF OUR SOLDIERS AND
THEIR FAMILIES**

Chp.: Howard J. Osofsky, M.D.
Participants: Neal Mazer, M.D., Robert J. Ursano, M.D., Marleen Wong, Ph.D.

ISSUE WORKSHOP 34 9:00 a.m.-10:30 a.m.
Rooms 1E03/4/5, Level 1, Javits Center

**THE IMPACT OF MIGRATION ON ADDICTIVE
DISORDERS: A CHALLENGE FOR THE AMERICAS**

Collaborative Session With the National Institute on Drug Abuse

Chp.: Amelia Musacchio de Zan, M.D.
Participants: Pedro Ruiz, M.D., Patricia I. Ordorica, M.D.

ISSUE WORKSHOP 35 9:00 a.m.-10:30 a.m.
Room 1E12, Level 1, Javits Center

**THE CLINICAL IMPACT OF TREATING CIVIL AND
CRIMINALLY-MANDATED PSYCHIATRIC PATIENTS**

Co-Chps.: Merrill R. Rotter, M.D., Ali Khadivi, Ph.D.
Participants: Scott D. Rogge, M.D., Patricia Mourilhe, M.D.

ISSUE WORKSHOP 36 9:00 a.m.-10:30 a.m.
Room 1E13, Level 1, Javits Center

**USING COGNITIVE THERAPY FOR PSYCHOSIS IN
PSYCHIATRIC PRACTICE**

Chp.: David G. Kingdon, M.D.
Participants: Douglas Turkington, M.D., Shanaya Rathod, M.D.

ISSUE WORKSHOP 37 9:00 a.m.-10:30 a.m.
Room 1E14, Level 1, Javits Center

THE THEATER OF EMOTIONS

Chp.: Ian E. Alger, M.D.
Participants: Ferruccio A. di Cori, M.D., Ferruccio Marotti, M.D., Stefania Papirio, Alessandro Nicolo, Lisa Colosimo, Cristiano Adiutori

ISSUE WORKSHOP 38 9:00 a.m.-10:30 a.m.
Room 1E16, Level 1, Javits Center

**INITIAL PSYCHIATRIC INTERVIEW: A
PSYCHODYNAMIC APPROACH TO 90801**

American Academy of Psychoanalysis and Dynamic Psychiatry

Chp.: Gopalakrishna K. Upadhyaya, M.D.
Participant: Moitri N. Datta, M.D.

ISSUE WORKSHOP 39 9:00 a.m.-10:30 a.m.
Room 3D02/11, Level 3, Javits Center

**HOW TO LAUNCH A SUCCESSFUL PRIVATE
PRACTICE, PART 1**

Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Jacqueline M. Melonas, J.D., Donna Vanderpool, J.D., Martin G. Tracy, J.D., Tracy R. Gordy, M.D., Chester W. Schmidt, Jr., M.D.

ISSUE WORKSHOP 40 9:00 a.m.-10:30 a.m.
Room 3D03/10, Level 3, Javits Center

MY NAME IS WALTER JAMES CROSS

Chp.: David L. Dawson, M.D.

ISSUE WORKSHOP 41 9:00 a.m.-10:30 a.m.
Rooms 3D04/9, Level 3, Javits Center

**ONLINE VIDEO GAMES: PSYCHOPATHOLOGICAL
OR PSYCHOTHERAPEUTIC?**

Co-Chps.: Jeffrey N. Wilkins, M.D., Jack Kuo, M.D.
Participants: William Huang, M.D., Kimberly S. Young, Ph.D., Kurt Squire, Ph.D., Stephanie M. Stewart, M.D., Maressa H. Orzack, Ph.D., Constance Steinkuehler, Ph.D.

ISSUE WORKSHOP 42 9:00 a.m.-10:30 a.m.
Odets Room, Fourth Floor, Marriott Marquis

INFERTILITY: A CHRONIC ILLNESS WITH CHRONIC CHALLENGES

Chp.: Roxanne C. Dryden-Edwards, M.D.

ISSUE WORKSHOP 43 9:00 a.m.-10:30 a.m.
Wilder Room, Fourth Floor, Marriott Marquis

VALUES-BASED TREATMENT OF RELATIONAL DISORDERS

Co-Chps.: Glenn N. Siegel, M.D., Mary Pittman, M.S.

ISSUE WORKSHOP 44 9:00 a.m.-10:30 a.m.
Ziegfeld Room, Fourth Floor, Marriott Marquis

ORAL BOARDS BOOT CAMP

Co-Chps.: Elyse D. Weiner, M.D., Eric D. Peselow, M.D.

ISSUE WORKSHOP 45 9:00 a.m.-10:30 a.m.
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

STEROID ABUSE: GROWING PROBLEM FOR ADOLESCENTS AND A HIDDEN PROBLEM FOR ADULTS

Collaborative Session With the National Institute on Drug Abuse

Chp.: Donald R. Vereen, Jr., M.D.

Participants: Gary I. Wadler, M.D., Harrison G. Pope, Jr., M.D., Linn Goldberg, M.D., Diane L. Elliot, M.D.

ISSUE WORKSHOP 46 9:00 a.m.-10:30 a.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

ENGAGING THE HOMELESS IN TREATMENT STRATEGIES AND RESULTS

Chp.: John S. McIntyre, M.D.

Participants: Kevin McIntyre, M.D., Linda Morgan, Ph.D., Odysseus Adamides, Jr., M.D.

ISSUE WORKSHOP 47 9:00 a.m.-10:30 a.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

NEW TECHNOLOGIES FOR THE ASSESSMENT OF ADHD

Co-Chps.: Martin H. Teicher, M.D., Gianni L. Faedda, M.D.

Participants: Carl M. Anderson, Ph.D., F. Xavier Castellanos, M.D.

ISSUE WORKSHOP 48 9:00 a.m.-10:30 a.m.
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

EMERGING PHARMACOTHERAPIES FOR TREATMENT OF STIMULANT DEPENDENCE

Collaborative Session With the National Institute on Drug Abuse

Chp.: Francis J. Vocci, Ph.D.

Participants: Steven Shoptaw, Ph.D., Kyle M. Kampman, M.D., Frances R. Levin, M.D., Stephen L. Dewey, Ph.D.

ISSUE WORKSHOP 49 9:00 a.m.-10:30 a.m.
Lyceum Room, Fifth Floor, Marriott Marquis

UPDATE ON HEPATITIS C AND PSYCHIATRIC ISSUES

Co-Chps.: Andrew F. Angelino, M.D., Glenn J. Treisman, M.D.

ISSUE WORKSHOP 50 9:00 a.m.-10:30 a.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

FIBROMYALGIA: CURRENT UNDERSTANDING AND FUTURE DIRECTIONS

Chp.: Alan Z.A. Manevitz, M.D.

Participant: James P. Halper, M.D.

ISSUE WORKSHOP 51 9:00 a.m.-10:30 a.m.
Plymouth/Uriis/Shubert Rooms, Sixth Floor, Marriott Marquis

THE ART OF THE UNCONSCIOUS: SHAKESPEARE, POETRY, FILM, AND PSYCHIATRY

Co-Chps.: Steven E. Pflanz, M.D., Charles R. Joy, M.D.

ISSUE WORKSHOP 52 9:00 a.m.-10:30 a.m.
Royale Room, Sixth Floor, Marriott Marquis

THE IMPACT OF 9/11 ON PSYCHIATRIC RESIDENTS AND TRAINING PROGRAMS

Chp.: Renato D. Alarcon, M.D.

Participants: Nyapati R. Rao, M.D., Maria A. Oquendo, M.D., Milton Kramer, M.D., Anne O'Connell, M.D.

ISSUE WORKSHOP 53 9:00 a.m.-10:30 a.m.
Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

IMPLEMENTING THE INSTITUTE OF MEDICINE REPORT: FOSTERING RESEARCH CAREERS VIA RESIDENCIES

Chp.: Joel Yager, M.D.

Participants: Wayne S. Fenton, M.D., Regina S. James, M.D., John F. Greden, M.D., Joel J. Silverman, M.D.

TUESDAY

ISSUE WORKSHOP 54 9:00 a.m.-10:30 a.m.
Gotham Room, Seventh Floor, Marriott Marquis

A SHARED-CARE MODEL FOR TREATING THE HOMELESS MENTALLY ILL

Chp.: Samuel Packer, M.D.
Participants: Carol Zoulalian, M.A., Sharon Gazely, M.D.

ISSUE WORKSHOP 55 9:00 a.m.-10:30 a.m.
Gramercy Room, Seventh Floor, Marriott Marquis

GROUP INTERVENTIONS WITH ADOLESCENTS IN OUTPATIENT, INPATIENT, AND SCHOOL SETTINGS

Chp.: Fady Hajal, M.D.
Participant: Saul Scheidlinger, Ph.D.

ISSUE WORKSHOP 56 9:00 a.m.-10:30 a.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

ADDICTION RESEARCH AS A CAREER CHOICE IN PSYCHIATRY

Collaborative Session With the National Institute on Drug Abuse

Chp.: Ivan D. Montoya, M.D.
Participants: Herbert D. Kleber, M.D., Douglas M. Ziedonis, M.D., Ronald L. Cowan, M.D., Nathalie Maullin, M.D., Kathleen T. Brady, M.D., Charles P. O'Brien, M.D.

ISSUE WORKSHOP 57 9:00 a.m.-10:30 a.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

IT DOESN'T HAPPEN TO US: EXPLORING TRAUMA AND RESILIENCY IN MINORITIES

Co-Chps.: Napoleon B. Higgins, Jr., M.D., Lacresha L. Hall, M.D.
Participants: Jean-Marie E. Alves-Bradford, M.D., Eric R. Williams, M.D., Aruna S. Rao, M.D.

ISSUE WORKSHOP 58 9:00 a.m.-10:30 a.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

CUTTING-EDGE MANAGEMENT OF TOURETTE'S SYNDROME AND ITS COMORBIDITIES

Co-Chps.: Cathy L. Budman, M.D., John T. Walkup, M.D.
Participants: Anthony L. Rostain, M.D., Fred Penzel, Ph.D.

MEDIA 3-4

MEDIA WORKSHOP 3 9:00 a.m.-12 noon
Room 1D06, Level 1, Javits Center

Cultural Assessment in Clinical Psychiatry: Two Training Videotapes

Co-Chps.: Francis G. Lu, M.D., Harriett Koskoff

MEDIA WORKSHOP 4 9:00 a.m.-12 noon
Room 1E06, Level 1, Javits Center

When Boys Fly: Club Drugs in the Gay Male Community

Chp.: Petros Levounis, M.D.
Participant: Steven J. Lee, M.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 14-17

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

14 Joel F. Paris, M.D., on Personality Disorders Over Time
(Meet the Authors)
Rooms 2D02/3, Level 2, Javits Center

15 Barton J. Blinder, M.D., on Psychiatric Comorbidity in the Eating Disorders: Diagnosis, Treatment, and Research
Rooms 2D04/5, Level 2, Javits Center

16 Paul S. Appelbaum, M.D., on Ethics in Psychiatric Practice
Room 2D08, Level 2, Javits Center

17 Nancy C. Andreasen, M.D., on Publishing and Grant Writing *(For Residents Only)*
Versailles Terrace, Second Floor, Sheraton New York

LECTURES 14-15

LECTURE 14

11:00 a.m.-12:30 p.m.
Rooms 1E07/8, Level 1, Javits Center

APA'S OSKAR PFISTER AWARD LECTURE

Elizabeth S. Bowman, M.D.

**Dialogue From the Rims of the Grand Canyon: On
Bridging the Post-Freudian Chasm Between
Religion and Psychiatry**

Chp.: George T. Harding IV, M.D.

Freud's theories on religion advanced psychiatric understanding of religion, but his dismissive reductionism created a wide gap of eroded trust between psychiatrists and clergy. Elizabeth S. Bowman, M.D., discusses the nature of this gap and proposes a bridge for discussion between science and religion that acknowledges the differences in language and methods between these disciplines. Dr. Bowman is Clinical Professor of Neurology at Indiana University School of Medicine in Indianapolis where she formerly was Professor of Psychiatry. She is also in the private practice of psychiatry and is Attending Psychiatrist in the epilepsy clinic at Indiana University Hospitals in Indianapolis. Her religion and psychiatry curriculum taught at the Indiana University School of Medicine served as the core of the 1996 *Model Curriculum for Psychiatry Residency Training Programs: Religion and Spirituality in Clinical Practice*. Dr. Bowman is a Distinguished Fellow of the American Psychiatric Association and former President of the Indiana Psychiatric Society and of the International Society for the Study of Dissociation. Dr. Bowman received her medical degree from Indiana University School of Medicine where she also completed her general psychiatry residency. She holds a Master of Sacred Theology degree from Christian Theological Seminary in Indianapolis.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 15

11:00 a.m.-12:30 p.m.
Room 1E15, Level 1, Javits Center

Charles P. O'Brien, M.D.

**Anticraving Medication: A New Class of
Psychoactive Medication?**

*Collaborative Session With the National Institute
on Drug Abuse*

Chp.: Eric D. Collins, M.D.

Co-Chp.: David A. Baron, M.D.

Charles P. O'Brien, M.D., is Kenneth Appel Professor and Vice-Chairman of the Department of Psychiatry at the University of Pennsylvania and Director of Research at the Mental Illness Research, Education and Clinical Center at the Veterans Affairs Medical Center in Philadelphia. He established and directs a clinical research program that has elucidated the basic nature of addiction and improved the treatment of addictive disorders through investigation of new medications, behavioral interventions, and instruments for measuring the severity of addiction. The findings of Dr. O'Brien's research group have been described in more than 400 publications. A Distinguished Life Fellow of the American Psychiatric Association (APA), Dr. O'Brien is Past President of the American College of Neuropsychopharmacology and the Association for Research in Nervous and Mental Disease. He is a member of the Institute of Medicine of the National Academy of Sciences and a recipient of several awards, including the APA Award for Research and the Smithers Distinguished Scientist Award from the American Society of Addiction Medicine. Dr. O'Brien received his medical degree and doctoral degree in physiology (neurophysiology) from Tulane University in New Orleans. He completed residency training at Harvard Medical School, Tulane University, the University of London, and the University of Pennsylvania.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

**MASTER EDUCATOR CLINICAL
CONSULTATIONS 6-7**

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

**6 Mark E. Servis, M.D., on Personality Disorders
Room 1D04, Level 1, Javits Center**

(Continued on next page)

TUESDAY

- 7 **Ira D. Glick, M.D.**, on Combining and Integrating Medication and Psychotherapy for Schizophrenia and Other Axis 1 Disorders
Room 1D05, Level 1, Javits Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATE 2

11:00 a.m.-12:30 p.m.
Room 1E13, Level 1, Javits Center

HEPATITIS B AND C: WHAT'S NEW?

Chp.: Silvia Hafliger, M.D.
Presenter: Robert S. Brown, Jr., M.D.
THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

- 2 **Matcheri S. Keshavan, M.D.**, on Brain Imaging Studies in Schizophrenia
Room 1D03, Level 1, Javits Center

SCIENTIFIC AND CLINICAL REPORT SESSIONS 9-18

SCIENTIFIC AND CLINICAL REPORT SESSION 9
11:00 a.m.-12:30 p.m.
Rooms 1E01/2, Level 1, Javits Center

BUPRENORPHINE THERAPY

Chp.: David M. McDowell, M.D.
Co-Chp.: Daniel W. Hicks, M.D.

- 11:00 a.m.
26 ***Challenges in Increasing Access to Buprenorphine Treatment**
Joyce C. West, Ph.D., Thomas R. Kosten, M.D., Joshua E. Wilk, Ph.D., Dace Svikis, Ph.D., Elisa G. Triffleman, M.D., Donald S. Rae, M.A., William E. Narrow, M.D.

- 11:30 a.m.
27 ***A Double-Blind, Double-Dummy, Randomized, Prospective, Efficacy Study of the Partial Mu Opiate Agonist Buprenorphine for Acute Detoxification of Heroin Addicts**
Michael R. Oreskovich, M.D., Andrew J. Saxon, M.D., Meiling K. Ellis, B.S., Carol A. Malte, M.S.W., Joseph P. Reoux, M.D., Patricia C. Knox, Ph.D.

** Collaborative Session With the National Institute on Drug Abuse*

12 noon

- 28 **Buprenorphine: An Effective Treatment for Heroin Addicts**
Paolo Marzorati, M.D., Livia Guglielmino, M.D., Rosella Silenzio, Pierluigi Vigezzi, M.D., Filomena Corrado, M.D., Margherita De Chiara, M.D., Edoardo Cozzolino, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 10
11:00 a.m.-12:30 p.m.
Room 1E11, Level 1, Javits Center

PANIC DISORDER

Chp.: David A. Casey, M.D.
Co-Chp.: Andrew O. Skinner, M.D.

- 11:00 a.m.
29 **Early Detection of Relapse in Patients with Panic Disorder With Agoraphobia**
Matig R. Mavissakalian, M.D., Shenyang Gou, Ph.D.

- 11:30 a.m.
30 **Three-Year Prophylaxis in Panic Disorder: To Continue or Discontinue?**
Yujuan Choy, M.D., Eric D. Peselow, M.D., Mary Paizis, M.D., Jamie A. Luff, M.D., Gonzalo Laje, M.D., Mary T. Guardino, B.A., Mary Anne Pressman, M.D.

12 noon

- 31 **Discontinuation of Medications in Panic Patients**
Eric D. Peselow, M.D., Mary Anne Pressman, M.D., Jamie A. Luff, M.D., Mary Paizis, M.D., Gonzalo Laje, M.D., Mary T. Guardino, B.A.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 11
11:00 a.m.-12:30 p.m.
Room 1E12, Level 1, Javits Center

ISSUES IN DEPRESSION

Chp.: Glenn J. Treisman, M.D.
Co-Chp.: Christine J. Truman, M.D.

- 11:00 a.m.
32 **Brain Bioenergetics and Thyroid Hormone Treatment in MDD**
Dan V. Iosifescu, M.D., Nicholas R. Bolo, Ph.D., John E. Jensen, Ph.D., Andrew A. Nierenberg, M.D., Julie L. Ryan, B.A., Perry F. Renshaw, M.D., Maurizio Fava, M.D.

- 11:30 a.m.
33 **Depressed Outpatients From Primary Care Versus Specialty Care Settings**
Bradley N. Gaynes, M.D., A. John Rush, M.D., Madhukar H. Trivedi, M.D., Donald Spencer, M.D., Timothy J. Petersen, Ph.D., Michael Klinkman, M.D., Robert N. Golden, M.D.

12 noon

34 **Limits to the Treatment of Major Depression**

Gabor I. Keitner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 12

11:00 a.m.- 12:30 p.m.

Room 3D03/10, Level 3, Javits Center

ADHD

Chp.: Frances R. Levin, M.D.

Co-Chp.: Rebecca W. Brendel, M.D.

11:00 a.m.

35 **ADHD Comorbidity in Preschool Children**Atilla Turgay, M.D., Rubaba Ansari, M.A., David Ng, M.D.,
Michael Schwartz, Ph.D., Aruz Mesci

11:30 a.m.

36 **Atomoxetine for Comorbid ADHD and Affective Symptoms**

Jeffrey H. Newcorn, M.D.

12 noon

37 **Abuse Liability Assessment of Atomoxetine in a Drug-Abusing Population**

Donald R. Jasinsky, M.D., Douglas E. Faries, Ph.D., Albert J. Allen, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 13

11:00 a.m.- 12:30 p.m.

Rooms 3D04/9, Level 3, Javits Center

UNDERSTANDING THE EFFECTS OF TERRORISM

Chp.: Randall D. Marshall, M.D.

Co-Chp.: Elspeth C. Ritchie, M.D.

11:00 a.m.

38 **Effects of 9/11 and Chronic Stress on Female Drinking and Anxiety**Judith A. Richman, Ph.D., Joseph A. Flaherty, M.D.,
Joseph S. Wislar, M.S., Michael Fendrich, Ph.D., Kathleen M. Rospenda, Ph.D.

11:30 a.m.

39 **Psychosocial Predictors of Long-Term Resilience Following the 9/11 Attacks**

David Spiegel, M.D., Lisa D. Butler, Ph.D., Cheryl Koopman, Ph.D., Jay Azarow, Ph.D., Juliette C. Desjardins, M.D., Xin- Hua Chen, B.A., Helena C. Kraemer, Ph.D.

12 noon

40 **The Terrorist as a Nonpatient Subject of Psychiatric Investigation**

David Rothstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 14

11:00 a.m.- 12:30 p.m.

Rooms 3D05/8, Level 3, Javits Center

PSYCHOPHARMACOLOGY

Chp.: David A. Gutman, M.D.

Co-Chp.: Jeffrey M. Friend, M.D.

11:00 a.m.

41 **Antipsychotic Treatment and Sexual Adverse Events: The Role of Prolactin**

Rikus Knegtering, M.D.

11:30 a.m.

42 **Three-Bead Extended-Release Carbamazepine Capsule (SPD417) Continuation: Maintenance Therapy in Bipolar Disorder**

Terence A. Ketter, M.D., Amir H. Kalali, M.D., Richard H. Weisler, M.D.

12 noon

43 **Parkinsonism in a Nursing Home: Underrecognition**

Hubert H. Fernandez, M.D., Joseph Friedman, M.D., Martha Trieschmann, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 15

11:00 a.m.- 12:30 p.m.

Rooms 3D06/7, Level 3, Javits Center

ISSUES IN PSYCHIATRIC RESEARCH AND PSYCHOPHARMACOLOGY

Chp.: Nikhil D. Nihalani, M.D.

Co-Chp.: Robert Kelly, M.D.

11:00 a.m.

44 **Concurrent Use of Multiple Antipsychotics in Psychiatric Inpatients**

Bonnie L. Szarek, R.N., John W. Goethe, M.D., Theodore F. Mucha, M.D.

11:30 a.m.

45 **How Do Psychiatric Patients Perceive Research Participation?**

Cherise Rosen, M.A., Linda S. Grossman, Ph.D.

12 noon

46 **Polypharmacy and Its Ramifications in a Chronic Psychiatric Hospital**

Jambur V. Ananth, M.D., Sarath Gunatilake, M.D., Sharat Parameswaran, B.S., Chris E. Marshall, B.S., Steven Brown, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

TUESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 16

11:00 a.m.-12:30 p.m.

Wilder Room, Fourth Floor, Marriott Marquis

CHILD AND ADOLESCENT PSYCHIATRY

Chp.: Cynthia R. Pfeffer, M.D.

Co-Chp.: Arun R. Kunwar, M.D.

11:00 a.m.

47 **Externalizing Behaviors in Preadolescent Children: A National Panel Study**

David J. Pevalin, Ph.D., John Cairney, Ph.D., Terrance J. Wade, Ph.D.

11:30 a.m.

48 **Gender and the Prediction of Drug and Alcohol Abuse in Adolescent Inpatients**

Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D.

12 noon

49 **Prevalence and Outcomes of Childhood Adversity in an Australian Population**

Stephen J. Rosenman, M.D., Bryan Rodgers, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 17

11:00 a.m.-12:30 p.m.

Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

SOCIAL AND COMMUNITY PSYCHIATRY

Chp.: Susan Stabinsky, M.D.

Co-Chp.: William A. James, M.D.

11:00 a.m.

50 **Evaluation of an HIV Intervention for Psychiatric Care Providers in South Africa**

Pamela Y. Collins, M.D., Kezziah Mestry, LL.B., Graham Lindegger, Ph.D., Thobile Nzama, Francine Cournos, M.D., Milton L. Wainberg, M.D.

11:30 a.m.

51 **Developing Capacity Within CBOs for Health Education and Outreach**

Mary Jane Massie, M.D., David Lounsbury, Ph.D., Bruce Rapkin, Ph.D.

12 noon

52 **Inter-European Countries Comparison on Treatment Use for Mental Health Disorders**

Viviane Kovess, M.D., Jordi Alonso, M.D., Mathias C. Angermeyer, Tery Brugha

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 18

11:00 a.m.-12:30 p.m.

Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

VIOLENCE, TRAUMA, AND VICTIMIZATION

Chp.: Paula G. Panzer, M.D.

Co-Chp.: Leslie L. Buckley, M.D.

11:00 a.m.

53 **Evaluation of a Therapeutic Interagency Preschool for Traumatized Children**

Terrance J. Wade, Ph.D., Jane Sites, Ed.D., Frank W. Putnam, Jr., M.D.

11:30 a.m.

54 **Mental Health in Postwar Afghanistan**

Barbara Lopes-Cardozo, M.D., Oleg Biluuma, M.D., Carol Gotway-Crawford, Ph.D., Maru Anderson

12 noon

55 **A Three-Dimensional Model of Violence in Schizophrenia**

Menahem I. Krakowski, M.D., Pal Czobor, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 27-32

COMPONENT WORKSHOP 27

11:00 a.m.-12:30 p.m.

Rooms 2D10/11, Level 2, Javits Center

WHEREFORE NEUROSCIENCE: HOW MUCH DOES THE PSYCHIATRIST NEED TO KNOW?

APA/GlaxoSmithKline Fellows

Co-Chps.: Joshua L. Roffman, M.D., Carrie L. Ernst, M.D.

Participants: Asher B. Simon, M.D., Jason M. Morrison, M.D., Konasale M.R. Prasad, M.D.

COMPONENT WORKSHOP 28

11:00 a.m.-12:30 p.m.

Rooms 2D12/13, Level 2, Javits Center

WHAT DO EMPLOYERS WANT? EMPLOYEE MENTAL HEALTH BENEFITS

APA Committee on APA/Business Relationships

Co-Chps.: Norman A. Clemens, M.D., Jeffrey P. Kahn, M.D.

Participants: Michael J. Thompson, Liisa Chider, M.A.

COMPONENT WORKSHOP 29 11:00 a.m.-12:30 p.m.
Rooms 2D14/15, Level 2, Javits Center

HELPING DISTRICT BRANCHES RELATE TO APA AND TO THEIR MEMBERS

APA Corresponding Committee on District Branch/State Association Relations

Chp.: Donald G. Langsley, M.D.

Participants: Nada L. Stotland, M.D., Ann Marie T. Sullivan, M.D., Margo S. Adams

COMPONENT WORKSHOP 30 11:00 a.m.-12:30 p.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

THE TEACHING OF GAY, LESBIAN, BISEXUAL, AND TRANSGENDER ISSUES

APA New York County District Branch's Committee on Gay and Lesbian Issues

Chp.: Kenneth B. Ashley, M.D.

Participants: Stewart L. Adelson, M.D., Richard O. Hire, M.D., Elizabeth LeQuesne, M.D., Khakasa H. Wapenyi, M.D.

COMPONENT WORKSHOP 31 11:00 a.m.-12:30 p.m.
Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis

SEX, DRUGS, AND HIV: SYNERGISTIC EPIDEMICS

APA New York County District Branch's AIDS Committee

Co-Chps.: Kristina L.N. Jones, M.D., John A.R. Grimaldi, Jr., M.D.

Participants: Bryan J. McGreal, M.D., Mary Ann Cohen, M.D., Elizabeth V. Getter, M.D.

COMPONENT WORKSHOP 32 11:00 a.m.-12:30 p.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

LOOKING BACK, LOOKING FORWARD: PATHWAYS FOR BLACKS IN PSYCHIATRY

APA Committee of Black Psychiatrists

Co-Chps.: Michelle O. Clark, M.D., N. Kalaya Okereke, M.D.

Participants: Carl C. Bell, M.D., Hugh Butts, M.D., Marketa M. Wills, M.D.

ISSUES 59-76

ISSUE WORKSHOP 59 11:00 a.m.-12:30 p.m.
Rooms 1E03/4/5, Level 1, Javits Center

APPROACHING MORAL ISSUES IN MENTAL HEALTH TREATMENT

Chp.: John R. Peteet, M.D.

Participants: Martha Jurchak, Ph.D., Leigh C. Bishop, M.D.

ISSUE WORKSHOP 60 11:00 a.m.-12:30 p.m.
Room 1E14, Level 1, Javits Center

THE PORTRAYAL OF PSYCHIATRY IN RECENT AMERICAN FILM

Chp.: Steven E. Pflanz, M.D.

ISSUE WORKSHOP 61 11:00 a.m.-12:30 p.m.
Room 3D02/11, Level 3, Javits Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 2

Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.

Participants: Tracy R. Gordy, M.D., Chester W. Schmidt, Jr., M.D.

ISSUE WORKSHOP 62 11:00 a.m.-12:30 p.m.
Odets Room, Fourth Floor, Marriott Marquis

USING ART AND POETRY: FROM MEDICATION MANAGEMENT TO COUNTERTRANSFERENCE

Chp.: Charles R. Joy, M.D.

Participant: Stuart A. Copans, M.D.

ISSUE WORKSHOP 63 11:00 a.m.-12:30 p.m.
O'Neill Room, Fourth Floor, Marriott Marquis

PSYCHIATRIC REHABILITATION AND PSYCHODYNAMICS

Co-Chps.: Anand Pandya, M.D., Grace Otto, R.N.

Participants: Veronica Popoiu, M.S.N., Eric Leventhal, C.S.W., Manuel Trujillo, M.D.

ISSUE WORKSHOP 64 11:00 a.m.-12:30 p.m.
Ziegfeld Room, Fourth Floor, Marriott Marquis

MANAGEMENT OF DIFFICULT SCHIZOPHRENIA

Chp.: Michael Y. Hwang, M.D.

Participants: Edward Kim, M.D., Faiq Hameedi, M.D., David P. Folsom, M.D., Samuel G. Siris, M.D.

ISSUE WORKSHOP 65 11:00 a.m.-12:30 p.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

THE APPLICATION OF BEDSIDE EXECUTIVE-FUNCTION MEASURES

Chp.: Jeffrey A. Cordes, M.D.

Participants: Jason E. Schillerstrom, M.D., Kaustubh G. Joshi, M.D.

TUESDAY

ISSUE WORKSHOP 66 11:00 a.m.-12:30 p.m.
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

THE PSYCHIATRY RESIDENT AS EDUCATOR: A PROPOSAL FOR CURRICULUM AND SUPERVISION

Co-Chps.: Ruth M. Lamdan, M.D., Autumn Ning, M.D.
Participants: Karriem L. Salaam, M.D., Diane B. Gottlieb, M.D., Edward A. Volkman, M.D., Roya Lewis, M.D.

ISSUE WORKSHOP 67 11:00 a.m.-12:30 p.m.
Lyceum Room, Fifth Floor, Marriott Marquis

INTERFACE BETWEEN PSYCHIATRY AND OBSTETRICS: COMPREHENSIVE PERINATAL CARE

Chp.: Johannes Bitzer
Participants: Maria F. Hofecker-Fallahp, M.D., Werner Tschan, M.D.

ISSUE WORKSHOP 68 11:00 a.m.-12:30 p.m.
Palace Room, Sixth Floor, Marriott Marquis

CLOSING A PSYCHIATRIC PRACTICE: CLINICAL AND RISK-MANAGEMENT ISSUES

Chp.: Robinette N. Bell, M.D.
Participants: Donna Vanderpool, J.D., Denny Rodriguez, J.D.

ISSUE WORKSHOP 69 11:00 a.m.-12:30 p.m.
Royale Room, Sixth Floor, Marriott Marquis

REHABILITATING TRAUMATIZED GIRLS IN RESIDENTIAL JUVENILE- JUSTICE SETTINGS

Chp.: Cheryl D. Wills, M.D.

ISSUE WORKSHOP 70 11:00 a.m.-12:30 p.m.
Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

THE OUT-OF-THE-SHADOW PROJECT

Co-Chps.: Edward F. Foulks, M.D., Susan E. Smiley
Participants: Suzanne E. Vogel-Scibilia, M.D., Stephen M. Goldfinger, M.D.

ISSUE WORKSHOP 71 11:00 a.m.-12:30 p.m.
Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

PSYCHOGENIC SEIZURES: A PROTOTYPE OF SOMATOFORM DISORDER

Chp.: Selim Benbadis, M.D.
Participant: Francisco Fernandez, M.D.

ISSUE WORKSHOP 72 11:00 a.m.-12:30 p.m.
Gotham Room, Seventh Floor, Marriott Marquis

CLINICAL EFFECTS OF SEXUAL ABUSE BY CATHOLIC PRIESTS: A FORENSIC PERSPECTIVE

Chp.: Allan S. Nineberg, M.D.

ISSUE WORKSHOP 73 11:00 a.m.-12:30 p.m.
Gramercy Room, Seventh Floor, Marriott Marquis

PROBLEMS IN THE PSYCHIATRIC EDUCATION OF INTERNATIONAL MEDICAL GRADUATES

Chp.: Milton Kramer, M.D.
Participants: Nyapati R. Rao, M.D., Brunhild Kring, M.D., Jeffrey Goldberg, D.O., Nalini V. Juthani, M.D.

ISSUE WORKSHOP 74 11:00 a.m.-12:30 p.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

DRUGS AND OTHER ADDICTIONS: DOES ONE SIZE FIT ALL?

Collaborative Session With the National Institute on Drug Abuse

Chp.: Steven J. Grant, Ph.D.
Participants: Linda Cottler, Ph.D., Nathan A. Shapira, M.D., Nancy M. Petry, Ph.D., Marc N. Potenza, M.D.

ISSUE WORKSHOP 75 11:00 a.m.-12:30 p.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

STRESS, TRAUMA, AND DRUG ABUSE

Collaborative Session With the National Institute on Drug Abuse

Chp.: Nancy Pilotte, Ph.D.
Participants: Paul Plotsky, Ph.D., Martin H. Teicher, M.D., Dean Kilpatrick, Ph.D., Lisa M. Najavits, Ph.D.

ISSUE WORKSHOP 76 11:00 a.m.-12:30 p.m.
Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

CHILDREN AND FAMILIES FACING TERRORISM, DISASTERS, AND COMPLEX EMERGENCIES

Chp.: Howard J. Osofsky, M.D.
Participants: Richard F. Mollica, M.D., Sandra J. Kaplan, M.D., Arieh Y. Shalev, M.D., Eric Noji, M.D.

12 noon Sessions

FORUMS 6-8

FORUM 6 12 noon-1:30 p.m.
 Room 1E10, Level 1, Javits Center

REVERSING THE CRIMINALIZATION OF THE SERIOUSLY MENTALLY ILL
APA Corresponding Committee on Jails and Prisons

Co-Chps.: Marcia Kraft Goin, M.D., Henry C. Weinstein, M.D.
Participants: H. Richard Lamb, M.D., Tom Hamilton, Ph.D., Erik J. Roskes, M.D.

FORUM 7 12 noon-1:30 p.m.
 Room 1E16, Level 1, Javits Center

UNCONSCIOUS PREDICTION, CONSCIOUS MONITORING, AND THERAPEUTIC CHANGE: IS THERE A MIND-BRAIN BARRIER?

Chp.: Mirian I. Butterfield, M.D.
Participant: Regina Pally, M.D.

FORUM 8 12 noon-1:30 p.m.
 Astor Ballroom, Seventh Floor, Marriott Marquis

SHOULD SEX BE PREVENTED IN PSYCHIATRIC UNITS? ARGUMENTS AND NEW DIRECTIONS

Chp.: Milton L. Wainberg, M.D.
Participants: Elizabeth B. Ford, M.D., Carol A. Bernstein, M.D., Marshall Forstein, M.D., Paulo E. Mattos, M.D.

NEW RESEARCH POSTER SESSION 6
 12 noon - 2:00 p.m.
 Galleria, Level 4, Javits Center

BIOLOGICAL PSYCHIATRY AND PSYCHOPHARMACOLOGY

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

1:00 p.m. Sessions

**COURSES 69-76**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 69 1:00 p.m.-5:00 p.m.
 Concourse B, Concourse Level, Hilton New York

BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE CONFLICTUAL RELATIONSHIP THEME METHOD

Director: Howard E. Book, M.D.

COURSE 70 1:00 p.m.-5:00 p.m.
 Concourse E, Concourse Level, Hilton New York

BASIC FAMILY SKILLS FOR AN INPATIENT PSYCHIATRIST

Director: Alison M. Heru, M.D.
Faculty: Laura Drury, M.S.W.

COURSE 71 1:00 p.m.-5:00 p.m.
 Beekman Parlor, Second Floor, Hilton New York

OVERVIEW AND UPDATE OF SLEEP DISORDERS MEDICINE

Director: Karl Doghramji, M.D.
Faculty: John W. Winkelman, M.D., Thomas D. Hurwitz, M.D.

COURSE 72 1:00 p.m.-5:00 p.m.
 Bryant Suite, Second Floor, Hilton New York

MEDITATION FOR PSYCHOTHERAPISTS AND THE PARADIGM OF HEALTH

Director: James T. Sacamano, M.D.

COURSE 73 1:00 p.m.-5:00 p.m.
 Gibson Suite, Second Floor, Hilton New York

WRITING ABOUT CLINICAL EXPERIENCES

Director: John S. Strauss, M.D.

COURSE 74 1:00 p.m.-5:00 p.m.
 Gramercy A, Second Floor, Hilton New York

THE EVALUATION AND IDENTIFICATION OF THE MAJOR DEMENTIAS

Director: Raymond A. Faber, M.D.
Faculty: Kevin F. Gray, M.D., Randolph B. Schiffer, M.D.

COURSE 75 1:00 p.m.-5:00 p.m.
Nassau Suite A, Second Floor, Hilton New York

HOW TO USE YOUR PALM OS PDA IN PSYCHIATRIC PRACTICE: ADVANCED

Director: John S. Luo, M.D.
Faculty: Richard A. Montgomery, M.D., Charles J. Rainey, M.D., Raymond J. Kloss, M.D., Hendry Ton, M.D.

COURSE 76 1:00 p.m.-5:00 p.m.
Sutton Center, Second Floor, Hilton New York

THE COMPLEXITIES OF CHRONIC PAIN: PSYCHIATRIC ISSUES AND TREATMENTS

Co-Directors: Allen Lebovits, Ph.D., Matthew B. Smith, M.D.
Faculty: Andrew F. Angelino, M.D., Robert Cancro, M.D., Michael R. Clark, M.D., Michel Dubois, M.D.

2:00 p.m. Sessions

LECTURES 16-18

LECTURE 16

2:00 p.m.-3:30 p.m.
Rooms 1E07/8, Level 1, Javits Center

James H. Scully, Jr., M.D.

How Many Psychiatrists Do We Need?

Chp.: Linda L.M. Worley, M.D.
Co-Chp.: Catherine C. Crone, M.D.

James H. Scully, Jr., M.D., became Medical Director of the American Psychiatric Association (APA) in January 2003. As Medical Director, Dr. Scully is responsible for overseeing approximately 250 full-time staff in the Association and its three corporate subsidiaries, the American Psychiatric Institute for Research and Education, the American Psychiatric Foundation, and American Psychiatric Publishing, Inc. Among his areas of responsibility are legislative advocacy and policy development, continuing medical education and lifelong learning, communications, member services, and health services research. Dr. Scully formerly was the Alexander Donald Professor and Chair of the Department of Neuropsychiatry and Behavioral Science and President of the Educational Trust at the University of South Carolina School of Medicine in Columbia, South Carolina. He served as interim director of the South Carolina Department of Mental Health from 2000 to 2001. A Distinguished Fellow of APA, Dr. Scully is the recipient

of numerous awards, including the American Academy of Child and Adolescent Psychiatry Leadership Award for Best Chairman of a Department of Psychiatry. A graduate of Tulane University School of Medicine in New Orleans, Dr. Scully completed his residency training in psychiatry at the University of Colorado Medical Center in Denver.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 17

2:00 p.m.-3:30 p.m.
Room 1E15, Level 1, Javits Center

APA'S MARMOR AWARD LECTURE

David Spiegel, M.D.

Feeling and Healing: Biopsychosocial Treatments and Their Effects on Medical Illness

Chp.: Alan F. Schatzberg, M.D.

David Spiegel, M.D., is the Jack, Lulu & Sam Willson Professor of Medicine and Associate Chair of the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine in Stanford, California, where he is also Director of the Center on Stress and Health. In addition, he is Medical Director of the Stanford Center for Integrative Medicine at Stanford Medical Center, which provides supportive care for medically ill patients. Dr. Spiegel is Second Vice-President of the American College of Psychiatrists (he will assume the Presidency in 2006) and Past President of the Society for Clinical and Experimental Hypnosis. A Distinguished Fellow of the American Psychiatric Association, he has received the Edward A. Strecker, M.D., Award from the Institute of Pennsylvania Hospital for his contributions to clinical psychiatry; and the Hilgard Award from the International Society of Hypnosis for his research contributions to the development of medical hypnosis. He serves on the editorial boards of numerous journals and was Editor of the American Psychiatric Press' *Progress in Psychiatry* series. Dr. Spiegel received his medical degree from Harvard Medical School and completed his residency training in psychiatry at the Massachusetts Mental Health Center and Cambridge Hospital and a fellowship at the Laboratory of Community Psychiatry, all at Harvard Medical School in Boston.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 18

2:00 p.m.-3:30 p.m.

Trianon Ballroom, Third Floor, Hilton New York

A. Thomas McLellan, Ph.D.

Conceptual and Methodological Flaws in the
Evaluation of Addiction Treatment*Collaborative Session With the National Institute
on Drug Abuse*

Chp.: Renee M. Sorrentino, M.D.

Co-Chp.: Shelly F. Greenfield, M.D.

A. Thomas McLellan, Ph.D., is Professor of Psychiatry at the University of Pennsylvania School of Medicine and the Director of the Treatment Research Institute in Philadelphia. He and his colleagues developed some of the most widely used measurement instruments in addiction research, including the Addiction Severity Index (ASI) and the Treatment Services Review (TSR), which have been translated into more than 20 languages. In their research, Dr. McLellan and his colleagues have used these instruments to evaluate a variety of therapies, medications, and interventions used in the treatment of alcohol and drug dependence. They are currently investigating the active and inactive ingredients of treatment, the appropriate duration and content of treatment for various types of patients, and methods for transferring findings from treatment research into practical applications for the practitioner and provider. Dr. McLellan is the author of more than 400 articles and book chapters in addiction research and serves as the Editor-in-Chief of *Journal of Substance Abuse Treatment*. His many honors include the 2003 Innovators Combating Substance Abuse Award from the Robert Wood Johnson Foundation. Dr. McLellan received his doctoral degree from Bryn Mawr College in Philadelphia and received postgraduate training in psychology at Oxford University in England.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIUM 2

2:00 p.m.-5:00 p.m.

Astor Ballroom, Seventh Floor, Marriott Marquis

WITHER GO THE STATES: THE IMPACT OF BUDGET CUTS

Chp.: David A. Pollack, M.D.

A Overview of the Impact of State Budget Cuts: Problems
and Solutions

Michael F. Hogan, Ph.D.

B Using Fiscal and Clinical Measures During Times of
Limited Resources

Theodore C. Lutterman, Lucille Schacht, Ph.D.

C State Policy Choices for Children's Mental Health in
Tough Budget Times

Chris Koyanagi

D The Impact of Budget Cuts on Rural Mental Health

Dennis Mohatt, M.A.

E Cuts Cutting Into the Possibility of Recovery

Tom Lane, Laura Lee Hall, Ph.D.

F After All This, Do You Still Want to Be a Public
Psychiatrist?

Allison M. Wehr, M.D., Jennifer K. Coffman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

REVIEW OF PSYCHIATRY: SECTION 2

2:00 p.m.-5:30 p.m.

Special Events Hall 1D, Level 1, Javits Center

COGNITIVE-BEHAVIOR THERAPY

Chp.: Jesse H. Wright, M.D.

6 Cognitive Therapy for Schizophrenia

Jan L. Scott, M.D., David G. Kingdon, M.D., Douglas
Turkington, M.D.

7 Cognitive Therapy for Bipolar Disorder

Monica A. Basco, Ph.D., A. John Rush, M.D., Noelle
McDonald, B.S., Megan Merlock, B.A.

8 Computer-Assisted Cognitive-Behavior Therapy

Jesse H. Wright, M.D.

9 Cognitive Therapy With Medical Patients

Thomas Sensky, M.B.

10 Cognitive Therapy for Children and Adolescents

Anne Marie Albano, Ph.D., Amy L. Krain, Ph.D., Elizabeth
Podniesinski, M.A., Keith Ditekowsky, M.D.

SYMPOSIA 27-58

SYMPOSIUM 27

2:00 p.m.-5:00 p.m.

Rooms 1E01/2, Level 1, Javits Center

BEHAVIORAL ACTIVATION, COGNITIVE THERAPY,
AND MEDICATION FOR MAJOR DEPRESSION

Chp.: Steven D. Hollon, Ph.D.

(Continued on next page)

TUESDAY

A Methods and Acute-Phase Outcomes

Sona A. Dimidjian, Steven D. Hollon, Ph.D., Keith S. Dobson, Ph.D., Karen B. Schmaling, Ph.D., Robert J. Kohlenberg, Ph.D., Michael Addis, Ph.D., David L. Dunner, M.D.

B Prevention of Relapse

Keith S. Dobson, Ph.D., Steven D. Hollon, Ph.D., Sona A. Dimidjian, Karen B. Schmaling, Ph.D., Robert J. Kohlenberg, Ph.D., Shireen Rizvi, David L. Dunner, M.D.

C Prediction of Treatment Response

Shireen Rizvi, Sona A. Dimidjian, Steven D. Hollon, Ph.D., Keith S. Dobson, Ph.D., Karen B. Schmaling, Ph.D., Robert J. Kohlenberg, Ph.D., David L. Dunner, M.D.

Discussants: Jan Fawcett, M.D., Marsha M. Linehan, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 28 2:00 p.m.-5:00 p.m.

Rooms 1E03/4/5, Level 1, Javits Center

NEW PERSPECTIVES IN THE TREATMENT OF COMPLEX PTSD

Chp.: James A. Chu, M.D.

A Update on the Memory Wars: Evaluating and Working With Traumatic Memory
James A. Chu, M.D.

B Betrayal Trauma Theory: Dimensions of Harm and Healing
Jennifer J. Freyd, Ph.D.

C Significance of Relationship in the Treatment of Complex Trauma
Christine Courtois, Ph.D.

D Using EMDR to Resolve Trauma-Based Distortions of the Self in Complex PTSD
Denise J. Gelinis, Ph.D.

E Treatment Outcome Research and Complex PTSD
Bessel A. Van Der Kolk, M.D., Joseph F. Spinazzola, Ph.D.

Discussant: Judith Herman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 29 2:00 p.m.-5:00 p.m.

Room 1E06, Level 1, Javits Center

BIPOLAR PATIENTS: TREATMENTS AND CULTURAL ISSUES IN LATIN AMERICA

Chp.: Carlos Leon-Andrade, M.D.
Co-Chp.: Ruby C. Castilla-Puentes, M.D.

A Interpersonal Psychotherapy in Brazil: Similarities and Differences With the U.S.
Ana C.F. Andrade, M.A., Francisco Lotufo-Neto, M.D., Beny Lafer, M.D., Marcelo Feijo

B From Practice to Theory: Group Music Therapy and Medication Compliance in Patients With Bipolar Disorder
Ruby C. Castilla-Puentes, M.D., James M. Perel, Ph.D.

C What Is the Role of Psychotherapy in Patients With Bipolar Disorders? Cultural Issues
Carlos Leon-Andrade, M.D., Roxana Galeno, M.D.

D Treatment of Sleep Problems in Bipolar Patients
Franklin Escobar, M.D.

E Some Useful Interventions in the Course of Bipolar Disorders in Argentina
Jose R. Bozzo, M.D.

Discussants: Ricardo Secin, M.D., Alberto Serrano, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 30 2:00 p.m.-5:00 p.m.

Room 1E09, Level 1, Javits Center

PSYCHOTHERAPY AND PHARMACOTHERAPY: DISSOLVING THE MIND-BRAIN BARRIER

APA Committee on Psychotherapy by Psychiatrists

Chp.: Barton J. Blinder, M.D.
Co-Chp.: Bernard D. Beitman, M.D.

A Dynamic Imaging of the Brain: Actions, Dysfunction, Therapeutic Transformation
George I. Viamontes, M.D.

B Psychotherapy and Pharmacotherapy: Theoretical Basis and Empirical Studies of Combined Treatment
Michael E. Thase, M.D.

C Split Treatment: Conflict and Collaboration
Michelle B. Riba, M.D.

D Integrating Psychotherapy and Pharmacotherapy: The Clinical Challenge
Bernard D. Beitman, M.D.

Discussant: Charles B. Nemeroff, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 31 2:00 p.m.-5:00 p.m.

Room 1E10, Level 1, Javits Center

**PRACTICE GUIDELINES, QUALITY INDICATORS,
AND A PRACTICE RESEARCH NETWORK: AN
INTERNATIONAL VIEW***World Psychiatric Association*

Chp.: John S. McIntyre, M.D.

Co-Chp.: Wolfgang Gaebel, M.D.

**A Treatment Guidelines in Psychiatry: Results of an
International Survey**

Wolfgang Gaebel, M.D., S. Weinmann, M.D.

B Clinically-Based Quality Indicators

John M. Oldham, M.D.

C APA Practice Guideline Project: Status and Challenges

John S. McIntyre, M.D.

**D Assessing Evidence-Based Practice Guidelines in
Routine Psychiatric Practice**

Darrel A. Regier, M.D., Joyce C. West, Ph.D., William E. Narrow, M.D., Farifteh F. Duffy, Ph.D., Joshua E. Wilk, Ph.D.

Discussants: Rodrigo A. Munoz, M.D., George Christodoulou, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 32 2:00 p.m.-5:00 p.m.

Room 1E11, Level 1, Javits Center

**THE SCARS OF SARS: ITS IMPACTS ON PATIENTS,
HEALTH CARE WORKERS, AND THE COMMUNITY**

Chp.: Rima Styra, M.D.

Co-Chp.: Francis G. Lu, M.D.

**A PTSD and Depression in Patients Diagnosed With
SARS**

Rima Styra, M.D., Wayne L. Gold, M.D., Susan Robinson, R.N., Laura Hawryluck, M.D., Gerald Devins, M.D., Kenneth Mah, Ph.D.

**B The Psychological Impact of SARS on the Uninfected
Health Care Worker**

Wayne L. Gold, M.D., Rima Styra, M.D., Laura Hawryluck, M.D., Susan Robinson, R.N., Allison McGeer, M.D., Sidney H. Kennedy, M.D., Calvin Fones, M.D.

**C Stress in the Time of SARS: Health Care Workers'
Reactions to the Singapore SARS Outbreak**

Calvin Fones, M.D., David Koh, M.D., M. K. Lim, M.D., S.E. Chia, F. Qian, N. Chew, S.M. Ko

D Impact of SARS on Health Care Professionals

Sharon Straus, M.D., Wayne L. Gold, M.D., Kumanan Wilson, M.D., Moira Kapral, M.D., Gloria Rambaldini, M.D., Darlyne Rath, M.S.C.

**E I Am So Alone: Lessons Learned From Experiences of
Quarantined Individuals During the SARS Outbreak in
Toronto**

Laura Hawryluck, M.D., Wayne L. Gold, M.D., Susan Robinson, R.N., Sandro Galea, M.D., Rima Styra, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 33 2:00 p.m.-5:00 p.m.

Room 1E12, Level 1, Javits Center

**INTERPERSONAL PSYCHOTHERAPY: RESEARCH
UPDATE**

Chp.: John C. Markowitz, M.D.

**A Group Interpersonal Psychotherapy for Depression in
Uganda**

Myrna M. Weissman, Ph.D., Paul Bolton, M.B., Helena Verdelli, Ph.D., Richard Neugebauer, Ph.D., Judith Bass, M.P.H., Kathleen Clougherty, M.S.W., Priya Wickramaratne, Ph.D.

**B Combination of IPT and Medication in Outpatients With
Depression: Is It the Best We Can Do?**

Marc B.J. Blom, M.D., Kosse Jonker, Erik Hoencamp, M.D., Philip Spinhovem, Ph.D., Judith Haffmans, Ph.D., Richard Van Dyck, M.D.

**C IPT for Anxiety and Depression in Primary Care in
Scotland**

Roslyn Law, Psy.D.

**D Brief Interpersonal Psychotherapy for Depression in
Women**

Holly A. Swartz, M.D., Ellen Frank, Ph.D., M. Katherine Shear, M.D., Michael E. Thase, M.D., John Scott, M.A.

**E Long-Term Prophylaxis and Other Benefits of
Maintenance Interpersonal Psychotherapy**

Ellen Frank, Ph.D., Jill M. Cyranowski, Ph.D., Holly A. Swartz, M.D., David J. Kupfer, M.D.

Discussant: Myrna M. Weissman, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

TUESDAY

SYMPOSIUM 34 2:00 p.m.-5:00 p.m.

Room 1E13, Level 1, Javits Center

WOMEN'S SEXUALITY UPDATE: OVERCOMING OBSTACLES TO PLEASURE

Chp.: Barbara D. Bartlik, M.D.

A How Sexual Attractiveness, Pheromones, Fertility, and Hysterectomy Are Related
Winnifred B. Cutler, Ph.D.

B Changes in Sexual Functioning Across the Menstrual Cycle and During and After Pregnancy
Catherine A. Birndorf, M.D.

C New Treatment Options for Women With Sexual Dysfunction
Barbara D. Bartlik, M.D., Amy Kossoy, B.A., Marina Rozenberg, Julie Kolzet, B.S., Adriel Gerard

D The Positive Uses of Adult Movies Catering to Women
Candida Royalle

E Antidepressants and Sexual Dysfunction: A Women's Issue
James H. Kocsis, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 35 2:00 p.m.-5:00 p.m.

Room 1E14, Level 1, Javits Center

CONTEMPORARY ISSUES IN SPORT PSYCHIATRY
International Society for Sport Psychiatry

Chp.: Ronald L. Kamm, M.D.

A FIST: A Unique Program for Boxers at Career End
Ronald L. Kamm, M.D.

B The Impact of Injury on the Adolescent Athlete and the Family
Thomas S. Newmark, M.D.

C Keeping the Athlete Out of Trouble
Eric D. Morse, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 36 2:00 p.m.-5:00 p.m.

Room 1E16, Level 1, Javits Center

EATING DISORDERS 2004: FROM PETS TO PSYCHE

Chp.: Joel Yager, M.D.

Co-Chp.: David B. Herzog, M.D.

A Effects of Weight Loss on 5HT Activity and Symptoms in Anorexia Nervosa
Walter H. Kaye, M.D., Ursula Bailer, M.D., Carolyn Meltzer, M.D., Guido K.W. Frank, M.D., Chet Mathis, Ph.D., Julie Price, Ph.D.

B Osteoporosis and Anorexia Nervosa: An Update

David B. Herzog, M.D., Anne Klibanski, M.D., Karen K. Miller, Madhu Misra, M.D., Mary P. Manzo, A.B., Safia C. Abidi, B.S.

C Predictors of Treatment Acceptance in Anorexia Nervosa

Katherine A. Halmi, M.D., W. Stewart Agras, M.D., Scott J. Crow, M.D., James E. Mitchell, M.D., G. Terrence Wilson, Ph.D., Susan Bryson, Ph.D., Helena C. Kraemer, Ph.D.

D Eating Problems and Disorders in Bariatric Surgery Patients

James E. Mitchell, M.D., Martina deZwaan, M.D., Ross D. Crosby, Ph.D., Stephen A. Wonderlich, Ph.D.

E Body Image: Evolutionary Neurobiology Meets Psychodynamic Psychiatry in the Agora

Arnold E. Andersen, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 37

2:00 p.m.-5:00 p.m.

Rooms 3D01/12, Level 3, Javits Center

PSYCHIATRIC INTERVENTIONS WITH MEDICALLY-EVACUATED SOLDIERS

Chp.: Stephen J. Cozza, M.D.

A A Medical Center Response to Combat Casualties
Thomas M. Fitzpatrick, M.D.

B A Psychiatry Consultation Service Response to Trauma Victims: Program to Prevent Psychiatric Comorbidity
Harold J. Wain, Ph.D.

C Global War on Terror: Walter Reed Army Medical Center Inpatient Psychiatry's Perspective
Theodore S. Nam, M.D.

D A Psychiatric Continuum of Care System in Support of the Global War on Terror
Douglas A. Waldrep, M.D.

Discussants: Robert J. Ursano, M.D., Matthew J. Friedman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 38

2:00 p.m.-5:00 p.m.

Room 3D02/11, Level 3, Javits Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 3

Chp.: William E. Callahan, Jr., M.D.

Co-Chp.: Keith W. Young, M.D.

A Personal Factors Leading to a Successful Private Practice
William E. Callahan, Jr., M.D.

B Office Location and Design for Efficiency and Success
Keith W. Young, M.D.

C Streamlining Overhead and Managing Your Business in Private Practice
Keith W. Young, M.D.

D Marketing Your Unique Private Practice
William E. Callahan, Jr., M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 39 2:00 p.m.-5:00 p.m.

Room 3D03/10, Level 3, Javits Center

USE OF MANDATES AND LEVERAGE IN COMMUNITY-BASED TREATMENT

Chp.: Paul S. Appelbaum, M.D.

A Leverage and Mandated Community Treatment
John Monahan, Ph.D.

B A Multisite Study of Mandated Community Treatment: Methods and Prevalence
Henry J. Steadman, Ph.D.

C When Are Mandates and Leverage Applied in Community Treatment?
Paul S. Appelbaum, M.D.

D Patients' Attitudes Toward the Use of Legal Leverage in Community Treatment
Jeffrey W. Swanson, Ph.D., Marvin S. Swartz, M.D., H. Ryan Wagner, Ph.D., Eric B. Elbogen, Ph.D.

E Mandated Treatment: Legal, Ethical, and Policy Implications
Marvin S. Swartz, M.D.

Discussant: Stephanie LeMelle, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 40 2:00 p.m.-5:00 p.m.

Rooms 3D04/9, Level 3, Javits Center

PERINATAL DEPRESSION: BURDEN, NEUROBIOLOGY, AND TREATMENT

Chp.: John F. Greden, M.D.
Co-Chp.: Heather A. Flynn, Ph.D.

A The Neuropsychobiology of Perinatal Mood Disorders: Are Hormonal Changes Relevant?
Meir Steiner, M.D.

B Perinatal Depression: Bridging the Gap Between Maternal Distress and Infant Well-Being
Sheila Marcus, M.D., Heather A. Flynn, Ph.D., Delia M. Vazquez, M.D., Juan F. Lopez, M.D., Susan C. McDonough, Ph.D.

C The Undertreatment and Morbidity of Perinatal Depression in Obstetrics Settings
Heather A. Flynn, Ph.D., Sheila Marcus, M.D.

D Mental Health Treatment Among Pregnant Underprivileged Women
Kimberly A. Yonkers, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 41 2:00 p.m.-5:00 p.m.

Rooms 3D05/8, Level 3, Javits Center

NEUROIMAGING SEMINAR

Chp.: Bruce M. Cohen, M.D.

A Tools and Methods of Neuroimaging Research
Perry F. Renshaw, M.D.

B Functional Neuroanatomy of Psychiatric Disorders
Deborah A. Yurgelun-Todd, Ph.D.

C Neuroimaging in Psychotic Disorders
Stephan H. Heckers, M.D.

D Brain Imaging Studies of Depressive Illness
Michael E. Henry

E Neuroimaging in Childhood Disorders
Jean A. Frazier, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 42 2:00 p.m.-5:00 p.m.

Rooms 3D06/7, Level 3, Javits Center

SMOKING AND COMORBID MENTAL DISORDERS

Collaborative Session With the National Institute on Drug Abuse

Chp.: John R. Hughes, M.D.

A Psychiatric Comorbidity of Smoking and Nicotine Dependence: An Epidemiologic Perspective
Naomi Breslau, Ph.D.

B The Neurobiology of Nicotine Dependence and Comorbid Psychiatric Disorders
George F. Koob, Ph.D., Athina Markou, Ph.D.

(Continued on next page)

TUESDAY

C Nicotine-Dependence Treatment in Individuals With Schizophrenia
Douglas M. Ziedonis, M.D.

D Behavioral and Pharmacological Treatments for Smokers With Depression
Richard A. Brown, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 43 2:00 p.m.-5:00 p.m.
Odets Room, Fourth Floor, Marriott Marquis

TRAGIC EVENTS IN THE EMERGENCY DEPARTMENT: THE ROLE OF PSYCHIATRY AND THE INSTITUTIONAL IMPACT

Chp.: John B. Herman, M.D.

A Preparation and Organization for Tragedies in the Emergency Room
Maryfran Hughes, R.N.

B Managing Grief in the Group Setting
Jennifer M. Lafayette, M.D.

C Staff Support in Responding to Tragedies
Lawrence T. Park, M.D.

D Residency Training and Tragedy in the Emergency Department
Felicia A. Smith, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 44 2:00 p.m.-5:00 p.m.
O'Neill Room, Fourth Floor, Marriott Marquis

CULTURE, ETHNICITY, RACE, AND PSYCHOPHARMACOLOGY: NEW RESEARCH PERSPECTIVES

Chp.: Pedro Ruiz, M.D.

A Ethnicity, Pharmacogenetics, and Psychopharmacotherapy
Keh-Ming Lin, M.D.

B Pharmacotherapy in African Americans
William B. Lawson, M.D.

C Ethnicity, Culture, and Psychopharmacology: Asian Perspectives
Edmond H.T. Pi, M.D.

D Hispanics: Disease, Genes, and Treatment Outcome
Ricardo P. Mendoza, M.D.

E An International Perspective on Ethnicity, Culture, and Psychopharmacology
Tarek A. Okasha, M.D.

Discussants: Tarek A. Okasha, M.D., Warachal E. Faison, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 45 2:00 p.m.-5:00 p.m.
Wilder Room, Fourth Floor, Marriott Marquis

DELUSIONAL DISORDER: A RECONSIDERATION OF THE SCIENTIFIC AND CONCEPTUAL BASIS FOR THE DSM RE FORMULATION OF PARANOIA

Chp.: Alan A. Stone, M.D.
Co-Chp.: C. Robert Cloninger, M.D.

A The Concept of Delusional Disorder in DSM-IV
Nancy C. Andreasen, M.D.

B The Importance of Narcissism in Delusional Disorders
C. Robert Cloninger, M.D.

C Delusional Disorder: The Validity of the Diagnosis
Theo C. Manschreck, M.D.

D Delusional Disorder: Does the DSM Diagnosis Make Clinical Sense?
Alan A. Stone, M.D.

E Involuntary Treatment: The Constitutional Issues
Richard G. Taranto, J.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 46 2:00 p.m.-5:00 p.m.
Ziegfeld Room, Fourth Floor, Marriott Marquis

TRANSLATIONAL RESEARCH ON EATING DISORDERS

Chp.: B. Timothy Walsh, M.D.
Co-Chp.: Michael J. Devlin, M.D.

A Excitatory and Inhibitory Neurobiological Controls of Eating
Gary J. Schwartz, Ph.D., Nori Geary, Ph.D.

B Dieting and Stress Combine Synergistically to Produce an Animal Model of Binge Eating
Mary M. Hagan, Ph.D., Pamela K. Wauford, B.S., Paula C. Chandler, B.S., Rachel J. Placidi, M.A., Kimberly D. Oswald, B.S., Jason B. Viana, B.S.

C An Animal Model of Food Addiction That May Relate to Binge Eating or Bulimia
Bartley G. Hoebel, Ph.D., Carlo Colantuoni, A.B., Nicole N. Avena, A.B., Pedro Rada

D Symptom Profiles and 5HT Regulation in Bulimia Nervosa
David C. Jimerson, M.D., Barbara E. Wolfe, Ph.D., Eran D. Metzger, M.D.

E Inhibitory and Excitatory Controls of Eating in Patients With Eating Disorders
Michael J. Devlin, M.D., B. Timothy Walsh, M.D., Diane A. Klein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 47 2:00 p.m.-5:00 p.m.
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

WHAT EVERY PSYCHIATRIST NEEDS TO KNOW ABOUT HIV/AIDS

Chp.: Francine Cournos, M.D.

A HIV Treatment Update
Roy M. Gulick, M.D.

B Ten Things You Need to Know About Brain Dysfunction
Stephen J. Ferrando, M.D.

C Five Things You Need to Know: Drug-Drug Interactions
Marshall Forstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 48 2:00 p.m.-5:00 p.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

PERSONALITY DISORDERS IN THE WORKPLACE

Chp.: James H. Reich, M.D.
Co-Chp.: Per Vaglum, M.D.

A Personality, Job Stress, and Mental Health Among Physicians
Per Vaglum, M.D.

B Avoidant and Dependent Personality Traits in the Workplace
James H. Reich, M.D.

C The Relationship Between Personality Disorders and Military Service
Paul S. Links, M.D., D. Randall Boddam, M.D.

D Interventions for Personality Disorders in the Workplace
David P. Bernstein, Ph.D.

E Personality Characteristics That Support Resuming of Interrupted Careers
Elsa F. Ronningstam, Ph.D.

Discussants: Ira D. Glick, M.D., Jack Maser, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 49 2:00 p.m.-5:00 p.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

OBSESSIVE-COMPULSIVE SPECTRUM DISORDERS: UPDATE ON CLINICAL MANAGEMENT

Chp.: Jon E. Grant, M.D.
Co-Chp.: Katharine A. Phillips, M.D.

A Neurobiology of the OCD Spectrum
Dan J. Stein, M.D.

B Obsessive-Compulsive Personality Disorder: Its Treatment and Relationship to OCD
Jane L. Eisen, M.D.

C Update on the Clinical Features and Treatment of BDD
Katharine A. Phillips, M.D.

D Identifying and Treating Hypochondriasis
Jonathan Abramowitz, Ph.D.

E Clinical Management of Pathological Gambling and Kleptomania
Jon E. Grant, M.D.

Discussant: Eric Hollander, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 50 2:00 p.m.-5:00 p.m.
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

GENETIC CORRELATES IN BIPOLAR DISORDERS

Chp.: Joseph F. Goldberg, M.D.
Co-Chp.: Anil K. Malhotra, M.D.

A Phenotype in Genetic Studies of Bipolar Disorder
Martin Alda, M.D.

B Pharmacogenetics of Bipolar Disorder
Anil K. Malhotra, M.D., Youssef Hasroun, M.D., Joseph F. Goldberg, M.D.

C Bipolar Disorder and Alcohol Abuse: Are There Shared Genetic Contributions?
Joseph F. Goldberg, M.D.

D Genetics of Suicidal Behavior in Bipolar Disorder
Maria A. Oquendo, M.D., J. John Mann, M.D.

E Genetic Evidence for a Bipolar Spectrum
J. Raymond DePaulo, Jr., M.D.
THIS SESSION WILL BE AUDIOTAPED.

TUESDAY

SYMPOSIUM 51 2:00 p.m.-5:00 p.m.

Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

CRITICAL PERSPECTIVES ON GENDER IDENTITY DISORDER IN CHILDREN AND ADOLESCENTS

Chp.: Richard R. Pleak, M.D.

A Diagnosing Gender-Atypical Youth: A History of Gender Identity Disorder in Childhood

Karl E. Bryant, M.A.

B Historical and Ethical Perspectives on Gender-Atypical and Transgender Youth

Richard R. Pleak, M.D.

C Transgender Teens: Gender Atypicality at Puberty and Beyond

Sarah E. Herbert, M.D.

D Gender Variance in Children and Adolescents: A Critical Reinterpretation of Case Studies

Darryl B. Hill, Ph.D.

E Childhood Gender Identity Disorder: What Should We Treat and Why?

Edgardo J. Menvielle, M.D., Catherine Tuerk, R.N.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 52 2:00 p.m.-5:00 p.m.

Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis

THE ART AND SCIENCE OF BRIEF THERAPIES

Chp.: Mantosh J. Dewan, M.D.

A Solution-Focused Brief Therapy: Doing What Works

Brett Steenbarger, Ph.D.

B Brief Behavior Therapy

Edna B. Foa, Ph.D.

C Cognitive Therapy: Practice and Training

Judith S. Beck, Ph.D.

D The Impact of Common Factors on Psychotherapy Outcomes

Roger P. Greenberg, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 53 2:00 p.m.-5:00 p.m.

Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

THE BOUNDARIES OF BPD

Chp.: Joel F. Paris, M.D.

A A New Examination of the Interface Between BPD and MDD

John G. Gunderson, M.D.

B Borderline or Bipolar?

Donald W. Black, M.D.

C Substance Abuse and Its Relationship to Remission From BPD

Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D., John Hennen, Ph.D., D. Bradford Reich, M.D.

D Why Psychiatrists Do Not Diagnose BPD

Joel F. Paris, M.D.

Discussant: Thomas H. McGlashan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 54 2:00 p.m.-5:00 p.m.

Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

ANTICONVULSANTS FOR TREATING MULTIPLE COMPONENTS OF ALCOHOL-DEPENDENCE SYNDROME

Chp.: Bankole A. Johnson, M.D.

Co-Chp.: Robert M. Swift, M.D.

A What Are the Critical Neurobiological Substrates Involved in the Development of Alcohol-Dependence?

Raymond F. Anton, Jr., M.D.

B What Is the Utility of Various Classes of Pharmacological Agents in Treating Different Components of the Alcohol-Dependence Syndrome?

Robert M. Swift, M.D., George Kenna, Ph.D.

C What Is the Effectiveness of Various Classes of Pharmacological Agents at Reducing Craving for Alcohol?

Nassima Ait-Daoud, M.D.

D How Effective Are Anticonvulsants at Treating Alcohol-Withdrawal Symptoms?

Robert J. Malcolm, Jr., M.D., Hugh Myrick, M.D., Elizabeth Noll, M.S.W., Brent Taylor

E How Effective Are Anticonvulsants at Improving the Overall Clinical Picture of Alcohol Dependence?

Bankole A. Johnson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 55 2:00 p.m.-5:00 p.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

**ADHD SUBTYPES AND SUBGROUPS AT RISK FOR
 SUBSTANCE USE DISORDERS**

Collaborative Session With the National Institute on Drug Abuse

Chp.: Naimah Z. Weinberg, M.D.

A Subtypes of ADHD Youth At Risk for Substance Abuse
 Timothy E. Wilens, M.D.

**B Childhood ADHD, Comorbidity, and Risk for Late-
 Adolescent Drug Abuse**
 Ken C. Winters, Ph.D., Gerald August, Ph.D., George M.
 Realmuto, M.D.

**C Developmental Twin Studies of Relations Between
 Substance Use and ADHD**
 James J. Hudziak, M.D., Dorett Boomsma, M.D., Richard D.
 Todd, M.D.

**D Variability in Risk for Substance Use and Disorder
 Among Children Diagnosed With ADHD**
 Brooke S.G. Molina, Ph.D., William E. Pelham, Jr., Ph.D.,
 Elizabeth M. Gnagy, B.S.

**E Behavioral and Cognitive Predictors of Adolescent
 Substance Use in Children With ADHD**
 Jeffrey Halperin, Ph.D., Seth Hart, M.S., Nicole Thorn, B.A.,
 Jeffrey H. Newcorn, M.D.

**F Long-Term Follow-Up of Childhood ADHD:
 Development of Adult Substance Abuse**
 F. Xavier Castellanos, M.D., Rachel G. Klein, Ph.D.,
 Sal Mannuzza, Ph.D., John L. Moulton, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 56 2:00 p.m.-5:00 p.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

**ALCOHOLICS ANONYMOUS AND SPIRITUALLY
 ORIENTED RECOVERY**

Chp.: Marc Galanter, M.D.
Co-Chp.: Edgar Nace, M.D.

A Research on Spirituality's Role in Recovery
 Marc Galanter, M.D.

**B The Effectiveness of AA: Empirical Research
 Perspectives**
 Barbara S. McCrady, Ph.D.

C The Interaction Between AA and Personality Disorder
 Edgar Nace, M.D.

D Integrating AA and Psychotherapy
 Richard K. Ries, M.D.

Discussants: Kathleen T. Brady, M.D., Michael H. Gendel, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 57 2:00 p.m.-5:00 p.m.

**Marquis Ballroom Salons A/B, Ninth Floor, Marriott
 Marquis**

**AN UPDATE ON PARKINSON'S DISEASE AND ITS
 PSYCHIATRIC COMPLICATIONS**

Chp.: Matthew A. Menza, M.D.

**A Parkinson's Disease: Update on Treatment, Etiology, and
 Pathogenesis**
 Margery Mark, M.D.

B Depression in Parkinson's Disease
 Jeffrey L. Cummings, M.D.

C Psychosis in Parkinson's Disease
 Laura Marsh, M.D.

**D Cognitive Impairment, Dementia, and Parkinson's
 Disease**
 Iracema Leroi, M.D.

**E Anxiety, Fatigue, and Sleep in Patients With Parkinson's
 Disease**
 Matthew A. Menza, M.D.

Discussant: Constantine Lyketsos, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 58 2:00 p.m.-5:00 p.m.

Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

UNIPOLAR MDD: INTERNATIONAL UPDATE
APA Council on Global Psychiatry

Chp.: Lewis L. Judd, M.D.
Co-Chp.: Juan J. Lopez-Ibor, Jr., M.D.

A MDD: A New Paradigm of Understanding and Treatment
 Lewis L. Judd, M.D.

**B A Psychobiological Model of Depression: Implications for
 Treatment**
 Hagop S. Akiskal, M.D.

**C Predictive Factors in Resistant Depression: New
 European Data**
 Julien Mendlewicz, M.D.

D A New Public Health Agenda for Depression
 Norman Sartorius, M.D.

Discussants: Giovanni B. Cassano, M.D., Costas Stefanis, M.D.
THIS SESSION WILL BE AUDIOTAPED.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 7

3:00 p.m.-5:00 p.m.

Galleria, Level 4, Javits Center

**CHILD AND ADOLESCENT PSYCHIATRY,
PSYCHOTHERAPIES, AND OUTCOME STUDIES**

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 43-49

INDUSTRY-SUPPORTED SYMPOSIUM 43

7:00 p.m.-10:00 p.m.

Grand Ballroom East, Third Floor, Hilton New York

**EMOTION REGULATION AND PLASTICITY OF
UNDERLYING CIRCUITRY: IMPLICATIONS FOR
DEPRESSION, ANXIETY, AND LONG-TERM BRAIN
FUNCTION**

Supported by Wyeth Pharmaceuticals

Chp.: Ned H. Kalin, M.D.

**A Amygdala and Prefrontal Cortical Interactions in
Emotion Regulation and Psychopathology**
Ned H. Kalin, M.D.

B Hippocampal Size in Depression: Cause and Effect
Alan F. Schatzberg, M.D.

**C Experience-Dependent Effects on Structural-Plasticity in
Limbic and Cortical Structures Involved in Emotion
Regulation**
Elizabeth Gould, Ph.D.

**D The Human Amygdala: Vigilance, Threat Assessment,
and Psychopathology**
Paul Whalen, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 44

7:00 p.m.-10:00 p.m.

Westside Ballroom 1-2, Fifth Floor, Marriott Marquis

**CHALLENGES IN TREATING BIPOLAR ILLNESS AND
COMORBID DISORDERS**

Supported by Abbott Laboratories

Chp.: Lori L. Davis, M.D.

A Evidence-Based Utilization of Antiepileptic Drugs
S. Nassir Ghaemi, M.D.

**B Integrated Treatment of Bipolar Disorder in Children and
Adolescents**
Kiki D. Chang, M.D.

**C Bipolar Disorders in Women: Clinical and Metabolic
Correlates**
Natalie L. Rasgon, M.D.

**D Recognizing and Treating Comorbid Depression and
Anxiety in Bipolar Disorder**
Lori L. Davis, M.D.

**E The Challenge of Treating Bipolar Disorder and
Substance Abuse**
Mark A. Frye, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 45

7:00 p.m.-10:00 p.m.

Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

**DOES THE PHARMACOLOGY OF ANTIDEPRESSANT
DRUGS MATTER?**

Supported by GlaxoSmithKline

Chp.: Maurizio Fava, M.D.

**A Antidepressant Treatment and the Effect of Medical and
Psychiatric Comorbidity**
Dan V. Iosifescu, M.D.

**B Response Versus Remission: Are There Meaningful
Differences Among Antidepressants?**
Michael E. Thase, M.D.

**C Short- and Long-Term Tolerability Issues With
Antidepressants**
Anita L.H. Clayton, M.D.

**D Augmentation and Combination Strategies in Depression:
What Is the Evidence?**
Maurizio Fava, M.D.

**E Translating Mechanisms of Action Into Clinical Outcome
of Depression**
J. Craig Nelson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 46

7:00 p.m.-10:00 p.m.

Broadway Ballroom, Sixth Floor, Marriott Marquis

**PANIC ANXIETY: UNDERSTANDING ITS NATURE
AND NURTURING RECOVERY**

Supported by Forest Laboratories, Inc.

Chp.: Murray B. Stein, M.D.

A Born or Made Anxious? The Role of Temperament and Environment
Murray B. Stein, M.D.

B Born or Made Anxious? Anxiety Disorder Gene Mapping and Identification
Joel Gelernter, M.D.

C Extreme Anxiety and Suicide
David C. Purselle, M.D.

D Understanding and Treating Primary Care Panic Disorder Using a Collaborative Care Approach
Peter P. Roy-Byrne, M.D.

E Choosing Medications for Panic Disorder
Jonathan R.T. Davidson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 47
7:00 p.m.- 10:00 p.m.
Grand Ballroom, Mezzanine Level, Roosevelt

ADULT ADHD DIAGNOSIS AND TREATMENT
Supported by Shire US, Inc

Chp.: Thomas J. Spencer, M.D.

A Adult ADHD: Clinical Overview
Thomas J. Spencer, M.D.

B Understanding and Utilization of Diagnostic Rating Scales
Lenard A. Adler, M.D.

C Cognitive-Behavioral Therapies: Treatments and Outcomes
Stephen P. McDermott, M.D.

D Treatment With Stimulants
Timothy E. Wilens, M.D.

E Treatment With Nonstimulants
James G. Waxmonsky, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 48
7:00 p.m.- 10:00 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York

BINGE-EATING DISORDER: GENES, TREATMENTS, AND CONSEQUENCES
Supported by Ortho-McNeil Pharmaceuticals

Chp.: James I. Hudson, M.D.

A The Neurobiology of Binge-Eating and Obesity
James F. List, M.D.

B Family and Genetic Studies of Binge-Eating Disorder
James I. Hudson, M.D.

C Treatment of Binge-Eating Disorder
B. Timothy Walsh, M.D.

D Psychiatric Comorbidity Associated With Binge-Eating Disorder
Justine K. Lalonde, M.D.

E Addressing Medical Comorbidity Associated With Binge-Eating Disorder
Louis J. Aronne, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 49
7:00 p.m.- 10:00 p.m.
Imperial Ballroom B, Second Floor, Sheraton New York

EXPLORING THE TRUE MORBIDITY OF INSOMNIA
Supported by Neurocrine Biosciences Inc

Chp.: John W. Winkelman, M.D.

A Assessing the Complaint of Insomnia
Mary B. O'Malley, M.D.

B Metabolic and Endocrine Effects of Sleep Deprivation
Eve Van Cauter, M.D.

C Psychiatric Morbidity of Insomnia
Ruth M. Benca, M.D.

D Quality of Life and Health Care Costs in Insomnia
Daniel J. Buysse, M.D.

E Current and Future Treatments of Insomnia
John W. Winkelman, M.D.

PRESIDENTIAL FORUM 9

7:00 p.m.- 10:00 p.m.
Astor Ballroom, Seventh Floor, Marriott Marquis

I AM SAM

Chp.: Marcia Kraft Goin, M.D.
Participants: Jessie Nelson, Daniel J. Siegel, M.D.



AMERICAN PSYCHIATRIC ASSOCIATION – 158TH ANNUAL MEETING

MAY 21-26, 2005

Atlanta, Georgia

CALL FOR PAPERS

PRESIDENT'S THEME:

Psychosomatic Medicine: Integrating Psychiatry & Medicine

Michelle Riba, M.D.

President

Marian I. Butterfield, M.D., Chairperson

Scientific Program Committee

THE SUBMISSION SCHEDULE

Format	Deadline
Industry-Supported Symposium	June 1, 2004
Course	September 7, 2004
Reports	September 7, 2004
Symposium	September 7, 2004
Workshops	Issue: September 7, 2004 Component: September 20, 2004
New Research	December 3, 2004

Incomplete and/or Incorrect Forms Will Not Be Considered.

For complete submission forms, you may download the forms at www.psych.org, click on the Annual Meeting logo, then click on submission forms. You may also contact the APA toll free at 1-888-357-7924, and speak directly with an Answer Center Coordinator.

If you want to volunteer to chair a session, please send a letter to the attention of Dr. Butterfield at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.

WEDNESDAY, MAY 5, 2004

157TH ANNUAL MEETING

7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 50-51

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 50, PART 1

7:00 a.m.-8:30 a.m.

Imperial Ballroom A, Second Floor, Sheraton New York

PTSD: SEARCHING FOR ANSWERS IN TRAUMATIC TIMES

Supported by Cephalon, Inc.

Chp.: Jonathan R.T. Davidson, M.D.

A PTSD: Its Burden and the Toll From Terrorism
Randall D. Marshall, M.D.

B Brain Imaging in PTSD: Going Beyond 5HT
David J. Nutt, M.D.

C Sleep in PTSD and Other Anxiety Disorders
Karl Dohramji, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 51, PART 1

7:00 a.m.-8:30 a.m.

Imperial Ballroom B, Second Floor, Sheraton New York

BIPOLAR DISORDER IN WOMEN: REPRODUCTIVE IMPLICATIONS OF TREATMENT

Supported by GlaxoSmithKline

Chp.: Adele C. Viguera, M.D.

Co-Chp.: Lee S. Cohen, M.D.

A Treatment of Bipolar Illness During Pregnancy
Lee S. Cohen, M.D.

B Bipolar Illness During the Postpartum Period: Update on Treatment
Adele C. Viguera, M.D.

C Treatment of Bipolar Illness in Adolescence: Implications for Younger Women
Janet Wozniak, M.D.

8:00 a.m. Sessions



COURSES 77-85

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 77 8:00 a.m.-12 noon
Concourse B, Concourse Level, Hilton New York

ASSESSING POSITIVE AND NEGATIVE SYMPTOMS IN PSYCHOSIS WITH THE PANSS

Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D.

COURSE 78 8:00 a.m.-12 noon
Concourse E, Concourse Level, Hilton New York

BIOETHICS UPDATE 2004

Director: Edmund G. Howe, M.D.

COURSE 79 8:00 a.m.-12 noon
Bryant Suite, Second Floor, Hilton New York

PSYCHIATRIC CONSULTATION IN LONG-TERM CARE

Director: George T. Grossberg, M.D.

Faculty: Judith H. W. Crosssett, M.D., Abhilash K. Desai, M.D.

COURSE 80 8:00 a.m.-12 noon
Gibson Suite, Second Floor, Hilton New York

INSANITY DEFENSE EVALUATIONS

Director: Phillip J. Resnick, M.D.

COURSE 81 8:00 a.m.-12 noon
Gramercy B, Second Floor, Hilton New York

CONTEMPORARY MALPRACTICE LIABILITY: A PRACTICAL GUIDE

Co-Directors: Eugene M. Lowenkopf, M.D., Abe M. Rychik, J.D.

Faculty: Jacqueline M. Melonas, J.D., Richard G. Hersh, M.D.

WEDNESDAY

COURSE 82 8:00 a.m.-12 noon
Murray Hill B, Second Floor, Hilton New York

PSYCHIATRY IN JAIL

Director: Ole J. Thienhaus, M.D.
Faculty: Melissa P. Piasecki, M.D., Jan Budetti, M.S.W., John N. Chappel, M.D., Richard Horton, M.D.

COURSE 83 8:00 a.m.-12 noon
Nassau Suite A, Second Floor, Hilton New York

**HELPING PARENTS FROM THE INSIDE OUT:
ATTACHMENT, MINDSIGHT, AND THE BRAIN**

Director: Daniel J. Siegel, M.D.

COURSE 84 8:00 a.m.-12 noon
Sutton North, Second Floor, Hilton New York

**INFANTICIDE: A DIALOGUE BETWEEN THE
PSYCHIATRIST AND THE ATTORNEY**

Co-Directors: Margaret G. Spinelli, M.D., Katherine L. Wisner, M.D.
Faculty: George Parnham, J.D.

COURSE 85 8:00 a.m.-5:00 p.m.
Gramercy A, Second Floor, Hilton New York

**OFFICE-BASED BUPRENORPHINE TREATMENT OF
OPIOID-DEPENDENT PATIENTS**

Co-Directors: Thomas R. Kosten, M.D., Eric C. Strain, M.D.
Faculty: Walter Ling, M.D., Laura F. McNicholas, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 3

9:00 a.m.-10:30 a.m.
Rooms 3D06/7, Level 3, Javits Center

**PSYCHIATRIC ISSUES IN THE MANAGEMENT OF
PATIENTS WITH HIV INFECTION**

Moderator: Glenn J. Treisman, M.D.
Presenters: Andrew F. Angelino, M.D., Heidi E. Hutton, Ph.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP
CARD REQUIRED FOR ADMITTANCE.**

**CONTINUOUS CLINICAL CASE CONFERENCE 2:
PART 1**

9:00 a.m.-12 noon
Rooms 3D01/12, Level 3, Javits Center

**TWO HOSPITALIZED PATIENTS WITH REFRACTORY
MOOD DISORDER AND COGNITIVE IMPAIRMENT**

Moderator: Stuart C. Yudofsky, M.D.
Presenters: Richard L. Munich, M.D., Efram Bleiberg, M.D.,
Lauren B. Marangell, M.D., Alice Rogan, M.D., Florence
Kim, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP
CARD REQUIRED FOR ADMITTANCE.**



COURSES 86-90

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 86 9:00 a.m.-4:00 p.m.
Concourse A, Concourse Level, Hilton New York

PSYCHOTHERAPY OF BORDERLINE PERSONALITY

Co-Directors: Otto F. Kernberg, M.D., Frank E. Yeomans, M.D.
Faculty: John F. Clarkin, Ph.D., Eve Caligor, M.D.

COURSE 87 9:00 a.m.-4:00 p.m.
Beekman Parlor, Second Floor, Hilton New York

**THE NEUROENDOCRINOLOGY OF MOOD
DISORDERS**

Co-Directors: Mark A. Frye, M.D., Natalie L. Rasgon, M.D.
Faculty: D. Jeffrey Newport, M.D., Michael Bauer, M.D.,
Catherine A. Roca, M.D., Charles DeBattista, M.D.

COURSE 88 9:00 a.m.-4:00 p.m.
Clinton Suite, Second Floor, Hilton New York

**MONEY MATTERS II: ADVANCED CLINICAL
PRACTICE**

Director: Cecilia M. Mikalac, M.D.

COURSE 89 9:00 a.m.-4:00 p.m.

Murray Hill A, Second Floor, Hilton New York

INTRODUCTION TO COGNITIVE-BEHAVIORAL THERAPY

Co-Directors: Robert M. Goisman, M.D., Philip G. Levendusky, Ph.D.

COURSE 90 9:00 a.m.-4:00 p.m.

Sutton Center, Second Floor, Hilton New York

MED-PSYCH DRUG-DRUG INTERACTIONS

Co-Directors: Scott C. Armstrong, M.D., Kelly L. Cozza, M.D.
Faculty: David M. Benedek, M.D., Jessica R. Oesterheld, M.D.,
Neil B. Sandson, M.D.

DISCUSSION GROUPS 18-19

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 18 Milton Viederman, M.D., on Psychological Engagement During the Consultation Process (*Meet the Authors*)
Rooms 2D02/3, Level 2, Javits Center
- 19 Geetha Jayaram, M.D., on Patient Safety (*For Residents Only*)
Versailles Terrace, Second Floor, Sheraton New York

LECTURES 19-20

LECTURE 19

9:00 a.m.-10:30 a.m.

Rooms 1E07/8, Level 1, Javits Center

Joseph T. Coyle, Jr., M.D.

The Role of Glutamate in the Pathophysiology of Schizophrenia

Chp.: Yoram Barak, M.D.
Co-Chp.: Larry E. Tune, M.D.

From 1991 to 2001, Joseph T. Coyle, Jr., M.D., served as Chairman of the Consolidated Department of Psychiatry at Harvard Medical School, which included the nine hospital programs of psychiatry affiliated with the Medical School. He now holds the Eben S. Draper Chair of Psychiatry and Neuroscience at Harvard. After graduating from Holy Cross College, he received his medical degree from Johns Hopkins School of Medicine in 1969.

Following an internship in pediatrics, he spent three years at the National Institutes of Health as a research fellow in the laboratory of Nobel Prize winner Julius Axelrod, Ph.D. He returned to Hopkins in 1973 to complete his Psychiatric residency, in which he is board certified, and joined the faculty. In 1980, he was promoted to Professor of Neuroscience, Pharmacology and Psychiatry; and in 1982 he assumed the Directorship of the Division of Child and Adolescent Psychiatry, being named the Distinguished Service Professor in 1985. Dr. Coyle's research interests include developmental neurobiology, mechanisms of neuronal vulnerability, and psychopharmacology. He has published over 500 scientific articles and has edited seven books. He has received NIH funding for his research for nearly 30 years and is the Director of an NIMH Conte Center on the Neurobiology of Schizophrenia. His research contributions have been recognized by the reception of the John Jacob Abel Award from the American Society for Pharmacology and Experimental Therapeutics, the Gold Medal Award from the Society for Biological Psychiatry, the Efron Award from the American College of Neuropsychopharmacology, the Foundation Fund Research Award from the American Psychiatric Association (APA), the McAlpin Award from the National Mental Health Association, the Salmon Award from the New York Academy of Medicine, and the Pasarow Foundation Award for Neuroscience. Dr. Coyle is a Distinguished Fellow of the APA. He is Past-President of the American College of Neuropsychopharmacology (2001) and Past-President (1991) of the Society for Neuroscience, which has over 30,000 members. He sits on over 20 journal editorial boards including *JAMA* and is the Editor-in-Chief of the *Archives of General Psychiatry*, the most highly cited journal in the field.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 20

9:00 a.m.-10:30 a.m.

Room 1E15, Level 1, Javits Center

APA'S SIMON BOLIVAR AWARD LECTURE

Andres J. Pumariega, M.D.

Latino Youth in the U.S.: Developmental and Mental Health Challenges

Chp.: Ana E. Campo, M.D.

Andres J. Pumariega, M.D., is Professor and Director of Child and Adolescent Psychiatry at East Tennessee State University (ETSU) in Johnson City, Tennessee; and Director of the ETSU Center of Excellence for Children

(Continued on next page)

in State Custody. Dr. Pumariega chairs the Community Psychiatry Committee and was the founding Chair of the Work Group on Community-Based Systems of Care of the American Academy of Child and Adolescent Psychiatry (AACAP); was a member of the National Advisory Council for the Center for Mental Health Services (CMHS); and chaired the Latino Panel for the CMHS Managed Care Initiative; and is a member of the Board of Directors of the American Association of Community Psychiatrists (AACP). He is the author of more than 100 scientific papers, book chapters, and monographs, mostly focusing on community child psychiatry and cross-cultural mental health. His books include *Clinical Assessment of Child and Adolescent Behavior* (co-edited with H. Vance) and *Handbook of Child and Adolescent Systems of Care: The New Community Psychiatry* (co-edited with N. Winters). A Distinguished Fellow of the American Psychiatric Association and a Fellow of AACAP, Dr. Pumariega has received numerous awards, including the Outstanding Mentor Award and the Ethics in Managed Care Award from the AACP, and the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill. Dr. Pumariega received his medical degree from the University of Miami and completed his residency in psychiatry and a fellowship in child and adolescent psychiatry at Duke University Medical Center in Durham, North Carolina.
THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 8-9

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

8 **Susan D. Block, M.D.**, on Psychiatric Issues and Interventions at the End of Life
 Room 1D04, Level 1, Javits Center

9 **Michael D. Garrett, M.D.**, on Can the Ordinary Mind Empathize With Psychotic Experiences?
 Room 1D05, Level 1, Javits Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

REVIEW OF PSYCHIATRY: SECTION 3

9:00 a.m.-12:30 p.m.

Special Events Hall 1D, Level 1, Javits Center

DEVELOPMENTAL PSYCHOBIOLOGY

Chp.: B.J. Casey, Ph.D.

11 **Developmental Psychobiology: An Overview**
 B.J. Casey, Ph.D.

12 **Withdrawn**

13 **The Developmental Psychobiology of Early Attachment**
 Myron Hofer, M.D.

14 **The Developmental Neurobiology of Face Perception**
 Charleston Nelson, Ph.D., Lisa Scott, B.S.

15 **Developmental Psychobiology of Tourette's Syndrome**
 Kathy A. Gallardo, M.D., James E. Swain, M.D., James F. Leckman, M.D.

WORKSHOPS

COMPONENTS 33-41

COMPONENT WORKSHOP 33 9:00 a.m.-10:30 a.m.
 Room 1D06, Level 1, Javits Center

TERRORISM IN AMERICA: THE DISTANT VICTIMS AND THE ROLE OF IMG PSYCHIATRISTS
APA Committee on International Medical Graduates

Co-Chps.: Fructuoso R. Irigoyen-Rascon, M.D., Godehard Oepen, M.D.
 Participants: Jose M. Canive, M.D., Chowallur D. Chacko, M.D.

COMPONENT WORKSHOP 34 9:00 a.m.-10:30 a.m.
 Rooms 2D10/11, Level 2, Javits Center

CPT CODING AND DOCUMENTATION UPDATE
APA Committee on RBRVS, Codes, and Reimbursements

Chp.: Chester W. Schmidt, Jr., M.D.
 Participants: Tracy R. Gordy, M.D., Edward Gordon, M.D., Napoleon B. Higgins, Jr., M.D., Melodie Morgan-Minott, M.D., Joseph M. Schwartz, M.D.

COMPONENT WORKSHOP 35 9:00 a.m.-10:30 a.m.
 Rooms 2D12/13, Level 2, Javits Center

THE PSYCHIATRIST IN THE SCHOOLS: MEDICATION, BOUNDARIES, AND TRANSFERENCE ISSUES
APA Corresponding Committee on Mental Health and Schools

Chp.: Eugenio M. Rothe, M.D.
 Participants: Hong Shen, M.D., Mary Ann Schaepper, M.D., Trina B. Allen, M.D.

COMPONENT WORKSHOP 36 9:00 a.m.-10:30 a.m.
 Rooms 2D14/15, Level 2, Javits Center

TAKING THE FIRST STEP: WHAT ARE MY OPTIONS IN THE TRANSITION TO PRACTICE?
APA Assembly Committee of Early Career Psychiatrists

Chp.: Murali Gopal, M.D.
 Participants: Jeffrey A. Naser, M.D., Matthew W. Norman, M.D., Angeliue D. Goodhue, M.D., Adam R. Chester, D.O.

COMPONENT WORKSHOP 37 9:00 a.m.-10:30 a.m.
O'Neill Room, Fourth Floor, Marriott Marquis

APA ETHICS PROCEDURES
APA Ethics Appeal Board

Chp.: Wade C. Myers, M.D.
Participants: William Arroyo, M.D., Harriet C. Stern, M.D.,
 Donald G. Langsley, M.D., Spencer Eth, M.D., Laura W.
 Roberts, M.D., Nada L. Stotland, M.D., Richard D. Milone, M.D.

COMPONENT WORKSHOP 38 9:00 a.m.-10:30 a.m.
Ziegfeld Room, Fourth Floor, Marriott Marquis

**DOLLARS: THE PHARMACEUTICAL INDUSTRY IN
 PSYCHIATRIC TRAINING**
APA Committee of Residents and Fellows

Co-Chps.: William C. Wood, M.D., Geoffrey M. Hopkins, M.D.
Participants: David A. Goldberg, M.D., John B. Herman, M.D.,
 Michael D. Jibson, M.D., Michele T. Pato, M.D., Michael E.
 Thase, M.D.

COMPONENT WORKSHOP 39 9:00 a.m.-10:30 a.m.
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

**REDUCING DISPARITIES IN ACCESS TO
 PSYCHIATRIC CARE: APA PERSPECTIVES**
APA Steering Committee to Reduce Disparities in Access to Psychiatric Care

Co-Chps.: Altha J. Stewart, M.D., Roger D. Walker, M.D.
Participants: Pedro Ruiz, M.D., Francis G. Lu, M.D., Edward F.
 Foulks, M.D., Carl C. Bell, M.D., Patricia I. Ordorica, M.D.,
 Richard K. Harding, M.D.

COMPONENT WORKSHOP 40 9:00 a.m.-10:30 a.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

**NEW CLASSIFICATION OF PSYCHOPATHOLOGY OF
 INFANTS AND YOUNG CHILDREN**
APA Corresponding Committee on Infancy and Early Childhood

Chp.: Irene Chatoor, M.D.
Participants: Thomas F. Anders, M.D., Daniel J. Siegel, M.D.,
 Jean M. Thomas, M.D.

COMPONENT WORKSHOP 41 9:00 a.m.-10:30 a.m.
**Majestic/Music Box/Winter Garden, Sixth Floor, Marriott
 Marquis**

**CONSULTATION AND LEGAL CLARIFICATION IN
 SEXUAL HARASSMENT**
APA New Jersey Psychiatric Association

Co-Chps.: Rita R. Newman, M.D., Annette J. Hollander, M.D.
Participants: Maria T. Lymberis, M.D., David W.
 Garland, Esq., Francine Weiss, Esq.

ISSUES 77-103

ISSUE WORKSHOP 77 9:00 a.m.-10:30 a.m.
Rooms 1E01/2, Level 1, Javits Center

**MIRROR, MIRROR ON THE WALL: AMBITION AND
 THE TEACHING PSYCHIATRIST**
Association for Academic Psychiatry

Co-Chps.: Susan J. Lieff, M.D., Philip R. Muskin, M.D.
Participant: Josepha A. Cheong, M.D.

ISSUE WORKSHOP 78 9:00 a.m.-10:30 a.m.
Rooms 1E03/4/5, Level 1, Javits Center

**THE TRAUMA OF MEDICAL MISTAKES: AN
 EXPERIENTIAL WORKSHOP**

Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
Participants: Rabbi Goldie Milgram, Barry Bub, M.D.

ISSUE WORKSHOP 79 9:00 a.m.-10:30 a.m.
Room 1E09, Level 1, Javits Center

**THE PORTRAYAL OF ECT ON TELEVISION, FILM,
 AND THE INTERNET**

Chp.: Patrick Ying, M.D.

ISSUE WORKSHOP 80 9:00 a.m.-10:30 a.m.
Room 1E10, Level 1, Javits Center

PSYCHODYNAMIC TREATMENT OF DEPRESSION

Chp.: Fredric N. Busch, M.D.
Participants: Marie G. Rudden, M.D., Theodore Shapiro, M.D.

ISSUE WORKSHOP 81 9:00 a.m.-10:30 a.m.
Room 1E11, Level 1, Javits Center

**WHEN USUAL TREATMENTS FAIL: ANTIPSYCHOTIC
 STRATEGIES FOR REFRACTORY SCHIZOPHRENIA**

Chp.: Jean-Pierre Lindenmayer, M.D.
Participants: John W. Rosenberger, M.D., Robert R.
 Conley, M.D., Richard P. Brown, M.D., Leslie L. Citrome, M.D.

ISSUE WORKSHOP 82 9:00 a.m.-10:30 a.m.
Room 1E12, Level 1, Javits Center

**TREATMENT OF PATIENTS WITH DRUG
 DEPENDENCE AND PSYCHIATRIC ILLNESS**
Collaborative Session With the National Institute on Drug Abuse

Co-Chps.: Wilson Compton III, M.D., Roger D. Weiss, M.D.
Participants: Edward V. Nunes, M.D., Alan S. Bellack, Ph.D.,
 Joy M. Schmitz, Ph.D.

WEDNESDAY

ISSUE WORKSHOP 83 9:00 a.m.-10:30 a.m.
Room 1E13, Level 1, Javits Center

KUNDALINI YOGA MEDITATION TECHNIQUES FOR PSYCHIATRIC DISORDERS

Chp.: David Shannahoff-Khalsa, B.A.

ISSUE WORKSHOP 84 9:00 a.m.-10:30 a.m.
Room 1E14, Level 1, Javits Center

PTSD IN THE NEW YORK FIRE DEPARTMENT: BODIES AND MINDS

Chp.: Kevin V. Kelly, M.D.
Participants: Kristina L.N. Jones, M.D., Claire Cammarata, C.S.W.

ISSUE WORKSHOP 85 9:00 a.m.-10:30 a.m.
Room 1E16, Level 1, Javits Center

WOMEN'S MENTAL HEALTH IN TIMES OF TURMOIL: AN INTERNATIONAL PERSPECTIVE

Association of Women Psychiatrists

Chp.: Sylvia W. Olarte, M.D.
Participants: Marta B. Rondon, M.D., Unaiza Niaz, M.D., Ana E. Campo, M.D., Marian I. Butterfield, M.D.

ISSUE WORKSHOP 86 9:00 a.m.-10:30 a.m.
Room 3D02/11, Level 3, Javits Center

MIGRATION AND PROFESSIONAL IDENTITY EXPERIENCE OF ORGANIZING RUSSIAN-AMERICAN PSYCHIATRY

Chp.: Nelly Katsnelson, M.D.
Participants: Rozaliya Vernikov, M.D., Michael L. Melamed, M.D.

ISSUE WORKSHOP 87 9:00 a.m.-10:30 a.m.
Room 3D03/10, Level 3, Javits Center

VASCULAR DEMENTIA: ASSESSMENT, IMAGING, AND TREATMENT

Chp.: F. Moises Gaviria, M.D.
Participants: Neil H. Pliskin, Glenn T. Stebbins, Ph.D., Christopher C. Duros, M.D.

ISSUE WORKSHOP 88 9:00 a.m.-10:30 a.m.
Rooms 3D04/9, Level 3, Javits Center

MEDICAL TRAINING FOR PSYCHIATRISTS: WHAT DO WE NEED TO KNOW?

Chp.: Peter Manu, M.D.
Participants: Raymond E. Suarez, M.D., James L. Levenson, M.D., Bruce R. Levy, M.D., Roger G. Kathol, M.D.

ISSUE WORKSHOP 89 9:00 a.m.-10:30 a.m.
Rooms 3D05/8, Level 3, Javits Center

THE SISSY DUCKLING: THE PERILS OF CHILDHOOD GENDER VARIANCE

Co-Chps.: Edgardo J. Menvielle, M.D., Catherine Tuerk, R.N.

ISSUE WORKSHOP 90 9:00 a.m.-10:30 a.m.
Wilder Room, Fourth Floor, Marriott Marquis

GERIATRIC PSYCHIATRY AROUND THE GLOBE: PRESENT AND FUTURE

Chp.: Dilip V. Jeste, M.D.
Participants: Hugh C. Hendrie, M.D., Kirsten Abelskov, M.D., Alvaro Camacho, M.D., Tonmoy Sharma, M.D.

ISSUE WORKSHOP 91 9:00 a.m.-10:30 a.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

PREMARITAL COUNSELING: THE FACTS OF LIFE AND MORE

Chp.: Lawrence Bryskin, M.D.
Participants: Rabbi Yaakov Neuberger, B.A., Judy Young, B.A., Sophia Simantov, Peshy Neuberger, B.A., Rabbi Shlomo Gissinger, Sori Teitelbaum, B.A.

ISSUE WORKSHOP 92 9:00 a.m.-10:30 a.m.
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

PSYCHOTHERAPY ISSUES THROUGHOUT THE LIFE CYCLE IN ASIAN WOMEN

Chp.: Albert C. Gaw, M.D.
Participants: Alice C. Tso, M.D., Nalini V. Juthani, M.D., Norma C. Panahon, M.D.

ISSUE WORKSHOP 93 9:00 a.m.-10:30 a.m.
Lyceum Room, Fifth Floor, Marriott Marquis

PRACTICAL MANAGEMENT OF MOOD DISORDERS

Co-Chps.: Gary E. Miller, M.D., Richard L. Noel, M.D.
Participant: Georgia Gaiser, PA-C

ISSUE WORKSHOP 94 9:00 a.m.-10:30 a.m.
Palace Room, Sixth Floor, Marriott Marquis

DISSOLVING THERAPEUTIC BARRIERS: SPIRITUALITY GROUP WORK WITH PSYCHIATRIC STAFF

Chp.: C. Paul Yang, M.D.
Participants: Hendry Ton, M.D., Heather M. Hall, M.D.

ISSUE WORKSHOP 95 9:00 a.m.-10:30 a.m.
Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis

GUIDELINE DEVELOPMENT FOR THE ASSESSMENT OF COMPETENCY

Chp.: Thomas S. Zaubler, M.D.
 Participants: Peter M. Bolo, M.D., Cynthia N. Hoen, J.D.

ISSUE WORKSHOP 96 9:00 a.m.-10:30 a.m.
Royale Room, Sixth Floor, Marriott Marquis

INNOVATIONS IN ACADEMIC EMERGENCY PSYCHIATRY

Co-Chps.: William R. Dubin, M.D., Henry W. Weisman, M.D.
 Participants: Brook E. Zitek, D.O., Mahrukh S. Khan, M.D., Robert O'Brien, Harris Strokoff, Margaret A. Minehart, M.D., Carolyn Ulmer, M.S.W., Marcella Maguire, Ph.D.

ISSUE WORKSHOP 97 9:00 a.m.-10:30 a.m.
Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

ADDICTION PSYCHIATRY: SCIENCE, CRAFT, AND SPIRITUALITY

Chp.: Richard J. Frances, M.D.
 Participants: Sheila B. Blume, M.D., Avram H. Mack, M.D., Marc Galanter, M.D., Sheldon I. Miller, M.D., Robert B. Millman, M.D., Edgar Nace, M.D., Lionel P. Solorsh, M.D.

ISSUE WORKSHOP 98 9:00 a.m.-10:30 a.m.
Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

UNDERSTANDING AND TREATING COMPULSIVE SEXUAL BEHAVIOR

Chp.: Eric Hollander, M.D.
 Participants: Eli Coleman, Ph.D., Jon Morgenstern, Ph.D., Frederick Muench, M.A., Jeffrey Parsons, Ph.D., Milton L. Wainberg, M.D.

ISSUE WORKSHOP 99 9:00 a.m.-10:30 a.m.
Gotham Room, Seventh Floor, Marriott Marquis

KENDRA'S LAW BECOMES REALITY: ASSISTED OUTPATIENT TREATMENT IN MANHATTAN

Co-Chps.: Andrew M. Kleiman, M.D., Gary R. Collins, M.D.
 Participant: Jennifer Correale, J.D.

ISSUE WORKSHOP 100 9:00 a.m.-10:30 a.m.
Gramercy Room, Seventh Floor, Marriott Marquis

SEXUAL SATISFACTION AND MENTAL HEALTH IN ORTHODOX JE WISH WOMEN

Co-Chps.: Rachel Yehuda, Ph.D., Michelle E. Friedman, M.D.
 Participant: Talli Rosenbaum, P.P.T.

ISSUE WORKSHOP 101 9:00 a.m.-10:30 a.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

TREATMENT OF ADULT ADHD: COMBINING COGNITIVE AND MEDICAL APPROACHES

Co-Chps.: Anthony L. Rostain, M.D., J. Russell Ramsay, Ph.D.

ISSUE WORKSHOP 102 9:00 a.m.-10:30 a.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

IMPLEMENTING PSYCHOSOCIAL TREATMENTS IN REAL-WORLD SETTINGS

Chp.: Edward Kim, M.D.
 Participants: Elizabeth Vreeland, M.S.N., Anna Marie Toto, M.Ed.

ISSUE WORKSHOP 103 9:00 a.m.-10:30 a.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

CRIMINAL JUSTICE SYSTEM AND SERIOUS MENTAL ILLNESS, PROBLEMS, AND SOLUTIONS

Co-Chps.: Joseph R. Calabrese, M.D., Janet Berry, J.D.
 Participants: Omar Elhaj, M.D., Sol Wachtler, J.D.

MEDIA 5-6

MEDIA WORKSHOP 5 9:00 a.m.-12 noon
Room 1E06, Level 1, Javits Center

Postgenocide Psychological Trauma in Film, *The Summer of Aviya*

Co-Chps.: Maurice Preter, M.D., Harold J. Bursztajn, M.D.
 Participants: Leonti H. Thompson, M.D., Yehuda Nir, M.D., Amira Kohn-Trattner, C.S.W., Gila Almagor

MEDIA WORKSHOP 6 9:00 a.m.-12 noon
Odets Room, Fourth Floor, Marriott Marquis

The Beginning Stages of Couples' Therapy: Video Case Studies

Chp.: Ian E. Alger, M.D.

11:00 a.m. Sessions

DISCUSSION GROUP 20

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

Larry B. Silver, M.D., on Clinical Management of ADHD With Children, Adolescents, and Adults (*Meet the Authors*)
Rooms 2D02/3, Level 2, Javits Center

LECTURES 21-22

LECTURE 21

11:00 a.m.-12:30 p.m.
Rooms 1E07/8, Level 1, Javits Center

Kathleen T. Brady, M.D.

Stress and Relapse to Substance Use Disorders
*Collaborative Session With the National Institute
on Drug Abuse*

Chp.: David W. Brook, M.D.
Co-Chp.: Sheila B. Blume, M.D.

Kathleen T. Brady, M.D., Ph.D., is Professor of Psychiatry at the Medical University of South Carolina in Charleston. She is also Director of Clinical Programs at the Neurosciences Institute, Associate Director of the General Clinical Research Center, and Director of the Addiction Psychiatry Fellowship Program at the Medical University of South Carolina. Dr. Brady became President of the American Academy of Addiction Psychiatry in 2003. The author of more than 150 scientific papers and book chapters, Dr. Brady is Associate Editor of *Substance Abuse* and a member of the Editorial Board of several journals, including *American Journal on Addictions*, *Drug and Alcohol Dependence*, and *American Journal of Drug and Alcohol Abuse*. She has received numerous honors for her work in addiction research, including the Betty Ford Award from the Association for Medical Education and Research in Substance Abuse. Dr. Brady received her medical degree from the Medical University of South Carolina and her doctoral degree in pharmacology from the Medical College of Virginia in Richmond. She completed her residency in psychiatry and an addiction psychiatry fellowship at the Medical University of South Carolina.
Distinguished Psychiatrist Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 22

11:00 a.m.-12:30 p.m.
Room 1E15, Level 1, Javits Center

APA'S ADMINISTRATIVE PSYCHIATRY
AWARD LECTURE

Peter F. Buckley, M.D.

Public Academic Liaison: Pursuit of Best Practices
in a Time of Economic Entrenchment

Chp.: Stuart B. Silver, M.D.

Peter F. Buckley, M.D., is Professor and Chairman of the Department of Psychiatry and Health Behavior at the Medical College of Georgia in Augusta. He formerly was Professor of Psychiatry and Vice Chairman of the Department of Psychiatry at Case Western Reserve University School of Medicine and Medical Director at Northcoast Behavioral Healthcare System, the state adult psychiatric services provider for Cleveland and Toledo, Ohio. Dr. Buckley conducts research on the neurobiology and treatment of schizophrenia. He is the author of more than 200 scientific articles, abstracts, and book chapters and the author or editor of seven books, including *The Neurodevelopmental Basis of Schizophrenia and Sexuality and Serious Mental Illness*. Dr. Buckley is the Editor-in-Chief of the *Journal of Dual Diagnosis* and serves on the editorial board of *Academic Psychiatry*, *Current Psychiatry*, *Drugs of Today*, and *Psychiatric Issues in Emergency Care Settings*. He has received numerous awards for his work, including the Mead Johnson Award from the American College of Neuropsychopharmacology and the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill. Dr. Buckley received his medical training and completed his psychiatry residency and a fellowship in schizophrenia research at University College Dublin School of Medicine in Dublin, Ireland.
THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL
CONSULTATIONS 10-11

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

10 James L. Griffith, M.D., on Engaging Patients' Spiritual Resources in Building Resilience to Relapse of Major Psychiatric Disorders
Room 1D04, Level 1, Javits Center

- 11 **Stephen M. Goldfinger, M.D.**, on Establishing Relationships, Enhancing Adherence, and Improving Outcomes
Room 1D05, Level 1, Javits Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATE 3

11:00 a.m.-12:30 p.m.
Room 1E13, Level 1, Javits Center

BETTER SEX: NATURALLY

Chp.: Philip R. Muskin, M.D.
Presenter: Richard P. Brown, M.D.
THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

- 3 **Jack M. Gorman, M.D.**, on Designing and Implementing Studies Contrasting Psychopharmacology and Psychotherapy
Room 1D03, Level 1, Javits Center

SCIENTIFIC AND CLINICAL REPORT SESSIONS 19-27

SCIENTIFIC AND CLINICAL REPORT SESSION 19
11:00 a.m.-12:30 p.m.
Rooms 1E01/2, Level 1, Javits Center

ALCOHOL ABUSE

Chp.: Harvey Stabinsky, M.D.
Co-Chp.: Robert Kelly, M.D.

- 11:00 a.m.
56 **The Effects of State Income Inequality and Alcohol Tax on Alcohol Dependence**
Claire Henderson, M.D., Xinhua Liu, Ph.D., Ana Diez Roux, Ph.D., Bruce G. Link, Ph.D., Deborah S. Hasin, Ph.D.

- 11:30 a.m.
57 **Effect of Age on Long-Term Outcomes of Inpatient Alcoholism Treatment**
Neelofar Khan, M.D., Elizabeth J. Nickel, M.A., Elizabeth C. Penick, Ph.D., Barbara J. Powell, Ph.D., Barry I. Liskow, M.D., Jan L. Campbell, M.D., Sandra B. Hall

12 noon

- 58 **Topiramate Treatment of Alcohol Dependence: Effects on Psychosocial Functioning and Its Relationship With Heavy Drinking**
Bankole A. Johnson, M.D., Nassima Ait-Daoud, M.D., Jennie Z. Ma, Ph.D., Fatema Z. Akhtar, M.S., John D. Roache, Ph.D., Norman Rosenthal, M.D., Charles L. Bowden, M.D., Carlo C. DiClemente, Ph.D., Martin A. Javors, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 20
11:00 a.m.-12:30 p.m.
Room 1E11, Level 1, Javits Center

CROSS-CULTURAL ISSUES

Chp.: Leslie A. Horton, M.D.
Co-Chp.: Claudio O. Cabrejos, M.D.

11:00 a.m.

- 59 **Prevalence of Maternal Depression in Honduras**
Lawson R. Wulsin, M.D., Eugene C. Somoza, M.D., Miguel Coello, M.D., Jeffrey Heck, M.D., Manuel Sierra

11:30 a.m.

- 60 **Screening for Depression Among Chinese Americans in Primary Care Using Two Items**
Albert Yeung, M.D., Jessica L. Murakami, B.A., Maurizio Fava, M.D., Wendy M. Guyker, B.S., Melissa E. Abraham, Ph.D.

12 noon

- 61 **Suicidal Thinking in Colombian Youth With a History of Attempted Suicide**
Ruby C. Castilla-Puentes, M.D., Wilma I. Castilla-Puentes, M.D., Sandra R. Castilla-Puentes, M.D., Leo Russo, Ph.D., Ivan S. Gomez, M.D., Gilma P. de Contreras, M.S.W., Miguel Habeych, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 21
11:00 a.m.-12:30 p.m.
Room 1E12, Level 1, Javits Center

SUICIDE

Chp.: Douglas G. Jacobs, M.D.
Co-Chp.: Robert M. Davis, M.D.

11:00 a.m.

- 62 **Suicidality and Second-Generation Antipsychotics in Patients With Schizophrenia**
Yoram Barak, M.D., Dov Alzenberg, M.D., Haim Knobler, M.D., Ilona Mirecki, M.D.

(Continued on next page)

11:30 a.m.

- 63 **Melancholia and Suicide Attempt Probability and Lethality**
Michael F. Grunebaum, M.D., Hanga G. Galfalvy, Ph.D.,
Maria A. Oquendo, M.D., Ainsley K. Burke, Ph.D., J. John
Mann, M.D.

12 noon

- 64 **Nonviolent Suicides in Women Are Increased During and After High Exposure to Tree Pollen**
Teodor T. Postolache, M.D., Mark A. Goldstein, B.A.,
Richard Herrell, Ph.D., Srirangam S. Shreeram, M.D.,
Courtney M. Throver, M.A., John W. Stiller, M.D., Hirsh
Kumarow, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 22

11:00 a.m.-12:30 p.m.

Room 3D03/10, Level 3, Javits Center

BIPOLAR DISORDER

Chp.: Robert M. Post, M.D.

Co-Chp.: Candace R. Good, M.D.

11:00 a.m.

- 65 **Characteristics of Patients Treated With Gabapentin Referred to a Bipolar Specialty Clinic**
Michael J. Ostacher, M.D., Heather Schloss, B.A., Lori R.
Eisner, B.A., Andrew A. Nierenberg, M.D.

11:30 a.m.

- 66 **Olanzapine/Fluoxetine Combination: Rapid Onset With Low Risk of Mania**
Sara A. Corya, M.D., Paul E. Keck, Jr., M.D., Michael E.
Thase, M.D., Sanjay Dube, M.D., Susan D. Briggs, Ph.D.,
Michael Case, M.S., Mauricio F. Tohen, M.D.

12 noon

- 67 **Psychotic Features in MDD Are Associated With Mania**
Ekkehard Othmer, M.D., Cheryl DeSouza, M.D.,
Elizabeth J. Nickel, M.A., Edward N. Hunter, Ph.D.,
Elizabeth C. Penick, Ph.D., Sieglinde C. Othmer, Ph.D.,
Barbara J. Powell, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 23

11:00 a.m.-12:30 p.m.

Rooms 3D04/9, Level 3, Javits Center

BIOLOGICAL PSYCHIATRY

Chp.: David A. Casey, M.D.

Co-Chp.: Katherine G. Ruiz-Mellott, M.D.

11:00 a.m.

- 68 **fMRI of Spatial Working Memory in Schizotypal Personality Disorder**
Harold W. Koenigsberg, M.D., Monte S. Buchsbaum, M.D.,
Bradley Buchsbaum, Ph.D., Jason Schneiderman, Cheuk
Tang, Ph.D., Antonia S. New, M.D., Larry J. Siever, M.D.

11:30 a.m.

- 69 **Hypofrontality in Patients With Schizophrenia and Bipolar Disorders: An fMRI Study**
Mircea C. Polosan, M.D., Monica Baciuc, Ph.D., Christoph
Segebarth, Ph.D., Thierry Bougerol, Ph.D.

12 noon

- 70 **Low Levels of Antibodies to Cardiolipin in First-Episode and Chronic Schizophrenia**
Pinkhas Sirota, M.D., Irene Bogdanov, M.D., Aviva
Katzav, M.S.C., Ruth Hershko, M.D., Joab Chapman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 24

11:00 a.m.-12:30 p.m.

Rooms 3D05/8, Level 3, Javits Center

PSYCHOPHARMACOLOGY RESEARCH IN DEPRESSION

Chp.: Susan Stabinsky, M.D.

Co-Chp.: Donld W. Hicks, M.D.

11:00 a.m.

- 71 **Prevalence of MTHFR C677T and Methionine Synthase A2756G Polymorphisms in Major Depression and Impact on Response to Fluoxetine Treatment**
David Mischoulon, M.D., Laura Kean Kramer, M.D.,
Stefania Lamoni-Fava, M.D., Jacob Selhub, Ph.D., Roy H.
Perlis, M.D., Jonathan E. Alpert, M.D., Maurizio Fava, M.D.

11:30 a.m.

- 72 **Oral S-Adenosyl Methionine (SAME) for Antidepressant Augmentation: An Open-Label Trial**
Jonathan E. Alpert, M.D., George I. Papakostas, M.D.,
John J. Worthington III, M.D., Timothy J. Petersen, Ph.D.,
David Mischoulon, M.D., Alana M. Burns, B.A., Teodoro
Bottiglieri, Ph.D., Andrew A. Nierenberg, M.D., Maurizio
Fava, M.D.

12 noon

- 73 **Somatic Symptoms as Predictors of Time to Onset of Response to Fluoxetine in MDD**
George I. Papakostas, M.D., Timothy J. Petersen, Ph.D.,
Dan V. Iosifescu, M.D., Katherine Sklarisky, B.A.,
Andrew A. Nierenberg, M.D., Jonathan E. Alpert, M.D.,
Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 25

11:00 a.m.-12:30 p.m.

Rooms 3D06/7, Level 3, Javits Center

OUTCOMES IN PSYCHOSIS

Chp.: Carol L. Trippitelli, M.D.

Co-Chp.: Mark N. Rudolph, M.D.

11:00 a.m.

74 IC-SOHO: Intercontinental Schizophrenia Outpatient Health Outcomes Study

Martin Dossenbach, M.D., Andrew Hodge, M.S.C., Ruth A. O'Halloran, Ph.D.

11:30 a.m.

75 Male Patients With Schizophrenia Have Impairment in the Processing of Spatial Information From Dissociated Spatial Reference Frames

Miranda H. Chakos, M.D., Yevgeny Gelfand, Andre Fenton, Ph.D., Peter J. Weiden, M.D., Narender Dargani, B.S.

12 noon

76 Predictors of Outcome in 52 Cases of Psychotic Nonaffective Disorders

Mauricio F. Tohen, M.D., Carlos A. Zarate, Jr., M.D., John Hennen, Ph.D., Hari M. Kaur Khalsa, A.B., Paola Salvatore, M.D., Ross J. Baldessarini, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 26

11:00 a.m.-12:30 p.m.

Wilder Room, Fourth Floor, Marriott Marquis

SUBSTANCE ABUSE

Collaborative Session With the National Institute on Drug Abuse

Chp.: Daniel P. Chapman, M.D.

Co-Chp.: Vital N. Shah, M.D.

11:00 a.m.

77 Risk Factors for DSM-IV Cannabis Abuse and Dependence

Jason P. Herrick, B.A., Jakob Meydan, Psy.D., Xinhua Liu, Ph.D., Deborah S. Hasin, Ph.D.

11:30 a.m.

78 Cannabis Use Reduces the Likelihood of Sustained Remission From Other Drugs

Edward V. Nunes, M.D., Efrat Aharonovich, Ph.D., Xinhua Liu, Ph.D., Rivka R. Galchen, M.D., Deborah S. Hasin, Ph.D.

12 noon

79 Substance-Induced Risk for Depression in a Substance-Dependent Population

Rivka R. Galchen, M.D., Xinhua Liu, Ph.D., Efrat Aharonovich, Ph.D., Edward V. Nunes, M.D., Deborah S. Hasin, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 27

11:00 a.m.-12:30 p.m.

Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

ISSUES IN PSYCHIATRIC EPIDEMIOLOGY

Chp.: Nikhil D. Nihalani, M.D.

Co-Chp.: Mark S. Wright, M.D.

11:00 a.m.

80 Ethnicity, Diagnosis, and Health Care Utilization in Incarcerated Women

Catherine F. Lewis, M.D.

11:30 a.m.

81 Psychotropic Drug Utilization in Six European Countries

Giovanni De Girolamo, M.D., Jordi Alonso, M.D., Isabelle Gasquet, Leo Russo, Ph.D., Gemma Vilagut, Gabriella Polidori, M.D., Heather Bryson

12 noon

82 Onset of DSM-IV Alcohol Abuse and Dependence: A 10-Year Prospective Study

Deborah S. Hasin, Ph.D., Xinhua Liu, Ph.D., Jason P. Herrick, B.A.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 42-48

COMPONENT WORKSHOP 42 11:00 a.m.-12:30 p.m.

Room 1D06, Level 1, Javits Center

ONLINE INTERACTION BETWEEN APA, MEMBERS, AND THE PUBLIC

APA Ad Hoc Work Group on Information Systems

Chp.: Robert C. Hsiung, M.D.

Participants: Herbert S. Peyser, M.D., William Bruce, B.A.

COMPONENT WORKSHOP 43 11:00 a.m.-12:30 p.m.

Room 3D02/11, Level 3, Javits Center

RESPONSE TO THE SIMON BOLIVAR AWARD LECTURE ON LATINO YOUTH IN THE U.S.: DEVELOPMENTAL AND MENTAL HEALTH CHALLENGES

APA Committee of Hispanic Psychiatrists

Co-Chps.: Ana E. Campo, M.D., Andres J. Pumariiega, M.D.

Participants: Ian A. Canino, M.D., Pedro Ruiz, M.D., Renato D. Alarcon, M.D.

COMPONENT WORKSHOP 44 11:00 a.m.-12:30 p.m.
O'Neill Room, Fourth Floor, Marriott Marquis

**PSYCHIATRIC ETHICS IN THE U.S. AND
THROUGHOUT THE WORLD**

APA Ethics Committee

Co-Chps.: Spencer Eth, M.D., Driss Moussaoui, M.D.
Participants: Wade C. Myers, M.D., Philip T. Merideth, M.D.,
Ahmed Okasha, M.D., Juan J. Lopez-Ibor, Jr., M.D.

COMPONENT WORKSHOP 45 11:00 a.m.-12:30 p.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

**THE 2004 MEDICARE UPDATE AND MAKING THE
MOST OF THE CARRIER ADVISORY COMMITTEE**

APA Medicare Advisory Corresponding Committee

Chp.: Edward Gordon, M.D.
Participants: Gerald Rogan, M.D., Ellen Jaffe, Seth P.
Stein, J.D.

COMPONENT WORKSHOP 46 11:00 a.m.-12:30 p.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

**IS THERE A STANDARD OF CARE FOR THE
TREATMENT OF DEMENTIA?**

*APA Committee on Access and Effectiveness of Psychiatric Services for the
Elderly*

Chp.: Allan A. Anderson, M.D.
Participants: Marsden H. McGuire, M.D., Julian Offsay, M.D.,
Douglas A. Kalunian, M.D.

COMPONENT WORKSHOP 47 11:00 a.m.-12:30 p.m.
**Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott
Marquis**

**BEND IT LIKE BECKHAM: ASIAN WOMEN,
ACHIEVEMENTS, AND CULTURAL CONFLICTS**

APA Council on Global Psychiatry

Co-Chps.: Ramaswamy Viswanathan, M.D., Jacquelyn B.
Chang, M.D.
Participants: Geetha Jayaram, M.D., Michelle B. Riba, M.D.,
Madelyn H. Hicks, M.D., Madhulika S. Khandelwal, Ph.D.,
Sudeepta Varma, M.D.

COMPONENT WORKSHOP 48 11:00 a.m.-12:30 p.m.
Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

**BUPRENORPHINE IN THE TRENCHES: WHAT THE
GENERAL PSYCHIATRIST NEEDS TO KNOW**

*APA Corresponding Committee on Training and Education in Addiction
Psychiatry and APA Corresponding Committee on Treatment Services for
Patients with Addictive Disorders*

Co-Chps.: Marianne T. Guschwan, M.D., John A.
Renner, Jr., M.D.
Participants: George F. Kolodner, M.D., Samuel M.
Silverman, M.D.

ISSUES 104-119

ISSUE WORKSHOP 104 11:00 a.m.-12:30 p.m.
Rooms 1E03/4/5, Level 1, Javits Center

**INNOVATIVE METHODS OF PROMOTING USE OF
EVIDENCE-BASED PSYCHOPHARMACOLOGY**

Chp.: David N. Osser, M.D.
Participants: Carole C. Upshur, Ed.D., Robert D.
Patterson, M.D., Kenneth O. Jobson, M.D., Richard C.
Hermann, M.D.

ISSUE WORKSHOP 105 11:00 a.m.-12:30 p.m.
Room 1E09, Level 1, Javits Center

**WHEN PSYCHIATRISTS HAVE SUFFERED A MENTAL
ILLNESS: THEIR STORIES AND INSIGHTS**

National Alliance for the Mentally Ill

Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
Participants: Elizabeth A. Baxter, M.D., Marian Fireman, M.D.,
Raymond M. Reyes, M.D., Suzanne E. Vogel-Scibilia, M.D.,
Francine Cournos, M.D., Kay R. Jamison, Ph.D.

ISSUE WORKSHOP 106 11:00 a.m.-12:30 p.m.
Rooms 2D10/11, Level 2, Javits Center

**WILL OUTCOMES EVALUATION AND RESEARCH
INITIATIVES SAVE THE THERAPEUTIC
COMMUNITY?**

Chp.: Gregory C. Bunt, M.D.
Participants: Charles Devlin, George DeLeon, Ph.D., Britta
Muehlbach, M.A., Marc Galanter, M.D.

ISSUE WORKSHOP 107 11:00 a.m.-12:30 p.m.
Rooms 2D12/13, Level 2, Javits Center

**NEGATIVE-SYMP TOM SPECTRUM DISORDERS:
RESPONSE TO PHARMACOTHERAPY OF
ASPERGER'S DISORDER**

Chp.: Elizabeth Sirota, M.D.
Participants: Donna L. Londino, M.D., Jeffrey L. Rausch, M.D.

ISSUE WORKSHOP 108 11:00 a.m.-12:30 p.m.
Rooms 2D14/15, Level 2, Javits Center

**SOMETIMES IT IS ABOUT YOU: THE USE OF SELF IN
ENGAGING AND TREATING HOMELESS
INDIVIDUALS**

Chp.: Marvin A. Nierenberg, M.D.
Participants: Amy Cohen, N.P., Dillon C. Euler, M.D.,
Van Yu, M.D.

ISSUE WORKSHOP 109 11:00 a.m.-12:30 p.m.
Ziegfeld Room, Fourth Floor, Marriott Marquis

MULTIPLE PERSPECTIVES ON THE PATHOLOGICAL FEAR RESPONSE: INTEGRATION OF PSYCHOTHERAPEUTIC AND PSYCHOPHARMACOLOGIC THERAPIES

Co-Chps.: David Steinman, M.D., Jennifer M. Bonovitz, Ph.D.

ISSUE WORKSHOP 110 11:00 a.m.-12:30 p.m.
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

THE DAY I DIED: A NEAR-DEATH DOCUMENTARY AND THE MIND-BRAIN BARRIER

Chp.: B. Jason MacLurg, M.D.

ISSUE WORKSHOP 111 11:00 a.m.-12:30 p.m.
Lyceum Room, Fifth Floor, Marriott Marquis

WHAT LOVE HAS TO DO WITH IT: EXPLORING THE ROLE OF LOVE IN MENTAL ILLNESS

Co-Chps.: Robert W. Hierholzer, M.D., Bita Ghafoori, Ph.D.

ISSUE WORKSHOP 112 11:00 a.m.-12:30 p.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

PSYCHIATRY AND HOMELAND SECURITY: AN EXERCISE IN WEAPONS OF MASS DESTRUCTION RESPONSE PLANNING

Co-Chps.: Larry H. Pastor, M.D., Dickson S. Diamond, M.D.
Participant: Richard T. Keller, R.N.

ISSUE WORKSHOP 113 11:00 a.m.-12:30 p.m.
Royale Room, Sixth Floor, Marriott Marquis

FITNESS-FOR-DUTY EVALUATIONS FOR LAW-ENFORCEMENT OFFICERS

Chp.: Marilyn Price, M.D.
Participants: Debra A. Pinals, M.D., Bernice Kelly, Psy.

ISSUE WORKSHOP 114 11:00 a.m.-12:30 p.m.
Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

EVALUATING TREATMENT WITH FUNCTIONAL BRAIN IMAGING

Co-Chps.: Daniel G. Amen, M.D., Joseph C. Wu, M.D.
Participant: Barton J. Blinder, M.D.

ISSUE WORKSHOP 115 11:00 a.m.-12:30 p.m.
Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

SUICIDE AND SCHIZOPHRENIA: A FAMILY INTERVIEW

Chp.: Paul A. Kettl, M.D.

ISSUE WORKSHOP 116 11:00 a.m.-12:30 p.m.
Gotham Room, Seventh Floor, Marriott Marquis

ETHICAL AND PRACTICAL CHALLENGES IN EMERGENCY PSYCHIATRIC RESEARCH

Co-Chps.: Rebecca W. Brendel, M.D., Melissa E. Abraham, Ph.D.
Participant: Lawrence T. Park, M.D.

ISSUE WORKSHOP 117 11:00 a.m.-12:30 p.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

DEVELOPING A COMMUNITY MENTAL HEALTH RESPONSE TO DISASTERS AND TERRORISM

Co-Chps.: John W. Burruss, M.D., Jennifer E. Pate, M.D.
Participant: Meg Crady

ISSUE WORKSHOP 118 11:00 a.m.-12:30 p.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

JUVENILE-JUSTICE SUCCESS SERIES, CHAPTER 1: MUSICIANSHIP, JAZZ, AND BLUES

Chp.: Cheryl D. Wills, M.D.

ISSUE WORKSHOP 119 11:00 a.m.-12:30 p.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

POLITICS AND PREGNANCY: THE REGINA MCKNIGHT CASE

Chp.: Andrea G. Stolar, M.D.
Participants: David J. McDowell, Ph.D., Lynn M. Paltrow, J.D.

12 noon Sessions

FORUMS 10-11

FORUM 10 12 noon-1:30 p.m.
Room 1E10, Level 1, Javits Center

BUPRENORPHINE: WHAT THE CLINICIAN SHOULD KNOW

Chp.: Herbert D. Kleber, M.D.
Participants: David M. McDowell, M.D., Roberta Sales, R.N., Erik W. Gunderson, M.D., Patricia I. Ordorica, M.D.

FORUM 11 12 noon-1:30 p.m.
 Astor Ballroom, Seventh Floor, Marriott Marquis

9/11 RESEARCH: A REVIEW AND REVIEWS

Chp.: Anand Pandya, M.D.
Participants: Carol S. North, M.D., Craig L. Katz, M.D., Sandro Galea, M.D., Ezra S. Susser, M.D.

NEW RESEARCH POSTER SESSION 8

12 noon-2:00 p.m.
 Galleria, Level 4, Javits Center

**SCHIZOPHRENIA AND PSYCHOTIC DISORDERS,
 AND BRAIN IMAGING**

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

1:00 p.m. Sessions



COURSES 91-97

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 91 1:00 p.m.-5:00 p.m.
 Concourse B, Concourse Level, Hilton New York

PSYCHIATRY AND THE INTERNET
American Association for Technology and Psychiatry

Co-Directors: Robert S. Kennedy, M.A., Thomas A.M. Kramer, M.D.

COURSE 92 1:00 p.m.-5:00 p.m.
 Concourse E, Concourse Level, Hilton New York

**THE CLINICAL APPLICATION OF CULTURAL
 PSYCHIATRY**

Director: Wen-Shing Tseng, M.D.
Faculty: J. David Kinzie, M.D., Keh-Ming Lin, M.D., Jon M. Streltzer, M.D., Joseph J. Westermeyer, M.D.

COURSE 93 1:00 p.m.-5:00 p.m.
 Bryant Suite, Second Floor, Hilton New York

**MEN SEXUALLY ABUSED AS BOYS: MEANINGS,
 CONSEQUENCES, AND TREATMENT**

Director: Murray D. Schane, M.D.
Faculty: Howard Fradkin, Ph.D., Bill Bumester, M.A., William Holmes, M.D., Kenneth Singer, M.S.W.

COURSE 94 1:00 p.m.-5:00 p.m.
 Gibson Suite, Second Floor, Hilton New York

DELIRIUM IN THE GENERAL HOSPITAL

Director: Peter J. Manos, M.D.
Faculty: J. H. Atkinson, Jr., M.D., William Breitbart, M.D., Edwin H. Cassem, M.D.

COURSE 95 1:00 p.m.-5:00 p.m.
 Gramercy B, Second Floor, Hilton New York

**INTEGRATING PSYCHOTHERAPY AND
 PHARMACOTHERAPY**

APA Committee on Psychotherapy by Psychiatrists

Director: Barton J. Blinder, M.D.
Faculty: Bernard D. Beitman, M.D., Jerald Kay, M.D.

COURSE 96 1:00 p.m.-5:00 p.m.
 Murray Hill B, Second Floor, Hilton New York

**STREET DRUGS AND MENTAL DISORDERS:
 OVERVIEW AND TREATMENT**

Director: John W. Tsuang, M.D.
Faculty: Thomas Newton, M.D., Karen A. Miotto, M.D.

COURSE 97 1:00 p.m.-5:00 p.m.
 Sutton North, Second Floor, Hilton New York

**I FOUND IT AT THE MOVIES: USING FILM CLIPS TO
 UNDERSTAND AND TEACH PSYCHIATRY**

Director: Frederick W. Engstrom, M.D.

2:00 p.m. Sessions

LECTURES 23-24

LECTURE 23

2:00 p.m.-3:30 p.m.
 Rooms 1E07/8, Level 1, Javits Center

Helen E. Fisher, Ph.D.

The Brain In Love

Chp.: Philip R. Muskin, M.D.

Helen E. Fisher, Ph.D., is Research Professor and Member of the Center for Human Evolutionary Studies in the Department of Anthropology at Rutgers University in New Brunswick, New Jersey. Dr. Fisher

has lectured widely on the evolution of human sexuality, romance and family life, and gender differences in the brain and behavior. Her most recent book *Why We Love: The Nature and Chemistry of Romantic Love* is based in part on research on brain physiology conducted with colleagues at the Albert Einstein College of Medicine and the State University of New York at Stony Brook. Her other books include *The First Sex: The Natural Talents of Women and How They Are Changing the World*; *Anatomy of Love: The Natural History of Monogamy, Adultery, and Divorce*; and *The Sex Contract: The Evolution of Human Behavior*. Dr. Fisher has served as an anthropological commentator and consultant for businesses and the media, including the BBC, NBC's "Today Show," WNET-TV (New York), the Canadian Broadcasting Corporation, *Reader's Digest*, and Time-Life Books. She has been honored with the Distinguished Service Award of the American Anthropological Association for her work in communicating anthropology to the broad public audience. Dr. Fisher received her doctorate in physical anthropology at the University of Colorado in Boulder. **THIS SESSION WILL BE AUDIOTAPED.**

LECTURE 24

2:00 p.m.-3:30 p.m.
Room 1E15, Level 1, Javits Center

APA/NIMH VESTERMARK PSYCHIATRY
EDUCATOR AWARD LECTURE

Eugene V. Beresin, M.D.

Striking Accord:
Tales of Teaching and the Heart

Chp.: Richard Balon, M.D.

Eugene V. Beresin, M.D., is Associate Professor of Psychiatry at Harvard Medical School and Director of the Consolidated Massachusetts General Hospital and McLean Hospital Child and Adolescent Psychiatry Residency Training Program in the Boston area. He is also Medical Director of the Massachusetts General Hospital Child and Adolescent Psychiatry Outpatient Clinic, Co-Director of the Harvard Medical School Center for Mental Health and Media, and Director of the Elizabeth Thatcher Acampora Endowment, an outreach program for underserved youth and families. Dr. Beresin is Media Editor for *Academic Psychiatry*, and Editor of the Child Psychiatry Residents In-Training Examination (Child PRITE), and has been appointed as the next Editor-in-Chief of PRITE. A former President of the American Association of Directors of Psychiatry Residency Training, Dr. Beresin has won a number of local and national teaching awards, including the Parker J. Palmer "Courage to Teach" Award of the Accreditation Council of Graduate Medical Education. He received his medical degree from the University of Pennsylvania

School of Medicine in Philadelphia, and completed his residency in psychiatry at Massachusetts General Hospital, and his residency in child psychiatry at Children's Hospital Medical Center and Judge Baker Guidance Center in Boston.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIUM 3

2:00 p.m.-5:00 p.m.
Room 1E11, Level 1, Javits Center

RECONSTRUCTING POSTWAR MENTAL HEALTH SERVICES

American Psychiatric Association and the World Psychiatric Association

Chp.: Marcia Kraft Goin, M.D.
Co-Chp.: Rodrigo A. Munoz, M.D.

- A **Wars and Mental Health in Iraq**
Abdul M. Al-Jadiry, M.D.
- B **Mental Health in Iraq and the U.S. Military**
Elspeth C. Ritchie, M.D.
- C **Strategies for Post-War Rehabilitation of Mental Health Services: Focusing on Iraq**
Ahmed Okasha, M.D.

Discussants: Norman Sartorius, M.D., Norwood Knight-Richardson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

REVIEW OF PSYCHIATRY: SECTION 4

2:00 p.m.-5:30 p.m.
Special Events Hall 1D, Level 1, Javits Center

DEEP BRAIN STIMULATION IN PSYCHIATRIC TREATMENT

Chp.: Sarah H. Lisanby, M.D.

- 16 **Transcranial Magnetic Stimulation in Depression**
Thomas E. Schlaepfer, M.D., Markus Kosel, M.D.
- 17 **Transcranial Magnetic Stimulation Studies of Schizophrenia and Other Disorders**
Ralph E. Hoffman, M.D.
- 18 **Deep Brain Stimulation in Psychiatry**
Benjamin D. Greenberg, M.D.
- 19 **Vagus Nerve Stimulation in Psychiatry**
Harold A. Sackeim, Ph.D.
- 20 **Magnetic Seizure Therapy: Development of a Novel Convulsive Technique**
Sarah H. Lisanby, M.D.

SYMPOSIA 59-89

SYMPOSIUM 59 2:00 p.m.-5:00 p.m.

Rooms 1E01/2, Level 1, Javits Center

WHAT YOU NEED TO KNOW ABOUT TREATMENT OF HIV-RELATED DISORDERS

Chp.: Marshall Forstein, M.D.

- A **Treating Mood Disorders**
Warren M. Liang, M.D.
- B **Treating Anxiety**
Antoine B. Douaihy, M.D.
- C **Treating Psychosis**
Shahrad Rod Amiri, M.D.
- D **Treating Sleep**
Marshall Forstein, M.D.
- E **Treating Pain**
Philip Bialer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 60 2:00 p.m.-5:00 p.m.

Rooms 1E03/4/5, Level 1, Javits Center

CHOOSING THE BEST TREATMENT FOR SUBSTANCE ABUSE

Collaborative Session With the National Institute on Drug Abuse

Chp.: Herbert D. Kleber, M.D.

Co-Chp.: David M. McDowell, M.D.

- A **Choosing the Right Treatment for Opioid Dependence**
Herbert D. Kleber, M.D.
- B **Choosing the Best Treatment for Cocaine Dependence**
Adam M. Bisaga, M.D.
- C **Choosing the Best Treatment: Marijuana and Club Drugs**
David M. McDowell, M.D.
- D **Treatment of Comorbid Conditions**
Frances R. Levin, M.D., Suzette M. Evans, Ph.D.,
Herbert D. Kleber, M.D.
- E **Choosing the Best Treatment for Psychosocial Interventions**
Jami Rothenberg, Ph.D.

Discussant: Edward V. Nunes, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 61

2:00 p.m.-5:00 p.m.

Room 1E09, Level 1, Javits Center

PRACTICAL TECHNIQUES IN THE ASSESSMENT AND TREATMENT OF TOBACCO DEPENDENCE

Collaborative Session With the National Institute on Drug Abuse

Chp.: Jill Williams, M.D.

- A **Assessment of Tobacco Dependence**
Jonathan Foulds, Ph.D.
- B **Motivational Assessment and Enhancement Strategies in Tobacco Treatment**
Jonathan Krejci, Ph.D.
- C **Pharmacotherapy Treatments for Tobacco Dependence**
Jill Williams, M.D.
- D **Psychosocial Treatment of Tobacco Dependence in Mental Health Settings**
Marc L. Steinberg, Ph.D.
- E **Addressing Tobacco Through Program and System Changes**
Douglas M. Ziedonis, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 62

2:00 p.m.-5:00 p.m.

Room 1E10, Level 1, Javits Center

TREATMENT-RESISTANT DEPRESSION

Chp.: Charles B. Nemeroff, M.D.

- A **Introduction to Treatment-Resistant Depression**
Charles B. Nemeroff, M.D.
- B **Long-Term Outcomes in Treatment-Resistant Depression**
A. John Rush, M.D.
- C **Introduction to a Treatment-Resistant Depression Patient Registry**
Martin B. Keller, M.D.
- D **Long-Term Treatment and Outcomes in Treatment-Resistant Depression With Pharmacotherapy, ECT, Repetitive Transcranial Magnetic Stimulation, MST, and VNS Therapy**
Thomas E. Schlaepfer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 63 2:00 p.m.-5:00 p.m.
 Room 1E12, Level 1, Javits Center

PSYCHOTIC DEPRESSION IN 2004: THE NIMH COLLABORATIVE SEVERE DEPRESSION STUDY

Chp.: Barnett S. Meyers, M.D.

- A Challenges in the Diagnosis of Psychotic Depression: Assessment, Epidemiology, and Biology**
 Anthony J. Rothschild, M.D., Michael A. Bell, M.D., Jayendra K. Patel, M.D., David P. Morin, M.D., Dorothy Sit, M.D., Colby Calkins, B.S., Denette Guerin, M.S.
- B Pharmacotherapy of Unipolar Major Depression: What Is the Evidence?**
 Benoit H. Mulsant, M.D., Robert H. Howland, M.D., Michael E. Thase, M.D., Mary C. McShea, M.S., Taafai S. Kamara, B.A.
- C NIMH Severe Depression Trial: Background and Design Choices**
 Barnett S. Meyers, M.D., Sibel Klimstra, M.D., Catherine Peasley-Miklus, Ph.D., Michelle Gabriele, M.S.W., Judith English, B.S.C., MoonSeong Heo, Ph.D., Melissa Carroll, Ph.D.
- D Challenges in Conducting a Pharmacotherapy Study in Psychotic Depression**
 Alastair J. Flint, M.B.
- E Real-Life Outcomes in Real-Life Patients: Discussion**
 Barry D. Lebowitz, Ph.D.

Discussant: Barry D. Lebowitz, Ph.D.
 THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 64 2:00 p.m.-5:00 p.m.
 Room 1E13, Level 1, Javits Center

SEPTEMBER 11TH: AFTER TWO-AND-A-HALF YEARS

Chp.: Zebulon C. Taintor, M.D.

- A The First Two Weeks Onsite**
 Antonio Abad, M.D.
- B New York State Office of Mental Health Response**
 William M. Tucker, M.D.
- C New York City Health and Mental Health: First Responders**
 Neal L. Cohen, M.D.
- D Disaster Psychiatry Outreach: Service and Training**
 Craig L. Katz, M.D.
- E Medical and Psychiatric Organizations and Findings**
 Zebulon C. Taintor, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 65 2:00 p.m.-5:00 p.m.
 Room 1E14, Level 1, Javits Center

NEUROIMAGING AND EMOTIONAL DYSREGULATION IN BPD

Chp.: Kenneth R. Silk, M.D.
 Co-Chp.: Martin Bohus, M.D.

- A Brain Imaging of Impulsivity and Affective Instability in BPD**
 Larry J. Siever, M.D., Antonia S. New, M.D., Monte S. Buchsbaum, M.D., W. Gordon Frankle, M.D., Harold W. Koenigsberg, M.D., Isak Prohovnik, Ph.D., Marc Laruelle, M.D.
- B Affect Regulation and BPD: fMRI and Daily Experience of Mood**
 Katherine M. Putnam, Ph.D.
- C Emotional Processing of Psychosocial Stimuli in BPD**
 Jill M. Hooley, D.Phil., Deborah A. Yurgelun-Todd, Ph.D., Staci A. Gruber, Ph.D.
- D Investigation of Pain Processing in BPD**
 Christian G. Schmahl, M.D., Martin Bohus, M.D.
- E A PET Study of u-Opioid Neurotransmission and Affective Lability in BPD**
 Kenneth R. Silk, M.D., Jon-Kar Zubieta, M.D., Robert Koeppe, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 66 2:00 p.m.-5:00 p.m.
 Room 1E16, Level 1, Javits Center

DIAGNOSING AND MANAGING AGGRESSIVE MOOD-DYSREGULATED YOUTH

Chp.: Joseph Biederman, M.D.

- A Parsing the Association Between Bipolar, Conduct, and Substance Use Disorders**
 Joseph Biederman, M.D., Stephen V. Faraone, Ph.D., Janet Wozniak, M.D., Micheal Monuteaux, Sc.D.
- B A Family Genetic Perspective on Childhood Mania**
 Stephen V. Faraone, Ph.D.
- C Risperidone Treatment of Affective Symptoms in Mentally Retarded Youth With Conduct Disorder**
 Eric Mick, Sc.D., Joseph Biederman, M.D., Georges Gharabawi, M.D., Stephen V. Faraone, Ph.D., Gahan J. Pandina, Ph.D.
- D Clinical Trials of a Mood Stabilizer for Aggressive, Mood-Dysregulated Youth**
 Janet Wozniak, M.D.

(Continued on next page)

WEDNESDAY

E Collaborative Problem-Solving Therapy for Aggressive Youth
Ross W. Greene, Ph.D.

F Anticonvulsants in the Management of Aggression in Youth
Joseph M. Gonzalez-Heydrich, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 67 2:00 p.m.-5:00 p.m.
Rooms 3D01/12, Level 3, Javits Center

**RESIDUAL SYMPTOMS IN DEPRESSION:
RECOGNITION AND TREATMENT**

Chp.: Matthew A. Menza, M.D.

A An Overview of Residual Symptoms in Depression
Andrew A. Nierenberg, M.D.

B Sleep Disturbance as a Residual Symptom in Depression
Matthew A. Menza, M.D.

C Anxiety as a Residual Symptom in Depression
Alexander Bystritsky, M.D.

D Residual Sexual Dysfunction Associated With MDD and SSRI Treatment
H. George Nurnberg, M.D.

E The Treatment of Residual Fatigue in Depression
Humberto Marin, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 68 2:00 p.m.-5:00 p.m.
Room 3D02/11, Level 3, Javits Center

WOMEN'S MENTAL HEALTH REVISITED: CURRENT PERSPECTIVES, FUTURE TRENDS
Association of Women Psychiatrists

Chp.: Sylvia W. Olatre, M.D.

A Depression in the Reproductive Years
Nada L. Stotland, M.D.

B Depression and Anxiety in Women in Late Life
Marion Z. Goldstein, M.D.

C Domestic Violence: Its Impact Across the Life Cycle
Leah J. Dickstein, M.D.

D PTSD in Women: Current Concepts and Treatments
Marian I. Butterfield, M.D., Mary Becker, M.S., Christine E. Marx, M.D.

E Racism and Women's Mental Health: The Intersection of Race and Gender
Altha J. Stewart, M.D.

Discussant: Donna E. Stewart, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 69 2:00 p.m.-5:00 p.m.
Room 3D03/10, Level 3, Javits Center

SUPPORTIVE PSYCHOTHERAPY: AN UPDATE

Chp.: Roger Peele, M.D.
Co-Chp.: Maryam Razavi, M.D.

A History of Supportive Psychotherapy
Stephen Rojcewicz, Jr., M.D.

B Role of Psychotherapy in the Management of Depression
Michael E. Thase, M.D.

C Use of Supportive Psychotherapy With Bipolar Disorder
Karen L. Swartz, M.D.

D Adapting Supportive Therapy for Treatment of BPD
David J. Hellerstein, M.D., Ron B. Aviram, Ph.D., Jessica Gerson, Ph.D., Kimberly Kotov, Ph.D., Barbara H. Stanley, Ph.D.

E Development of Competencies in Supportive Therapy: Process and Problems
Lisa A. Mellman, M.D.

Discussants: Henry Pinsker, M.D., Julia B. Frank, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 70 2:00 p.m.-5:00 p.m.
Rooms 3D04/9, Level 3, Javits Center

ANXIETY DISORDERS IN YOUTH: CLINICAL AND RESEARCH UPDATES

Chp.: Marcia J. Slattery, M.D.

A Evidence-Based Assessment Instruments With Children and Adolescents
Thomas H. Ollendick, Ph.D.

B Pharmacological Treatment of Anxiety Disorder in Youth
Marcia J. Slattery, M.D.

C Anxiety Disorders in Children and Adolescents: Are We Ready To Move Beyond The Study of Treatment Efficacy?
Anne Marie Albano, Ph.D.

D A Cognitive Neuroscience Perspective on Childhood Anxiety Disorders
Amy L. Krain, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 71 2:00 p.m.-5:00 p.m.
Rooms 3D05/8, Level 3, Javits Center

DSM-V CLASSIFICATION OF PERSONALITY DISORDERS: THE WHITE PAPER AND BEYOND

Chp.: Michael B. First, M.D.

- A Dimensional Models of Personality Disorder**
Thomas A. Widiger, Ph.D.
- B Relationship of Personality Traits and Disorders to Axis I Disorders**
M. Tracie Shea, Ph.D.
- C Axis I/Axis II Boundary: Spectrum Diseases and Molecular Neuroscience**
John H. Krystal, M.D., Robert T. Malison, M.D., Jaakko A. Lappalainen, M.D., Joel Gelernter, M.D.
- D Temperament, Personality, and Personality Disorder: The Externalizing Spectrum Model**
Robert F. Krueger, Ph.D.
- E The Neurobiology of Personality Traits: Focus on Aggression**
Emil F. Coccaro, M.D.
- THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 72 2:00 p.m.-5:00 p.m.
Rooms 3D06/7, Level 3, Javits Center

GROUP THERAPY IN MEDICAL/PSYCHIATRIC CARE

Chp.: David Spiegel, M.D.

- A Group Therapy for Breast Cancer: Feeling and Healing**
David Spiegel, M.D., Janine Giese-Davis, Ph.D., Lisa D. Butler, Ph.D., Catherine Classen, Ph.D., Cheryl Koopman, Ph.D.
- B Impact of Group Therapy on Anticancer Treatment Adherence**
David W. Kissane, M.D., David M. Clarke, Ph.D., Graeme C. Smith, M.D., Brenda Grabsch, B.S.W.
- C Mindfulness-Based Stress-Reduction Groups**
Susan E. Abbey, M.D.
- D Psychiatrist-Led Group Psychotherapy for the Chronically Mentally Ill**
Leslie H. Gise, M.D., Annette Crisanti, Ph.D., Robert Randall, Ph.D., Dana Kiyabu, R.N., Travis Ho, B.A.
- E Group Therapy for Substance Abuse**
David W. Brook, M.D.

- F Group Interventions for Psychological Trauma and Terrorism**
Henry I. Spitz, M.D.

Discussant: Henry Grunebaum, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 73 2:00 p.m.-5:00 p.m.
Odets Room, Fourth Floor, Marriott Marquis

DISSOCIATIVE DISORDERS: ISSUES OF CULTURE AND ISSUES OF TRUST
Association for the Advancement of Philosophy and Psychiatry

Chp.: Deborah Spitz, M.D.

- A Diversity in Presentation of Dissociative Disorders in Turkey**
Vedat Sar, M.D.
- B Differences Between Western and South African Models of Dissociation**
Christa Kruger, M.D.
- C Dissociation, Trances, and Transcendence: Cultural Values and Their Effects on Trust**
Nancy L. Potter, Ph.D.
- THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 74 2:00 p.m.-5:00 p.m.
O'Neill Room, Fourth Floor, Marriott Marquis

NEUROPSYCHIATRY OF TRAUMATIC BRAIN INJURY: CURRENT RESEARCH
American Neuropsychiatric Association

Chp.: Jonathan M. Silver, M.D.

- A The Cholinergic Hypothesis of Cognitive Impairment Due to Traumatic Brain Injury**
David B. Arciniegas, M.D.
- B Catecholaminergic Dysfunction After Traumatic Brain Injury: Impact on Cognition**
Thomas McAllister, M.D., Laura Flashman, Ph.D., Brenna McDonald, Psy.D., Heather Wishart, Ph.D., Richard B. Ferrell, M.D., Andrew Saykin, Psy.D.
- C Traumatic Brain Injury, Gene Expression, and Risk for Schizophrenia**
Dolores Malaspina, M.D., Cheryl M. Corcoran, M.D., Jill Harkavy-Friedman, Ph.D., Raymond Goetz, Ph.D., David J. Prinz, M.D., Roberto Gil, M.D.

(Continued on next page)

D Blast Injuries to the Brain: Armed Forces Injured During Operation Iraqi Freedom
Deborah Lee Warden, M.D., Louis M. French, Psy.D.,
Elisabeth Moy-Martin, R.N.C., Robert J. Labutta, M.D.,
James M. Ecklund, M.D.

E Multicenter, Placebo-Controlled Trials in Traumatic Brain Injury: A Work in Progress
Jonathan M. Silver, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 75 2:00 p.m.-5:00 p.m.
Wilder Room, Fourth Floor, Marriott Marquis

PSYCHIATRY, ETHNICITY, AND CULTURE: AN UPDATE ON ETHNOPSYCHOPHARMACOLOGY, MOOD, AND ANXIETY DISORDERS IN MINORITY POPULATIONS

Chp.: Shamsah B. Sonawalla, M.D.
Co-Chp.: Rajesh M. Parikh, M.D.

- A Ethnopsychopharmacology Update**
David C. Henderson, M.D.
- B Treatment of Anxiety and Depression Among Chinese Americans**
Albert Yeung, M.D.
- C Psychiatric Management of Hispanic Patients: Cross-Cultural Issues and Ethnopsychopharmacology**
David Mischoulon, M.D.
- D Depression and Anxiety in Women: An Update on Cross-Cultural Aspects and Pharmacologic Strategies**
Claudio N. Soares, M.D.
- E Cultural Differences in the Diagnosis and Treatment of Mood and Anxiety Disorders: Considerations in the Asian Indian Population**
Rajesh M. Parikh, M.D., Shamsah B. Sonawalla, M.D.

Discussant: Jerrold F. Rosenbaum, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 76 2:00 p.m.-5:00 p.m.
Ziegfeld Room, Fourth Floor, Marriott Marquis

ADOPTING EVIDENCE-BASED PRACTICE IN THE TREATMENT OF MOOD DISORDERS: THE CANADIAN EXPERIENCE

Chp.: Sidney H. Kennedy, M.D.
Co-Chp.: Roumen V. Milev, M.D.

- A Treating Depression Effectively: Applying Clinical Guidelines**
Sidney H. Kennedy, M.D.

B Strategies to Enhance Mental Health Care in the Primary Care Sector: Working With Family Physicians
Sagar V. Parikh, M.D.

C Evidence-Based Practice Leads to Improved Efficiency in the Work of a Specialized Mood-Disorders Service
Roumen V. Milev, M.D., Gaby Abraham, M.D., Fia Voutsilakos, M.D.

D Translating Research Into Practice: The Application of Clinical Guidelines in Mood Disorders
Valerie Taylor, M.D., Glenda M. MacQueen, M.D.

E Developing a Community-Based Strategy for Depression: The British Columbia Experience
Raymond W. Lam, M.D., Elliot M. Goldner, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 77 2:00 p.m.-5:00 p.m.
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

IMPACT OF TRAUMA AND LIFE STRESS IN BIPOLAR DISORDER

Chp.: Joseph F. Goldberg, M.D.
Co-Chp.: David Miklowitz, Ph.D.

- A Psychosocial Stress and Vulnerability to Affective Relapse**
Michael J. Gitlin, M.D.
- B Childhood Trauma and Outcome in Bipolar Patients**
Joseph F. Goldberg, M.D., Jessica L. Garno, Ph.D.
- C Bipolar Disorder and the Family Environment**
David Miklowitz, Ph.D.
- D Neurofunctional Correlates of Affective Stressors in Bipolar Patients**
Caleb M. Adler, M.D., Stephen M. Strakowski, M.D., Scott Holland, Ph.D., Melissa P. DelBello, M.D.

E Implications of the Kindling Model for Affective Relapse
Robert M. Post, M.D., Gabriele S. Leverich, L.C.S.W.,
Andrew M. Speer, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 78 2:00 p.m.-5:00 p.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

GAY AND LESBIAN ORTHODOX JEWS: A PRIMER FOR CLINICIANS

Chp.: Jack Drescher, M.D.

- A Orthodox Jewish Gays and Lesbians: The Filmmaker's Perspective**
Sandi Dubowski

- B Failed Reparative Therapy of Orthodox Jewish Homosexual Men and Women**
Abba E. Borowich, M.D.
- C Identities in Conflict: Treating Gay and Lesbian Orthodox Jews**
Naomi Mark, M.S.W.
- D Gayness and God: The Gay Orthodox Rabbi's Perspective**
Steven Greenberg

Discussant: Paul S. Appelbaum, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 79 2:00 p.m.-5:00 p.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

PERSONALITY, THERAPEUTIC ALLIANCE, AND OUTCOME IN BRIEF PSYCHOTHERAPY

Chp.: Arnold Winston, M.D.
Co-Chp.: J. Christopher Muran, Ph.D.

- A Personality, Therapeutic Alliance, and Outcome in Short-Term Dynamic and Cognitive-Behavioral Psychotherapies**
Sarah L. Aderholt, M.D., Elena Bruck, M.D., J. Christopher Muran, Ph.D., Arnold Winston, M.D.
- B Personality, Therapeutic Alliance, and Overall Outcome in Brief Relational Therapy**
Regina Biscoglio, M.A., J. Christopher Muran, Ph.D., Paul Watchel, Ph.D., Bernard S. Gorman, Ph.D.
- C Patient-Rated Alliance and Overall Outcome in Brief Psychotherapies**
Christopher Stevens, Ph.D., J. Christopher Muran, Ph.D., Jeremy D. Safran, Ph.D., Bernard S. Gorman, Ph.D.
- D Therapist-Rated Alliance and Overall Outcome in Brief Psychotherapies**
Kevin Gillett, J. Christopher Muran, Ph.D., Bernard S. Gorman, Ph.D., Karen Riggs-Skean, Ph.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 80 2:00 p.m.-5:00 p.m.
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

CONSEQUENCES AND TREATMENT OF MARIJUANA ABUSE

Collaborative Session With the National Institute on Drug Abuse

Chp.: Susan R.B. Weiss, Ph.D.
Co-Chp.: Jag Khalsa, Ph.D.

- A Cognitive Toxicity of Cannabis: The Devil Is in the Confounding Variables**
Harrison G. Pope, Jr., M.D., Deborah A. Yurgelun-Todd, Ph.D.

- B Cognitive Effects in Adolescents Exposed Prenatally to Marijuana or Cigarettes**
Peter A. Fried, Ph.D.
- C Effects of Chronic Marijuana Use and THC on Brain Function in Humans: A fMRI Study**
Alan S. Bloom, Ph.D.
- D Behavioral and Treatment Research on Marijuana Withdrawal and Dependence**
Alan J. Budney, Ph.D.
- E The Endogenous Cannabinoids and the Control of Drug Craving**
Billy R. Martin, Ph.D.

Discussant: Billy R. Martin, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 81 2:00 p.m.-5:00 p.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

PERSONALITY DISORDERS: MULTIPLE PERSPECTIVES IN THE UNDERSTANDING AND TREATMENT OF RESISTANCE

Chp.: Joseph DiGiacomo, M.D.

- A Resistance in Personality Disorders From a Psychodynamic Perspective**
R. Rao Gogineni, M.D.
- B Resistance in BPD: Cognitive-Behavioral Strategies That Facilitate Change**
Donna M. Sudak, M.D.
- C Family Therapy With Personality Disorders**
G. Pirooz Sholevar, M.D.
- D Clinical Practices That Lead to Treatment Resistance**
William R. Dubin, M.D.

Discussant: Thomas S. Newmark, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 82 2:00 p.m.-5:00 p.m.
Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis

CLINICAL CONTROVERSIES IN ECT

Chp.: Conrad M. Swartz, M.D.

- A Controversies in ECT: Electrode Placement**
Conrad M. Swartz, M.D.
- B Controversies in ECT: Stimulus Dosing**
W. Vaughn McCall, M.D.

(Continued on next page)

C **Controversies in ECT: Physiological Monitoring**
Charles H. Kellner, M.D.

D **Denying Patients Treatments That Work**
William H. Reid, M.D.

Discussant: J. Stuart Lawson, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 83 2:00 p.m.-5:00 p.m.
Astor Ballroom, Seventh Floor, Marriott Marquis

TOXIC LOVE ON FILM: ROMANTIC LOVE, FROM NORMAL TO PATHOLOGIC

Chp.: Anton C. Trinidad, M.D.
Co-Chp.: Robert J. Boland, M.D.

A **Obsessive Love and the Loss of Self in Film**
Anton C. Trinidad, M.D.

B **The Teaching of What is Normal and Abnormal in Romantic Love**
Robert J. Boland, M.D.

C **Femme Fatale and Its Allusions**
Harvey R. Greenberg, M.D.

D **Love: What Is Normal?**
Anton C. Trinidad, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 84 2:00 p.m.-5:00 p.m.
Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

MOVING THE TARGETS: THE NEUROBIOLOGY OF ADDICTION

Collaborative Session With the National Institute on Drug Abuse

Chp.: Nancy Pilotte, Ph.D.

A **Neuroadaptation in Addiction: The Extended Amygdala and Brain-Reward System**
George F. Koob, Ph.D.

B **Neural Circuitry of Relapse**
Peter W. Kalivas, Ph.D.

C **Drugs, Neuroplasticity, and Addiction**
Terry E. Robinson, Ph.D.

D **How Do Drugs of Abuse Rewire the Motivational Circuitry?**
Marina E. Wolf, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 85 2:00 p.m.-5:00 p.m.
Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

DRUG ABUSE TREATMENT ISSUES IN WOMEN
Collaborative Session With the National Institute on Drug Abuse

Chp.: Cora Lee Wetherington, Ph.D.

A **Gender Differences in Treatment Needs, Services, Utilization, and Outcomes**
Karol A. Kaltenbach, Ph.D.

B **Treatment Issues in Drug-Dependent Women With Comorbid Depression**
Rajita Sinha, Ph.D.

C **Trauma and PTSD: Issues in the Treatment of Drug-Dependent Women**
Denise Hien, Ph.D.

D **Drug-Dependent Women With Partner Violence: Treatment Issues**
Brenda A. Miller, Ph.D., Linda P. King, Ph.D., Eugene Maguin, Ph.D., Nancy J. Smyth, Ph.D.

E **Drug-Treatment Issues in Drug-Dependent, Pregnant Women**
Hendree Jones, Ph.D.

Discussant: Kathleen T. Brady, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 86 2:00 p.m.-5:00 p.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

MANAGING HIPAA-RELATED TENSIONS IN CLINICAL PRACTICE

Chp.: John O. Beahrs, M.D.

A **Intended and Actual Effects of HIPAA on Clinical Practice**
Claudette H. Beahrs, M.S.W.

B **The Impact of HIPAA on Psychiatric Hospital Care: The Good, the Bad, and the Ugly**
Steven S. Sharfstein, M.D., Robert P. Roca, M.D., Angela Niparko, Erin Scally

C **Regulation, HIPAA, and the Quest for Optimum Constraint**
John O. Beahrs, M.D.

D **Complying With HIPAA Made Less Difficult**
Jeffrey L. Metzner, M.D.

Discussant: Harold I. Eist, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 87 2:00 p.m.-5:00 p.m.

Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

MEMORY IN THE U.S. AND FRANCE: VIVE LA DIFFERENCE

Chp.: John A. Talbott, M.D.

Co-Chp.: Francois C. Petitjean, M.D.

- A What Can We Learn From the False-Memory Wars?**
Paul R. McHugh, M.D.
- B PTSD: Too Much or Too Little Memory?**
Anne-Marie F. Pezous, M.D., Barbara Cochet, Eric Guillem, M.D., Saena Bouchez, M.D., Jean-Pierre Lepine, Ph.D.
- C The Nature of Traumatic Memory: Implications for Treatment**
Bessel A. Van Der Kolk, M.D.
- D Depression and Dementia: Looking for Specific Memory Impairments**
Eric Fakra, M.D., Bernard Michel, M.D., Jean-Michel Azorin, M.D.
- E Cognitive Impairment in Late-Life Depression**
Charles F. Reynolds III, M.D., Meryl A. Butters, Ph.D.
- F Depression: Remembering the Bad Things**
Natacha Foulhoux, M.D., Francois C. Petitjean, M.D.

Discussant: Alexandra Malean, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 88 2:00 p.m.-5:00 p.m.

Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

QUALITY OF CARE FOR CHILDREN: MULTIPLE PERSPECTIVES

Chp.: Bonnie T. Zima, M.D.

- A Quality of Care From the Agency's Perspective: Are Medicaid Claims Data Valid?**
Penelope Knapp, M.D., Bonnie T. Zima, M.D., Michael Hulburt, Ph.D., Lingqi Tang, Ph.D., Heather Ladd, M.S., Naihua Duan, Ph.D., Kenneth B. Wells, M.D.
- B Quality of Care for Children in Outpatient Mental Health Programs**
Bonnie T. Zima, M.D., Michael Hulburt, Ph.D., Penelope Knapp, M.D., Lingqi Tang, Ph.D., Heather Ladd, M.S., Naihua Duan, Ph.D., Kenneth B. Wells, M.D.

- C Unraveling Variations in Access to ADHD Care: Deductive Analysis Findings**
Regina Bussing, M.D., Mirka K. Ljungberg, Ph.D., Cynthia Garvan, Ph.D., Dana Mason, B.S., Christine Leon, M.A.

- D Quality Improvement of Mental Health Services for Children in Special Education**
Sheryl H. Kataoka, M.D., Jeanne Miranda, Ph.D.

Discussant: John M. Oldham, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 89 2:00 p.m.-5:00 p.m.

Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

MEETING THE MENTAL HEALTH NEEDS OF LATINOS IN COMMUNITY AND PRIMARY CARE

Chp.: Myrna M. Weissman, Ph.D.

Co-Chp.: Amarendra Das, M.D.

- A PTSD in Latinos: Reactions in Primary Care to the World Trade Center Attacks**
Yuval Y. Neria, Ph.D., Amarendra Das, M.D., Rafael Lantigua, M.D., Marc J. Gameroff, Ph.D., Mark Olfson, M.D., Adriana Feder, M.D., Myrna M. Weissman, Ph.D.
- B Depression and Diabetes in an Urban General Medicine Clinic**
Raz Gross, M.D., Mark Olfson, M.D., Marc J. Gameroff, Ph.D., Olveen Carrasquillo, M.D., Steven Shea, M.A., Rafael Lantigua, M.D., Myrna M. Weissman, Ph.D.
- C Bipolar Spectrum Disorder in Hispanic Primary Care Patients**
Amarendra Das, M.D., Marc J. Gameroff, Ph.D., Rafael Lantigua, M.D., Steven Shea, M.A., Mark Olfson, M.D., Myrna M. Weissman, Ph.D.
- D Disparities in Mental Health Treatment for Latinos in Community Care**
William Vega, Shula Minsky, Ed.D., Michael Gara, Ph.D., Theresa M. Miskimen, M.D.

Discussant: Roberto Lewis-Fernandez, M.D.

THIS SESSION WILL BE AUDIOTAPED.

3:00 p.m. Sessions

NEW RESEARCH POSTER SESSION 9

3:00 p.m.-5:00 p.m.
Galleria, Level 4, Javits Center

MOOD DISORDERS

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 52-54

INDUSTRY-SUPPORTED SYMPOSIUM 52
7:00 p.m.-10:00 p.m.
Grand Ballroom East, Third Floor, Hilton New York

OPTIMIZING ANTIPSYCHOTIC TREATMENT IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER

Supported by Bristol-Myers Squibb Company

Chp.: Rajiv Tandon, M.D.

- A **Optimizing Pharmacotherapy for Maximized Outcomes**
Alan J. Mendelowitz, M.D.
- B **Keeping Tolerability in Mind: Ensuring Adherence to Maintain Recovery**
Henry A. Nasrallah, M.D.
- C **Finding Effectiveness Across Patient Age Groups**
Rajiv Tandon, M.D.
- D **Balancing the Efficacy and Tolerability for Pediatric Bipolar Disorder**
Melissa P. DelBello, M.D.
- E **Treatment Considerations in Special Populations: Sex Differences**
Diana O. Perkins, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 53
7:00 p.m.-10:00 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York

CORE SYMPTOM DOMAINS IN THE ANXIETY DISORDERS

Supported by Wyeth Pharmaceuticals

Chp.: Michael R. Liebowitz, M.D.
Co-Chp.: Eric Hollander, M.D.

- A **Differential Diagnosis and Biology of Panic and GAD**
Jack M. Gorman, M.D.

- B **Symptoms and Biologic Correlates of PTSD: From Early Adulthood to Old Age**
Rachel Yehuda, Ph.D.
- C **The Social Anxiety Spectrum**
Michael R. Liebowitz, M.D., Franklin R. Schneier, M.D., Jonathan E. Shaywitz, M.D.
- D **The Repetitive Behavior Domain in Obsessive-Compulsive and Developmental Disorders**
Eric Hollander, M.D., Stacey Wasserman, M.D.
- E **Mixed Anxiety and Depression: A Gordian Knot**
Joseph Zohar, M.D., Yehuda Sasson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 54
7:00 p.m.-10:00 p.m.
Imperial Ballroom B, Second Floor, Sheraton New York

BACK TO THE FUTURE: THE ROLE OF GAMMA-AMINOBUTYRIC ACID IN PSYCHIATRIC DISORDERS AND TREATMENT

Supported by Cephalon, Inc.

Chp.: Mark H. Pollack, M.D.

- A **Gamma-Aminobutyric Acid in the CNS**
Philip T. Ninan, M.D.
- B **Neuroimaging and Anxiety**
Justine M. Kent, M.D.
- C **Gamma-Aminobutyric Acidergic Agents in Anxiety Treatment: A Look Back and Ahead**
Mark H. Pollack, M.D.
- D **Emerging Gamma-Aminobutyric Acidergic Targets for Insomnia**
John W. Winkelman, M.D.
- E **Beyond Anxiety Disorders: The Role of Gamma-Aminobutyric Acid in Mood Disorders**
Naomi M. Simon, M.D.

THURSDAY, MAY 6, 2004

157TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 50-51

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 50, PART 2

7:00 a.m.-8:30 a.m.

Imperial Ballroom A, Second Floor, Sheraton New York

PTSD: SEARCHING FOR ANSWERS IN TRAUMATIC TIMES

Supported by Cephalon, Inc.

Chp.: Jonathan R.T. Davidson, M.D.

A Treatment and Prevention of Chronic PTSD: Psychosocial Approaches
Edna B. Foa, Ph.D.

B Novel Drug Treatments for PTSD Beyond SSRIs
Wei Zhang, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 51, PART 2

7:00 a.m.-8:30 a.m.

Imperial Ballroom B, Second Floor, Sheraton New York

BIPOLAR DISORDER IN WOMEN: REPRODUCTIVE IMPLICATIONS OF TREATMENT

Supported by GlaxoSmithKline

Chp.: Adele C. Viguera, M.D.

Co-Chp.: Lee S. Cohen, M.D.

A Use of Antiepileptic Medications in Women
Martha J. Morrell, M.D.

B Reproductive Endocrine Consequences of Treatment
Hadine Joffe, M.D.

8:00 a.m. Sessions



COURSES 98-100

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 98

8:00 a.m.-12 noon

Concourse A, Concourse Level, Hilton New York

INTRODUCTION TO TRANSCRANIAL MAGNETIC STIMULATION (TMS)

Co-Directors: Ziad H. Nahas, M.D., Leon J. Grunhaus, M.D.
Faculty: Sarah H. Lisanby, M.D., Ehud M. Klein, M.D.

COURSE 99

8:00 a.m.-12 noon

Bryant Suite, Second Floor, Hilton New York

ONLINE COMMUNICATION IN MENTAL HEALTH: DIFFERENT CONTEXTS, DIFFERENT ISSUES

Director: Robert C. Hsiung, M.D.

Faculty: Ivan K. Goldberg, M.D., Alfred Herzog, M.D.,
Ronald W. Pies, M.D., Joel Yager, M.D.,
Elizabeth Zelvin, A.C.S.W.

COURSE 100

8:00 a.m.-12 noon

Sutton North, Second Floor, Hilton New York

NEUROPSYCHIATRY OF TRAUMATIC BRAIN INJURY

American Neuropsychiatric Association

Director: David B. Arciniegas, M.D.

Faculty: Thomas McAllister, M.D., Jonathan M. Silver, M.D.

9:00 a.m. Sessions

CONTINUOUS CLINICAL CASE CONFERENCE 2: PART 2

9:00 a.m.-12 noon

Rooms 3D01/12, Level 3, Javits Center

TWO HOSPITALIZED PATIENTS WITH REFRACTORY MOOD DISORDER AND COGNITIVE IMPAIRMENT

Moderator: Stuart C. Yudofsky, M.D.

Presenters: Richard L. Munich, M.D., Efram Bleiberg, M.D.,
Lauren B. Marangell, M.D., Alice Rogan, M.D., Florence
Kim, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

LECTURE 25

9:00 a.m.-10:30 a.m.
Rooms 1E07/8, Level 1, Javits Center

Godfrey D. Pearson, M.D.

Through the Looking Glass: Uses of Simulation and Virtual Reality in Clinical Practice and Brain Imaging Research

Chp.: Mahmoud A. Mohamed, M.D.
Co-Chp.: Maria A. Oquendo, M.D.

The concept of virtual reality goes back almost 40 years, but only recently have advances in computing and associated hardware allowed for clinical applicability. Godfrey D. Pearson, M.D., reviews current achievements, caveats, and future prospects of virtual reality applications in psychiatry, including uses in the treatment of phobias and eating disorders, assessment and rehabilitation, and as stimuli in brain imaging studies of complex behaviors such as driving, substance abuse, and pathological gambling. Dr. Pearson is Professor of Psychiatry at Yale University School of Medicine in New Haven, Connecticut, and Director of the Olin Neuropsychiatry Research Center at the Institute of Living in Hartford, Connecticut. His work in psychiatric neuroimaging has spanned the investigation of Alzheimer's Disease, Huntington's Disease, schizophrenia, bipolar disorder, neurodevelopmental disorders, and normal aging. He is the author of over 200 scientific papers and book chapters. Dr. Pearson founded and formerly directed the Psychiatry Neuroimaging Laboratory at Johns Hopkins University School of Medicine in Baltimore, Maryland. A Distinguished Fellow of the American Psychiatric Association, Dr. Pearson has received the Ziskind-Somerfeld Research Award of the Society of Biological Psychiatry and the Distinguished Investigator Award of the National Alliance for Research on Schizophrenia and Depression. He received his medical degree from the Newcastle Upon Tyne University Medical School in Newcastle Upon Tyne, England.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATION 12

9:00 a.m.-10:30 a.m.

This session is limited to 25 participants on a first-come, first-served basis.

Iqbal Ahmed, M.D., on Psychiatric Disorders in the Elderly
Room 1D04, Level 1, Javits Center

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

WORKSHOPS

COMPONENT WORKSHOP 49

9:00 a.m.-10:30 a.m.
Rooms 1E01/2, Level 1, Javits Center

THE BLAME AND SHAME GAME IN MEDICAL ERRORS: DO YOU WANT TO PLAY IT?

APA Committee on Patient Safety

Co-Chps.: Geetha Jayaram, M.D., Benjamin C. Grasso, M.D.
Participants: David M. McDowell, M.D., Robert Michels, M.D.

ISSUES 120-137

ISSUE WORKSHOP 120 9:00 a.m.-10:30 a.m.
Rooms 1E03/4/5, Level 1, Javits Center

THE HORNS OF A DILEMMA: MYTHS AND REALITIES OF DRUG-INDUSTRY INTERACTION

Chp.: John W. Burruss, M.D.
Participants: Woodie M. Zachry, Ph.D., Ali A. Asghar-Ali, M.D.

ISSUE WORKSHOP 121 9:00 a.m.-10:30 a.m.
Room 1E09, Level 1, Javits Center

GROUP PSYCHOTHERAPY WITH SUBSTANCE ABUSERS

American Group Psychotherapy Association

Co-Chps.: David W. Brook, M.D., Henry I. Spitz, M.D.

ISSUE WORKSHOP 122 9:00 a.m.-10:30 a.m.
 Room 1E11, Level 1, Javits Center

MILIEU THERAPIES IN THE AGE OF MANAGED CARE, REVISITED

Chp.: C. Deborah Cross, M.D.
Participants: Howard D. Kibel, M.D., Saul Scheidlinger, Ph.D., Janet A. Bezmen, R.N.

ISSUE WORKSHOP 123 9:00 a.m.-10:30 a.m.
 Room 1E12, Level 1, Javits Center

PSYCHIATRIC CONSULTATION REPORTS IN MINUTES: EXPLORING NEW TECHNOLOGIES

Chp.: Henry H. Leung, M.D.
Participant: Anna E. Rogers, M.D.

ISSUE WORKSHOP 124 9:00 a.m.-10:30 a.m.
 Room 1E14, Level 1, Javits Center

A COMPREHENSIVE APPROACH TO THE TREATMENT OF PAIN IN HIV ILLNESS

Chp.: David G. Krefetz, D.O.
Participants: Richard T. Jermyn, D.O., David M. Kietrys, M.P.T., Maryann Andrews, B.S.N.

ISSUE WORKSHOP 125 9:00 a.m.-10:30 a.m.
 Room 1E16, Level 1, Javits Center

DETECTION OF MALINGERING

Chp.: Alan R. Hirsch, M.D.
Participants: David E. Hartman, Ph.D., Paul Ekman, Ph.D., Carl M. Wahlstrom, Jr., M.D.

ISSUE WORKSHOP 126 9:00 a.m.-10:30 a.m.
 Rooms 2D10/11, Level 2, Javits Center

CAN SOCIAL THEORY BE INTEGRATED INTO THE LIBERATORY GOALS OF PSYCHIATRY?

Co-Chps.: Carl I. Cohen, M.D., Kenneth S. Thompson, M.D.
Participants: Astrid N. Rusquellas, M.D., Bradley E. Lewis, M.D., Sami Timimi

ISSUE WORKSHOP 127 9:00 a.m.-10:30 a.m.
 Rooms 2D14/15, Level 2, Javits Center

TREATMENT-RESISTANT PATIENTS WITH BULIMIA NERVOSA

Co-Chps.: Edi Cooke, Psy.D., Frampton Gwynette, M.D.
Participants: Nettie Levine, RD., Waguih W. Ishak, M.D., Antonia Noble-Ludwig, M.F.T.

ISSUE WORKSHOP 128 9:00 a.m.-10:30 a.m.
 O'Neill Room, Fourth Floor, Marriott Marquis

LEASH ON LIFE: HUMAN ATTACHMENT TO ANIMALS

Chp.: Debra A. Katz, M.D.
Participants: Jon Katz, Debra A. Glueck, M.D., Tagalie Heister, M.S.L.S.

ISSUE WORKSHOP 129 9:00 a.m.-10:30 a.m.
 Wilder Room, Fourth Floor, Marriott Marquis

AVOIDING DUAL-AGENCY PITFALLS OF WORK-RELATED NEUROPSYCHIATRIC IMPAIRMENTS

Chp.: Harold J. Bursztajn, M.D.
Participants: Robindra K. Paul, M.D., David M. Reiss, M.D., Christine A. Martone, M.D.

ISSUE WORKSHOP 130 9:00 a.m.-10:30 a.m.
 Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

TEACHING CORE COMPETENCIES: THE CHALLENGE FOR ACADEMIC PSYCHIATRY

Co-Chps.: Mary S. Scitutto, M.D., Mary E. Bongiovi-Garcia, M.D.
Participants: Kareem D. Ghalib, M.D., David A. Lowenthal, M.D.

ISSUE WORKSHOP 131 9:00 a.m.-10:30 a.m.
 Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

KEEP IT REAL: PSYCHOLOGICAL PREPAREDNESS AND ACTIVE-COPING GROUP

Chp.: Paula G. Panzer, M.D.
Participants: Robert H. Abramovitz, M.D., Susan E. Paula, Ph.D.

ISSUE WORKSHOP 132 9:00 a.m.-10:30 a.m.
 Booth/Edison Rooms, Fifth Floor, Marriott Marquis

PSYCHIATRIC ASPECTS OF TREATING PRIMARY CAREGIVERS OF HOSPICE PATIENTS

Co-Chps.: Jay L. Wung, M.D., Robert Taub, M.D.
Participant: Linda Gorman, R.N.

THURSDAY

ISSUE WORKSHOP 133 9:00 a.m.-10:30 a.m.
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

PSYCHIATRY TRAINING FOR PRIMARY-CARE PHYSICIANS: WHAT, HOW, AND WHEN?

Chp.: Hoyle Leigh, M.D.

Participants: Tana A. Grady-Weliky, M.D., Don R. Lipsitt, M.D., Seth M. Powsner, M.D., Deborah C. Stewart, M.D.

ISSUE WORKSHOP 134 9:00 a.m.-10:30 a.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

WHOSE RESPONSIBILITY IS IT ANYWAY? THE TREATING PSYCHIATRIST'S?

Chp.: Bernard J. Arseneau, D.O.

ISSUE WORKSHOP 135 9:00 a.m.-10:30 a.m.
Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis

SAD DAYS: A VIDEO OF PSYCHIATRIC PROBLEMS IN AFGHANISTAN AND ITS REFUGEES

Chp.: Nigel M. Bark, M.D.

Participants: Khalid A. Mufti, M.D., Haroon R. Chaudhry, M.D.

ISSUE WORKSHOP 136 9:00 a.m.-10:30 a.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

PROGRAM EVALUATION MADE SIMPLE

Co-Chps.: Barbara A. Johnson, M.D., James A. Schuster, M.D.

Participants: John G. Lovelace, M.S., Frank A. Ghinassi, Ph.D., Mario Cruz, M.D.

ISSUE WORKSHOP 137 9:00 a.m.-10:30 a.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

THE STALKING VICTIM: CAUSES, CONSEQUENCES, AND THE RAPEUTIC CONSIDERATIONS

Chp.: Gail E. Robinson, M.D.

Participant: Karen M. Abrams, M.D.

MEDIA 7-8

MEDIA SESSION 7 9:00 a.m.-12 noon
Room 1E06, Level 1, Javits Center

Robot Stories: Emotional and Ethical Challenges of a Technological Age

Co-Chps.: Ravi Chandra, M.D., John E. Beebe III, M.D.

Participants: Paul S. Appelbaum, M.D., Arthur Caplan, Ph.D., Raj Reddy, Ph.D., Greg Pak, B.A.

MEDIA SESSION 8 9:00 a.m.-12 noon
Ziegfeld Room, Fourth Floor, Marriott Marquis

Personality Disorders and the Film, *Noir Femme Fatale*

Chp.: Scott Snyder, M.D.

11:00 a.m. Sessions

MEDICAL UPDATE 4

11:00 a.m.-12:30 p.m.

Room 1E13, Level 1, Javits Center

HOW TO SHRINK OBESITY

Chp.: Evelyn Attia, M.D.

Presenter: Judith Korner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 28-35

SCIENTIFIC AND CLINICAL REPORT SESSION 28

11:00 a.m.-12:30 p.m.

Rooms 1E01/2, Level 1, Javits Center

EATING DISORDERS

Chp.: Theodore E. Weltzin, M.D.

Co-Chp.: Andrew O. Skinner, M.D.

11:00 a.m.

83 *Weight and Relapse to Cocaine and Alcohol Use in Patients With Eating Disorders

Olivera J. Bogunovic, M.D., David R. Gastfriend, M.D.

11:30 a.m.

84 DSM-IV Comorbidity in Binge-Eating Disorder

Carlos M. Grilo, Ph.D., Robin M. Masheb, Ph.D.

12 noon

85 Males at Risk: Hawaiian and Filipino Adolescents

Alayne Yates, M.D., Jeanne Edman, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

*Collaborative Session With the National Institute on Drug Abuse

SCIENTIFIC AND CLINICAL REPORT SESSION 29

11:00 a.m.-12:30 p.m.

Room 1E12, Level 1, Javits Center

ADDICTION PSYCHIATRY

Collaborative Session With the National Institute on Drug Abuse

Chp.: Lisa M. Goldfarb, M.D.

Co-Chp.: Marketa M. Wills, M.D.

11:00 a.m.

86 PRISM-IV: Reliable Diagnosis in Alcohol and Drug Abusers

Sharon Samet, M.S.W., Edward V. Nunes, M.D., Jakob Meydan, Psy.D., Karen Matseoane, B.A., Deborah S. Hasin, Ph.D.

11:30 a.m.

87 Cognitive Functioning: Predictors of Outcome in Cocaine-Dependent Patients

Efrat Aharonovich, Ph.D., Edward V. Nunes, M.D., Xinhua Liu, Ph.D., Adam M. Bisaga, M.D., David M. McDowell, M.D., Deborah S. Hasin, Ph.D.

12 noon

88 Cocaine Expectancy Questionnaire: Psychometric and Underlying Model

Marie C. Martin, Ph.D., Bruce J. Rounsaville, M.D., Adam J. Jaffe, Ph.D., Charles H. Wilber, MEd.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 30

11:00 a.m.-12:30 p.m.

Room 3D03/10, Level 3, Javits Center

ISSUES IN ADDICTIONS

Chp.: David A. Casey, M.D.

Co-Chp.: Jesse H. Wright, M.D.

11:00 a.m.

89 *Psychosocial Therapies for Cocaine Dependence: A Controlled Study

Adam J. Jaffe, Ph.D., Charles H. Wilber, MEd., Bruce J. Rounsaville, M.D.

11:30 a.m.

90 Patient Treatment Matching With Ambulatory Cocaine Abusers

Charles H. Wilber, MEd., Adam J. Jaffe, Ph.D., Joshua J. Brandt, Psy.D., Marie C. Martin, Ph.D., Richard A. Rodriguez, B.S., Bruce J. Rounsaville, M.D.

12 noon

91 Virtual Reality Cue-Reactivity-Controlled Trial for Nicotine Dependence

Patrick S. Bordnick, Ph.D., Ken Graap, MEd., Hilary Copp, M.S.W., Jeremy Brooks, Bobby Logue, B.S., Mirtha Ferrer, M.S.

THIS SESSION WILL BE AUDIOTAPED.

* Collaborative Session With the National Institute on Drug Abuse

SCIENTIFIC AND CLINICAL REPORT SESSION 31

11:00 a.m.-12:30 p.m.

Rooms 3D04/9, Level 3, Javits Center

SLEEP AND SEASONALITY

Chp.: Karl Doghramji, M.D.

Co-Chp.: Gerald F. Donovan, M.D.

11:00 a.m.

92 Modafinil Improves Patient Functioning in Shift Work Sleep Disorder

Milton K. Erman, M.D., Charles A. Czeisler, Ph.D., David F. Dinges, Ph.D., James K. Walsh, Ph.D., Thomas Roth, Ph.D.

11:30 a.m.

93 Modafinil Treatment of Chronic Shift Work Sleep Disorder

James K. Walsh, Ph.D., Charles A. Czeisler, Ph.D., David F. Dinges, Ph.D., Thomas Roth, Ph.D.

12 noon

94 A Comparison of Seasonality of Mood and Behavior in African and African-American Students

Samina M. Yousufi, M.D., Kelly J. Rohan, Ph.D., Courtney M. Thrower, M.A., Michael A. Jackson, B.S., John J. Bartko, Ph.D., Charles O. Agumadu, M.D., Teodor T. Postolache, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 32

11:00 a.m.-12:30 p.m.

Rooms 3D06/7, Level 3, Javits Center

ISSUES IN BPD

Chp.: Anthony J. Rothschild, M.D.

Co-Chp.: John J. Schwab, M.D.

11:00 a.m.

95 The Frequency of DSM-IV Personality Disorders in Psychiatric Outpatients

Mark Zimmerman, M.D., Louis Rothschild, Ph.D.

11:30 a.m.

96 Inhibitory Functioning in BPD: A fMRI Study

Sabine Herpertz, Knut Schnell, M.D., Britta Winter, Ph.D., Martina Ahrens, M.D., Armin Thron, M.D.

12 noon

97 Life Changes, Social Adjustment, and Attempted Suicide in BPD and MDD

Thomas M. Kelly, Ph.D., Paul H. Soloff, M.D., J. John Mann, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 33

11:00 a.m.- 12:30 p.m.

Wilder Room, Fourth Floor, Marriott Marquis

CONSULTATION LIAISON PSYCHIATRY

Chp.: Anton C. Trinidad, M.D.

Co-Chp.: Sermsak Lolak, M.D.

11:00 a.m.

98 Depression and Nonlinear Heart Rate Dynamics in Older Coronary Patients

Salvador M. Guinjoan, M.D., Daniel E. Vigo, M.D.,
Rodolfo D. Fahrner, M.D., M. Soledad
Laorondeguevara, B.S.C., Daniel Cardinali, M.D., Leonardo
Nicola Siri, Ph.D., Eduardo Sampo, M.D.

11:30 a.m.

99 The Role of Dexmedetomidine in Reducing Delirium in Cardiotomy Patients

Jose R. Maldonado, M.D., Ashley Wysong, M.S., Thaddeus S.
Block, M.D.

12 noon

100 Psychiatry Training in Primary Care: Factors for a Satisfactory Program

Hoyle Leigh, M.D., Deborah C. Stewart, M.D., Ronna
Mallios, M.P.H.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 34

11:00 a.m.- 12:30 p.m.

Alvin/ Carnegie Rooms, Fifth Floor, Marriott Marquis

OCD

Chp.: Carl I. Cohen, M.D.

Co-Chp.: Geoffrey M. Hopkins, M.D.

11:00 a.m.

101 Self-Administered Versus Therapist-Administered Cognitive-Behavior Therapy for Medication Nonresponders With OCD

David Tolin, Ph.D., Scott Hannan, Ph.D., Gretchen
Diefenbach, Ph.D., Nicholas Maltby, Ph.D., Patrick
Worhunsky, B.S.

11:30 a.m.

102 Effectiveness of Intensive Residential Treatment of Severe Refractory OCD

S. Evelyn Stewart, M.D., Colleen Farrell, B.A., Denise
Egan-Stack, M.A., Michael A. Jenike, M.D.

12 noon

103 Hyperactive Error Processing in OCD

Nicholas Maltby, Ph.D., Patrick Worhunsky, B.S., Kent A.
Kiehl, Ph.D., David Tolin, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 35

11:00 a.m.- 12:30 p.m.

Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

ADULT ADHD

Chp.: Catherine C. Crone, M.D.

Co-Chp.: Robert Kelly, M.D.

11:00 a.m.

104 Cognitive-Behavioral Therapy for Residual ADHD in Adults

Steven A. Safren, Ph.D., Michael W. Otto, Ph.D., Timothy E.
Wilens, M.D., Susan Sprich, Ph.D., Joseph Biederman, M.D.,
Carol Winette, Ph.D.

11:30 a.m.

105 A Controlled Study of Functional Impairments in 500 ADHD Adults

Stephen V. Faraone, Ph.D., Joseph Biederman, M.D.

12 noon

106 Long-Term Safety and Efficacy of Mixed Amphetamine Salts Extended-Release for Adult ADHD

Joseph Biederman, M.D., Thomas J. Spencer, M.D., Allan K.
Chrisman, M.D., Timothy E. Wilens, M.D., Simon J.
Tulloch, M.D., Richard H. Weisler, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

ISSUES 138-146

ISSUE WORKSHOP 138

11:00 a.m.-12:30 p.m.

Rooms 1E03/4/5, Level 1, Javits Center

DIVERSE CULTURAL EXPRESSIONS AND INTERVENTIONS FOR ANXIETY AND DEPRESSIVE DISORDERS

Chp.: Nalini V. Juthani, M.D.

Participants: Virginia Contreras, M.D., Kingsley Nwokeji, M.D.,
Akhtar Hossain, M.D.

ISSUE WORKSHOP 139

11:00 a.m.-12:30 p.m.

Room 1E09, Level 1, Javits Center

SPIRITUAL AND RELIGIOUS ASSESSMENT IN CLINICAL PRACTICE

Co-Chps.: Francis G. Lu, M.D., Christina M. Puchalski, M.D.

Participant: James L. Griffith, M.D.

ISSUE WORKSHOP 140 11:00 a.m.-12:30 p.m.
Room 1E11, Level 1, Javits Center

LONG-TERM CARE INSURANCE DENIALS TO ONE-TIME PSYCHIATRIC PATIENTS

Co-Chps.: Rita R. Newman, M.D., Ruth B. Kantor, M.D.
Participants: Lynn Lavendar, Esq., Brenda McElnea, Esq., Mark Wilensky, MBA

ISSUE WORKSHOP 141 11:00 a.m.-12:30 p.m.
Room 1E14, Level 1, Javits Center

AN EXTENSION OF THE ANALYSIS OF RESTORATIVE JUSTICE AND THERAPEUTIC JURISPRUDENCE

Co-Chps.: Lawrence K. Richards, M.D., Abraham L. Halpern, M.D.
Participants: Michael L. Perlin, Bruce J. Winick, Marjorie A. Silver

ISSUE WORKSHOP 142 11:00 a.m.-12:30 p.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

CHALLENGING SLEEP PROBLEMS: LOOKING AT SLOW-WAVE SLEEP

Chp.: Lois E. Krahn, M.D.
Participants: Peter C. Gleason, M.D., Martin B. Scharf, Ph.D.

ISSUE WORKSHOP 143 11:00 a.m.-12:30 p.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

WORKPLACE BURNOUT IN PSYCHIATRISTS: EVIDENCE FROM THE UNITED KINGDOM

Co-Chps.: Alex P. Mears, Ph.D., John Sharkey, M.D.

ISSUE WORKSHOP 144 11:00 a.m.-12:30 p.m.
Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis

REACTIONS AFTER 9/11 IN A PRETRAUMATIZED COMMUNITY IN THE SOUTH BRONX

Co-Chps.: Jeffrey M. Levine, M.D., Andreas Evdokas, Ph.D.
Participants: Ibet Hernandez, C.S.W., Patrick J. Moynihan

ISSUE WORKSHOP 145 11:00 a.m.-12:30 p.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

TREATMENT OF RECENT-ONSET SCHIZOPHRENIA IN COMMUNITY AND RESEARCH SETTINGS

Chp.: Raman C. Patel, M.D.
Participants: Gilbert Robinson, M.D., Rachel Miller, M.S.W., Jose M. Soto, M.D., Beth Lorell, C.S.W.

ISSUE WORKSHOP 146 11:00 a.m.-12:30 p.m.
Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

EVIDENCE-BASED TREATMENT FOR SCHIZOPHRENIA IN A CORRECTIONAL SETTING

Chp.: Larry H. Dizmang, M.D.
Participants: John A. Chiles, M.D., Karen Alexander, Ph.D., David Silbaugh, Ph.D., Ira D. Glick, M.D.

12 noon Sessions

FORUM 12

12 noon-1:30 p.m.
Room 1E16, Level 1, Javits Center

APA AND THE PHARMACEUTICAL INDUSTRY: AN OPEN FORUM

Chp.: Stephen M. Goldfinger, M.D.
Participants: Charles R. Goldman, M.D., Geetha Jayaram, M.D., David M. McDowell, M.D., Trevor R.P. Price, M.D., Nyapati R. Rao, M.D., Anand Pandya, M.D., David B. Mallott, M.D.

NEW RESEARCH POSTER SESSION 10

12 noon-2:00 p.m.
Galleria, Level 4, Javits Center

MEDICAL PSYCHIATRY AND GERIATRIC PSYCHIATRY

For further information on New Research Sessions, please refer to the *New Research Program Book* included in your registration packet.

2:00 p.m. Sessions

SYMPOSIA 90-116

SYMPOSIUM 90 2:00 p.m.-5:00 p.m.
Rooms 1E01/2, Level 1, Javits Center

NEW CLINICAL INDICATIONS FOR LIGHT TREATMENT: STATUS REPORT

Chp.: Raymond W. Lam, M.D.

- A Treatment of Winter Depression: Light or Drugs?**
Raymond W. Lam, M.D., Anthony J. Levitt, M.D., Robert D. Levitan, M.D., Murray W. Enns, M.D., Rachel L. Morehouse, M.D.

(Continued on next page)

THURSDAY

B Light Treatment for Antepartum Depression
Katherine L. Wisner, M.D.

C Bright Light and Negative Ion Treatment for Chronic Depression
Namni Goel, Ph.D., Jiuan Su Terman, Ph.D.,
Michael Terman, Ph.D., Mela M. Macchi, Ph.D.,
Jonathan W. Stewart, M.D.

D A Meta-Analysis of Light Treatment for Nonseasonal Depression
Arja L. Tuunainen, M.D., Daniel F. Kripke, M.D.,
Takuro Endo, M.D.

Discussant: Michael Terman, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 91 2:00 p.m.-5:00 p.m.
Rooms 1E03/4/5, Level 1, Javits Center

MOOD DISORDERS IN WOMEN THROUGHOUT THE LIFE CYCLE

Chp.: Nina E. Cerfolio, M.D.

A Pregnant Addicts Do Not Use Drugs
Leslie H. Gise, M.D.

B Postpartum Psychosis: Phenomenology, Treatment, and Prevention
Margaret G. Spinelli, M.D.

C Cyclic Moods and Acyclic Moods
Kimberly A. Yonkers, M.D.

D The Greatest Experiment Ever Performed on Women
Barbara Seaman, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 92 2:00 p.m.-5:00 p.m.
Room 1E06, Level 1, Javits Center

OVERCOMING BARRIERS TO LONG-TERM CARE AND TREATMENT OF THE ELDERLY
APA Corresponding Committee on Long-Term Care and Treatment for the Elderly

Chp.: Helen H. Kyomen, M.D.

A An Inspirational Model of Care in Rural Long-Term-Care Facilities
David W. Hodo, M.D.

B The PACE Model of Community-Based Care
Robert K. Dolgoff, M.D.

C An Ethno-Cultural Model of Care in Long-Term-Care Facilities
Ronald Brenner, M.D.

D Can You Ever Get Paid for Treating Patients in Long-Term Care Settings?
Istvan J.E. Boksay, M.D.

E Barriers to Psychiatric Care in Assisted-Living Facilities
Helen H. Kyomen, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 93 2:00 p.m.-5:00 p.m.
Room 1E09, Level 1, Javits Center

DEVELOPMENTAL DISABILITIES FROM CHILDHOOD TO ADULTHOOD

Chp.: Roxanne C. Dryden-Edwards, M.D.
Co-Chp.: Paula J. Lockhart, M.D.

A Fetal Alcohol Spectrum Disorders for Mental Health Professionals: A Brief Review
Paula J. Lockhart, M.D.

B Behavioral Interventions for Autism and Developmental Disorders in Adults
Joel D. Bregman, M.D., John Gertz, M.D.

C Substance Use Disorders in Young Adults With and Without Learning Disabilities
Joseph H. Beitchman, M.D., Lori Wilson, Arlene Young,
Edward Adlaf

D Psychopharmacology in Mental Retardation and Pervasive Developmental Disorders
Bryan H. King, M.D.

Discussants: Joseph H. Beitchman, M.D., Bryan H. King, M.D., Joel D. Bregman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 94 2:00 p.m.-5:00 p.m.
Room 1E10, Level 1, Javits Center

UPDATE ON TREATMENT OF STIMULANT ABUSE
Collaborative Session With the National Institute on Drug Abuse

Chp.: David A. Gorelick, M.D.

A Recovery-Oriented Psychosocial Treatment
Douglas M. Ziedonis, M.D.

B Therapy and Placement Approaches for Cocaine Abuse Treatments
David R. Gastfriend, M.D., Gurmit Shimi Kang, M.D.,
Sandrine Pirard, M.D., Estee Sharon, Psy.D.

C Pharmacological Treatment of Stimulant Abuse
David A. Gorelick, M.D.

D Psychiatric Comorbidity in Stimulant Abusers
Richard N. Rosenthal, M.D.

E Methamphetamine Abuse: 2004 Update
Steven L. Batki, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 95 2:00 p.m.-5:00 p.m.

Room 1E11, Level 1, Javits Center

**DEPRESSIVE PERSONALITY DISORDER VERSUS
DYSTHYMIC DISORDER**

Chp.: John C. Markowitz, M.D.
Co-Chp.: Andrew E. Skodol II, M.D.

**A Conceptual Issues in the Overlap of Depressive
Personality and Dysthymia**
Steven Huprich, Ph.D.

**B Longitudinal Comparison of Depressive Personality
Disorder and Dysthymic Disorder**
John C. Markowitz, M.D., Andrew E. Skodol II, M.D.,
Eva Petkova, Ph.D., Hui Xie, Ph.D., David J.
Hellerstein, M.D.

C Depressive Personality: Ten-Year Follow-Up
Daniel N. Klein, Ph.D.

**D Impact of Comorbid Dysthymic Disorder on Outcome
in Personality Disorders**
David J. Hellerstein, M.D., Andrew E. Skodol II, M.D.,
John C. Markowitz, M.D., Eva Petkova, Ph.D.,
Hui Xie, Ph.D.

**E Clinical Correlates of Chronicity in Depression: Results
From the Rhode Island MIDAS Project**
Mark Zimmerman, M.D., Iwona Chelminski, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 96 2:00 p.m.-5:00 p.m.

Room 1E13, Level 1, Javits Center

**BEHAVIORAL TREATMENTS FOR DRUG
DEPENDENCE**

Collaborative Session With the National Institute on Drug Abuse

Chp.: Lisa S. Onken, Ph.D.
Co-Chp.: Bruce J. Rounsaville, M.D.

**A Durability of Cognitive-Behavioral Therapy Efficacy for
Substance Abusers**
Bruce J. Rounsaville, M.D.

B HIV Risk Reduction and Substance Abuse Treatment
George E. Woody, M.D.

**C Low-Cost Contingency Management in Community
Settings**
Nancy M. Petry, Ph.D.

**D Cognitive-Behavioral Therapy and Naltrexone for
Cocaine Dependence**
Joy M. Schmitz, Ph.D., Angela L. Stotts, Ph.D.,
John Grabowski, Ph.D.

**E Behavioral Family Counseling and Naltrexone for Male,
Opioid-Dependent Patients**
William S. Fals-Stewart, Ph.D., Timothy J. O'Farrell, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 97 2:00 p.m.-5:00 p.m.

Room 1E14, Level 1, Javits Center

ITALIAN PSYCHIATRY: 25 YEARS OF CHANGES

Chp.: Mariano Bassi, M.D.
Co-Chp.: Allan Tasman, M.D.

**A Italian Psychiatrists and Italian Psychiatry: 25 Years of
Changes**
Mariano Bassi, M.D.

**B Intensive Community Care: Is It the Same in Italy and
the Rest of the World?**
Angelo Fioritti, M.D.

**C Variations in Mental Health Service Provision in Italy
and Their Links With Socioeconomic Predictors**
Giuseppe Tibaldi

D Residential Care in Italy: A National Survey
Giovanni De Girolamo, M.D., Angelo Picardi, M.D.,
Giovanni Santone, M.D.

E Community Treatment of Schizophrenia in Italy
Mirella Ruggeri, M.D., Antonio Lasaluia, M.D.,
Michele Tansella, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 98 - WITHDRAWN

THURSDAY

SYMPOSIUM 99 2:00 p.m.-5:00 p.m.
Rooms 3D01/12, Level 3, Javits Center

**MIND, BRAIN, AND INTERPERSONAL EXPERIENCE
IN PSYCHOTHERAPY**

Chp.: Daniel J. Siegel, M.D.
Co-Chp.: Marcia Kraft Goin, M.D.

- A **The Present Moment in Psychotherapy**
Daniel N. Stern, M.D.
- B **The Central Role of Emotion in Psychotherapy**
Diana Fosha, Ph.D.
- C **Intersubjectivity, Narrative, and the Brain in
Psychotherapy**
Daniel J. Siegel, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 100 2:00 p.m.-5:00 p.m.
Room 3D02/11, Level 3, Javits Center

**FROM RESEARCH TO CLINICAL PRACTICES IN
TREATING PATIENTS WITH BPD**

Chp.: John G. Gunderson, M.D.

- A **Levels of Care: A Scientific and Clinical Overview**
John G. Gunderson, M.D.
 - B **Intensive Outpatient and Partial Hospital Care for BPD**
Anthony Bateman, M.D.
 - C **Comparing Psychotherapies for Patients With BPD:
A Progress Report**
Otto F. Kernberg, M.D.
 - D **Effects of Psychotherapy on MDD in Patients With BPD**
Janine L. Stevenson, M.D., Russell Meares, M.D.
 - E **A Randomized Trial of Psychoeducation for Patients
With BPD**
Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 101 2:00 p.m.-5:00 p.m.
Room 3D03/10, Level 3, Javits Center

**MEANING IN SUICIDE: OVERCOMING BARRIERS
AND CONNECTING DIVERSE PERSPECTIVES**

Chp.: Michael F. Myers, M.D.

- A **Existential Meaning: Unifying Diverse Perspectives to
Understanding Suicide**
James R. Rogers, Ph.D., Karen M. Soyka, M.S.

- B **Meaning in Suicide From the Survivor's Perspective**
Carla Fine, M.S.

- C **Approaches to Engaging People of Color in Program
Initiatives for Suicide Prevention and Intervention**
Donna H. Barnes, Ph.D.

- D **Suicide: What Survivors Want From Mental Health Care
Professionals**
Frank R. Campbell, Ph.D.

- E **The Clinician's Perspective: Why Is This Subject So
Tough for Us?**
Michael F. Myers, M.D.

Discussant: Morton Silverman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 102 2:00 p.m.-5:00 p.m.
Rooms 3D04/9, Level 3, Javits Center

**INDIVIDUALIZING INTERPERSONAL
PSYCHOTHERAPY FOR MOOD DISORDERS**

Chp.: Ellen Frank, Ph.D.
Co-Chp.: Nancy K. Grote, Ph.D.

- A **Interpersonal and Social Rhythm Therapy for
Bipolar I Disorder**
Ellen Frank, Ph.D.
 - B **Individualizing Treatment for Depressed Patients With
Co-Occurring Panic or Anxiety**
Jill M. Cryanowski, Ph.D., Ellen Frank, Ph.D.,
M. Katherine Shear, M.D.
 - C **Motivational Interviewing and IPT: An Approach to
Treatment Engagement**
Holly A. Swartz, M.D., Nancy K. Grote, Ph.D.,
Allan Zuckoff, M.D., Ellen Frank, Ph.D., M. Katherine
Shear, M.D.
 - D **Group Psychotherapy for Infertile Women With
Depression**
Ellen F. Olshansky, D.Sc., Ellen Frank, Ph.D.
- THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 103 2:00 p.m.-5:00 p.m.
Rooms 3D05/8, Level 3, Javits Center

**BDD: IS IT A MIND, BODY, OR SOCIOCULTURAL
PROBLEM AND HOW DO YOU TREAT IT?**

Chp.: Fugen Neziroglu, Ph.D.

- A **BDD: Phenomenology, Etiology, and Sociocultural
Influences**
Sony Khemlani-Patel, Ph.D.

B How to Apply Cognitive and Behavior Therapy for BDD
Fugen Neziroglu, Ph.D.

C Update on Pharmacotherapy for BDD
Katharine A. Phillips, M.D.

D Cosmetic Surgery in BDD
David Veale

E SNRI Treatment and Functional Imaging of BDD
Eric Hollander, M.D., Andrea Allen, Ph.D., Lauren
Friday, B.A.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 104 2:00 p.m.-5:00 p.m.
Rooms 3D06/7, Level 3, Javits Center

**MODEL PSYCHIATRY RESIDENCY PROGRAMS ON
RELIGION AND SPIRITUALITY**

Chp.: Francis G. Lu, M.D.

Co-Chp.: Christina M. Puchalski, M.D.

**A Religion, Spirituality, and Culture in Psychiatric Practice
at the University of Louisville**
James Hyde, Ph.D.

**B Enhancing Spirituality Teaching at the Medical
University of South Carolina**
David W. Hiott, M.D., Dana King, M.D.

**C University of Saskatchewan Curriculum on
Spirituality and Mental Health**
Marilyn D. Baetz, M.D.

Discussants: John R. Peteet, M.D., Allan M. Josephson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 105 2:00 p.m.-5:00 p.m.
Odets Room, Fourth Floor, Marriott Marquis

**HEALTH AND LIFESTYLE OF PEOPLE WITH
SCHIZOPHRENIA: THE VIEW FROM SCOTLAND**

Chp.: Robin G. McCreadie, D.Sc.

Co-Chp.: Ciara Kelly, M.D.

A Smoking Habits of Scottish People With Schizophrenia
Ciara Kelly, M.D., Robin G. McCreadie, D.Sc.,
Roch Cantwell, M.D., John Eagles, M.D., Paul Sclare, M.D.,
Simon Naji, M.D.

**B Diet and Cardiovascular Risk: Descriptive Study and
Randomized, Controlled Trial**
Robin G. McCreadie, D.Sc.

**C Ocular Abnormalities in Community-Based Patients
With Schizophrenia**
Moirra A. Connolly, Roch Cantwell, M.D., Ciara Kelly, M.D.,
Michael Smith, Norman Button, John Norrie

D Sexual Dysfunction in Schizophrenia
Shiona M. Macdonald, M.B., Jennifer Halliday, M.B.,
Susan Farrington, B.A., Thomas Macewan, M.B.,
Susan Wall, Valerie Sharkey, B.S.C., Robin G.
McCreadie, D.Sc.

E The Dental Health of People With Schizophrenia
Robin G. McCreadie, D.Sc.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 106 2:00 p.m.-5:00 p.m.
O'Neill Room, Fourth Floor, Marriott Marquis

**DO NOT WAIT UNTIL YOU PRACTICE, KNOW IT
NOW: WHAT RESIDENTS AND EARLY
PSYCHIATRISTS NEED TO KNOW**

Chp.: Consuelo C. Cagande, M.D.

Co-Chp.: Thomas S. Newmark, M.D.

**A Professional Liability Insurance: A Primer for
Psychiatrists**
Martin G. Tracy, J.D.

B Understanding Managed Care
Shivkumar Hatti, M.D.

C Private Versus Administrative Versus Academic Practice
David A. Baron, D.O.

**D Ethics for Psychiatry Residents and Early Career
Psychiatrists**
Thomas S. Newmark, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 107 2:00 p.m.-5:00 p.m.
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

**PSYCHIATRY, ETHICS, AND END-OF-LIFE CARE:
NEW INSIGHTS AND CHALLENGES**

Chp.: David W. Kissane, M.D.

Co-Chp.: Brian J. Kelly, M.B.

**A Impact of Demoralization on Decision Making in
Physician-Assisted Suicide**
David W. Kissane, M.D., David M. Clarke, Ph.D.,
Anthony Love, Ph.D., Simon Wein, M.D.

**B Spiritual Interpretation of the Demoralization Syndrome
as Alienation From Self**
Constance A. Jennings, M.D., David W. Kissane, M.D.

(Continued on next page)

C Countertransference and Ethical Issues in End-of-Life Care
 Brian J. Kelly, M.B., Frances T. Varghese, M.B., Dan Pelusi, B.A., Paul Burnett, Ph.D., Marguerite Robertson, M.B., Shirlene Badger, B.A.

D Competing Paradigms of Responding to Assisted-Suicide Requests in Oregon: Case Report
 N. Gregory Hamilton, M.D., Catherine Hamilton, M.A.

Discussant: Herbert Hendin, M.D.
 THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 108 2:00 p.m.-5:00 p.m.
 Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

AN INTEGRATION OF THE PATHOPHYSIOLOGY AND PHARMACOTHERAPY FOR PTSD

Chp.: Lori L. Davis, M.D.

- A Noradrenergic Function in the Pathophysiology and Treatment of PTSD**
 Steven M. Southwick, M.D.
- B Hypothalamic Pituitary Adrenal Axis and Serotonergic Function in PTSD**
 J. Douglas Bremner, M.D.
- C Amino Acid Neurotransmitter Modulation in PTSD**
 Lori L. Davis, M.D., Frederick Petty, M.D.

Discussant: Charles R. Marmar, M.D.
 THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 109 2:00 p.m.-5:00 p.m.
 Booth/Edison Rooms, Fifth Floor, Marriott Marquis

FEELING UNREAL: A CONTEMPORARY OVERVIEW OF DEPERSONALIZATION DISORDER

Chp.: Daphne Simeon, M.D.

- A The Phenomenology of Depersonalization Disorder**
 Daphne Simeon, M.D., Margaret Knutelska, M.P.H., Dorothy Nelson, B.S.C., Orna Guralnik, Psy.D.
- B The Neurophysiological Basis of Depersonalization Disorder**
 Anthony S. David, M.D., Mary L. Phillips, M.D., Nicholas Medford, M.D., Mauricio Sierra, M.D.
- C Neurobiology of the Dissociative States Produced by Ketamine**
 John H. Krystal, M.D., J. Douglas Bremner, M.D., Amit Anand, M.D., Dennis S. Charney, M.D., Cyril Dsouza, M.D.

D Cognitive Processes in Depersonalization Disorder
 Orna Guralnik, Psy.D., Margaret Knutelska, M.P.H., Daphne Simeon, M.D.

E Neurochemistry and Pharmacological Treatment of Depersonalization Disorder
 Daphne Simeon, M.D., Margaret Knutelska, M.P.H., Orna Guralnik, Psy.D., Dorothy Nelson, B.S.C.

F A Cognitive-Behavioral Approach to Depersonalization Disorder
 Anthony S. David, M.D., Dawn Baker, Ph.D., Elaine Hunter, Ph.D., Mauricio Sierra, M.D., Mary L. Phillips, M.D.
 THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 110 2:00 p.m.-5:00 p.m.
 Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

PSYCHOSOCIAL IMPACT OF SARS ON PATIENTS, HOSPITALS, AND HEALTH CARE PROVIDERS

Chp.: Donna E. Stewart, M.D.

- A The Traumatic Impact of SARS on Nurses and Health Care Workers With Children**
 Robert G. Maunder, M.D., William J. Lancee, Ph.D., Jonathan J. Hunter, M.D., Kenneth E. Balderson, M.D., Sean B. Rourke, Ph.D., Patricia M. Petryshen, Ph.D., David S. Goldbloom, M.D., Donald A. Wasylenki, M.D., Calvin Fones, M.D.
- B Academic Physicians Coping During SARS**
 Donna E. Stewart, M.D., Sherry Grace, Ph.D., Karen Hershenfield, B.S.C., Emma K. Robertson, Ph.D.

C Consultation-Liaison Psychiatry During the SARS Outbreak: Response to Patients and Administration
 Jonathan J. Hunter, M.D.

D Psychosocial Effects of Quarantine Due to SARS in Health Care Workers
 Emma K. Robertson, Ph.D., Karen Hershenfield, B.S.C., Sherry Grace, Ph.D., Donna E. Stewart, M.D.

E Group Psychological Perspectives on the SARS Epidemic in Toronto
 Melyn Leszcz, M.D.
 THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 111 2:00 p.m.-5:00 p.m.
 Plymouth/Uri/ Shubert Rooms, Sixth Floor, Marriott Marquis

TRAUMATIC STRESS: THE BRIDGE BETWEEN NEUROSCIENCE AND PSYCHODYNAMIC PSYCHIATRY

Chp.: Andrei Novac, M.D.

A Disorganized Attachment Alters the Cortisol Stress Response in Human Infants

Robert D. Levitan, M.D., Eman Leung, M.A., Susan Goldberg, Ph.D., Stephen Matthews, Ph.D., Leslie Atkinson, Ph.D.

B Biological Aspects of Intergenerational Responses to Traumatic Stress

Rachel Yehuda, Ph.D.

C The Neurobiology of Cognitive Bias

Andrei Novac, M.D.

D Psychodynamic Neurobiology

Barton J. Blinder, M.D.

Discussant: Roger K. Pitman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 112

2:00 p.m.-5:00 p.m.

Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

INSTITUTIONAL ETHICS IN PSYCHIATRY: A MULTIDISCIPLINARY PERSPECTIVE

Chp.: David H. Brendel, M.D.

A Ethical and Legal Aspects of Confidentiality in Psychiatric Institutions

Rebecca W. Brendel, M.D.

B Institutional Obligation to Balance Science With Ethics in Research: Role of the IRB

Scott E. Lukas, Ph.D.

C Some Functions of a Psychiatric Hospital Ethics Committee

J. Alexander Bodkin, M.D.

D Ethical Roles, Identity, and Bureaucratic Health Care

Jennifer Radden, Ph.D.

Discussant: Alan A. Stone, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 113

2:00 p.m.-5:00 p.m.

Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

THE EFFECTS OF SEXUAL AND PHYSICAL ABUSE ON WOMEN'S HEALTH

Chp.: Jane Leserman, Ph.D.

Co-Chp.: Samantha Meltzer-Brody, M.D.

A The Lasting Effects of Sexual Abuse on Health: What Is the Evidence?

Jane Leserman, Ph.D.

B The Health Impact of Sexual and Physical Abuse and PTSD Among Women With Pelvic Pain

Samantha Meltzer-Brody, M.D., Jane Leserman, Ph.D., Wilma I. Castilla-Puentes, M.D., Marian I. Butterfield, M.D.

C Does Having a Disability Increase Women's Risk of Sexual and Physical Assault?

Kathryn E. Moracco, Ph.D., Neepa Ray, M.S.C., Daniela Sotres-Alvarez, M.S.C., Lawrence L. Kupper, Pamela A. Dickens, M.P.H., Donna Scandlin, M.Ed., Sandra L. Martin, Ph.D.

D Treating PTSD Related to Sexual Trauma in Women

Marian I. Butterfield, M.D.

E Sexual Abuse in the Context of Psychiatric Disorders

Anita L.H. Clayton, M.D.

Discussants: Ruby C. Castilla-Puentes, M.D.,

Wilma I. Castilla-Puentes, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 114

2:00 p.m.-5:00 p.m.

Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

PROVIDING PSYCHIATRIC SERVICES AROUND THE WORLD WITH A SHORTAGE OF PSYCHIATRISTS

The Royal College of Psychiatrists

Chp.: Nigel M. Bark, M.D.

Co-Chp.: A. Hamid Ghodse, Ph.D.

A Peer-Specialists, Self-Help Groups, and Psychiatrists: An Opportunity to Expand Resources and Horizons

Peter Stastny, M.D.

B The New U.K. Graduate Mental Health Worker

Andrew Kent, M.D.

C Setting Up a Psychiatric Service for a Group of Afghan Refugees Living in Pakistan

Khalid A. Mufti, M.D., Farooq Naeem, M.R.C.

D Management of Mental Health Services With Scarce Resources: The Kenyan Experience

Marx O. Okonji, M.A.

E The Marriage of Modern and Traditional Methods in Mental Health Care in Egypt

Nasser F. Loza, M.B., Sherif F. Atallah, M.R.C.

Discussant: Martin Gittelman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 115 2:00 p.m.-5:00 p.m.

Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

MEETING THE CHALLENGE OF ADOLESCENT ADHD

Chp.: Timothy E. Wilens, M.D.

- A Functional Outcomes in Adolescents With ADHD**
Eric Mick, Sc.D.
- B Diagnostic Issues: The Challenge of Adolescent ADHD**
Laurence L. Greenhill, M.D.
- C Comorbidities in Adolescents With ADHD**
Joseph Biederman, M.D.
- D Safety and Efficacy of OROS Methylphenidate in Adolescents With ADHD**
Timothy E. Wilens, M.D.
- E Improvements in Adolescents' Driving Performance With OROS Methylphenidate**
Daniel J. Cox, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 116 2:00 p.m.-5:00 p.m.

Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

HOW TO PRACTICE EVIDENCE-BASED MEDICINE

Chp.: Donna M. Sudak, M.D.

- A Introduction to Evidence-Based Medicine**
Bryce Templeton, M.D.
- B Review of Basic Statistical Concepts**
Maju Mathews, M.D.
- C Critical Appraisal of Randomized Controlled Trials**
Adedapo B. Williams, M.D.
- D Critical Appraisal of Systematic Reviews and Meta-Analysis**
Babatunde A. Adetunji, M.D.

THIS SESSION WILL BE AUDIOTAPED.

2004 ANNUAL MEETING

TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

DISORDERS

1. AIDS and HIV-Related Disorders
2. Alcohol and Drug-Related Disorders
3. Anxiety Disorders
4. Attention Spectrum Disorders
5. Cognitive Disorders (Delirium, Dementia, Amnestic, etc.)
6. Dissociative Disorders
7. Eating Disorders
8. Mental Retardation (Child/Adolescent/Adult)
9. Mood Disorders
10. Personality Disorders
11. Schizophrenia and Other Psychotic Disorders
12. Sexual and Gender Identity Disorders
13. Sleep Disorders
14. Somatoform Disorders

PRACTICE AREAS/SETTINGS

15. Psychiatric Administration and Services: Public, Private, and University

SUBSPECIALTY AREAS OR SPECIAL INTERESTS

16. Addiction Psychiatry
17. Biological Psychiatry and Neuroscience
18. Brain Imaging
19. Child and Adolescent Psychiatry and Disorders
20. Consultation-Liaison and Emergency Psychiatry
21. Cross-Cultural and Minority Issues
22. Diagnostic Issues
23. Epidemiology
24. Ethics and Human Right
25. Forensic Psychiatry
26. Genetics
27. Geriatric Psychiatry
28. Neuropsychiatry
29. Psychiatric Education
30. Psychiatric Rehabilitation
31. Psychoanalysis
32. Psychoimmunology
33. Research Issues

34. Social and Community Psychiatry
35. Stress
36. Suicide
37. Violence, Trauma, and Victimization

TREATMENTS

38. Behavior and Cognitive Therapies
39. Combined Pharmacotherapy and Psychotherapy
40. Couple and Family Therapies
41. Group Therapy
42. Individual Psychotherapies
43. Psychopharmacology
44. Other Somatic Therapies
45. Treatment Techniques and Outcome Studies

OTHER ISSUES

46. Computers
47. Creativity and the Arts
48. Gender Issues
49. Health Services Research
50. Historical Questions
51. Information Technology
52. Internet
53. Lesbian/Gay/Bisexual/Transgender Issues
54. Managed Care and Health Care Funding
55. Men's Health Issues
56. National Institute on Drug Abuse
57. Personal Digital Assistants (PDAs)
58. Political Questions
59. Presidential Theme: Psychotherapy and Psychopharmacology: Dissolving the Mind-Brain Barrier
60. Professional and Personal Issues
61. Religion, Spirituality, and Psychiatry
62. Resident and Medical Student Concerns
63. Stigma/Advocacy
64. Telepsychiatry
65. Virtual Reality
66. Women's Health Issues

GUIDE TO USING THE TOPIC INDEX

Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas/Settings, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format, you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this *Program Book* to obtain further details about the session.

DISORDERS		Page #			Page #
TOPIC 1: AIDS AND HIV-RELATED DISORDERS					
CLINICAL CASE CONFERENCE					
3	Psychiatric Issues in the Management of Patients With HIV Infection	70	16	Broadening Horizons: Advances in Understanding the Etiology, Effects, and Treatment of Anxiety Disorders	6
DISCUSSION GROUP					
9	HIV (<i>For Residents Only</i>)	20	17	The Hidden Faces of Anxiety	6
MASTER EDUCATOR CLINICAL CONSULTATION					
5	Neuropsychiatric Complications of HIV-1 Infection	44	43	Emotion Regulation and Plasticity of Underlying Circuitry: Implications for Depression, Anxiety, and Long-Term Brain Function	66
SCIENTIFIC AND CLINICAL REPORT					
50	Evaluation of an HIV Intervention for Psychiatric Care Providers in South Africa	52	46	Panic Anxiety: Understanding Its Nature and Nurturing Recovery	66
SYMPOSIA					
47	What Every Psychiatrist Needs to Know About HIV/AIDS	63	50	PTSD: Searching for Answers in Traumatic Times, Part 1	69
59	What You Need to Know About Treatment of HIV-Related Disorders	84	50	PTSD: Searching for Answers in Traumatic Times, Part 2	93
COMPONENT WORKSHOP					
31	Sex, Drugs, and HIV: Synergistic Epidemics	53	53	Core Symptom Domains in the Anxiety Disorders	92
ISSUE WORKSHOPS					
14	Early Trauma, PTSD, and HIV: Association With Transmission and Nonadherence	19	54	Back to the Future: The Role of Gamma-Aminobutyric Acid in Psychiatric Disorders and Treatment	92
124	A Comprehensive Approach to the Treatment of Pain in HIV Illness	95	SCIENTIFIC AND CLINICAL REPORTS		
TOPIC 2: ALCOHOL AND DRUG-RELATED DISORDERS					
COURSE					
12	Systemic Therapies for Substance Abuse Disorders	3	5	Carbon Dioxide Test in Respiratory Panic Disorder: A Clonazepam Trial	23
SCIENTIFIC AND CLINICAL REPORTS					
56	The Effects of State Income Inequality and Alcohol Tax on Alcohol Dependence	77	6	Child Abuse and the Development of PTSD in a Canadian Epidemiological Sample	23
57	Effect of Age on Long-Term Outcomes of Inpatient Alcoholism Treatment	77	29	Early Detection of Relapse in Patients with Panic Disorder With Agoraphobia	50
58	Topiramate Treatment of Alcohol Dependence: Effects on Psychosocial Functioning and Its Relationship With Heavy Drinking	77	30	Three-Year Prophylaxis in Panic Disorder: To Continue or Discontinue?	50
SYMPOSIUM					
54	Anticonvulsants for Treating Multiple Components of Alcohol-Dependence Syndrome	64	31	Discontinuation of Medications in Panic Patients	50
ISSUE WORKSHOP					
25	Drug Abuse and Mental Health Treatment in Lieu of Imprisonment	26	102	Effectiveness of Intensive Residential Treatment of Severe Refractory OCD	98
TOPIC 3: ANXIETY DISORDERS					
FOCUS LIVE SESSION					
2	PTSD and Anxiety Disorders: Test Your Knowledge	21	SYMPOSIA		
INDUSTRY-SUPPORTED SYMPOSIA					
7	Impulsivity: Emerging Clinical Perspectives	3	18	Evolutionary and Ethological Perspectives on Social Anxiety Disorder	34
9	GAD: Evidence-Based Considerations From Pathophysiology to Long-Term Management	4	108	An Integration of the Pathophysiology and Pharmacotherapy for PTSD	104
14	The Many Faces of Anxiety: Origins, Pathogenesis, and Management	6	COMPONENT WORKSHOP		
TOPIC 4: ATTENTION SPECTRUM DISORDERS					
COURSES					
2	ADD in Children and Adolescents	1	15	Update on Practice Guidelines: PTSD and Acute Stress Disorder	25
14	ADD in Adults	5	ISSUE WORKSHOPS		
38	Advanced Assessment and Treatment of ADD	14	111	What Love Has to Do With It: Exploring the Role of Love in Mental Illness	81
DISCUSSION GROUP					
20	Clinical Management of ADHD With Children, Adolescents, and Adults (<i>Meet the Authors</i>)	76	138	Diverse Cultural Expressions and Interventions for Anxiety and Depressive Disorders	98
INDUSTRY-SUPPORTED SYMPOSIA					
4	Adult ADHD: Clinical Utility and Validity	2	SCIENTIFIC AND CLINICAL REPORTS		
18	Targeting Executive Dysfunctions for Treatment	7	35	ADHD Comorbidity in Preschool Children	51
38	Conceptualizing and Treating ADHD Adults	39	36	Atomoxetine for Comorbid ADHD and Affective Symptoms	51
47	Adult ADHD Diagnosis and Treatment	67	37	Abuse Liability Assessment of Atomoxetine in a Drug-Abusing Population	51
SCIENTIFIC AND CLINICAL REPORTS					
35	ADHD Comorbidity in Preschool Children	51	104	Cognitive-Behavioral Therapy for Residual ADHD in Adults	98
36	Atomoxetine for Comorbid ADHD and Affective Symptoms	51	105	A Controlled Study of Functional Impairments in 500 ADHD Adults	98
37	Abuse Liability Assessment of Atomoxetine in a Drug-Abusing Population	51	106	Long-Term Safety and Efficacy of Mixed Amphetamine Salts Extended-Release for Adult ADHD	98
104	Cognitive-Behavioral Therapy for Residual ADHD in Adults	98			
105	A Controlled Study of Functional Impairments in 500 ADHD Adults	98			
106	Long-Term Safety and Efficacy of Mixed Amphetamine Salts Extended-Release for Adult ADHD	98			

SYMPOSIUM	Page #
115 Meeting The Challenge of Adolescent ADHD	106

ISSUE WORKSHOP	
47 New Technologies for the Assessment of ADHD	47

TOPIC 5: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)

COURSES	
74 The Evaluation and Identification of the Major Dementias	55
94 Delirium in the General Hospital	82

INDUSTRY-SUPPORTED SYMPOSIA	
15 From Pathology to Practice: Evolving Therapeutic Strategies for Alzheimer's Disease	6
25 Novel Intervention Strategies Across the Spectrum of Dementia: Real Patients and Real Outcomes	11
32 Current Alzheimer's Disease Treatments and Beyond: Advances Impacting Clinical Practice, Part 1	13
32 Current Alzheimer's Disease Treatments and Beyond: Advances Impacting Clinical Practice, Part 2	41
42 Reaching Beyond Alzheimer's Disease With Cholinergic Therapy	40

REVIEW OF PSYCHIATRY: SECTION 2	
Cognitive-Behavior Therapy	57

SCIENTIFIC AND CLINICAL REPORT	
99 The Role of Dexmedetomidine in Reducing Delirium in Cardiotomy Patients	98

COMPONENT WORKSHOP	
46 Is There a Standard of Care for the Treatment of Dementia?	80

ISSUE WORKSHOP	
87 Vascular Dementia: Assessment, Imaging, and Treatment	74

TOPIC 6: DISSOCIATIVE DISORDERS

SYMPOSIA	
73 Dissociative Disorders: Issues of Culture and Issues of Trust	87
109 Feeling Unreal: A Contemporary Overview of Depersonalization Disorder	104

TOPIC 7: EATING DISORDERS

COURSES	
22 Therapeutic Interventions in Eating Disorders: Basic Principles	7
28 Current Concepts in Child and Adolescent Eating Disorders	8

DISCUSSION GROUP	
15 Psychiatric Comorbidity in the Eating Disorders: Diagnosis, Treatment, and Research	48

INDUSTRY-SUPPORTED SYMPOSIUM	
48 Binge-Eating Disorder: Genes, Treatments, and Consequences	67

MASTER EDUCATOR CLINICAL CONSULTATION	
2 Evaluation and Treatment of Eating Disorders	17

MEDICAL UPDATE	
4 How to Shrink Obesity	96

SCIENTIFIC AND CLINICAL REPORTS	
84 DSM-IV Comorbidity in Binge-Eating Disorder	96
85 Males at Risk: Hawaiian and Filipino Adolescents	96

SYMPOSIA	Page #
36 Eating Disorders 2004: From PETs to Psyche	60
46 Translational Research on Eating Disorders	62

ISSUE WORKSHOP	
127 Treatment-Resistant Patients With Bulimia Nervosa	95

TOPIC 8: MENTAL RETARDATION (CHILD/ADOLESCENT/ADULT)

FORUM	
9 <i>I Am Sam</i>	67

SYMPOSIUM	
93 Developmental Disabilities From Childhood to Adulthood	100

COMPONENT WORKSHOP	
9 Mission Possible: The Science of Psychiatry and the Art of Advocacy	18

TOPIC 9: MOOD DISORDERS

CONTINUOUS CLINICAL CASE CONFERENCE	
2 Two Hospitalized Patients With Refractory Mood Disorder and Cognitive Impairment, Part 1	70
2 Two Hospitalized Patients With Refractory Mood Disorder and Cognitive Impairment, Part 2	93

COURSE	
87 The Neuroendocrinology of Mood Disorders	70

DISCUSSION GROUPS	
4 Dementia and Delirium	15
8 Depression in Alzheimer's and Other Neurologic Conditions: Evaluation and Treatment	20

INDUSTRY-SUPPORTED SYMPOSIA	
2 Preventive Psychiatry in Mood Disorders: A New Frontier	1
3 Bipolar Disorder and Alcoholism: Diagnostic Challenges and Therapeutic Interventions	2
5 Towards DSM-V: Phenomenology, Neurobiology, and Treatment Response in Depression	2
8 Bipolar Disorder: Improving Outcomes When Theory, Science, and Clinical Practice Converge	4
11 Interface Between Depression and Medical Illness	4
12 Antidepressant Treatments You May Not Know About, But Should...	5
19 The Treacherous Triad for Depression	8
20 Beyond 5HT: New Treatments for Depression	9
23 Unmasking Bipolar Disorder: Overcoming the Barriers to Treatment Success	9
27 Moderators and Mediators of Antidepressant Response	11
33 Recognizing the Many Faces of Bipolar Disorder, Part 1	13
33 Recognizing the Many Faces of Bipolar Disorder, Part 2	41
39 Plotting a Course to Remission: Navigating the Intersection of Mind, Brain, and Body	39
44 Challenges in Treating Bipolar Illness and Comorbid Disorders	66
45 Does the Pharmacology of Antidepressant Drugs Matter?	66

LECTURE	
6 The Search for Genes of Bipolar Disorder: From Classical Genetics to Novel Molecular Targets	21

SCIENTIFIC AND CLINICAL REPORTS	
20 Duloxetine Versus Placebo in the Prevention of Relapse of MDD	24
21 Response to Antidepressants Is Independent of Gender	24
22 Depression and BPD During the Immediate Prepartum Period	24

(Continued on next page)

TOPIC INDEX

	Page #		Page #
32	50	SYMPOSIA	
33	50	2	30
34	51	48	63
59	77	53	64
65	78	65	85
66	78	71	87
67	78	81	89
76	79	95	101
		100	102
		ISSUE WORKSHOP	
		43	47
		MEDIA WORKSHOP	
		8	96
		TOPIC 11: SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS	
		ADVANCES IN RESEARCH	
		Evidence-Based Treatment in Schizophrenia	20
		COURSES	
		64	43
		77	69
		DISCUSSION GROUP	
		3	15
		FOCUS LIVE SESSION	
		3	28
		INDUSTRY-SUPPORTED SYMPOSIA	
		21	9
		24	10
		26	11
		31	13
		31	41
		35	13
		35	41
		52	92
		LECTURE	
		19	71
		MASTER EDUCATOR CLINICAL CONSULTATIONS	
		7	50
		9	72
		RESEARCH CONSULTATION	
		2	50
SYMPOSIUM			
8	31		
21	35		
40	61		
50	63		
58	65		
62	84		
66	85		
67	86		
76	88		
77	88		
90	99		
ISSUE WORKSHOP			
93	74		
132	95		
TOPIC 10: PERSONALITY DISORDERS			
ADVANCES IN RESEARCH			
Epidemiology and Treatment Implications of Personality Disorders	20		
COURSES			
19	5		
62	43		
86	70		
DISCUSSION GROUPS			
7	20		
14	48		
INDUSTRY-SUPPORTED SYMPOSIUM			
36	38		
LECTURE			
7	22		
MASTER EDUCATOR CLINICAL CONSULTATION			
6	49		
SCIENTIFIC AND CLINICAL REPORTS			
8	23		
9	23		
95	97		
96	97		

SCIENTIFIC AND CLINICAL REPORTS		Page #
11	Do Patients With Schizophrenia Show Periods of Complete Recovery? A 20-Year Follow-Up	23
12	Twenty-Year Outcome in Schizophrenia: What's Sex Got to Do With It?	23
13	Recovery From Schizophrenic Psychoses Until Age 35	23
74	IC-SOHO: Intercontinental Schizophrenia Outpatient Health Outcomes Study	79
75	Male Patients With Schizophrenia Have Impairment in the Processing of Spatial Information From Dissociated Spatial Reference Frames	79

SYMPOSIA		Page #
13	Neurodevelopment and Schizophrenia: Clinical and Basic Science Perspectives	33
45	Delusional Disorder: A Reconsideration of the Scientific and Conceptual Basis for the DSM Reformulation of Paranoia	62
105	Health and Lifestyle of People With Schizophrenia: The View From Scotland	103

ISSUE WORKSHOPS		Page #
10	Can Early Intervention Prevent Psychosis? Management of the Prodromal Phase	19
40	My Name is Walter James Cross	46
64	Management of Difficult Schizophrenia	53
70	The Out-of-the-Shadow Project	54
145	Treatment of Recent-Onset Schizophrenia in Community and Research Settings	99

MEDIA WORKSHOP		Page #
1	<i>Dinner Boy</i>	20

TOPIC 12: SEXUAL AND GENDER IDENTITY DISORDERS

INDUSTRY-SUPPORTED SYMPOSIUM		Page #
10	Sex, Sexuality, and 5HT	4

MEDICAL UPDATE		Page #
3	Better Sex: Naturally	77

SYMPOSIA		Page #
34	Women's Sexuality Update: Overcoming Obstacles to Pleasure	60
51	Critical Perspectives on Gender Identity Disorder in Children and Adolescents	64

ISSUE WORKSHOPS		Page #
89	The Sissy Duckling: The Perils of Childhood Gender Variance	74
98	Understanding and Treating Compulsive Sexual Behavior	75
100	Sexual Satisfaction and Mental Health in Orthodox Jewish Women	75

TOPIC 13: SLEEP DISORDERS

COURSES		Page #
24	Melatonin and Light Treatment of SAD, Sleep, and Other Body Clock Disorders	8
32	Irresistible Sleep: Narcolepsy Update	14
71	Overview and Update of Sleep Disorders Medicine	55

INDUSTRY-SUPPORTED SYMPOSIA		Page #
28	Beyond Sleep Onset: New Perspectives on the Treatment of Insomnia	11
49	Exploring the True Morbidity of Insomnia	67

SCIENTIFIC AND CLINICAL REPORTS		Page #
92	Modafinil Improves Patient Functioning in Shift Work Sleep Disorder	97
93	Modafinil Treatment of Chronic Shift Work Sleep Disorder	97

ISSUE WORKSHOP		Page #
142	Challenging Sleep Problems: Looking at Slow-Wave Sleep	99

TOPIC 14: SOMATOFORM DISORDERS

CLINICAL CASE CONFERENCE		Page #
1	Boundary Issues and the Challenge of the Somatizing Patient	15

COURSES		Page #
61	Pain Management for Psychiatrists: An Overview of Treatment Approaches	42
76	The Complexities of Chronic Pain: Psychiatric Issues and Treatments	56

SYMPOSIUM		Page #
103	BDD: Is It a Mind, Body, or Sociocultural Problem and How Do You Treat It?	102

ISSUE WORKSHOPS		Page #
21	Chronic Fatigue Syndrome: Disease or Abnormal Illness Behavior?	25
50	Fibromyalgia: Current Understanding and Future Directions	47
71	Psychogenic Seizures: A Prototype of Somatoform Disorder	54

PRACTICE AREAS/SETTINGS

TOPIC 15: PSYCHIATRIC ADMINISTRATION AND SERVICES: PUBLIC, PRIVATE, AND UNIVERSITY

LECTURES		Page #
3	The Changing Face of Mental Health Services	16
16	How Many Psychiatrists Do We Need?	56
22	Public Academic Liaison: Pursuit of Best Practices in a Time of Economic Entrenchment	76

SCIENTIFIC AND CLINICAL REPORT		Page #
52	Inter-European Countries Comparison on Treatment Use for Mental Health Disorders	52

SYMPOSIA		Page #
38	How to Launch a Successful Private Practice, Part 3	60
86	Managing HIPAA-Related Tensions in Clinical Practice	90

COMPONENT WORKSHOPS		Page #
7	State Hospital Psychiatry: Been Down so Long It Looks Like up to Me	18
29	Helping District Branches Relate to APA and to Their Members	53

ISSUE WORKSHOPS		Page #
19	Psychiatry in the Primary Care Setting: Making It Work for the Psychiatrist	25
39	How to Launch a Successful Private Practice, Part 1	46
61	How to Launch a Successful Private Practice, Part 2	53
102	Implementing Psychosocial Treatments in Real-World Settings	75

SUBSPECIALTY AREAS OR SPECIAL INTERESTS

TOPIC 16: ADDICTION PSYCHIATRY		Page #
COURSES		Page #
85	Office-Based Buprenorphine Treatment of Opioid-Dependent Patients	70
96	Street Drugs and Mental Disorders: Overview and Treatment	82
98	Introduction to Transcranial Magnetic Stimulation (TMS)	93

TOPIC INDEX

FORUM	Page #	SCIENTIFIC AND CLINICAL REPORTS	Page #
10 Buprenorphine: What the Clinician Should Know	81	47 Externalizing Behaviors in Preadolescent Children: A National Panel Study	52
INDUSTRY-SUPPORTED SYMPOSIUM		48 Gender and the Prediction of Drug and Alcohol Abuse in Adolescent Inpatients	52
40 Pharmacotherapy of Addictions: From Clinics Into Office Practice	39	SYMPOSIUM	
LECTURE		70 Anxiety Disorders in Youth: Clinical and Research Updates	86
23 The Brain In Love	82	COMPONENT WORKSHOPS	
SYMPOSIUM		19 Approaches to Assessment and Diagnosis of Infants and Small Children	25
56 Alcoholics Anonymous and Spiritually Oriented Recovery	65	35 The Psychiatrist in the Schools: Medication, Boundaries, and Transference Issues	72
COMPONENT WORKSHOP		40 New Classification of Psychopathology of Infants and Young Children	73
48 Buprenorphine in the Trenches: What the General Psychiatrist Needs to Know	80	ISSUE WORKSHOP	
ISSUE WORKSHOP		58 Cutting-Edge Management of Tourette's Syndrome and Its Comorbidities	48
97 Addiction Psychiatry: Science, Craft, and Spirituality	75	TOPIC 20: CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY	
MEDIA WORKSHOP		DISCUSSION GROUPS	
2 The Movie <i>Traffic</i> : Hollywood, Teen Substance Abuse, and U.S. Drug Policy	20	1 The Medical Care for the Chronically Mentally Ill: The Role of the Psychiatrist (<i>Meet the Authors</i>)	15
TOPIC 17: BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE		18 Psychological Engagement During the Consultation Process (<i>Meet the Authors</i>)	71
REVIEW OF PSYCHIATRY: SECTION 3		LECTURE	
Developmental Psychobiology	72	17 Feeling and Healing: Biopsychosocial Treatments and Their Effects on Medical Illness	56
SCIENTIFIC AND CLINICAL REPORT		MEDICAL UPDATES	
103 Hyperactive Error Processing in OCD	98	1 Irritable Bowel Syndrome	22
SYMPOSIUM		2 Hepatitis B and C: What's New?	50
14 Current Concepts of the Neurobiology of the Self	33	SCIENTIFIC AND CLINICAL REPORT	
TOPIC 18: BRAIN IMAGING		98 Depression and Nonlinear Heart Rate Dynamics in Older Coronary Patients	98
LECTURE		SYMPOSIA	
25 Through the Looking Glass: Uses of Simulation and Virtual Reality in Clinical Practice and Brain Imaging Research	94	32 The Scars of SARS: Its Impacts on Patients, Health Care Workers, and the Community	59
REVIEW OF PSYCHIATRY: SECTION 4		43 Tragic Events in the Emergency Department: The Role of Psychiatry and the Institutional Impact	62
Brain Stimulation in Psychiatric Treatment	83	107 Psychiatry, Ethics, and End-of-Life Care: New Insights and Challenges	103
SCIENTIFIC AND CLINICAL REPORTS		110 Psychosocial Impact of SARS on Patients, Hospitals, and Health Care Providers	104
68 fMRI of Spatial Working Memory in Schizotypal Personality Disorder	78	COMPONENT WORKSHOP	
69 Hypofrontality in Patients With Schizophrenia and Bipolar Disorders: An fMRI Study	78	22 Blood on the Floor: Responding to Catastrophic Events and High Risks	45
SYMPOSIUM		ISSUE WORKSHOPS	
41 Neuroimaging Seminar	61	49 Update on Hepatitis C and Psychiatric Issues	47
ISSUE WORKSHOPS		96 Innovations in Academic Emergency Psychiatry	75
4 Functional Imaging in Court: Uses and Controversies	19	TOPIC 21: CROSS-CULTURAL AND MINORITY ISSUES	
114 Evaluating Treatment With Functional Brain Imaging	81	CLINICAL CASE CONFERENCE	
TOPIC 19: CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS		2 Assessing and Treating Psychiatric Symptoms in Individuals With Cardiovascular Disease	42
ADVANCES IN RESEARCH			
Treatment of Child Adolescent Anxiety and Depression: What Have We Learned?	20		
RESEARCH ADVANCES IN MEDICINE			
Comorbidity of Psychiatric and Addictive Disorders in Children	45		

COURSES **Page #**

- 16 DSM-IV-TR Cultural Formulations: Diagnosis and Therapy 5
- 92 The Clinical Application of Cultural Psychiatry 82

LECTURE

- 20 Latino Youth in the U.S.: Developmental and Mental Health Challenges 71

SCIENTIFIC AND CLINICAL REPORTS

- 24 Ethnic-Matched, Culturally-Competent, Model-Based ACT Team: Early Outcome Report 24
- 60 Screening for Depression Among Chinese Americans in Primary Care Using Two Items 77
- 61 Suicidal Thinking in Colombian Youth With a History of Attempted Suicide 77
- 80 Ethnicity, Diagnosis, and Health Care Utilization in Incarcerated Women 79

SYMPOSIA

- 75 Psychiatry, Ethnicity, and Culture: An Update on Ethnopsychopharmacology, Mood, and Anxiety Disorders in Minority 88
- 87 Memory in the U.S. and France: Vive La Difference 91
- 89 Meeting the Mental Health Needs of Latinos in Community and Primary Care 91

COMPONENT WORKSHOPS

- 1 How to Teach and Learn Cultural Competence in Geriatric Psychiatry 17
- 6 Facilitating Research on Minority Populations by Minority Researchers 18
- 10 Bridging Across Culture and Generations: An Asian-American Perspective 18
- 23 The 'Ties' That Bind: Considerations of Culture and Family in Mental Health Treatment 45
- 39 Reducing Disparities in Access to Psychiatric Care: APA Perspectives 73
- 43 Response to the Simon Bolivar Award Lecture on Latino Youth in the U.S.: Developmental and Mental Health Challenges 79

ISSUE WORKSHOPS

- 31 Treating African-American Patients With Psychotherapy: A Training Dilemma 26
- 57 It Doesn't Happen to Us: Exploring Trauma and Resiliency in Minorities 48
- 86 Migration and Professional Identity Experience of Organizing Russian-American Psychiatry 74
- 91 Premarital Counseling: The Facts of Life and More 74
- 92 Psychotherapy Issues Throughout the Life Cycle in Asian Women 74

MEDIA WORKSHOP

- 3 Cultural Assessment in Clinical Psychiatry: Two Training Videotapes 48

TOPIC 22: DIAGNOSTIC ISSUES

SYMPOSIUM

- 12 Behavioral Dimensions of Psychiatric Disorders 33

TOPIC 23: EPIDEMIOLOGY

RESEARCH ADVANCES IN MEDICINE

- Epidemiology of Comorbid Psychiatric and Addictive Disorders 45
- Depression in Hepatitis C Patients and Interferon Treatment 45
- Research Advances in HIV Care 45

SCIENTIFIC AND CLINICAL REPORTS **Page #**

- 38 Effects of 9/11 and Chronic Stress on Female Drinking and Anxiety 51
- 49 Prevalence and Outcomes of Childhood Adversity in an Australian Population 52
- 81 Psychotropic Drug Utilization in Six European Countries 79
- 82 Onset of DSM-IV Alcohol Abuse and Dependence: A 10-Year Prospective Study 79
- 94 A Comparison of Seasonality of Mood and Behavior in African and African-American Students 97

TOPIC 24: ETHICS AND HUMAN RIGHTS

COURSE

- 78 Bioethics Update 2004 69

DISCUSSION GROUP

- 16 Ethics in Psychiatric Practice 48

FOCUS LIVE SESSION

- 1 Forensic and Ethical Issues in Psychiatry 16

FORUMS

- 2 Ethical Dilemmas in Practice and Research 27
- 8 Should Sex Be Prevented in Psychiatric Units? Arguments and New Directions 55
- 12 APA and the Pharmaceutical Industry: An Open Forum 99

MASTER EDUCATOR CLINICAL CONSULTATION

- 8 Psychiatric Issues and Interventions at the End of Life 72

ROUND TABLE DISCUSSION

- Coercion and Treatment: Medical, Legal, and Ethical Issues 45

SCIENTIFIC AND CLINICAL REPORT

- 45 How Do Psychiatric Patients Perceive Research Participation? 51

SYMPOSIA

- 16 The Death Penalty: Law and Medical Ethics in the Face of New Court Opinions 34
- 112 Institutional Ethics in Psychiatry: A Multidisciplinary Perspective 105

COMPONENT WORKSHOPS

- 25 Revision of the APA Ethics Annotations: Fostering Dialogue 46
- 37 APA Ethics Procedures 73
- 44 Psychiatric Ethics in the U.S. and Throughout the World 80

ISSUE WORKSHOPS

- 8 Are There Limits to Boundary Limits? 19
- 29 Boundary Violation: History, Typology, and Prevention 26
- 59 Approaching Moral Issues in Mental Health Treatment 53
- 95 Guideline Development for the Assessment of Competency 75

TOPIC 25: FORENSIC PSYCHIATRY

COURSES

- 35 The Psychiatrist as Expert Witness 14
- 58 The Detection of Malingered Mental Illness 42
- 80 Insanity Defense Evaluations 69
- 81 Contemporary Malpractice Liability: A Practical Guide 69
- 84 Infanticide: A Dialogue Between the Psychiatrist and the Attorney 70

FORUMS

- 4 Jails or Treatment? Alternatives to Incarceration 27
- 6 Reversing the Criminalization of the Seriously Mentally Ill 55

LECTURE

- 1 Infanticide: The Hope of Prevention and the Promise of Saved Lives 10
- 113

TOPIC INDEX

SYMPOSIUM		Page #
17	The Scientific Basis of Expert Testimony: Its Application to Matrimonial Disputes	34
COMPONENT WORKSHOPS		
13	What's New in Psychiatry and the Law at APA?	24
17	Fitness to Practice Medicine: The Roles of the Evaluating Psychiatrist	25
26	The Juvenile Justice System: Assessment, Services, and Data Use	46
ISSUE WORKSHOPS		
9	Brooklyn Mental Health Court: Felony Offenders With Mental Illness	19
35	The Clinical Impact of Treating Civil and Criminally-Mandated Psychiatric Patients	46
69	Rehabilitating Traumatized Girls in Residential Juvenile-Justice Settings	54
99	Kendra's Law Becomes Reality: Assisted Outpatient Treatment in Manhattan	75
113	Fitness-for-Duty Evaluations for Law-Enforcement Officers	81
118	Juvenile-Justice Success Series, Chapter 1: Musicianship, Jazz, and Blues	81
119	Politics and Pregnancy: The Regina McKnight Case	81
125	Detection of Malingering	95
129	Avoiding Dual-Agency Pitfalls of Work-Related Neuropsychiatric Impairments	95
134	Whose Responsibility Is It Anyway? The Treating Psychiatrist's?	96
141	An Extension of the Analysis of Restorative Justice and Therapeutic Jurisprudence	99

TOPIC 26: GENETICS

COURSE		
9	Psychiatric Genomics: Applications for Clinical Practice	3
SCIENTIFIC AND CLINICAL REPORT		
71	Prevalence of MTHFR C677T and Methionine Synthase A2756G Polymorphisms in Major Depression and Impact on Response to Fluoxetine Treatment	78

TOPIC 27: GERIATRIC PSYCHIATRY

COURSES		
45	Depression in Later Life: An Interdisciplinary Approach	27
79	Psychiatric Consultation in Long-Term Care	69
MASTER EDUCATOR CLINICAL CONSULTATION		
12	Psychiatric Disorders in the Elderly	94
SCIENTIFIC AND CLINICAL REPORT		
17	Interpersonal Psychotherapy for Depressed Elders With Cognitive Dysfunction	24
SYMPOSIUM		
92	Overcoming Barriers to Long-Term Care and Treatment of the Elderly	100
COMPONENT WORKSHOP		
20	Helping Older Persons With Schizophrenia: Treatment, Research, and Policy	25
ISSUE WORKSHOPS		
13	The After-Death Telephone Call to Family Members: Clinical Perspectives	19
28	The Transitional Object in Dementia	26
90	Geriatric Psychiatry Around the Globe: Present and Future	74

TOPIC 28: NEUROPSYCHIATRY

COURSES		Page #
20	Advances in Neuropsychiatry	7
26	Determining Medical Fitness to Drive: Relevant Issues for Psychiatrists	8
42	Traumatic Brain Injury: Neuropsychiatric Assessment	15
51	Temporal Lobe and Limbic System Anatomy and the Relation to Psychiatric Illness	28
57	The Missing Piece of the Puzzle: Tic Disorders in Adults With OCD or ADD	42
66	Updates in Neuropsychiatry: Delirium, Traumatic Brain Injury, and Post-Stroke Depression	43
100	Neuropsychiatry of Traumatic Brain Injury	93
INDUSTRY-SUPPORTED SYMPOSIUM		
37	Interferon-Induced Depression: Consequences of Treating Chronic Hepatitis C	38
LECTURE		
8	Social Neuroscience: A New Basic Science for Psychiatry	28
MASTER EDUCATOR CLINICAL CONSULTATION		
3	Neuropsychiatry of Stroke: Recent Advances	22
REVIEW OF PSYCHIATRY: SECTION 1		
Neuropsychiatric Assessment		45
SYMPOSIA		
57	An Update on Parkinson's Disease and Its Psychiatric Complications	65
74	Neuropsychiatry of Traumatic Brain Injury: Current Research	87
111	Traumatic Stress: The Bridge Between Neuroscience and Psychodynamic Psychiatry	104

COMPONENT WORKSHOPS		
21	The Neurobiology of Self-Awareness: Learning From Autism and BPD About How We Know Ourselves	45
ISSUE WORKSHOP		
65	The Application of Bedside Executive-Function Measures	53

TOPIC 29: PSYCHIATRIC EDUCATION

COURSES		
5	The Biopsychosocial Formulation: An Approach to Oral Board Presentations	1
18	Teaching Psychiatry? Let Hollywood Help!	5
21	Evidence-Based Medicine: An Introduction for Psychiatrists	7
47	Dimensions of Psychotherapy Supervision: A Case-Based Approach	27
68	How to Pass the Boards! The Part II Oral Exam	43
97	I Found It at the Movies: Using Film Clips to Understand and Teach Psychiatry	82
DISCUSSION GROUP		
6	The Future Structure of Psychiatric Classification and Its Role in Enhancing Therapy, Teaching, and Research	20
FORUM		
3	ABPN Update: Requirements for ABPN Examination	27
LECTURE		
24	Striking Accord: Tales of Teaching and the Heart	83
SCIENTIFIC AND CLINICAL REPORT		
100	Psychiatry Training in Primary Care: Factors for a Satisfactory Program	98

SYMPOSIUM	Page #	RESEARCH CONSULTATION	Page #
116 How to Practice Evidence-Based Medicine	106	1 Evaluating Evidence in Clinical Trials and Research Papers	22
COMPONENT WORKSHOPS		ISSUE WORKSHOP	
27 Wherefore Neuroscience: How Much Does the Psychiatrist Need to Know?	52	18 Psychiatric Research Perspectives in Latin America	20
49 The Blame and Shame Game in Medical Errors: Do You Want to Play It?	94		
ISSUE WORKSHOPS		TOPIC 34: SOCIAL AND COMMUNITY PSYCHIATRY	
66 The Psychiatry Resident as Educator: A Proposal for Curriculum and Supervision	54		
73 Problems in the Psychiatric Education of International Medical Graduates	54	CONTINUOUS CLINICAL CASE CONFERENCE	
77 Mirror, Mirror on the Wall: Ambition and the Teaching Psychiatrist	73	1 Helping Patients Counter Demoralization While Living With a Chronic or Recurrent Psychiatric Illness, Part 1	15
88 Medical Training for Psychiatrists: What Do We Need to Know?	74	1 Helping Patients Counter Demoralization While Living With a Chronic or Recurrent Psychiatric Illness, Part 2	43
130 Teaching Core Competencies: The Challenge for Academic Psychiatry	95		
133 Psychiatry Training for Primary-Care Physicians: What, How, and When?	96	COURSES	
		60 Disaster Psychiatry: Terrorism, Trauma, and Things to Do	42
		82 Psychiatry in Jail	70
TOPIC 32: PSYCHIATRIC REHABILITATION		DISCUSSION GROUPS	
COURSE		12 Cross-Cultural Psychotherapy	43
33 Recovery From Mental Illness and Stigma: Integrating Medicine and Rehabilitation	14	13 Public Psychiatry: Leading the Way in Transforming Service Delivery in the 21st Century	43
SYMPOSIUM		FORUM	
25 Psychiatric Rehabilitation: Integrating Mind and Body Globally	36	11 9/11 Research: A Review and Reviews	82
ISSUE WORKSHOP		LECTURE	
63 Psychiatric Rehabilitation and Psychodynamics	53	10 Language, Psychosis, and the Speciation Event	29
TOPIC 31: PSYCHOANALYSIS		PRESIDENTIAL SYMPOSIUM	
DISCUSSION GROUP		3 Reconstructing Postwar Mental Health Services	83
2 Who Should Be Psychoanalyzed?	15	SCIENTIFIC AND CLINICAL REPORTS	
ISSUE WORKSHOP		14 A Program for Treating Weight Gain Induced by Atypical Antipsychotics	23
38 Initial Psychiatric Interview: A Psychodynamic Approach to 90801	46	51 Developing Capacity Within CBOs for Health Education and Outreach	52
TOPIC 32: PSYCHOIMMUNOLOGY		SYMPOSIA	
SCIENTIFIC AND CLINICAL REPORT		15 The Development of ADAP: The Adolescent Depression Awareness Program	33
70 Low Levels of Antibodies to Cardiolipin in First-Episode and Chronic Schizophrenia	78	39 Use of Mandates and Leverage in Community-Based Treatment	61
TOPIC 33: RESEARCH ISSUES		114 Providing Psychiatric Services Around the World With a Shortage of Psychiatrists	105
COURSES		COMPONENT WORKSHOP	
1 Assessment and Treatment of Drug-Induced Movement Disorders	1	16 Public Psychiatry: Leading the Way in Transforming Service Delivery in the 21st Century	25
53 Doing Research on a Shoestring Budget	42	ISSUE WORKSHOPS	
LECTURE		46 Engaging the Homeless in Treatment Strategies and Results	47
12 Adventures in Psychiatric Research: Neurobiology to Public Policy	44	54 A Shared-Care Model for Treating the Homeless Mentally Ill	48
NEW RESEARCH SESSIONS		103 Criminal Justice System and Serious Mental Illness, Problems, and Solutions	75
1 Young Investigators' Poster Session	17	108 Sometimes It Is About You: The Use of Self in Engaging and Treating Homeless Individuals	80
2 Young Investigators' Oral/Slide Session	28	126 Can Social Theory Be Integrated Into the Liberatory Goals of Psychiatry?	95
3 Young Investigators' Oral/Slide Session	28		
4 Young Investigators' Oral/Slide Session	28	TOPIC 35: STRESS	
5 Poster Session	37		
6 Poster Session	55	COURSE	
7 Poster Session	66	52 Child Murder by Parents	28
8 Poster Session	82	SYMPOSIA	
9 Poster Session	92	10 Mental Health Teams: Health Promotion and Preservation in War and Peace	32
10 Poster Session	99	64 September 11th: After Two-and-a-Half Years	85

TOPIC INDEX

COMPONENT WORKSHOP	Page #
33 Terrorism in America: The Distant Victims and the Role of IMG Psychiatrists	72

ISSUE WORKSHOPS

42 Infertility: A Chronic Illness With Chronic Challenges	47
131 Keep It Real: Psychological Preparedness and Active-Coping Group	95

TOPIC 36: SUICIDE

DISCUSSION GROUP

10 Assessing and Managing Suicide Risk: Clinically-Based Guidelines for Risk Management (<i>Meet the Authors</i>)	43
---	----

SCIENTIFIC AND CLINICAL REPORTS

10 High-Lethality Suicide Attempts in BPD	23
62 Suicidality and Second-Generation Antipsychotics in Patients With Schizophrenia	77
63 Melancholia and Suicide Attempt Probability and Lethality	78
64 Nonviolent Suicides in Women Are Increased During and After High Exposure to Tree Pollen	78
97 Life Changes, Social Adjustment, and Attempted Suicide in BPD and MDD	97

SYMPOSIA

97 Italian Psychiatry: 25 Years of Changes	101
101 Meaning in Suicide: Overcoming Barriers and Connecting Diverse Perspectives	102

ISSUE WORKSHOPS

12 Death by Suicide: The Words of Those Left Behind	19
15 Responding to the Impact of Suicide on Clinicians	19
20 No-Suicide Decisions, Contracts, and Assessment of Risk: Values and Cautions	25
115 Suicide and Schizophrenia: A Family Interview	81

TOPIC 37: VIOLENCE, TRAUMA, AND VICTIMIZATION

COURSES

11 Assessing the Risk of Violence in Both Forensic and Sex Offender Settings	3
13 Risk Assessment for Violence	5
30 Psychiatric Interventions in Disasters: Lessons From Experience	8
93 Men Sexually Abused as Boys: Meanings, Consequences, and Treatment	82

SCIENTIFIC AND CLINICAL REPORTS

39 Psychosocial Predictors of Long-Term Resilience Following the 9/11 Attacks	51
40 The Terrorist as a Nonpatient Subject of Psychiatric Investigation	51
53 Evaluation of a Therapeutic Interagency Preschool for Traumatized Children	52
54 Mental Health in Postwar Afghanistan	52
55 A Three-Dimensional Model of Violence in Schizophrenia	52

SYMPOSIA

5 Child Soldiers, Child and Adolescent Victims of War and Terrorism: Biopsychosocial Treatment for Reintegration Into Family and Society	31
6 New Directions in Terrorism and Political Violence: Causes and Responses	31
11 PTSD in Persons With Serious Mental Illness	32
28 New Perspectives in the Treatment of Complex PTSD	58
35 Contemporary Issues in Sport Psychiatry	60
37 Psychiatric Interventions With Medically-Evacuated Soldiers	60
113 The Effects of Sexual and Physical Abuse on Women's Health	105

COMPONENT WORKSHOPS	Page #
---------------------	--------

3 Public Health and Mental Health Partnership in Terrorism and Disasters	17
4 Child Soldiers: Child Victims of War and Terrorism: Psychosocial and Spiritual Needs	17
11 VA Mental Health's Response to Terrorism	18
18 Terror at Home: Addressing Domestic Violence in Your Practice	25
41 Consultation and Legal Clarification in Sexual Harassment	73

ISSUE WORKSHOPS

1 Disruptive Employees: Feedback-Assisted Counseling and Treatment	18
33 Mental Health Needs of Our Soldiers and Their Families	46
72 Clinical Effects of Sexual Abuse by Catholic Priests: A Forensic Perspective	54
76 Children and Families Facing Terrorism, Disasters, and Complex Emergencies	54
84 PTSD in the New York Fire Department: Bodies and Minds	74
112 Psychiatry and Homeland Security: An Exercise in Weapons of Mass Destruction Response Planning	81
117 Developing a Community Mental Health Response to Disasters and Terrorism	81
135 <i>Sad Days</i> : A Video of Psychiatric Problems in Afghanistan and Its Refugees	96
137 The Stalking Victim: Causes, Consequences, and Therapeutic Considerations	96
144 Reactions After 9/11 in a Pretraumatized Community in the South Bronx	99

MEDIA WORKSHOP

5 Postgenocide Psychological Trauma in Film, <i>The Summer of Aya</i>	75
---	----

TREATMENTS

TOPIC 38: BEHAVIOR AND COGNITIVE THERAPIES

ADVANCES IN RESEARCH

Hippocampal Volume in Major Depression: Effect of Antidepressant Treatment	20
--	----

COURSES

8 Behavioral Neuroanatomy: An Introduction	3
10 Cognitive Therapy for Severe Mental Disorders	3
15 Engaging Resistant and Hostile Patients Into Participatory Treatment	5
23 Basic Hypnosis: Principles and Applications	7
25 Cognitive Therapy for Schizophrenia	8
40 Cognitive-Behavior Therapy for Adult and Pediatric OCD: The Basics	14
44 Advanced Hypnosis: Applications in Psychiatry	15
89 Introduction to Cognitive-Behavioral Therapy	71

SCIENTIFIC AND CLINICAL REPORT

101 Self-Administered Versus Therapist-Administered Cognitive-Behavior Therapy for Medication Nonresponders With OCD	98
--	----

ISSUE WORKSHOP

36 Using Cognitive Therapy for Psychosis in Psychiatric Practice	46
--	----

TOPIC 39: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY

COURSES

65 A Psychodynamic Approach to Treatment-Refractory Mood Disorders	43
95 Integrating Psychotherapy and Pharmacotherapy	82

SCIENTIFIC AND CLINICAL REPORT	Page #		Page #
18 Integrating Psychotherapy With Medication to Improve Outcome	24	79 Personality, Therapeutic Alliance, and Outcome in Brief Psychotherapy	89
SYMPOSIA			
9 Recent Advances in the Treatment of Psychiatric Disorders in Primary Care: A U.S./U.K. Perspective	32	102 Individualizing Interpersonal Psychotherapy for Mood Disorders	102
29 Bipolar Patients: Treatments and Cultural Issues in Latin America	58	COMPONENT WORKSHOP	
30 Psychotherapy and Pharmacotherapy: Dissolving the Mind-Brain Barrier	58	2 Can't Work, Shouldn't Work, Mustn't Work: Assessing Function and Mental Impairment in Psychiatric Illness	17
49 Obsessive-Compulsive Spectrum Disorders: Update on Clinical Management	63	ISSUE WORKSHOPS	
ISSUE WORKSHOPS			
30 Cognitive Therapy and Pharmacotherapy: Teaching Residents Integrated Treatment Methods	26	80 Psychodynamic Treatment of Depression	73
101 Treatment of Adult ADHD: Combining Cognitive and Medical Approaches	75	128 Leash on Life: Human Attachment to Animals	95
TOPIC 40: COUPLE AND FAMILY THERAPIES			
COURSES			
37 Families Coping With Medical Illness: An Integrative Treatment Approach	14	TOPIC 43: PSYCHOPHARMACOLOGY	
70 Basic Family Skills for an Inpatient Psychiatrist	55	ADVANCES IN PSYCHOPHARMACOLOGY	
MEDIA WORKSHOP			
6 The Beginning Stages of Couples' Therapy: Video Case Studies	75	An Update for Clinicians 28	
TOPIC 41: GROUP THERAPY			
SYMPOSIUM			
72 Group Therapy in Medical/Psychiatric Care	87	COURSES	
ISSUE WORKSHOPS			
55 Group Interventions With Adolescents in Outpatient, Inpatient, and School Settings	48	34 Drug Treatment of Schizophrenia	14
121 Group Psychotherapy With Substance Abusers	94	63 Psychiatry Update: In Spanish	43
122 Milieu Therapies in the Age of Managed Care, Revisited	95	90 Med-Psych Drug-Drug Interactions	71
TOPIC 42: INDIVIDUAL PSYCHOTHERAPIES			
COURSES			
4 Interpersonal Psychotherapy	1	INDUSTRY-SUPPORTED SYMPOSIA	
17 Interpersonal Psychotherapy	5	22 Combination Therapy: New Strategies in the Management of Severe Mental Disorders	9
29 Using Boundary Crossings as Creative Therapy Instead of Slippery Slopes	8	29 Psychopharmacology and Reproductive Transitions: Impact of Psychotropic Medications and Sex Hormones on Brain Functioning, Weight, and Reproductive Safety	12
43 Davanloo's Intensive Short-Term Dynamic Psychotherapy in Clinical Practice	15	30 Choosing the Right Dose of Atypical Antipsychotics: Art or Science?	12
46 Dream Translation: One Empirically-Based Approach	27	RESEARCH CONSULTATION	
49 The Advanced Practice of Psychotherapy	27	3 Designing and Implementing Studies Contrasting Psychopharmacology and Psychotherapy	77
69 Brief Psychodynamic Psychotherapy: The Core Conflictual Relationship Theme Method	55	SCIENTIFIC AND CLINICAL REPORTS	
FORUM			
1 Evidence-Based Psychotherapy	27	2 Rivastigmine and Glantamine Treatment of Schizophrenic Cognitive Impairment	22
MASTER EDUCATOR CLINICAL CONSULTATION			
4 Finding the Hidden Self: Engaging Difficult Patients in Exploratory Psychotherapy	22	3 Dosing of Second-Generation Antipsychotics in a Large State Hospital System	22
SCIENTIFIC AND CLINICAL REPORT			
19 Review of Psychotherapy Research Involving a Pill-Placebo Control	24	7 Tiagabine Treatment of Social Anxiety Disorder	23
SYMPOSIA			
33 Interpersonal Psychotherapy: Research Update	59	15 Increased Lipid Levels and Antipsychotic Medication	23
52 The Art and Science of Brief Therapies	64	16 QTc Prolongation Associated With Ziprasidone	23
69 Supportive Psychotherapy: An Update	86	28 Buprenorphine: An Effective Treatment for Heroin Addicts	50
SYMPOSIA			
19 Beyond B12: An Update on Nutrition and Psychiatry	34	41 Antipsychotic Treatment and Sexual Adverse Events: The Role of Prolactin	51
44 Culture, Ethnicity, Race, and Psychopharmacology: New Research Perspectives	62	42 Three-Bead Extended-Release Carbamazepine Capsule (SPD417) Continuation: Maintenance Therapy in Bipolar Disorder	51
63 Psychotic Depression in 2004: The NIMH Collaborative Severe Depression Study	85	43 Parkinsonism in a Nursing Home: Underrecognition	51
SYMPOSIA			
19 Beyond B12: An Update on Nutrition and Psychiatry	34	44 Concurrent Use of Multiple Antipsychotics in Psychiatric Inpatients	51
44 Culture, Ethnicity, Race, and Psychopharmacology: New Research Perspectives	62	46 Polypharmacy and Its Ramifications in a Chronic Psychiatric Hospital	51
63 Psychotic Depression in 2004: The NIMH Collaborative Severe Depression Study	85	72 Oral S-Adenosyl Methionine (SAMe) for Antidepressant Augmentation: An Open-Label Trial	78
SYMPOSIA			
19 Beyond B12: An Update on Nutrition and Psychiatry	34	73 Somatic Symptoms as Predictors of Time to Onset of Response to Fluoxetine in MDD	78
44 Culture, Ethnicity, Race, and Psychopharmacology: New Research Perspectives	62	SYMPOSIA	
63 Psychotic Depression in 2004: The NIMH Collaborative Severe Depression Study	85	19 Beyond B12: An Update on Nutrition and Psychiatry	34
SYMPOSIA			
19 Beyond B12: An Update on Nutrition and Psychiatry	34	44 Culture, Ethnicity, Race, and Psychopharmacology: New Research Perspectives	62
44 Culture, Ethnicity, Race, and Psychopharmacology: New Research Perspectives	62	63 Psychotic Depression in 2004: The NIMH Collaborative Severe Depression Study	85
63 Psychotic Depression in 2004: The NIMH Collaborative Severe Depression Study	85	SYMPOSIA	

TOPIC INDEX

ISSUE WORKSHOPS	Page #
7 The Benzodiazepine Controversy Revisited	19
81 When Usual Treatments Fail: Antipsychotic Strategies for Refractory Schizophrenia	73
104 Innovative Methods of Promoting Use of Evidence-Based Psychopharmacology	80
107 Negative-Symptom Spectrum Disorders: Response to Pharmacotherapy of Asperger's Disorder	80

TOPIC 44: OTHER SOMATIC THERAPIES

COURSES

3 Using Neurofeedback in Your Practice: Introduction With Hands-On Experience	1
39 ECT Practice Update	14
55 The Way of Yoga and Herbs in the Treatment of Stress, Depression, and Aggression	42

SYMPOSIA

1 Brain Stimulation: New Treatments for Mood Disorders	30
82 Clinical Controversies in ECT	89

ISSUE WORKSHOP

83 Kundalini Yoga Meditation Techniques for Psychiatric Disorders	74
---	----

TOPIC 45: TREATMENT TECHNIQUES AND OUTCOME STUDIES

COURSE

50 Rating Scales: A Basic Overview	27
------------------------------------	----

DISCUSSION GROUP

5 Evidence-Based Psychiatry (<i>Meet the Authors</i>)	20
---	----

INDUSTRY-SUPPORTED SYMPOSIA

1 Treatment Resistance: Concepts and Management in Mood and Anxiety Disorders	1
13 Broadening the Horizon of Atypical Antipsychotic Applications	5
34 Evidence-Based Medicine: The Next Generation, Part 1	13
34 Evidence-Based Medicine: The Next Generation, Part 2	41

MASTER EDUCATOR CLINICAL CONSULTATION

11 Establishing Relationships, Enhancing Adherence, and Improving Outcomes	77
--	----

SCIENTIFIC AND CLINICAL REPORTS

4 The Meaning of Response in Acute Schizophrenia	22
90 Patient Treatment Matching With Ambulatory Cocaine Abusers	97

SYMPOSIA

27 Behavioral Activation, Cognitive Therapy, and Medication for Major Depression	57
31 Practice Guidelines, Quality Indicators, and a Practice Research Network: An International View	59

ISSUE WORKSHOPS

11 Detoxification of the Opioid-Dependent Chronic-Pain Patient	19
106 Will Outcomes Evaluation and Research Initiatives Save the Therapeutic Community?	80
146 Evidence-Based Treatment for Schizophrenia in a Correctional Setting	99

OTHER ISSUES

TOPIC 46: COMPUTERS

ISSUE WORKSHOPS

2 The Office of the Future: Technology in Psychiatry	18
123 Psychiatric Consultation Reports in Minutes: Exploring New Technologies	95

TOPIC 47: CREATIVITY AND THE ARTS

COURSE

73 Writing About Clinical Experiences	55
---------------------------------------	----

FORUM

5 Music and the Mind: Beethoven	27
---------------------------------	----

LECTURE

11 Body and Soul	38
------------------	----

SYMPOSIA

20 Telling Stories: The Psychiatrist as Novelist	35
83 Toxic Love on Film: Romantic Love, From Normal to Pathologic	90

ISSUE WORKSHOPS

37 The Theater of Emotions	46
51 The Art of the Unconscious: Shakespeare, Poetry, Film, and Psychiatry	47
60 The Portrayal of Psychiatry in Recent American Film	53
62 Using Art and Poetry: From Medication Management to Countertransference	53
79 The Portrayal of ECT on Television, Film, and the Internet	73

MEDIA WORKSHOP

7 <i>Robot Stories</i> : Emotional and Ethical Challenges of a Technological Age	96
--	----

TOPIC 48: GENDER ISSUES

COMPONENT WORKSHOPS

14 Novel Careers in Psychiatry: Women Who Have Made Their Own Way	25
47 Bend It Like Beckham: Asian Women, Achievements, and Cultural Conflicts	80

ISSUE WORKSHOP

22 Career Development for Minority Women Psychiatrists	26
--	----

TOPIC 49: HEALTH SERVICES RESEARCH

SCIENTIFIC AND CLINICAL REPORTS

23 Treatment Effectiveness and Functional Recovery in Schizophrenia	24
25 Work Disability and Treatment Access in Psychiatry	24

SYMPOSIUM

88 Quality of Care for Children: Multiple Perspectives	91
--	----

COMPONENT WORKSHOP

28 What Do Employers Want? Employee Mental Health Benefits	52
--	----

ISSUE WORKSHOPS	Page #
116 Ethical and Practical Challenges in Emergency Psychiatric Research	81
136 Program Evaluation Made Simple	96
143 Workplace Burnout in Psychiatrists: Evidence From the United Kingdom	99

TOPIC 50: HISTORICAL QUESTIONS

COMPONENT WORKSHOP	Page #
12 Whither Our Own History? Debating the Value of the Study of Psychiatry's Past	24

TOPIC 51: INFORMATION TECHNOLOGY

LECTURE	Page #
9 I Am a Fact, Not a Fiction	29

TOPIC 52: INTERNET

COURSE	Page #
91 Psychiatry and the Internet	82
99 Online Communication in Mental Health: Different Contexts, Different Issues	93

COMPONENT WORKSHOP	Page #
42 Online Interaction Between APA, Members, and the Public	79

ISSUE WORKSHOP	Page #
41 Online Video Games: Psychopathological or Psychotherapeutic?	46

TOPIC 53: LESBIAN/GAY/BISEXUAL/
TRANSGENER Issues

COURSE	Page #
48 Gay Men and the Problem of Romantic Love	27

COMPONENT WORKSHOP	Page #
30 The Teaching of Gay, Lesbian, Bisexual, and Transgender Issues	53

MEDIA WORKSHOP	Page #
4 <i>When Boys Fly</i> : Club Drugs in the Gay Male Community	48

TOPIC 54: MANAGED CARE AND HEALTH CARE FUNDING

COURSE	Page #
36 Current CPT Coding and Documentation Requirements	14

PRESIDENTIAL SYMPOSIUM	Page #
2 Wither Go the States: The Impact of Budget Cuts	57

COMPONENT WORKSHOPS	Page #
24 Universal Health Care and Other Models	45
34 CPT Coding and Documentation Update	72
45 The 2004 Medicare Update and Making the Most of the Carrier Advisory Committee	80

TOPIC 55: MEN'S HEALTH ISSUES

LECTURE	Page #
5 Surviving Jock Culture	21

TOPIC 56: NATIONAL INSTITUTE ON DRUG ABUSE SPECIAL TRACK

LECTURES	Page #
2 Signal Integration in the Brain	16
13 Why Does the Human Brain Become Addicted?	44
15 Anticraving Medication: A New Class of Psychoactive Medication?	49
18 Conceptual and Methodological Flaws in the Evaluation of Addiction Treatment	57
21 Stress and Relapse to Substance Use Disorders	76

SCIENTIFIC AND CLINICAL REPORTS	Page #
26 Challenges in Increasing Access to Buprenorphine Treatment	50
27 A Double-Blind, Double-Dummy, Randomized, Prospective, Efficacy Study of the Partial Mu Opiate Agonist Acute Detoxification of Heroin Addicts	77
78 Cannabis Use Reduces the Likelihood of Sustained Remission From Other Drugs	79
79 Substance-Induced Risk for Depression in a Substance-Dependent Population	79
83 Weight and Relapse to Cocaine and Alcohol Use in Patients With Eating Disorders	96
86 PRISM-IV: Reliable Diagnosis in Alcohol and Drug Abusers	97
87 Cognitive Functioning: Predictors of Outcome in Cocaine-Dependent Patients	97
88 Cocaine Expectancy Questionnaire: Psychometric and Underlying Model	97
89 Psychosocial Therapies for Cocaine Dependence: A Controlled Study	97

SYMPOSIA	Page #
3 Functional Brain Imaging of Addiction	30
4 Treatment of Chronic Pain in Recovering Addicts	30
22 Obesity: Lessons Learned From Addiction	35
23 Alcohol, Drug, and Psychiatric Disorders in the U.S.: Current Status and Trends	36
24 Genetic and Environmental Factors Contributing to Vulnerability to Addiction	36
42 Smoking and Comorbid Mental Disorders	61
55 ADHD Subtypes and Subgroups at Risk for Substance Use Disorders	65
60 Choosing the Best Treatment for Substance Abuse	84
61 Practical Techniques in the Assessment and Treatment of Tobacco Dependence	84
80 Consequences and Treatment of Marijuana Abuse	89
84 Moving the Targets: The Neurobiology of Addiction	90
85 Drug Abuse Treatment Issues in Women	90
94 Update on Treatment of Stimulant Abuse	100
96 Behavioral Treatments for Drug Dependence	101

ISSUE WORKSHOPS	Page #
3 E, K, and GHB: The New ABCs of Substance Abuse	18
6 Drug Abuse and Suicidal Behavior	19
16 Cocaine and Tobacco Use During Pregnancy: Adverse Outcomes in Offspring	20
26 Obtaining Research Funding From NIH: Keys to Successful Grant Writing	26
27 To Smoke or Not to Smoke: The Dilemmas of Tobacco-Free Addiction Treatments	26
34 The Impact of Migration on Addictive Disorders: A Challenge for the Americas	46
45 Steroid Abuse: Growing Problem for Adolescents and a Hidden Problem for Adults	47
48 Emerging Pharmacotherapies for Treatment of Stimulant Dependence	47
56 Addiction Research as a Career Choice in Psychiatry	48
74 Drugs and Other Addictions: Does One Size Fit All?	54
75 Stress, Trauma, and Drug Abuse	54
82 Treatment of Patients With Drug Dependence and Psychiatric Illness	73

	Page #
TOPIC 57: PERSONAL DIGITAL ASSISTANTS (PDA)	
COURSES	
56 How to Use Your Palm OS PDA in Psychiatric Practice: Basic	42
75 How to Use Your Palm OS PDA in Psychiatric Practice: Advanced	56
TOPIC 58: POLITICAL QUESTIONS	
COURSE	
67 Personality and Political Behavior	43
TOPIC 59: PRESIDENTIAL THEME: PSYCHOTHERAPY AND PSYCHOPHARMACOLOGY: DISSOLVING THE MIND-BRAIN BARRIER	
COURSE	
83 Helping Parents From the Inside Out: Attachment, Mindsight, and the Brain	70
DISCUSSION GROUP	
11 What Can Brain Diseases Teach Us About the Mind-Brain Interface?	43
FORUM	
7 Unconscious Prediction, Conscious Monitoring, and Therapeutic Change: Is There a Mind-Brain Barrier?	55
PRESIDENTIAL SYMPOSIUM	
1 The Biopsychosocial Model: Myth or Reality?	29
SYMPOSIA	
26 Effective Treatment of PTSD: What Works Best for Whom?	37
99 Mind, Brain, and Interpersonal Experience in Psychotherapy	102
ISSUE WORKSHOP	
109 Multiple Perspectives on the Pathological Fear Response: Integration of Psychotherapeutic and Psychopharmacologic Therapies	81
TOPIC 60: PROFESSIONAL AND PERSONAL ISSUES	
COURSES	
6 The Conceptual Basis of Psychiatry	1
31 Improving Your Presentation Skills: A Coaching Approach	8
41 Money Matters I: Using Theory in Clinical Practice	15
59 Treating Medical Students and Physicians	42
88 Money Matters II: Advanced Clinical Practice	70
MASTER EDUCATOR CLINICAL CONSULTATION	
1 Treating One's Students and Colleagues: The Eternal Challenge of Boundaries	17
COMPONENT WORKSHOP	
32 Looking Back, Looking Forward: Pathways for Blacks in Psychiatry	53
ISSUE WORKSHOPS	
5 Reinventing Careers: Transitions and Later-Life Strategies for Psychiatrists	19
24 Treating Physicians: Issues in Diversity	26
32 Risk-Management Issues in Psychiatric Practice	26
68 Closing a Psychiatric Practice: Clinical and Risk-Management Issues	54
78 The Trauma of Medical Mistakes: An Experiential Workshop	73
120 The Horns of a Dilemma: Myths and Realities of Drug-Industry Interaction	94

	Page #
TOPIC 61: RELIGION, SPIRITUALITY, AND PSYCHIATRY	
COURSE	
72 Meditation for Psychotherapists and the Paradigm of Health	55
LECTURES	
4 Psychiatry and Spirituality: A Holistic Perspective	17
14 Dialogue From the Rims of the Grand Canyon: On Bridging the Post-Freudian Chasm Between Religion and Psychiatry	49
MASTER EDUCATOR CLINICAL CONSULTATION	
10 Engaging Patients' Spiritual Resources in Building Resilience to Relapse of Major Psychiatric Disorders	76
SYMPOSIA	
78 Gay and Lesbian Orthodox Jews: A Primer for Clinicians	88
104 Model Psychiatry Residency Programs on Religion and Spirituality	103
ISSUE WORKSHOPS	
17 Controversies at the Interface Between Religion and Psychiatric Practice	20
94 Dissolving Therapeutic Barriers: Spirituality Group Work With Psychiatric Staff	74
110 The Day I Died: A Near-Death Documentary and the Mind-Brain Barrier	81
139 Spiritual and Religious Assessment in Clinical Practice	98
TOPIC 62: RESIDENT AND MEDICAL STUDENT CONCERNS	
DEBATE	
Resolved: The RRC Should Continue to Require That Psychiatric Residency Programs Must Demonstrate That the Residents Have Achieved Competency in Psychodynamic Psychotherapy	15
DISCUSSION GROUPS	
17 Publishing and Grant Writing (<i>For Residents Only</i>)	48
19 Patient Safety (<i>For Residents Only</i>)	71
RESIDENT'S SESSION	
Meet the Experts: Sunny-Side Up	14
SYMPOSIUM	
106 Do Not Wait Until You Practice, Know It Now: What Residents and Early Psychiatrists Need to Know	103
COMPONENT WORKSHOPS	
5 Career Choices in Psychiatry: Exploring Fellowship Training	18
36 Taking the First Step: What Are My Options in the Transition to Practice?	72
38 Dollars: The Pharmaceutical Industry in Psychiatric Training	73
ISSUE WORKSHOPS	
23 What Psychiatry Residents Can Expect From NIMH-Sponsored Research Training	26
44 Oral Boards Boot Camp	47
52 The Impact of 9/11 on Psychiatric Residents and Training Programs	47
53 Implementing the Institute of Medicine Report: Fostering Research Careers via Residencies	47

	Page #		Page #
TOPIC 63: STIGMA/ADVOCACY		TOPIC 66: WOMEN'S HEALTH ISSUES	
SYMPOSIUM		COURSE	
7 I Rest My Case	31	7 Management of Psychiatric Disorders in Pregnant and Postpartum Mothers: Overview	3
COMPONENT WORKSHOP		INDUSTRY-SUPPORTED SYMPOSIA	
8 Leadership Skills for Public Advocacy	18	41 Hormones, Mood, and Cognition: Treatment Considerations in Older Women	39
ISSUE WORKSHOP		51 Bipolar Disorder in Women: Reproductive Implications of Treatment, Part 1	69
105 When Psychiatrists Have Suffered a Mental Illness: Their Stories and Insights	80	51 Bipolar Disorder in Women: Reproductive Implications of Treatment, Part 2	93
TOPIC 64: TELEPSYCHIATRY		SYMPOSIA	
COURSE		68 Women's Mental Health Revisited: Current Perspectives, Future Trends	86
54 Expanding Health Care Delivery? Let Telepsychiatry Help!	42	91 Mood Disorders in Women Throughout the Life Cycle	100
TOPIC 65: VIRTUAL REALITY		ISSUE WORKSHOPS	
SCIENTIFIC AND CLINICAL REPORT		67 Interface Between Psychiatry and Obstetrics: Comprehensive Perinatal Care	54
91 Virtual Reality Cue-Reactivity-Controlled Trial for Nicotine Dependence	97	85 Women's Mental Health in Times of Turmoil: An International Perspective	74
ISSUE WORKSHOP			
140 Long-Term Care Insurance Denials to One-Time Psychiatric Patients	99		

PARTICIPANT INDEX

APA 157TH ANNUAL MEETING

A

- Abad, Antonio85
Abbey, Susan E.87
Abelskov, Kirsten74
Abelson, James L.34
Abi-Dargham, Anissa11
Abidi, Safia C.60
Ablow, Keith R.35
Abou-Allaban, Yousef20
Abraham, Gaby.....88
Abraham, Melissa E. 77, 81
Abram, Karen M.32
Abramovitz, Robert H.95
Abramowitz, Jonathan 14, 63
Abrams, Karen M.96
Adamides, Jr., Odysseus47
Adams, Margo S.53
Addis, Michael58
Adelson, Stewart L.53
Aderholt, Sarah L.89
Adetunji, Babatunde A. 106
Adityanjee, A. 6
Adiutori, Cristiano.....46
Adlaf, Edward 100
Adler, Caleb M.88
Adler, Lenard A.2, 67
Agras, W. Stewart60
Agumadu, Charles O.97
Aharonovich, Efrat..... 79, 97
Ahmed, Iqbal 17, 94
Ahrens, Martina97
Ait-Daoud, Nassima 64, 77
Akerele, Evaristo O.23
Akhtar, Fatema Z.77
Akhtar, Salman 18, 43
Aliskal, Hagop S.65
Akman, Jeffrey S. 15, 43
Alarcon, Renato D. 18, 47, 79
Albano, Anne Marie..... 57, 86
Albert, David B.32
Alda, Martin.....63
Alexander, Karen.....99
Alexander, Mary-Jane 32
Alexopoulos, George S.7
Alger, Ian E. 19, 37, 46, 75
Al-Jadiry, Abdul M.83
Allen, Albert J.51
Allen, Andrea 103
Allen, David M.30
Allen, Trina B.72
Almagor, Gila75
Alonso, Jordi 52, 79
Alpert, Jonathan E. 34, 35, 78
Altkhuler, Steven I. 14, 45
Alva, Gustavo.....40
Alves-Bradford, Jean-Marie E.48
Alzenberg, Dov77
Amen, Daniel G. 19, 81
Amiri, Shahrad Rod84
Anand, Amit 104
Ananth, Jambur V.51
Anders, Thomas F. 73
Andersen, Arnold E. 60
Anderson, Allan A. 80
Anderson, Berry 30
Anderson, Carl M. 47
Anderson, Maru 52
Anderson, Mary Beth 19
Anderson, Tanya R. 26
Andrade, Ana C.F. 58
Andreasen, Nancy C. 48, 62
Andrews, Maryann 95
Anfang, Stuart A. 25
Angelino, Andrew F. 47, 56, 70
Angermeyer, Mathias C. 52
Ansari, Rubaba 51
Anscombe, Roderick J. 35
Anton, Jr., Raymond F. 64
Appelbaum, Paul S. 16, 34, 48, 61, 89, 96
Apter-Danon, Gisele 24
Araghiniknam, M. 33
Arambula, Michael R. 46
Arciniegas, David B. 87, 93
Armstrong, Scott C. 71
Arnow, Bruce A. 39
Aronne, Louis J. 67
Arroyo, William 73
Arseneau, Bernard J. 96
Asghar-Ali, Ali A. 94
Ashkenazy, Yaacov 23
Ashley, Kenneth B. 53
Asnis, Gregory M. 38
Atallah, Sherif F. 105
Atkinson, Leslie 105
Atkinson, Jr., J. H. 82
Atua, Evelyn 96
Auchincloss, Elizabeth 22
August, Gerald 65
Avena, Nicole N. 62
Aviram, Ron B. 86
Azarow, Jay 51
Azorin, Jean-Michel 91
- ### B
- Baciu, Monica 78
Bacon, Bryan 32
Badger, Shirlene 104
Baetz, Marilyn D. 103
Bailer, Ursula 60
Baker, Dawn 104
Baldassano, Claudia F. 12
Balderson, Kenneth E. 104
Baldessarini, Ross J. 79
Balon, Richard 83
Barak, Yoram 71, 77
Barchas, Jack D. 44
Bardey, A. Sasha 45
Bark, Nigel M. 96, 105
Barkin, Evelyn 31
Barkley, Russell A. 39
Barlow, David 27
Barnes, Donna H. 102
Baron, David A. 21, 49, 103
Barr, A. 30
Barr, Heather 45
Barratt, Ernest S. 3
Barrett, James E. 19
Bartels, Stephen J. 25
Bartko, John J. 97
Bartlik, Barbara D. 60
Barwell, Michelle M. 19
Basco, Monica A. 3, 57
Baskys, Andrius 13
Bass, Judith 59
Bassi, Mariano 101
Bateman, Anthony 102
Batki, Steven L. 101
Bauer, Michael 18, 70
Baxter, Elizabeth A. 80
Beahrs, Claudette H. 90
Beahrs, John O. 90
Beardslee, William R. 35
Beaubrun, Gabrielle F. 7
Beck, Judith S. 26, 64
Becker, Daniel F. 52
Becker, Judith V. 3
Becker, Mary 86
Beebe III, John E. 96
Beeber, Alan R. 15
Begg, Melissa D. 33
Beitchman, Joseph H. 100
Beitman, Bernard D. 45, 58, 82
Belger, Aysenil 10
Bell, Carl C. 46, 53, 73
Bell, Michael A. 85
Bell, Robinette N. 54
Bellack, Alan S. 73
Benbadis, Selim 54
Benca, Ruth M. 67
Benedek, David M. 25, 71
Benedek, Elissa P. 19
Benson, Timothy G. 45
Beresin, Eugene V. 17, 83
Bergmans, Yvonne 30
Bernstein, Carol A. 5, 7, 55
Bernstein, David P. 30, 63
Berry, Janet 75
Bezmen, Janet A. 95
Bhat, Shyam K. 14
Bialer, Philip A. 84
Biederman, Joseph 2, 45, 85, 98, 106
Bierut, Laura J. 36
Biluuma, Oleg 52
Binder, Renee L. 24
Birmdorf, Catherine A. 60
Bisaga, Adam M. 84, 97
Biscoglio, Regina 89
Bishop, Leigh C. 53
Bitzer, Johannes 54
Black, Donald W. 64
Black, Jed E. 11
Black, John L. 3
Bland, Walter P. 17
Blaustein, Margaret 37

- Blehar, Mary12
 Bleiberg, Efram 70, 93
 Blinder, Barton J.28, 48, 58, 81, 82, 105
 Block, Susan D.72
 Block, Thaddeus S.98
 Blom, Marc B.J.59
 Bloom, Alan S.89
 Bloom, Sandra L.25
 Blume, Sheila B. 37, 75, 76
 Blumenfield, Michael42
 Boddam, D. Randall63
 Bodkin, J. Alexander 105
 Bogdanov, Irene78
 Bogunovic, Olivera J.96
 Bohus, Martin 38, 85
 Boksay, Istvan J.E. 100
 Boland, Robert J. 42, 90
 Bolo, Nicholas R.50
 Bolo, Peter M.75
 Bolton, Paul59
 Bongiovi-Garcia, Mary E.95
 Bonnie, Richard34
 Bonovitz, Jennifer M.81
 Book, Howard E.8, 55
 Boomsma, Dorett65
 Bordnick, Patrick S.97
 Borowich, Abba E.89
 Bottiglieri, Teodoro78
 Bouchez, Saena91
 Bougerol, Thierry78
 Boutros, Nashaat N. 3, 45
 Bowden, Charles L.77
 Bowman, Elizabeth S.49
 Boyle, Michael23
 Bozzo, Jose R.58
 Brady, Kathleen T.48, 65, 76, 90
 Brandt, Joshua J.97
 Bregman, Joel D. 100
 Breitbart, William82
 Breiter, Hans C. 30, 36
 Bremner, J. Douglas 104
 Brendel, David H. 1, 105
 Brendel, Rebecca W.51, 81, 105
 Brenner, Ronald 100
 Breslau, Naomi61
 Bresnahan, Michaeline33
 Briggs, Susan D.78
 Brod, Thomas M. 1
 Broitmand, Marina35
 Brook, David W. 76, 87, 94
 Brooks, Jeremy97
 Brown, Alan S.33
 Brown, E. Sherwood 5
 Brown, Gregory19
 Brown, Richard30
 Brown, Richard A.62
 Brown, Richard P. 17, 42, 73, 77
 Brown, Jr., Robert S.50
 Brown, Steven51
 Brown, Thomas E. 1, 5, 14
 Brown, Walter A.13
 Bruce, William79
 Bruck, Elena89
 Brugh, Terry52
 Brunette, Mary F.43
 Bryant, Karl E.64
 Bryskin, Lawrence74
 Bryson, Heather79
 Bryson, Susan 60
 Bub, Barry 73
 Buchsbaum, Bradley 78
 Buchsbaum, Monte S.78, 85
 Buckley, Peter F. 12, 76
 Budetti, Jan 70
 Budman, Cathy L. 48
 Budney, Alan J. 89
 Bunt, Gregory C.36, 43, 80
 Burgoyne, Karl S. 19
 Burk, Isabel 20
 Burke, Ainsley K. 78
 Burks, Ginny 35
 Burmester, Bill 82
 Burnett, Paul 104
 Burns, Alana M. 78
 Burns, Gretchen 26
 Burruss, John W. 81, 94
 Bursztajn, Harold J.19, 75, 95
 Burt, Vivien K. 8, 39
 Busch, Fredric N. 73
 Bussing, Regina 91
 Butler, Lisa D. 51, 87
 Buttenwieser, Paul A. 35
 Butterfield, Marian I. 34, 35, 55, 74, 86, 105
 Butters, Meryl A. 91
 Button, Norman 103
 Butts, Hugh 53
 Buxton, Martin 32
 Buysse, Daniel J. 67
 Bystritsky, Alexander 32, 86
- C
- Cabrejos, Claudio O. 77
 Cagande, Consuelo C. 103
 Caine, Eric D. 19
 Cairney, John 52
 Calabrese, Joseph R.26, 75
 Caldas de Almeida, Jose M. 20
 Caley, Charles F. 23
 Caligor, Eve 70
 Calkins, Colby 85
 Callahan, Jr., William E. 46, 53, 60, 61
 Camacho, Alvaro 74
 Cammarata, Claire 74
 Campbell, Frank R. 102
 Campbell, Jan L. 77
 Campbell, William H. 1
 Campo, Ana E.71, 74, 79
 Cancro, Robert 36, 56
 Candilis, Philip 46
 Canino, Ian A. 79
 Canive, Jose M. 72
 Cannavo Antognini, Francesca 27
 Cantwell, Roch 103
 Caplan, Arthur 96
 Capuron, Lucile 38
 Cardinali, Daniel 98
 Carlezon, William 41
 Carlson, Gabrielle 13
 Carpenter, Linda L. 6, 9
 Carrasquillo, Olveen 91
 Carroll, Melissa 85
 Carter, Diana 3
 Carty, Patricia 32
 Case, Michael 78
 Casey, B.J. 72
 Casey, David A. 24, 50, 78, 97
 Cash, Charles D. 26
 Cassano, Giovanni B. 65
 Cassem, Edwin H. 82
 Castellanos, F. Xavier47, 65
 Castellanos, Francisco 39
 Castilla-Puentes, Ruby C. 58, 77, 105
 Castilla-Puentes, Sandra R.77
 Castilla-Puentes, Wilma I. 77, 105
 Celenza, Andrea 26
 Cerda, Gabrielle M. 35
 Cerfolio, Nina E.100
 Chacko, Chowallur D.72
 Chaitin, Barry F. 45
 Chakos, Miranda H. 79
 Chan, Carlyle H. 42
 Chandler, Paula C. 62
 Chandra, Ravi 96
 Chang, Jacquelyn B. 80
 Chang, Kiki D. 66
 Chang, Linda 30
 Chapman, Daniel P.26, 79
 Chapman, Joab 78
 Chappel, John N. 70
 Charney, Dennis S. 4, 6, 104
 Chatoor, Irene 73
 Chaudhry, Haroon R. 96
 Chaudhry, Zubaida A. 22
 Chelminski, Iwona 101
 Chen, Xin-Hua 51
 Chengappa, K.N. Roy 12
 Cheong, Josepha A.28, 73
 Chester, Adam R. 72
 Chester, Janis G. 31
 Chew, N. 59
 Chia, S.E. 59
 Chider, Luisa 52
 Chiles, Catherine 1
 Chiles, John A. 99
 Chou, James C.Y. 43
 Chou, S. Patricia 36
 Chow, Wendy 24
 Choy, Yujuan 18, 50
 Chrisman, Allan K. 98
 Christensen, Daniel D. 11
 Christodoulou, George 59
 Chu, James A. 58
 Chung, Christopher K. 19
 Ciccone, J. Richard 37
 Ciechanowski, Paul 32
 Citrome, Leslie L.22, 73
 Claes, Stephan 2
 Clark, David L. 3
 Clark, H. Westley 39
 Clark, Michael R. 56
 Clark, Michelle O.29, 53
 Clarke, David M. 87, 103
 Clarkin, John F. 70
 Classen, Catherine 87
 Clayton, Anita L.H. 4, 66, 105
 Clemens, Norman A. 52
 Cloitre, Marylene 37
 Cloninger, C. Robert 62
 Clougherty, Kathleen 59
 Coccaro, Emil F. 33, 38, 87
 Cochet, Barbara 91
 Coello, Miguel 77
 Coffey, C. Edward 7

PARTICIPANT INDEX

- Coffman, Jennifer K.57
 Cohen, Amy.....80
 Cohen, Bruce M. 13, 41, 61
 Cohen, Carl I. 25, 95, 98
 Cohen, Lee S. 39, 69, 93
 Cohen, Mary Ann 19, 53
 Cohen, Michael..... 1
 Cohen, Neal L.....85
 Cohen, Patricia R.35
 Coiro, Maryjo.....35
 Colantuoni, Carlo.....62
 Coleman, Eli.....75
 Collins, Eric D.49
 Collins, Gary R.....75
 Collins, Pamela Y.....52
 Colliver, James36
 Colosimo, Lisa46
 Combrinck-Graham, Lee18
 Combrinck-Hertz, Mark.....18
 Compton III, Wilson 36, 73
 Conley, Robert R. 15, 73
 Connolly, Moira A. 103
 Connor, Kathryn M.34
 Contreras, Virginia98
 Cooke, Edi95
 Copans, Stuart A.....53
 Coplan, Jeremy D.....6
 Copp, Hilary97
 Corcoran, Cheryl M.87
 Cordes, Jeffrey A.53
 Cornelius, Thor J.18
 Corrado, Filomena50
 Corral, Maria R. 3
 Correale, Jennifer.....75
 Corya, Sara A.....78
 Cott, Jerry M.34
 Cottler, Linda54
 Cournois, Francine.....23, 52, 63, 80
 Courtis, Christine58
 Cowan, Ronald L.48
 Cowley, Deborah S.29
 Cox, Daniel J.106
 Cox, Todd S. 33, 34
 Coyle, Jr., Joseph T.71
 Cozza, Kelly L.71
 Cozza, Stephen J.60
 Cozzolino, Edoardo.....50
 Crady, Meg.....81
 Craske, Michelle G.32
 Crisanti, Annette87
 Crone, Catherine C. 15, 56, 98
 Crosby, Ross D.60
 Cross, C. Deborah95
 Crossett, Judith H. W.69
 Crow, Scott J.60
 Crow, Timothy J.29
 Crowe, Raymond R.....36
 Cruz, Mario96
 Cryanowski, Jill M. 102
 Csemansky, John G.33
 Cummings, Jeffrey L. 7, 13, 65
 Cutler, Winnifred B.....60
 Cyranowski, Jill M.59
 Czeisler, Charles A.....97
 Czobor, Pal.....52
- D**
- Dargani, Narender..... 79
 Das, Amarendra 91
 Datta, Moitri N..... 46
 David, Anthony S. 104
 David, Panakkal..... 32
 Davidoff, Donald A. 27
 Davidson, Jonathan R.T..... 21, 35, 67, 69, 93
 Davis, Jack..... 28
 Davis, Lori L.66, 104
 Davis, Mary H. 18
 Davis, Robert M. 77
 Dawson, David L. 20, 46
 Dawson, Deborah A..... 36
 DeBattista, Charles2, 7, 70
 De Chiara, Margherita..... 50
 de Contreras, Gilma P..... 77
 De Crisce, Dean M. 19
 De Girolamo, Giovanni.....79, 101
 Deitch, David 26
 de Kloet, Ronald..... 30
 DelBello, Melissa P. 5, 88, 92
 DeLeon, George..... 80
 Delgado, Pedro L. 39, 43
 D'Emic, Matthew..... 19, 27
 DePaulo, Jr., J. Raymond 34, 63
 Desai, Abhilash K..... 69
 Desai, Prakash N.....7
 Desjardins, Juliette C. 51
 DeSouza, Cheryl..... 78
 Detke, Michael J. 24
 Deutschman, Daniel A. 18
 DeVane, C. Lindsay 28
 Devins, Gerald 59
 Devlin, Charles..... 80
 Devlin, Michael J..... 62, 63
 Devouche, Emmanuel 24
 Dewan, Mantosh J. 18, 42, 64
 Dewey, Stephen L. 47
 deZwaan, Martina 60
 Diamond, Dickson S. 81
 Diamond, Guy..... 35
 Dickens, Pamela A..... 105
 Dickstein, Leah J..... 42, 73, 80, 86
 DiClemente, Carlo C. 77
 di Cori, Ferruccio A. 46
 Diefenbach, Gretchen..... 98
 Diez Roux, Ana 77
 DiGiacomo, Joseph 89
 Dimidjian, Sona A. 58
 Dinges, David F..... 97
 Ditkowsky, Keith 57
 Dizmang, Larry H..... 99
 Dobson, Keith S. 58
 Doghramji, Karl55, 69, 97
 Dolgoff, Robert K. 100
 Donovan, Gerald F. 97
 Doraiswamy, P. Murali..... 11, 41
 Dossenbach, Martin 79
 Douaihy, Antoine B. 84
 Drake, Robert E. 10, 43
 Drescher, Jack..... 88
 Drury, Laura 55
 Dryden-Edwards, Roxanne C.47, 100
 Drye, Robert C. 25
 Dsouza, Cyril.....104
 Duan, Naihua 91
- E**
- Dube, Sanjay..... 78
 Dubin, William R.....75, 89
 Dubois, Michel..... 56
 Dubowski, Sandi..... 88
 Duckworth, Sarah..... 31
 Duffy, Farifteh F.24, 59
 Dufour, Mary C. 36
 Dunayevich, Eduardo 43
 Dunlop, Boadie W. 2
 Dunner, David L. 58
 Duque, Luis 31
 Durfee, Sandra 33
 Duros, Christopher C.....74
 Dvorak, Ramona..... 27
 Dwyer, R. Gregg 46
- E**
- Eagles, John103
 Ebert, Michael H. 27
 Ecklund, James M..... 88
 Edenberg, Howard 36
 Edman, Jeanne 96
 Egan-Stack, Denise 98
 Eisen, Jane L..... 63
 Eisner, Lori R..... 78
 Eist, Harold I. 31, 90
 Ekman, Paul..... 95
 Elbogen, Eric B. 61
 Elferink, Andre J.A. 24
 Elhaj, Omar26, 75
 Elliot, Diane L. 47
 Ellis, James W. 34
 Ellis, Meiling K..... 50
 Ellison, James M. 27
 Elmouchtari, Abdelouahed 3
 Endo, Takuro100
 Engeriser, Jason L..... 32
 England, Mary Jane 24
 English, Judith 85
 Engstrom, Frederick W..... 82
 Enns, Murray W. 99
 Epstein, Steven A. 24
 Erman, Milton K..... 97
 Ernst, Carrie L..... 45, 52
 Escobar, Franklin 58
 Escobar, Javier I.20, 43
 Eth, Spencer.....73, 80
 Euler, Dillon C. 80
 Evans, Dwight L. 4
 Evans, Suzette M..... 84
 Evdokas, Andreas..... 99
 Everett, Anita S..... 45
- F**
- Faber, Raymond A. 55
 Fabio, Anthony 23
 Faedda, Gianni L. 47
 Fahrer, Rodolfo D.20, 98
 Faison, Warachal E. 6, 17, 62
 Fakra, Eric 91
 Fals-Stewart, William S.101
 Faraone, Stephen V. 36, 39, 85, 98
 Faries, Douglas E. 51
 Farlow, Martin K..... 40
 Farrell, Colleen 98
 Farrington, Susan103

- Fatemi, S. Hossein33
 Faulkner, Larry R.27
 Faull, Robert23
 Fava, Maurizio2, 34, 50, 66, 77, 78
 Fawcett, Jan58
 Feder, Adriana91
 Feijo, Marcelo58
 Feinberg, Todd E.33
 Fendrich, Michael51
 Fenton, Andre79
 Fenton, Wayne S.23, 47
 Ferguson, Yvonne B.7
 Fernandez, Francisco44, 54
 Fernandez, Hubert H.51
 Ferrando, Stephen J.63
 Ferrell, Richard B.87
 Ferrer, Mirtha97
 Fichtner, Christopher G.23
 Findling, Robert L.13, 26
 Fine, Carla19, 102
 Fioritti, Angelo101
 Fireman, Marian80
 First, Michael B.5, 87
 Fischbein, Ellen R.26
 Fisher, Helen E.4, 82
 Fisler, Carol19, 45
 Fitzpatrick, Thomas M.60
 Flaherty, Joseph A.51
 Flashman, Laura87
 Fleming, Candace M.5
 Flint, Alastair J.85
 Flynn, Cynthia35
 Flynn, Heather A.61
 Foa, Edna B.1, 64, 93
 Folsom, David P.53
 Fones, Calvin59, 104
 Ford, Elizabeth B.55
 Foroud, Tatiana36
 Forstein, Marshall55, 63, 84
 Forster, Robert D.32
 Fosha, Diana102
 Fouilhoux, Natacha91
 Foulds, Jonathan84
 Foulks, Edward F.54, 73
 Fouwels, Annemarie24
 Fowler, Joanna S.35
 Fox, Lindy43
 Fox, Michelle32
 Fradkin, Howard82
 Frances, Richard J.75
 Frank, Ellen1, 59, 102
 Frank, Guido K. W.60
 Frank, Julia B.15, 43, 86
 Frankenburg, Frances R.64, 102
 Frankle, W. Gordon85
 Frascella, Joseph35
 Frazier, Jean A.61
 Frazier, Shervert H.31
 Frederick, Struve45
 Freedman, Alfred M.34
 Freemantle, Nick13
 French, Louis M.88
 Freyd, Jennifer J.58
 Fried, Peter A.89
 Friedman, Edward S.26
 Friedman, Joseph51
 Friedman, Matthew J.18, 25, 60
 Friedman, Michelle E.75
 Friend, Jeffrey M.51
 Frierson, Richard L.46
 Fromson, John A.25
 Frye, Mark A.2, 66, 70
 Fullerton, Carol31
- G
- Gabbard, Glen O.22, 29, 38, 45
 Gabriele, Michelle85
 Gaby, Lynne M.15, 43
 Gaebel, Wolfgang59
 Gaiser, Georgia74
 Galanter, Marc3, 65, 75, 80
 Galchen, Rivka R.79
 Galea, Sandro59, 82
 Galeno, Roxana58
 Galfalvy, Hanga G.78
 Gallant, Joel45
 Gallardo, Kathy A.72
 Gameraff, Marc J.91
 Gara, Michael91
 Garber, Judy35
 Garland, David W.73
 Gamo, Jessica L.88
 Garrett, Michael D.29, 72
 Garvan, Cynthia91
 Garver, David L.22
 Gasic, Gregory P.30, 36
 Gasquet, Isabelle79
 Gastfriend, David R.96, 100
 Gaviria, F. Moises74
 Gaw, Albert C.18, 26, 74
 Gaynes, Bradley N.50
 Gaytan, Jr., Osvaldo45
 Gazely, Sharon48
 Geary, Nori62
 Geldmacher, David11
 Gelemter, Joel67, 87
 Gelfand, Yevgeny79
 Gelinas, Denise J.58
 Geller, Jeffrey L.18, 25
 Gellerman, David M.18
 Gendel, Michael H.25, 65
 George, Mark S.7, 30
 Gerard, Adriel60
 Gerbarg, Patricia L.42
 Gerson, Jessica86
 Gertz, John100
 Getter, Elizabeth V.53
 Getz, Glen45
 Ghaemi, S. Nassir1, 9, 46, 66
 Ghafoori, Bita81
 Ghalib, Kareem D.95
 Gharabawi, Georges85
 Ghinassi, Frank A.96
 Ghodse, A. Hamid105
 Gianoli-Valente, Marina24
 Giese-Davis, Janine87
 Gil, Roberto87
 Gilaberte, Inmaculada24
 Gillespie, Ian A.8
 Gillett, Kevin89
 Ginter, Walter39
 Gise, Leslie H.87, 100
 Gissinger, Rabbi Shlomo74
 Gitlin, Michael J.88
 Gittelman, Martin105
 Glatt, Stephen36
 Gleason, Peter C.99
 Glick, Ira D.24, 50, 63, 99
 Glueck, Dehra A.95
 Gnagy, Elizabeth M.65
 Goate, Alison36
 Goekoop, Jaap G.30
 Goel, Namni100
 Goethe, John W.23, 51
 Goetz, Raymond33, 87
 Gogineni, R. Rao89
 Goin, Marcia Kraft7, 10, 14, 22, 29,
 37, 55, 67, 83, 102
 Goisman, Robert M.71
 Gold, Liza H.7
 Gold, Philip W.4
 Gold, Wayne L.59
 Goldberg, David A.73
 Goldberg, Ivan K.93
 Goldberg, Jeffrey54
 Goldberg, Joseph F.2, 4, 23, 63, 88
 Goldberg, Linn47
 Goldberg, Pablo38
 Goldberg, Susan105
 Goldbloom, David S.104
 Golden, Robert N.4, 50
 Goldfarb, Lisa M.97
 Goldfinger, Stephen M.27, 54, 77, 99
 Goldman, Charles R.99
 Goldman, Morris B.14
 Goldman-Rakic, Patricia S.33
 Goldner, Elliot M.88
 Goldstein, Marion Z.86
 Goldstein, Mark A.78
 Goldston, David B.19
 Gomez, Ivan S.77
 Gonzales, Lizza C.33, 34
 Gonzalez, Gerado39
 Gonzalez-Heydrich, Joseph M.86
 Good, Candace R.78
 Goodhue, Angelique D.72
 Goodwin, Ericka L.18
 Gopal, Murali72
 Gordon, Edward72, 80
 Gordy, Tracy R.14, 46, 53, 72
 Gorelick, David A.100
 Gorman, Bernard S.89
 Gorman, Jack M.9, 19, 77, 92
 Gorman, Linda95
 Gottlieb, Diane B.54
 Gotway-Crawford, Carol52
 Gou, Shenyang50
 Gould, Elizabeth66
 Graap, Ken97
 Grabowski, John101
 Grabsch, Brenda87
 Grace, Sherry104
 Gracious, Barbara L.12
 Grady-Weliky, Tana A.18, 96
 Graignic-Phillippe, Rozenn24
 Granacher, Jr., Robert P.15
 Grant, Bridget F.36
 Grant, Jon E.63
 Grant, Steven J.54
 Grasso, Benjamin C.94
 Gravenstein, Stefan33
 Gray, Gregory E.7, 20
 Gray, Kevin F.55

PARTICIPANT INDEX

- Greden, John F. 8, 20, 47, 61
 Green, Melva I.25
 Greenberg, Benjamin D.83
 Greenberg, Harvey R.90
 Greenberg, Roger P.64
 Greenberg, Steven.89
 Greene, Ross W.86
 Greenfield, Shelly F.57
 Greengard, Paul16
 Greenhill, Laurence L. 106
 Greenleaf, Marcia7, 15
 Greist, John H. 4
 Griffith, Ezra E.H.34
 Griffith, James L. 15, 43, 76, 98
 Grilo, Carlos M. 52, 96
 Grimaldi, Jr., John A.R.53
 Gross, Raz91
 Grossberg, George T.69
 Grossman, Linda S. 23, 51
 Grote, Nancy K. 102
 Gruber, Staci A.85
 Grunebaum, Henry87
 Grunebaum, Michael F.78
 Grunhaus, Leon J.93
 Guardino, Mary T.50
 Guerin, Denette85
 Guerrero, Angela L.17
 Guglielmino, Livia50
 Guillem, Eric91
 Guinjoan, Salvador M.98
 Gulick, Roy M.63
 Gunatilake, Sarath51
 Gunderson, Erik W.81
 Gunderson, John G. 64, 102
 Gupta, Dipak31
 Guralnik, Orna 104
 Guschwan, Marianne T. 16, 80
 Gutheil, Thomas G.26
 Gutman, David A.51
 Guyker, Wendy M.77
 Gwynette, Frampton95
- H**
- Habeych, Miguel77
 Haffmans, Judith59
 Hafliger, Silvia 39, 50
 Hagan, Mary M.62
 Hajal, Fady48
 Hales, Deborah J. 16, 21, 28
 Hales, Robert E. 13, 41
 Hall, Heather M.74
 Hall, Lacresha L.48
 Hall, Laura Lee57
 Hall, Sandra B.77
 Halliday, Jennifer 103
 Halmi, Katherine A.7, 60
 Halper, James P.47
 Halperin, Jeffrey65
 Halpern, Abraham L.99
 Hamblen, Jessica32
 Hameedi, Faiq53
 Hamid, Hamada28
 Hamilton, Catherine 104
 Hamilton, N. Gregory 104
 Hamilton, Tom55
 Hamner, Mark B. 5
 Hanford, Russ35
 Hanin, Edward 19
 Hanning III, William F. 32
 Hann, Della M. 26
 Hannan, Scott 98
 Hansen, Mark R. 14
 Hanson, Graeme 25
 Harding, Richard K. 73
 Harding IV, George T. 49
 Harkavy-Friedman, Jill 87
 Harlan, William 12
 Harlap, Susan 33
 Harmon, Larry 18
 Harper, Thomasetta 45
 Harrison-Ross, Phyllis 29
 Harrow, Martin 23
 Hartman, David E. 95
 Hart, Seth 65
 Harvey, Philip D. 25
 Hasin, Deborah S. 36, 77, 79, 97
 Hassoun, Youssef 63
 Hatti, Shivkumar 103
 Hawryluck, Laura 59
 Hayes, Rosalind 17, 31
 Heck, Jeffrey 77
 Heckers, Stephan H. 13, 41, 61
 Heimberg, Richard G. 34
 Heinze, Gerardo 20
 Heister, Tagalie 95
 Hellerstein, David J. 27, 35, 86, 101
 Henderson, Claire 77
 Henderson, David C. 88
 Henderson, Shanta P. 45
 Hendin, Herbert 104
 Hendrie, Hugh C. 74
 Hennen, John 64, 79
 Henry, Michael E. 61
 Heo, MoonSeong 85
 Herbener, Ellen S. 23
 Herbert, Sarah E. 64
 Herman, John B. 62, 73
 Herman, Judith 32, 58
 Hermann, Richard C. 80
 Hernandez, Ibet 99
 Herpertz, Sabine 97
 Herrell, Richard 78
 Herrick, Jason P. 79
 Hersh, Richard G. 69
 Hershberger, Jason E. 52
 Hershenfield, Karen 104
 Hershko, Ruth 78
 Heru, Alison M. 55
 Herzog, Alfred 93
 Herzog, David B. 60
 Hess, Sally G. 33, 34
 Hicklin, Thomas A. 32
 Hicks, Daniel W. 50, 78
 Hicks, Madelyn H. 80
 Hieble, J. Paul 42
 Hien, Denise 90
 Hierholzer, Robert W. 81
 Higgins, Jr., Napoleon B. 48, 72
 Hill, Darryl B. 64
 Hinrichs, Anthony 36
 Hiott, David W. 103
 Hire, Richard O. 53
 Hirsch, Alan R. 95
 Hirschfeld, Robert M.A. 9
 Hirshberg, Laurence 1
 Ho, Travis 87
 Hobfoll, Stevan 31
 Hodge, Andrew 79
 Hodo, David W. 26, 100
 Hoebel, Bartley G. 62
 Hoen, Cynthia N. 75
 Hoencamp, Erik 59
 Hofecker-Fallahp, Maria F. 54
 Hofer, Myron 72
 Hoffer, Axel 26
 Hoffman, Ralph E. 83
 Hoffman, Rosalind G. 19
 Hoffmann-Rieken, Kristina 8
 Hogan, Michael F. 18, 57
 Holland, Scott 88
 Hollander, Annette J. 73
 Hollander, Eric 3, 63, 75, 92, 103
 Hollon, Steven D. 57, 58
 Holmes, William 82
 Hooley, Jill M. 85
 Hopkins, Geoffrey M. 73, 98
 Hopper, Elise 37
 Hopper, James 37
 Horton, Leslie A. 77
 Horton, Richard 70
 Horwood, Jeremy 23
 Hossain, Akhtar 98
 Howe, Edmund G. 69
 Howland, Robert H. 85
 Hsiung, Robert C. 18, 42, 79, 93
 Hu, Rona 7
 Huang, William 46
 Hudson, James I. 67
 Hudziak, James J. 65
 Hughes, Carrol 35
 Hughes, John R. 61
 Hughes, Maryfran 62
 Hulburt, Michael 91
 Hunter, Edward N. 78
 Hunter, Elaine 104
 Hunter, Jonathan J. 104
 Huprich, Steven 101
 Hurwitz, Thomas D. 55
 Hussain, Mohammad Z. 22
 Hutton, Heidi E. 19, 70
 Hwang, Michael Y. 53
 Hyde, James 103
 Hyler, Steven E. 5, 20, 42
 Hymowitz, Paul 34
 Hynes, Charles J. 27
- I**
- Inderbitzin, Lawrence B. 19
 Insel, Thomas R. 28
 Iosifescu, Dan V. 50, 66, 78
 Irigoyen-Rascon, Fructuoso R. 72
 Isay, Richard A. 27
 Ishak, Waguih W. 1, 95
 Isohanni, Matti K. 23
- J**
- Jabbarpour, Yad M. 18
 Jackson, Lucille 19
 Jackson, Michael A. 97
 Jackson-Siegel, Jeanne 41
 Jacobs, Douglas G. 77

- Jaffe, Adam J. 97
 Jaffe, Ari B. 22
 Jaffe, Ellen 80
 Jaffe, Richard L. 14
 Jain, Vivek 14
 James, Regina S. 47
 James, William A. 52
 Jamison, Kay R. 80
 Janicak, Philip G. 14
 Jankowski, Kay 32
 Jasinsky, Donald R. 51
 Javors, Martin A. 77
 Jayaram, Geetha 6, 10, 17, 20, 45, 71, 80, 94, 99
 Jenike, Michael A. 98
 Jennings, Constance A. 103
 Jensen, John E. 50
 Jermyn, Richard T. 95
 Jeste, Dilip V. 13, 74
 Jibson, Michael D. 73
 Jimerson, David C. 7, 63
 Jobe, Thomas H. 23
 Jobson, Kenneth O. 80
 Joffe, Hadine 39, 40, 93
 Johnson, Bankole A. 2, 64, 77
 Johnson, Barbara A. 96
 Johnson, Bradley R. 3
 Johnson, Brian 19
 Jones, Billy E. 26
 Jones, Hendree 90
 Jones, Kristina L.N. 53, 74
 Jones, Peter B. 23
 Jones, Ronald A. 28
 Jonker, Kosse 59
 Jorgenson, Linda M. 8, 19
 Josephson, Allan M. 20, 103
 Joshi, Kaustubh G. 53
 Joshi, Paramjit 34
 Joy, Charles R. 47, 53
 Judd, Lewis L. 21, 65
 Judge, Rajinder A. 5
 Judge, Sheila 15
 Jurchak, Martha 53
 Juthani, Nalini V. 20, 26, 37, 54, 74, 98
- K**
- Kahn, Jeffrey P. 52
 Kalali, Amir H. 51
 Kalin, Ned H. 66
 Kalivas, Peter W. 90
 Kaltenbach, Karol A. 90
 Kalunian, Douglas A. 80
 Kamara, Taafai S. 85
 Kamm, Ronald L. 21, 60
 Kampman, Kyle M. 47
 Kane, John M. 11
 Kang, Gurmit Shimi 100
 Kantor, Ruth B. 99
 Kaplan, Ana 43
 Kaplan, Gabriel 43
 Kaplan, Sandra J. 54
 Kapral, Moira 59
 Kapur, Shitij 3, 12
 Karasu, T. Byram 27
 Kastelic, Elizabeth A. 33, 34
 Kataoka, Sheryl H. 91
 Kathol, Roger G. 74
 Katon, Wayne J. 32
 Katsnelson, Nelly 74
 Katz, Craig L. 82, 85
 Katz, Debra A. 95
 Katz, Jon 95
 Katzav, Aviva 78
 Kaur Khalsa, Hari M. 79
 Kay, Jerald 82
 Kaye, Walter H. 6, 60
 Keairns, Yvonne 31
 Keck, Jr., Paul E. 4, 31, 78
 Keefe, Frank 4
 Keefe, Richard S.E. 10
 Keenan, Julian P. 33
 Kehayan, V. Alex 42
 Keisling, Robert W. 15, 43
 Keitner, Gabor I. 51
 Keller, Martin B. 6, 84
 Keller, Richard T. 81
 Kelley, Ann E. 35
 Kellner, Charles H. 14, 90
 Kelly, Bernice 81
 Kelly, Brian J. 103, 104
 Kelly, Ciara 103
 Kelly, David 19
 Kelly, Kevin V. 74
 Kelly, Robert 23, 51, 77, 98
 Kelly, Thomas M. 23, 97
 Kendrick, Anthony 32
 Kenna, George 64
 Kennedy, Robert S. 82
 Kennedy, Sidney H. 59, 88
 Kent, Andrew 105
 Kent, Justine M. 34, 92
 Kernberg, Otto F. 70, 102
 Keshavan, Matcheri S. 50
 Kessler, Ronald C. 2, 4
 Kestenbaum, Clarice J. 19, 42
 Ketter, Terence A. 51
 Kettl, Paul A. 81
 Khadivi, Ali 46
 Khalsa, Jag 30, 89
 Khan, Arifulla 13
 Khan, Mahrukh S. 75
 Khan, Neelofar 77
 Khan, Shirin R.F. 13
 Khandelwal, Madhulika S. 80
 Khemlani-Patel, Sony 102
 Kibel, Howard D. 95
 Kiehl, Kent A. 98
 Kietrys, David M. 95
 Kilpatrick, Dean 54
 Kim, Edward 53, 75
 Kim, Florence 45, 70, 93
 Kim, Kathleen M. 26
 Kim, Scott Y. 46
 King, Bryan H. 18, 100
 King, Cheryl 35
 King, Dana 103
 King, Linda P. 90
 Kingdon, David G. 8, 46, 57
 Kinzie, J. David 82
 Kirwin, Paul D. 1
 Kissane, David W. 87, 103
 Kiyabu, Dana 87
 Klagsbrun, Samuel C. 27
 Kleber, Herbert D. 48, 81, 84
 Kleiman, Andrew M. 75
 Klein, Daniel N. 101
 Klein, Diane A. 63
 Klein, Ehud M. 93
 Klein, Rachel G. 65
 Kleivins, L.F. 31
 Klibanski, Anne 60
 Klimstra, Sibel 85
 Klinkman, Michael 50
 Kloss, Raymond J. 56
 Knapp, Penelope 91
 Knegeting, Rikus 51
 Knight-Richardson, Norwood 83
 Knobler, Haim 77
 Knox, Patricia C. 50
 Knutelska, Margaret 104
 Ko, S. M. 59
 Kocsis, James H. 60
 Koen, Lisa 26
 Koenigsberg, Harold W. 78, 85
 Koeppel, Robert 85
 Kogan, Richard 27
 Koh, David 59
 Kohlenberg, Robert J. 58
 Kohn-Trattner, Amira 75
 Kolodner, George F. 80
 Kolzet, Julie 60
 Komarow, Hirsch 78
 Koob, George F. 61, 90
 Koopman, Cheryl 51, 87
 Kopala, Lili 9
 Koplun, Brett A. 3
 Koponen, Hannu J. 23
 Korczyn, Amos 40
 Korner, Judith 96
 Kornstein, Susan G. 11
 Korts, Russel 13
 Kosel, Markus 83
 Koskinen, Johanna 23
 Koskoff, Harriett 48
 Kossoy, Amy 60
 Kosten, Thomas R. 19, 39, 50, 70
 Kosza, Ida 36
 Kotov, Kimberly 86
 Kotwal, Renu 3
 Koutsemok, Igor 26
 Kovasznay, Beatrice M. 18
 Kovess, Viviane 52
 Koyanagi, Chris 57
 Kozel, Andrew F. 30
 Kraemer, Helena C. 51, 60
 Krahn, Lois E. 14, 99
 Krain, Amy L. 57, 86
 Krakowski, Menahem I. 52
 Kramer, Laura Kean 78
 Kramer, Milton 27, 47, 54
 Kramer, Peter D. 35
 Kramer, Thomas A.M. 82
 Krefetz, David G. 95
 Krejci, Jonathan 84
 Kremen, William 36
 Kriger, Paul F. 42
 Kring, Brunhild 54
 Kripke, Daniel F. 100
 Krishnan, K. Ranga R. 9, 13, 28, 41
 Kroenke, Kurt 8
 Krueger, Lynnette 42
 Krueger, Robert F. 87
 Kruger, Christa 87
 Krystal, Andrew D. 11

PARTICIPANT INDEX

Krystal, John H. 87, 104
 Kudler, Harold S. 18
 Kunwar, Arun R. 52
 Kuo, Jack. 46
 Kupfer, David J. 11, 59
 Kupper, Lawrence L. 105
 Kushner, Mara. 18
 Kweder, Sandra L. 12
 Kyomen, Helen H. 100

L

Labutta, Robert J. 88
 Ladd, Heather. 91
 Lafayette, Jennifer M. 62
 Lafer, Beny. 58
 Laje, Gonzalo. 50
 Lalonde, Justine K. 67
 Lam, Raymond W. 88, 99
 Lamb, H. Richard. 55
 Lamdan, Ruth M. 54
 Lamon-Fava, Stefania. 78
 Lancee, William J. 104
 Lane, Tom. 57
 Langsley, Donald G. 53, 73
 Lantigua, Rafael. 91
 Laorondeguevara, M. Soledad. 98
 Lappalainen, Jaakko A. 87
 Laruelle, Marc. 34, 85
 Lasaluia, Antonio. 101
 Lathlean, Judith. 32
 Laurence, Jessica. 33
 Lauriello, John. 28
 Lauronen, Erika. 23
 Lauterbach, Edward C. 3
 Lautin, Andrew L. 28
 Lavendar, Lynn. 99
 Lavori, Philip. 11
 Lavretsky, Helen. 11
 Law, Roslyn. 59
 Law, Samuel F. 24
 Lawson, J. Stuart. 90
 Lawson, William B. 62
 Lebovits, Allen. 56
 Lebowitz, Barry D. 85
 Leckman, James F. 72
 LeDoux, Joseph. 33
 Lee, Karen L. 14
 Lee, Steven J. 48
 Lee, Susanne. 33
 Lee, Thomas C. 24
 Lefley, Harriet P. 25
 Legault, Claudine. 12, 40
 Lehman, Anthony F. 20, 27
 Lehmann, Laurent S. 18
 Leigh, Hoyle. 96, 98
 LeMelle, Stephanie. 61
 Le Nestour, Annick. 24
 Leo, Raphael J. 42
 Leon, Christine. 91
 Leon-Andrade, Carlos. 58
 Lepine, Jean-Pierre. 91
 LeQuesne, Elizabeth. 53
 Leroi, Iracema. 65
 Leserman, Jane. 105
 Lester, Barry M. 20
 Leszcz, Mohyn. 104
 Leung, Eman. 105

Leung, Henry H. 95
 Levendusky, Philip G. 71
 Levenson, Alan I. 26
 Levenson, James L. 15, 74
 Leventhal, Eric. 53
 Leverich, Gabriele S. 88
 Levin, Barry. 35
 Levin, Frances R. 47, 51, 84
 Levine, Jeffrey M. 99
 Levine, Jerome. 22
 Levine, Nettie. 95
 Levitan, Robert D. 99, 105
 Levitt, Anthony J. 99
 Levounis, Petros. 18, 26, 48
 Levy, Bruce R. 74
 Lewis, Bradley E. 95
 Lewis, Catherine F. 79
 Lewis, Lydia J. 4
 Lewis, Roya. 54
 Lewis-Fernandez, Roberto. 5, 91
 Lewy, Alfred J. 8
 Li, Eric C. 18
 Li, Xingbao. 30
 Liang, Warren M. 84
 Lieberman, Jeffrey A. 10, 28, 38
 Liebowitz, Michael R. 34, 92
 Lieff, Susan J. 73
 Lim, M. K. 59
 Lim, Russell F. 5
 Limoges, Richard F. 25
 Lin, Elizabeth. 32
 Lin, Keh-Ming. 62, 82
 Lindegger, Graham. 52
 Lindeman, Sari. 23
 Lindenmayer, Jean-Pierre. 73
 Linehan, Marsha M. 19, 27, 58
 Ling, Walter. 30, 39, 70
 Link, Bruce G. 77
 Links, Paul S. 30, 63
 Linn, Kenneth. 27
 Lipsitt, Don R. 96
 Lipsyte, Robert. 21
 Lisanby, Sarah H. 30, 83, 93
 Liskow, Barry I. 77
 List, James F. 67
 Liu, Xinhua. 77, 79, 97
 Livesley, John. 30, 43
 Ljungberg, Mirka K. 91
 Loboprabhu, Sheila M. 19, 26
 Lockhart, Paula J. 100
 Loebel, J. Pierre. 29
 Logsdon, Linda. 25
 Logue, Bobby. 97
 Lolak, Sermsak. 98
 Lomax II, James W. 19, 26
 Londino, Donna L. 80
 Lonesome, Ronald B. 26
 Loonen, Anton J.M. 1
 Lopes, Fabiana L. 23
 Lopes-Cardozo, Barbara. 52
 Lopez, Juan F. 61
 Lopez-Ibor, Jr., Juan J. 65, 80
 Lorell, Beth. 99
 Lotufo-Neto, Francisco. 58
 Lounsbury, David. 52
 Love, Anthony. 103
 Lovelace, John G. 96
 Lovell, Mark. 45

Lowe, Chet. 17
 Lowenkopf, Eugene M. 69
 Lowenthal, David A. 27, 95
 Loza, Nasser F. 105
 Lu, Francis G. 5, 48, 59, 73, 98, 103
 Luby, Joan L. 25
 Lucak, Susan. 22
 Ludman, Evette. 32
 Luff, Jamie A. 50
 Lukas, Scott E. 105
 Luo, John S. 18, 42, 56
 Lutterman, Theodore C. 57
 Lyketsos, Constantine. 20, 65
 Lymbenis, Maria T. 73
 Lynch, Thomas. 41
 Lyons, Michael. 36

M

Ma, Jennie Z. 77
 Macchi, Mela M. 100
 Macdonald, Shiona M. 103
 Macewan, Thomas. 103
 Mack, Avram H. 16, 24, 75
 MacKenzie, K. Roy. 21
 MacLurg, B. Jason. 81
 MacQueen, Glenda M. 88
 Maguin, Eugene. 90
 Maguire, Marcella. 75
 Mah, Kenneth. 59
 Malaspina, Dolores. 33, 87
 Malcolm, Jr., Robert J. 64
 Maldonado, Jose R. 7, 15, 43, 98
 Malean, Alexandra. 91
 Malhotra, Anil K. 63
 Malison, Robert T. 87
 Mallios, Ronna. 98
 Mallott, David B. 99
 Malloy, Erin M. 35
 Malmquist, Carl P. 19
 Malone, Kevin M. 23
 Maltby, Nicholas. 98
 Malte, Carol A. 50
 Mancini, Catherine L. 23
 Manevitz, Alan Z.A. 47
 Manji, Hussein K. 28
 Mann, Henry B. 1
 Mann, J. John. 23, 63, 78, 97
 Mannuzza, Sal. 65
 Manos, Peter J. 82
 Manschreck, Theo C. 62
 Manu, Peter. 25, 74
 Manzo, Mary P. 60
 Marangell, Lauren B. 30, 70, 93
 Marano, Anthony. 34
 March, John S. 20
 Marcus, Eric R. 19, 20
 Marcus, Sheila. 61
 Marder, Stephen R. 11, 14
 Marin, Humberto. 43, 86
 Mark, Margery. 65
 Mark, Naomi. 89
 Markou, Athina. 61
 Markowitz, John C. 5, 59, 101
 Marmar, Charles R. 104
 Marotti, Ferruccio. 46
 Marrocco, Mary K. 7
 Marsh, Laura. 65

- Marshall, Chris E.51
 Marshall, Geraldine36
 Marshall, Randall D. 37, 51, 69
 Martin, Billy R.89
 Martin, Marie C.97
 Martin, Sandra L. 105
 Martinez, Humberto36
 Martone, Christine A.95
 Marx, Christine E.86
 Marzorati, Paolo50
 Masand, Prakash S. 6, 9
 Maser, Jack63
 Masheb, Robin M.96
 Mason, Dana91
 Massie, Mary Jane52
 Mathews, Maju 106
 Mathis, Chet60
 Matorin, Anu A.26
 Matseoane, Karen97
 Matthews, Stephen 105
 Mattos, Paulo E.55
 Mattson, Marlin R.A.45
 Maullin, Nathalie48
 Maunder, Robert G. 104
 Mavissakalian, Matig R.50
 May, Matthew7, 15
 Mayberg, Helen S. 2
 Mayers, Harold A.34
 Mayes, Linda C.20
 Mazer, Neal46
 Mazzasalma, Marco A.23
 McAllister, Thomas 87, 93
 McCall, W. Vaughn 14, 89
 McCauley, Elizabeth35
 McClelland, Gary M.32
 McCrady, Barbara S.65
 McCreadie, Robin G. 103
 McCurtis, Henry L.26
 McDermott, Stephen P.67
 McDonald, Brenna87
 McDonald, Noelle57
 McDonald, William M. 4
 McDonough, Susan C.61
 McDowell, David J.81
 McDowell, David M.27, 44, 50, 81, 84, 94, 97, 99
 McElnea, Brenda99
 McElroy, Susan L. 2, 9
 McEwen, Bruce S. 8
 McGeer, Allison59
 McGlashan, Thomas H.64
 McGreal, Bryan J.53
 McGuire, Marsden H.80
 McHugh, Paul R. 20, 91
 McIntyre, John S.25, 27, 47, 59
 McIntyre, Kevin47
 McIntyre, Roger S. 9
 McKeith, Ian G.40
 McLellan, A. Thomas57
 McLoughlin, Kris A.18
 McNicholas, Laura F. 39, 70
 McQuery, Joy D.25
 McShea, Mary C.85
 Meares, Russell 102
 Mears, Alex P.99
 Mechanic, David16
 Medford, Nicholas 104
 Medoza, Richardo19
 Mee-Lee, David 5
 Melamed, Michael L. 74
 Mellman, Lisa A.15, 27, 86
 Melonas, Jacqueline M.26, 46, 69
 Meltzer, Carolyn 60
 Meltzer, Herbert Y.9
 Meltzer-Brody, Samantha 105
 Mendelowitz, Alan J. 92
 Mendlewicz, Julien21, 65
 Mendoza, Ricardo P. 62
 Menvielle, Edgardo J. 64, 74
 Menza, Matthew A.65, 86
 Merideth, Philip T. 80
 Merikangas, Kathleen 45
 Merlock, Megan57
 Mesci, Aruz 9, 15
 Mestry, Kezziah 52
 Metzger, Eran D. 63
 Metzner, Jeffrey L.24, 90
 Meydan, Jakob79, 97
 Meyer, Jonathan M. 9, 15
 Meyers, Barnett S. 85
 Michel, Bernard 91
 Michels, Robert15, 27, 94
 Mick, Eric85, 106
 Miettunen, Jouko 23
 Mikalac, Cecilia M. 15, 70
 Mikdowitz, David 88
 Milev, Roumen V. 88
 Milgram, Rabbi Goldie73
 Miller, Alexander L. 12
 Miller, Andrew H. 28
 Miller, Brenda A. 90
 Miller, Dinah 35
 Miller, Gary E. 74
 Miller, Karen K. 60
 Miller, Mark D. 24
 Miller, Rachel 99
 Miller, Sheldon I. 75
 Millman, Robert B. 75
 Milone, Richard D.46, 73
 Minehart, Margaret A. 75
 Miner, Lucinda L. 26
 Mink, Sallie 33, 34
 Minsky, Shula 91
 Mintz, David L. 43
 Mintzer, Jacobo E. 6, 43
 Miotto, Karen A. 82
 Miranda, Jeanne 91
 Mirecki, Ilona 77
 Mischoulon, David34, 78, 88
 Mishory, Alexander 30
 Miskimen, Theresa M. 91
 Misra, Madhu 60
 Misri, Shaila3
 Mitchell, James E. 7, 60
 Mohamed, Mahmoud A. 94
 Mohatt, Dennis 57
 Molina, Brooke S.G. 65
 Mollica, Richard F. 54
 Monahan, John 61
 Montgomery, Richard A.18, 42, 56
 Montoya, Ivan D. 48
 Monuteaux, Micheal 85
 Morocco, Kathryn E. 105
 Mordecai, Donald J. 18
 Morehouse, Rachel L. 99
 Morgan, Linda 47
 Morgan-Minott, Melodie 72
 Morgenstern, Jon75
 Morin, David P. 85
 Morrell, Martha J. 93
 Morris, John C. 6
 Morrison, Jason M. 52
 Morse, Eric D. 60
 Moszynski, Peter 17
 Moulton, John L. 65
 Mourilhe, Patricia 46
 Moussaoui, Driss 80
 Moy-Martin, Elisabeth 88
 Moynihan, Patrick J. 99
 Mrazek, David A. 3, 27
 Mucha, Theodore F. 51
 Muehlbach, Britta 80
 Muench, Frederick 75
 Muenzenmaier, Kristina H. 32
 Mueser, Kim T.32, 43
 Mufti, Khalid A. 96, 105
 Mullen, Jamie 22
 Mulsant, Benoit H. 85
 Munich, Richard L.70, 93
 Munoz, Rodrigo A.20, 26, 45, 59, 83
 Murakami, Jessica L.77
 Muran, J. Christopher 89
 Musacchio de Zan, Amelia 46
 Muskin, Philip R. 4, 22, 73, 77, 82
 Musselman, Dominique L. 4
 Myers, Michael F. 19, 26, 42, 73, 80, 102
 Myers, Nicholas 18
 Myers, Wade C.73, 80
 Mynors-Wallis, Lawrence 32
 Myrick, Hugh 2, 64
- N
- Nace, Edgar65, 75
 Nadelson, Carol C. 19
 Nader, Michael 36
 Naem, Farooq105
 Nahas, Ziad H.30, 93
 Nair, Jyotsna 45
 Najavits, Lisa M. 54
 Naji, Simon103
 Nam, Theodore S. 60
 Nand, Surinder S.18, 26
 Napoli, Joseph C. 42
 Nardi, Antonio E. 23
 Narrow, William E. 24, 50, 59
 Nascimento, Isabella 23
 Naser, Jeffrey A.23, 72
 Nasrallah, Henry A. 9, 24, 92
 Ndlela, J. Charles 5
 Needell, Nancy J. 19
 Nehama, Yael 23
 Nelson, Charleston 72
 Nelson, Dorothy104
 Nelson, J. Craig 66
 Nelson, Jessie 67
 Nemeroff, Charles B. 1, 2, 4, 29, 58, 84
 Nene, Sudhandshu 26
 Neria, Yuval Y. 91
 Nesse, Randolph M. 34
 Nestadt, Gerald 20
 Neuberger, Peshy 74
 Neuberger, Rabbi Yaakov 74
 Neugebauer, Richard 59
 New, Antonia S.78, 85

PARTICIPANT INDEX

- Newcomer, John W. 13, 41
 Newcorn, Jeffrey H. 51, 65
 Newman, Michelle G. 4
 Newman, Rita R. 73, 99
 Newmark, Thomas S. 60, 89, 103
 Newport, D. Jeffrey 70
 Newton, Thomas 82
 Neziroglu, Fugen 102, 103
 Ng, Anthony T. 8
 Ng, David 51
 Niaz, Unaiza 74
 Nickel, Elizabeth J. 77, 78
 Nicola Siri, Leonardo 98
 Nicolo, Alessandro 46
 Nierenberg, Andrew A. 5, 34, 50, 78, 86
 Nierenberg, Marvin A. 80
 Nihalani, Nikhil D. 51, 79
 Ninan, Philip T. 2, 23, 92
 Nineberg, Allan S. 54
 Ning, Autumn 54
 Nininger, James E. 7
 Niparko, Angela 90
 Nir, Yehuda 75
 Njenga, Frank G. 31
 Noble-Ludwig, Antonia 95
 Noel, Richard L. 74
 Noji, Eric 54
 Noll, Elizabeth 64
 Nonacs, Ruta M. 39
 Noordsy, Douglas 43
 Nordahl, Thomas E. 45
 Norko, Michael A. 10
 Norman, Matthew W. 72
 Norrie, John 103
 Norris, Donna M. 26
 North, Carol S. 8, 17, 82
 Notman, Malkah T. 19
 Novac, Andrei 104, 105
 Nunes, Edward V. 26, 73, 79, 84, 97
 Nurnberg, H. George 86
 Nutt, David J. 69
 Nwokeji, Kingsley 98
 Nzama, Thobile 52
- Oakman, Jonathan 23
 O'Brien, Charles P. 48, 49
 O'Brien, Robert 75
 O'Connell, Anne 47
 Oepen, Godehard 72
 Oesterheld, Jessica R. 71
 O'Farrell, Timothy J. 101
 Offsay, Julian 80
 O'Halloran, Ruth A. 79
 Ohayon, Maurice M. 39
 Okasha, Ahmed 80, 83
 Okasha, Tarek A. 62
 O'Keefe, Kelly 19
 Okereke, N. Kalaya 53
 Okonji, Marx O. 105
 Olarte, Sylvia W. 74, 86
 Oldham, John M. 23, 38, 59, 91
 Olfson, Mark 91
 Ollendick, Thomas H. 86
 Olshansky, Ellen F. 102
 O'Malley, Mary B. 67
 Onken, Lisa S. 101
- Opler, Lewis A. 19, 32, 69
 Oquendo, Maria A. 38, 47, 63, 78, 94
 Ordorica, Patricia I. 18, 26, 44, 46, 73, 81
 Orskovich, Michael R. 50
 Orzack, Maressa H. 46
 Osinowo, Thomas O. 14
 Osofsky, Howard J. 46, 54
 Osser, David N. 80
 Ostacher, Michael J. 78
 Oswald, Kimberly D. 62
 Othmer, Ekkehard 78
 Othmer, Sieglinde C. 78
 Otto, Grace 53
 Otto, Michael W. 6, 9, 98
 Oulvey, Eugene A. 14
- P
- Packer, Samuel 48
 Page, Everet 31
 Painter, Albert F. 27
 Paizis, Mary 50
 Pak, Greg 96
 Pally, Regina 55
 Palmer, Christopher M. 32
 Palmer, Orrin 42
 Paltrow, Lynn M. 81
 Panadero, Charles V. 18
 Panahon, Norma C. 74
 Pandina, Gahan J. 85
 Pandurangi, Ananda K. 29
 Pandya, Anand 23, 53, 82, 99
 Panzer, Paula G. 52, 95
 Papakostas, George I. 34, 78
 Papirio, Stefania 46
 Papp, Laszlo A. 23
 Parameswaran, Sharat 51
 Pardes, Herbert 20
 Parikh, Rajesh M. 88
 Parikh, Sagar V. 88
 Paris, Joel F. 48, 64
 Park, Lawrence T. 62, 81
 Parnham, George 70
 Parsons, Jeffrey 75
 Passik, Steve 30
 Pastor, Larry H. 81
 Pate, Jennifer E. 19, 81
 Patel, Jayendra K. 85
 Patel, Raman C. 99
 Pato, Michele T. 42, 73
 Patterson, Robert D. 80
 Paul, Robindra K. 95
 Paul, Susan E. 95
 Pearlson, Godfrey D. 94
 Peasley-Miklus, Catherine 85
 Peel, Deborah C. 31
 Peele, Roger 31, 86
 Pelchat, Marcia L. 35
 Pelham, Jr., William E. 65
 Pelusi, Dan 104
 Penick, Elizabeth C. 77, 78
 Penzel, Fred 48
 Perahia, David G. 24
 Perel, James M. 58
 Perkins, Diana O. 41, 92
 Perlin, Michael L. 99
 Perlis, Roy H. 4, 78
 Person, Ethel S. 4
- Peselow, Eric D. 22, 23, 47, 50
 Petet, John R. 20, 53, 103
 Petersen, Timothy J. 5, 34, 50, 78
 Petersen-Crair, Pamela J. 26
 Petitjean, Francois C. 91
 Petkova, Eva 101
 Petry, Nancy M. 54, 101
 Petryshen, Patricia M. 104
 Petty, Frederick 104
 Pevalin, David J. 52
 Peveler, Robert C. 32
 Peyser, Herbert S. 79
 Pezous, Anne-Marie F. 91
 Pfeffer, Cynthia R. 25, 52
 Pfefferbaum, Betty 8
 Pflanz, Steven E. 17, 47, 53
 Phillips, Katharine A. 63, 103
 Phillips, Mary L. 104
 Pi, Edmond H.T. 62
 Piasecki, Melissa P. 70
 Picardi, Angelo 101
 Pickering, Roger P. 36
 Pickering, Ruth 32
 Pies, Ronald W. 93
 Piez, Deborah A. 23
 Pilotte, Nancy 54, 90
 Pilowsky, Daniel J. 35
 Pinals, Debra A. 81
 Pincus, Simon H. 32
 Pine, Daniel 20
 Pinsker, Henry 86
 Pinson, Letitia A. 7
 Pipe, Beth 23
 Pirard, Sandrine 100
 Pittman, Roger K. 105
 Pittman, Mary 47
 Placidi, Rachel J. 62
 Plakun, Eric M. 19, 43
 Pleak, Richard R. 64
 Pliskin, Neil H. 74
 Plotsky, Paul 54
 Podniesinski, Elizabeth 57
 Polidori, Gabriella 79
 Pollack, David A. 57
 Pollack, Mark H. 6, 92
 Pollack, William S. 31
 Pollock, Jonathan D. 36
 Polosan, Mircea C. 78
 Pope, Jr., Harrison G. 47, 89
 Popoiu, Veronica 53
 Portenoy, Russ 30
 Post, Jerrold M. 31, 43
 Post, Robert M. 78, 88
 Postolache, Teodor T. 78, 97
 Potenza, Marc N. 54
 Potkin, Steven G. 40
 Potter, Nancy L. 87
 Powell, Barbara J. 77, 78
 Powsner, Seth M. 18, 96
 Prasad, Konasale M.R. 52
 Pressman, Mary Anne 22, 50
 Preter, Maurice 75
 Price, Julie 60
 Price, Marilyn 81
 Price, Trevor R.P. 99
 Friday, Lauren 103
 Prince, Jefferson B. 1, 5, 14, 39
 Printz, David J. 87

- Prohovnik, Isak.....85
Puchalski, Christina M.98, 103
Puddester, Derek.....7
Pugliese, Maria A.42
Pullen, Ian M.25
Pumariega, Andres J.....71, 79
Purselle, David C.67
Putnam, Katherine M.85
Putnam, Jr., Frank W.....52
Pyles, Robert L.31
Qian, F.59
- Q
- Quanbeck, Cameron D.2
Quesada, Gonzalo F.....18
- R
- Rabins, Peter V.43
Racy, John C.17
Rada, Pedro62
Radden, Jennifer.....46, 105
Rae, Donald S.50
Raine, Charles J.56
Raison, Charles39
Rajouria, Namita.....42
Rakic, Pasko.....33
Rambaldini, Gloria59
Ramirez, C.31
Ramirez, Luis F.8, 27
Ramirez, Paul M.69
Ramsay, J. Russell75
Randall, Robert87
Rao, Aruna S.48
Rao, Nyapati R.47, 54, 99
Rapaport, Mark H.1, 16, 21, 28
Rapkin, Bruce.....52
Rapp, Stephen R.12
Rasgon, Natalie L.....66, 70
Rath, Darlyne59
Rathod, Shanaya46
Rausch, Jeffrey L.....80
Ravitz, Paula1
Ray, Neepa105
Razavi, Maryam.....86
Realmuto, George M.65
Reddy, Raj.....96
Regier, Darrel A.24, 27, 44, 59
Reich, D. Bradford64
Reich, James H.30, 63
Reid, William H.90
Reifler, Burton V.27
Reinblatt, Shauna P.....18, 25
Reinus, John F.38
Reiss, David M.95
Reissman, Dori B.17
Renner, Jr., John A.80
Renshaw, Perry F.41, 50, 61
Reoux, Joseph P.50
Resnick, Patricia32
Resnick, Phillip J.5, 14, 28, 42, 69
Resnikoff, Roy O.5
Ressler, Kerry J.2
Reus, Victor I.27
Reyes, Raymond M.80
Reynolds III, Charles F.91
Riba, Michelle B.10, 14, 37, 58, 80
- Rice, John.....36
Richards, Lawrence K.99
Richardson, Denise M.45
Richardson, Jarrett W.....14
Richman, Judith A.51
Ries, Richard K.19, 65
Rifkin, Arthur24
Riggs-Skean, Karen.....89
Riley, Anne35
Rinaldi, Paul J.26
Rinne, Thomas30
Ritchie, Elspeth C.51, 83
Ritvo, Eva C.18
Rizvi, Shireen.....58
Roache, John D.77
Roberts, Laura W.16, 46, 73
Robertson, Emma K.104
Robertson, Judith35
Robertson, Marguerite104
Robinowitz, Carolyn B.19
Robinson, Gail E.8, 96
Robinson, Gilbert99
Robinson, Robert G.22
Robinson, Susan59
Robinson, Terry E.90
Roca, Catherine A.....70
Roca, Robert P.90
Rodenhauser, Paul.....27
Rodgers, Bryan.....52
Rodriguez, Denny54
Rodriguez, Richard A.....97
Roffman, Joshua L.....52
Rogan, Alice.....70, 93
Rogan, Gerald.....80
Rogers, Anna E.95
Rogers, James R.102
Rogge, Scott D.46
Rohan, Kelly J.97
Rohrbaugh, Robert M.1
Rojcewicz, Jr., Stephen.....86
Rolland, John S.14
Rondon, Marta B.74
Ronningstam, Elsa F.63
Roose, Steven P.5, 11
Rosen, Cherise23, 51
Rosenbaum, Jerrold F.5, 30, 88
Rosenbaum, Talli75
Rosenberg, Stanley32
Rosenberger, John W.....73
Rosenfeld, Alvin A.....35
Rosenman, Stephen J.52
Rosenthal, Norman.....77
Rosenthal, Richard N.....18, 101
Roskes, Erik J.55
Rospenda, Kathleen M.51
Rostain, Anthony L.48, 75
Roth, Thomas11, 97
Rothe, Eugenio M.72
Rothenberg, Jami84
Rothschild, Anthony J.....85, 97
Rothschild, Louis97
Rothstein, David31, 51
Rotter, Merrill R.46
Rounsaville, Bruce J.97, 101
Rourke, Sean B.104
Royalle, Candida60
Roy-Byrne, Peter P.32, 67
Rozenberg, Marina60
- Rubenstein, Michael N.42
Rubin, Eugene H.15
Rudden, Marie G.73
Rudisill, John R.27
Rudinis, Ilze24
Rudolph, Mark N.79
Rudolph, Steven E.19
Rueda-Lara, Maria A.42
Ruggeri, Mirella101
Ruiz, Pedro20, 26, 46, 62, 73, 79
Ruiz, Robert T.32
Ruiz-Mellot, Katherine G.78
Rush, A. John5, 27, 30, 50, 57, 84
Rusquellas, Astrid N.95
Russo, Leo77, 79
Ryan, Deirdre M.3
Ryan, J. Michael13, 41
Ryan, Julie L.50
Rychik, Abe M.69
Ryk, Roel H.30
- S
- Saari, Kaisa23
Sacamano, James T.55
Sachs, Gary S.9
Sackeim, Harold A.11, 30, 83
Sadavoy, Joel24
Safran, Jeremy D.89
Safren, Steven A.98
Said, Tewfik15
Sajatovic, Martha.....27
Sakauye, Kenneth M.17
Salaam, Karriem L.54
Sales, Roberta81
Salloway, Stephen P.11
Salo, Ruth E.45
Salvatore, Paola79
Salzman, Carl.....4
Samet, Sharon97
Sampo, Eduardo98
Sandson, Neil B.71
Sano, Mary.....6
Santone, Giovanni101
Sar, Vedat87
Sartorius, Norman36, 65, 83
Sasson, Yehuda.....92
Savage, Seddon R.30
Savolainen, Markku J.23
Saxon, Andrew J.50
Saykin, Andrew.....87
Scally, Erin90
Scandlin, Donna105
Schacht, Lucille.....57
Schaefer, Catherine A.33
Schaepper, Mary Ann.....72
Schane, Murray D.82
Scharf, Martin B.99
Schatzberg, Alan F.28, 39, 44, 56, 66
Scheiber, Stephen C.27
Scheidlinger, Saul48, 95
Schetky, Diane H.34
Schiffer, Randolph B.55
Schillerstrom, Jason E.53
Schlaepfer, Thomas E.83, 84
Schloredt, Kelly35
Schloss, Heather78
Schmahl, Christian G.38, 85

PARTICIPANT INDEX

Schmaling, Karen B.	58	Shulman, Kenneth I.	13	Speer, Andrew M.	88
Schmidt, Jr., Chester W.	14, 46, 53, 72	Shumaker, Sally A.	12, 40	Spencer, Donald	50
Schmitz, Joy M.	73, 101	Sidwell, Robert	33	Spencer, Thomas J.	2, 67, 98
Schneiderman, Jason	78	Siegel, Carole	36	Spiegel, David	4, 7, 15, 51, 56, 87
Schneier, Franklin R.	34, 92	Siegel, Daniel J.	67, 70, 73, 102	Spiegel, Herbert	7, 15
Schnell, K.nut	97	Siegel, Glenn N.	47	Spinazzola, Joseph F.	37, 58
Schoener, Gary R.	8	Sierra, Manuel	77	Spinelli, Margaret G.	10, 70, 100
Schore, Allan N.	33	Sierra, Mauricio	104	Spinhovem, Philip	59
Schreibersdorf, Lisa	19, 27	Siever, Larry J.	78, 85	Spitz, Deborah	87
Schubmehl, James Q.	15	Silbaugh, David	99	Spitz, Henry I.	87, 94
Schultz, Susan K.	25	Silberman, Edward K.	42	Sprich, Susan	98
Schulz, S. Charles	5, 6	Silenzio, Rosella	50	Squire, Kurt.	46
Schuster, James A.	96	Silk, Kenneth R.	85	Srinivasaraghavan, Jagannathan	18
Schwab, John J.	97	Silver, Jonathan M.	87, 88, 93	Stabinsky, Harvey	77
Schwartz, Bruce J.	45	Silver, Larry B.	76	Stabinsky, Susan.	52, 78
Schwartz, Gary J.	62	Silver, Marjorie A.	99	Stahl, Stephen M.	7, 9
Schwartz, Joseph M.	25, 72	Silver, Stuart B.	76	Stangler, Ronnie S.	18
Schwartz, Michael	51	Silverman, Joel J.	47	Stanley, Barbara H.	38, 86
Schwartz, Thomas L.	24	Silverman, Morton.	102	Stary, Joel	33
Sciutto, Mary S.	95	Silverman, Samuel M.	80	Stastny, Peter	105
Sclare, Paul	103	Simantov, Sophia	74	Staudenmeier, Jr., James J.	32
Scott, Jan L.	57	Simeon, Daphne	104	Steadman, Henry J.	61
Scott, John	59	Simon, Asher B.	52	Stebbins, Glenn T.	74
Scott, Lisa	72	Simon, Gregory	32	Steenbarger, Brett	64
Scott, Marcia A.	17	Simon, Naomi M.	6, 92	Stefanis, Costas	65
Scully, Jr., James H.	7, 27, 56	Simon, Robert I.	25, 43	Steiker, Carol	34
Seaman, Barbara	100	Simons, Lucy	32	Stein, Dan J.	3, 63
Secin, Ricardo	58	Simpson, George M.	10	Stein, Elliot A.	30
Seeman, Mary V.	19	Simpson, William	37	Stein, Murray B.	6, 32, 34, 66, 67
Segal, Gerald	42	Singer, Kenneth	82	Stein, Seth P.	80
Segebarth, Christoph.	78	Sinha, Rajita	90	Steinberg, Marc L.	84
Seidman, Larry J.	39	Siris, Samuel G.	53	Steinberg, Rosalie	24
Seidman, Stuart N.	12	Sirota, Elizabeth	80	Steiner, Meir	39, 61
Selemmon, Lynn D.	33	Sirota, Pinkhas	78	Steinglass, Peter J.	3
Selhub, Jacob	78	Sit, Dorothy	85	Steinkuehler, Constance	46
Sensky, Thomas	57	Sites, Jane	52	Steinman, David	81
Serrano, Alberto	58	Sivnioglu, Yusuf	27	Stern, Daniel N.	102
Servis, Mark E.	49	Skinner, Andrew O.	24, 50, 96	Stern, Harriet C.	73
Shafii, Mohammad	17	Skarsky, Katherine	78	Stevens, Christopher.	89
Shah, Manoj R.	45	Skodol II, Andrew E.	38, 101	Stevenson, Janine L.	102
Shah, Vital N.	23, 79	Skotzko, Christine E.	42	Stewart, Altha J.	25, 43, 73, 86
Shalev, Arie H. Y.	54	Slattery, Marcia J.	86	Stewart, Deborah C.	96, 98
Shanfield, Stephen B.	33	Small, Dana.	35	Stewart, Donna E.	86, 104
Shankar, Sri Sri Ravi.	17	Small, Gary W.	11	Stewart, Jonathan W.	100
Shannahoff-Khalsa, David	74	Smeriglio, Vincent L.	20	Stewart, S. Evelyn.	98
Shapira, Nathan A.	54	Smiley, Susan E.	54	Stewart, Stephanie M.	46
Shapiro, Edward R.	19, 43	Smith, Felicia A.	62	Stiller, John W.	78
Shapiro, Theodore	73	Smith, Graeme C.	87	Stinson, Frederick S.	36
Sharfstein, Steven S.	90	Smith, Matthew B.	56	Stoddard, Jr., Frederick J.	45
Sharkey, John	99	Smith, Michael	103	Stolar, Andrea G.	17, 81
Sharkey, Valerie.	103	Smith, Michael W.	5	Stoll, Andrew L.	41
Sharma, Tonmoy	74	Smyth, Nancy J.	90	Stone, Alan A.	24, 34, 62, 105
Sharon, Estee	100	Snyder, Scott	96	Storosum, Jitschak G.	24
Shaw, Jon A.	17	Soares, Claudio N.	12, 39, 88	Stotland, Nada L.	7, 53, 73, 86
Shaywitz, Jonathan E.	92	Sokol, Mae S.	8	Stotts, Angela L.	101
Shea, M. Tracie	87	Solkhah, Ramon	18	Stowe, Zachary N.	2
Shea, Steven	91	Solloway, Scott	22	Strain, Eric C.	70
Shear, M. Katherine	59, 102	Soloff, Paul H.	23, 97	Strakowski, Stephen M.	88
Sheehan, David V.	6, 22	Solursh, Lionel P.	75	Straus, Sharon	59
Sheline, Yvette I.	20	Sommers, Denise	14	Strauss, John S.	55
Shelley, Anne-Marie	32	Somoza, Eugene C.	77	Streltzer, Jon M.	19, 82
Shen, Hong	72	Sonawalla, Shamsah B.	88	Strokoff, Harris	75
Sherbourne, Cathy D.	32	Sood, Bella	35	Stroup, T. Scott	10
Shinfuku, Naotaka.	36	Sorrentino, Renee M.	57	Stuart, Scott P.	1
Sholevar, G. Pirooz	89	Soto, Jose M.	99	Stunkard, Albert J.	4
Shoptaw, Steven	47	Sotres-Alvarez, Daniela	105	Styra, Rima.	59
Shrager, Daniel	31	Southwick, Steven M.	104	Suarez, Raymond E.	74
Shreeram, Srirangam S.	78	Soyka, Karen M.	102	Sudak, Donna M.	26, 89, 106

- Sullivan, Ann Marie T.53
 Sullivan, Carl R.19
 Sullivan, Gregory B.23
 Sullivan, J. Greer32
 Sunderland, Trey 13, 41
 Suomi, Stephen J.34
 Susser, Ezra S. 33, 82
 Svikis, Dace50
 Swain, James E.72
 Swann, Alan C.3, 33
 Swanson, James M.7
 Swanson, Jeffrey W.61
 Swartz, Conrad M. 33, 89
 Swartz, Holly A.59, 102
 Swartz, Karen L. 33, 34, 86
 Swartz, Marvin S.61
 Swern, Anne J.27
 Swift, Robert M.64
 Szabo, Boglarka 33, 34
 Szarek, Bonnie L. 23, 51
 Szigethy, Eva M.45
 Szor, Henry23
- T**
- Taintor, Zebulon C. 36, 85
 Talbott, John A.91
 Tandon, Rajiv 3, 14, 92
 Tang, Cheuk78
 Tang, Lingqi91
 Tansella, Michele 101
 Tanzi, Rudolph13
 Taranto, Richard G. 24, 62
 Tariot, Pierre N. 13, 41
 Tasman, Allan10, 15, 101
 Taub, Robert95
 Taylor, Brent64
 Taylor, Valerie88
 Taylor, Warren D.6, 41
 Teicher, Martin H. 47, 54
 Teitelbaum, Sori74
 Templeton, Bryce 106
 Teplin, Linda A.32
 Terman, Jiuan Su100
 Terman, Michael 8, 100
 Thakur, Mugdha E.11
 Thase, Michael E.3, 9, 13, 58, 59,
 66, 73, 78, 85, 86
 Thielke, Stephen M.25
 Thienhaus, Ole J.70
 Thomas, Christopher R.42
 Thomas, Jean M. 25, 73
 Thompson, Christopher32
 Thompson, Kenneth S. 25, 95
 Thompson, Leonti H.75
 Thompson, Michael J.52
 Thomson, Captane P.45
 Thorn, Nicole65
 Thron, Armin97
 Thrower, Courtney M. 78, 97
 Thuluvath, Paul45
 Tibaldi, Giuseppe 101
 Tillman, Jane G.19
 Timimi, Sami95
 Todd, Richard D.65
 Tohen, Mauricio F. 78, 79
 Tolin, David98
 Ton, Hendry 56, 74
- Toto, Anna Marie 75
 Tracy, Martin G. 26, 46, 103
 Tran, Pierre V. 24
 Treisman, Glenn J. 19, 20, 47, 50, 70
 Trieschmann, Martha 51
 Triffleman, Elisa G. 50
 Trimble, Michael R.7
 Trinidad, Anton C.23, 90, 98
 Trippitelli, Carol L.79
 Trivedi, Madhukar H. 50
 Trosch, Richard N. 13
 Trujillo, Manuel 53
 Truman, Christine J. 50
 Tschan, Werner 54
 Tseng, Wen-Shing 82
 Tso, Alice C. 74
 Tsodikov, Faina 23
 Tsuang, John W. 19, 82
 Tsuang, Ming T. 36
 Tucker, Phebe M.8
 Tucker, William M. 42, 85
 Tuerk, Catherine 64, 74
 Tulloch, Simon J. 98
 Tune, Larry E. 15, 71
 Turgay, Atilla 51
 Turkington, Douglas 8, 46, 57
 Tuunainen, Arja L. 100
- U**
- Uhl, George 36
 Ulmer, Carolyn 75
 Umbrell, Laura J. 42
 Upadhyya, Gopalakrishna K. 46
 Upshur, Carole C. 80
 Urbaitis, John C. 25
 Ursano, Robert J. 17, 25, 31, 46, 60
 Ustun, T. Bedirhan2
- V**
- Vaglum, Per 30, 63
 Vaitya, Nutan A. 26
 Valenca, Alexandre M. 23
 Van Ameringen, Michael A. 23
 Van Cauter, Eve 67
 Van Den Brink, Wim 24, 30
 Van Der Kolk, Bessel A.37, 58, 91
 Vanderpool, Donna 46, 54
 Van Dyck, Richard 59
 Van Praag, Herman M.1
 van Zwieten, Barbara J. 24
 Varghese, Frances T. 104
 Varma, Satish C. 16
 Varma, Sudeepta 80
 Vazquez, Delia M. 61
 Veale, David 103
 Veenstra-VanderWeele, Jeremy 18
 Vega, William 91
 Veijola, Juha M. 23
 Verdelli, Helena 59
 Vereen, Jr., Donald R. 47
 Verma, Sumer 32
 Vernikov, Rozaliya 74
 Viamontes, George I. 45, 58
 Viana, Jason B. 62
 Viederman, Milton 71
 Vigezzi, Pierluigi 50
- Vigo, Daniel E. 98
 Viguera, Adele C. 4, 69, 93
 Vilagut, Gemma79
 Viswanathan, Ramaswamy 80
 Vocci, Francis J. 47
 Vogel-Scibilia, Suzanne E. 25, 54, 80
 Volkman, Edward A. 54
 Volkov, Marina 26
 Volkov, Nora D.3, 20, 35, 44
 Volpp, Serena Y. 4
 Von Korff, Michael 32
 Voutsilakos, Fia 88
 Vreeland, Elizabeth 75
 Wachtler, Sol75
 Wade, Terrance J. 52
- W**
- Wadler, Gary I. 47
 Wagner, H. Ryan 61
 Wagner, Karen D. 9
 Wahlstrom, Jr., Carl M. 95
 Wain, Harold J. 60
 Wainberg, Milton L. 52, 55, 75
 Walschlag, Lauren S.20
 Waldrep, Douglas A. 60
 Walker, Edward A. 32
 Walker, Roger D. 18, 73
 Walkup, John T. 48
 Wall, Susan 103
 Wallace, Joel J. 45
 Walsh, B. Timothy 62, 63, 67
 Walsh, James K. 97
 Wang, Fujun 24
 Wang, Gene-Jack 35
 Wang, Lei 33
 Wapenyi, Khakasa H. 53
 Warden, Deborah Lee 88
 Warshaw, Carole L. 25
 Wasserman, Stacey 92
 Wasylenski, Donald A. 104
 Watchel, Paul 89
 Wauford, Pamela K. 62
 Waxmonsky, James G. 67
 Waylen, Andrea 23
 Wehr, Allison M. 45, 57
 Weiden, Peter J. 3, 11, 79
 Weinmann, Gabriel 31
 Wein, Simon 103
 Weinberg, Naimah Z. 65
 Weine, Stevan M. 31
 Weiner, Elyse D. 47
 Weiner, Richard D. 14
 Weinmann, S. 59
 Weinstein, Henry C. 55
 Weintrob, Alex 34
 Weisberg, Risa B. 6
 Weisler, Richard H. 51, 98
 Weisman, Henry W. 75
 Weiss, Francine 73
 Weiss, Jeffrey 19
 Weiss, Margaret D. 2
 Weiss, Roger D. 73
 Weiss, Susan R.B. 89
 Weissman, Myrna M. 27, 35, 59, 91
 Weller, Elizabeth B. 27
 Wells, Kenneth B. 91
 Weltzin, Theodore E. 96

PARTICIPANT INDEX

Wenk, Gary L6
Wessells, Michael31
West, Joyce C24, 50, 59
Westermeyer, Joseph J82
Wetherington, Cora Lee90
Whalen, Paul66
Whiteside, Stephen14
Whitman, Anne31
Wick, Paul H45
Wickramaratne, Priya59
Widiger, Thomas A87
Wiesner, Irving S20
Wilber, Charles H97
Wilens, Timothy E39, 65, 67, 98, 106
Wilensky, Mark99
Wilk, Joshua E27, 50, 59
Wilkins, Jeffrey N46
Williams, Adedapo B106
Williams, Eric R48
Williams, Jill84
Williamson, Johnny L46
Wills, Cheryl D54, 81
Wills, Marketa M24, 45, 53, 97
Wilson, G. Terrence60
Wilson, Kumanan59
Wilson, Lori100
Winette, Carol98
Winick, Bruce J99
Winkelman, John W55, 67, 92
Winstead, Daniel K27
Winston, Arnold89
Winter, Britta97
Winters, Ken C65
Wise, Brian K25
Wise, Robert A45
Wishart, Heather87
Wislar, Joseph S51
Wisner, Katherine L70, 100
Wohlfarth, Tamar D24
Wohlreich, Madelaine M25
Wolf, Marina E90
Wolfe, Barbara E7, 63
Wolfe, Tom38
Wolke, Dieter23
Wolkin, Adam28
Wonderlich, Stephen A60
Wong, Marleen46
Wood, William C25, 73
Woody, George E101
Worhunsky, Patrick98
Worley, Linda L.M56
Worthington III, John J34, 78
Wozniak, Janet69, 85
Wright, Harry H25
Wright, Jesse H3, 8, 26, 57, 97
Wright, Mark S79
Wu, Joseph C19, 81
Wulsin, Lawson R77
Wung, Jay L95
Wyatt, Richard J33
Wynn, John D29
Wysong, Ashley98

X


Xie, Hui101

Y

Yager, Joel7, 15, 47, 60, 93
Yang, C. Paul74
Yang, Jian24
Yates, Alayne96
Yehuda, Rachel75, 92, 105
Yeomans, Frank E70
Yeung, Albert77, 88
Ying, Patrick73
Yonkers, Kimberly A6, 61, 100
Young, Arlene100
Young, Judy74
Young, Keith W46, 53, 60, 61
Young, Kimberly S46
Yousufi, Samina M97
Yu, Van80
Yudofsky, Stuart C13, 41, 45, 70, 93
Yurgelun-Todd, Deborah A4, 41, 61, 85, 89

Z

Zachry, Woodie M94
Zanarini, Mary C23, 38, 64, 102
Zarate, Jr., Carlos A79
Zatzick, Douglas F25
Zaubler, Thomas S75
Zdanowicz, Mary45
Zelvin, Elizabeth93
Zhang, Wei4, 93
Ziedonis, Douglas M48, 62, 84, 100
Zima, Bonnie T91
Zimmerman, Mark97, 101
Zin, Walter A23
Zitek, Brook E75
Zohar, Joseph92
Zonana, Howard V24, 34
Zoulalian, Carol48
Zubieta, Jon-Kar8, 30, 85
Zuckoff, Allan102



AMERICAN PSYCHIATRIC ASSOCIATION – 158TH ANNUAL MEETING

MAY 21-26, 2005

Atlanta, Georgia

CALL FOR PAPERS

PRESIDENT'S THEME:

Psychosomatic Medicine: Integrating Psychiatry & Medicine

Michelle Riba, M.D.

President

Marian I. Butterfield, M.D., Chairperson

Scientific Program Committee

THE SUBMISSION SCHEDULE

Format	Deadline
Industry-Supported Symposium	June 1, 2004
Course	September 7, 2004
Reports	September 7, 2004
Symposium	September 7, 2004
Workshops	Issue: September 7, 2004 Component: September 20, 2004
New Research	December 3, 2004

Incomplete and/or Incorrect Forms Will Not Be Considered.

For complete submission forms, you may download the forms at www.psych.org, click on the Annual Meeting logo, then click on submission forms. You may also contact the APA toll free at 1-888-357-7924, and speak directly with an Answer Center Coordinator.

If you want to volunteer to chair a session, please send a letter to the attention of Dr. Butterfield at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.

American Psychiatric Association

**Audiotapes
Recorded Live!**

***High Quality Continues for
the 2004 Annual Meeting ...***



**Live recordings will be available
for most of the following:**

- Lectures • Advances in Research
- Advances in Psychopharmacology
- Presidential Symposia • Medical Updates
- Scientific and Clinical Reports • Symposia
 - Debate • Roundtable Discussion
 - Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth at the Javits Convention Center.

Mobiltape Company, Incorporated

24730 Avenue Tibbitts, Suite 170

Valencia, CA 91355

Phone: (661) 295-0504 ♦ (800) 369-5718

Fax: (661) 295-8474

Website: www.mobiltape.com

American Psychiatric Association

Mental Health Disparities in the Community

Who Should Attend?

- Psychiatrists in community practice or public sector including state, community, and Veterans Affairs hospitals, community clinics, and jails
- Psychiatric administrators
- Persons interested in social issues that have an impact on patients
- Minority psychiatrists and International Medical Graduates
- Psychiatric Residents
- Medical Students

Why Should You Attend?

- Earn up to 48 hours of category 1 credit
- Receive a 40% discount on APA member registration fees
- Industry-Supported Lunch and Dinner Symposia are presented each day

How Will You Benefit?

- Learn the latest knowledge and skills in clinical psychiatry, which can be utilized to improve patient care
- Acquire a deeper understanding of how the current health care system affects patient care
- Gain new knowledge and skills useful in clinical and public psychiatry settings
- Recognize and improve mental health disparities in the community

IPS is your comprehensive educational and networking event with a clinical focus on topics including:

- | | |
|---|--|
| ■ Cross-cultural and minority issues | ■ AIDS |
| ■ Social and community psychiatry | ■ Psychiatric administration and services |
| ■ Psychopharmacology | ■ Treatment techniques and outcome studies |
| ■ Resident and medical student concerns | ■ And much more |
| ■ Substance abuse | |
| ■ Child and adolescent issues | |

Registration starts June 1, 2004.

Visit www.psych.org for detailed program information and to register.



Questions?

Call: 1-888-357-7924 (Toll Free) or 703-907-7300

Fax: 703-907-1090

Email: apa@psych.org

Visit: www.psych.org

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 48 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.



**56th Institute
on Psychiatric
Services**

October 6-10, 2004

**Hilton Atlanta Hotel
Atlanta, GA**

The *First* and *Last* Word

AT YOUR ANNUAL MEETING BOOKSTORE

APPI Bookstore at the 2004 APA Annual Meeting

Psychiatry's premiere publisher brings the cutting-edge titles you've been waiting for directly to you! Come check out APPI's latest groundbreaking selection, from the newest textbooks, review series, and journals, to electronic products for your handheld or online. The APPI Bookstore is the one place you can go to gather all the resources you'll need in the next year. Update subscriptions, complete your series collections, browse through hard to find titles, and even develop your course adoptions—all in one stop. Don't miss the Author Book Signings or the Sunrise Special, with discounts of 25% for APA Members-in-Training—see you there!

APPI Bookstore Hours

Saturday, May 1.....10:00am – 5:00pm
Sunday, May 2.....10:00am – 4:30pm
Monday, May 3.....10:00am – 5:30pm
Tuesday, May 4.....10:00am – 6:00pm
Wednesday, May 5.....10:00am – 3:00pm

Sunrise Special

Deep Discounts for APA Members-in-Training!
APPI is committed to helping APA MITs gain the knowledge needed to excel in the psychiatric profession. Between the hours of 8am and 11am, on Sunday, May 2, the APPI Bookstore will be open to members-in-training only for our annual Sunrise Special, and will offer a 25% discount. Don't miss out on this enormous opportunity to stock up!



American Psychiatric Publishing, Inc.
1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209-3901
Phone: 703-907-7322 or 1-800-368-5777
Mon.-Fri., 9 am to 5:30 pm, ET
Fax: 703-907-1091
Email: appi@psych.org
Web: www.appi.org

The *First* and *Last* Word in Psychiatry

Please reference priority code AH421 when ordering



Treatment Companion to the DSM-IV®-TR Casebook

Edited by Robert L. Spitzer, M.D.,
Michael B. First, M.D., Miriam Gibbon, M.S.W.,
and Janet B. W. Williams, D.S.W.


2004 • 360 pages • ISBN 1-58562-139-0
paperback • \$39.00 • Item #62139
2004 • 360 pages • ISBN 1-58562-194-3
hardcover • \$54.00 • Item #62194



The American Psychiatric Publishing Textbook of Child and Adolescent Psychiatry, Third Edition

Edited by Jerry M. Wiener, M.D., and
Mina K. Dulcan, M.D.

2004 • 1,140 pages • ISBN 1-58562-057-2
hardcover • \$165.00 • Item #62057



The American Psychiatric Publishing Textbook of Psychopharmacology, Third Edition

Edited by Alan F. Schatzberg, M.D., and
Charles B. Nemeroff, M.D., Ph.D.


2004 • 1296 pages • ISBN 1-58562-060-2
hardcover • \$178.00 • Item #62060



The American Psychiatric Publishing Textbook of Geriatric Psychiatry, Third Edition

Edited by Dan G. Blazer, M.D., Ph.D.,
David C. Steffens, M.D., M.H.S., and Ewald W. Busse, M.D.

2004 • 608 pages • ISBN 1-58562-065-3
hardcover • \$110.00 • Item #62065



The American Psychiatric Publishing Textbook of Forensic Psychiatry

Edited by Robert I. Simon, M.D.,
and Liza H. Gold, M.D.

2004 • 656 pages • ISBN 1-58562-087-4
hardcover • \$75.00 • Item #62087



The American Psychiatric Publishing Textbook of Substance Abuse Treatment, Third Edition

Edited by Marc Galanter, M.D., and
Herbert D. Kleber, M.D.

2004 • 704 pages • ISBN 1-58562-099-8
hardcover • \$125.00 • Item #62099

in Psychiatry

Special Benefits for American
Psychiatric Association Members!
10% Discount for All APA Members
25% Discount for Members-in-Training

Review of Psychiatry, Volume 23

Series Editors: John M. Oldham, M.D., M.S.,
and Michelle B. Riba, M.D., M.S.

Brain Stimulation in Psychiatric Treatment

Edited by Sarah H. Lisanby, M.D.

2004 • 160 pages • ISBN 1-58562-175-7
paperback • \$34.95 • Item #62175

Cognitive-Behavior Therapy

Edited by Jesse H. Wright, M.D., Ph.D.

2004 • 160 pages • ISBN 1-58562-178-1
paperback • \$34.95 • Item #62178

Neuropsychiatric Assessment

Edited by Stuart C. Yudofsky, M.D., and H.
Florence Kim, M.D.

2004 • 176 pages • ISBN 1-58562-177-3
paperback • \$34.95 • Item #62177

Developmental Psychobiology

Edited by B. J. Casey, Ph.D.

2004 • 176 pages • ISBN 1-58562-176-5
paperback • \$34.95 • Item #62176

SET of Review of Psychiatry, Volume 23

2004 • \$109.00 • Item #5082

JANUARY

Essentials of Clinical Psychiatry, Second Edition

Edited by Robert E. Hales, M.D., M.B.A., and
Stuart C. Yudofsky, M.D.

2004 • 1032 pages • ISBN 1-58562-033-5
paperback • \$72.00 • Item #62033

Doing the Right Thing

An Approach to Moral Issues in
Mental Health Treatment

John R. Peteet, M.D.

2004 • 144 pages • ISBN 1-58562-083-1
paperback • \$24.95 • Item #62083

FEBRUARY

Clinical Manual of Anxiety Disorders

Edited by Dan J. Stein, M.D., Ph.D.

2004 • 200 pages • ISBN 1-58562-076-9
paperback • \$32.00 • Item #62076

MARCH

Essentials of Neuroimaging for Clinical Practice

Edited by Darin D. Dougherty, M.D., M.Sc.,
Scott L. Rauch, M.D., and Jerrold F. Rosenbaum, M.D.

2004 • 176 pages • ISBN 1-58562-079-3
hardcover • \$42.00 • Item #62079

Concise Guide to Ethics in Mental Health Care

Laura Weiss Roberts, M.D., and
Allen R. Dyer, M.D., Ph.D.

2004 • 384 pages • ISBN 0-89048-944-8
paperback • \$29.95 • Item #8944

APRIL

2005 Appointment Book

American Psychiatric Association

2004 • 192 pages • ISBN 0-89042-331-8
spiralbound • \$32.95 • Item #2331

American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders

Compendium 2004

American Psychiatric Association

2004 • 896 pages • ISBN 0-89042-375-X
hardcover • \$83.50 • Item #2375

2004 • 896 pages • ISBN 0-89042-376-8
paperback • \$64.00 • Item #2376

Quick Reference to the American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders

Compendium 2004

American Psychiatric Association

2004 • 208 pages • ISBN 0-89042-377-6
paperback • \$32.00 • Item #2377

Psychodynamic Treatment of Depression

Fredric N. Busch, M.D., Marie Rudden, M.D., and
Theodore Shapiro, M.D.

2004 • 320 pages • ISBN 1-58562-084-X
paperback • \$32.95 • Item #62084

Catatonia

From Psychopathology to Neurobiology

Edited by Stanley N. Caroff, M.D.,
Stephan C. Mann, M.D., Andrew Francis, M.D.,
Ph.D., and Gregory L. Fricchione, M.D.

2004 • 256 pages • ISBN 1-58562-085-8
paperback • \$38.00 • Item #62085

DSM-IV[®]-TR Guidebook

Michael B. First, M.D., Allen Frances, M.D., and
Harold Alan Pincus, M.D.

2004 • 512 pages • ISBN 1-58562-188-9
hardcover • \$69.50 • Item #62188

2004 • 512 pages • ISBN 1-58562-068-8
paperback • \$59.50 • Item #62068

Prices subject to change without notice.

New Core Competencies!

Core Competencies for Psychiatric Education

Defining, Teaching, and Assessing
Resident Competence

Linda Boerger Andrews, M.D., and
John William Burruss, M.D.

2004 • 176 pages • ISBN 1-58562-130-7
paperback • \$32.50 • Item #62130

The Art and Science of Brief Psychotherapies

A Practitioner's Guide
(Core Competencies in Psychotherapy)

Edited by Mantosh J. Dewan, M.D.,
Brett N. Steenbarger, Ph.D., and
Roger P. Greenberg, Ph.D.

2004 • 336 pages • ISBN 1-58562-067-X
paperback • \$38.50 • Item #62067

Long-Term Psychodynamic Psychotherapy

A Basic Text
(Core Competencies in Psychotherapy)

Glen O. Gabbard, M.D.

2004 • 224 pages • ISBN 1-58562-144-7
paperback • \$33.95 • Item #62144

Introduction to Supportive Psychotherapy

(Core Competencies in Psychotherapy)

Arnold Winston, M.D.,
Richard N. Rosenthal, M.D., and
Henry Pinsker, M.D.

2004 • 192 pages • ISBN 1-58562-147-1
paperback • \$32.50 • Item #62147

APRIL

Fear and Anxiety

The Benefits of Translational Research
Edited by Jack M. Gorman, M.D.

2004 • 336 pages • ISBN 1-58562-149-8
paperback • \$39.95 • Item #62149

CPT Handbook for Psychiatrists, Third Edition

Chester W. Schmidt, Jr., M.D., Rebecca Yowell,
and Ellen Jaffe

2004 • 160 pages • ISBN 1-58562-157-9
spiralbound • \$39.00 • Item #62157

Trance and Treatment

Clinical Uses of Hypnosis, Second Edition

Herbert Spiegel, M.D., and David Spiegel, M.D.

2004 • 448 pages • ISBN 1-58562-190-0
paperback • \$52.00 • Item #62190

INDUSTRY-SUPPORTED SYMPOSIUM 1
 Saturday, May 1, 12:30 p.m. - 3:30 p.m.
 Special Events Hall 1D, Level 1, Javits Center

A symposium to be held during the APA 2004 Annual Meeting



Mark H. Rapaport, MD (Chair)
 May 1, 2004
 12:30 PM - 3:30 PM
 Special Events Hall 1D, Level 1
 Javits Center
 New York, NY

Treatment Resistance: Concepts and Management in Mood and Anxiety Disorders

Agenda

12:00 PM - 12:30 PM

Lunch

12:30 PM - 12:35 PM

Welcome and Introduction

Mark H. Rapaport, MD (Chair)
 Cedars-Sinai Medical Center

12:35 PM - 12:55 PM

Treatment Resistance in Mood and Anxiety Disorders: Evidence From Clinical Trials

Ellen Frank, PhD
 University of Pittsburgh

12:55 PM - 1:15 PM

Psychotherapeutic Approaches for Treatment-Resistant Patients

Edna B. Foa, PhD
 University of Pennsylvania

1:15 PM - 1:35 PM

Current Strategies for Treatment-Resistant Patients

Alan F. Schatzberg, MD
 Stanford University

1:35 PM - 1:55 PM

Clinical Pathways for Mood and Anxiety Disorders

Wagdy W. IsHak, MD
 Cedars-Sinai Medical Center

1:55 PM - 2:15 PM

Emerging Treatment Options in

Treatment-Resistant Depression and Anxiety Disorders

Mark H. Rapaport, MD

2:15 PM - 2:45 PM

Multimedia Case Studies

Panel Discussion

2:45 PM - 3:30 PM

Questions and Answers

3:30 PM

Symposium Adjourned

At the conclusion of this symposium, the participant should be able to:

- Review cutting-edge pharmacologic and somatic treatments for resistant mood and anxiety disorders
- Describe rates of treatment for various mood and anxiety disorders in clinical trials
- Present an overview of outcome of cognitive behavioral therapy for obsessive compulsive disorder and post-traumatic stress disorder
- Optimally select treatments in refractory depression and anxiety disorders

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or at 703-907-7300.

Supported by an unrestricted educational grant from **JANSSEN**

Sponsored by the American Psychiatric Association

RS-1452

INDUSTRY-SUPPORTED SYMPOSIUM 2
 Saturday, May 1, 12:30 p.m. - 3:30 p.m.
 Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

Preventive Psychiatry in Mood Disorders: The New Frontier

Symposium to be held at the American Psychiatric Association 157th Annual Meeting

SATURDAY, MAY 1, 2004
12:30 PM - 3:30 PM

Grand Hyatt New York
 Park Avenue at Grand Central
 Empire State Ballroom B/C/D
 New York, New York

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from GlaxoSmithKline

PROGRAM OBJECTIVES

After attending this continuing medical education symposium, the psychiatrist should be able to:

- Understand the effects of early-life trauma on neurobiology and the subsequent development of psychiatric illness
- Provide psychiatrists and psychologists with available information on medication use during pregnancy and lactation
- Discuss the emerging role of neuroimaging as it affects psychiatry
- Become familiar with data suggesting various genetic changes may be associated with psychiatric disease.



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

AGENDA

12:00 PM Lunch

12:30 PM Welcome and Introduction
 CHARLES B. NEMEROFF, MD, PhD
 SYMPOSIUM CHAIR
 Emory University School of Medicine

12:35 PM Identification of Risk Factors for Development of Depression: Focus on Early-Life Trauma
 CHARLES B. NEMEROFF, MD, PhD

1:05 PM Achieving the Optimal Balance Between Treatment of Maternal Depression and Infant Medication Exposure
 ZACHARY N. STOWE, MD
 Emory University School of Medicine

1:35 PM Functional Brain Imaging: Subtyping Depression
 HELEN S. MAYBERG, MD
 Emory University School of Medicine

2:05 PM Genetic Research in Psychiatry: Diagnostic and Therapeutic Implications
 STEPHAN CLAES, MD, PhD
 University of Antwerp (UA)

2:35 PM Panel Discussion With Questions and Answers

3:30 PM Closing Remarks, Adjournment
 CHARLES B. NEMEROFF, MD, PhD

INDUSTRY-SUPPORTED SYMPOSIUM 3
 Saturday, May 1, 12:30 p.m. - 3:30 p.m.
 Grand Ballroom East, Third Floor, Hilton New York



Bipolar Disorder and Alcoholism:
 Diagnostic Challenges and Therapeutic Interventions

An educational symposium to be presented at the 2004 Annual Meeting of the American Psychiatric Association

Saturday, May 1, 2004
 12:30 PM - 3:30 PM

Hilton New York
 Grand Ballroom East
 Third Floor
 New York, New York

Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Ortho-McNeil Pharmaceutical, Inc.



Program Agenda

12:00 PM - 12:30 PM Lunch

12:30 PM - 12:40 PM Welcome and Introduction
 Program Chair: Mark A. Frye, MD
 David Geffen School of Medicine at UCLA

12:40 PM - 1:05 PM Neurobiology of Alcohol Withdrawal
 Hugh Myrick, MD
 Medical University of South Carolina

1:05 PM - 1:30 PM Pharmacotherapy for Alcoholism
 Bankole A. Johnson, MD, PhD
 The University of Texas Health Science Center at San Antonio

1:30 PM - 1:55 PM The Impact of Alcoholism on the Presentation and Course of Bipolar Disorder
 Susan L. McElroy, MD
 University of Cincinnati College of Medicine

1:55 PM - 2:20 PM The Role of Mood Stabilizers in Bipolar Disorder With Comorbid Alcohol Dependence
 Joseph F. Goldberg, MD
 Zucker Hillside Hospital North Shore-Long Island Jewish Health System

2:20 PM - 2:45 PM Bipolar Illness, Substance Abuse Comorbidity, and the Legal System
 Cameron D. Ouanbeck, MD
 University of California, Davis

2:45 PM - 3:10 PM Panel Discussion: Questions and Answers
 Faculty

3:10 PM - 3:30 PM Summary and Conclusions: Questions and Answers
 Mark A. Frye, MD

3:30 PM Adjournment

Educational Objectives

Upon completion of the program, participants should be able to discuss the neurobiology of alcohol withdrawal, dependence, and relapse prevention in patients with bipolar disorder; address pharmacotherapy of alcohol dependence; comprehend the impact of alcoholism on the presentation and course of bipolar disorder; determine the role of mood stabilizers in bipolar disorder with comorbid alcohol dependence; and understand bipolar illness, substance abuse comorbidity and their implications for the legal system.


Accreditation Statement

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

The APA designates this educational activity for a maximum of 3 Category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA, toll free, at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 4
 Saturday, May 1, 12:30 p.m. - 3:30 p.m.
 Broadway Ballroom, Sixth Floor, Marriott Marquis



Held During the APA 2004 Annual Meeting

**Adult ADHD:
 Clinical Utility
 and Validity**

Don't Miss This Important Educational Program!

Saturday, May 1, 2004
 12:00PM-12:30PM Luncheon
 12:30PM-3:30PM Educational Program

Marriott Marquis
 Sixth Floor, Broadway Ballroom
 New York, New York

Learning Objectives

Upon completion of the program, participants should be able to:

1. Describe the magnitude and consequences of ADHD in adults based on empirical data in the US and in different countries around the world.
2. Identify the diagnostic instruments for screening people with possible ADHD in community and clinical settings.
3. Name the state-of-the-art clinical assessments of ADHD diagnosis and differential diagnosis.
4. Cite the latest possible treatment interventions to prevent the disability associated with ADHD.
5. Recognize the prevalence of adult ADHD in the US and patterns of treatment for adult ADHD and list objective studies of future pharmacologic therapies for the treatment of ADHD.
6. Identify the burden of undiagnosed adult ADHD for people with the disorder as well as their families and employers, the comorbidities of adult ADHD with other DSM disorders, and the effects of untreated adult ADHD on the severity and course of comorbid disorders.
7. Demonstrate the utility of the adult-specific diagnostic and self-assessment (ASRS) in adult ADHD.
8. Recognize that ADHD is clinically heterogeneous and that the verifiability of findings from neurobiological studies may be interpreted as support for the etiologic and pathophysiologic heterogeneity of the disorder.

12:00PM-12:30PM Luncheon

12:30PM Welcome and Introduction
 T. Bedirhan Üstün, MD
 Program Chairperson
 World Health Organization

12:40PM Prevalence of Adult ADHD in the United States: Results from the National Comorbidity Survey Replication (NCS-R)
 Ronald C. Kessler, PhD
 Harvard Medical School

1:05PM Adult ADHD Diagnostic and Self-Report Symptom Scales: Development and Validation in the National Comorbidity Survey Replication (NCS-R) Cohort
 Lenard A. Adler, MD
 NYU School of Medicine

1:30PM Current Concepts in the Neurobiology of ADHD
 Joseph Biederman, MD
 Harvard Medical School
 Massachusetts General Hospital

1:55PM Treatment Options and Response Patterns in Adult ADHD
 Margaret D. Weiss, MDCM, PhD
 ADHD Clinic
 Children's and Women's Health Centre of British Columbia

2:20PM Our New Understanding of the Prevalence, Impairments, Comorbidity, and Treatment of Adults With ADHD
 Thomas J. Spencer, MD
 Harvard Medical School
 Massachusetts General Hospital

2:45PM Question and Answer Session

3:30PM Program Adjournment

9. Review clinical literature on psychological strategies for management of ADHD with findings from the clinical trials for treatment of ADHD with medication to develop a step-by-step guide to management of adults with ADHD that integrates psychological and medication treatment.

10. Summarize the prevalence, symptomatology, impairments, manifestations, and comorbidities of ADHD in adults, comparing data to a large epidemiologic study with those of younger adults.

Accreditation Statement


The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Eli Lilly and Company



Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 5
 Saturday, May 1, 12:30 p.m. - 3:30 p.m.
 Imperial Ballroom A, Second Floor, Sheraton New York

TOWARDS DSM-V: PHENOMENOLOGY, NEUROBIOLOGY, AND TREATMENT RESPONSE IN DEPRESSION

PROGRAM AGENDA

12:00 PM - 12:30 PM	Lunch
12:30 PM - 12:40 PM	Introduction Philip T. Ninan, MD Professor, Psychiatry and Behavioral Sciences Director, Mood and Anxiety Disorders Program Emory University School of Medicine Atlanta, Georgia
12:40 PM - 1:05 PM	Pathophysiology of Major Depression: Monoamines, Neuropeptides, and Neurotrophins Kerry J. Ressler, MD, PhD Assistant Professor, Department of Psychiatry Emory University School of Medicine Atlanta, Georgia
1:05 PM - 1:30 PM	Homology Between Pathophysiology and Symptoms in Major Depression Bosdie W. Dunlop, MD Postdoctorate Fellow, Department of Psychiatry Emory University School of Medicine Atlanta, Georgia
1:30 PM - 1:55 PM	Enhancing Emergence of Antidepressant Benefit Charles DeBattista, DMH, MD Associate Professor, Psychiatry and Behavioral Sciences Depression Research Clinic Stanford University School of Medicine Stanford, California
1:55 PM - 2:20 PM	Pharmacological Approaches to the Management of Residual Symptoms in Depression Maurizio Fava, MD Professor of Psychiatry Harvard Medical School Boston, Massachusetts
2:20 PM - 2:45 PM	MINDI Lessons from the Brain Philip T. Ninan, MD
2:45 PM - 3:30 PM	Panel Discussion/Q & A
3:30 PM	Meeting Adjourns



SATURDAY, MAY 1, 2004 • 12:30 PM - 3:30 PM
 SHERATON NEW YORK HOTEL & TOWERS
 IMPERIAL BALLROOM A • NEW YORK CITY
 HELD AT THE APA 2004 ANNUAL MEETING

EDUCATIONAL OBJECTIVES

- Upon completion of the symposium, participants should be able to
- Describe recent developments in the pathophysiology of depression
 - Better understand mechanisms of poor treatment response in major depression
 - Practically apply acquired knowledge regarding pharmacologic options in poor treatment responders and residual depression

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she spent in the activity.

Attendees must be registered for the APA 2004 Annual Meeting to attend this symposium. Seating is limited and will be based on first come, first served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.



Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Cephalon, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 6
 Saturday, May 1, 6:00 p.m. - 9:00 p.m.
 Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt



This symposium will be held at the 2004 APA Annual Meeting

THE ROLE of DOPAMINE in HEALTH and ILLNESS: FROM SCIENCE to PRACTICE

SATURDAY, MAY 1, 2004 • DINNER: 5:30-6:00 PM • SYMPOSIUM: 6:00-9:00 PM
 EMPIRE STATE BALLROOMS B/C/D, BALLROOM LEVEL • GRAND HYATT • NEW YORK, NEW YORK

AGENDA:

5:30-6:00 PM	Dinner	7:25-7:50 PM	The Role of Dopaminergic/Cholinergic Interaction in Cognition and Psychosis Rajiv Tandon, MD University of Michigan Medical Center
6:00-6:10 PM	Welcome & Introductions Peter J. Weiden, MD Chairperson SUNY Health Science Center	7:50-8:15 PM	The Role of Dopamine in the Neurobiology of Sexual Dysfunction Abdel Elmouchari, MD SUNY Downstate Medical Center
6:10-6:35 PM	The Role of Dopamine as a Mediator of Normal Human Reward Nora Volkow, MD National Institute on Drug Abuse	8:15-9:00 PM	Question & Answer Session All Faculty
6:35-7:00 PM	From Dopamine to Salience to Psychosis: Why Antipsychotics Are Anti-"Psychotic" Shitij Kapur, MD University of Toronto	9:00 PM	Adjourn
7:00-7:25 PM	Dopamine and Neuroleptic Dysphoria in Practice Peter J. Weiden, MD SUNY Health Science Center		

LEARNING OBJECTIVES:

- Describe the neurophysiologic mechanism of dopamine in reinforcement, motivation, drive, and self-control as it relates to normal human reward
- Review different theories regarding dopamine and how the theories relate to psychosis and antipsychotics
- Describe neuroleptic dysphoria and its possible impact on poor compliance in patients treated with neuroleptics; discuss dopamine's role in this response, as it occurs in approximately one third of patients treated with neuroleptics; and discuss how differences in activity of D₂ receptors may be responsible for differences in occurrence of neuroleptic dysphoria
- Review dopamine's critical role in the working memory functions of the prefrontal cortex
- Define the role of dopamine in the neurobiology of sexual dysfunction in schizophrenia and ways to manage this problem in clinical practices

CME STATEMENT:

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3.0 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first come, first served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.


If any participant in this educational activity is in need of accommodations, please call 860-434-1650 by April 15, 2004, in order to receive service.



Sponsored by the American Psychiatric Association



INDUSTRY-SUPPORTED SYMPOSIUM 7
 Saturday, May 1, 6:00 p.m. - 9:00 p.m.
 Grand Ballroom East, Third Floor, Hilton New York




**Impulsivity:
Emerging Clinical Perspectives**

An educational symposium to be presented at the 2004 Annual Meeting of the American Psychiatric Association


**Saturday, May 1, 2004
6:00 PM - 9:00 PM**

**Hilton New York
Grand Ballroom East
Third Floor
New York, New York**

Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Ortho-McNeil Pharmaceutical, Inc.



Program Agenda

5:30 PM - 6:00 PM Dinner

6:00 PM - 6:10 PM Welcome and Introduction
Program Chair, Eric Hollander, MD
Mount Sinai School of Medicine

6:10 PM - 6:35 PM Neurobiology of Impulsive Behavior
Alan C. Swann, MD
The University of Texas Health Science Center at Houston

6:35 PM - 7:00 PM When Does Impulsive Behavior Become Pathologic?
Ernest S. Barratt, PhD
The University of Texas Medical Branch at Galveston

7:00 PM - 7:25 PM Clinical Issues of Impulsivity in Psychiatry
Dan J. Stein, MD
University of Stellenbosch

7:25 PM - 7:50 PM Addressing Impulsive Behavior in Eating Disorders
Renu Kotwal, MD
University of Cincinnati College of Medicine

7:50 PM - 8:15 PM Identifying the Spectrum of Impulse Control Disorders
Eric Hollander, MD

8:15 PM - 8:30 PM Summary and Conclusions/Questions and Answers
Eric Hollander, MD

8:30 PM - 9:00 PM Panel Discussion/Questions and Answers

9:00 PM Adjournment

Educational Objectives

Upon completion of the program, participants should be able to understand the basic mechanisms of neurobiology of impulsivity; determine when impulsive behavior becomes pathologic; address characteristics of impulsivity and psychiatric illness, such as bipolar disorder and alcohol dependence; highlight impulsive traits in disorders associated with binge eating; and identify the spectrum of impulse control disorders.

Accreditation Statement

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

The APA designates this educational activity for a maximum of 3 Category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-967-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 8
 Saturday, May 1, 6:00 p.m. - 9:00 p.m.
 Broadway Ballroom, Sixth Floor, Marriott Marquis

Held During the APA 2004 Annual Meeting

**BIPOLAR DISORDER:
IMPROVING OUTCOMES WHEN THEORY, SCIENCE,
AND CLINICAL PRACTICE CONVERGE**

Saturday, May 1, 2004

5:30PM-6:00PM Dinner • 6:00PM-9:00PM Educational Program
 Marriott Marquis • Sixth Floor, Broadway Ballroom • New York, New York

5:30PM-6:00PM Dinner

6:00PM Welcome and Introduction
Joseph F. Goldberg, MD
Program Chairperson
The Zuckerman Hillside Hospital
North Shore-LIJ Health System

6:10PM The Convergence of Pharmacotherapy and Psychotherapy in Maintenance Treatment of Bipolar Disorder
Paul E. Keck, Jr, MD
University of Cincinnati College of Medicine

6:35PM Considerations in the Female Patient During Childbearing Years
Adele C. Viguera, MD
Massachusetts General Hospital
Harvard Medical School



7:00PM Choosing Treatments in Bipolar Depression: What, When, and Why?
Roy H. Perlis, MD
Massachusetts General Hospital
Mood and Anxiety Disorders Institute
Harvard Medical School

7:25PM Cognitive Functioning Outcomes: From First Episode to Functional Recovery
Deborah A. Yurgelun-Todd, PhD
McLean Hospital
Harvard Medical School

7:50PM Translating Research into Clinical Practice: From the Bench to the Trenches
Joseph F. Goldberg, MD
Program Chairperson

8:15PM Question and Answer Session

9:00PM Program Adjournment

Learning Objectives

Upon completion of the program, participants should be able to:

1. Incorporate evidence-based studies into clinical practice for the effective treatment/management of patients with bipolar disorder.
2. Utilize pharmacological and psychotherapeutic approaches to prevent relapse in patients with bipolar disorder.
3. Discuss the clinical considerations in pharmacological treatment selection for women of childbearing age.
4. Describe the factors that guide treatment selection in bipolar disorder.
5. Recognize and treat cognitive deficits associated with bipolar disorder to achieve functional recovery.
6. Evaluate pharmacotherapy outcome data from clinical trials so as to make better-informed treatment decisions for real-world patients with bipolar disorder.

Accreditation Statement

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The APA designates this educational activity for a maximum of 3 Category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Eli Lilly and Company



Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-967-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 9
 Saturday, May 1, 6:00 p.m. - 9:00 p.m.
 Grand Ballroom, Mezzanine Level, Roosevelt

Saturday | May 1 | 2004 | 6:00 PM - 9:00 PM

APA 157th ANNUAL MEETING
 The Roosevelt Hotel | Grand Ballroom | Mezzanine Level
 New York | New York

GENERALIZED ANXIETY DISORDER:

Evidence-Based Considerations from PATHOPHYSIOLOGY to LONG-TERM MANAGEMENT

AGENDA

5:30 PM	Dinner	5:55	Molecular and Cellular Pathophysiology of Anxiety Carl Salzman, MD Professor of Psychiatry Harvard Medical School Boston, Massachusetts
6:00	Welcome and Introduction John H. Greist, MD, Program Chairperson CEO, Healthcare Technology Systems, LLC Distinguished Senior Scientist Madison Institute of Medicine, Inc. Clinical Professor of Psychiatry University of Wisconsin Medical School Madison, Wisconsin	7:20	Cognitive Behavioral Therapy for the Treatment of GAD Michelle G. Newman, PhD Associate Professor of Psychology Director, Center for Treatment of Anxiety and Depression Director, Clinical Training Pennsylvania State University University Park, Pennsylvania
6:05	Prevalence of Generalized Anxiety Disorder (GAD) in the United States: Results from the National Comorbidity Survey Replication Ronald C. Kessler, PhD Psychiatric Epidemiologist Professor of Health Care Policy Harvard Medical School Boston, Massachusetts	7:45	Pharmacotherapies for GAD: From Rough Empiricism to Elegant Evidence John H. Greist, MD
6:30	Distinguishing Generalized Anxiety Disorder: Unique Characteristics Wei Zhang, MD, PhD Assistant Clinical Professor Department of Psychiatry and Behavioral Science Duke University Medical Center Durham, North Carolina	8:15	Panel Discussion/Question and Answer Session Faculty Panel
		8:00	Adjournment

OBJECTIVES

At the conclusion of this program, participants should be able to:

- Discuss the prevalence of GAD and its comorbidities as well as the impact of GAD on patient quality of life.
- Review the molecular and cellular pathophysiology of anxiety.
- Recognize the clinical characteristics of GAD.
- Assess the importance of psychotherapy in the treatment of GAD and realize how to incorporate it into the treatment regimen.
- Compare the available and emerging pharmacotherapies used in the management of GAD and review links to the underlying anxiety pathophysiologies.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7324 (within the United States or Canada) or 703-907-7200.

Supported by an unrestricted educational grant from Pfizer Inc.

Supported by the American Psychiatric Association

INDUSTRY-SUPPORTED SYMPOSIUM 10
 Saturday, May 1, 6:00 p.m. - 9:00 p.m.
 Imperial Ballroom A, Second Floor, Sheraton New York

SEX, SEXUALITY, & SEROTONIN

APRIL 29 - MAY 1, 2004
 APA 2004 Annual Meeting

SATURDAY, MAY 1

5:30-6 PM DINNER • 6-9 PM CLINICAL PROGRAM
 SHERATON NEW YORK HOTEL & TOWERS
 IMPERIAL BALLROOM A - 2ND FLOOR

6:00 PM - Introduction
Phillip R. Muskin, MD
 Symposium Chair & Speaker

Anita H. Clayton, MD
 Symposium Co-Chair & Speaker

6:10 PM - Do Sexual Side Effects of Most Antidepressants Jeopardize Romantic Love & Marriage?
Helen E. Fisher, PhD
 Rutgers University

6:35 PM - Love & Sex
Ethel S. Person, MD
 Columbia University College of Physicians & Surgeons

7:00 PM - Talking to Gay Patients About Sex: What Do You Need to Know?
Serena Yuan Volpp, MD, MPH
 New York University School of Medicine

7:25 PM - Effects of Psychiatric Illness & Medication on Sexual Function
Anita H. Clayton, MD
 University of Virginia Health System

7:50 PM - Talking About Sexual Dysfunction to Enhance Adherence with Medication
Phillip R. Muskin, MD
 Columbia University College of Physicians & Surgeons

8:15 PM - Question & Answer Session

9:00 PM - Program Concludes

EDUCATIONAL OBJECTIVE
 To understand the separate brain circuitry/psychodynamics for love and sex, the impact of psychotics on love, sex, and sexuality, and strategies to enhance adherence.

Supported by the American Psychiatric Association
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA 2004 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7324 (within the US or Canada) or 703-907-7200.

Supported by an unrestricted educational grant from

INDUSTRY-SUPPORTED SYMPOSIUM 11
 Saturday, May 1, 6:00 p.m. - 9:00 p.m.
 Imperial Ballroom B, Second Floor, Sheraton New York

Presented at the APA 157th Annual Meeting

INTERFACE BETWEEN DEPRESSION AND MEDICAL ILLNESS

Saturday, May 1, 2004

6:00 PM - 9:00 PM

Sheraton New York Hotel
 Imperial Ballroom B, Second Floor
 New York, New York

Dwight L. Evans, MD, Co-Chair
 Dennis Charney, MD, Co-Chair



Faculty and Agenda

5:30 PM - 6:00 PM	Dinner
6:00 PM - 6:05 PM	Welcome and Introduction Dwight L. Evans, MD, Co-Chair University of Pennsylvania, Philadelphia, Pennsylvania
6:05 PM - 6:30 PM	Heartache and Heartbreak: Depression and Cardiovascular Disease Charles B. Nemeroff, MD, PhD Emory University School of Medicine, Atlanta, Georgia
6:30 PM - 6:55 PM	The Relationship of Depression to Cancer and HIV Infection David Spiegel, MD Stanford University School of Medicine, Stanford, California
6:55 PM - 7:20 PM	Comorbidity of Depression in Neurological Disorders William M. McDonald, MD Emory University School of Medicine, Atlanta, Georgia
7:20 PM - 7:45 PM	Mood Disorders and Medical Illness: Diabetes, Osteoporosis, Obesity, Pain Robert N. Golden, MD University of North Carolina School of Medicine, Chapel Hill, North Carolina
7:45 PM - 8:10 PM	Mood Disorders in the Medically Ill: The Patient Perspective Lydia Lewis Depression and Bipolar Support Alliance, Chicago, Illinois
8:10 PM - 8:15 PM	Conclusion Dennis Charney, MD, Co-Chair NIMH, Bethesda, Maryland
8:15 PM - 9:00 PM	Panel/Questions and Answers Adjournment

Target Audience

This activity is designed specifically for psychiatrists.

Learning Objective

Upon completion of this symposium, the participants should be able to:
 - Discuss the relationship between depression and comorbid medical conditions

Accreditation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Registration Policy

Attendees must be registered for the APA (Annual Meeting or Institute on Psychiatric Services) to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703/907-7300.



Sponsored by the American Psychiatric Association.
 Supported by an unrestricted educational grant from Wyeth.

INDUSTRY-SUPPORTED SYMPOSIUM 12
 Sunday, May 2, 8:00 a.m. - 11:00 a.m.
 Special Events Hall 1D, Level 1, Javits Center

Antidepressant Treatments You May Not Know About... But Should

Program Chair: *Jerrold F. Rosenbaum, MD*
 Massachusetts General Hospital
 Boston, Massachusetts

**Held At The American Psychiatric Association's
 157th Annual Meeting**

Sunday, May 2, 2004

7:30 - 8:00 AM Breakfast - 8:00 - 11:00 AM Symposium
 Special Events Hall 1D, Level 1, Javits Center

Overall Educational Objectives: Attendees will become familiar with a broad array of technologies for the treatment of depression with a concentrated focus on those in development, soon to be available, or less well-known to the practitioner.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spend in the activity.

8:00 - 8:10 AM	Introduction <i>Jerrold F. Rosenbaum, MD</i> Massachusetts General Hospital Boston, Massachusetts
8:10 - 8:35 AM	The Next Generation of Antidepressants: What's in the Pipeline? <i>Rajinder Judge, MD</i> New York, New York
8:35 - 9:00 AM	Alternative Medications for Depression <i>Andrew A. Nierenberg, MD</i> Massachusetts General Hospital Boston, Massachusetts
9:00 - 9:25 AM	Evidence-Based Psychotherapy for Depression: Principles and Practice <i>Timothy J. Petersen, MD</i> Massachusetts General Hospital Boston, Massachusetts
9:25 - 9:50 AM	Device-Based Treatments for Depression <i>A. John Rush, MD</i> University of Texas-Southwestern Dallas, Texas
9:50 - 10:15 AM	The Future of Treatment-Matching in Depression <i>Steven P. Roose, MD</i> Columbia University New York, New York
10:15 - 11:00 AM	Question and Answer Session/Adjourn



Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Organon Inc.



INDUSTRY-SUPPORTED SYMPOSIUM 13
 Sunday, May 2, 8:00 a.m. - 11:00 a.m.
 Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt



This symposium will be held at the 2004 APA Annual Meeting

**BROADENING *the* HORIZON *of* ATYPICAL
 ANTIPSYCHOTIC APPLICATIONS**

SUNDAY, MAY 2, 2004 • BREAKFAST: 7:30-8:00 AM • SYMPOSIUM: 8:00-11:00 AM

EMPIRE STATE BALLROOMS B/C/D, BALLROOM LEVEL • GRAND HYATT • NEW YORK, NEW YORK

AGENDA:


7:30-8:00 AM	Breakfast	9:00-9:25 AM	Role of Atypicals in the Treatment of Pediatric Psychotic Disorders and Common Comorbidities Melissa P. DeBello, MD <i>University of Cincinnati College of Medicine</i>
8:00-8:10 AM	Welcome & Introductions S. Charles Schulz, MD Chairperson <i>University of Minnesota Medical School</i>	9:25-9:50 AM	Atypicals in the Treatment of Anorexia Nervosa Walter H. Kaye, MD <i>University of Pittsburgh School of Medicine</i>
8:10-8:35 AM	Atypical Antipsychotics in Anxiety and Post-Traumatic Stress Disorder Mark B. Hamner, MD <i>Medical University of South Carolina</i>	9:50-10:15 AM	Atypicals in Borderline Personality Disorders S. Charles Schulz, MD <i>University of Minnesota Medical School</i>
8:35-9:00 AM	Atypical Antipsychotics in the Treatment of Substance Abuse E. Sherwood Brown, MD, PhD <i>The University of Texas Southwestern Medical Center</i>	10:15-11:00 AM	Question & Answer Session All Faculty
		11:00 AM	Adjourn

LEARNING OBJECTIVES:


- Examine possible indications for atypicals, especially for anxiety disorders and for anxiety disorders with comorbid psychosis
- Assess the possible role of atypical antipsychotics in the treatment of persons with substance-related disorders
- Demonstrate the role of atypical antipsychotic agents in the treatment of pediatric psychotic disorders and the common associated comorbidities
- Understand the use of atypicals in the treatment of anorexia nervosa and how symptoms may be affected
- Review the data regarding the use of atypical antipsychotic medications and the strengths and weaknesses of the studies

CME STATEMENT:

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 The APA designates this educational activity for a maximum of 3.0 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.
 Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.
 If any participant in this educational activity is in need of accommodations, please call 800-434-1650 by April 15, 2004, in order to receive service.



Sponsored by the American Psychiatric Association



INDUSTRY-SUPPORTED SYMPOSIUM 14
 Sunday, May 2, 8:00 a.m. - 11:00 a.m.
 Grand Ballroom East, Third Floor, Hilton New York

Sunday | May 2 | 2004 | 8:00 AM - 11:00 AM

THE MANY FACES OF ANXIETY:
 Origins, Pathogenesis, and Management

APA 157TH ANNUAL MEETING
 Hilton New York | Grand Ballroom East
 New York | New York

OBJECTIVES

At the completion of this program, participants should be able to:

- Recognize the differences and similarities of generalized anxiety disorder, social anxiety disorder, and panic disorder;
- Treat anxiety symptoms and syndromes by incorporating the neurobiologic origins and pathogenesis;
- Select and appropriately use medications for treating panic disorder;
- Understand the current pharmacologic and nonpharmacologic treatment options available as well as potential future treatments for generalized anxiety disorder.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.
 Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 703-907-7300.

AGENDA

7:30 AM	Breakfast	9:15	Pharmacologic Approaches for Panic Disorder David V. Sheehan, MD, MBA Professor of Psychiatry and Psychology Director, Office of Research Department of Psychiatry and Behavioral Medicine University of South Florida Tampa, Florida
8:00	Welcome and Introduction Martin B. Koller, MD Mary E. Zuckler Professor and Chairman Department of Psychiatry and Human Behavior Brown University Executive Psychiatrist-in-Chief Brown Affiliated Hospitals Providence, Rhode Island	9:45	Generalized Anxiety Disorder: Current Opinions and Future Options Linda L. Carpenter, MD Assistant Professor Department of Psychiatry and Human Behavior Brown University Providence, Rhode Island
8:15	Generalized Anxiety, Social Anxiety, and Panic Disorder: New Views on Validity and Nosology Risa B. Weisberg, PhD Assistant Professor Department of Psychiatry and Human Behavior Brown University Providence, Rhode Island	10:15	Question and Answer Session Faculty Panel
8:45	Origins and Pathogenesis of Anxiety Symptoms and Syndromes Dennis S. Charney, MD Chief, Program in Mood and Anxiety Disorders National Institute of Mental Health Bethesda, Maryland	11:00	Adjournment

Sponsored by the American Psychiatric Association

Sponsored by an unrestricted educational grant from Pfizer Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 15
 Sunday, May 2, 8:00 a.m. - 11:00 a.m.
 Broadway Ballroom, Sixth Floor, Marriott Marquis

Please join our distinguished faculty for a CME Symposium to be held at the APA 157th Annual Meeting

From Pathology to Practice: Evolving Therapeutic Strategies for Alzheimer's Disease
 Sunday, May 2, 2004 | Breakfast 7:30 AM - 8:00 AM, Scientific Program 8:00 AM - 11:00 AM | Marriott Marquis, Broadway Ballroom

Agenda & Faculty

7:30 AM - 8:00 AM	Breakfast	
8:00 AM - 8:10 AM	Introduction and Objectives	Jacobo Mintzer, MD (Chairman) Professor of Psychiatry, Neurology, Physiology, & Neuroscience Medical University of South Carolina
8:10 AM - 8:35 AM	Synaptic Dysfunction and Neurodegeneration in Alzheimer's Disease	Gary Wenk, PhD Professor of Psychology & Neurology, University of Arizona
8:35 AM - 9:00 AM	Alzheimer's Disease Update: New Targets, New Options	Jacobo Mintzer, MD Professor of Psychiatry, Neurology, Physiology, & Neuroscience Medical University of South Carolina
9:00 AM - 9:25 AM	AD and VaD: Where is the Overlap?	John Morris, MD Professor of Pathology and Immunology & Harvey A. and Donsmae Hasker Friedman Distinguished Professor of Neurology Washington University School of Medicine
9:25 AM - 9:45 AM	Multicultural Issues in Addressing Barriers to Diagnosis and Treatment	Warachal Faison, MD Research Fellow, Medical University of South Carolina
9:45 AM - 10:10 AM	A Rational Approach to Combination Treatment	Mary Sano, PhD Professor of Psychiatry, Mount Sinai School of Medicine
10:10 AM - 10:55 AM	Discussion/Q&A	Faculty
10:55 AM - 11:00 AM	Concluding Remarks & Close	Jacobo Mintzer, MD Professor of Psychiatry, Neurology, Physiology & Neuroscience Medical University of South Carolina

Educational Objectives

Upon completion of this program, participants should be able to:

- Comprehend the pathological basis supporting the development of novel anti-dementia agents
- Review placebo-controlled trials examining the safety and efficacy of noncholinergic agents in the treatment of AD and vascular dementia
- Understand how cultural barriers prevent early diagnosis and treatment of AD and how specific strategies can be employed to better manage these special patient populations
- Describe the rationale for a combination therapeutic approach to AD management

The program is sponsored by the American Psychiatric Association.



The program is made possible by an unrestricted educational grant from

Forest Laboratories, Inc.

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 1-713-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 16
 Sunday, May 2, 8:00 a.m. - 11:00 a.m.
 Grand Ballroom, Mezzanine Level, Roosevelt

BROADENING HORIZONS

Advances in Understanding the Etiology, Effects, and Treatment of Anxiety Disorders

Held During the APA 2004 Annual Meeting

Sunday, May 2, 2004

7:30AM-8:00AM Breakfast / 8:00AM-11:00AM Educational Program

Don't Miss This Important Educational Program!

Learning Objectives

Upon completion of the program, participants should be able to

1. Describe the impact of anxiety disorders in the community.
2. Summarize emerging data regarding the role of glutamate in pathologic anxiety.
3. Cite the application of cognitive-behavioral principles to improving compliance with pharmacologic and psychosocial therapies.
4. Review the epidemiology and burden of illness associated with anxiety disorders in community and general medical settings.
5. Define the importance of glutamate in stress and anxiety.
6. Summarize the current psychosocial and pharmacologic treatments for the anxiety disorders and potential emerging therapies.
7. Discuss the gender differences in the prevalence, severity, and impact of panic and other anxiety disorders.
8. Recognize specific therapy issues relative to the treatment of anxiety disorders in women.
9. Identify and apply specific strategies designed to enhance medication adherence among patients receiving pharmacotherapy.

PROGRAM

7:30AM-8:00AM Breakfast

8:00AM **Welcome and Introduction**
NAOMI M. SIMON, MD
PROGRAM CO-CHAIRPERSON
Center for Anxiety and Traumatic Stress-Related Disorders
Massachusetts General Hospital

8:10AM **Anxiety on the Upswing? A Public Health Perspective**
MURRAY S. STEIN, MD
University of California, San Diego
VA San Diego Healthcare System

8:35AM **Neural Substrates of Stress, Anxiety, and Early Adversity: Neurotropic Perspectives**
JEREMY D. COPLAN, MD
SUNY Downstate Medical Center
Brooklyn, New York

9:00AM **Gender and Anxiety Disorders: Impact and Treatment Implications**
NAOMI M. SIMON, MD
PROGRAM CO-CHAIRPERSON

9:25AM **Treating Anxiety: Current Therapies and Beyond**
MARK H. POLLACK, MD
PROGRAM CO-CHAIRPERSON
Harvard Medical School
Massachusetts General Hospital

9:50AM **Treatment Works, Now What Do We Do? Strategies to Enhance Treatment Adherence**
MICHAEL W. OTTO, PhD
Harvard Medical School
Massachusetts General Hospital

10:15AM **Question and Answer Session**

11:00AM **Program Adjournment**

Accreditation Statement The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Sponsored by the American Psychiatric Association Supported by an unrestricted educational grant from UCB Pharma, Inc.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1.888.357.7924 (within the US or Canada) or 703.907.7300.

The Roosevelt Hotel / Mezzanine Level, Grand Ballroom / New York, New York

INDUSTRY-SUPPORTED SYMPOSIUM 17
 Sunday, May 2, 8:00 a.m. - 11:00 a.m.
 Imperial Ballroom A, Second Floor, Sheraton New York

<p>The Hidden Faces of Anxiety</p> <p><i>Symposium to be held at the American Psychiatric Association 157th Annual Meeting</i></p> <p>SUNDAY, MAY 2, 2004 8:00 AM – 11:00 AM</p> <p>Sheraton New York Hotel and Towers Imperial Ballroom A New York, New York</p> <p><i>Sponsored by the American Psychiatric Association</i></p> <p><i>Supported by an unrestricted educational grant from GlaxoSmithKline</i></p>	<p>PROGRAM OBJECTIVES</p> <p>After attending this continuing medical education symposium, the psychiatrist should be able to:</p> <ul style="list-style-type: none"> • Become familiar with the physical comorbidities associated with anxiety disorders and their bidirectional relationship • Identify gender differences associated with anxiety disorders with respect to presentation, progression of disease, and response to treatment • Appreciate the wide variation in presentation, prevalence, and treatment response of anxiety disorders in different cultures and ethnic groups • Increase awareness of the difficulties in recognizing and treating anxiety in the elderly. <p> <i>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</i></p> <p><i>The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.</i></p> <p><i>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.</i></p>	<p>AGENDA</p> <p>7:30 AM Breakfast</p> <p>8:00 AM Welcome and Program Introduction PRAKASH S. MASAND, MD SYMPOSIUM CHAIR Duke University Medical Center</p> <p>8:05 AM The Somatic Face of Anxiety PRAKASH S. MASAND, MD</p> <p>8:35 AM Anxiety in Men and Women: Two Faces of the Same Coin KIMBERLY A. YONKERS, MD Yale University School of Medicine</p> <p>9:05 AM The Many Faces of Anxiety: Understanding Cultural and Ethnic Variation in Psychiatric Illness GEETHA JAYARAM, MD The Johns Hopkins Hospital</p> <p>9:35 AM Facets of Anxiety in the Elderly WARREN D. TAYLOR, MD Duke University Medical Center</p> <p>10:05 AM Panel Discussion With Questions and Answers</p> <p>11:00 AM Closing Remarks, Adjournment PRAKASH S. MASAND, MD</p>
---	--	---

INDUSTRY-SUPPORTED SYMPOSIUM 18
 Sunday, May 2, 8:00 a.m. - 11:00 a.m.
 Imperial Ballroom B, Second Floor, Sheraton New York

<p>TARGETING EXECUTIVE DYSFUNCTIONS FOR TREATMENT</p>	
<p>EDUCATIONAL OBJECTIVES</p> <p>Upon completion of the symposium, participants should be able to</p> <ul style="list-style-type: none"> • Identify neurobiologic mechanisms of executive dysfunctions in psychiatric disorders • Evaluate the utility of treatment strategies in addressing executive dysfunctions • Practically apply acquired knowledge regarding treatment strategies for executive dysfunctions in late-life and adult depression and in ADHD <p>ACCREDITATION STATEMENT</p> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>CREDIT DESIGNATION</p> <p>The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she spent in the activity.</p> <p>Attendees must be registered for the APA 2004 Annual Meeting to attend this symposium. Seating is limited and will be based on first come, first served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.</p> <p> Sponsored by the American Psychiatric Association</p> <p> Supported by an unrestricted educational grant from Cephalon, Inc.</p>	<p>PROGRAM AGENDA</p> <p>7:30 AM – 8:00 AM Breakfast</p> <p>8:00 AM – 8:10 AM Introduction Charles DeBattista, DMH, MD Associate Professor, Psychiatry and Behavioral Sciences Depression Research Clinic Stanford University School of Medicine</p> <p>8:10 AM – 8:20 AM Interactive Discussion Charles DeBattista, DMH, MD</p> <p>8:20 AM – 8:45 AM Executive Function: Circuits and Symptoms Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry University of California, San Diego</p> <p>8:45 AM – 9:10 AM Addressing the Neurobiological Dysfunctions of Deficit Syndrome Rosa J. Hu, MD Assistant Professor, Psychiatry and Behavioral Sciences Stanford University School of Medicine</p> <p>9:10 AM – 9:35 AM Late-Life Depression – Executive Dysfunction: Novel Treatment Developments George S. Alexopoulos, MD Professor, Department of Psychiatry Weill Medical College of Cornell University</p> <p>9:35 AM – 10:00 AM Addressing Executive Dysfunction in ADHD James M. Swanson, PhD Professor, Department of Pediatrics University of California, Irvine</p> <p>10:00 AM – 10:15 AM Interactive Discussion Charles DeBattista, DMH, MD</p> <p>10:15 AM – 11:00 AM Panel Discussion/Q & A</p> <p>11:00 AM Meeting Adjourns</p>
<p>SUNDAY, MAY 2, 2004 • 8:00 AM – 11:00 AM • SHERATON NEW YORK HOTEL & TOWERS IMPERIAL BALLROOM B • NEW YORK CITY • HELD AT THE APA 2004 ANNUAL MEETING</p>	

INDUSTRY-SUPPORTED SYMPOSIUM 19
 Sunday, May 2, 1:30 p.m. - 4:30 p.m.
 Special Events Hall 1D, Level 1, Javits Center

PRESENTED AT THE APA 157TH ANNUAL MEETING

The Treacherous Triad for Depression:

Physical Symptoms, Absence of Remission, and Systemic Consequences

John F. Greden, MD, Chairperson

Sunday, May 2, 2004
 1:30 PM - 4:30 PM
 Javits Center
 Special Events Hall 1D
 New York, New York

Faculty and Agenda

1:00 PM - 1:30 PM	Lunch
1:30 PM - 1:55 PM	Underdetection and Inadequate Treatment of Physical Symptoms of Depression Kurt Kroenke, MD Regenstrief Institute Indianapolis, Indiana
1:55 PM - 2:20 PM	Neurochemical Systems Interfacing Physical and Emotional Stressors Jon-Kar Zubieta, MD, PhD University of Michigan Ann Arbor, Michigan
2:20 PM - 2:45 PM	Stress Effects on the Hippocampus: Relevance to Depression Bruce S. McEwen, PhD Rockefeller University New York, New York
2:45 PM - 3:15 PM	Gender Considerations in Treatment of Physical Symptoms of Depression Vivien K. Burt, MD, PhD UCLA Neuropsych Institute Los Angeles, California
3:15 PM - 3:45 PM	Best Practices for Achieving Remission in Depression With Physical Symptoms: Current and Future John F. Greden, MD, Chairperson University of Michigan Ann Arbor, Michigan
3:45 PM - 4:30 PM	Wrap-up Discussion/Questions and Answers
4:30 PM	Adjournment

Target Audience

This activity is designed specifically for psychiatrists.

Learning Objectives

Upon completion of this symposium, the participants should be able to:

- Discuss the role of physically unexplained symptoms in depression
- Describe recent neuroimaging studies linking the underlying mechanisms of affective disorders and pain
- Discuss changes observed in the hippocampus in response to stress
- Describe why major depression is often overlooked in perimenopausal women

Accreditation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Registration Policy

Attendees must be registered for the APA (Annual Meeting or Institute on Psychiatric Services) to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703/907-7300.



Sponsored by the American Psychiatric Association.
 Supported by an unrestricted educational grant from Wyeth.

INDUSTRY-SUPPORTED SYMPOSIUM 20
 Sunday, May 2, 1:30 p.m. - 4:30 p.m.
 Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt



BEYOND SEROTONIN NEW TREATMENTS FOR DEPRESSION

Empire State Ballrooms
 B/C/D, Ballroom Level
 Grand Hyatt Hotel, New York, NY
SUNDAY, MAY 2, 2004
1:30 PM - 4:30 PM



Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Merck & Co., Inc.

Held during the 157th Annual Meeting of the American Psychiatric Association

At the conclusion of this symposium, the participant should be able to:

- Have a working knowledge of existing strategies, both based on research and on anecdotal evidence, for enhancing the response of depressed patients to the standard pharmacotherapy, the SSRIs. In addition, they will be informed about new medications that may be available soon for the treatment of depression.
- Understand what evidence exists for combining an SSRI with another treatment in order to improve outcome for patients with depression
- Discuss the relative merits of combining or switching antidepressants when an initial SSRI trial has failed
- Review and summarize biological data describing relationships between substance P (NK1 receptor) and other neurotransmitter systems implicated in mood and anxiety disorders
- Learn about the utility of substance P antagonists in psychiatry

PROGRAM AGENDA MAY 2, 2004

1:00 PM - 1:30 PM: **Lunch**
 1:30 PM - 1:40 PM
Welcome and Introduction
 Jack Gorman, MD
 Esther and Joseph Klingenstein
 Professor & Chair, Dept of
 Psychiatry, Mount Sinai School
 of Medicine, New York, NY
 1:40 PM - 2:10 PM
**Combining Treatments to
 Enhance SSRI Response**
 Jack Gorman, MD
 2:10 PM - 2:20 PM: **Q&A**

2:20 PM - 2:50 PM
What To Do for SSRI Nonresponders
 Michael Thase, MD, Professor of
 Psychiatry, Western Psychiatric
 Institute and Clinic, University of
 Pittsburgh, Pittsburgh, PA
 2:50 PM - 3:00 PM: **Q&A**
 3:00 PM - 3:30 PM: **The Relationship
 Between Substance P, Serotonin, &
 Other Neurotransmitter Systems**
 Linda Carpenter, MD, Asst Professor
 of Psychiatry & Human Behavior,
 Brown University, Providence, RI

3:30 PM - 3:40 PM: **Q&A**
 3:40 PM - 4:10 PM: **Substance P
 Agonists: Mechanism of Action and
 Clinical Implications (Phase 3 Data)**
 Ranga Rama Krishnan, MD
 Professor and Chair, Department of
 Psychiatry and Behavioral Sciences,
 Duke University Medical Center,
 Durham, NC
 4:10 PM - 4:20 PM: **Q&A**
 4:20 PM - 4:30 PM: **General Q&A**
 4:30 PM: **Adjournment**

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits he/she actually spent in the activity.

Attendees must be registered for the APA 2004 Annual Meeting to attend this ISS. Seating is limited and will be based on a first-come, first-served policy. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 21
 Sunday, May 2, 1:30 p.m. - 4:30 p.m.
 Grand Ballroom East, Third Floor, Hilton New York

Don't miss this symposium

Are All Atypical Antipsychotics Equal for the TREATMENT OF COGNITION AND AFFECT in Schizophrenia?

APA 157TH ANNUAL MEETING
 Sunday | May 2 | 2004 | 1:30 PM - 4:30 PM
 Hilton New York | Grand Ballroom East
 New York | New York

OBJECTIVES

At the conclusion of this program, participants should be able to:

- Describe the scientific rationale for the mechanistic distinctions among atypical antipsychotics and the related effects on cognition and affect for patients with schizophrenia.
- Recognize multiple dimensions that contribute to overall functional outcomes of patients with schizophrenia, including health considerations, medication tolerability, and adherence.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim those credits that he/she actually spent in the activity.

Attendees must be registered for the APA 2004 Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the United States or Canada) or 703-907-7300.

AGENDA

<p>1:00 PM Lunch</p> <p>1:30 Welcome and Introduction Stephen M. Stahl, MD, PhD <i>Program Chairperson</i> Chairman and CEO Neuroscience Education Institute Carlsbad, California Adjunct Professor of Psychiatry University of California, San Diego La Jolla, California</p> <p>1:40 Schizophrenia: From Circuits to Symptoms Stephen M. Stahl, MD, PhD</p> <p>2:10 Effects of Atypical Antipsychotic Drugs on Cognition and Negative Symptoms Herbert Y. Meltzer, MD Biele Professor of Psychiatry and Pharmacology Director, Division of Psychopharmacology Department of Psychiatry Vanderbilt University Medical Center Nashville, Tennessee</p>	<p>2:40</p> <p>3:10</p> <p>3:40</p> <p>4:30</p>	<p>Optimal Health Outcomes in Schizophrenia Jonathan M. Meyer, MD Staff Psychiatrist, VA San Diego Healthcare System Assistant Adjunct Professor of Psychiatry University of California, San Diego La Jolla, California</p> <p>Maximizing Function from a First Episode of Psychosis Di Kopala, MD Clinical Professor of Psychiatry Center for Complex Brain Disorders University of British Columbia Department of Psychiatry Powell River, British Columbia, Canada</p> <p>Panel Discussion/Question and Answer Session</p> <p>Adjournment</p>
--	---	---

INDUSTRY-SUPPORTED SYMPOSIUM 22
 Sunday, May 2, 1:30 p.m. - 4:30 p.m.
 Broadway Ballroom, Sixth Floor, Marriott Marquis

**Combination Therapy:
 NEW STRATEGIES IN
 THE MANAGEMENT OF
 Severe Mental Disorders**

LEARNING OBJECTIVE

- Review clinical trials of combination therapy and implement treatment strategies to improve outcomes in patients with severe mental disorders.

ACCREDITATION

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates these educational activities for a maximum of 3 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Sponsored by the American Psychiatric Association.

This activity is supported by an unrestricted educational grant from Abbott Laboratories.


HELD AT THE APA 2004 ANNUAL MEETING

Susan L. McElroy, MD – Program Chair
Sunday, May 2, 2004
Marriott Marquis – Broadway Ballroom, 6th Floor

<p>1:00–1:30 pm</p> <p>1:30–1:35 pm</p> <p>1:35–2:00 pm</p> <p>2:00–2:25 pm</p> <p>2:25–2:50 pm</p> <p>2:50–3:15 pm</p> <p>3:15–3:40 pm</p> <p>3:40–4:30 pm</p> <p>4:30 pm</p>	<p>Lunch</p> <p>Welcome and Introductions Susan L. McElroy, MD – Program Chair University of Cincinnati College of Medicine</p> <p>Rational Combination Therapy vs. Irrational Polypharmacy Susan L. McElroy, MD – Program Chair</p> <p>Combination Treatment for Acute Mania Gary S. Sachs, MD Harvard Medical School</p> <p>Management of Bipolar Depression: Combination vs. Monotherapy Robert M.A. Hirschfeld, MD University of Texas Medical Branch</p> <p>Managing Bipolar Disorder in Children and Adolescents Karen Dineen Wagner, MD, PhD University of Texas Medical Branch</p> <p>Evidence for the Mechanisms and Efficacy of Anticonvulsants in the Treatment of Schizophrenia Carol A. Tamminga, MD UT Southwestern Medical School</p> <p>Panel Discussion / Q&A All Faculty</p> <p>Adjourn</p>
---	--

INDUSTRY-SUPPORTED SYMPOSIUM 23
 Sunday, May 2, 1:30 p.m. - 4:30 p.m.
 Imperial Ballroom A, Second Floor, Sheraton New York

A symposium to be held during the APA 2004 Annual Meeting



S. Nassir Ghaemi, MD (Chair)
 May 2, 2004
 1:30 PM - 4:30 PM
 Imperial Ballroom A
 2ND FLOOR
 Sheraton New York
 New York, NY

Unmasking Bipolar Disorder: Overcoming Barriers to Treatment Success


Agenda

<p>1:00 PM - 1:30 PM Lunch</p> <p>1:30 PM - 1:35 PM Welcome and Introduction S. Nassir Ghaemi, MD (Chair) Cambridge Hospital</p> <p>1:35 PM - 2:10 PM Bipolar Disorder: A National Health Concern Roger S. McIntyre, MD University of Toronto</p> <p>2:10 PM - 2:45 PM Redefining Mood Stabilizing Agents: Improved Treatment Options for Bipolar Disorder S. Nassir Ghaemi, MD</p>	<p>2:45 PM - 3:15 PM Safety Considerations in Treating the Bipolar Patient Prakash Masand, MD Duke University Medical Center</p> <p>3:15 PM - 3:45 PM Managing Bipolar Disorder From the Acute to the Long-Term: What Are the Treatment Goals? Michael Otto, PhD Massachusetts General Hospital</p> <p>3:45 PM - 4:30 PM Questions and Answers</p> <p>4:30 PM Symposium Adjourned</p>	<p>At the conclusion of this symposium, the participant should be able to:</p> <ul style="list-style-type: none"> • Describe the safety profiles of common polypharmacologic regimens • Discuss differences in the nosology and epidemiology of bipolar disorder among different countries • Increase awareness regarding the elements of psychosocial treatment and the results of recent studies documenting the efficacy of specific psychosocial approaches to treating bipolar disorder • Identify the goals for different phases of treatment of bipolar disorder
--	---	--

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or at 703-907-7300.

Supported by an unrestricted educational grant from   Sponsored by the American Psychiatric Association 

RS-1451


INDUSTRY-SUPPORTED SYMPOSIUM 24
 Sunday, May 2, 7:00 p.m. - 10:00 p.m.
 Special Events Hall 1D, Level 1, Javits Center

Sunday, May 2, 2004

6:30PM-7:00PM Dinner • 7:00PM-10:00PM Educational Program
 Javits Center • Level 1, Special Events Hall 1D • New York, New York

Don't Miss This Important Educational Program!

Held During the APA 2004 Annual Meeting



6:30PM-7:00PM Dinner

7:00PM Welcome and Introduction
 Jeffrey A. Lieberman, MD
 Program Chairperson
 University of North Carolina School of Medicine

7:10PM Laboratory and Imaging Aids to Diagnosis and Assessment of Schizophrenia
 Aysenil Belger, PhD
 University of North Carolina at Chapel Hill
 Duke University
 Duke-UNC Brain Imaging and Analysis Center

7:35PM Treating First-Episode Schizophrenia: Differential Effects of Atypical and Typical Antipsychotics on Brain Pathomorphology
 Jeffrey A. Lieberman, MD
 Program Chairperson

8:00PM Approaches to Improved Maintenance Treatment and Relapse Prevention
 T. Scott Stroup, MD, MPH
 University of North Carolina at Chapel Hill

8:25PM Psychiatric Rehabilitation
 Robert E. Drake, MD, PhD
 New Hampshire Charitable Foundation
 Research Center
 Dartmouth Medical School

8:50PM Cognitive Improvement and Therapeutic Alliance
 Richard S.E. Keefe, PhD
 Duke University Medical Center



9:15PM Question and Answer Session

10:00PM Program Adjournment

Recovering From SCHIZOPHRENIA

How Treatment Can Improve Outcomes and Prevent Chronicity

Sponsored by the American Psychiatric Association
 Supported by an unrestricted educational grant from Eli Lilly and Company

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1.888.357.7924 (within the US or Canada) or 703.907.7300.

Learning Objectives
 Upon completion of the program, participants should be able to

1. Explain the importance of early diagnosis and intervention and the fostering of patient adherence in improving the long-term outcomes of schizophrenia.
2. Describe the effects of atypical and typical antipsychotics on the progression of changes in brain morphology in first-episode schizophrenia.
3. Discuss how techniques such as electrophysiological recording and magnetic resonance imaging can be used to track brain changes associated with treatment effects and disease progression in patients with schizophrenia.
4. Identify several consequences of poor treatment adherence and multiple approaches to improve adherence and reduce the risk of relapse.
5. Recognize a competent psychiatric rehabilitation plan.
6. Assess treatments for first-episode psychosis based upon cognitive deficits, therapeutic alliance, and long-term outcome.

Accreditation Statement
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

INDUSTRY-SUPPORTED SYMPOSIUM 25
 Sunday, May 2, 7:00 p.m. - 10:00 p.m.
 Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt



Sunday | May 2 | 2004 | 7:00 PM - 10:00 PM

**Novel Intervention Strategies
 Across the Spectrum of Dementia:**

**REAL PATIENTS
 REAL OUTCOMES**

APA 157TH ANNUAL MEETING

Grand Hyatt | Empire State Ballrooms
 New York, New York

AGENDA

6:30 PM **Dinner**

7:00 **Welcome and Introductions**
 Gary W. Small, MD, Chairperson
 Director, Center on Aging
 Neuropsychiatric Institute
 The David Geffen School of Medicine
 University of California at Los Angeles
 Los Angeles, California

7:10 **Identifying Early Dementia:
 Mild Cognitive Impairment and
 Early Stage Alzheimer's Disease**
 R. Maroli Dorzowaty, MD
 Chief of the Division of Biological Psychiatry
 Department of Psychiatry
 Duke University Medical Center
 Durham, North Carolina

7:30 **Identifying and Treating Early Dementia:
 Case Studies**
 Dan Christensen, MD
 Clinical Professor of Psychiatry and Neurology
 University of Utah School of Medicine
 Salt Lake City, Utah

7:50 **Exploring Vascular Dementia:
 Diagnosis, Treatment, and Behavior**
 Helen Lavretsky, MD
 Assistant Professor of Psychiatry in Residence
 Neuropsychiatric Institute
 The David Geffen School of Medicine
 University of California at Los Angeles
 Los Angeles, California

8:10 **Exploring Differences Between
 Vascular Dementia and Alzheimer's
 Disease: Case Studies**
 Stephen Salloway, MD, MS
 Associate Professor of Clinical
 Neuroscience and Psychiatry
 Brown University Medical School
 Providence, Rhode Island

8:35 **Defining and Achieving Positive
 Outcomes in Dementia
 Pharmacotherapy**
 David Gelinascher, MD
 Associate Professor of Neurology
 University of Virginia Health System
 Charlottesville, Virginia

8:55 **Alzheimer's Disease Prevention:
 Strategies for Improving Brain and
 Memory Fitness**
 Gary W. Small, MD

9:15 **Question and Answer Session**

10:00 **Adjournment**

OBJECTIVES

At the conclusion of this program, participants should be able to:

- Recognize the complexities of dementia and differentiate between mild cognitive impairment (MCI) and early-stage Alzheimer's disease (AD);
- Evaluate management options for MCI and early AD;
- Describe cognitive and behavioral disturbances associated with vascular dementia;
- Distinguish between vascular dementia and AD and discuss existing treatment options;
- Identify positive treatment outcomes associated with cholinesterase inhibitors;
- Discuss novel technologies and strategies for improving and maintaining memory and brain fitness.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 703-907-7300.







INDUSTRY-SUPPORTED SYMPOSIUM 26
 Sunday, May 2, 7:00 p.m. - 10:00 p.m.
 Grand Ballroom East, Third Floor, Hilton New York

NEW YORK

APA 2004

ANNUAL MEETING

**Effective Long-Term Management
 of Schizophrenia: Real-World Considerations**

Agenda

SUNDAY, MAY 2, 2004

HILTON NEW YORK • 1335 AVENUE OF THE AMERICAS
 GRAND BALLROOM EAST

DINNER: 6:30 - 7:00 PM SYMPOSIUM: 7:00 - 10:00 PM

Chairperson:
JOHN M. KANE, MD
 Albert Einstein College of Medicine

Learning Objectives

At the conclusion of this educational activity, the participant should be better able to:

- Discuss the evolution of antipsychotic mechanism of action and the implications for efficacy, safety, and tolerability profiles;
- Understand the impact of adverse effects on overall patient health and antipsychotic treatment outcomes;
- Optimize the management of patients who are refractory to treatment with various antipsychotic agents;
- Evaluate clinical trials that include real-world measures of antipsychotic effectiveness.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA 2004 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Sponsored by the
 American Psychiatric Association

INDUSTRY-SUPPORTED SYMPOSIUM 27
 Sunday, May 2, 7:00 p.m. - 10:00 p.m.
 Broadway Ballroom, Sixth Floor, Marriott Marquis

APA 2004 <small>ANNUAL MEETING</small>		<h2 style="margin: 0;">Moderators and Mediators of Antidepressant Response</h2>	
Sunday, May 2, 2004 7:00-10:00 p.m.; Dinner 6:30-7 p.m. Broadway Ballroom, Sixth Floor, Marriott Marquis, New York, New York			
SYMPOSIUM AGENDA	7:40 - 8:05 p.m.	8:40 - 9:05 p.m.	At the conclusion of this symposium participants should be able to:
7:00 - 7:10 p.m. Welcome and Introduction Steven P. Roose, MD Symposium Chair Columbia University College of Physicians & Surgeons	Gender as a Moderator of Antidepressant Response Susan G. Kornstein, MD Medical College of Virginia 8:05 - 8:10 a.m. QUESTIONS	Antidepressant Treatment Duration: The Decision To Continue or Switch Treatment Harold A. Sackeim, PhD Columbia University College of Physicians & Surgeons 9:05 - 9:10 p.m. QUESTIONS	<ul style="list-style-type: none"> • recognize that demographic and clinical characteristics can affect treatment outcome, as can variable aspects of treatment itself (such as duration of treatment and adherence to medication regimen) • reach better informed treatment decisions
7:10 - 7:35 p.m. Moderators and Mediators of Treatment Effects in Antidepressant Trials Philip W. Lavori, PhD Stanford University 7:35 - 7:40 p.m. QUESTIONS	Moving the Goalposts: Is Response a Mediator of Remission? David J. Kupfer, MD University of Pittsburgh Medical Center 8:35 - 8:40 p.m. QUESTIONS	Placebo, Comparator, or Open Treatment: Design Counts Steven P. Roose, MD Columbia University College of Physicians & Surgeons 9:35 - 10:00 p.m. QUESTIONS	The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spends in the activity. Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300. This program is sponsored by the American Psychiatric Association and supported by an unrestricted educational grant from Forest Pharmaceuticals, Inc.
		10:00 p.m. ADJOURNMENT	 

INDUSTRY-SUPPORTED SYMPOSIUM 28
 Sunday, May 2, 7:00 p.m. - 10:00 p.m.
 Grand Ballroom, Mezzanine Level, Roosevelt

Beyond Sleep Onset New Perspectives on the Treatment of Insomnia		
Sunday, May 2, 2004 7:00 PM - 10:00 PM Grand Ballroom, Mezzanine Level The Roosevelt Hotel New York City, New York	Scientific Program Agenda 6:30 PM - 7:00 PM Dinner 7:00 PM - 7:10 PM Introduction and Welcome Chair: Andrew Krystal, MD 7:10 PM - 7:40 PM Prevalence and Impact of Insomnia: Treating the Entire Insomnia Syndrome Mugdha Thakur, MD 7:40 PM - 8:10 PM Differential Diagnosis of Insomnia and Co-morbid Conditions: Importance of Sleep History Jed Black, MD 8:10 PM - 8:40 PM Measures of Treatment Efficacy Thomas Roth, PhD 8:40 PM - 9:10 PM Overview of the Treatment of Insomnia Andrew Krystal, MD 9:10 PM - 10:00 PM Question-and-Answer Session Chair: Andrew Krystal, MD 10:00 PM Adjournment time	Accreditation Statement The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Registration Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first come, first served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within US or Canada) or 703/907-7300. Sponsored by the American Psychiatric Association. Supported by an unrestricted educational grant from Sepracor.
Faculty Andrew Krystal, MD (Program Chair) Director, Sleep Research Laboratory and Insomnia Program Associate Professor of Psychiatry and Behavioral Sciences Duke University Medical Center Durham, North Carolina Mugdha Thakur, MD Clinical Associate, Psychiatry and Behavioral Sciences Duke University Medical Center Durham, North Carolina Jed Black, MD Director, Stanford Sleep Disorders Clinic Stanford University Stanford, California Thomas Roth, PhD Chief, Division Head, Sleep Disorders and Research Center Henry Ford Hospital Detroit, Michigan		

INDUSTRY-SUPPORTED SYMPOSIUM 29
 Sunday, May 2, 7:00 p.m. - 10:00 p.m.
 Imperial Ballroom A, Second Floor, Sheraton New York

Psychopharmacology and Reproductive Transitions: The Impact of Psychotropic Medications and Sex Hormones on Brain Functioning, Weight, and Reproductive Safety

Symposium to be held at the American Psychiatric Association 157th Annual Meeting

**SUNDAY, MAY 2, 2004
 7:00 PM – 10:00 PM**

**Sheraton New York Hotel and Towers
 Imperial Ballroom A
 New York, New York**

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from GlaxoSmithKline

PROGRAM OBJECTIVES

After attending this continuing medical education symposium, the psychiatrist should be able to:

- Understand some of the complex interactions between gender-based characteristics, psychopharmacologic interventions, and reproductive biology
- Recognize the challenges of labeling products for use in pregnancy and lactation, and to better understand different sources available to assist physicians in assessing toxicities from drug exposures
- Identify gender-related characteristics associated with weight gain while using psychotropic medications, and to learn about novel strategies to manage this problem
- Understand the concept of a male menopause or andropause and its clinical implications, with particular emphasis on the role of testosterone as a potential hormonal intervention for depression
- Examine the association between menopausal transition and the occurrence of mood disturbances, and to understand the extent to which symptomatic women may benefit from hormonal and non-hormonal interventions
- Understand the impact of hormone therapy on the incidence of dementia and cognitive impairment in postmenopausal women, and how these findings should be interpreted



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada), or 703-907-7300.

AGENDA

- 6:30 PM Dinner**
- 7:00 PM Introduction**
 CLAUDIO N. SOARES, MD, PhD, SYMPOSIUM CHAIR
 Massachusetts General Hospital
 AND MARY C. BLEHAR, PhD, COCHAIR
 National Institute of Mental Health
- 7:05 PM Labeling Products for Use in Pregnancy: Moving Forward**
 SANDRA KWEDER, MD
 U.S. Food & Drug Administration
- 7:30 PM Questions and Answers**
- 7:35 PM Weight Gain, Psychotropic Medications, and Gender: Potential Pharmacologic Strategies**
 BARBARA GRACIOUS, MD
 University of Rochester Medical Center
- 8:00 PM Questions and Answers**
- 8:05 PM Testosterone Decline in the Aging Male: Does "Andropause" Exist?**
 STUART SEIDMAN, MD
 Columbia University College of Physicians & Surgeons
- 8:30 PM Questions and Answers**
- 8:35 PM Perimenopause-Related Mood Disturbance: An Update on Risk Factors and Novel Treatment Strategies Available**
 CLAUDIO N. SOARES, MD, PhD
- 9:00 PM Questions and Answers**
- 9:05 PM Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study — Updates**
 SALLY SHUMAKER, PhD
 Wake Forest University
- 9:30 PM Panel Discussion with Questions and Answers**
 CLAUDIO N. SOARES, MD, PhD,
 MARY C. BLEHAR, PhD, AND WILLIAM HARLAN, MD
 National Institute of Mental Health
- 10:00 PM Adjournment**

INDUSTRY-SUPPORTED SYMPOSIUM 30
 Sunday, May 2, 7:00 p.m. - 10:00 p.m.
 Imperial Ballroom B, Second Floor, Sheraton New York



This symposium will be held at the 2004 APA Annual Meeting

CHOOSING *the RIGHT DOSE* of *the* ATYPICAL ANTIPSYCHOTICS: ART or SCIENCE?

SUNDAY, MAY 2, 2004 • DINNER: 6:30–7:00 PM • SYMPOSIUM: 7:00–10:00 PM

IMPERIAL BALLROOM B, SECOND FLOOR • SHERATON NEW YORK HOTEL & TOWERS • NEW YORK, NEW YORK

AGENDA:

- | | |
|---|---|
| <p>6:30–7:00 PM Dinner</p> <p>7:00–7:10 PM Welcome & Opening Remarks
 Peter F. Buckley, MD
 Chairperson
 Medical College of Georgia</p> <p>7:10–7:35 PM Dosing With Atypicals: Receptor Occupancy as a Guide to Titration and Maintenance
 Shitij Kapur, MD
 University of Toronto</p> <p>7:35–8:00 PM Acute Stabilization of Psychosis: Options and Approaches
 K.N. Roy Chengappa, MD
 Western Psychiatric Institute and Clinic</p> <p>8:00–8:25 PM Strategies for Maintenance Pharmacotherapy: High, Low, or Switch?
 Peter F. Buckley, MD
 Medical College of Georgia</p> | <p>8:25–8:50 PM Administration of Atypicals in Bipolar Disorder
 Claudia E. Baldassano, MD
 University of Pennsylvania School of Medicine</p> <p>8:50–9:15 PM Is Polypharmacy the Result of Confused Dosing Strategies for Atypical Antipsychotics?
 Alexander L. Miller, MD
 The University of Texas Health Science Center</p> <p>9:15–10:00 PM Question & Answer Session
 All Faculty</p> <p>10:00 PM Adjourn</p> |
|---|---|

LEARNING OBJECTIVES:

- Explain the optimal doses of antipsychotic medications
- Evaluate data on the dosage and administration strategies of the newer second-generation antipsychotic agents for acute psychoses, either by oral or intramuscular routes, and evaluate the data on combining benzodiazepines or anticonvulsants/lithium in patients with schizophrenia or bipolar disorder
- Assess the decision points when to raise or maintain the present dose of an antipsychotic or switch to another agent during maintenance pharmacotherapy
- Review the data concerning the use of atypical antipsychotic medications in bipolar disorder, review dosing strategies, and offer a practical algorithm for clinicians treating bipolar patients
- Recognize and avoid polypharmacy that results from medication management errors in dosing, titrating, or monitoring the effects of antipsychotic monotherapy



CME STATEMENT:

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3.0 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

If any participant in this educational activity is in need of accommodations, please call 860-434-1690 by April 15, 2004, in order to receive service.



INDUSTRY-SUPPORTED SYMPOSIUM 31
 Monday, May 3, and Tuesday, May 4, 7:00 a.m. - 8:30 a.m.
 Grand Ballroom East, Third Floor, Hilton New York

NEW YORK MONDAY, MAY 3, 2004, and TUESDAY, MAY 4, 2004

APA 2004



ANNUAL MEETING

New Advances in the Treatment of Psychosis

Agenda

DAY ONE:		DAY TWO:	
7:00 AM - 7:05 AM	Welcome and Introductions <i>Robert E. Hales, MD</i> <i>Stuart C. Yudofsky, MD</i>	7:00 AM - 7:05 AM	Welcome and Introductions Brief Overview of Day One <i>Robert E. Hales, MD</i> <i>Stuart C. Yudofsky, MD</i>
7:05 AM - 7:30 AM	Psychosis Associated With Dementia: Efficacy of the Newer Antipsychotics <i>Dilip V. Jeste, MD</i> University of California, San Diego	7:05 AM - 7:30 AM	Antipsychotic Therapies in Pediatric Patients: The Importance of Safety and Tolerability <i>Robert L. Findling, MD</i> University Hospitals of Cleveland
7:30 AM - 7:55 AM	Antipsychotic Therapies in Geriatric Patients: The Importance of Safety and Tolerability <i>J. Michael Ryan, MD</i> University of Rochester School of Medicine and Dentistry	7:30 AM - 7:55 AM	Unique Challenges in the Pharmacotherapy of First-Episode Schizophrenia <i>Joseph P. McEvoy, MD</i> Duke University Medical Center
7:55 AM - 8:05 AM	Summary Remarks <i>Robert E. Hales, MD</i> <i>Stuart C. Yudofsky, MD</i>	7:55 AM - 8:05 AM	Summary Remarks <i>Robert E. Hales, MD</i> <i>Stuart C. Yudofsky, MD</i>
8:05 AM - 8:30 AM	Panel Discussion/Q&A	8:05 AM - 8:30 AM	Panel Discussion/Q&A
8:30 AM	Adjournment	8:30 AM	Adjournment

Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 32
 Monday, May 3, and Tuesday, May 4, 7:00 a.m. - 8:30 a.m.
 Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

Current Alzheimer's Disease Treatments and Beyond: Advances Impacting Clinical Practice

HELD AT THE APA 2004 ANNUAL MEETING | Monday and Tuesday, May 3 and 4, 2004
 7:00 - 8:30 a.m.; Breakfast 6:30 - 7:00 a.m. | Westside Ballroom 3-4, Fifth Floor | Marriott Marquis

SYMPOSIUM AGENDA

DAY 1 MONDAY, MAY 3	DAY 2 TUESDAY, MAY 4
6:30 - 7:00 Breakfast	6:30 - 7:00 Breakfast
7:00 - 7:10 Welcome and Introduction Trey Sunderland, MD, <i>Symposium Chair</i> National Institute of Mental Health	7:00 - 7:10 Brief Overview of Day 1 Discussion Trey Sunderland, MD, <i>Symposium Chair</i> National Institute of Mental Health
7:10 - 7:30 The Molecular Genetics of Alzheimer's Disease Rudolph E. Tanzi, PhD Massachusetts General Hospital Genetics and Aging Research Unit	7:10 - 7:30 Neuroimaging in Alzheimer's Disease: Diagnosis, Treatment and Prevention P. Murali Doraiswamy, MD Duke University Medical Center
7:30 - 7:50 Interactive Panel Discussion With Q&A	7:30 - 7:50 Interactive Panel Discussion With Q&A
7:50 - 8:10 Diversity of Neuropsychiatric Impairment: Cognitive and Behavioral Implications Jeffrey L. Cummings, MD University of California, Los Angeles	7:50 - 8:10 New Treatment Strategies for Alzheimer's Disease: The Role of Early Diagnosis Trey Sunderland, MD National Institute of Mental Health
8:10 - 8:30 Interactive Panel Discussion With Q&A	8:10 - 8:30 Interactive Panel Discussion with Summary Statement
8:30 Adjournment	8:30 Adjournment

At the conclusion of this symposium participants should be able to:


- recognize how current findings in Alzheimer's disease (AD) genetics provide insights for new treatments
- discuss the assessment and treatment of AD-associated neuropsychiatric symptoms
- understand the impact of emerging neuroimaging techniques
- evaluate alternative therapeutic options for possible treatment and prevention of AD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spends in the activity.


Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

This program is sponsored by the American Psychiatric Association and supported by an unrestricted educational grant from Forest Pharmaceuticals, Inc.

 **Forest Pharmaceuticals, Inc.**
 Pharmaceuticals • Therapeutics • Healthcare • Patient Management • Specialty Care

INDUSTRY-SUPPORTED SYMPOSIUM 33
 Monday, May 3, and Tuesday, May 4, 7:00 a.m. - 8:30 a.m.
 Broadway Ballroom, Sixth Floor, Marriott Marquis

Recognizing the Many Faces of Bipolar Disorder



Part 1
6:30AM-7:00AM Breakfast

7:00AM
Welcome and Introduction
Bruce M. Cohen, MD, PhD
Program Chairperson
McLean Hospital
Harvard Medical School

7:05AM
Differential Diagnosis of Bipolar Disorder: Clinical Findings
Stephan Heckers, MD
McLean Hospital
Harvard Medical School

7:25AM
Recognizing Bipolar Disorder in Children and Adolescents
Gabrielle A. Carlson, MD
Stony Brook University

7:45AM
Bipolarity in Old Age: Diagnostic and Management Issues
Kenneth L. Shulman, MD
Sunysbrook and Women's University of Toronto

8:05AM
Question and Answer Session

8:30AM
Program Adjournment

Part 2
6:30AM-7:00AM Breakfast

7:00AM
Welcome and Introduction
Bruce M. Cohen, MD, PhD
Program Chairperson
McLean Hospital
Harvard Medical School

7:05AM
Optimizing Functional Outcome in Bipolar Disorder
Deborah A. Yurgelou-Todd, PhD
McLean Hospital
Harvard Medical School

7:25AM
Neuroimaging Findings in Bipolar Disorder
Stephan Heckers, MD
McLean Hospital
Harvard Medical School

7:45AM
New Directions in Medication Development for Bipolar Disorder
Bruce M. Cohen, MD, PhD
Program Chairperson

8:05AM
Question and Answer Session

8:30AM
Program Adjournment

Don't Miss These Important Educational Programs!

Part 1
Monday, May 3, 2004
6:30AM-7:00AM Breakfast
7:00AM-8:30AM Educational Program

Part 2
Tuesday, May 4, 2004
6:30AM-7:00AM Breakfast
7:00AM-8:30AM Educational Program

Marriott Marquis
Sixth Floor, Broadway Ballroom
New York, New York


Learning Objectives
Upon completion of the program, participants should be able to:

1. Recognize the presentation of bipolar disorder in childhood and late life.
2. Discuss the functional outcomes of bipolar disorder and the new directions in medication development.
3. Review the assessment and differential diagnosis of bipolar disorder in children and adolescents.
4. Recognize clinical features and novel neuroimaging findings useful for the differential diagnosis of bipolar disorder.
5. Cite the significance of comorbid neurologic disease associated with bipolarity in old age and develop an effective and safe approach to management.
6. Explain the importance of cognitive deficits and their treatment in bipolar disorder.
7. Discuss the key strengths and shortcomings of existing treatments and the manner in which new technologies are leading to new targets and agents to improve the treatment of bipolar disorder.

Accreditation Statement
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Eli Lilly and Company



Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Held During the APA 2004 Annual Meeting

INDUSTRY-SUPPORTED SYMPOSIUM 34
 Monday, May 3, and Tuesday, May 4, 7:00 a.m. - 8:30 a.m.
 Imperial Ballroom A, Second Floor, Sheraton New York

Presented at the APA 157th Annual Meeting

EVIDENCE-BASED MEDICINE: THE NEXT GENERATION, PARTS 1 & 2

K. Ranga R. Krishnan, MD, Chairperson

Faculty and Agenda

Monday, May 3, 2004 - Part 1

6:30 AM - 7:00 AM **Breakfast**

7:00 AM - 7:20 AM **How to Make Judgments Under Uncertainty**
K. Ranga R. Krishnan, MD, Chairperson
Duke University, Durham, North Carolina

7:20 AM - 7:45 AM **Combining Information to Compare Antidepressants**
Nick Freemantle, PhD
University of Birmingham, Birmingham, United Kingdom

7:45 AM - 8:10 AM **Research Design Features Associated With Outcome in Antidepressant Clinical Trials**
Anfulla Khan, MD
Northwest Clinical Research Center, Bellevue, Washington

8:10 AM - 8:30 AM **Question-and-Answer Session**

8:30 AM **Adjournment**

Tuesday, May 4, 2004 - Part 2

6:30 AM - 7:00 AM **Breakfast**

7:00 AM - 7:30 AM **Psychotherapy for Treatment of Depression: Recent Developments**
Thomas R. Lynch, PhD
Duke University, Durham, North Carolina

7:30 AM - 8:05 AM **Pharmacological Treatment of Agitation in Dementia: Evidence-Based Recommendations**
Warren D. Taylor, MD
Duke University, Durham, North Carolina

8:05 AM - 8:30 AM **Question-and-Answer Session**

8:30 AM **Adjournment**

Monday, May 3, 2004
Tuesday, May 4, 2004
 7:00 AM - 8:30 AM
 Sheraton New York Hotel
 Imperial Ballroom A, Second Floor
 New York, New York

Target Audience
This activity is designed specifically for psychiatrists.


Learning Objective
Upon completion of this symposium, the participants should be able to:


- Teach how we make judgments and how to use evidence in the treatment of depression and agitation

Accreditation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Registration Policy
Attendees must be registered for the APA (Annual Meeting or Institute on Psychiatric Services) to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

 Sponsored by the American Psychiatric Association.
Supported by an unrestricted educational grant from Wyeth.



INDUSTRY-SUPPORTED SYMPOSIUM 35
 Monday, May 3, and Tuesday, May 4, 7:00 a.m. - 8:30 a.m.
 Imperial Ballroom B, Second Floor, Sheraton New York



This symposium will be held at the 2004 APA Annual Meeting

**TRANSCENDING EFFICACY: EFFECTIVE
 TREATMENT of PSYCHOSIS ACROSS DISORDERS**

MONDAY, MAY 3 & TUESDAY, MAY 4, 2004 • BREAKFAST: 6:30-7:00 AM • SYMPOSIUM: 7:00-8:30 AM
 IMPERIAL BALLROOM B, SECOND FLOOR • SHERATON NEW YORK HOTEL & TOWERS • NEW YORK, NEW YORK

AGENDA:

MONDAY, MAY 3

- 6:30-7:00 AM Breakfast
- 7:00-7:05 AM Welcome & Introductions
Pierre N. Tariot, MD
 Chairperson
University of Rochester Medical Center
John W. Newcomer, MD
 Co-Chairperson
Washington University School of Medicine
- 7:05-7:25 AM Managing Psychosis and Agitation in Dementia
J. Michael Ryan, MD
University of Rochester Medical Center
- 7:25-7:45 AM Movement Disorders in the Elderly: How Safe Are the Atypical Neuroleptics?
Richard M. Trosch, MD
Wayne State University School of Medicine
- 7:45-8:05 AM Lewy Body Dementia: What the Psychiatrist Needs to Know
Andrius Baskys, MD, PhD
Long Beach VA Medical Center
- 8:05-8:30 AM Question & Answer Session
All Faculty
- 8:30 AM Adjourn

TUESDAY, MAY 4



- 6:30-7:00 AM Breakfast
- 7:00-7:05 AM Welcome & Introductions
Pierre N. Tariot, MD
 Chairperson
University of Rochester Medical Center
John W. Newcomer, MD
 Co-Chairperson
Washington University School of Medicine
- 7:05-7:35 AM Avoiding Comorbidities in Treatment
John W. Newcomer, MD
Washington University School of Medicine
- 7:35-8:05 AM Transcending Efficacy in Psychosis: Where the Rubber Meets the Road
Jeanne M. Jackson Siegal, MD
Yale University School of Medicine
- 8:05-8:30 AM Question & Answer Session
All Faculty
- 8:30 AM Adjourn

LEARNING OBJECTIVES:

- Review the prevalence of psychotic disorders in the elderly, with special emphasis on dementia; develop a practical evaluation and management strategy; and discuss the potential and perils of available forms of antipsychotic and other psychotropic treatment
- Describe the spectrum of neuroleptic-induced movement disorders, as well as natural history, incidence, and risk factors for development of tardive dyskinesia and movement disorders by the elderly patient and the clinical features which distinguish these disorders
- Recognize and treat psychiatric symptoms of Lewy body dementia
- Describe abnormalities in weight caused by antipsychotic medications, the relationship between increased adiposity and abnormalities in glucose and lipid metabolism, define the metabolic syndrome, and explain how these disturbances are related to cardiovascular disease; cite new recommendations for screening patients for impaired glucose regulation and diabetes
- Describe the unique aspects of Lewy body dementia, especially in considering differential diagnosis

CME STATEMENT:

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the AEA. Each physician should claim only those credits that he/she actually spent in the activity.
 Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.
 If any participant in this educational activity is in need of accommodations, please call 800-434-1650 by April 15, 2004, in order to receive service.



INDUSTRY-SUPPORTED SYMPOSIUM 36
 Monday, May 3, 7:00 p.m. - 10:00 p.m.
 Grand Ballroom East, Third Floor, Hilton New York

NEW YORK

APA 2004

ANNUAL MEETING

MONDAY, MAY 3, 2004

Borderline Personality Disorder: Regulation of Affect and Impulse Control

Agenda

<p>7:00 PM - 7:10 PM Welcome and Opening Remarks <i>John M. Oldham, MD</i> <i>Andrew E. Skodol, MD</i></p> <p>7:10 PM - 7:35 PM New Findings in the Biology of Borderline Personality Disorder (BPD) <i>Martin Bohus, MD</i> <i>Institute of Mental Health</i></p> <p>7:35 PM - 8:00 PM BPD and Mood Disorder Spectrum <i>Pablo Goldberg, MD</i> <i>New York State Psychiatric Institute</i></p> <p>8:00 PM - 8:25 PM BPD and the Impulse Control Spectrum <i>Emil Coccaro, MD</i> <i>University of Chicago School of Medicine</i></p>	<p>8:25 PM - 8:50 PM Evidence-Based Psychotherapy for BPD <i>Glen Gabbard, MD</i> <i>Baylor College of Medicine</i></p> <p>8:50 PM - 9:15 PM Pharmacologic Treatment of BPD: Current and Future Strategies <i>Jeffrey Lieberman, MD</i> <i>University of North Carolina School of Medicine</i></p> <p>9:15 PM - 10:00 PM Q&A/Panel Discussion <i>Discussant: Mary Zanarini, EdD</i> <i>Harvard Medical School</i></p> <p>10:00 PM Adjournment</p>
--	---

Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Bristol-Myers Squibb Company
 Otsuka America Pharmaceutical, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 37
 Monday, May 3, 7:00 p.m. - 10:00 p.m.
 Westside Ballroom 1-2, Fifth Floor, Marriott Marquis

American Psychiatric Association's 157th Annual Meeting

INTERFERON INDUCED DEPRESSION: CONSEQUENCES FOR TREATING CHRONIC HEPATITIS C

Marriott Marquis—New York City | Westside Ballrooms 1&2 | Monday, May 3, 2004 | 7:00–10:00PM

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

- Discuss the pathophysiology of the neuropsychiatric symptoms produced by interferon.
- Appreciate the efficacy of pegylated interferon in the treatment of Hepatitis C
- Understand the effect of pegylated interferon on decreasing depression in Hepatitis C patients
- Develop a plan for the diagnosis, and treatment of Interferon induced psychiatric side effects in Hepatitis C patients

AGENDA

- 6:30–7:00 PM** Dinner Program
7:00–10:00 PM Program
7:00–7:25 **Interferon Induced Depression: An Overview and Analysis** G. Asnis, MD
7:25–7:55 **Pathophysiological Mechanisms of Interferon Induced Neuropsychiatric Symptoms** L. Capuron, MD
7:55–8:25 **Audience Q&A** Faculty
8:25–8:55 **Pegylated Interferon: Therapy of Hepatitis C with Less Depressive Effects** J. Reinus, MD
8:55–9:30 **Diagnosis and Treatment of Interferon Induced Psychiatric Side Effects in Patients with Hepatitis C** C. Raison, MD
9:30–10:00 **Audience Q&A** Faculty

FACULTY

- | | |
|---|---|
| Gregory M. Asnis, MD
<i>Montefiore Medical Center</i> | Lucile Capuron, MD
<i>Emory University,
School of Medicine</i> |
| Charles Raison, MD
<i>Emory University,
School of Medicine</i> | John Reinus, MD
<i>Montefiore Medical Center</i> |

ACCREDITATION

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting please visit the APA website at www.psych.org or contact the APA toll free number at 1-888-357-7924 (within the U.S. or Canada) or 703/907-7300*



Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Roche Laboratories, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 38
 Monday, May 3, 7:00 p.m. - 10:00 p.m.
 Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

A P A 2 0 0 4 A n n u a l M e e t i n g
Conceptualizing and Treating ADHD Adults

- 6:30 PM**
Dinner
- 7:00 PM**
Welcome/Introduction
 Timothy E. Wilens, MD, Chair
 Massachusetts General Hospital
- 7:05 PM**
ADHD Adult Case
 Jefferson Prince, MD
 Massachusetts General Hospital
- 7:20 PM**
Adult ADHD: A Conceptual Model
 Russell A. Barkley, PhD
 Medical University of South Carolina
- 7:43 PM**
Neurobiology of Adult ADHD
 F. Xavier Castellanos, MD
 New York University School of Medicine

- 8:06 PM**
Adult ADHD: A Family Genetic Perspective
 Stephen V. Faraone, PhD
 Massachusetts General Hospital
- 8:29 PM**
Adult ADHD: What Does Neuropsychology Tell Us?
 Larry Seidman, PhD
 Massachusetts Mental Health Center
- 8:52 PM**
Pharmacologic Treatment of Adult ADHD
 Timothy E. Wilens, MD
 Massachusetts General Hospital
- 9:15 – 10:00 PM**
Question and Answer Session
 Faculty
- 10:00 PM**
Adjournment

Learning objectives: At the conclusion of this symposium, the participant should be able to:
 1. Identify the emerging executive function model of adult ADHD impairment and recognize the neurobiological function model of adult ADHD impairment as well as describe the neuropsychological substantiation for the disorder
 2. Recall the various pharmacological treatment options.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours of category 1 credit towards the Physician's Recognition Award of the American Medical Association and for the CME requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Monday, May 3, 2004
6:30 – 7:00 PM Dinner
7:00 – 10:00 PM Program

Marriott Marquis
Fifth Floor
Westside Ballroom 3-4

Attendees must be registered for the APA 2004 Annual Meeting to attend the symposium. Seating is limited and based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 1-703-907-7300.


Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from

Shire

INDUSTRY-SUPPORTED SYMPOSIUM 39
 Monday, May 3, 7:00 p.m. - 10:00 p.m.
 Broadway Ballroom, Sixth Floor, Marriott Marquis




Plotting a Course to Remission:
 Navigating the Intersection of Mind, Brain, and Body

Held During the APA 2004 Annual Meeting
Monday, May 3, 2004
 6:30PM-7:00PM Dinner
 7:00PM-10:00PM Educational Program

Marriott Marquis
 Sixth Floor, Broadway Ballroom
 New York, New York

Sponsored by the American Psychiatric Association
 Supported by an unrestricted educational grant through a partnership of Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc.



Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

6:30PM-7:00PM Dinner

7:00PM Welcome and Introduction
 Ruta M. Nonacs, MD, PhD
 Program Co-Chairperson
 Harvard Medical School
 Massachusetts General Hospital

7:10PM Does Everybody Hurt? Epidemiology of Physical Symptoms and Depression
 Maurice M. Ohayon, MD, DSc, PhD
 Stanford Sleep Epidemiology Research Center
 Stanford University School of Medicine

7:35PM Comorbidity With Painful Physical Symptoms: Understanding the Intersection of Brain and Body
 Bruce A. Arnow, PhD
 Stanford University Medical Center

8:00PM Serotonin and Norepinephrine: Navigating the Broad Range of Symptoms
 Pedro L. Delgado, MD, MA
 Case Western Reserve University School of Medicine
 University Hospitals of Cleveland

8:25PM Plotting the Course to Remission: Balanced Strategies to Improve Outcomes
 Vivien K. Burt, MD, PhD
 UCLA School of Medicine
 Women's Life Center
 UCLA Neuropsychiatric Institute

8:50PM Looking Beyond the Symptoms of Depression: Considerations for Special Populations
 Ruta M. Nonacs, MD, PhD
 Program Co-Chairperson

9:15PM Question and Answer Session
 Alan F. Schatzberg, MD
 Program Chairperson
 Stanford University School of Medicine

10:00PM Program Adjournment

Learning Objectives
 Upon completion of the program, participants should be able to:

1. Discuss the epidemiology of the physical and emotional symptoms associated with depression.
2. Identify the link between neurotransmitter activity and efficacy for symptoms.
3. Explain the gender differences in patient symptomatology of depression and response to antidepressant treatment and provide considerations for treatment selection in the elderly patient with depression.
4. Describe the effects of painful physical symptoms in depression on healthcare utilization.
5. Appraise the high prevalence of chronic pain among patients with depression.
6. Recognize that prescribed pain medication use and overuse is more common when depression is present and that those with depression and adult pain syndromes are notable for histories of childhood maltreatment.
7. Point out the brain areas involved in emotion regulation, cognition, and perception of pain and physical symptoms.
8. Cite the clinical evidence that supports the use of dual-acting antidepressants, which inhibit both serotonin and norepinephrine reuptake to maximize the likelihood of achieving remission of depression.

Accreditation Statement
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.


INDUSTRY-SUPPORTED SYMPOSIUM 40
 Monday, May 3, 7:00 p.m. - 10:00 p.m.
 Grand Ballroom, Mezzanine Level, Roosevelt

**Pharmacotherapy of Addictions:
 From Clinics Into Office Practice**


APA 2004 Annual Meeting
 Monday, May 3, 2004

The Roosevelt Hotel
 Madison Avenue at 45th Street
 Grand Ballroom,
 Mezzanine Level
 New York, NY

Dinner: 6:30 PM – 7:00 PM
Symposium: 7:00 PM – 10:00 PM
Chair: Thomas Kosten, MD



Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Reckitt-Benckiser Pharmaceuticals Inc.

AGENDA

7:00 PM Welcome and Introduction
 Thomas Kosten, MD
 Yale University

7:20 PM Prescription Drug Abuse and Psychiatric Co-Morbidity
 Westley Clark, MD, JD, MPH
 Center for Substance Abuse Treatment (CSAT), Washington, DC

7:40 PM Opiate Pharmacotherapy and the Neurobiology of Opiate Abuse and Dependence
 Thomas Kosten, MD
 Yale University

8:05 PM Pain and Depression: Gateway to Addiction and Opportunity for Treatment
 Walter Ling, MD
 University of California/Los Angeles

8:30 PM Buprenorphine for Office-Based Opiate Treatment
 Laura McNicholas, MD, PhD
 University of Pennsylvania

8:55 PM Cultural Sensitivity in Addictions Treatment
 Gerardo Gonzalez, MD
 Yale University

9:15 PM Questions and Group Discussion

10:00 PM Adjournment

Learning Objectives
 After completion of the symposium, participants should be better able to:

- Understand illicit and prescription opiate dependence, its psychiatric comorbidity, and the federal legislation that allows office-based treatment with buprenorphine
- Know the neurobiology of opiates and pharmacology of partial agonists
- Compare buprenorphine to methadone for induction, maintenance, and detoxification of opiate dependence and for pain, depression, and AIDS management

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 41
 Monday, May 3, 7:00 p.m. - 10:00 p.m.
 Imperial Ballroom A, Second Floor, Sheraton New York

Presented at the APA 157th Annual Meeting

Hormones, Mood, and Cognition: Treatment Considerations in Older Women

Lee S. Cohen, MD, *Chairperson* • Hadine Joffe, MD, MSc, *Co-Chairperson*

Monday, May 3, 2004

7:00 PM - 10:00 PM

Sheraton New York Hotel
 Imperial Ballroom A, Second Floor
 New York, New York

Faculty and Agenda

- 6:30 PM - 7:00 PM **Dinner**
- 7:00 PM - 7:25 PM **Gonadal Steroids and the Brain: Implications in Aging Women**
 Meir Steiner, MD, PhD, FRCP, McMaster University,
 Ontario, Canada
- 7:25 PM - 7:30 PM **Discussion/Questions and Answers**
- 7:30 PM - 7:55 PM **Depression in Perimenopausal Women: Women at Risk
 and Response to Antidepressant Treatment**
 Lee S. Cohen, MD, Chairperson, Massachusetts General Hospital,
 Boston, Massachusetts
- 7:55 PM - 8:00 PM **Discussion/Questions and Answers**
- 8:00 PM - 8:25 PM **Menopause and Mood Disturbances: From Theory to Novel
 Treatment Strategies**
 Claudio N. Soares, MD, PhD, Massachusetts General Hospital,
 Boston, Massachusetts
- 8:25 PM - 8:30 PM **Discussion/Questions and Answers**
- 8:30 PM - 8:55 PM **Assessment and Treatment of Hot Flashes in Menopausal Women**
 Hadine Joffe, MD, MSc, Co-Chairperson, Massachusetts General Hospital,
 Boston, Massachusetts
- 8:55 PM - 9:00 PM **Discussion/Questions and Answers**
- 9:00 PM - 9:25 PM **The WHI Memory Study: Updates on the Impact of Estrogen
 Plus Progestin on the Incidence of Dementia and Mild
 Cognitive Impairment in Postmenopausal Women**
 Sally Shumaker, PhD, Wake Forest University School of Medicine,
 Winston-Salem, North Carolina
- 9:25 PM - 10:00 PM **Wrap-up Discussion/Questions and Answers**
- 10:00 PM **Adjournment**



Target Audience

This activity is designed specifically for psychiatrists.

Learning Objective

Upon completion of this symposium, the participants should be able to:

- Recognize the impact of reproductive hormones on mood and cognitive function and potential treatment-emergent side effects noted in subpopulations of patients

Accreditation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Registration Policy

Attendees must be registered for the APA (Annual Meeting or Institute on Psychiatric Services) to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703/907-7300.



Sponsored by the American Psychiatric Association.
 Supported by an unrestricted educational grant from Wyeth.

INDUSTRY-SUPPORTED SYMPOSIUM 42
 Monday, May 3, 7:00 p.m. - 10:00 p.m.
 Imperial Ballroom B, Second Floor, Sheraton New York

APA 2004 ANNUAL MEETING

REACHING BEYOND ALZHEIMER'S DISEASE WITH CHOLINERGIC THERAPY

MONDAY, MAY 3, 2004 6:30 PM | DINNER 7:00 PM-10:00 PM | EDUCATIONAL PROGRAM
 SHERATON NEW YORK HOTEL AND TOWERS | IMPERIAL BALLROOM B, 2ND FLOOR

Sponsored by the American
 Psychiatric Association

NOVARTIS

Supported by an unrestricted educational grant
 from Novartis Pharmaceuticals Corporation

EDUCATIONAL OBJECTIVES

At the conclusion of this symposium, the participant should be able to:

- Recognize diagnostic criteria and treatment options for DLB, PDD, and vascular dementias.
- Recognize strategies for maximizing use of ChEIs and identify potential future applications of cholinergic therapy.

PARTICIPATION

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

AGENDA

- 6:30 pm-7:00 pm Dinner
- 7:00 pm-7:10 pm Welcome and Introduction
 Steven G. Potkin, MD
- 7:10 pm-7:40 pm Dementia with Lewy Bodies within Our Grasp
 Ian G. McKeith, MD, FRCPsych
- 7:40 pm-8:10 pm Parkinson's Disease Beyond Dopaminergic Therapy
 Amos D. Korczyn, MD, MSc
- 8:10 pm-8:40 pm Exploring and Managing Vascular Features of Dementia
 Martin R. Farlow, MD
- 8:40 pm-9:10 pm Extending Treatment Options and Not Letting Go
 Gustavo Alva, MD
- 9:10 pm-10:00 pm Question and Answer Session
- 10:00 pm Adjourn

FACULTY

Chairperson

Steven G. Potkin, MD
 University of California, Irvine
 Irvine, California

Martin R. Farlow, MD
 Indiana University
 School of Medicine
 Indianapolis, Indiana

Ian G. McKeith, MD,
 FRCPsych
 Newcastle General
 Hospital
 Newcastle-upon-Tyne,
 England

Gustavo Alva, MD
 University of California, Irvine
 Irvine, California

Amos D. Korczyn, MD, MSc
 Tel-Aviv University
 Medical School
 Tel-Aviv, Israel

INDUSTRY-SUPPORTED SYMPOSIUM 43
 Tuesday, May 4, 7:00 p.m. - 10:00 p.m.
 Grand Ballroom East, Third Floor, Hilton New York

Presented at the APA 157th Annual Meeting

**Emotion Regulation and Plasticity of Underlying Circuitry:
 Implications for Depression, Anxiety, and Long-Term Brain Function**

Ned H. Kalin, MD, PhD, *Chairperson*

Tuesday, May 4, 2004

7:00 PM - 10:00 PM
 Hilton New York
 Grand Ballroom East
 New York, New York

Faculty and Agenda

6:30 PM - 7:00 PM	Dinner
7:00 PM - 7:10 PM	Welcome and Introduction Ned H. Kalin, MD, PhD, Chairperson University of Wisconsin, Madison, Wisconsin
7:10 PM - 7:40 PM	Amygdala and Prefrontal Cortical Interactions Involved in Emotion Regulation and Psychopathology Ned H. Kalin, MD, PhD, Chairperson University of Wisconsin, Madison, Wisconsin
7:40 PM - 8:10 PM	The Human Amygdala: Vigilance, Threat Assessment, and Psychopathology Paul Whalen, PhD University of Wisconsin, Madison, Wisconsin
8:10 PM - 8:40 PM	Experience-Dependent Effects on Structural Plasticity in Limbic and Cortical Structures Involved in Emotion Regulation Elizabeth Gould, PhD Princeton University, Princeton, New Jersey
8:40 PM - 9:10 PM	Hippocampal Size in Depression: Cause or Effect? Alan F. Schatzberg, MD Stanford University, Stanford, California
9:10 PM - 10:00 PM	Wrap-up Discussion/Questions and Answers
10:00 PM	Adjournment

Target Audience

This activity is designed specifically for psychiatrists.



Learning Objectives

- Upon completion of this symposium, the participants should be able to:
- Identify the relationship between maladaptive emotion regulation and anxiety and depression
 - Address interactions between prefrontal cortex and limbic regions as a substrate for emotion regulation
 - Describe environmental influences that promote and impair structural plasticity in brain regions associated with emotion regulation
 - Discuss the influence of stress and depression on hippocampal structure

Accreditation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Registration Policy

Attendees must be registered for the APA Annual Meeting or Institute on Psychiatric Services to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703/907-7300.



Sponsored by the American Psychiatric Association.
 Supported by an unrestricted educational grant from Wyeth.

INDUSTRY-SUPPORTED SYMPOSIUM 44
 Tuesday, May 4, 7:00 p.m. - 10:00 p.m.
 Westside Ballroom 1-2, Fifth Floor, Marriott Marquis

**CHALLENGES IN TREATING
 Bipolar Illness &
 COMORBID DISORDERS**

LEARNING OBJECTIVES

- Discuss the impact of differential diagnosis and comorbid disorders on the clinical course of bipolar disorder.
- Implement pharmacologic treatment strategies for bipolar disorder and comorbid disorders.

ACCREDITATION

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates these educational activities for a maximum of 3 category 1 credits towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.



Sponsored by the American Psychiatric Association.



This activity is supported by an unrestricted educational grant from Abbott Laboratories.

HELD AT THE APA 2004 ANNUAL MEETING



Lori Davis, MD - Program Chair


Tuesday, May 4, 2004

Marriott Marquis - Westside Ballroom 1-2, 5th Floor

6:30 - 7:00 pm	Dinner
7:00 - 7:05 pm	Welcome and Introductions Lori Davis, MD - Program Chair Tusculoosa VA Medical Center
7:05 - 7:30 pm	Evidence-Based Utilization of AEDs S. Nassir Ghaemi, MD Harvard Medical School
7:30 - 7:55 pm	Integrated Treatment of Bipolar Disorder in Children and Adolescents Kiki D. Chang, MD Stanford University School of Medicine
7:55 - 8:20 pm	Bipolar Disorders in Women: Clinical and Metabolic Correlates Natalie Rasgon, MD, PhD Stanford University School of Medicine
8:20 - 8:45 pm	Recognizing and Treating Comorbid Depression and Anxiety in Bipolar Disorder Lori Davis, MD - Program Chair
8:45 - 9:10 pm	The Challenge of Treating Bipolar Disorder and Substance Abuse Mark A. Frye, MD UCLA Medical Center
9:10 - 10:00 pm	Panel Discussion / Q&A All Faculty
10:00 pm	Adjourn

INDUSTRY-SUPPORTED SYMPOSIUM 45
 Tuesday, May 4, 7:00 p.m. - 10:00 p.m.
 Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

To be held at the APA 2004 Annual Meeting




DOES THE PHARMACOLOGY OF ANTIDEPRESSANT DRUGS MATTER?

Tuesday May 4
 6:30-10:00 PM
 Marriott Marquis Westside Ballroom 3-4, Fifth Floor

EDUCATIONAL OBJECTIVES
 To examine the clinical implications of such differences in terms of efficacy, tolerability, and the use of pharmacological strategies to boost the effect of antidepressants.

Sponsored by the American Psychiatric Association
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA 2004 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 703-907-7300. Supported by an unrestricted educational grant from  Forest Pharmaceuticals.

<p>7:00 PM - Introduction Maurizio Fava, MD <i>Symposium Chair & Speaker</i></p> <p>7:10 PM - Antidepressant Treatment & the Impact of Medical & Psychiatric Comorbidity Dan V. Iosifescu, MD <i>Harvard Medical School</i></p> <p>7:35 PM - Response vs. Remission: Are There Meaningful Differences Among Antidepressants? Michael E. Thase, MD <i>University of Pittsburgh Medical Center</i></p> <p>8:00 PM - Short- & Long-Term Tolerability Issues with Antidepressants Anita H. Clayton, MD <i>University of Virginia Health System</i></p>	<p>8:25 PM - Augmentation & Combination Strategies in Depression: What Is the Evidence? Maurizio Fava, MD <i>Harvard Medical School</i></p> <p>8:50 PM - Translating Mechanisms of Action into Clinical Outcome in Depression J. Craig Nelson, MD <i>University of California - San Francisco</i></p> <p>9:15 PM - Question & Answer Session</p> <p>10:00 PM - Program Concludes</p>
--	--

INDUSTRY-SUPPORTED SYMPOSIUM 46
 Tuesday, May 4, 7:00 p.m. - 10:00 p.m.
 Broadway Ballroom, Sixth Floor, Marriott Marquis

Panic Anxiety: Understanding Its Nature and Nurturing Recovery

Tuesday, May 4, 2004
 Dinner 6:30 PM - 7:00 PM
 Scientific Program 7:00 PM - 10:00 PM

Marriott Marquis
 Broadway Ballroom • Sixth Floor
 New York, NY

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Educational Objectives

- Review the possible basis for panic disorder
- Discuss and evaluate data regarding the genetic substrates of panic disorder and other anxiety traits and disorders
- Examine the incidence of suicide in patients with panic disorder
- Discuss the identification of panic disorder in primary care and a collaborative approach for treatment
- Review strategies for the pharmacological treatment of panic disorder, recognize advantages and disadvantages of antidepressants and benzodiazepines, and learn about the comparative and combined effects of drug and cognitive behavioral therapy

7:00 Introduction
 Murray B. Stein, MD—Chairman • University of California, San Diego

7:10 Born or Made Anxious? The Role of Temperament and Environment
 Murray B. Stein, MD

7:35 Genetics and Panic Disorder
 Joel E. Gelernter, MD • Yale University School of Medicine


8:00 Extreme Anxiety and Suicide
 David C. Purselle, MD • Emory University Medical School


8:25 Understanding and Treating Primary Care Panic Disorder Using a Collaborative Care Approach
 Peter P. Roy-Byrne, MD • University of Washington School of Medicine

8:50 Choosing Medications for Panic Disorder
 Jonathan R.T. Davidson, MD • Duke University Medical Center

9:15 Question-and-Answer Session

10:00 Conclusion

Sponsored by the  American Psychiatric Association

Supported by an unrestricted educational grant from  Forest Pharmaceuticals, Inc.
 Pharmaceuticals • Therapeutics • Devices • Managed Care • Specialty Sites

Held at the APA 2004 Annual Meeting

INDUSTRY-SUPPORTED SYMPOSIUM 47

Tuesday, May 4, 7:00 p.m. - 10:00 p.m.
Grand Ballroom, Mezzanine Level, Roosevelt

APA 2004 Annual Meeting Adult ADHD: Diagnosis and Treatment

6:30 PM

Dinner

7:00 PM

Welcome/Introduction

Thomas Spencer, MD, Chair
Massachusetts General Hospital

7:10 PM

Adult ADHD: Clinical Overview

Thomas Spencer, MD
Massachusetts General Hospital

7:35 PM

**Understanding & Utilization
of Diagnostic Rating Scales**

Lenard Adler, MD
New York University School of Medicine

8:00 PM

**Cognitive-Behavioral Therapies:
Treatments and Outcomes**

Stephen McDermott, MD
Massachusetts General Hospital

8:25 PM

Treatment with Stimulants

Timothy E. Wilens, MD
Massachusetts General Hospital

8:50 PM

Treatment with Non-Stimulants

James Waxmonsky, MD
State University of New York/Buffalo

9:15 - 10:00 PM

Question and Answer Session

Faculty

10:00 PM

Adjournment

Tuesday, May 4, 2004

6:30 - 7:00 PM Dinner

7:00 - 10:00 PM Program

**Roosevelt Hotel
Mezzanine Level
Grand Ballroom**

Attendees must be registered for the APA 2004 Annual Meeting to attend the symposium. Seating is limited and based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 1-703-907-7300.

Sponsored by the
American Psychiatric Association



Supported by an unrestricted
educational grant from

Shire

Learning objectives: At the conclusion of this symposium, the participant should be able to:

1. Evaluate the scientific substantiation and diagnostic scales used in adult ADHD.
2. Assess the validity and use of cognitive therapy and evidence supporting the use of stimulant and non-stimulant treatments.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours of category 1 credit towards the Physician's Recognition Award of the American Medical Association and for the CME requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 48

Tuesday, May 4, 7:00 p.m. - 10:00 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York



Binge Eating Disorder: Genes, Treatments, and Consequences

An educational symposium to be
presented at the 2004 Annual Meeting
of the American Psychiatric Association

Tuesday, May 4, 2004
7:00 PM - 10:00 PM

Sheraton New York
Imperial Ballroom A
Second Floor
New York, New York

Sponsored by the American
Psychiatric Association



Supported by an unrestricted
educational grant from
Ortho-McNeil Pharmaceutical, Inc.

ORTHO-MCNEIL

Educational Objectives

Upon completion of the program, participants should be able to understand the neurobiology of binge eating and obesity; understand family and genetic studies of binge eating disorder; review new treatment options for binge eating disorder; understand psychiatric comorbidity associated with binge eating disorder; and address medical comorbidity associated with binge eating disorder.

Accreditation Statement

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

The APA designates this educational activity for a maximum of 3 Category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

Program Agenda

6:30 PM - 7:00 PM	Dinner
7:00 PM - 7:05 PM	Welcome and Introduction Program Chair: James I. Hudson, MD, ScD Harvard Medical School/McLean Hospital
7:05 PM - 7:30 PM	The Neurobiology of Binge Eating and Obesity James F. List, MD, PhD Harvard Medical School/Massachusetts General Hospital
7:30 PM - 7:55 PM	Questions and Answers
7:55 PM - 8:00 PM	Family and Genetic Studies of Binge Eating Disorder James I. Hudson, MD, ScD
8:00 PM - 8:05 PM	Questions and Answers
8:05 PM - 8:30 PM	Treatments for Binge Eating Disorder B. Timothy Walsh, MD Columbia University
8:30 PM - 8:35 PM	Questions and Answers
8:35 PM - 9:00 PM	Psychiatric Comorbidity Associated With Binge Eating Disorder Justine K. Lalonde, MD Harvard Medical School/McLean Hospital
9:00 PM - 9:05 PM	Questions and Answers
9:05 PM - 9:30 PM	Addressing Medical Comorbidity Associated With Binge Eating Disorder Louis I. Aronnie, MD, FACP Weill Medical College of Cornell University
9:30 PM - 9:35 PM	Questions and Answers
9:35 PM - 9:40 PM	Summary and Conclusions James I. Hudson, MD, ScD
9:40 PM - 10:00 PM	Questions and Answers
10:00 PM	Adjournment

INDUSTRY-SUPPORTED SYMPOSIUM 49
 Tuesday, May 4, 7:00 p.m. - 10:00 p.m.
 Imperial Ballroom B, Second Floor, Sheraton New York

Tuesday | May 4 | 2004 | 7:00 PM - 10:00 PM

Exploring the True Morbidity of
INSOMNIA

APA 157th ANNUAL MEETING
 Sheraton New York | Imperial Ballroom
 New York | New York

OBJECTIVES

At the conclusion of this program, participants should be able to:

- Assess sleep quality in patients;
- Discuss the impact of sleep deprivation on metabolic/endocrine functions;
- Recognize the bidirectional relationship of psychiatric disorders and insomnia;
- Discuss the impact of sleep disorders on individuals' lives and the economic impact on the population;
- Compare current and future pharmacologic and non-pharmacologic treatments for insomnia.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7524 (within the United States or Canada) or 703-907-7000.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Neurocrine Biosciences and Pfizer Inc.

NEUROCRINE
 BIOSCIENCES

Pfizer
 NEUROCRINE

AGENDA

6:30 PM	Dinner	8:00	Psychiatric Morbidity of Insomnia Ruth M. Benca, MD, PhD Associate Chair, Department of Psychiatry Professor of Psychiatry University of Wisconsin Madison, Wisconsin
7:00	Welcome and Introductions John W. Winkelman, MD, PhD Program Chairperson Medical Director, Sleep Health Center Brigham and Women's Hospital Assistant Professor of Psychiatry Harvard University Medical School Boston, Massachusetts	8:25	Quality of Life and Health Care Costs in Insomnia Daniel J. Buysse, MD Associate Professor of Psychiatry Western Psychiatric Institute Pittsburgh, Pennsylvania
7:10	Assessing the Complaint of "Insomnia" Mary B. O'Malley, MD, PhD Fellowship Director, Sleep Disorders Center Norwalk Hospital Norwalk, Connecticut	8:50	Current and Future Treatments for Insomnia John W. Winkelman, MD, PhD
7:35	Metabolic and Endocrine Effects of Sleep Deprivation Eve Van Cauter, PhD Professor, Department of Medicine University of Chicago Chicago, Illinois	9:15	Question and Answer Session Faculty Panel
		10:00	Adjournment

INDUSTRY-SUPPORTED SYMPOSIUM 50
 Wednesday, May 5, and Thursday, May 6, 7:00 a.m. - 8:30 a.m.
 Imperial Ballroom A, Second Floor, Sheraton New York

PTSD: Searching for Answers in Traumatic Times

Wednesday and Thursday, May 5 & 6, 2004

Breakfast 6:30am-7:00am
 Symposium 7:00am-8:30am

Sheraton New York Hotel & Towers
 Imperial Ballroom A, Second Floor

Educational Council

Program Chair

Jonathan Davidson, MD
 Duke University Medical Center
 Durham, North Carolina

Faculty

Karl Dohgramji, MD
 Thomas Jefferson University Hospital
 Philadelphia, Pennsylvania

Edna Foa, PhD

University of Pennsylvania
 Philadelphia, Pennsylvania

Randall Marshall, MD
 New York State Psychiatric Institute
 New York, New York

Wei Zhang, MD, PhD
 Duke University Medical Center
 Durham, North Carolina

David Nutt, MD, PhD
 University of Bristol
 Bristol, England, United Kingdom

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Participation

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7524 (within the U.S. or Canada) or 703-907-7000.

An educational symposium to be presented
 at the 2004 APA Annual Meeting

Sponsored by the
 American Psychiatric Association

This program is supported by an unrestricted
 educational grant from Cephalon, Inc.



Educational Objectives

At the conclusion of this symposium, the participants should be able to:

- Understand the overall consequences of PTSD.
- Describe the impact of terrorist actions on mental health.
- Understand the neurobiology of PTSD, including the roles of GABA and glutamate.
- Recognize the nature of sleep disturbance and its treatment.
- Discuss effective and ineffective forms of psychotherapy and pharmacotherapy.

Agenda

Wednesday, May 5, 2004

6:30am-7:00am Breakfast
 7:00am-7:05am Welcome & Introduction • Jonathan Davidson, MD (Program Chair)
 7:05am-7:30am PTSD: Its Burden and the Toll From Terrorism • Randall Marshall, MD
 7:30am-7:55am Treatment and Prevention of Chronic PTSD: Psychosocial Approaches • Edna Foa, PhD

7:55am-8:30am Discussion Q&A
 8:30am Program Adjourns

Thursday, May 6, 2004


6:30am-7:00am Breakfast
 7:00am-7:05am Introduction & Review • Jonathan Davidson, MD (Program Chair)
 7:05am-7:30am Brain Imaging in PTSD: Going Beyond Serotonin • David Nutt, MD, PhD
 7:30am-7:55am Sleep in PTSD and Other Anxiety Disorders • Karl Dohgramji, MD
 7:55am-8:20am Novel Drug Treatments for PTSD Beyond SSRIs • Wei Zhang, MD, PhD
 8:20am-8:30am Q&A Panel Discussion
 8:30am Program Adjourns

INDUSTRY-SUPPORTED SYMPOSIUM 51
 Wednesday, May 5, and Thursday, May 6, 7:00 a.m. - 8:30 a.m.
 Imperial Ballroom B, Second Floor, Sheraton New York

TO BE HELD AT THE APA 2004 ANNUAL MEETING



BIPOLAR DISORDER IN WOMEN REPRODUCTIVE IMPLICATIONS OF TREATMENT

TWO-PART SYMPOSIUM • WEDNESDAY & THURSDAY • MAY 5-6



6:30-7 AM BREAKFAST • 7-8:30 AM CLINICAL PROGRAM
 SHERATON NEW YORK HOTEL & TOWERS
 IMPERIAL BALLROOM B, 2ND FLOOR

EDUCATIONAL OBJECTIVES
 At the conclusion of the symposium, the participants will be acquainted with the clinical management issues for bipolar women ranging from efficacy of treatment to the impact of treatment on reproductive endocrine function.

 sponsored by the American Psychiatric Association
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.
 Attendees must be registered for the APA 2004 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.
 Supported by an unrestricted educational grant from  Cassini.

PART 1 • WEDNESDAY, MAY 5	PART 2 • THURSDAY, MAY 6
6:30 AM - Breakfast	6:30 AM - Breakfast
7:00 AM - Introduction Adele C. Viguera, MD <i>Symposium Chair & Speaker</i>	7:00 AM - Introduction & Recap of Part 1 Adele C. Viguera, MD
7:05 AM - Treatment of Bipolar Illness During Pregnancy Lee S. Cohen, MD <i>Symposium Co-Chair</i> Harvard Medical School	7:10 AM - Use of Antiepileptic Medications in Women Martha J. Morrell, MD Columbia University College of Physicians & Surgeons
7:25 AM - Bipolar Illness During the Postpartum Period: Update on Treatment Adele C. Viguera, MD Harvard Medical School	7:40 AM - Reproductive Endocrine Consequences of Treatment Hadine Joffe, MD, MSc Harvard Medical School
7:45 AM - Treatment of Bipolar Illness in Adolescence Implications for Younger Women Janet Wozniak, MD Harvard Medical School	8:05 AM - Question & Answer Session
8:05 AM - Question & Answer Session	8:30 AM - Program Concludes
8:30 AM - Program Concludes	

INDUSTRY-SUPPORTED SYMPOSIUM 52
 Wednesday, May 5, 7:00 p.m. - 10:00 p.m.
 Grand Ballroom East, Third Floor, Hilton New York

NEW YORK

APA 2004

WEDNESDAY, MAY 5, 2004

ANNUAL MEETING

Optimizing Antipsychotic Treatment in Patients With Schizophrenia and Bipolar Disorder



Agenda

7:00 PM - 7:10 PM	Welcome and Opening Remarks Rajiv Tandon, MD	8:25 PM - 8:50 PM	Balancing Efficacy and Tolerability in Pediatric Bipolar Disorder Melissa DelBello, MD University of Cincinnati/Children's Hospital Medical Center
7:10 PM - 7:35 PM	Optimizing Pharmacotherapy for Maximized Outcomes Alan Mendelowitz, MD Albert Einstein College of Medicine	8:50 PM - 9:15 PM	Treatment Considerations in Special Populations: Sex Differences Diana Perkins, MD University of North Carolina at Chapel Hill
7:35 PM - 8:00 PM	Keeping Tolerability in Mind: Ensuring Adherence to Maintain Recovery Henry Nasrallah, MD University of Cincinnati Medical Center	9:15 PM - 10:00 PM	Q&A/Panel Discussion
8:00 PM - 8:25 PM	Finding Effectiveness Across Patient Age Groups Rajiv Tandon, MD	10:00 PM	Adjournment

Learning Objectives

-
-
-
-

Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

 Bristol-Myers Squibb Company
  Otsuka America Pharmaceutical, Inc.


INDUSTRY-SUPPORTED SYMPOSIUM 53
 Wednesday, May 5, 7:00 p.m. - 10:00 p.m.
 Imperial Ballroom A, Second Floor, Sheraton New York

PRESENTED AT THE APA 157TH ANNUAL MEETING

Core Symptom Domains in the Anxiety Disorders

Michael Liebowitz, MD, Co-Chair
Eric Hollander, MD, Co-Chair

Wednesday, May 5, 2004
 7:00 PM - 10:00 PM
 Sheraton New York Hotel
 Imperial Ballroom A
 New York, New York

<p>Faculty and Agenda</p> <p>6:30 PM - 7:00 PM Dinner</p> <p>7:00 PM - 7:30 PM Differential Diagnosis and Biology of Panic and GAD Jack Gorman, MD Mount Sinai School of Medicine, New York, New York</p> <p>7:30 PM - 7:55 PM Symptoms and Biologic Correlates of PTSD: From Early Adulthood to Old Age Rachel Yehuda, PhD Mount Sinai School of Medicine, New York, New York</p> <p>7:55 PM - 8:20 PM Social Anxiety Disorder Spectrum Michael Liebowitz, MD, Co-Chair NYS Psychiatric Institute, New York, New York</p> <p>8:20 PM - 8:45 PM The Repetitive Behavior Domain in Obsessive-Compulsive and Developmental Disorders Eric Hollander, MD, Co-Chair Mount Sinai School of Medicine, New York, New York</p> <p>8:45 PM - 9:15 PM Mixed Anxiety and Depression: A Gordian Knot Joseph Zohar, MD Sheba Medical Center, Tel Hashomer, Israel</p> <p>9:15 PM - 10:00 PM Wrap-up Discussion/Questions and Answers</p> <p>10:00 PM Adjournment</p>	<p>Target Audience This activity is designed specifically for psychiatrists.</p> <p>Learning Objectives Upon completion of this symposium, the participants should be able to:</p> <ul style="list-style-type: none"> - Recognize symptom domains in the anxiety disorders - Differentiate symptoms from disorders - Utilize an understanding of the neurobiology to select targeted treatments for anxiety disorders <p>Accreditation The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.</p> <p>Registration Policy Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703/907-7300.</p> <p style="text-align: center;"> Sponsored by the American Psychiatric Association. Supported by an unrestricted educational grant from Wyeth.</p>
--	--

INDUSTRY-SUPPORTED SYMPOSIUM 54
 Wednesday, May 5, 7:00 p.m. - 10:00 p.m.
 Imperial Ballroom B, Second Floor, Sheraton New York

APA 2004 ANNUAL MEETING

BACK TO THE FUTURE


The Role of Gamma-Aminobutyric-Acid in Psychiatric Disorders and Treatment


Sheraton New York Hotel & Towers • Imperial Ballroom B, 2nd Floor • Wednesday, May 5, 2004 • 6:30pm-7pm Dinner • 7pm-10pm Symposium

<p>EDUCATIONAL COUNCIL</p> <p><i>Program Chair</i> Mark H. Pollack, MD Massachusetts General Hospital Boston, Massachusetts</p> <p>Justine M. Kent, MD Columbia University New York, New York</p> <p>Philip T. Ninan, MD Emory University Atlanta, Georgia</p> <p>Naomi M. Simon, MD Massachusetts General Hospital Boston, Massachusetts</p> <p>John W. Winkelman, MD, PhD Harvard Medical School Boston, Massachusetts</p>	<p>EDUCATIONAL OBJECTIVES</p> <p><i>At the conclusion of this symposium, the participant should be able to:</i></p> <ul style="list-style-type: none"> • Understand the role of GABA in the pathophysiology of anxiety, sleep, and mood disorders. • Discuss the potential role of GABAergic agents in treatment of anxiety, sleep and mood disorders. <p>PARTICIPATION</p> <p>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.</p>	<p>AGENDA</p> <p>7:00PM-7:10PM Welcome & Introduction, Mark H. Pollack, MD</p> <p>7:10PM-7:35PM GABA in the CNS, Philip T. Ninan, MD</p> <p>7:35PM-8:00PM Neuroimaging and Anxiety, Justine M. Kent, MD</p> <p>8:00PM-8:25PM GABAergic Agents in the Treatment of Anxiety: A Look Back & Ahead, Mark H. Pollack, MD</p> <p>8:25PM-8:50PM Emerging GABAergic Targets for Insomnia, John W. Winkelman, MD, PhD</p> <p>8:50PM-9:15PM Beyond Anxiety Disorders: The Role of GABA in Mood Disorders, Naomi M. Simon, MD</p> <p>9:15PM-10:00PM Panel Discussion/Questions and Answers, Panel</p> <p>10:00PM Program Concludes</p>
---	---	--

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

 Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from **Cephalon, Inc.**


Now Playing
at the Javits

American Psychiatric Association Exhibit

Look for us right next door to the APPI Bookstore in the Exhibit Hall.



SHOW TIMES

Saturday, May 1	10:00 am – 5:00 pm
Sunday, May 2	8:00 am – 4:30 pm
Monday, May 3	10:00 am – 5:30 pm
Tuesday, May 4	10:00 am – 6:00 pm
Wednesday, May 5	10:00 am – 3:00 pm

Presenting...

...all the benefits of membership in the nation's oldest medical specialty society. APA's mission is to promote the highest **quality care** for individuals with mental disorders and their families, promote psychiatric **education and research** advances, **represent the profession** of psychiatry, and serve the **professional needs** of its members.

Whether you're a prospective, new, long-time, or international member, visit the APA exhibit and find out how APA can help you in your professional life.

At the exhibit you can:

- Pick up your APA membership information and resource handbook
- Learn about new APA programs and initiatives
- Participate in APA advocacy efforts
- Search the Job Bank for the latest employment opportunities
- Activate your online subscriptions to APA journals
- Submit your new member application and enter to win an APPI gift certificate
- And more!

While at the exhibit, take a moment to learn about the key roles of these APA subsidiary organizations

AMERICAN PSYCHIATRIC INSTITUTE
APIRE
for RESEARCH and EDUCATION

Our mission is to contribute to psychiatry's science base and to improve the quality of psychiatric care through research, education, health policy analysis and dissemination.

 **American Psychiatric Foundation**
Advancing public understanding of mental illnesses

The charitable and educational subsidiary, our mission is to advance public understanding that mental illnesses are real and can be effectively treated.